new orleans - AUA2015 Annual Meeting

Transcription

AUA2015
new orleans
Sharing Knowledge/Setting Standards
Meeting
Program
www.AUA2015.org
XTANDI (enzalutamide) capsules is indicated for the treatment of
patients with metastatic castration-resistant prostate cancer (CRPC).
ression g
o
r
p
e
s
a
s
e
NDI at dis PC for your patient
A
T
X
t
r
a
t
S
atic CR
to metast therapy*1
on GnRH
omy.
chiect
eral or
r bilat
1
e
*Or aft
Important Safety Information
Contraindications XTANDI (enzalutamide) capsules can cause
fetal harm when administered to a pregnant woman based on
its mechanism of action and findings in animals. XTANDI is not
indicated for use in women. XTANDI is contraindicated in women
who are or may become pregnant.
Warnings and Precautions In Study 1, conducted in patients
with metastatic castration-resistant prostate cancer (CRPC) who
previously received docetaxel, seizure occurred in 0.9% of patients
who were treated with XTANDI and 0% treated with placebo. In
Study 2, conducted in patients with chemotherapy-naïve metastatic
CRPC, seizure occurred in 0.1% of patients who were treated with
XTANDI and 0.1% treated with placebo. Patients experiencing a
seizure were permanently discontinued from therapy and all seizure
events resolved. There is no clinical trial experience re-administering
XTANDI to patients who experienced a seizure, and limited clinical
trial experience in patients with predisposing factors for seizure.
Study 1 excluded the use of concomitant medications that may
lower threshold, whereas Study 2 permitted the use of these
medications. Because of the risk of seizure associated with XTANDI
use, patients should be advised of the risk of engaging in any activity
during which sudden loss of consciousness could cause serious
harm to themselves or others. Permanently discontinue XTANDI in
patients who develop a seizure during treatment.
Adverse Reactions The most common adverse reactions
(≥ 10%) reported from the two combined clinical trials
that occurred more commonly (≥ 2% over placebo) in the
XTANDI-treated patients were asthenia/fatigue, back pain,
decreased appetite, constipation, arthralgia, diarrhea, hot flush,
upper respiratory tract infection, peripheral edema, dyspnea,
musculoskeletal pain, weight decreased, headache, hypertension,
and dizziness/vertigo.
Other Adverse Reactions include:
•Laboratory Abnormalities: In the two studies, Grade 1-4
neutropenia occurred in 15% of patients treated with XTANDI
(1% Grade 3-4) and in 6% of patients treated with placebo (0.5%
Grade 3-4). The incidence of Grade 1-4 thrombocytopenia was
6% of patients treated with XTANDI (0.3% Grade 3-4) and 5%
of patients on placebo (0.5% Grade 3-4). Grade 1-4 elevations
in ALT occurred in 10% of patients treated with XTANDI (0.2%
Grade 3-4) and 16% of patients treated with placebo (0.2%
Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3%
of patients treated with XTANDI (0.1% Grade 3-4) and 2% of
patients treated with placebo (no Grade 3-4).
•Infections: In Study 1, 1% of XTANDI versus 0.3% of placebo
patients and in Study 2, 1 patient in each treatment group
(0.1%) had an infection resulting in death.
Significantly extended radiographic
progression-free survival†1
Significantly improved overall survival†1
• 2
9% reduction in risk of death with XTANDI +
GnRH therapy* vs placebo + GnRH therapy*
(co-primary endpoint: HR = 0.71 [95% CI,
0.60-0.84]; P < 0.0001)
• 8
3% reduction in risk of radiographic disease
progression or death with XTANDI + GnRH therapy*
vs placebo + GnRH therapy* (co-primary endpoint:
HR = 0.17 [95% CI, 0.14-0.21]; P < 0.0001)
• E
stimated median overall survival was 32.4 months
(95% CI, 30.1-not reached) for XTANDI + GnRH
therapy* and 30.2 months (95% CI, 28.0-not
reached) for placebo + GnRH therapy*1
• E
stimated median radiographic progression-free
survival was not reached (95% CI, 13.8-not reached)
for XTANDI + GnRH therapy* and was 3.7 months
(95% CI, 3.6-4.6) for placebo + GnRH therapy*1
Oral, once-daily dosing with no required
steroid coadministration1
Significantly delayed time to
chemotherapy initiation†1
• Delayed time to chemotherapy initiation
by a median of 28.0 months with XTANDI +
GnRH therapy* vs 10.8 months with placebo +
GnRH therapy* (HR = 0.35 [95% CI,
0.30-0.40]; P < 0.0001)
• D
osage: XTANDI 160 mg (four 40 mg capsules)
is administered orally, once daily
• Steroids were allowed but not required‡
patient lives
94% ofareinsured
covered for XTANDI
§3
§
As of February 2015. A product’s placement on a plan formulary involves
a variety of factors known only to the plan and is subject to eligibility.
To learn more, please visit XtandiHCP.com
•Falls: In the two studies, falls including fall-related injuries
occurred in 9% of XTANDI patients vs 4% treated with placebo.
Falls were not associated with loss of consciousness or seizure.
Fall-related injuries were more severe in XTANDI patients and
included non-pathologic fractures, joint injuries, and hematomas.
•Hypertension: In the two studies, hypertension was reported
in 11% of patients receiving XTANDI and 4% of patients
receiving placebo. No patients experienced hypertensive crisis.
Medical history of hypertension was balanced between arms.
Hypertension led to study discontinuation in < 1% of XTANDI
or placebo treated patients.
Drug Interactions
•Effect of Other Drugs on XTANDI - Administration of strong
CYP2C8 inhibitors can increase the plasma exposure to
XTANDI. Co-administration of XTANDI with strong CYP2C8
inhibitors should be avoided if possible. If co-administration of
XTANDI cannot be avoided, reduce the dose of XTANDI.
Co-administration of XTANDI with strong or moderate CYP3A4
and CYP2C8 inducers may alter the plasma exposure of XTANDI
and should be avoided if possible.
© 2015 Astellas Pharma US, Inc. All rights reserved. Printed in USA. 076-0839-PM 3/15
XTANDI, Astellas, and the flying star logo are trademarks of Astellas Pharma Inc.
•Effect of XTANDI on Other Drugs - XTANDI is a strong CYP3A4
inducer and a moderate CYP2C9 and CYP2C19 inducer in
humans. Avoid CYP3A4, CYP2C9 and CYP2C19 substrates with
a narrow therapeutic index, as XTANDI may decrease the plasma
exposures of these drugs. If XTANDI is co-administered with
warfarin (CYP2C9 substrate), conduct additional INR monitoring.
Please see adjacent pages for Brief Summary
of Full Prescribing Information.
†As seen in the PREVAIL trial (Study 2): a multinational, double-blind, randomized,
phase 3 trial that enrolled 1717 patients with metastatic CRPC that progressed
on GnRH therapy or after bilateral orchiectomy, and who had not received prior
cytotoxic chemotherapy. All patients continued on GnRH therapy.1,2
‡In the PREVAIL trial, 27% of patients in the XTANDI arm and 30% of patients
in the placebo arm received glucocorticoids for varying reasons. In the AFFIRM
trial (Study 1), 48% of patients in the XTANDI arm and 46% of patients in
the placebo arm received glucocorticoids. AFFIRM was a phase 3, multicenter,
placebo‑controlled, randomized trial that enrolled 1199 patients with metastatic
CRPC who had previously received docetaxel.1
References: 1. XTANDI [package insert]. Northbrook, IL: Astellas Pharma US, Inc.
2. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate
cancer before chemotherapy. N Engl J Med. 2014;371:424-433. 3. Data on file,
Medivation, Inc.
XTANDI® (enzalutamide) capsules for oral use
Initial U.S. Approval: 2012
BRIEF SUMMARY OF PRESCRIBING INFORMATION
The following is a brief summary. Please see the package
insert for full prescribing information.
INDICATIONS AND USAGE
Grade 3 and higher adverse reactions were reported
among 47% of XTANDI-treated patients and 53% of
placebo-treated patients. Discontinuations due to adverse
events were reported for 16% of XTANDI-treated patients
and 18% of placebo-treated patients. The most common
adverse reaction leading to treatment discontinuation was
seizure, which occurred in 0.9% of the XTANDI-treated
patients compared to none (0%) of the placebo-treated
patients. Table 1 shows adverse reactions reported in Study
1 that occurred at a ≥ 2% higher frequency in the XTANDI
arm compared to the placebo arm.
Table 1. Adverse Reactions in Study 1 (cont.)
Respiratory Disorders
Table 1. Adverse Reactions in Study 1
Study 2: Chemotherapy-naive Metastatic CastrationResistant Prostate Cancer Study 2 enrolled 1717 patients
with metastatic CRPC who had not received prior cytotoxic
chemotherapy, of whom 1715 received at least one dose
of study drug. The median duration of treatment was 17.5
months with XTANDI and 4.6 months with placebo. Grade
3-4 adverse reactions were reported in 44% of XTANDItreated patients and 37% of placebo-treated patients.
Discontinuations due to adverse events were reported for
6% of XTANDI-treated patients and 6% of placebo-treated
patients. The most common adverse reaction leading to
treatment discontinuation was fatigue/asthenia, which
occurred in 1% of patients on each treatment arm. Table
2 includes adverse reactions reported in Study 2 that
occurred at a ≥ 2% higher frequency in the XTANDI arm
compared to the placebo arm.
XTANDI
N = 800
XTANDI is indicated for the treatment of patients with
metastatic castration-resistant prostate cancer (CRPC).
Grade
1-4a
(%)
CONTRAINDICATIONS
Pregnancy XTANDI can cause fetal harm when
administered to a pregnant woman based on its
mechanism of action and findings in animals. XTANDI is
not indicated for use in women. XTANDI is contraindicated
in women who are or may become pregnant. If this drug
is used during pregnancy, or if the patient becomes
pregnant while taking this drug, apprise the patient of
the potential hazard to the fetus and the potential risk for
pregnancy loss [see Use in Specific Populations (8.1)].
WARNINGS AND PRECAUTIONS
Seizure In Study 1, which enrolled patients who previously
received docetaxel, 7 of 800 (0.9%) patients treated with
XTANDI experienced a seizure and no patients treated with
placebo experienced a seizure. Seizure occurred from 31
to 603 days after initiation of XTANDI. In Study 2, 1 of
871 (0.1%) chemotherapy-naive patients treated with
XTANDI and 1 of 844 (0.1%) patients treated with placebo
experienced a seizure. Patients experiencing seizure were
permanently discontinued from therapy and all seizure
events resolved. There is no clinical trial experience readministering XTANDI to patients who experienced seizure.
Limited safety data are available in patients with
predisposing factors for seizure because these patients
were generally excluded from the trials. These exclusion
criteria included a history of seizure, underlying brain
injury with loss of consciousness, transient ischemic
attack within the past 12 months, cerebral vascular
accident, brain metastases, and brain arteriovenous
malformation. Study 1 excluded the use of concomitant
medications that may lower the seizure threshold,
whereas Study 2 permitted the use of these medications.
Because of the risk of seizure associated with XTANDI
use, patients should be advised of the risk of engaging
in any activity where sudden loss of consciousness could
cause serious harm to themselves or others. Permanently
discontinue XTANDI in patients who develop a seizure
during treatment.
ADVERSE REACTIONS
Clinical Trial Experience Because clinical trials are
conducted under widely varying conditions, adverse
reaction rates observed in the clinical trials of a drug
cannot be directly compared to rates in the clinical trials
of another drug and may not reflect the rates observed
in practice.
Two randomized clinical trials enrolled patients with
metastatic prostate cancer that has progressed on
androgen deprivation therapy (GnRH therapy or bilateral
orchiectomy), a disease setting that is also defined as
metastatic CRPC. In both studies, patients received
XTANDI 160 mg orally once daily in the active treatment
arm or placebo in the control arm. All patients continued
androgen deprivation therapy. Patients were allowed, but
not required, to take glucocorticoids.
The most common adverse reactions (≥ 10%) that
occurred more commonly (≥ 2% over placebo) in the
XTANDI-treated patients from the two randomized
clinical trials were asthenia/fatigue, back pain, decreased
appetite, constipation, arthralgia, diarrhea, hot flush, upper
respiratory tract infection, peripheral edema, dyspnea,
musculoskeletal pain, weight decreased, headache,
hypertension, and dizziness/vertigo.
Study 1: Metastatic Castration-Resistant Prostate
Cancer Following Chemotherapy Study 1 enrolled
1199 patients with metastatic CRPC who had previously
received docetaxel. The median duration of treatment
was 8.3 months with XTANDI and 3.0 months with
placebo. During the trial, 48% of patients on the XTANDI
arm and 46% of patients on the placebo arm received
glucocorticoids.
General Disorders
Asthenic
Conditionsb
Peripheral Edema
Placebo
N = 399
Grade Grade Grade
3-4
1-4
3-4
(%)
(%)
(%)
50.6
9.0
44.4
9.3
15.4
1.0
13.3
0.8
Musculoskeletal And Connective Tissue Disorders
Back Pain
26.4
5.3
24.3
4.0
Arthralgia
20.5
Musculoskeletal
15.0
Pain
Muscular
9.8
Weakness
Musculoskeletal
2.6
Stiffness
Gastrointestinal Disorders
2.5
17.3
1.8
1.3
11.5
0.3
1.5
6.8
1.8
0.3
0.3
0.0
21.8
1.1
17.5
0.3
Hot Flush
20.3
0.0
10.3
0.0
Hypertension
6.4
2.1
2.8
1.3
Diarrhea
Vascular Disorders
Nervous System Disorders
Headache
12.1
0.9
5.5
0.0
Dizzinessc
Spinal Cord
Compression and
Cauda Equina
Syndrome
Paresthesia
Mental
Impairment
Disordersd
Hypoesthesia
9.5
0.5
7.5
0.5
Epistaxis
3.3
0.1
1.3
0.3
a CTCAE v4
b Includes asthenia and fatigue.
c Includes dizziness and vertigo.
d Includes amnesia, memory impairment, cognitive disorder, and
disturbance in attention.
e Includes nasopharyngitis, upper respiratory tract infection, sinusitis,
rhinitis, pharyngitis, and laryngitis.
f Includes pneumonia, lower respiratory tract infection, bronchitis, and
lung infection.
Table 2. Adverse Reactions in Study 2
XTANDI
N = 871
Grade
1-4a
(%)
Grade
3-4
(%)
Placebo
N = 844
Grade
1-4
(%)
Grade
3-4
(%)
General Disorders
Asthenic
46.9
3.4
33.0
2.8
Conditionsb
Peripheral
11.5
0.2
8.2
0.4
Edema
Musculoskeletal And Connective Tissue Disorders
Back Pain
28.6
2.5
22.4
3.0
Arthralgia
21.4
1.6
16.1
1.1
Gastrointestinal Disorders
7.4
6.6
4.5
3.8
6.6
0.0
4.5
0.0
4.3
0.3
1.8
0.0
4.0
Infections And Infestations
Upper
Respiratory Tract 10.9
Infectione
Lower
Respiratory
8.5
Tract And Lung
Infectionf
Psychiatric Disorders
0.3
0.0
1.8
6.5
0.0
0.3
2.4
4.8
1.3
Insomnia
8.8
0.0
6.0
0.5
Anxiety
6.5
0.3
4.0
0.0
Renal And Urinary Disorders
Hematuria
6.9
1.8
4.5
1.0
Pollakiuria
4.8
0.0
2.5
0.0
Injury, Poisoning And Procedural Complications
Fall
4.6
0.3
1.3
Non-pathologic
4.0
1.4
0.8
Fractures
Skin And Subcutaneous Tissue Disorders
0.0
0.3
Pruritus
3.8
0.0
1.3
0.0
Dry Skin
3.5
0.0
1.3
0.0
Constipation
23.2
0.7
17.3
0.4
Diarrhea
16.8
0.3
14.3
0.4
Vascular Disorders
Hot Flush
18.0
0.1
7.8
0.0
Hypertension
14.2
7.2
4.1
2.3
Nervous System Disorders
Dizzinessc
11.3
0.3
7.1
0.0
Headache
11.0
0.2
7.0
0.4
Dysgeusia
7.6
0.1
3.7
0.0
5.7
0.0
1.3
0.1
2.1
0.1
0.4
0.0
0.6
8.5
0.6
0.0
10.5
0.0
1.5
4.7
1.1
0.1
5.7
0.0
Mental
Impairment
Disordersd
Restless Legs
Syndrome
Respiratory Disorders
Dyspneae
11.0
Infections And Infestations
Upper
Respiratory
16.4
Tract
Infectionf
Lower
Respiratory
Tract And
7.9
Lung
g
Infection
Psychiatric Disorders
Insomnia
8.2
Table 2. Adverse Reactions in Study 2 (cont.)
Renal And Urinary Disorders
Hematuria
8.8
1.3
5.8
1.3
Injury, Poisoning And Procedural Complications
Fall
12.7
1.6
NonPathological
8.8
2.1
Fracture
Metabolism and Nutrition Disorders
Decreased
18.9
0.3
Appetite
5.3
0.7
3.0
1.1
16.4
0.7
8.5
0.2
Investigations
Weight
Decreased
12.4
0.8
Reproductive System and Breast Disorders
Gynecomastia
3.4
0.0
1.4
0.0
a
b
c
d
CTCAE v4
Includes asthenia and fatigue.
Includes dizziness and vertigo.
Includes amnesia, memory impairment, cognitive disorder, and
disturbance in attention.
e Includes dyspnea, exertional dyspnea, and dyspnea at rest.
f Includes nasopharyngitis, upper respiratory tract infection, sinusitis,
rhinitis, pharyngitis, and laryngitis.
g Includes pneumonia, lower respiratory tract infection, bronchitis, and
lung infection.
Laboratory Abnormalities In the two randomized
clinical trials, Grade 1-4 neutropenia occurred in 15%
of patients treated with XTANDI (1% Grade 3-4) and in
6% of patients treated with placebo (0.5% Grade 3-4).
The incidence of Grade 1-4 thrombocytopenia was 6% of
patients treated with XTANDI (0.3% Grade 3-4) and 5% of
patients treated with placebo (0.5% Grade 3-4). Grade 1-4
elevations in ALT occurred in 10% of patients treated with
XTANDI (0.2% Grade 3-4) and 16% of patients treated
with placebo (0.2% Grade 3-4). Grade 1-4 elevations in
bilirubin occurred in 3% of patients treated with XTANDI
(0.1% Grade 3-4) and 2% of patients treated with placebo
(no Grade 3-4).
Infections In Study 1, 1% of patients treated with XTANDI
compared to 0.3% of patients treated with placebo died
from infections or sepsis. In Study 2, 1 patient in each
treatment group (0.1%) had an infection resulting in
death.
Falls and Fall-related Injuries In the two randomized
clinical trials, falls including fall-related injuries, occurred
in 9% of patients treated with XTANDI compared to 4% of
patients treated with placebo. Falls were not associated with
loss of consciousness or seizure. Fall-related injuries were
more severe in patients treated with XTANDI and included
non-pathologic fractures, joint injuries, and hematomas.
Hypertension In the two randomized trials, hypertension
was reported in 11% of patients receiving XTANDI and
4% of patients receiving placebo. No patients experienced
hypertensive crisis. Medical history of hypertension
was balanced between arms. Hypertension led to study
discontinuation in < 1% of patients in each arm.
DRUG INTERACTIONS
Drugs that Inhibit or Induce CYP2C8 Co-administration
of a strong CYP2C8 inhibitor (gemfibrozil) increased the
composite area under the plasma concentration-time curve
(AUC) of enzalutamide plus N-desmethyl enzalutamide
by 2.2-fold in healthy volunteers. Co-administration of
XTANDI with strong CYP2C8 inhibitors should be avoided
if possible. If co-administration of XTANDI with a strong
CYP2C8 inhibitor cannot be avoided, reduce the dose of
XTANDI [see Dosage and Administration (2.2) and Clinical
Pharmacology (12.3)].
The effects of CYP2C8 inducers on the pharmacokinetics
of enzalutamide have not been evaluated in vivo.
Co-administration of XTANDI with strong or moderate
CYP2C8 inducers (e.g., rifampin) may alter the plasma
exposure of XTANDI and should be avoided if possible.
Selection of a concomitant medication with no or minimal
CYP2C8 induction potential is recommended [see Clinical
Drugs that Inhibit or Induce CYP3A4 Co-administration
of a strong CYP3A4 inhibitor (itraconazole) increased
the composite AUC of enzalutamide plus N-desmethyl
enzalutamide by 1.3-fold in healthy volunteers [see
Clinical Pharmacology (12.3)].
The effects of CYP3A4 inducers on the pharmacokinetics
of enzalutamide have not been evaluated in vivo.
Co-administration of XTANDI with strong CYP3A4
inducers (e.g., carbamazepine, phenobarbital, phenytoin,
rifabutin, rifampin, rifapentine) may decrease the plasma
exposure of XTANDI and should be avoided if possible.
Selection of a concomitant medication with no or minimal
CYP3A4 induction potential is recommended. Moderate
CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine,
modafinil, nafcillin) and St. John’s Wort may also reduce
the plasma exposure of XTANDI and should be avoided if
possible [see Clinical Pharmacology (12.3)].
Effect of XTANDI on Drug Metabolizing Enzymes
Enzalutamide is a strong CYP3A4 inducer and a moderate
CYP2C9 and CYP2C19 inducer in humans. At steady
state, XTANDI reduced the plasma exposure to midazolam
(CYP3A4 substrate), warfarin (CYP2C9 substrate), and
omeprazole (CYP2C19 substrate). Concomitant use of
XTANDI with narrow therapeutic index drugs that are
metabolized by CYP3A4 (e.g., alfentanil, cyclosporine,
dihydroergotamine, ergotamine, fentanyl, pimozide,
quinidine, sirolimus and tacrolimus), CYP2C9 (e.g.,
phenytoin, warfarin) and CYP2C19 (e.g., S-mephenytoin)
should be avoided, as enzalutamide may decrease their
exposure. If co-administration with warfarin cannot be
avoided, conduct additional INR monitoring [see Clinical
USE IN SPECIFIC POPULATIONS
Pregnancy - Pregnancy Category X [see Contraindications
(4)].
Risk Summary
XTANDI can cause fetal harm when administered to a
pregnant woman based on its mechanism of action and
findings in animals. While there are no human data on the
use of XTANDI in pregnancy and XTANDI is not indicated
for use in women, it is important to know that maternal
use of an androgen receptor inhibitor could affect
development of the fetus. Enzalutamide caused embryofetal toxicity in mice at exposures that were lower than
in patients receiving the recommended dose. XTANDI
is contraindicated in women who are or may become
pregnant while receiving the drug. If this drug is used
during pregnancy, or if the patient becomes pregnant
while taking this drug, apprise the patient of the potential
hazard to the fetus and the potential risk for pregnancy
loss. Advise females of reproductive potential to avoid
becoming pregnant during treatment with XTANDI.
Animal Data
In an embryo-fetal developmental toxicity study in
mice, enzalutamide caused developmental toxicity
when administered at oral doses of 10 or 30 mg/kg/day
throughout the period of organogenesis (gestational days
6-15). Findings included embryo-fetal lethality (increased
post-implantation loss and resorptions) and decreased
anogenital distance at ≥ 10 mg/kg/day, and cleft palate
and absent palatine bone at 30 mg/kg/day. Doses of 30
mg/kg/day caused maternal toxicity. The doses tested
in mice (1, 10 and 30 mg/kg/day) resulted in systemic
exposures (AUC) approximately 0.04, 0.4 and 1.1 times,
respectively, the exposures in patients. Enzalutamide
did not cause developmental toxicity in rabbits when
administered throughout the period of organogenesis
(gestational days 6-18) at dose levels up to 10 mg/kg/day
(approximately 0.4 times the exposures in patients based
on AUC).
Nursing Mothers XTANDI is not indicated for use in
women. It is not known if enzalutamide is excreted
in human milk. Because many drugs are excreted in
human milk, and because of the potential for serious
adverse reactions in nursing infants from XTANDI, a
decision should be made to either discontinue nursing, or
discontinue the drug taking into account the importance
of the drug to the mother.
Pediatric Use Safety and effectiveness of XTANDI in
pediatric patients have not been established.
Geriatric Use Of 1671 patients who received XTANDI
in the two randomized clinical trials, 75% were 65 and
over, while 31% were 75 and over. No overall differences
in safety or effectiveness were observed between these
patients and younger patients. Other reported clinical
experience has not identified differences in responses
between the elderly and younger patients, but greater
sensitivity of some older individuals cannot be ruled out.
Patients with Renal Impairment A dedicated renal
impairment trial for XTANDI has not been conducted.
Based on the population pharmacokinetic analysis
using data from clinical trials in patients with metastatic
CRPC and healthy volunteers, no significant difference
in enzalutamide clearance was observed in patients
with pre-existing mild to moderate renal impairment
(30 mL/min ≤ creatinine clearance [CrCL] ≤ 89 mL/min)
compared to patients and volunteers with baseline
normal renal function (CrCL ≥ 90 mL/min). No initial
dosage adjustment is necessary for patients with mild
to moderate renal impairment. Severe renal impairment
(CrCL < 30 mL/min) and end-stage renal disease have not
been assessed [see Clinical Pharmacology (12.3)].
Patients with Hepatic Impairment A dedicated hepatic
impairment trial compared the composite systemic
exposure of enzalutamide plus N-desmethyl enzalutamide
in volunteers with baseline mild or moderate hepatic
impairment (Child-Pugh Class A and B, respectively)
versus healthy controls with normal hepatic function.
The composite AUC of enzalutamide plus N-desmethyl
enzalutamide was similar in volunteers with mild or
moderate baseline hepatic impairment compared to
volunteers with normal hepatic function. No initial dosage
adjustment is necessary for patients with baseline mild
or moderate hepatic impairment. Baseline severe hepatic
impairment (Child-Pugh Class C) has not been assessed
[see Clinical Pharmacology (12.3)].
OVERDOSAGE
In the event of an overdose, stop treatment with
XTANDI and initiate general supportive measures taking
into consideration the half-life of 5.8 days. In a dose
escalation study, no seizures were reported at < 240
mg daily, whereas 3 seizures were reported, 1 each at
360 mg, 480 mg, and 600 mg daily. Patients may be at
increased risk of seizure following an overdose.
NONCLINICAL TOXICOLOGY
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term animal studies have not been conducted to
evaluate the carcinogenic potential of enzalutamide.
Enzalutamide did not induce mutations in the bacterial
reverse mutation (Ames) assay and was not genotoxic in
either the in vitro mouse lymphoma thymidine kinase (Tk)
gene mutation assay or the in vivo mouse micronucleus
assay.
Based on nonclinical findings in repeat-dose toxicology
studies, which were consistent with the pharmacological
activity of enzalutamide, male fertility may be impaired
by treatment with XTANDI. In a 26-week study in rats,
atrophy of the prostate and seminal vesicles was observed
at ≥ 30 mg/kg/day (equal to the human exposure based
on AUC). In 4-, 13-, and 39-week studies in dogs,
hypospermatogenesis and atrophy of the prostate and
epididymides were observed at ≥ 4 mg/kg/day (0.3 times
the human exposure based on AUC).
Manufactured by: Catalent Pharma Solutions, LLC, St.
Petersburg, FL 33716
Manufactured for and Distributed by: Astellas Pharma
US, Inc., Northbrook, IL 60062
Marketed by:
Astellas Pharma US, Inc., Northbrook, IL 60062
Medivation, Inc., San Francisco, CA 94105
Revised: September 2014
14B006-XTA-BRFS
Rx Only
© 2014 Astellas Pharma US, Inc.
XTANDI® is a registered trademark of Astellas Pharma Inc.
076-0472-PM
For your patients with overactive bladder (OAB)
Rethin
OAB
Treatment
Myrbetriq is a ß3-adrenergic agonist treatment indicated for patients with
OAB symptoms of urge urinary incontinence, urgency, and urinary frequency.
It may be time to take another look at OAB treatment with Myrbetriq.
Myrbetriq® (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive
bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
IMPORTANT SAFETY INFORMATION
Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended,
especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled
hypertensive patients (defined as systolic blood pressure ≥180 mm Hg
and/or diastolic blood pressure ≥110 mm Hg).
Urinary retention in patients with bladder outlet obstruction (BOO) and in patients taking
antimuscarinic medications for the treatment of OAB has been reported in postmarketing experience
in patients taking mirabegron. A controlled clinical safety study in patients with BOO did not
demonstrate increased urinary retention in Myrbetriq patients; however, Myrbetriq should be
administered with caution to patients with clinically significant BOO. Myrbetriq should also be
administered with caution to patients taking antimuscarinic medications for the treatment of OAB.
IMPORTANT SAFETY INFORMATION (cont’d)
Since Myrbetriq is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates such as
metoprolol and desipramine is increased when co-administered with Myrbetriq. Therefore, appropriate
monitoring and dose adjustment may be necessary, especially with narrow therapeutic index drugs
metabolized by CYP2D6, such as thioridazine, flecainide, and propafenone.
Most commonly reported adverse reactions (>2% and >placebo) for Myrbetriq 25 mg and 50 mg
vs placebo, respectively, were hypertension (11.3%, 7.5% vs 7.6%), nasopharyngitis (3.5%, 3.9% vs
2.5%), urinary tract infection (4.2%, 2.9% vs 1.8%), and headache (2.1%, 3.2% vs 3.0%).
Please see Brief Summary of Prescribing Information for Myrbetriq (mirabegron)
on following page.
Visit Booth #1017 to learn more
Myrbetriq® is a registered trademark of Astellas Pharma Inc.
©2015 Astellas Pharma US, Inc.
All rights reserved.
Printed in USA
057-0391-PM
May 2015
BRIEF SUMMARY OF PRESCRIBING INFORMATION
The following information is a brief summary only. See full prescribing information for
MYRBETRIQ.
MYRBETRIQ® (mirabegron) extended-release tablets
Myrbetriq is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder
(OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
---------------------------------------CONTRAINDICATIONS---------------------------------------None
----------------------------------WARNINGS AND PRECAUTIONS--------------------------------Increases in Blood Pressure
Myrbetriq can increase blood pressure. Periodic blood pressure determinations are
recommended, especially in hypertensive patients. Myrbetriq is not recommended for
use in patients with severe uncontrolled hypertension (defined as systolic blood pressure
greater than or equal to 180 mmHg and/or diastolic blood pressure greater than or equal
to 110 mmHg) [see Clinical Pharmacology (12.2)].
In two, randomized, placebo-controlled, healthy volunteer studies, Myrbetriq was
associated with dose-related increases in supine blood pressure. In these studies, at the
maximum recommended dose of 50 mg, the mean maximum increase in systolic/diastolic
blood pressure was approximately 3.5/1.5 mmHg greater than placebo.
In contrast, in OAB patients in clinical trials, the mean increase in systolic and diastolic
blood pressure at the maximum recommended dose of 50 mg was approximately
0.5 - 1 mmHg greater than placebo. Worsening of pre-existing hypertension was reported
infrequently in Myrbetriq patients.
Urinary Retention in Patients with Bladder Outlet Obstruction and in Patients Taking
Antimuscarinic Medications for OAB
Urinary retention in patients with bladder outlet obstruction (BOO) and in patients taking
antimuscarinic medications for the treatment of OAB has been reported in postmarketing
experience in patients taking mirabegron. A controlled clinical safety study in patients
with BOO did not demonstrate increased urinary retention in Myrbetriq patients; however,
Myrbetriq should be administered with caution to patients with clinically significant BOO.
Myrbetriq should also be administered with caution to patients taking antimuscarinic
medications for the treatment of OAB [see Clinical Pharmacology (12.2)].
Patients Taking Drugs Metabolized by CYP2D6
Since mirabegron is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6
substrates such as metoprolol and desipramine is increased when co-administered
with mirabegron. Therefore, appropriate monitoring and dose adjustment may be
necessary, especially with narrow therapeutic index drugs metabolized by CYP2D6, such
as thioridazine, flecainide, and propafenone [see Drug Interactions (7.1) and Clinical
---------------------------------------ADVERSE REACTIONS--------------------------------------Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction
rates observed in the clinical trials of a drug cannot be directly compared to rates in the
clinical trials of another drug and may not reflect the rates observed in clinical practice.
In three, 12 week, double-blind, placebo-controlled, safety and efficacy studies in patients
with overactive bladder (Studies 1, 2, and 3), Myrbetriq was evaluated for safety in
2736 patients, [see Clinical Studies (14)]. Study 1 also included an active control. For
the combined Studies 1, 2, and 3, 432 patients received Myrbetriq 25 mg, 1375 received
Myrbetriq 50 mg, and 929 received Myrbetriq 100 mg once daily. In these studies, the
majority of the patients were Caucasian (94%), and female (72%) with a mean age of
59 years (range 18 to 95 years).
Myrbetriq was also evaluated for safety in 1632 patients who received Myrbetriq 50 mg
once daily (n=812 patients) or Myrbetriq 100 mg (n=820 patients) in a 1 year, randomized,
fixed dose, double-blind, active controlled, safety study in patients with overactive bladder
(Study 4). Of these patients, 731 received Myrbetriq in a previous 12 week study. In Study
4, 1385 patients received Myrbetriq continuously for at least 6 months, 1311 patients
received Myrbetriq for at least 9 months, and 564 patients received Myrbetriq for at least
1 year.
The most frequent adverse events (0.2%) leading to discontinuation in Studies 1, 2 and 3
for the 25 mg or 50 mg dose were nausea, headache, hypertension, diarrhea, constipation,
dizziness and tachycardia.
Atrial fibrillation (0.2%) and prostate cancer (0.1%) were reported as serious adverse
events by more than 1 patient and at a rate greater than placebo.
Table 1 lists adverse reactions, derived from all adverse events, that were reported in
Studies 1, 2 and 3 at an incidence greater than placebo and in 1% or more of patients
treated with Myrbetriq 25 mg or 50 mg once daily for up to 12 weeks. The most commonly
reported adverse reactions (greater than 2% of Myrbetriq patients and greater than
placebo) were hypertension, nasopharyngitis, urinary tract infection and headache.
Table 1: Percentages of Patients with Adverse Reactions, Derived from All Adverse
Events, Exceeding Placebo Rate and Reported by 1% or More Patients Treated With
Myrbetriq 25 mg or 50 mg Once Daily in Studies 1, 2, and 3
Number of Patients
Hypertension*
Nasopharyngitis
Urinary Tract Infection
Headache
Placebo
(%)
1380
7.6
2.5
1.8
3.0
Myrbetriq 25 mg
(%)
432
11.3
3.5
4.2
2.1
Myrbetriq 50 mg
(%)
1375
7.5
3.9
2.9
3.2
Placebo Myrbetriq 25 mg Myrbetriq 50 mg
(%)
(%)
(%)
Number of Patients
1380
432
1375
Constipation
1.4
1.6
1.6
Upper Respiratory Tract Infection
1.7
2.1
1.5
Arthralgia
1.1
1.6
1.3
Diarrhea
1.3
1.2
1.5
Tachycardia
0.6
1.6
1.2
Abdominal Pain
0.7
1.4
0.6
Fatigue
1.0
1.4
1.2
*Includes reports of blood pressure above the normal range, and BP increased from
baseline, occurring predominantly in subjects with baseline hypertension.
Other adverse reactions reported by less than 1% of patients treated with Myrbetriq in
Studies 1, 2, or 3 included:
Cardiac disorders: palpitations, blood pressure increased [see Clinical Pharmacology (12.2)]
Eye disorders: glaucoma [see Clinical Pharmacology (12.2)]
Gastrointestinal disorders: dyspepsia, gastritis, abdominal distension
Infections and Infestations: sinusitis, rhinitis
Investigations: GGT increased, AST increased, ALT increased, LDH increased
Renal and urinary disorders: nephrolithiasis, bladder pain
Reproductive system and breast disorders: vulvovaginal pruritus, vaginal infection
Skin and subcutaneous tissue disorders: urticaria, leukocytoclastic vasculitis, rash,
pruritus, purpura, lip edema
Table 2 lists the rates of the most commonly reported adverse reactions, derived from all
adverse events in patients treated with Myrbetriq 50 mg for up to 52 weeks in Study 4.
The most commonly reported adverse reactions (>3% of Myrbetriq patients) were
hypertension, urinary tract infection, headache, and nasopharyngitis.
Table 2: Percentages of Patients with Adverse Reactions, Derived from all Adverse
Events, Reported by Greater Than 2% of Patients Treated With Myrbetriq 50 mg Once
Daily in Study 4
Myrbetriq 50 mg
Active Control
(%)
(%)
Number of Patients
812
812
Hypertension
9.2
9.6
Urinary Tract Infection
5.9
6.4
Headache
4.1
2.5
Nasopharyngitis
3.9
3.1
Back Pain
2.8
1.6
Constipation
2.8
2.7
Dry Mouth
2.8
8.6
Dizziness
2.7
2.6
Sinusitis
2.7
1.5
Influenza
2.6
3.4
Arthralgia
2.1
2.0
Cystitis
2.1
2.3
In Study 4, in patients treated with Myrbetriq 50 mg once daily, adverse reactions leading
to discontinuation reported by more than 2 patients and at a rate greater than active control
included: constipation (0.9%), headache (0.6%), dizziness (0.5%), hypertension (0.5%),
dry eyes (0.4%), nausea (0.4%), vision blurred (0.4%), and urinary tract infection (0.4%).
Serious adverse events reported by at least 2 patients and exceeding active control included
cerebrovascular accident (0.4%) and osteoarthritis (0.2%). Serum ALT/AST increased
from baseline by greater than 10-fold in 2 patients (0.3%) taking Myrbetriq 50 mg, and
these markers subsequently returned to baseline while both patients continued Myrbetriq.
In Study 4, serious adverse events of neoplasm were reported by 0.1%, 1.3%, and 0.5%
of patients treated with Myrbetriq 50 mg, Myrbetriq 100 mg and active control once daily,
respectively. Neoplasms reported by 2 patients treated with Myrbetriq 100 mg included
breast cancer, lung neoplasm malignant and prostate cancer.
In a separate clinical study in Japan, a single case was reported as Stevens-Johnson
syndrome with increased serum ALT, AST and bilirubin in a patient taking Myrbetriq
100 mg as well as an herbal medication (Kyufu Gold).
Postmarketing Experience
Because these spontaneously reported events are from the worldwide postmarketing
experience, from a population of uncertain size, the frequency of events and the role of
mirabegron in their causation cannot be reliably determined.
The following events have been reported in association with mirabegron use in worldwide
postmarketing experience:
Urologic: urinary retention [see Warnings and Precautions (5.2)]
---------------------------------------DRUG INTERACTIONS--------------------------------------Drug interaction studies were conducted to investigate the effect of co-administered
drugs on the pharmacokinetics of mirabegron and the effect of mirabegron on the
pharmacokinetics of co-administered drugs (e.g., ketoconazole, rifampin, solifenacin,
tamsulosin, and oral contraceptives) [see Clinical Pharmacology (12.3)]. No dose
adjustment is recommended when these drugs are co-administered with mirabegron.
Although no dose adjustment is recommended with solifenacin or tamsulosin based on
the lack of pharmacokinetic interaction, Myrbetriq should be administered with caution
to patients taking antimuscarinic medications for the treatment of OAB and in patients
with clinically significant BOO because of the risk of urinary retention [see Warnings and
Precautions (5.2)].
The following are drug interactions for which monitoring is recommended:
Drugs Metabolized by CYP2D6
Since mirabegron is a moderate CYP2D6 inhibitor, the systemic exposure of drugs
metabolized by CYP2D6 enzyme such as metoprolol and desipramine is increased when
co-administered with mirabegron. Therefore, appropriate monitoring and dose adjustment
may be necessary when Myrbetriq is co-administered with these drugs, especially
with narrow therapeutic index CYP2D6 substrates, such as thioridazine, flecainide, and
propafenone [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].
Digoxin
When given in combination, mirabegron increased mean digoxin Cmax from 1.01 to 1.3 ng/mL
(29%) and AUC from 16.7 to 19.3 ng.h/mL (27%). Therefore, for patients who are initiating
a combination of mirabegron and digoxin, the lowest dose for digoxin should initially be
considered. Serum digoxin concentrations should be monitored and used for titration of the
digoxin dose to obtain the desired clinical effect [see Clinical Pharmacology (12.3)].
Warfarin
The mean Cmax of S- and R-warfarin was increased by approximately 4% and AUC by
approximately 9% when administered as a single dose of 25 mg after multiple doses of
100 mg mirabegron. Following a single dose administration of 25 mg warfarin, mirabegron
had no effect on the warfarin pharmacodynamic endpoints such as International Normalized
Ratio (INR) and prothrombin time. However, the effect of mirabegron on multiple doses of
warfarin and on warfarin pharmacodynamic end points such as INR and prothrombin time
has not been fully investigated [see Clinical Pharmacology (12.3)].
----------------------------------USE IN SPECIFIC POPULATIONS--------------------------------Pregnancy
Pregnancy Category C
There are no adequate and well-controlled studies using Myrbetriq in pregnant women.
Myrbetriq should be used during pregnancy only if the potential benefit to the patient
outweighs the risk to the patient and fetus. Women who become pregnant during Myrbetriq
treatment are encouraged to contact their physician.
Risk Summary
Based on animal data, mirabegron is predicted to have a low probability of increasing
the risk of adverse developmental outcomes above background risk. Reversible adverse
developmental findings consisting of delayed ossification and wavy ribs in rats and
decreased fetal body weights in rabbits occurred at exposures greater than or equal
to 22 and 14 times, respectively, the maximal recommended human dose (MRHD). At
maternally toxic exposures decreased fetal weights were observed in rats and rabbits, and
fetal death, dilated aorta, and cardiomegaly were reported in rabbits.
Nursing Mothers
It is not known whether Myrbetriq is excreted in human milk. Mirabegron was found in the
milk of rats at concentrations twice the maternal plasma level. Mirabegron was found in
the lungs, liver, and kidneys of nursing pups. No studies have been conducted to assess
the impact of Myrbetriq on milk production in humans, its presence in human breast milk,
or its effects on the breast-fed child. Because Myrbetriq is predicted to be excreted in
human milk and because of the potential for serious adverse reactions in nursing infants, a
decision should be made whether to discontinue nursing or to discontinue the drug, taking
into account the importance of the drug to the mother.
Pediatric Use
The safety and effectiveness of Myrbetriq in pediatric patients have not been established.
Geriatric Use
No dose adjustment is necessary for the elderly. The pharmacokinetics of Myrbetriq is
not significantly influenced by age [see Clinical Pharmacology (12.3)]. Of 5648 patients
who received Myrbetriq in the phase 2 and 3 studies, 2029 (35.9%) were 65 years of age
or older, and 557 (9.9%) were 75 years of age or older. No overall differences in safety
or effectiveness were observed between patients younger than 65 years of age and those
65 years of age or older in these studies.
Renal Impairment
Myrbetriq has not been studied in patients with end stage renal disease (CLcr <15 mL/min
or eGFR <15 mL/min/1.73 m2 or patients requiring hemodialysis), and, therefore is not
recommended for use in these patient populations.
In patients with severe renal impairment (CLcr 15 to 29 mL/min or eGFR 15 to
29 mL/min/1.73 m2), the daily dose of Myrbetriq should not exceed 25 mg. No dose
adjustment is necessary in patients with mild or moderate renal impairment (CLcr 30 to
89 mL/min or eGFR 30 to 89 mL/min/1.73 m2) [see Clinical Pharmacology (12.3)].
Hepatic Impairment
Myrbetriq has not been studied in patients with severe hepatic impairment (Child-Pugh
Class C), and therefore is not recommended for use in this patient population.
In patients with moderate hepatic impairment (Child-Pugh Class B), the daily dose of
Myrbetriq should not exceed 25 mg. No dose adjustment is necessary in patients with
mild hepatic impairment (Child-Pugh Class A) [see Clinical Pharmacology (12.3)].
Gender
No dose adjustment is necessary based on gender. When corrected for differences
in body weight, the Myrbetriq systemic exposure is 20% to 30% higher in females
compared to males.
--------------------------------------------OVERDOSAGE-------------------------------------------Mirabegron has been administered to healthy volunteers at single doses up to 400 mg. At
this dose, adverse events reported included palpitations (1 of 6 subjects) and increased pulse
rate exceeding 100 bpm (3 of 6 subjects). Multiple doses of mirabegron up to 300 mg daily
for 10 days showed increases in pulse rate and systolic blood pressure when administered
to healthy volunteers. Treatment for overdosage should be symptomatic and supportive. In
the event of overdosage, pulse rate, blood pressure and ECG monitoring is recommended.
------------------------------------CLINICAL PHARMACOLOGY----------------------------------Pharmacodynamics
Urodynamics
The effects of Myrbetriq on maximum urinary flow rate and detrusor pressure at maximum
flow rate were assessed in a urodynamic study consisting of 200 male patients with lower
urinary tract symptoms (LUTS) and BOO. Administration of Myrbetriq once daily for
12 weeks did not adversely affect the mean maximum flow rate or mean detrusor pressure
at maximum flow rate in this study. Nonetheless, Myrbetriq should be administered with
caution to patients with clinically significant BOO [see Warnings and Precautions (5.2)].
Cardiac Electrophysiology
The effect of multiple doses of Myrbetriq 50 mg, 100 mg and 200 mg once daily on QTc
interval was evaluated in a randomized, placebo- and active- controlled (moxifloxacin
400 mg) four-treatment-arm parallel crossover study in 352 healthy subjects. In a study
with demonstrated ability to detect small effects, the upper bound of the one-sided
95% confidence interval for the largest placebo adjusted, baseline-corrected QTc based
on individual correction method (QTcI) was below 10 msec. For the 50 mg Myrbetriq
dose group (the maximum approved dosage), the mean difference from placebo on QTcI
interval at 4-5 hours post-dose was 3.7 msec (upper bound of the 95% CI 5.1 msec).
For the Myrbetriq 100 mg and 200 mg doses groups (dosages greater than the maximum
approved dose and resulting in substantial multiples of the anticipated maximum blood
levels at 50 mg), the mean differences from placebo in QTcI interval at 4-5 hours post-dose
were 6.1 msec (upper bound of the 95% CI 7.6 msec) and 8.1 msec (upper bound of the
95% CI 9.8 msec), respectively. At the Myrbetriq 200 mg dose, in females, the mean effect
was 10.4 msec (upper bound of the 95% CI 13.4 msec).
In this thorough QT study, Myrbetriq increased heart rate on ECG in a dose dependent
manner. Maximum mean increases from baseline in heart rate for the 50 mg, 100 mg, and
200 mg dose groups compared to placebo were 6.7 beats per minutes (bpm), 11 bpm, and
17 bpm, respectively. In the clinical efficacy and safety studies, the change from baseline
in mean pulse rate for Myrbetriq 50 mg was approximately 1 bpm. In this thorough
QT study, Myrbetriq also increased blood pressure in a dose dependent manner (see
Effects on Blood Pressure).
Effects on Blood Pressure
In a study of 352 healthy subjects assessing the effect of multiple daily doses of 50 mg,
100 mg, and 200 mg of Myrbetriq for 10 days on the QTc interval, the maximum
mean increase in supine SBP/DBP at the maximum recommended dose of 50 mg was
approximately 4.0/1.6 mmHg greater than placebo. The 24-hour average increases in SBP
compared to placebo were 3.0, 5.5, and 9.7 mmHg at Myrbetriq doses of 50 mg, 100 mg
and 200 mg, respectively. Increases in DBP were also dose-dependent, but were smaller
than SBP.
In another study in 96 healthy subjects to assess the impact of age on pharmacokinetics
of multiple daily doses of 50 mg, 100 mg, 200 mg, and 300 mg of Myrbetriq for 10 days,
SBP also increased in a dose-dependent manner. The mean maximum increases in SBP
were approximately 2.5, 4.5, 5.5 and 6.5 mmHg for Myrbetriq exposures associated with
doses of 50 mg, 100 mg, 200 mg and 300 mg, respectively.
In three, 12-week, double-blind, placebo-controlled, safety and efficacy studies (Studies
1, 2 and 3) in OAB patients receiving Myrbetriq 25 mg, 50 mg, or 100 mg once daily,
mean increases in SBP/DBP compared to placebo of approximately 0.5 - 1 mmHg were
observed. Morning SBP increased by at least 15 mmHg from baseline in 5.3%, 5.1%, and
6.7% of placebo, Myrbetriq 25 mg and Myrbetriq 50 mg patients, respectively. Morning
DBP increased by at least 10 mmHg in 4.6%, 4.1% and 6.6% of placebo, Myrbetriq 25 mg,
and Myrbetriq 50 mg patients, respectively. Both SBP and DBP increases were reversible
upon discontinuation of treatment.
------------------------------------NONCLINICAL TOXICOLOGY----------------------------------Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity
Long-term carcinogenicity studies were conducted in rats and mice dosed orally with
mirabegron for two years. Male rats were dosed at 0, 12.5, 25, or 50 mg/kg/day and
female rats and both sexes of mice were dosed at 0, 25, 50, or 100 mg/kg/day. Mirabegron
showed no carcinogenic potential at systemic exposures (AUC) 38 to 45-fold higher in rats
and 21 to 38-fold higher in mice than the human systemic exposure at the 50 mg dose.
Mutagenesis
Mirabegron was not mutagenic in the Ames bacterial reverse mutation assay, did not induce
chromosomal aberrations in human peripheral blood lymphocytes at concentrations that
were not cytotoxic, and was not clastogenic in the rat micronucleus assay.
Impairment of Fertility
Fertility studies in rats showed that mirabegron had no effect on either male or female
fertility at non-lethal doses up to 100 mg/kg/day. Systemic exposures (AUC) at
100 mg/kg in female rats was estimated to be 22 times the MRHD in women and
93 times the MRHD in men.
PATIENT COUNSELING INFORMATION
Inform patients that Myrbetriq may increase blood pressure. Periodic blood pressure
determinations are recommended, especially in patients with hypertension. Myrbetriq has
also been associated with infrequent urinary tract infections, rapid heartbeat, rash, and
pruritus. Inform patients that urinary retention has been reported when taking mirabegron in
combination with antimuscarinic drugs used in the treatment of overactive bladder. Instruct
patients to contact their physician if they experience these effects while taking Myrbetriq.
Patients should read the patient leaflet entitled “Patient Information” before starting
therapy with Myrbetriq.
Rx Only
PRODUCT OF JAPAN OR IRELAND – See bottle label or blister package for origin
Manufactured by:
Astellas Pharma Technologies, Inc.
Norman, Oklahoma 73072
Marketed and Distributed by:
Astellas Pharma US, Inc.
Northbrook, Illinois 60062
*Myrbetriq® is a registered trademark of Astellas Pharma Inc. All other trademarks or
registered trademarks are the property of their respective owners.
© 2012 Astellas Pharma US, Inc.
Revised: February 2014
13C011-MIR-BRFS
057-0463-PM
NOTES
COURSES
Table of Contents
Board of Directors .................................................................................................................................................................. 3
Committees ............................................................................................................................................................................. 4
Sunday
Plenary Sessions I and II ............................................................................................................................................... 117
Society of Women in Urology (SWIU) Annual Breakfast Meeting .................................................................. 119
Poster, Podium and Video Sessions ......................................................................................................................... 120
Urologic Care for the Allied Health Professional ................................................................................................. 135
1
SATURDAY
SUNDAY
MONDAY
Saturday
Sexual Medicine Society of North America ............................................................................................................ 55
Engineering and Urology Society ............................................................................................................................... 56
Residents Forum ............................................................................................................................................................... 57
Live Surgery I ..................................................................................................................................................................... 58
Arab Association of Urology ........................................................................................................................................ 58
Society for Pediatric Urology ....................................................................................................................................... 59
Poster and Podium Sessions ......................................................................................................................................... 59
Society for Basic Urologic Research/Society of Urologic Oncology Joint Session ..................................... 70
World Chinese Urological Society .............................................................................................................................. 70
Indian American Urological Association .................................................................................................................. 71
AUA/Confederación Americana de Urologı́a ....................................................................................................... 72
AUA/American College of Osteopathic Surgeons Urology Program ............................................................. 72
Science of Female Pelvic Health ............................................................................................................................... 73
Poster and Podium Sessions ......................................................................................................................................... 73
Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction ................................... 84
Society of Urologic Oncology ..................................................................................................................................... 84
Bangladesh Association of Urological Surgeons ................................................................................................... 85
Poster, Podium and Video Sessions ........................................................................................................................... 86
Society for Basic Urologic Research .......................................................................................................................... 99
Second Opinion Cases ................................................................................................................................................ 100
Urology Care by the APN/PA .................................................................................................................................... 100
Innovations in Urology: AUA and the Endourological Society ....................................................................... 100
AUA-Eurasian Urology Platform ................................................................................................................................. 101
Joint Program of the Hungarian and Polish Urological Associations ............................................................ 101
TUESDAY
Friday
Society for Pediatric Urology ....................................................................................................................................... 17
Basic Sciences Symposium ........................................................................................................................................... 17
Society of University Urologists/Society of Urology Chairpersons and Program Directors ........................ 18
Urologic Oncology Research Symposium ............................................................................................................... 19
Society of Genitourinary Reconstructive Surgeons/Society of Urologic Prosthetic Surgeons ................. 20
A Decade of Pharmacotherapy for OAB ............................................................................................................... 21
Society for Fetal Urology ............................................................................................................................................... 31
Crossfire - Controversies in Urology ............................................................................................................................ 44
EXHIBITORS
Office of Education Courses .............................................................................................................................................. 9
INDEXES
Specialty Programs ............................................................................................................................................................... 8
FRIDAY
CME Information .................................................................................................................................................................... 6
Urologic Oncology Forum .......................................................................................................................................... 136
International Prostate Forum ..................................................................................................................................... 136
Society for the Study of Male Reproduction ........................................................................................................ 153
Society of Urologic Robotic Surgery ....................................................................................................................... 153
AUA/AACU Health Policy Forum .............................................................................................................................. 154
Research Forum Sessions I and II .............................................................................................................................. 169
Society for Infection and Inflammation in Urology ............................................................................................. 169
Live Surgery II .................................................................................................................................................................. 170
History Forums I and II .................................................................................................................................................. 170
Korean World Urologic Congress ............................................................................................................................. 172
Geriatric Urological Society ....................................................................................................................................... 173
British Association of Urological Surgeons/Urological Society of Australia and New Zealand ............. 173
Japanese Urological Association ............................................................................................................................. 173
AUA/FDA/SUO Workshop ............................................................................................................................................ 174
Urological Congenitalism Forum .............................................................................................................................. 175
R. Frank Jones Urological Society ............................................................................................................................ 175
Sociedad Argentina de Urologı́a ............................................................................................................................. 176
Association Française d’Urologie ............................................................................................................................. 176
Monday
Young Urologists Forum ............................................................................................................................................... 219
Research on Calculus Kinetics (ROCK) Society ................................................................................................... 219
AUA/Brazilian/Portuguese Urology Program ......................................................................................................... 220
Russian Urology Program ............................................................................................................................................ 221
AUA Town Hall: Testosterone: Too Much or Not Enough? ............................................................................... 221
Egyptian Urological Society ....................................................................................................................................... 234
Urologic Society for Transplantation and Renal Surgery .................................................................................. 234
American Society for Men’s Health ........................................................................................................................ 234
Pan African Urological Surgeons Association/Caribbean Urological Association ................................... 235
Società Italiana di Urologia/AUA Joint Meeting ................................................................................................. 236
Endocrine Forum ........................................................................................................................................................... 236
Large Urology Group Practice Association .......................................................................................................... 237
SWIU Women Leaders in Urology Forum ................................................................................................................ 251
AQUA Registry Forum ................................................................................................................................................... 251
Tuesday
Poster and Podium Sessions ....................................................................................................................................... 255
Exhibitor Listing ................................................................................................................................................................... 283
Author Index ....................................................................................................................................................................... 285
Subject Index ...................................................................................................................................................................... 346
2
2014-2015 Board of Directors
Officers of the Board of Directors
President .......................................................................................................................................William W. Bohnert
President-Elect.....................................................................................................................................William F. Gee
Immediate Past President...........................................................................................................Pramod C. Sogani
Secretary.........................................................................................................................................Gopal H. Badlani
Treasurer .................................................................................................................................Steven M. Schlossberg
Section Representatives to the Board of Directors
Mid-Atlantic ........................................................................................................................................Craig A. Peters
New England ..................................................................................................................................Kevin R. Loughlin
New York ........................................................................................................................Muhammad S. Choudhury
North Central .............................................................................................................................Stephen Y. Nakada
Northeastern...................................................................................................................................John D. Denstedt
South Central ..........................................................................................................................Randall B. Meacham
Southeastern .................................................................................................................................Thomas F. Stringer
Western.........................................................................................................................................Jeffrey E. Kaufman
AUA Headquarters
American Urological Association, Inc.
1000 Corporate Boulevard
Linthicum, Maryland 21090
Telephone: 410-689-3700
FAX: 410-689-3800
E-mail: aua@auanet.org
Website: www.auanet.org
Annual Business Meeting
New Orleans Morial Convention Center
Room 214
Tuesday, May 19, 2015 @ 12:30 pm
3
2014-2015 Committees
Program Planning Committee
Keith A. Jarvi
Mark J. Jordan
Anil Kapoor
Edward D. Kim
David J. Klumpp
Kathleen C. Kobashi
Barry A. Kogan
Peter N. Kolettis
Badrinath R. Konety
John C. Lieske
Armando J. Lorenzo
Jill A. Macoska
Andrew E. MacNeily
Thomas P. McBride
Elspeth McDougall
Kurt A. McCammon
Stephen Y. Nakada
R. Corey O’Connor
Lane S. Palmer
Michel A. Pontari
Christopher R. Porter
Gail S. Prins
Daniel I. Rosenstein
Hossein Sadeghi-Nejad
Jennifer S. Singer
Eila D. Skinner
J. Brantley Thrasher
Dean A. Tripp
Johannes W. G. Vieweg
Elaine Worcester
Elizabeth Yerkes
Gopal H. Badlani, Chair
Jeff Albaugh
Dean G. Assimos
Gregory T. Bales
John M. Barry
Carolyn Best
Arthur L. Burnett, II
Jeffrey B. Campbell
Douglas A. Canning
Culley C. Carson, III
Patrick C. Cartwright
Erik P. Castle
Gaetano Ciancio
Peter E. Clark
J. Quentin Clemens
Rodney D. Cotten
Ashleigh Decker
Ross M. Decter
Ananias C. Diokno
Sean P. Elliott
Christopher P. Evans
Gina Fries
Pat F. Fulgham
David A. Ginsberg
David S. Goldfarb
Leonard G. Gomella
Tomas L. Griebling
Frederick A. Gulmi
Lawrence S. Hakim
Jeffrey M. Holzbeierlein
David F. Jarrard
Program Video Review Committee
Altan K. Ilkay
Richard K. Lee
Jay D. Raman
Jaspreet S. Sandhu
Alexis E. Te
Jay T. Bishoff
Toby C. Chai
Joseph J. Del Pizzo
Matthew T. Gettman
Mohan Gundeti
Misop Han
Program Abstract Review Committee
Tamer Abou Youssif
Rolf Ackermann
Rosalyn M. Adam
Kourosh Afshar
Madhusudan Agarwal
Thomas E. Ahlering
Karl-Erik Andersson
Gerald L. Andriole
Kenneth W. Angermeier
Noel A. Armenakas
William J. Aronson
Dean G. Assimos
Anthony Atala
J. Chris Austin
Paul F. Austin
Riccardo Autorino
Gopal H. Badlani
K.C. Balaji
Chris Bangma
Daniel A. Barocas
Arie S. Belldegrun
Sam S. Chang
Ben Chew
Joseph Chin
George J. Christ
Peter E. Clark
J. Quentin Clemens
Michael Coburn
Craig V. Comiter
Michael Cookson
Christopher S. Cooper
Hillary L. Copp
Nicholas G. Cost
Anthony D’Amico
Rajvir Dahiya
Douglas Dahl
Philipp Dahm
Guido Dalbagni
Firouz Daneshgari
Sakti Das
John W. Davis
Donna Deng
Enrique G. Bellver
Nelson Bennett
Ryan K. Berglund
Trinity Bivalacqua
Jerry G. Blaivas
Stephane Bolduc
Stephen A. Boorjian
James F. Borin
Robert Brannigan
Peter N. Bretan
Benjamin Breyer
Arthur L. Burnett, II
Ralph Buttyan
Jeffrey A. Cadeddu
Daniel J. Canter
Culley C. Carson, III
H. Ballantine Carter
William J. Catalona
Toby Chai
David Chan
Michael Chancellor
4
Louis J. Denis
John D. Denstedt
Mahesh Desai
Mihir M. Desai
Serkan Deveci
Jordan Dimitrakov
Colin P.N. Dinney
Michael E. DiSanto
S. Machele Donat
Marcus Drake
James A. Eastham
Scott E. Eggener
Mostafa M. Elhilali
Sean P. Elliott
Rainer M.E. Engel
Erdal Erturk
Gregg R. Eure
Christopher P. Evans
Amr F. Fergany
Fernando Ferrer
Robert C. Flanigan
Neil E. Fleshner
Richard S. Foster
Matthew O. Fraser
Patricio Gargollo
Mark Garzotto
Jason R. Gee
Matthew Gettman
Robert H. Getzenberg
Reza Ghavamian
Inderbir Gill
Peter J. Gilling
Jeffrey R. Gingrich
Jordan Gitlin
Martin E. Gleave
David A. Goldfarb
Marc Goldstein
Leonard G. Gomella
Alex Gomelsky
Ricardo R. Gonzalez
Mark L. Gonzalgo
E. Ann Gormley
Michael Grasso
Tomas L. Griebling
Andreas Gross
Mohan S. Gundeti
Khurshid A. Guru
Jorge Gutierrez Aceves
Thomas J. Guzzo
Gabriel Haas
Oliver W. Hakenberg
Lawrence S. Hakim
Joanna Hannan
Kazunori Hattori
Richard E. Hautmann
Wayne J. G. Hellstrom
Ashok K. Hemal
Gerard D. Henry
Adonis K. Hijaz
Nicholas M. Holmes
Jeffrey M. Holzbeierlein
Michael H. Hsieh
William C. Huang
Robert E. Hurst
David F. Jarrard
Keith Jarvi
Rama Jayanthi
Ted Johnson
J. Stephen Jones
Steven Joniau
Mark L. Jordan
Jean Joseph
Dov Kadmon
Martin Kaefer
Ashish M. Kamat
Jihad H. Kaouk
Steven A. Kaplan
Ronald Kaufman
Louis R. Kavoussi
Francis X. Keeley
Saeed R. Khan
Allen F. Morey
Elizabeth R. Mueller
John P. Mulhall
Ravi Munver
Stephen Y. Nakada
Ajay Nangia
Durwood E. Neal
Ajay Nehra
Caleb P. Nelson
Joel B. Nelson
Casey Ng
J. Curtis Nickel
Alan M. Nieder
Craig S. Niederberger
Victor W. Nitti
Robert Oates
Takehiko Ogawa
Zhamshid H. Okhunov
Kenneth Pace
Lane S. Palmer
Allan J. Pantuck
Dipen Parekh
Alan W. Partin
Anup Patel
Sutchin Patel
John G. Pattaras
Margaret Pearle
David F. Penson
Drew Peterson
Daniel P. Petrylak
Michael Phelan
John L. Phillips
Peter A. Pinto
Louis Pisters
Carol Podlasek
Michel Pontari
Christopher R. Porter
Michael P. Porter
Glenn M. Preminger
Joseph C. Presti
Raj S. Pruthi
Marcus L. Quek
Ranjith Ramasamy
Abhay M. Rane
Ardeshir Rastinehad
Ashish V. Rawandale
Leonardo O. Reis
Jerome P. Richie
Claus G. Roehrborn
Nirit Rosenblum
Eric S. Rovner
Michael Ruggieri
Daniel B. Rukstalis
Paul Russo
Fred Saad
Arthur Sagalowsky
Martin G. Sanda
Jaspreet Singh Sandhu
Makarand K. Khochikar
Antoine E. Khoury
Adam S. Kibel
Kathleen Kobashi
Michael Koch
Thomas F. Kolon
Badrinath R. Konety
John N. Krieger
John Kryger
Sanjay B. Kulkarni
Natasha Kyprianou
M. Pilar Laguna
Dolores Lamb
Jaime Landman
Paul H. Lange
Jerilyn M. Latini
Cheryl T. Lee
Chung Lee
Bradley C. Leibovich
Gary E. Lemack
Michael P. Leonard
Herb Lepor
Lori Lerner
Seth Lerner
John A. Libertino
Deborah J. Lightner
Hans Lilja
Daniel W. Lin
W. Marston Linehan
James E. Lingeman
Larry I. Lipshultz
Mark S. Litwin
Vinata Lokeshwar
Armando Lorenzo
Yair Lotan
Kevin Loughlin
Franklin C. Lowe
William T. Lowrance
Tom F. Lue
Dawn L. MacLellan
Danil V. Makarov
Stanley B. Malkowicz
Jodi K. Maranchie
Viraj Master
Brian R. Matlaga
Tadashi Matsuda
Christopher McClung
Patrick McKenna
Kevin T. McVary
Mani M. Menon
Edward Messing
Peter D. Metcalfe
David C. Miller
Martin Miner
Rosalia Misseri
James L. Mohler
Robert Moldwin
Manoj Monga
Drogo K. Montague
Michael Moran
5
Jay Sandlow
Richard Santucci
Michael Sarosdy
Harriette M. Scarpero
Anthony J. Schaeffer
Douglas S. Scherr
Peter N. Schlegel
Mark P. Schoenberg
Bradley F. Schwartz
Allen D. Seftel
John Seigne
Jay Shah
Ojas Shah
Arieh Shalhav
Joel Sheinfeld
Patrick J. Shenot
Alan W. Shindel
Neal Shore
Daniel A. Shoskes
Mark Sigman
Robert A. Sikes
Matthew N. Simmons
Ajay Singla
Joseph A. Smith
Mark S. Soloway
Rene Sotelo
Philippe E. Spiess
John P. Spirnak
Gary Steinberg
Arnulf Stenzl
M. Lynn Stothers
Seth A. Strope
Urs E. Studer
Chandru P. Sundaram
Douglas Sutherland
Robert M. Sweet
Scott Tagawa
Samir S. Taneja
Simon Tanguay
Alexis E. Te
Serdar Tekgul
Ryan P. Terlecki
John C. Thomas
Edouard J. Trabulsi
Quoc-Dien Trinh
Thomas Turk
Robert Uzzo
Sandip P. Vasavada
Vijaya Vemulakonda
Run Wang
Wolfgang Weidner
Alan J. Wein
Robert M. Weiss
Howard N. Winfield
J. Stuart Wolf, Jr.
Christopher G. Wood
Guan Wu
Armand Zini
Kevin Zorn
CME Information
Urologists need a thorough knowledge of the most
recent developments and techniques in urology to ensure the highest standards of patient care and safety.
commencement of the educational activity. The intent
of this disclosure is not to prevent individuals with relevant financial relationships from participating, but
rather to provide learners with information so they can
make their own judgments.
Learning Objectives
Resolution of Conflict of Interest
At the conclusion of the 2015 Annual Meeting, participants should be able to:
● describe recent developments in the medical and
surgical management of urology patients
● identify new technologies for the treatment of urologic problems
● outline the role of simulators in urologic training
● analyze the potential threats to urologic practice
and specify possible solutions
All disclosures will be reviewed by the program/
course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the
mechanism(s) for management and resolution of the
conflict of interest and final approval of the activity
will be documented prior to implementation. Any of
the mechanisms below can/will be used to resolve
conflict of interest:
● Peer review for valid, evidence-based content of all
materials associated with an educational activity by
the course/program director and/or Education
Content Review Committee or its subgroup
● Limit content to evidence with no recommendations
● Introduction of a debate format with an unbiased
moderator (point-counterpoint)
● Inclusion of moderated panel discussion
● Publication of a parallel or rebuttal article for an
article that is felt to be biased
● Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
● Divestiture of the relationship by faculty
Statement of Need
Accreditation Statement
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical
education for physicians.
Credit Designation
The American Urological Association designates this live
activity for a maximum of 65.0 AMA PRA Category 1
Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the
activity.
Off-label or Unapproved Use of Drugs or
Devices
Non-physician Health Professionals
The AUA is not accredited to offer credit for nonphysician health professionals. However, the AUA will
issue documentation of participation that states that
the activity was certified for AMA PRA Category 1
Credit™.
It is the policy of the AUA to require the disclosure of all
references to off-label or unapproved uses of drugs or
devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to
off-label or unapproved uses of drugs or devices.
Please consult the prescribing information for full disclosure of approved uses.
Evidence-Based Content
It is the policy of the AUA to ensure that the content
contained in this CME activity is valid, fair, balanced,
scientifically rigorous, and free of commercial bias.
Disclaimer
The opinions and recommendations expressed by faculty, authors, and other experts whose input is included
in this program are their own and do not necessarily
represent the viewpoint of the AUA.
AUA Disclosure Policy
All persons in a position to control the content of an
educational activity (i.e., activity planners, presenters,
authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the
individual’s relationships may influence the educational
content and resolve any conflicts of interest prior to the
Consent to Use of Photographic Images: Attendance at
or participation in AUA meetings and other activities
constitutes an agreement by the registrant to AUA’s use
and distribution (both now and in the future) of the
attendee’s image or voice in photographs and electronic reproductions of such meetings and activities.
6
CME Information
●
Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by
attendees is prohibited inside AUA meeting rooms.
Onsite: Hall B2, CME Booth in Registration
Saturday, Noon – 6 p.m.
Sunday & Monday, 6:30 a.m. – 4 p.m.
Tuesday, 6:30 a.m. – 5 p.m.
● Online: www.AUA2015.org
● Mobile App (iPhone®, iPad®, Android™ phones and
tablets)
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and
the American Urological Association.
Note: All 2015 Annual Meeting CME credits/participation must be claimed by December 31, 2015. Credits/
participation for the 2015 Annual Meeting cannot be
claimed after this date. You must scan your badge
upon entrance into courses and sessions (except for
Plenary) offered for credit to have your credits automatically entered onto your transcript. All Plenary Session credits must be self-claimed with a valid badge
log-in at the CME Booth, online, or via the Annual
Meeting Mobile App. Credits will be awarded only to
the person whose name is associated with the badge.
Special Assistance/Dietary Needs: The American Urological Association complies with the Americans with
Disabilities Act §12112(a). If any participant is in need of
special assistance or has any dietary restrictions, please
see the registration desk.
Getting Your CME Credits or Certificate of
Attendance
You can claim your CME/Certificate of Attendance
several ways:
Questions about CME? Email CME@AUAnet.org.
7
Specialty Programs
Page
American Society for Men’s Health ............................................................................................................................ 234
Arab Association of Urology ............................................................................................................................................ 58
Association Française d’Urologie ................................................................................................................................. 176
AUA/American College of Osteopathic Surgeons ................................................................................................... 72
AUA/Brazilian/Portuguese Urology Program ............................................................................................................. 220
AUA/Confederación Americana de Urologı́a ........................................................................................................... 72
AUA-Eurasian Urology Platform ..................................................................................................................................... 101
Bangladesh Association of Urological Surgeons ....................................................................................................... 85
British Association of Urological Surgeons/Urological Society of Australia and New Zealand ................. 173
Egyptian Urological Society ........................................................................................................................................... 234
Engineering and Urology Society ................................................................................................................................... 56
Geriatric Urological Society ........................................................................................................................................... 173
Indian American Urological Association ...................................................................................................................... 71
Innovations in Urology: AUA and the Endourological Society ........................................................................... 100
Japanese Urological Association ................................................................................................................................. 173
Joint Program of the Hungarian and Polish Urological Associations ................................................................ 101
Korean World Urologic Congress ................................................................................................................................. 172
Large Urology Group Practice Association .............................................................................................................. 237
Pan African Urological Surgeons Association/Caribbean Urological Association ....................................... 235
R. Frank Jones Urological Society ................................................................................................................................ 175
Research on Calculus Kinetics (ROCK) Society ....................................................................................................... 219
Russian Urology Program ................................................................................................................................................ 221
Sexual Medicine Society of North America ................................................................................................................ 55
Sociedad Argentina de Urologı́a ................................................................................................................................. 176
Società Italiana di Urologia ........................................................................................................................................... 236
Society for Basic Urologic Research .............................................................................................................................. 99
Society for Basic Urologic Research/Society of Urologic Oncology ................................................................... 70
Society for Fetal Urology ................................................................................................................................................... 31
Society for Infection and Inflammation in Urology ................................................................................................. 169
Society for Pediatric Urology .................................................................................................................................... 17, 59
Society for the Study of Male Reproduction ............................................................................................................ 153
Society of Genitourinary Reconstructive Surgeons/Society of Urologic Prosthetic Surgeons ..................... 20
Society of University Urologists/Society of Urology Chairpersons and Program Directors ............................ 18
Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction ....................................... 84
Society of Urologic Oncology ......................................................................................................................................... 84
Society of Urologic Robotic Surgery ........................................................................................................................... 153
Society of Women in Urology ........................................................................................................................................ 251
Urologic Society for Transplantation and Renal Surgery ...................................................................................... 234
World Chinese Urological Society .................................................................................................................................. 70
8
Friday, May 15, 2015
8:30 am - 6:30 pm
8:30 am - 11:30 am
01 PG
02 PG
03 PG
04 PG
05 PG
DISORDERS OF THE PENIS: PEYRONIE’S
DISEASE, PRIAPISM, CONGENITAL
CURVATURE, ADULT ACQUIRED BURIED
PENIS AND CORPORAL FRACTURE
Laurence Levine, Director
David Ralph, Gregory Broderick
Room: RO-2-3
REOPERATIVE PELVIC FLOOR MEDICINE: FOR
THE UROLOGIST AND GYNECOLOGIST
Howard Goldman, Director
Mickey Karram, Kamran Sajadi
Room: RO-5
ROBOT-ASSISTED RADICAL PROSTATECTOMY:
BEYOND THE LEARNING CURVE
John Davis, Director
Koon Rha, Fatih Atug, Declan Murphy, Kevin Zorn
Room: RO-6-7
MANAGEMENT OF URETERAL STRICTURE
DISEASE
Louis Kavoussi, Director
Richard Link, Thomas Jarrett, Sammy Elsamra
Room: RO-8
MANAGEMENT OF PROSTATE CANCER: A
CASE BASED APPROACH WITH EMPHASIS ON
INTEGRATING NEW MOLECULAR
DIAGNOSTICS INTO CLINICAL PRACTICE
Eric Klein, Director
Andrew Stephenson
Room: RO-9
07 IC
ESTABLISHING AN ADVANCED PROSTATE
CANCER CLINIC: A GUIDE FOR THE
COMMUNITY UROLOGIST
Basir Tareen, Director
Raoul Concepcion, Gregory Hanson
Room: RO-2-3
08 IC
EVALUATION AND MANAGEMENT OF
UROGENITAL PAIN
Michael Sabia, Director
Hossein Sadeghi-Nejad, Allen Seftel
Room: RO-4
09 IC
PROSTATE CANCER DIAGNOSTICS: PSA,
PROSTATE BIOPSY AND BEYOND
J. Stephen Jones, Director
Daniel Barocas
Room: RO-5
10 IC
TESTOSTERONE THERAPY: NEW CONCEPTS
FOR A RAPIDLY CHANGING FIELD
Abraham Morgentaler, Director
Abdul Traish
Room: RO-6-7
11 IC
GUIDELINES BASED EVALUATION AND
TREATMENT OF MLUTS AND BPH
Steven Kaplan, Director
Claus Roehrborn, Alexis Te
Room: RO-8
12 IC
NOCTURIA: ADVANCES IN DIAGNOSIS AND
MANAGEMENT
Jeffrey Weiss, Director
Room: RO-9
1:00 pm - 3:00 pm
3:30 pm - 6:30 pm
06 IC
51 PG
PRACTICAL CONSIDERATIONS IN
GENITOURINARY PROSTHETIC SURGERY
Drogo Montague, Director
Room: RO-1
ENDOUROLOGÍA AVANZADA - MANEJO DE
CIRUGIA RENAL PERCUTEA Y CIRUGIA
INTRARRENAL RETROGRADA COMPLEJA (ESTE
CURSO SE PRESENTA SÓLO EN ESPAÑOL)
Jorge Gutierrez-Aceves, Director
Jose Amon-Sesmero, Francisco Daels
Room: RO-4
Saturday, May 16, 2015
8:30 am - 6:30 pm
16 PG
8:30 am - 11:30 am
13 PG
NERVE SPARING RADICAL CYSTECTOMY
AND ORTHOTOPIC BLADDER SUBSTITUTION:
KEYS TO SUCCESS AND UPDATES
Urs Studer, Director
Room: RO-2-3
14 PG
SURGEONS AS EDUCATORS: A PRIMER FOR
ACADEMIC DEVELOPMENT AND TEACHING
EXCELLENCE
Tobias Kohler, Director
Bradley Schwartz, Kurt McCammon, Patrick
McKenna
Room: RO-4
15 PG
COMPLICATIONS OF ROBOTIC UROLOGICAL
SURGERY: PREVENTION, RECOGNITION AND
MANAGEMENT
Rene Sotelo, Director
Reza Ghavamian, Joseph Smith, Monish Aron
Room: RO-8
1:00 pm - 3:00 pm
VASECTOMY REVERSAL AND MALE
INFERTILITY TREATMENT IN THE ICSI ERA
Peter Schlegel, Director
Robert Oates, Sheldon Marks
Room: RO-5
9
18 IC
NUTRITION COUNSELING FOR THE
PREVENTION OF UROLITHIASIS
Patrick Lowry, Director
Kristina Penniston, Sutchin Patel
Room: RO-2-3
19 IC
LAPAROSCOPIC DONOR NEPHRECTOMY:
STEP-BY-STEP APPROACH
Mahesh Desai, Director
Arvind Ganpule
Room: RO-4
COURSES
OFFICE OF EDUCATION COURSES
ALL COURSES ARE APPROVED FOR AMA PRA CATEGORY 1 CREDITTM
20 IC
21 IC
BOTULINUM TOXIN: WHY USE IT, HOW TO DO
IT, WHAT ARE THE RESULTS?
Michael Chancellor, Director
Room: RO-6-7
22 IC
UROLOGY 911: HANDLING INTRAOPERATIVE
CONSULTS
Michael Schwartz, Director
Brian Duty, Jessica Kreshover
Room: RO-8
23 IC
3:30 pm - 6:30 pm
SUCCESSFUL INTEGRATION OF ADVANCED
PRACTICE NURSES AND PHYSICIAN
ASSISTANTS INTO UROLOGY PRACTICES
Claus Roehrborn, Director
Brad Hornberger
Room: RO-5
PHYSICIAN CONTRACT NEGOTIATION:
EMPLOYMENT AND OWNERSHIP IN THE
CURRENT ECONOMIC CLIMATE
Thomas Stringer, Director
Thomas Crawford, Michael Igel
Room: RO-9
24 PG
REAL MEN GET REAL PELVIC PAIN
Jeannette Potts, Director
Stanley Antolak, Dean Tripp, Christopher Payne,
Rhonda Kotarinos
Room: RO-2-3
25 PG
MALE HEALTH: STRATEGIES FOR MANAGING
LIFELONG WELLNESS
Richard Pelman, Director
Mark Moyad, Kevin Loughlin, S. Larry Goldenberg,
Stacy Loeb, Martin Miner
Room: RO-4
26 PG
RESIDENT PERFORMED ULTRASOUND: THE
ESSENTIALS
Bruce Gilbert, Director
R. Ernest Sosa, Frederick Gulmi, Pat F. Fulgham
Room: RO-5
27 PG
UROLOGICAL TRAUMA AND
RECONSTRUCTION
Allen Morey, Director
Michael Coburn, Noel Armenakas
Room: RO-6-7
28 PG
VASECTOMY: A VERY PRACTICAL COURSE
ON PREOPERATIVE, INTRAOPERATIVE AND
POSTOPERATIVE MANAGEMENT
Ira Sharlip, Director
Joel Marmar, Stanton Honig, Jay Sandlow
Room: RO-9
Sunday, May 17, 2015
6:00 am - 6:30 pm
34 IC
6:00 am - 8:00 am
29 IC
MANAGEMENT OF LOCALLY ADVANCED AND
METASTATIC RENAL CELL CARCINOMA: A
CASE BASED APPROACH
Christopher Wood, Director
E. Jason Abel, Vitaly Margulis
Room: RO-2-3
ROBOTIC RADICAL CYSTECTOMY: GETTING
STARTED AND TIPS AND TRICKS FROM THE
EXPERTS
Michael Woods, Director
Erik Castle, Angela Smith
Room: RO-9
8:30 am - 11:30 am
30 IC
NEW TECHNIQUES IN BPH SURGERY:
ENDOSCOPIC ENUCLEATION
Peter Gilling, Director
Andreas Gross, Lori Lerner
Room: RO-4
35 PG
URINARY DIVERSION AFTER ROBOTASSISTED RADICAL CYSTECTOMY
Hani Rashid, Director
Ahmed Ghazi, Khurshid Guru, Guan Wu
Room: RO-1
31 IC
CONTEMPORARY TREATMENT STRATEGIES
IN THE MANAGEMENT OF PENILE CANCER
Philippe Spiess, Director
Sukhbinder Minhas, Chris Protzel
Room: RO-5
36 PG
UROLITHIASIS: METABOLIC EVALUATION
AND MEDICAL TREATMENT
Margaret Pearle, Director
Glenn Preminger, Michael Lipkin, Sara Best
Room: RO-2-3
32 IC
AUA GUIDELINE: CASTRATION-RESISTANT
PROSTATE CANCER UPDATE
Michael Cookson, Director
William Lowrance, Adam Kibel
Room: RO-6-7
37 PG
33 IC
CONTEMPORARY RECONSTRUCTIVE
STRATEGIES IN PROSTHETIC UROLOGY
Jay Simhan, Co-Director
Allen Morey, Co-Director
Room: RO-8
PRACTICAL URORADIOLOGY: THE OFFICE
BASED INTERPRETATION OF UROLOGIC
RADIOGRAPHIC STUDIES
Jay Bishoff, Director
Srinivas Vourganti, Sero Andonian, Shane Anderson
Room: RO-4
38 PG
MEDICAL MALPRACTICE IN UROLOGY: HOW
TO PREVENT AND DEFEND
Christopher Coogan, Director
David Sobel, Elizabeth Kavaler, James Saxton
Room: RO-5
10
39 PG
MANAGEMENT OF COMMON PSA DILEMMAS
Gerald Andriole, Director
Adam Kibel, Anthony D’Amico, A. Oliver Sartor
Room: RO-6-7
40 PG
URODYNAMIC EVALUATION AND ADVANCES
IN MANAGEMENT OF ADULT NEUROGENIC
BLADDER: A CASE BASED APPROACH
Hari Tunuguntla, Director
Stephen Kraus, Angelo Gousse
Room: RO-8
41 PG
HOW GENERAL UROLOGISTS CAN EVALUATE
AND TREAT MALE INFERTILITY
Marc Goldstein, Director
Mark Sigman, Peter Chan
Room: RO-9
47 IC
CONTEMPORARY CONCEPTS AND
CONTROVERSIES IN THE DIAGNOSIS AND
MANAGEMENT OF UPPER TRACT
UROTHELIAL CARCINOMA (UTUC)
Shahrokh Shariat, Director
Surena Matin, Wes Kassouf, Douglas Scherr
Room: RO-8
48 IC
COMMON PROBLEMS IN PEDIATRIC
UROLOGY: WHAT EVERY UROLOGIST
SHOULD KNOW
Richard Rink, Director
Mark Cain
Room: RO-9
3:30 pm - 6:30 pm
49 PG
RENAL BIOPSY UPDATE: INDICATIONS,
TECHNIQUES, PITFALLS AND RECENT
PATHOLOGICAL MODIFICATIONS TO
OPTIMIZE RESULTS
Raymond Leveillee, Director
J. Stuart Wolf, Merce Jorda
Room: RO-1
HOW TO IMPLEMENT THE AUA MEN’S
HEALTH CHECKLIST IN PRACTICE
Ridwan Shabsigh, Director
Steve Kopecky, Allen Seftel, Bruce Campbell
Room: RO-1
50 PG
TESTICULAR CANCER: CURRENT CONCEPTS
AND CONTROVERSIES
Joel Sheinfeld, Director
Brett Carver, George Bosl
Room: RO-2-3
MANAGEMENT OF NONMUSCLE INVASIVE
BLADDER CANCER: PRACTICAL SOLUTIONS
FOR COMMON PROBLEMS
Cheryl Lee, Director
J. Alfred Witjes, Theresa Koppie, Ashish Kamat
Room: RO-2-3
52 PG
OPTIMIZATION OF SEXUAL FUNCTION
OUTCOMES IN THE PATIENT WITH PROSTATE
CANCER
John Mulhall, Director
Francesco Montorsi, Andrew McCullough
Room: RO-5
53 PG
PROSTATE CANCER UPDATE 2015
William Catalona, Director
Stacy Loeb, Stanley Liauw, Douglas Dahl, Robert
Nadler, Russell Szmulewitz
Room: RO-6-7
54 PG
ADVANCED PERCUTANEOUS
NEPHROLITHOTOMY
Evangelos Liatsikos, Director
John Denstedt, Thomas Knoll
Room: RO-8
55 PG
GLOBAL PERSPECTIVES IN URETHRAL
RECONSTRUCTION
Hunter Wessells, Director
Sanjay Kulkarni, Guido Barbagli
Room: RO-9
1:00 pm - 3:00 pm
42 IC
43 IC
44 IC
45 IC
46 IC
THE USE OF ROBOTIC TECHNOLOGY IN
FEMALE PELVIC FLOOR RECONSTRUCTION
Jennifer Anger, Director
Kimberly Kenton, Karyn Eilber
Room: RO-4
MANEJO MÉDICO DEL PACIENTE MASCULINO
CON SÍNTOMAS DE VÍAS URINARIAS BAJAS
(ESTE CURSO SE PRESENTA SOLO EN
ESPANOL)
Enrique Lenero-Llaca, Director
Arturo Garcia-Mora, Mariano Sotomayor
Room: RO-5
UROLITHIASIS: SURGICAL MANAGEMENT,
PERCUTANEOUS, SHOCK WAVE
LITHOTRIPSY AND URETEROSCOPY - HOW
WE DO IT
Stephen Nakada, Director
Manoj Monga, Bodo Knudsen
Room: RO-6-7
Monday, May 18, 2015
6:00 am - 6:30 pm
6:00 am - 8:00 am
56 IC
THE OPTIMIZED SURGICAL JOURNEY: USING
ENHANCED RECOVERY TECHNIQUES AND
FAST TRACK PROTOCOLS TO IMPROVE
SURVIVORSHIP AFTER MAJOR UROLOGIC
SURGERY
Jay Shah, Director
Janet Baack Kukreja
Room: RO-1
11
57 IC
UPDATE ON AUA CANCER RELATED
GUIDELINES: PREPARATION FOR
CERTIFICATION
Sam Chang, Director
Peter Clark, Daniel Lin
Room: RO-2-3
58 IC
THE ROLE OF SACRAL NEUROMODULATION
IN UROLOGICAL PRACTICE
Steven Siegel, Director
Norbert Kaula
Room: RO-4
COURSES
59 IC
OPTIMIZING PROSTATE CANCER
DIAGNOSTICS: TRANSPERINEAL,
TRANSRECTAL AND MRI-ULTRASOUND
FUSION TARGETED BIOPSIES
Richard Popert, Director
Janette Kinsella, John Ward, Ben Challacombe,
Haesun Choi
Room: RO-5
60 IC
ACTIVE SURVEILLANCE FOR PROSTATE
CANCER
Laurence Klotz, Co-Director
Ian Thompson, Co-Director
Mark Emberton
Room: RO-6-7
61 IC
CONTROVERSIES AND CONSENSUS IN
FEMALE UROLOGY: A CASE BASED
APPROACH
Eric Rovner, Director
David Ginsberg, J. Quentin Clemens, David
Sussman
Room: RO-8
62 IC
68 PG
IMPROVING THE OUTCOMES OF ROBOTIC
UROLOGIC SURGERY: A STATE-OF-THE-ART
VIDEO-BASED COURSE
Vipul Patel, Director
Sam Bhayani, David Albala, Alexandre Mottrie,
Rafael Coelho, Bernardo Rocco
Room: RO-8
69 PG
COMPREHENSIVE MANAGEMENT OF T1A
RENAL CELL CARCINOMA: A PRACTICAL
REVIEW TO OPTIMIZE PATIENT TREATMENT
AND OUTCOMES
Jaime Landman, Director
James McKiernan, Anthony Chang, Laura Findeiss
Room: RO-9
1:00 pm - 3:00 pm
FULL SPECTRUM OF UPPER TRACT TCC
TREATMENT
Majid Eshghi, Director
John Phillips, Muhammad Choudhury
Room: RO-9
70 IC
TRATAMIENTO CONTEMPORÂNEO DEL
PROLAPSO DE ÓRGANOS PÉLVICOS SIN
MALLAS (ESTE CURSO SE PRESENTA SÓLO
EN ESPAÑOL)
Paulo Palma, Director
Cassio Riccetto, Larissa Rodriguez
Room: RO-1
71 IC
MANAGEMENT OF SMALL RENAL MASSES,
TECHNICAL ADVANCES IN NEPHRON
SPARING SURGERY, AND MANAGEMENT OF
LOCALLY ADVANCED RCC: A CASE BASED
APPROACH
Steven Campbell, Director
Robert Uzzo, Brian Lane
Room: RO-2-3
72 IC
GERIATRIC UROLOGY: BASIC PRINCIPLES
FOR UROLOGIC PRACTICE
Tomas Griebling, Director
E. Camille Vaughan, Theodore Johnson
Room: RO-4
73 IC
URINARY TRACT BLEEDING: FROM
ASYMPTOMATIC MICROHEMATURIA TO
INTRACTABLE HEMORRHAGIC CYSTITIS
Stephen Boorjian, Director
Jay Raman, Daniel Barocas
Room: RO-5
74 IC
SURGICAL AND MINIMALLY INVASIVE
MANAGEMENT OF FEMALE STRESS URINARY
INCONTINENCE
Victor Nitti, Director
Harriette Scarpero
Room: RO-6-7
75 IC
DIFFICULT CASES IN HIGH RISK BLADDER
CANCER: AN EVIDENCE-BASED APPROACH
Michael Cookson, Director
Timothy Masterson, Jeffrey Holzbeierlein
Room: RO-8
76 IC
AUA GUIDELINE: PEYRONIE’S DISEASE
Ajay Nehra, Director
Arthur Burnett, Alan Shindel
Room: RO-9
8:30 am - 11:30 am
63 PG
64 PG
65 PG
66 PG
67 PG
PRIMARY AND REOPERATIVE HYPOSPADIAS
REPAIR: EVIDENCE-BASED DECISION
MAKING
Warren Snodgrass, Director
Nicol Bush
Room: RO-1
CONTEMPORARY UROLOGICAL
MANAGEMENT OF WOMEN WITH SEXUAL
DYSFUNCTION
Irwin Goldstein, Director
Kenneth Peters, Noel Kim, Andrew Goldstein
Room: RO-2-3
INFERTILITY UPDATE 2015: A
COMPREHENSIVE APPROACH TO THE
CLINICAL DIAGNOSIS AND TREATMENT OF
THE INFERTILE MALE
Larry Lipshultz, Director
Edmund Sabanegh, Craig Niederberger, Robert
Brannigan
Room: RO-4
CHALLENGES IN THE EVALUATION AND
MANAGEMENT OF POST-PROSTATECTOMY
INCONTINENCE
Craig Comiter, Co-Director
Ajay Singla, Co-Director
Zaki Almallah
Room: RO-5
UTI CLINICAL STRATEGIES FOR UROLOGICAL
PRACTICE
John Krieger, Director
Richard Grady, Kurt Naber, Wolfgang Weidner
Room: RO-6-7
12
3:30 pm - 6:30 pm
77 PG
PEDIATRIC VOIDING DYSFUNCTION
Lane Palmer, Director
Christopher Cooper, Paul Austin
Room: RO-1
17 PG
HARNESSING THE TELEMEDICINE AND
MHEALTH REVOLUTIONS TO IMPROVE YOUR
CLINICAL PRACTICE
Matthew Gettman, Co-Director
Todd Morgan, Co-Director
Ted Skolarus, Alexander Kutikov, Benjamin Lee,
Jeremy Shelton
Room: RO-2-3
78 PG
TREATMENT OF COMPLEX UROLITHIASIS
AND ENDOUROLOGIC COMPLICATIONS
Amy Krambeck, Director
Nicole Miller, Vernon Pais, John Lieske
Room: RO-4
79 PG
FOUNDATIONS OF FEMALE UROLOGY
J. Christian Winters, Director
Nirit Rosenblum, Stephen Kraus
Room: RO-5
80 PG
SURVEILLANCE OR TREATMENT: THE 3
MS - MARKERS, MAPPING AND MRI FOR
LOCALIZED PROSTATE CANCER
E. David Crawford, Director
Matthew Cooperberg, M. Scott Lucia, Nelson Stone
Room: RO-6-7
81 PG
CODING AND REIMBURSEMENT UPDATE 2015
Ronald Kaufman, Co-Director
Stephanie Stinchcomb, Jonathan Rubenstein
Room: RO-8
82 PG
INTEGRATION OF MULTIPARAMETRIC MRI
INTO THE UROLOGIC MANAGEMENT OF
PROSTATE CANCER
Samir Taneja, Co-Director
Peter Pinto, Co-Director
Peter Choyke, Ardeshir Rastinehad, Sadhna Verma
Room: RO-9
Tuesday, May 19, 2015
6:00 am - 11:30 am
6:00 am - 8:00 am
83 IC
84 IC
85 IC
86 IC
URINARY DIVERSION: CURRENT
INDICATIONS, TECHNIQUES AND
MANAGEMENT OF COMPLICATIONS
Siamak Daneshmand, Director
Eila Skinner
Room: RO-4
NATIVE TISSUE REPAIRS FOR
INCONTINENCE AND PROLAPSE
Philippe Zimmern, Director
Elise Billings De
Room: RO-5
TESTOSTERONE: DIAGNOSIS AND
MANAGEMENT OF THE HYPOGONADAL MALE
Wayne Hellstrom, Director
Mohit Khera, Martin Miner
Room: RO-6-7
PHOTOSELECTIVE VAPORIZATION OF THE
PROSTATE (PVP) AND GREEN LASER
ENUCLEATION OF THE PROSTATE
(GREENLEP) USING THE 532NM LITHIUM
TRIBORATE LASER
Henry Woo, Director
Fernando Sancha, Oliver Reich
Room: RO-8
89 PG
CATASTROPHES, COMPLICATIONS AND
CORRECTIONS
Arthur Smith, Director
Jean de la Rosette, Ralph Clayman, David Hoenig
Room: RO-2-3
90 PG
URETHRAL RECONSTRUCTION
Kenneth Angermeier, Director
Daniel Rosenstein, Kennon Miller, Kenneth Carney
Room: RO-4
91 PG
BUILDING A STATEWIDE QUALITY
COLLABORATIVE: LESSONS FROM THE
MUSIC EXPERIENCE
Frank Burks, Director
Brian Lane, Susan Linsell, David Miller
Room: RO-5
92 PG
ADVANCED URETEROSCOPY: OVERCOMING
CHALLENGING PROBLEMS
Michael Grasso, Director
Scott Hubosky, Olivier Traxer, Demetrius Bagley
Room: RO-6-7
93 PG
SEQUENCING NOVEL AGENTS AND
UNDERSTANDING NOVEL CONCEPTS IN
HORMONE NAÏVE AND CASTRATION
RESISTANT PROSTATE CANCER 2015
Judd Moul, Director
Christopher Sweeney, Lawrence Karsh
Room: RO-8
94 PG
INTERSTITIAL CYSTITIS/BLADDER PAIN
SYNDROME: A PRIMER AND A WORLD VIEW
Philip Hanno, Director
Mauro Cervigni, Arndt Van Ophoven, Jorgen
Nordling, David Burks
Room: RO-9
8:30 am - 11:30 am
88 PG
THE MANAGEMENT OF UROLITHIASIS: A
CASE AND EVIDENCE-BASED APPROACH
Brian Matlaga, Director
James Lingeman, Dean Assimos, Ojas Shah
Room: RO-1
13
COURSES
NOTES
NOTES
NOTES
Visit Janssen Booth #1617 to learn more.
Janssen Biotech, Inc.
© Janssen Biotech, Inc. 2015 3/15 030662-150304
Program by Day
EVERYONE HAS A STORY.
SEE THE NEXT
CHAPTER TODAY.
Program by Day
3 THINGS YOU
CAN’T MISS AT
OUR BOOTH
- REGISTRATION AREA CELEBRATE 40 YEARS OF RESEARCH
Cake Cutting
Sunday, May 17 | 2:30 pm
NETWORK with the leading patient
advocacy groups
Patient Advocacy Meet and Greet
Monday, May 18 | 4 to 6 pm
Pick up your FREE T-SHIRT
and learn about our new website*
Hurry as t-shirts are limited!
*Must attend a short website demo in order to receive the t-shirt.
MP ⫽ Moderated Poster Session, PD ⫽ Podium Session
7:30 am - 5:30 pm
FRIDAY
SOCIETY FOR PEDIATRIC UROLOGY - FRIDAY
Grand Ballroom BC @ Hilton New Orleans Riverside
7:30
SESSION 1: PRIZE ABSTRACTS
Moderators: Stephane Bolduc, Earl Cheng
1:30
SESSION 3: SFU PERINATAL UROLOGY
Moderators: Travis Groth, Miguel Castellan
8:45
PANEL DISCUSSION: HYPOSPADIAS PANEL
Moderator: Michael Leonard
Panelists: Mark Zaontz, Rafael Gosalbez, Keith
Rourke
2:30
SFU PANEL: BLADDER EXSTROPHY
Panelists: Michael Mitchell, Barry Duel, Bradley
Kropp, John Kryger
4:00
BREAK
9:45
BREAK
4:30
10:15
SESSION 2: COMPLEX INCONTINENCE
Moderators: Peter Metcalfe, Katie WillihnganzLawson
SESSION 4: PENIS/HYPOSPADIAS
Moderators: Gianpaolo Capolicchio, Dawn McLellan
5:30
ADJOURN
11:15
MEREDITH CAMPBELL LECTURE: “TINY TOTS
PROJECT”
John Heaton
12:00
LUNCH (ON OWN)
APPROVED FOR AMA PRA CATEGORY 1
CREDITTM
8:00 am - 5:00 pm
BASIC SCIENCES SYMPOSIUM - “AGING AND UROLOGIC MANIFESTATIONS”
Room 214 @ New Orleans Morial Convention Center
11:25
REVERSING DYSFUNCTION IN AGING TISSUE
BY TARGETING SYSTEMIC SIGNALS
Amy Wagers
LIFE COURSE FACTORS & LOWER URINARY
TRACT DYSFUNCTION: THE GUCARDIA
STUDY
Stephen Van Den Eeden
11:45
Q&A
8:55
Q&A
12:00
LUNCH
9:10
AGING, HYPOGONADISM, AND UROLOGIC
MANIFESTATIONS IN MEN
Moderator: Barry Zirkin
1:15
ADVANCES IN UNDERSTANDING AGINGRELATED INCONTINENCE IN WOMEN
Moderator: Tomas Griebling
8:00
OPENING REMARKS
Carolyn Best, George Christ
8:15
GENETIC PREDICTORS OF THE RESPONSE
TO URGE INCONTINENCE THERAPY
Jennifer Wu
AGING AND DECLINING TESTOSTERONE:
PAST, PRESENT AND FUTURE
Barry Zirkin
1:35
ESTROGEN REGULATION IN BPH AND THE
LOWER URINARY TRACT
William Ricke
UROTHELIAL PHYSIOLOGY IN URINARY
CONTINENCE AND INCONTINENCE
Lori Birder
1:55
ACTIONS OF TESTOSTERONE ON THE AGING
MALE GH AXIS
Johannes Veldhuis
URINARY INCONTINENCE, BODY MASS, AND
BODY COMPOSITION IN OLDER WOMEN
Alison Huang
2:15
URGENCY INCONTINENCE IN OLDER ADULTS
Tomas L. Griebling
10:30
Q&A
2:35
Q&A
10:45
GENITOURINARY COMPLICATIONS OF AGING
MEN
Moderator: Kevin McVary
2:50
BRAIN ACTIVITY IN OVERACTIVE BLADDER
Neil Resnick
3:10
ADVANCED THERAPEUTIC DIRECTIONS TO
TREAT THE UNDERACTIVE BLADDER
Michael Chancellor
3:30
FEMALE PELVIC FLOOR CHANGES WITH
AGING
Margot Damaser
3:50
Q&A
9:30
ANDROGENS AND PROSTATE DISEASE RISK
Stephanie Page
9:50
10:10
AGING AND LUTS IN MEN
Kevin McVary
11:05
AGING AND THE INTERPLAY BETWEEN THE
PROSTATE AND CHANGES IN THE BLADDER
Claus Roehrborn
*Presenting author
17
4:05
CENTRAL NERVOUS SYSTEM
MANIFESTATIONS OF AGING AND UROLOGIC
CONSEQUENCES
Moderator: Sylvia Suadicani
4:25
MULTIPLE SCLEROSIS MODELS
Sylvia Suadicani
4:45
Q&A
VOIDING DYSFUNCTION AND PARKINSON’S
DISEASE
Lysanne Campeau
5:00
CLOSING REMARKS AND ADJOURN
Carolyn Best
8:00 am - 5:00 pm
SOCIETY OF UNIVERSITY UROLOGISTS / SOCIETY OF UROLOGY CHAIRPERSONS AND PROGRAM DIRECTORS (SUU/SUCPD)
La Nouvelle C @ New Orleans Morial Convention Center
8:00
SUU PROGRAM WELCOME
Program Chair: Douglas Canning
8:05
THE UROLOGY MATCH: WHERE WE WERE,
WHERE WE ARE, AND WHERE WE SHOULD
GO
HOW COMPETITIVE IS THE MATCH?
Fatima Husain
8:15
WOULD APPLICATION LIMITS IMPROVE THE
MATCH?
Steven Weissbart
8:25
WAYS TO IMPROVE THE MATCH
Moderators: Jeffrey Stock, Steven Weissbart
Panelists: Steven Campbell, Kirtishri Mishra, Eila
Skinner, Alan Wein
8:45
9:15
ANNUAL SUCPD BUSINESS MEETING
1:00
SUCPD PROGRAM
WELCOME
Program Chair: Eila Skinner
HISTORY OF THE MATCH
Steven Weissbart
8:10
12:30
1:05
THE EXPERIENCE OF STUDENTS GOING
THROUGH THE MATCH
Eila Skinner
1:20
UROLOGY FELLOWSHIP PROGRAMS
PEDIATRICS
Richard Grady
MANAGING RESIDENTS IN THE 21ST
CENTURY
Moderators: Steven Weissbart, Jeffrey Stock
Panelists: Carl Olsson, Byron Joyner, J. Christopher
Austin
LEGAL PITFALLS OF THE ELECTRONIC
MEDICAL RECORD: A PLAINTIFF’S
ATTORNEY’S PERSPECTIVE
Ben Rubinowitz
1:30
ONCOLOGY
Peter Clark
1:40
FPMRS
Craig Comiter
1:50
LAP/ENDO
Stephen Nakada
2:00
INFERTILITY
Robert Brannigan
2:10
TRAUMA/RECONSTRUCTION
Jill Buckley
2:20
PANEL DISCUSSION WITH QUESTIONS
Moderator: Eila Skinner
9:45
MEDICAL MALPRACTICE DISCUSSION
Moderator: Mitchell Benson
2:45
CLOUD SOURCING FOR VIDEO EVALUATION
Thomas Lendvay
10:00
AUA UPDATE: ELECTRONIC EDUCATION AND
DATA REGISTRY
Gopal Badlani
3:00
TRAINING FELLOWS TO BE EFFECTIVE
TEACHERS
Sapan Ambani, Cheryl Lee
10:10
BREAK
3:15
BREAK
10:25
VALUE BASED HEALTH CARE AND ACADEMIC
UROLOGY: HOW DO WE PREPARE?
David Penson
3:30
RRC REPORT
Randall Meacham
3:40
11:00
VALUE BASED CARE AS APPLIED TO
UROLOGY
Moderator: Steve Kim
Panelists: David Miller, Mark Litwin, Gregory Tasian
ACGME REPORT
Mary Turner
3:50
ABU UPDATE
J. Brantley Thrasher
4:00
AUA OFFICE OF EDUCATION REPORT
Elspeth McDougall
4:10
AUA MEDICAL STUDENT CURRICULUM
William Hulbert
4:20
AUA CORE CURRICULUM UPDATE
John Mulhall
11:25
ACADEMIC/INDUSTRY PUBLICATION
PRACTICE: DOS AND DON’TS
Grannum Sant
11:45
DOS AND DON’TS DISCUSSION
Moderator: Barry Kogan
12:00
ANNUAL SUU BUSINESS MEETING
18
GRANT RECIPIENT REPORTS
4:50
FEASIBILITY OF A DESKTOP SIMULATION
USING DIGITAL AVATARS TO TEACH
UROLOGY RESIDENTS DIFFICULT
COMMUNICATION SKILLS (2013)
Bruce Kava
4:55
SERIOUS GAMES: COMPETITION VS.
INCENTIVES TO ENGAGE RESIDENT IN
QUALITY-IMPROVEMENT EDUCATION (2014)
Charles Scales
5:00
ADJOURN
UROLOGY ULTRASOUND TRAINING
PROTOCOL AND ASSESSMENT PROGRAM
(2011)
Geoffrey Box
4:35
FUNDAMENTALS IN RESEARCH TEACHING IN
UROLOGY RESIDENCY PROGRAMS: NEEDS
ASSESSMENT AND DEVELOPMENT OF A
FORMAL RESEARCH DIDACTIC CURRICULUM
(2012)
Dennis Liu
4:40
DEVELOPMENT AND VALIDATION OF AN IPAD
LAPAROSCOPY TRAINER (2012)
Jaime Landman
4:45
DEVELOPMENT OF AN IPAD SURGICAL
ATLAS APPLICATION FOR UROLOGY
TRAINEES (2013)
Jaime Landman
CREDITTM
8:00 am - 5:00 pm
UROLOGIC ONCOLOGY RESEARCH SYMPOSIUM:
“HIGH IMPACT SCIENCE IN UROLOGIC ONCOLOGY AND PROGRESS IN BIOMEDICAL IMAGING”
Room 211-213 @ New Orleans Morial Convention Center
8:00
WELCOME
10:35
8:05
SESSION I: BEST OF SCIENCE IN UROLOGIC
ONCOLOGY, PART I
Moderator: William Isaacs
NEW HORIZONS: CHROMATIN MODIFIERS IN
KIDNEY CANCER
Kim Rathmell
10:55
Q&A
11:05
SESSION III: BEST SCIENCE FROM THE
UROLOGIC RESEARCH SOCIETY
Moderator: Ganesh Palapattu
THE ROLE OF IMMUNE CHECKPOINT
MODULATION IN THE TREATMENT OF
ADVANCED BLADDER CANCER
Daniel Petrylak
8:25
INTRODUCTION TO THE UROLOGIC
RESEARCH SOCIETY (URS)
Samir Taneja
INTRINSIC SUBTYPES OF BLADDER CANCER:
IMPLICATIONS FOR PROGNOSTICATION AND
THERAPY
David McConkey
11:15
RESISTANCE TO AR PATHWAY INHIBITORS
Martin Gleave
11:35
ROLE FOR THE HEXOSAMINE BIOSYNTHETIC
PATHWAY IN ANDROGEN DEPENDENT
PROSTATE CANCER
Ganesh Palapattu
11:55
THE MECHANISMS AND THE BIOLOGY OF
MICRO- AND BONE- METASTASES IN
PROSTATE CANCER
George Thalmann
LESSONS LEARNED FROM PREVENTION
TRIALS IN GU ONCOLOGY
Ian Thompson
12:15
Q&A
12:25
LUNCH
9:35
DISCOVERING THE GENES FOR INHERITED
PROSTATE CANCER
William Isaacs
1:15
SESSION IV: BASIC CONCEPTS AND
TECHNOLOGIES FOR BIOMEDICAL IMAGING
Moderator: Martin Pomper
9:55
THE GENETIC AND METABOLIC BASIS OF
KIDNEY CANCER
Marston Linehan
1:35
10:15
MOLECULAR CHARACTERIZATION OF
CHROMOPHOBIC RCC
Chad Creighton
PSMA-TARGETED IMAGING OF PROSTATE
CANCER
Martin Pomper
1:55
IMAGE-GUIDED ROBOTS
Dan Stoianovici
8:45
EXPLOITING VULNERABILITIES CAUSED BY
GENES THAT REPROGRAM CANCER
METABOLISM
Dan Theodorescu
9:05
Q&A
9:15
SESSION II: BEST OF SCIENCE IN UROLOGIC
ONCOLOGY, PART 2
Moderator: Marston Linehan
*Presenting author
IMAGING PROBES FOR TARGETED THERAPY
Peter Choyke
19
FRIDAY
4:30
2:15
TISSUE-LEVEL IMAGING IN 3-D
George Christ
2:35
Q&A
2:45
SESSION V: TRANSLATIONAL RESEARCH
AND APPLICATION
Moderator: Inderbir Gill
EMERGING USE OF MRI FOR DETERMINING
TUMOR TYPE AND FOR ASSESSING RENAL
FUNCTION
William Huang
3:05
3:25
INTRAOPERATIVE IMAGING FOR PARTIAL
NEPHRECTOMY
Inderbir Gill
3:45
THE ROLE OF IMAGING IN PROSTATE
CANCER FOCAL THERAPY
Samir Taneja
4:05
LYMPH NODE IMAGING FOR PROSTATE AND
BLADDER CANCER
Urs Studer
4:25
FIBEROPTIC CONFOCAL LASER
ENDOMICROSCOPY: TOWARDS OPTICAL
BIOPSY FOR TISSUE CHARACTERIZATION
DURING UROLOGIC SURGERY
Li-Ming Su
4:45
Q&A
5:00
ADJOURN
STATUS OF GENOMIC STUDIES IN PROSTATE
CANCER
Ashutosh Tewari
CREDITTM
9:30 am - 4:00 pm
SOCIETY OF GENITOURINARY RECONSTRUCTIVE SURGEONS (GURS) / SOCIETY OF UROLOGIC PROSTHETIC SURGEONS
(SUPS)
La Nouvelle AB @ New Orleans Morial Convention Center
9:30
9:40
10:00
OPENING REMARKS
Society Chairs: Sean Elliott, Allen Morey, Ajay Nehra
12:00
INDUSTRY SPONSORED LUNCH SYMPOSIUM
(NON-CME PORTION OF PROGRAM)
OPENING SESSION
1:00
MALE INCONTINENCE SESSION
Moderators: Jack Walter, Anna Lawrence
DEVINE LECTURE: CHALLENGES IN MALE
GENITAL TRAUMA
Moderator: Daniel Dugi
Michael Coburn
ROLE OF 3.5 CM AUS CUFF
Jay Simhan
SCOTT LECTURE: DEVELOPMENT OF THE
MALE TRANSOBTURATOR SLING
Moderator: Raul Ordorica
Peter Rehder
10:20
DISCUSSION
10:30
URETHRA SESSION
Moderators: Hadley Wood, Keith Rourke
ROLE OF STAGED URETHROPLASTY IN
ADULTS
Paul Anderson
10:40
ROLE OF STAGED URETHROPLASTY IN
CHILDREN
Nicol Bush
10:50
ROLE OF PENILE INVERSION IN
URETHROPLASTY
Justin Chee
11:00
ROLE OF PROSTATIC URETHRAL LIFT IN BPH
Peter Chin
11:10
DISCUSSION AND AUDIENCE RESPONSE
QUESTIONS
11:30
11:40
1:10
ROLE OF TRANSCORPORAL AND TANDEM
AUS CUFF
Kurt McCammon
1:20
ROLE OF URETHRAL LIGATION
Kenneth Angermeier
1:30
ROLE OF URETHROPLASTY (AND NONTRANSECTING TECHNIQUES) IN AUS
PATIENT
Daniela Andrich
1:40
QUESTIONS
2:00
BREAK WITH EXHIBITS
2:30
PENIS SESSION
Moderators: Michael Metro, Andrew Kramer
ROLE OF YACHIA CORPOROPLASTY IN
PEYRONIE’S DISEASE
Ronald Lewis
2:40
THE ROLE OF COLLAGENASE CLOSTRIDIUM
HISTOLYTICUM (CCH) IN PEYRONIE’S
DISEASE
Wayne Hellstrom
URETER SESSION
Moderators: Jeremy Myers, Lee Zhao
2:50
ROLE OF ULTRASOUND IN PENILE FRACTURE
Andre Cavalcanti
ROLE OF BUCCAL MUCOSA GRAFT IN
URETERAL RECONSTRUCTION
Michael Stifelman
3:00
ROLE OF GLANS RESURFACING IN BXO AND
PENILE CANCER
David Sofield
DISCUSSION
20
3:20
4:00
ROLE OF KETOCONAZOLE IN MANAGING
RECURRENT ISCHEMIC PRIAPISM
Laurence Levine
ADJOURN
CREDITTM
QUESTIONS
10:00 am - 12:05 pm
A DECADE OF PHARMACOTHERAPY FOR OAB: WHAT HAVE WE LEARNED?
10:00
INTRODUCTION: GOALS & OBJECTIVES
Alan Wein
11:25
BETA 3 AGONISTS: WILL IT FILL THE VOID?
Victor Nitti
10:05
ORIGIN OF THE TERM OAB
Paul Abrams
11:45
WHAT IS NEW IN THE PIPELINE?
Karl-Erik Andersson
10:25
CRITICAL LOOK AT THE TERM
Jerry Blaivas
12:05
CONCLUDING REMARKS
Alan Wein
10:45
ANTICHOLINERGICS: HAVE THEY STOOD THE
TEST OF TIME
Marcus Drake
11:05
CLINICAL TRIALS VS. REAL WORLD
EXPERIENCE OF ANTICHOLINERGICS
Sender Herschorn
CREDITTM
10:30 am - 12:30 pm
Moderated Poster Session 1
PROSTATE CANCER: MARKERS I
Moderators: Daniel Lin and Mark Frydenberg
ABSTRACT
NUMBER TITLE
MP1-01 THE 17-GENE GENOMIC PROSTATE
SCORE (GPS) ASSAY: INITIAL CLINICAL
EXPERIENCE OF 4,000 PATIENTS
Aaron Katz*, Andrew Ho, Garden City, NY,
Emily Burke, Bela Denes, Ruixiao Lu, Megan
Rothney, Michael Bonham, Athanasios
Tsiatis, Jeffrey Lawrence, Phillip Febbo,
Redwood City, CA
MP1-02
MP1-03
*Presenting author
ABSTRACT
NUMBER TITLE
MP1-04 EVALUATION OF GENOMIC SIGNATURES
IN INTERMEDIATE TO HIGH RISK MEN
TREATED WITH RADICAL
PROSTATECTOMY BUT WITHOUT
ADDITIONAL THERAPY UPON PSA RISE
Michael Johnson*, Baltimore, MD, Kasra
Yousefi, Nicholas Erho, Voleak Choeurng,
Lucia Lam, Vancouver, Canada, Helen L.
Fedor, Baltimore, MD, Elai Davicioni,
Vancouver, Canada, Edward Schaeffer,
Ashley Ross, Baltimore, MD
ASSOCIATION OF GENETIC VARIANTS IN
TELOMERE-RELATED GENES WITH
PROSTATE CANCER RISK AND
RECURRENCE
Chengyuan Gu*, Yao Zhu, Dingwei Ye,
Shanghai, China, People’s Republic of
MP1-05
VALIDATED URINE-BASED MULTIGENE
SIGNATURE FOR DETECTION OF
AGGRESSIVE PROSTATE CANCER
Jean-François Haince, Guillaume Beaudry,
Eric Paquet, Quebec City, Canada, Lorne
Aaron, Greenfield Park, Canada, Robert
Sabbagh, Sherbrooke, Canada, Vincent
Fradet*, Quebec City, Canada, Neil Fleshner,
Toronto, Canada, Yves Fradet, Quebec City,
Canada
21
A MULTI-CENTER COMPARISON OF A 17GENE GENOMIC PROSTATE SCORE (GPS)
AS A PREDICTOR OF OUTCOMES IN
AFRICAN-AMERICAN (AA) AND
CAUCASIAN (CA) MEN WITH CLINICALLY
LOCALIZED PROSTATE CANCER (PCA)
Jennifer Cullen*, Rockville, MD, Isabell
Sesterhenn, Silver Spring, MD, Eric Klein,
Cleveland, OH, James Mohler, Buffalo, NY,
Peter Carroll, Matthew Cooperberg, San
Francisco, CA, Nan Zhang, Tara Maddala,
Dejan Knezevic, Athanasios Tsiatis, H.
Jeffrey Lawrence, Phillip Febbo, Redwood
City, CA
FRIDAY
3:10
MP1-06
CLINICAL BENEFITS AND COSTS OF A
17-GENE ASSAY DESIGNED TO ASSESS
DISEASE-PROGRESSION RISK AFTER
POSITIVE PROSTATE CANCER BIOPSY
Marc Dall’Era*, Davis, CA, Steven N.
Michalopoulos, Menlo Park, CA, Béla S.
Denes, Redwood City, CA, Jennifer Tighe,
Menlo Park, CA, John Hornberger, Stanford,
CA
MP1-07
ENRICHMENT OF CIRCULATING TUMOR
CELLS IN PATIENTS WITH LOCALIZED
PROSTATE CANCER USING A
MICROFLUIDIC DEVICE
Tilman Todenhöfer*, Emily Park, Hamid Abdi,
Alex Li, Richard Ross, Xiaoyan Deng, Chao
Jin, Simon Duffy, Martin Gleave, Hongshen
Ma, Peter Black, Vancouver, Canada
MP1-08
MP1-09
MP1-10
MP1-11
PATIENT AUA RISK CLASSIFICATION
BASED ON COMBINED CLINICAL CELL
CYCLE RISK (CCR) SCORE
Jack Cuzick*, London, United Kingdom,
Steven Stone, Julia Reid, Salt Lake City, UT,
Gabrielle Fisher, Henrik Møller, London,
United Kingdom, Michael Brawer, Salt Lake
City, UT, Peter Scardino, New York, NY, Neal
Shore, Myrtle Beach, SC
PROSPECTIVE CORRELATION BETWEEN
PROBABILITY OF FAVORABLE
PATHOLOGY ON THE 17-GENE GENOMIC
PROSTATE SCORE AND ACTUAL
PATHOLOGIC OUTCOMES AT RADICAL
PROSTATECTOMY
Michael Whalen*, James McKiernan, Mitchell
Benson, Ketan Badani, New York, NY
VALIDATION OF AN ACTIVE
SURVEILLANCE THRESHOLD FOR THE
CCP SCORE IN CONSERVATIVELY
MANAGED MEN WITH LOCALIZED
PROSTATE CANCER
Jack Cuzick*, London, United Kingdom,
Steven Stone, Salt Lake City, UT, Gabrielle
Fisher, Zi Hua Yang, Bernard North, Daniel
Berney, Luis Beltran, London, United
Kingdom, David Greenberg, Cambridge,
United Kingdom, Henrik Møller, London,
United Kingdom, Julia Reid, Alexander Gutin,
Jerry Lanchbury, Michael Brawer, Salt Lake
City, UT, Peter Scardino, New York, NY
VALIDATION OF THE DECIPHER®
PROSTATE CANCER CLASSIFIER IN
INTERMEDIATE TO HIGH RISK MEN
PROSTATECTOMY BUT WITHOUT
ADDITIONAL THERAPY UPON PSA RISE
Ashley Ross*, Michael Johnson, Baltimore,
MD, Kasra Yousefi, Vancouver, Canada,
Bruce Trock, Baltimore, MD, Voleak
Choeurng, Lucia Lam, Vancouver, Canada,
Helen L. Fedor, Baltimore, MD, Mercedeh
Ghadessi, Christine Buerki, Vancouver,
Canada, Stephanie Glavaris, Debasish Sundi,
Jeffrey Tosoian, Misop Han, Elizabeth
Humphreys, Alan Partin, George Netto,
Baltimore, MD, Elai Davicioni, Vancouver,
Canada, Edward Schaeffer, Baltimore, MD
22
MP1-12
COMPARATIVE ANALYSIS OF AFRICAN
AMERICAN AND EUROPEAN AMERICAN
MEN USING A PROSTATE CANCER
GENOMIC CLASSIFIER
Michael Johnson*, Baltimore, MD, Voleak
Choeurng, Kasra Yousefi, Vancouver,
Canada, Elai Davicioni, San Diego, CA, Eric
Klein, Cleveland, OH, Robert Den, Adam
Dicker, Philadelphia, PA, Ashley Ross,
Edward Schaeffer, Baltimore, MD
MP1-13
EXTENSION AND SEVERITY OF
PROSTATE INFLAMMATION AND
ATROPHY ARE INDEPENDENTLY
ASSOCIATED WITH LOWER PSA LEVELS
IN MEN UNDERGOING PROSTATE BIOPSY
Daniel Moreira*, Rochester, MN, Gerald
Andriole, St Louis, MO, Ramiro CastroSantamaria, King of Prussia, PA, Stephen
Freedland, Durham, NC
MP1-14
DEFINING ADVERSE PATHOLOGY FOR
LOWER RISK MEN UNDERGOING
RADICAL PROSTATECTOMY
Michael A. Kozminski*, Scott Tomlins, Udit
Singhal, Louis Lu, Ted A. Skolarus, Ganesh
S. Palapattu, Jeffrey S. Montgomery, Alon Z.
Weizer, Rohit Mehra, Brent K. Hollenbeck,
David C. Miller, Felix Y. Feng, Todd M.
Morgan, Ann Arbor, MI
MP1-15
QUANTITATIVE HISTOMORPHOMETRIC
ANALYSIS OF PROSTATE BIOPSY
IMAGES PREDICT FAVORABLE OUTCOME
IN ACTIVE SURVEILLANCE PATIENTS
George Lee*, Cleveland, OH, Robert Veltri,
Guangjing Zhu, H. Ballentine Carter, Patricia
Landis, Jonathan Epstein, Baltimore, MD,
Anant Madabhushi, Cleveland, OH
MP1-16
DETECTION OF APOPTOTIC AND NONAPOPTOTIC DISSEMINATED TUMOR
CELLS IN THE BONE MARROW AT THE
TIME OF RADICAL PROSTATECTOMY
Tilman Todenhöfer*, Vancouver, Canada,
Jörg Hennenlotter, Frank Faber, Ursula Kühs,
Tuebingen, Germany, Tanja Fehm,
Duesseldorf, Germany, Diethelm Wallwiener,
Tuebingen, Germany, David Schilling,
Frankfurt, Germany, Georgios Gakis, Simone
Bier, Johannes Mischinger, Stefan
Aufderklamm, Arnulf Stenzl, Christian
Schwentner, Tuebingen, Germany
MP1-17
PTEN STATUS DETERMINATION IN
PROSTATE CANCER: COMPARISON OF
IHC AND FISH IN A LARGE MULTICENTER COHORT
Tamara L. Lotan*, Carlos L. Morais,
Baltimore, MD, Wei Wei, Houston, TX,
Tamara Jamaspishvili, Kingston, Canada,
Ziding Feng, Houston, TX, Jesse McKenney,
Cleveland, OH, Jeff Simko, San Francisco,
CA, Dean Troyer, Fairfax, VA, Lawrence
True, Seattle, WA, James D. Brooks, Palo
Alto, CA, Jeremy Squire, Sao Paulo, Brazil,
CAnary Pathology Team Investigating Tissue
Biomarkers (CAPIT), Palo Alto, CA
PROGNOSTIC IMPACT OF SECOND
PRIMARY MALIGNANCIES ON THE
OVERALL SURVIVAL OF PATIENTS WITH
METASTATIC PROSTATE CANCER
Kyo Chul Koo*, Ki Hong Kim, Sang Un Park,
Koon Ho Rha, Sung Joon Hong, Byung Ha
Chung, Seoul, Korea, Republic of
MP1-19
A NOVEL LIVE CELL MICROFLUIDIC
DIAGNOSTIC USING PHENOTYPIC
BIOMARKERS WITH OBJECTIVE
ALGORITHMIC ANALYSIS FOR PROSTATE
CANCER RISK STRATIFICATION
Kimberly Rieger-Christ*, Travis Sullivan,
Burlington, MA, Naveen Kella, Ray
Hernandez, San Antonio, TX, Vladimir
Mouraviev, Syracuse, NY, Kevin Knopf, San
Francisco, CA, Hani Rashid, Rochester, NY,
Michael Manak, Wendell Su, Brad Hogan,
Andrew Min, Delaney Berger, Matthew
Whitfield, Jonathan Varsanik, Mani Foroohar,
Ashok Chander, Beverly, MA, David Albala,
Syracuse, NY, Grannum Sant, Boston, MA
MP1-20
DISTINGUISHING INDOLENT FROM
AGGRESSIVE PROSTATE CANCER IN
ACTIVE SURVEILLANCE USING
PARTIALWAVE SPECTROSCOPY TO
MEASURE NANOCYTOLOGICAL FIELD
CARCINOGENESIS
James Kearns*, Chicago, IL, Brian Helfand,
Charles Brendler, Evanston, IL, Hemant Roy,
Boston, MA, Chi-Hsiung Wang, Kristian
Novakovic, Evanston, IL, Hariharan
Subramanian, Di Zhang, Charles Maneval,
Vadim Backman, Chicago, IL
CREDITTM
10:30 am - 12:30 pm
BLADDER CANCER: UPPER TRACT TCC I
Moderators: Michael Droller and Maurizio Brausi
ABSTRACT
NUMBER TITLE
MP2-01 CONTRALATERAL UPPER TRACT
UROTHELIAL CARCINOMA AFTER
NEPHROURETERECTOMY: THE
PREDICTIVE ROLE OF METHYLATION
STATUS
Lei Zhang*, Gengyan Xiong, Dong Fang,
Xuesong Li, Jin Liu, Weimin Ci, Wei Zhao,
Beijing, China, People’s Republic of, Nirmish
Singla, Dallas, TX, Zhisong He, Li Zhou,
Beijing, China, People’s Republic of
MP2-02
MP2-03
*Presenting author
ABSTRACT
NUMBER TITLE
MP2-04 PROGNOSTIC VALUE OF SERUM CYFRA
21-1 IN PATIENTS WITH G3 OR MUSCLE
INVASIVE UPPER URINARY TRACT
CANCER
Akihiro Yano*, Hironori Sugiyama, Eiken Cho,
Hideki Takeshita, Yohei Okada, Hideki
Nagamatsu, Makoto Morozumi, Satoru
Kawakami, Takumi Yamada, Kawagoe,
Japan
HIGH EXPRESSION OF KARYOPHERIN ␣2
DEFINES POOR PROGNOSIS IN PATIENTS
WITH UPPER TRACT UROTHELIAL
CARCINOMA TREATED WITH RADICAL
NEPHROURETERECTOMY
Boxing Su*, Beijing, China, People’s Republic
of, Bentao Shi, Shenzhen, China, People’s
Republic of, Yuan Tang, Dong Fang, Genyan
Xiong, Zhongqiang Guo, Xuesong Li, Liqun
Zhou, Beijing, China, People’s Republic of
PROGNOSTIC AND PREDICTIVE VALUE
OF EPIGENETIC BIOMARKERS IN UPPER
TRACT UROTHELIAL CARCINOMA
Gengyan Xiong, Jin Liu, Dong Fang,
Xuesong Li, Liqun Zhou*, Beijing, China,
People’s Republic of
23
MP2-05
IDENTIFICATION OF CIRCULATING
MICRORNA SIGNATURES FOR UPPER
DETECTION
Jun Tao*, Pengchao Li, Chao Qin, Qiang Lu,
Nanjing, China, People’s Republic of
MP2-06
MULTI-INSTITUTIONAL VALIDATION OF
THE PREDICTIVE VALUE OF KI-67 IN
PATIENTS WITH HIGH-GRADE
UROTHELIAL CARCINOMA OF THE
UPPER URINARY TRACT
Laura-Maria Krabbe*, Muenster, Germany,
Aditya Bagrodia, Ahmed Haddad, Payal
Kapur, Dina Khalil, Linda Hynan, Dallas, TX,
Christopher Wood, Jose Karam, Houston, TX,
Alon Weizer, Ann Arbor, MI, Jay Raman,
Hershey, PA, Mesut Remzi, Vienna, Austria,
Nathalie Rioux-Leclerq, Rennes, France,
Andrea Haitel, Vienna, Austria, Marco
Roscigno, Bergamo, Italy, Christian Bolenz,
Mannheim, Germany, Karim Bensalah,
Rennes, France, Arthur Sagalowsky, Dallas,
TX, Shahrokh Shariat, Vienna, Austria, Yair
Lotan, Vitaly Margulis, Dallas, TX
FRIDAY
MP1-18
MP2-07
A SYSTEMATIC REVIEW AND METAANALYSIS OF CLINICOPATHOLOGIC
FACTORS LINKED WITH INTRAVESICAL
RECURRENCE AFTER RADICAL
NEPHROURETERECTOMY TO TREAT
UPPER TRACT UROTHELIAL CARCINOMA
Thomas Seisen*, Benjamin Granger, Paris,
France, Pierre Colin, Lille, France, Priscilla
Léon, Guillemette Utard, Raphaële RenardPenna, Eva Compérat, Pierre Mozer, Olivier
Cussenot, Paris, France, Shahrokh Shariat,
Vienna, Austria, Morgan Rouprêt, Paris,
France
MP2-08
URINARY PH IS HIGHLY ASSOCIATED
WITH BLADDER RECURRENCE AFTER
NEPHROURETERECTOMY FOR UPPER
URINARY TRACT UROTHELIAL
CARCINOMA PATIENTS WITH POSITIVE
SMOKING HISTORY
Hiroki Ide*, Eiji Kikuchi, Nobuyuki Tanaka,
Akira Miyajima, Mototsugu Oya, Tokyo,
Japan
MP2-09
MP2-10
MP2-11
NOMOGRAM FOR PREDICTION OF
RECURRENCE-FREE SURVIVAL IN
PATIENTS WITH HIGH-GRADE UPPER
TRACT UROTHELIAL CARCINOMA AFTER
EXTIRPATIVE THERAPY
Laura-Maria Krabbe*, Muenster, Germany,
Okyaz Eminaga, Cologne, Germany,
Shahrokh Shariat, Vienna, Austria, Yair
Lotan, Arthur Sagalowsky, Dallas, TX, Jay
Raman, Hershey, PA, Christopher Wood,
Houston, TX, Alon Weizer, Ann Arbor, MI,
Marco Roscigno, Bergamo, Italy, Francesco
Montorsi, Milan, Italy, Christian Bolenz,
Mannheim, Germany, Mesut Remzi, Vienna,
Austria, Karim Bensalah, Rennes, France,
Wassim Kassouf, Montreal, Canada, Vitaly
Margulis, Dallas, TX
THE IMPACT OF PERIOPERATIVE BLOOD
TRANSFUSION AND NUMBER OF
TRANSFUSED UNITS ON SURVIVAL
FOLLOWING RADICAL
Michael Rink*, Armin Soave, Atiqullah Aziz,
Hamburg, Germany, Fahmy Al-Sayed,
Tübingen, Germany, Oliver Engel, Sven
Peine, Luis A. Kluth, Felix K. Chun, Roland
Dahlem, Hamburg, Germany, Arnulf Stenzl,
Tübingen, Germany, Maximilian Burger,
Regensburg, Germany, Margit Fisch,
Hamburg, Germany, Hans-Martin Fritsche,
Regensburg, Germany, Georgios Gakis,
Tübingen, Germany
STAGE-SPECIFIC IMPACT OF TUMOR
LOCATION ON ONCOLOGIC OUTCOMES
IN PATIENTS WITH UPPER URINARY
Yi-Sheng Tai*, Yunlin, Taiwan, Chung-Hsin
Chen, Chao-Yuan Huang, Huai-Chin Tai,
Sho-Mon Wang, Yeong-Shiau Pu, Taipei,
Taiwan
24
MP2-12
PROGNOSTIC IMPACT OF TUMOR STAGE
ON POSITIVE LYMPH NODE STATUS IN
FOLLOWING RADICAL
NEPHROURETERECTOMY
Atiqullah Aziz*, Hamburg, Germany,
Shahrokh F. Shariat, Vienna, Austria, Luis
Alex Kluth, Hamburg, Germany, Georgios
Gakis, Tübingen, Germany, Hans-Martin
Fritsche, Regensburg, Germany, Morgan
Roupret, Paris, France, Harun Fajkovic,
Vienna, Austria, Armin Soave, Hamburg,
Germany, Giacomo Novara, Padua, Italy,
Armin Pycha, Bolzano, Italy, Mesut Remzi,
Korneuburg, Austria, Richard Zigeuner, Graz,
Austria, Jay D. Raman, Hershey, PA, Alberto
Briganti, Milan, Italy, Karim Bensalah,
Rennes, France, Vitaly Margulis, Dallas, TX,
Evanguelos Xylinas, Paris, France, Margit
Fisch, Michael Rink, Hamburg, Germany
MP2-13
RADIOGRAPHIC FINDINGS ON CT SCAN
ASSOCIATED WITH LYMPH NODE
METASTASES IN UPPER TRACT
UROTHELIAL CARCINOMA
Eugene Cha*, Alyssa Yee, Melissa Assel,
Maura Micco, John Sfakianos, Philip Kim,
Fara Friedman, Itay Sternberg, Daniel
Sjoberg, H. Alberto Vargas, Jonathan
Coleman, New York, NY
MP2-14
SIMULTANEOUS PRESENCE OF BLADDER
CANCER AND PREVIOUS HISTORY OF
BLADDER CANCER HAVE DIFFERENT
IMPACTS ON CLINICAL OUTCOME OF
FOLLOWING RADICAL
NEPHROURETERECTOMY
masayuki hagiwara*, Ichikawa, Japan, Eiji
Kikuchi, Tokyo, Japan, jyun Hagiuda, Hidaka
Kouno, Ken Nakagawa, Ichikawa, Japan,
Mototsugu Oya, Tokyo, Japan
MP2-15
PATTERNS OF LYMPHATIC METASTASES
IN UPPER TRACT UROTHELIAL
CARCINOMA
Patrick Espiritu, Tampa, FL, Jonathan
Coleman, John Sfakianos, New York, NY,
Philippe Spiess, Tampa, FL, Surena Matin*,
Houston, TX
MP2-16
NATIONAL VARIATION IN PERFORMANCE
OF LYMPHADENECTOMY DURING
NEPHROURETERECTOMY FOR
UROTHELIAL CARCINOMA: THE IMPACT
OF SURGICAL APPROACH AND
HOSPITAL CHARACTERISTICS
Shane Pearce*, Joseph Pariser, Sanjay
Patel, Gary Steinberg, Arieh Shalhav, Norm
Smith, Chicago, IL
TEMPLATE-BASED LYMPHADENECTOMY
REDUCES THE RISK OF REGIONAL
LYMPH NODE RECURRENCE IN
PATIENTS WITH UPPER/MIDDLE
URETERAL CANCER
Tsunenori Kondo*, Tokyo, Japan, Isao Hara,
Wakayama, Japan, Toshio Takagi, Tokyo,
Japan, Yoshiki Kodama, Wakayama, Japan,
Yasunobu Hashimoto, Hirohito Kobayashi,
Junpei Iizuka, Kenji Omae, Kazuhiko
Yoshida, Kazunari Tanabe, Tokyo, Japan
MP2-18
PREOPERATIVE SELECTION ALGORITHM
FOR ELIGIBLE NEOADJUVANT
CHEMOTHERAPY PATIENTS IN UPPER
TRACT UROTHELIAL CARCINOMAS
Shingo Moriyama*, Kazutaka Saito, Junichiro
Ishioka, Masaya Ito, Manabu Tatokoro,
Soichiro Yoshida, Minato Yokoyama, Yoh
Matsuoka, Noboru Numao, Yasuhisa Fujii,
Kazunori Kihara, Tokyo, Japan
MP2-19
HIGH RISK UPPER URINARY TRACT
UROTHELIAL CARCINOMA PATIENTS
WITH LYMPHOVASCULAR INVASION
HAVE THE ADVANTAGE OF ADJUVANT
CHEMOTHERAPY
Shinichi Yamashita*, Akihiro Ito, Sendai,
Japan, Ichiro Shintaku, Higashimatsushima,
Japan, Tatsuo Tochigi, Natori, Japan,
Fumihiko Soma, Hachinohe, Japan,
Takashige Namima, Sendai, Japan,
Shinnosuke Katoh, Yuzawa, Japan, Shozo
Ota, Sendai, Japan, Atsushi Kyan,
Shirakawa, Japan, Kazuhiko Orikasa,
Kesennuma, Japan, Kenji Numahata,
Yamagata, Japan, Atsushi Takeda,
Ichinoseki, Japan, Masataka Aizawa,
Naomasa Ioritani, Yasuhiro Kaiho, Haruo
Nakagawa, Yoichi Arai, Sendai, Japan
MP2-20
FEASIBILITY STUDY OF PERSONALIZED
PEPTIDE VACCINATION FOR PLATINUMBASED CHEMOTHERAPY RESISTANT
METASTATIC UPPER TRACT
UROTHELIAL CARCINOMA PATIENTS
Shigetaka Suekane*, Masanori Noguchi,
Kousuke Ueda, Tsukasa Igawa, Tetsuro
Sasada, Kyogo Itoh, Kurume, Japan
CREDITTM
10:30 am - 12:30 pm
BENIGN PROSTATIC HYPERPLASIA: SURGICAL THERAPY & NEW TECHNOLOGY I
Moderators: Peter Gilling and Bilal Chughtai
ABSTRACT
NUMBER TITLE
MP3-01 BPH6 RANDOMIZED STUDY OF
PROSTATIC URETHRAL LIFT (PUL) VS
TRANSURETHRAL RESECTION OF THE
PROSTATE (TURP): OUTCOMES AND
PATIENT SATISFACTION
Neil Barber*, Frimley, United Kingdom, Jens
Sønsken, Herlev, Denmark, Christian Gratze,
Munich, Germany, Mark Speakman, Taunton,
United Kingdom, Richard Berges, Cologne,
Germany, Ulrich Wetterauer, Freiburg,
Germany, Damien Greene, Sunderland,
United Kingdom, Karl-Dietrich Sievert,
Tuebingen, Germany, Christopher Chapple,
Sheffield, United Kingdom, Francesco
Montorsi, Milan, Italy
MP3-02
*Presenting author
ABSTRACT
NUMBER TITLE
MP3-03 IMAGE GUIDED ROBOTIC WATERJET
ABLATION (AQUABLATION) OF THE
PROSTATE: CLINICAL EXPERIENCE OF A
NOVEL TECHNOLOGY FOR BPH
Mihir Desai*, Los Angeles, CA, Abhishek
Laddha, Nadiad, India, Raed A Azhar, Los
Angeles, CA, Shashikant Mishra, Mahesh
Desai, Ravindra Ravindra Sabnis, Nadiad,
India
CROSSOVER STUDY OF THE PROSTATIC
URETHRAL LIFT FOR LUTS SECONDARY
TO BPH: 2 YEAR RESULTS
Henry Woo*, Sydney, Australia, Anthony
Cantwell, Daytona Beach, FL, William
Bogache, Myrtle Beach, SC, Stephen
Richardson, Salt Lake City, UT, Ronald
Tutrone, Towson, MD, Prem Rashid, Port
Macquarie, Australia, Jack Barkin, Toronto,
Canada, James Fagelson, Denver, CO, Peter
Chin, Figtree, Australia
25
MP3-04
WITHDRAWN
MP3-05
MULTI-INSTITUTIONAL RETROSPECTIVE
REVIEW OF ROBOT-ASSISTED
LAPAROSCOPIC SIMPLE
PROSTATECTOMY
Andrew Harbin*, Philadelphia, PA, Jeff
Villanueva, Washington, DC, Benjamin Katz,
Philadelphia, PA, Vineet Agrawal, Guan Wu,
Hani Rashid, Jean Joseph, Rochester, NY,
Jonathan Hwang, Washington, DC, David
Lee, Daniel Eun, Philadelphia, PA
FRIDAY
MP2-17
MP3-06
MATCHED COMPARISON OF OUTCOMES
FOLLOWING OPEN AND ROBOTICASSISTED SIMPLE PROSTATECTOMY AT
A SINGLE INSTITUTION
Philip Zhao*, Nikhil Gupta, David Leavitt, New
Hyde Park, NY, Sammy Elsamra, New
Brunswick, NJ, Louis Kavoussi, Zeph Okeke,
Richard Ashley, Lee Richstone, New Hyde
Park, NY
MP3-07
REPORT OF TRANSURETHRAL
RESECTION OF PROSTATE IN THE PAST
TWENTY YEARS:THE EXPERIENCE OF
3112 CASES FROM ONE CENTER
Li Zuo*, JianGang Zou, ZhongXing Zhou,
ShuYan Lu, Yangzhi Chen, Changzhou,
China, People’s Republic of
MP3-08
MP3-09
MP3-10
BIPOLAR VAPORIZATION CAUSES
HIGHER COMPLICATION RATES
COMPARED TO BIPOLAR LOOP
RESECTION: A RANDOMIZED
PROSPECTIVE TRIAL
Osama Abdelwahab*, Tarek Soliman,
Hammoda Sherif, Benha, Egypt, Mohamad
Habous, Jedda, Saudi Arabia, Osama Laban,
Tabouk, Saudi Arabia, Richard Santucci,
Detroit, MI
COMPARISON OF SURGICAL OUTCOMES
IN BENIGN PROSTATIC HYPERTROPHY
MANAGEMENT USING THE NATIONAL
SURGICAL QUALITY IMPROVEMENT
PROGRAM
Devin Haddad*, Louis Krane, Gopal Badlani,
Majid Mirzazadeh, Winston-Salem, NC
REDUCTION OF ENLARGED PROSTATE
DECREASES THE INCIDENCE OF
INGUINAL HERNIA
Yu-Hua Fan*, Hsiao-Jen Chung, Eric Huang,
Alex Lin, Kuang-Kuo Chen, Taipei, Taiwan
MP3-11
RESULTS OF TRANS URETHRAL
ENUCLEATION AND RESECTION OF
PROSTATE (TUERP) USING UNIPOLAR
RESECTOSCOPE: A COST EFFECTIVE
NEW TECHNIQUE!
Muhammad Salam*, Jahangir Kabir,
Ehetesham Haque, Faisal Islam, Ghazi
Shahinul Islam, Ibrahim Kaisar, Dhaka,
Bangladesh
MP3-12
LONG-TERM EVALUATION OF
TRANSURETHRAL INCISION OF THE
PROSTATE FOR TREATMENT OF BENIGN
PROSTATE HYPERPLASIA: ANALYSIS OF
75 CASES WITH A MEAN 8-YEAR
FOLLOW-UP PERIOD
Paulo Cordeiro*, Hugo Barone, Eduardo
Muracca Yoshinaga, Élcio Nakano, William C
Nahas, Miguel Srougi, Alberto A Antunes,
Sao Paulo, Brazil
26
MP3-13
EFFICACY OF THERMO-EXPANDABLE
INTRA-PROSTATIC STENT
(MEMOKATHTM028) AS AN ALTERNATIVE
APPROACH FOR BENIGN PROSTATIC
HYPERPLASIA PATIENTS WITH
SIGNIFICANT COMORBIDITIES:
COMPARISON WITH TRANSURETHRAL
RESECTION OF THE PROSTATE
Phil Hyun Song*, Yeong Uk Kim, Jae Young
Choi, Young Hwii Ko, Ki Hak Moon, Hee
Chang Jung, Daegu, Korea, Republic of
MP3-14
CHANGES OF THE URINARY NERVE
GROWTH FACTOR (NGF) LEVELS AFTER
RELIEF OF OBSTRUCTION IN THE
PATIENTS WITH SYMPTOMATIC BENIGN
PROSTATIC OBSTRUCTION (BPO) USING
HOLMIUM LASER ENUCLEATION OF THE
PROSTATE (HOLEP)
Jeongyun Jeong*, Tae Heon Kim, Hyun
Hwan Sung, Myung-Soo Choo, Kyu-Sung
Lee, Seoul, Korea, Republic of
MP3-15
PREDICTORS OF ENUCLEATION AND
MORCELLATION TIME DURING HOLMIUM
LASER ENUCLEATION OF THE PROSTATE
(HOLEP)
Marawan El Tayeb*, M. Francesca Monn,
Naeem Bhojani, Matthew J. Mellon, James C.
Sloan, Ronald S. Boris, James E. Lingeman,
Indianapolis, IN
MP3-16
DETAILED ASSESSMENT OF LOWER
URINARY TRACT SYMPTOMS AND
ERECTILE FUNCTION AFTER HOLEP: A
PROSPECTIVE STUDY
Sascha Ahyai*, Irina Marik, Armin Soave,
Andreas Becker, Marianne Schmid, Derya
Tilki, Luis Kluth, Felix Chun, Margit Fisch,
Hamburg, Germany
MP3-17
ENUCLEATION TIME-ENERGY-EFFICACY
(ETEE, ENUCLEATED
WEIGHT/ENUCLEATION TIME/CONSUMED
ENERGY): A MORE APPROPRIATE
PARAMETER FOR ESTIMATING THE
OPERATIVE LEARNING CURVE FOR
PROSTATE (HOLEP)
Tae Beom Kim*, Jin Hyu Oh, Han Jung,
Kyung Jin Chung, Incheon, Korea, Republic
of, Sung Tae Cho, , Korea, Republic of, Khae
Hawn Kim, Kwang Taek Kim, Sang Jin Yoon,
Incheon, Korea, Republic of
MP3-18
URINARY INCONTINENCE AFTER LASER
PROSTATECTOMY FOR BPH –
CONTEMPORARY EXPERIENCE
Abdulrahman Alruwaily*, Rabia Siddiqui,
Maggie Bierlein, Sara Lenherr, John Wei,
Ann Arbor, MI
MP3-20
DEEPGREEN: PROSPECTIVE MRI
EVALUATION OF TISSULAR EFFECTS
AFTER PHOTOSELECTIVE
VAPORIZATION OF THE PROSTATE WITH
GREENLIGHT AMS XPS-180W
Romain Huet*, Romain Mathieu, Tanguy
Rohou, Gregory Verhoest, Karim Bensalah,
Sébastien Vincendeau, Rennes, France
PREDICTORS OF PERIOPERATIVE
COMPLICATIONS AND REOPERATION IN
PATIENTS TREATED WITH
PHOTOSELECTIVE VAPORIZATION OF
THE PROSTATE
Malte Rieken*, Sanwei Guo, Georg Müller,
Gernot Bonkat, Jan Ebbing, Thomas Gasser,
Alexander Bachmann, Basel, Switzerland
CREDITTM
10:30 am - 12:30 pm
PROSTATE CANCER: EPIDEMIOLOGY & NATURAL HISTORY I
Moderators: Neil Fleshner and Stacy Loeb
ABSTRACT
NUMBER TITLE
MP4-01 DEVELOPMENT OF INTERMEDIATE AND
HIGH-RISK PROSTATE CANCER AFTER
TESTICULAR CANCER
Andrew Riggin*, M. Minhaj Siddiqui,
Baltimore, MD
MP4-02
INFLAMMATION IN BENIGN PROSTATE
TISSUE AND PROSTATE CANCER IN THE
FINASTERIDE ARM OF THE PROSTATE
CANCER PREVENTION TRIAL
Teemu Murtola*, Tampere, Finland, Bora
Gurel, Kocaeli, Turkey, Martin Umbehr,
Zurich, Switzerland, Scott Lucia, Denver, CO,
Ian Thompson, San Antonio, TX, Phyllis
Goodman, Alan Kristal, Seattle, WA, Howard
Parnes, Bethesda, MD, Scott Lippman, La
Jolla, CA, Siobhan Sutcliffe, St Louis, MO,
Sarah Peskoe, Charles Drake, William
Nelson, Angelo De Marzo, Elizabeth Platz,
Baltimore, MD
MP4-03
CONTEMPORARY ACTIVE
SURVEILLANCE RATES FOR NEWLY
DIAGNOSED PROSTATE CANCER
PATIENTS IN COMMUNITY UROLOGY
PRACTICES
Jeremy Shelton*, Los Angeles, CA, Phillip
Buffington, Cincinnati, OH, Alec Koo,
Torrance, CA, Neal Shore, Myrtle Beach, SC
MP4-04
CLINICAL OUTCOMES OF
CONSERVATIVELY MANAGED PROSTATE
CANCER AMONG AFRICAN AMERICAN
MEN
Amar Patel*, Martin Sanda, Dattatraya Patil,
Muta Issa, John Petros, Atlanta, GA
MP4-05
USE OF INITIAL ACTIVE SURVEILLANCE
AMONG MEN WITH LOW-RISK PROSTATE
CANCER – FOLLOW UP AND FALL OUT
Maria Komisarenko*, Narhari Timilshina,
Shabbir Alibhai, Alexandre Zlotta, Robert
Hamilton, Girish Kulkarni, Neil Fleshner,
Antonio Finelli, Toronto, Canada
*Presenting author
ABSTRACT
NUMBER TITLE
MP4-06 METASTATIC PROSTATE CANCER IN
MEN ON ACTIVE SURVEILLANCE
Toshihiro Yamamoto*, Danny Vespirini,
Andrew Loblaw, Alezandre Mamedov, Liying
Zhang, Laurence Klotz, Toronto, Canada
27
MP4-07
IS A THRESHOLD VOLUME OF DISEASE
NECESSARY FOR GG3ⴙ4ⴝ7 PROSTATE
CANCER TO METASTASIZE?
Christine Murekeyisoni*, Kristopher Attwood,
Shervin Badkhshan, Kurshid Guru, James
Mohler, Eric Kauffman, Buffalo, NY
MP4-08
ASSOCIATION OF GENETIC
POLYMORPHISMS ACROSS THE TERT
GENE
Jian Kang*, Shanghai, China, People’s
Republic of
MP4-09
ENDOGENOUS AND EXOGENOUS
TESTOSTERONE AND THE RISK OF
PROSTATE CANCER AND PROSTATE
SPECIFIC ANTIGEN
Peter Boyle*, Alice Koechlin, Maria Bota,
Ecully, France, Alberto d’Onofrio, Lyon,
France, David G Zaridze, Moscow, Russian
Federation, Paul Perrin, Lyon, France, John
Fitzpatrick, Dublin, Ireland, Arthur L Burnett,
Baltimore, MD, Mathieu Boniol, Ecully,
France
MP4-10
ONE OUT OF THREE INFERTILE MEN
YOUNGER THAN 40 YEARS HAVE A
TOTAL SERUM PSA VALUE GREATER
THAN 1 NG/ML - FINDINGS OF A CROSSSECTIONAL SURVEY IN WHITEEUROPEAN MEN PRESENTING FOR
COUPLE’S INFERTILITY
Alessandro Serino*, Paolo Capogrosso, Luca
Boeri, Eugenio Ventimiglia, Giovanni La
Croce, Giulia Castagna, Angela Pecoraro,
Marco Paciotti, Silvia Ippolito, Roberta Scano,
Milan, Italy, Rocco Damiano, Catanzaro, Italy,
Francesco Montorsi, Andrea Salonia, Milan,
Italy
FRIDAY
MP3-19
MP4-11
RADICAL PROSTATECTOMY TRENDS IN
THE UNITED STATES: 1998-2011
Mark Tyson*, Scottsdale, AZ, Paul Andrews,
Erik Castle, Phoenix, AZ, Alexander Parker,
Jacksonville, FL
MP4-12
POPULATION-BASED ANALYSIS OF
ADJUVANT RADIATION THERAPY
FOLLOWING RADICAL PROSTATECTOMY
Charles Nottingham*, Sanjay Patel, Scott
Eggener, Stanley Liauw, chicago, IL
MP4-13
CONDITIONAL CANCER SPECIFIC
SURVIVAL FOLLOWING RADICAL
PROSTATECTOMY DEPENDS ON
PREOPERATIVE RISK CLASSIFICATION
Sung-Woo Park, Yangsan-si, Gyeongnam,
Korea, Republic of, Debasish Sundi*,
Zhaoyong Feng, Bruce Trock, Elizabeth
Humphreys, Alan Partin, Misop Han,
Baltimore, MD
MP4-14
MP4-15
LONG-TERM CANCER CONTROL
OUTCOMES IN PROSTATE CANCER (PCA)
PATIENTS TREATED WITH ROBOTICASSISTED LAPAROSCOPIC RADICAL
PROSTATECTOMY (RALP): A MULTIINSTITUTIONAL DATABASE ANALYSIS
Firas Abdollah*, Dane Klett, Akshay Sood,
Jesse Sammon, Daniel Pucheril, Detroit, MI,
Burkhard Beyer, Hamburg, Germany, Nicola
Fossati, Giorgio Gandaglia, Milan, Italy, Craig
Rogers, Hans Stricker, Wooju Jeong, James
Peabody, Detroit, MI, Alexander Haese,
Hamburg, Germany, Francesco Montorsi,
Milan, Italy, Markus Graefen, Hamburg,
Germany, Alberto Briganti, Milan, Italy, Mani
Menon, Detroit, MI
IMPACT OF POSITIVE SURGICAL
MARGINS ON MORTALITY AFTER
RADICAL PROSTATECTOMY BY DISEASE
RISK GROUP
Alexa Meyer*, Danny Lascano, Jamie S Pak,
LaMont Barlow, Jared C Levinson, Rajat E
Lamington, James M McKiernan, Mitchell C
Benson, Manhattan, NY
MP4-16
PATTERNS OF CLINICAL RECURRENCE
AND IMPACT OF SITE OF METASTASIS
ON MORTALITY OF PATIENTS WITH
NODE POSITIVE PROSTATE CANCER
AFTER RADICAL PROSTATECTOMY AND
EXTENDED PELVIC LYMPH NODE
DISSECTION
Alessandro Nini*, Giorgio Gandaglia, Nicola
Fossati, Marco Bianchi, Nazareno Suardi,
Milan, Italy, Firas Abdollah, Detroit, MI,
Shahrokh F. Shariat, Vienna, Austria, Walter
Cazzaniga, Stefano Luzzago, Vito Cucchiara,
Roberto Bertini, Francesco Montorsi, Alberto
Briganti, Milan, Italy
MP4-17
PATHOLOGIC GLEASON 8-10: DO ALL
MEN DO POORLY? RESULTS FROM THE
SEARCH DATABASE
Sean Fischer*, Ross Simon, Lauren Howard,
Durham, NC, William Aronson, Los Angeles,
CA, Martha Terris, August, GA, Christopher
Kane, San Diego, CA, Christopher Amling,
Portland, OR, Matt Cooperberg, San
Francisco, CA, Stephen Freedland, Adriana
Vidal, Durham, NC
MP4-18
REGIONAL VARIATION IN PROSTATE
CANCER DIAGNOSIS IN THE UNITED
STATES: A STUDY OF CONTEMPORARY
MEDICARE BENEFICIARIES
Rachel Moses*, Nino Dsebisashvili, Philip
Goodney, Elias Hyams, Lebanon, NH
MP4-19
NINETY-DAY PERIOPERATIVE
MORTALITY IN RADICAL
PROSTATECTOMY AMONG SWEDISH
MEN 1998 TO 2012
Alexander P Cole*, Boston, MA, Johan
Björklund, Solna, Sweden, Yasin Folkvaljon,
Uppsala, Sweden, Stefan Carlsson,
Stockholm, Sweden, David Robinson,
Jönköping, Sweden, Stacy Loeb, New York,
NY, Pär Stattin, Umeå, Sweden, Olof Akre,
Stockholm, Sweden
MP4-20
CONTEMPORARY INCIDENCE AND
MORTALITY RATES OF
NEUROENDOCRINE PROSTATE CANCER
Aaron Moore*, Shaheen Alanee, Max Nutt,
Danuta Dynda, Ahmed El-Zawahry, Kevin
McVary, Springfield, IL
CREDITTM
28
10:30 am - 12:30 pm
Podium Session 1
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: NEUROGENIC VOIDING DYSFUNCTION I
Moderator: Eric Rovner
ABSTRACT
TIME NUMBER TITLE
10:30 PD1-01 LONG-TERM EFFICACY AND SAFETY OF
ONABOTULINUMTOXINA IN PATIENTS
WITH NEUROGENIC DETRUSOR
OVERACTIVITY: ANALYSIS AMONG
PATIENTS WHO COMPLETED 4 YEARS OF
TREATMENT
Eric Rovner*, Charleston, SC, Alfred Kohan,
Bethpage, NY, Emmanuel Chartier-Kastler,
Paris, France, Klaus-Peter Jünemann, Kiel,
Germany, Giulio Del Popolo, Florence, Italy,
Sender Herschorn, Toronto, Canada, Manher
Joshi, Brenda Jenkins, Irvine, CA, Quanhong
Ni, Bridgewater, NJ, Victor Nitti, New York,
NY
10:40
10:50
11:00
PD1-02
PD1-03
PD1-04
*Presenting author
ABSTRACT
TIME NUMBER TITLE
11:10 PD1-05 HIGHER NEURAL CORRELATES
FOLLOWING INTRAVESICAL BOTULINUM
TOXIN- A IN MULTIPLE SCLEROSIS (MS)
PATIENTS VIA CONCURRENT
FUNCTIONAL MAGNETIC RESONANCE
IMAGING (FMRI) AND URODYNAMIC
STUDIES (UDS)
Michael Shy*, Christof Karmonik, Jeff
Anderson, Abdulaziz Alkattan, Timothy
Boone, Steve Fung, Houston, TX, Sophie
Fletcher, Santa Rosa, CA, Rose Khavari,
Houston, TX
EFFECT OF DETRUSOR BOTULINUM
TOXIN AINJECTION ON THE UROTHELIAL
DYSFUNCTION IN CHRONIC SPINAL
CORD INJUREDBLADDERS ¡V
COMPARISON AMONG BASELINE, 3
MONTHS AND 6 MONTHS AFTER
INJECTION
Sheng-Fu Chen*, Cheng-Ling Lee, Jia-Hui
Chang, Hann-Chorng Kuo, Hualien, Taiwan
DOES REDUCTION OF NUMBER OF
INTRADETRUSOR INJECTION SITES OF
ABOBOTULINUMTOXINA IMPACT
EFFICACY AND SAFETY IN A RAT MODEL
OF NEUROGENIC DETRUSOR
OVERACTIVITY?
Amélie Huynh Le Maux, Montigny-LeBretonneux, France, Bernadette Pignol, Les
Ulis, France, Delphine Behr-Roussel*,
Montigny-Le-Bretonneux, France, Jean-Luc
Blachon, Pierre-Etienne Chabrier, Philippe
Picaut, Les Ulis, France, Jacques Bernabé,
Montigny-Le-Bretonneux, France, Francois
Giuliano, Pierre Denys, Garches, France
DETRUSOR INJECTIONS OF
ONABOTULINUM TOXIN A (BOTOX®)
VERSUS ABOBOTULINUM TOXIN A
(DYSPORT®) IN THE MANAGEMENT OF
NEUROGENIC DETRUSOR
OVERACTIVITY: A CASE CONTROL
STUDY
benoit peyronnet*, Rennes, France, castellacanal evelyne, roumiguie mathieu, marque
philippe, rischmann pascal, game xavier,
Toulouse, France
29
11:20
PD1-06
EFFECT OF ONABOTULINUMTOXINA
TREATMENT FOR NEUROGENIC
DETRUSOR OVER ACTIVITY ON THE
PREVENTION OF AUTONOMIC
DYSREFLEXIA FOLLOWING SPINAL CORD
INJURY
Renee Fougere, Katharine Currie, Lynn
Stothers*, Mark Nigro, Daniel Rapaport,
Andrei Krassioukov, Vancouver, Canada
11:30
PD1-07
INTRADETRUSOR BOTULINUM TOXIN
INJECTIONS FOR THE MANAGEMENT OF
IMPAIRED BLADDER COMPLIANCE
REFRACTORY TO ANTI-CHOLINERGIC
DRUGS
Dane Johnson*, Robert O’Connor, Michael
Guralnick, Milwaukee, WI
11:40
PD1-08
DOES ASYMPTOMATIC BACTERIURIA
INCREASES THE RISK OF UROSEPSIS OR
MODIFIES INTRA-DETRUSOR BOTULINUM
TOXIN A (BONTA) EFFICACY?
Shachar Aharony*, Ornella Lam Van-Ba,
Jaques Corcos, Montreal, Canada
11:50
PD1-09
UROLOGICAL SURVEILLANCE AND
MEDICAL COMPLICATIONS AFTER
SPINAL CORD INJURY IN THE UNITED
STATES
Anne P Cameron*, Ann Arbor, MI, Julie Lai,
Santa Monica, CA, Christopher S Saigal, Los
Angeles, CA, J Quentin Clemens, Ann Arbor,
MI, NIDDK Urological Diseases in America
Project, Santa Monica, CA
12:00
PD1-10
SUPRASPINAL CONTROL OF LOWER
URINARY TRACT FUNCTION IN PATIENTS
WITH SPINAL CORD INJURY: AN FMRI
STUDY
Lorenz Leitner*, Matthias Walter, Patrick
Freund, Ulrich Mehnert, Zürich, Switzerland,
Martina D. Liechti, London, United Kingdom,
Lars Michels, Spyros Kollias, Thomas M.
Kessler, Zürich, Switzerland
FRIDAY
12:10
PD1-11
12:20
SPINAL CORD INJURY INDUCED
TEMPORAL CHANGES IN BLADDER
EXPRESSION OF CYTOKINES INDICATE
ROLE OF INFLAMMATION IN VOIDING
DYSFUNCTION
Subrata Pore*, Mahendra Kashyap, Katsumi
Kadekawa, Naoki Yoshimura, Pradeep Tyagi,
Pittsburgh, PA
PD1-12
HEATING OF THE INTERSTIM SACRAL
NEUROMODULATION DEVICE IN A
SIMULATED PHANTOM MODEL DURING
LUMBAR AND PELVIC MAGNETIC
RESONANCE IMAGING (MRI)
Adrienne Quirouet*, Stephen Jones, Pallab
Bhattacharyya, Howard Goldman, Cleveland,
OH
CREDITTM
10:30 am - 12:30 pm
Podium Session 2
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: PENIS/TESTIS/URETHRA: BENIGN DISEASE
Moderator: Culley Carson, III
ABSTRACT
TIME NUMBER TITLE
10:30 PD2-01 BURIED PENIS IN ADULTS –
PRESENTATION, SURGICAL TECHNIQUES
AND OUTCOME
Tet Yap*, Matus Chocolaty, Raheem Amr,
Giulio Garaffa, Nim Christopher, Suks
Minhas, Ralph David, London, United
Kingdom
ABSTRACT
TIME NUMBER TITLE
11:20 PD2-06 THE ASSESSMENT OF THE ROLE OF
ANDROGEN RECEPTORS AT THE
DEVELOPMENT OF CONGENITAL PENILE
CURVATURE DISEASE
Emre Salabas*, Canan Kucukgergin, Harun
Ozkan, Murat Dincer, Sule Seckin, Ates
Kadioglu, Istanbul, Turkey
10:40
PD2-02
TRENDS IN THE UTILIZATION OF PENILE
PROSTHESES IN THE TREATMENT OF
ERECTILE DYSFUNCTION
Daniel Lee*, Bobby Najari, Wesley Davison,
Bashir Al Hussein Al Awamlh, Fujun Zhao,
John Mulhall, Darius Paduch, Bilal Chughtai,
Richard Lee, New York, NY
11:30
PD2-07
FUNCTIONAL OUTCOMES AND FOLLOWUP CARE AFTER PRIAPISM TREATMENT:
A CONTEMPORARY EXPERIENCE AT A
SINGLE INSTITUTION
Stephen Kappa*, Elizabeth Green, Shreyas
Joshi, Melissa Kaufman, Doug Milam,
Nashville, TN
10:50
PD2-03
NONINFECTED PENILE PROSTHESES
CULTURE DURING REVISION
SURGERIES; COMPARISON BETWEEN
ANTIBIOTIC COATED AND UNCOATED
DEVICES
Seyfettin Ciftci, Kocaeli, Turkey, Tijen Nemut,
Sakarya, Turkey, Melih Culha*, Hasan
Yilmaz, Murat Ustuner, Ufuk Yavuz, Levend
Ozkan, Kocaeli, Turkey
11:40
PD2-08
HIGH RISK OF PRIAPISM IN
RECREATIONAL INTRACAVERNOSAL
DRUG ABUSERS
Gustavo Diaz*, Rafael Yanes, Akshay
Bhandari, Alan Nieder, Miami Beach, FL
11:50
PD2-09
PATIENT SATISFACTION WITH
TESTICULAR PROSTHESIS AFTER
ORCHIECTOMY FOR TESTICULAR
CANCER
Brian Hu*, Hooman Djaladat, Sepehr Shojaei,
Siamak Daneshmand, Los Angeles, CA
12:00
PD2-10
INFLATABLE PENILE PROSTHESIS
FAILURE AND COMPLICATIONS: REVIEW
OF A NATIONAL DATABASE
Judith C Hagedorn, Nathan Osburn*, Scott
Lundy, Seattle, WA, Tanner Miest, Rochester,
MN, Bryan B Voelzke, Seattle, WA
12:10
PD2-11
DOES TUMOR SIZE,
ULTRASONOGRAPHIC FINDINGS, SERUM
HUMAN CHORIONIC
GONADOTROPIN(HCG) LEVEL CAN
PREDICT THE LIKELIHOOD OF BENIGN
TESTICULAR HISTOLOGY?
Gang Song*, Beijing, China, People’s
Republic of
11:00
11:10
PD2-04
PD2-05
TESTOSTERONE REPLACEMENT
THERAPY (TRT) INFREQUENTLY USED IN
HYPOGONADAL MEN
Wendy Poage*, Aurora, CO, Nelson Stone,
New York, NY, E. David Crawford, aurora,
CO
IDIOPATHIC PARTIAL THROMBOSIS IS
ASSOCIATED WITH CYCLING AND THE
PRESENCE OF A FIBROUS WEB ON MRI
Emmanuel Weyne*, Charlotte Schillebeeckx,
Caroline Jamaer, Pieter D’hulst, Leuven,
Belgium, Giorgio Bozzini, Milan, Italy, Richard
Grunert, Burlinghton, VT, Piet Hoebeke,
Gent, Belgium, Steven Joniau, Maarten
Albersen, Leuven, Belgium
30
PD2-12
CREDITTM
TREATMENT OF PRIAPISM IN THE
EMERGENCY DEPARTMENT PRIOR TO
UROLOGIC SURGERY CONSULTATION: A
CONTEMPORARY EXPERIENCE AT A
SINGLE INSTITUTION
Elizabeth Green*, Stephen Kappa, Shreyas
Joshi, Melissa Kaufman, Doug Milam,
Nashville, TN
FRIDAY
12:20
10:30 am - 12:00 pm
Video Session 1
AWARD WINNING VIDEO SESSION
The videos in this session as well as the video libraries from the 2011-2014 Annual Meetings may be viewed in the Surgical Video Library and
purchased in the Products Store during the Annual Meeting. Both are located in Registration Hall B2. All years of the Surgical Video Library may
also be purchased online at www.auanet.org/education/dvdsstreaming-video.cfm.
Moderators: Misop Han and Jay Raman
ABSTRACT
TIME NUMBER TITLE
1st Place
ABSTRACT
TIME NUMBER TITLE
Honorable Mention
V9-10
V5-04
SIMULATED INANIMATE MODEL FOR PHYSICAL
LEARNING EXPERIENCE (SIMPLE) FOR ROBOTIC
PARTIAL NEPHRECTOMY USING A 3-D PRINTED
KIDNEY MODEL
Ahmed Ghazi*, Jonathan Stone, Braden Candela, Michael
Richards, Jean Joseph, Rochester, NY
RESECTABLE PHYSICAL 3-D MODELS UTILIZING
3-D PRINTER TECHNOLOGY FOR ROBOTIC
PARTIAL NEPHRECTOMY
Michael Maddox*, Allison Feibus, Benjamin Lee, Julie
Wang, Raju Thomas, Jonathan Silberstein, New Orleans,
LA
2nd Place
Honorable Mention
V6-01
V8-02
ROBOT ASSISTED FLEXIBLE URETEROSCOPIC
LASER LITHOTRIPSY, WITH AVICENNA ROBOFLEX
Jens Rassweiler*, Heillbronn, Germany, Remzi Saglam,
Ankara, Turkey, Olivier Traxer, Paris, France, A. Sinan
Kabakci, Zafer Tokatli, Abdurrahim Imamoglu, Ankara,
Turkey, Glenn Preminger, Durham, NC
MANAGEMENT OF CHALLENGING URETHRO-ILEAL
ANASTOMOSIS DURING ROBOTIC
INTRACORPOREAL NEOBLADDER FORMATION
Nima Almassi*, Homayoun Zargar, Vishnu Ganesan, Amr
Fergany, Georges Pascal Haber, Cleveland, OH
APPROVED FOR AMA PRA CATEGORY 1 CREDITTM
3rd Place
V11-01 NOTES-ASSISTED LAPAROSCOPIC TRANSVESICAL
BLADDER DIVERTICULECTOMY
Ahmed Magdy*, Michael Mitterberger, Günter Janetschek,
Salzburg, Austria
Honorable Mention
V4-01
PERINEAL ROBOT ASSISTED LAPAROSCOPIC
RADICAL PROSTATECTOMY (P-RALP)
Oktay Akca*, Peter Caputo, Humberto Laydner, Homayoun
Zargar, Daniel Ramirez, Juan Jimenez, Hiury Andrade,
Robert J Stein, Cleveland, OH, Selami Albayrak, Istanbul,
Turkey, Kenneth Angermeier, Jihad H Kaouk, Cleveland,
OH
12:00 pm - 4:00 pm
SOCIETY FOR FETAL UROLOGY (SFU)
Grand BC @ Hilton New Orleans Riverside
12:00
SFU BUSINESS MEETING (SFU MEMBERS
ONLY)
1:30
SESSION 3: SFU PERINATAL UROLOGY
Moderators: Travis Groth, Miguel Castellan
*Presenting author
2:30
SFU PANEL: BLADDER EXSTROPHY
Panelists: Michael Mitchell, Barry Duel, Bradley
Kropp, John Kryger
CREDITTM
31
1:00 pm - 3:00 pm
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: EVIDENCE-BASED MEDICINE & OUTCOMES I
Moderators: Michael Porter and John Hollingsworth
ABSTRACT
NUMBER TITLE
MP5-01 GEOGRAPHIC AND TEMPORAL TRENDS
IN GLOBAL BLADDER CANCER
MORBIDITY AND MORTALITY 1990-2010
Catherine Harris*, Jonathan Brajtbord,
Maxwell Meng, Anobel Odisho, San
Francisco, CA
MP5-02
MP5-03
MP5-04
MP5-05
MP5-06
MP5-07
ABSTRACT
NUMBER TITLE
MP5-08 METFORMIN USE IS ASSOCIATED WITH
DECREASED RISK OF RENAL CELL
CANCER
Abdo Kabarriti*, Ben Boursi, Ronac Mamtani,
Thomas Guzzo, Kevin Haynes, Yu-Xiao
Yang, S. Bruce Malkowicz, Philadelphia, PA
MP5-09
CLEAR CELL RENAL CELL CARCINOMA:
SOCIOECONOMIC PREDICTORS OF
METASTATIC DISEASE AT DIAGNOSIS
Zachary Klaassen*, Augusta, GA, John M.
DiBianco, Roseau, Dominica, Rita P. Jen,
Lael Reinstatler, Austin J. Evans, Qiang Li,
Rabii Madi, Martha K. Terris, Augusta, GA
MP5-10
PROPHYLACTIC PELVIC LYMPH NODE
DISSECTION IN PENILE CANCER
PATIENTS
Rosa Djajadiningrat*, Erik van Werkhoven,
Simon Horenblas, Amsterdam, Netherlands
MP5-11
PERIOPERATIVE OUTCOMES OF
TRANSURETHRAL RESECTION OF
BLADDER TUMORS USING THE
NATIONAL SURGICAL QUALITY
IMPROVEMENT PROGRAM (NSQIP)
DATABASE
David C Brooks*, Devin A. Haddad, Robert C
Kovell, Ryan P Terlecki, Winston Salem, NC
PRIMARY GENITO-URINARY MELANOMA
AMONG MEN AND WOMEN
Alejandro Sanchez*, Dayron Rodriguez,
Christopher B. Allard, Seth K. Bechis, Mark
A. Preston, Jed-Sian Cheng, Glen W.
Barrisford, Adam S. Feldman, Boston, MA
MP5-12
UNDERSTANDING THE RELATIONSHIP
BETWEEN 30- AND 90- DAY EMERGENCY
ROOM VISITS AND READMISSIONS
FOLLOWING RADICAL CYSTECTOMY
E. Sophie Spencer*, Peter Greene, Matthew
Lyons, Anne Marie Meyer, Ke Meng, Raj
Pruthi, Eric Wallen, Michael Woods, Matthew
Nielsen, Angela Smith, Chapel Hill, NC
UNDERSTANDING THE LIMITATIONS OF
PROSTATE-SPECIFIC ANTIGEN TESTING
DOES NOT DETER MEN FROM
UNDERGOING PROSTATE CANCER
SCREENING
Michael Fenstermaker*, Stacy Loeb, Heather
T. Gold, Joseph Ravenell, Danil Makarov,
New York, NY
MP5-13
DOES DIGITAL RECTAL EXAMINATION
PROVIDE ADDITIONAL VALUE IN THE
ERA OF PSA SCREENING?: LESSONS
FROM THE PLCO STUDY
Tao Cui*, Robert C Kovell, David C Brooks,
Ryan P Terlecki, Winston Salem, NC
MP5-14
RANDOMIZED, SINGLE CENTER TRIAL OF
THE EFFECT OF EXTENDING TIME FROM
PERI-PROSTATIC LIDOCAINE INJECTION
TO ONSET OF TRANSRECTAL
ULTRASOUND-GUIDED PROSTATE
BIOPSY ON PATIENT-REPORTED PAIN
SCORES
Ram Pathak*, Alexander Parker, Andrea
Tavlarides, Julia Crook, Nancy Diehl, Scott
Alford, Michael Heckman, Todd Igel,
Jacksonville, FL
PARTIAL CYSTECTOMY FOR
BLADDER: PRACTICE PATTERNS AND
OUTCOMES IN THE GENERAL
POPULATION
Michael Leveridge*, D Robert Siemens,
Jason Izard, Xuejiao Wei, William Mackillop,
David Berman, Christopher Booth, Kingston,
Canada
ADHERENCE AND ADEQUACY OF THE
BLADDER CANCER GUIDELINES FOR
POST-TUR FOLLOW-UP INTERVAL
Takuro Sunada, Takashi Kobayashi*,
Yoshiyuki Matsui, Takahiro Inoue, Tomomi
Kamba, Osamu Ogawa, Kyoto, Japan
90-DAY COMPLICATIONS IN PATIENTS
UNDERGOING RADICAL CYSTECTOMY
ON ENHANCED RECOVERY PROTOCOL
Behrod Katebian*, Soroush Bazargani, Los
Angeles, CA, Hamed Ahmadi, Portland, OR,
Gus Miranda, Jie Cai, Anne Schuckman,
Siamak Daneshmand, Hooman Djaladat, Los
Angeles, CA
AN EMPIRICAL EVALUATION OF
VARIATION IN INTENSITY OF
SURVIVORSHIP CARE AND ITS EFFECT
ON KIDNEY CANCER-SPECIFIC SURVIVAL
William Sohn*, Amy Graves, Sam Chang,
Daniel Barocas, David Penson, Matthew
Resnick, Nashville, TN
32
EMERGING DISPARITY IN TREATMENT
FOR PROSTATE CANCER AMONG
HISPANIC MEN- DATA FROM SEER 20042009
Kelvin Moses*, Nashville, TN, Heather Orom,
Alicia Brasel, Buffalo, NY, Jacquelyne Gaddy,
Chicago, IL, Willie Underwood, III, Buffalo,
NY
MP5-16
EXTERNAL VALIDATION OF 10-YEAR
OTHER CAUSE MORTALITY RISK
ESTIMATION TOOLS FOR MEN NEWLY
DIAGNOSED WITH PROSTATE CANCER
Daniel Frendl*, Gordon FitzGerald, Mara
Epstein, Jennifer Yates, Robert Blute, Jr,
Mitchell Sokoloff, John Ware, Jr, Worcester,
MA
MP5-17
MP5-18
MP5-19
THE IMPACT OF CARE COORDINATION
ON RADICAL PROSTATECTOMY
OUTCOMES
John M. Hollingsworth*, Ann Arbor, MI,
Russell J. Funk, Minneapolis, MN, Spencer
A. Garrison, Jason Owen-Smith, Samuel R.
Kaufman, Ann Arbor, MI, Bruce E. Landon,
Boston, MA, James E. Montie, Brahmajee K.
Nallamothu, Ann Arbor, MI
MP5-20
NOTABLE OUTCOMES AND TRACKABLE
EVENTS AFTER SURGERY (NOTES): A
COMPOSITE MEASURE TO ASSESS
UNCOMPLICATED RECOVERY AFTER
Stacie Myers*, Khurshid Ghani, Rodney
Dunn, Ann Arbor, MI, Brian Lane, Grand
Rapids, MI, Yuqing Gao, Susan Linsell, David
Miller, James Montie, Ann Arbor, MI
RELATIONSHIP BETWEEN PATIENT
EXPECTATIONS, FUNCTIONAL
OUTCOMES, AND PATIENT
SATISFACTION FOLLOWING RADICAL
PROSTATECTOMY
Michael Fenstermaker*, Herbert Lepor, New
York, NY
CREDITTM
A MULTI-INSTITUTIONAL ANALYSIS OF
THE IMPACT OF OBESITY ON
COMPLICATIONS AFTER ROBOTIC VS.
OPEN RADICAL PROSTATECTOMY
Elodi Dielubanza, Apas Aggarwal*, Nicholas
Hackett, Oluwarotimi Nettey, John Kim,
Shilajit Kundu, Chicago, IL
1:00 pm - 3:00 pm
PROSTATE CANCER: MARKERS II
Moderator: Alexander Kutikov
ABSTRACT
NUMBER TITLE
MP6-01 URINARY BIOMARKERS FOR THE
DETECTION OF PROSTATE CANCER IN
PATIENTS WITH HIGH-GRADE
PROSTATIC INTRAEPITHELIAL
NEOPLASIA (HGPIN)
Juan M Bastarós*, Tamara Sequeiros, José
Placer, Jacques Planas, Lucas Regis,
Milagros Sánchez, Marina Rigau, Melania
Montes, Inés de Torres, Jaume Reventós,
Andreas Doll, Juan Morote, Barcelona, Spain
MP6-02
*Presenting author
ABSTRACT
NUMBER TITLE
MP6-03 A NOVEL BIOMARKER SIGNATURE
WHICH MAY PREDICT AGGRESSIVE
DISEASE IN AFRICAN-AMERICAN MEN
WITH PROSTATE CANCER
Kosj Yamoah*, Philadelphia, PA, Michael
Johnson, Baltimore, MD, Voleak Choeurng,
Kasra Yousefi, Zaid Haddad, Vancouver,
Canada, Robert Den, Priti Lal, Michael
Feldman, Adam Dicker, Philadelphia, PA, Eric
Klein, Cleveland, OH, Elai Davicioni, San
Diego, CA, Timothy Rebbeck, Philadelphia,
PA, Edward Schaeffer, Baltimore, MD
LOCATION OF DISEASE DOES NOT
IMPACT PCA3’S ABILITY TO PREDICT
CANCER ON BIOPSY
Padraic O’Malley*, Bashir Al Hussein Al
Awamlh, Daniel P Nguyen, New York, NY,
Martin G Sanda, Atlanta, GA, Ian M
Thompson, San Antonio, TX, John T Wei,
Ann Arbor, MI, Richard Lee, Mark A Rubin,
Christopher E Barbieri, Michael P Hermann,
Douglas S Scherr, New York, NY
MP6-04
33
THE 4KSCORE TEST PREDICTS HIGHGRADE PROSTATE CANCER ON BIOPSY
WITH PSA LESS THAN 4 NG PER
MILLILITER
Vinita Mathur, Vincent Linder, Yan Dong,
Miami, FL, Dan Sjoberg*, New York, NY,
Richard Roberts, Michael Reeve, David
Okrongly, Jay Newmark, Grannum Sant,
Mitchell Steiner, Miami, FL
FRIDAY
MP5-15
MP6-05
MP6-06
MP6-07
MP6-08
MP6-09
THE ASSOCIATION OF PREOPERATIVE
NEUTROPHIL TO LYMPHOCYTE RATIO
WITH ONCOLOGIC OUTCOMES
FOR PROSTATE CANCER
Vidit Sharma*, Patrick A Cockerill, Boyd R
Viers, Laureano J Rangel, Rachel E Carlson,
R. Jeffrey Karnes, Matthew K Tollefson,
Rochester, MN
PROSTATE HEALTH INDEX PREDICTS
UPGRADING OF MEN ON 5-ALPHA
REDUCTASE INHIBITORS
E. David Crawford*, Paul Arangua, Clifford
Jones, Wendy Poage, Aurora, CO, Nelson
Stone, New York, NY, Francisco G. La Rosa,
Aurora, CO, Stacy Loeb, New York, NY,
Priya N. Werahera, Aurora, CO
SENSITIVITY OF [-2]PROPSA AS AN
ULTRASENSITIVE PSA SURROGATE FOR
THE PREDICTION OF EARLY
BIOCHEMICAL RECURRENCE AFTER
RADICAL PROSTATECTOMY: AN
OBSERVATIONAL COHORT STUDY
Massimo Lazzeri*, Giovanni Lughezzani,
Alberto Abrate, Andrea Losa, Alessandro
Mistretta, Nicolò Maria Buffi, Giuliana Lista,
Giulio Maria Gadda, Alessandro Larcher,
Nicola Fossati, Paolo Dell’Oglio, Milan, Italy,
Vittorio Bini, Perugia, Italy, Ferruccio Ceriotti,
Giorgio Guazzoni, Milan, Italy
A RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED STUDY OF THE
EFFECTS OF POMEGRANATE EXTRACT
ON RISING PROSTATE SPECIFIC
ANTIGEN (PSA) LEVELS IN MEN
FOLLOWING PRIMARY THERAPY FOR
PROSTATE CANCER
Allan Pantuck*, Los Angeles, CA, Curtis
Pettaway, Houston, TX, Robert Dreicer,
Cleveland, OH, John Corman, Seattle, WA,
Andrew Ho, Aaron Katz, Garden City, NY,
William Aronson, Sylmar, CA, William Clark,
Anchorage, AK, Garrick Simmons, Missoula,
MT, David Heber, Los Angeles, CA
MOLECULAR AND CLINICAL
CHARACTERIZATION OF 1,577 PRIMARY
PROSTATE CANCER TUMORS REVEALS
NOVEL CLINICAL AND BIOLOGICAL
INSIGHTS INTO ITS SUBTYPES
Scott Tomlins*, Ann Arbor, MI, Mohammed
Alshalalfa, Nicholas Erho, kasra yousefi,
Vancouver, Canada, shuang zhao, Ann
Arbor, MI, robert den, adam dicker,
philadelphia, PA, bruce trock, Angelo
Demarzo, Ashley Ross, Edward Schaeffer,
Baltimore, MD, Erick Klein, Cristina MagiGalluzzi, cleveland, OH, jeffery karnes, Rober
Jenkins, Rochester, MN, elai davicioni,
vancouver, Canada, Felix Feng, Ann Arbor,
MI
34
MP6-10
TISSUE SPECIFIC EXPRESSION OF
ANDROGEN RECEPTOR VARIANT 7 IN
PROSTATE CANCER PROGRESSION: A
POTENTIAL ROLE OF ARV7 IN
CARCINOGENESIS
Tyler M. Bauman*, Emily A. Ricke, Wei
Huang, William A. Ricke, Madison, WI
MP6-11
A NOVEL BLOOD-BASED ASSAY FOR
DETECTING ANDROGEN RECEPTOR
SPLICE VARIANTS IN PATIENTS WITH
ADVANCED PROSTATE CANCER
Xichun Liu, Elisa Ledet, Yanfeng Qi, Yan
Dong, Oliver Sartor, Haitao Zhang*, New
Orleans, LA
MP6-12
EPIGENETIC ASSAY STRATIFIES
PROSTATE CANCER PATIENTS’ RISK
FOR AGGRESSIVENESS
Leander Van Neste, Maastricht, Netherlands,
Wim Van Criekinge*, Ghent, Belgium, Joseph
Bigley, Irvine, CA, William E Grizzle, George
W Adams, Birmingham, AL, Gary P Kearney,
Sandra M Gaston, Boston, MA
MP6-13
PTEN LOSS BY
IMMUNOHISTOCHEMISTRY IS
ASSOCIATED WITH BIOCHEMICAL
RECURRENCE IN ERG-NEGATIVE
PROSTATE TUMORS: A STUDY OF THE
CANARY COHORT
Tamara L. Lotan*, Baltimore, MD, Wei Wei,
Houston, TX, Carlos L. Morais, Baltimore,
MD, Ziding Feng, Houston, TX, Sarah
Hawley, Baltimore, MD, Ladan Fazli, Antonio
Hurtado-Coll, Vancouver, Canada, Dean
Troyer, Fairfax, VA, Jesse McKenney,
Cleveland, OH, Jeff Simko, San Francisco,
CA, Lawrence True, Seattle, WA, James D.
Brooks, CAnary Pathology Team
Investigating Tissue Biomarkers (CAPIT),
Palo Alto, CA
MP6-14
DNA METHYLATION ABERRATIONS IN
GLEASON PATTERN 4 PROSTATIC
CARCINOMA WITH CRIBRIFORM
ARCHITECTURE OR INTRADUCTAL
CARCINOMA: A RADICAL
PROSTATECTOMY STUDY
Ekaterina Olkhov-Mitsel*, Farshid Siadat,
Toronto, Canada, Dominique Trudel,
Montreal, Canada, Ken Kron, liyang Liu, Neil
E. Fleshner, Theodorus Van der Kwast,
Bharati Bapat, Toronto, Canada
MP6-15
PTEN LOSS AND ERG EXPRESSION IN
PROSTATE CANCER SURVIVAL
Thomas Ahearn*, Andreas Pettersson, Ericka
Ebot, Travis Gerke, Boston, MA, Carlos De
Morais, Jessica Hicks, Baltimore, MD,
Kathryn Wilson, Jennifer Rider, Boston, MA,
Michelangelo Fiorentino, Bologna, Israel,
Stephen Finn, Dublin, Ireland, Edward
Giovannucci, Massimo Loda, Meir Stampfer,
Boston, MA, Angelo De Marzo, Baltimore,
MD, Lorelei Mucci, Boston, MA, Tamara
Lotan, Baltimore, MD
MP6-17
MP6-18
GERMLINE VARIANTS WITHIN THE PTEN/
PI3K AXIS AND ASSOCIATION WITH
CASTRATE RESISTANT PROSTATE
CANCER AND PROSTATE CANCER
SPECIFIC MORTALITY
Ryan Kopp*, New York, NY, John Sullivan,
Dublin, Ireland, James Hayes, James
Eastham, Kenneth Offit, Joseph Vijai, Robert
Klein, New York, NY
MP6-19
PREOPERATIVE SERUM TRIGLYCERIDE
LEVEL IS A POTENTIAL PREDICTOR OF
Minyong Kang*, Chang Wook Jeong, Ja
Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim,
Seoul, Korea, Republic of
MP6-20
THE ROLE OF THE INSULIN LIKE
GROWTH FACTOR (IGF) AXIS IN
PREDICTING BIOCHEMICAL
RECURRENCE FOLLOWING RADICAL
PROSTATECTOMY
Kieran J Breen*, Noel M Fitzgerald, Yue Fan,
Susie Boyce, Amanda O’Neill, John M
Fitzpatrick, R William Watson, Dublin, Ireland
PREDICTIVE VALUE OF PLASMA
SOLUBLE MET PROTEIN
CONCENTRATION IN PATIENTS WITH
PROSTATE CANCER
Deborah R. Kaye, Baltimore, MD, Peter A.
Pinto, Fabiola Cecchi, Joseph Reilly,
Bethesda, MD, Alice Semerjian*, Washington,
DC, Alessio Giubellino, Bethesda, MD, Gopal
Gupta, Chicago, IL, Peter L. Choyke, W.
Marston Linehan, Donald P. Bottaro,
Bethesda, MD
CREDITTM
PROSTATE CANCER RECURRENCE CAN
BE PREDICTED BY MEASURING
NUCLEAR ORGANIZATION AND SHAPE
PARAMETERS IN ADJACENT BENIGN
REGIONS ON RADICAL PROSTATECTOMY
SPECIMENS
George Lee*, Cleveland, OH, Robert Veltri,
Baltimore, MD, Sahirzeeshan Ali, Cleveland,
OH, Jonathan Epstein, Christhunesa
Christudass, Baltimore, MD, Anant
Madabhushi, Cleveland, OH
1:00 pm - 3:00 pm
BLADDER CANCER: UPPER TRACT TCC II
Moderators: Thomas Jarrett and Michael Grasso
ABSTRACT
NUMBER TITLE
MP7-01 PREOPERATIVE NOMOGRAM TO
PREDICT PERIOPERATIVE
COMPLICATIONS AFTER RADICAL
NEPHROURETERECTOMY
Yu-Kuan Lin*, Hershey, PA, Tobias Klatte,
Shahrokh Shariat, Vienna, Austria, LauraMaria Krabbe, Vitaly Margulis, Dallas, TX,
Alex Arnouk, Costas Lallas, Edouard
Trabulsi, Philadelphia, PA, Gregory Bozzini,
Pierre Colin, CHRU Lille, France, Sarah
Drouin, Morgan Rouprêt, Paris, France,
Benoit Peyronnet, Karim Bensalah, Rennes,
France, Kari Bailey, David Canes, Burlington,
MA, Jay Raman, Hershey, PA
*Presenting author
ABSTRACT
NUMBER TITLE
MP7-02 THE SYSTEMIC INFLAMMATION-BASED
GLASGOW PROGNOSTIC SCORE AS A
POWERFUL PROGNOSTIC FACTOR IN
PATIENTS WITH UPPER TRACT
Teruo Inamoto*, Takatsuki, Japan, Shigeru
Sakano, Kitakyushu, Japan, Tomoaki Takai,
Kazumasa Komura, Taizo Uchimoto, Kenkichi
Saito, Naoki Tanda, Koichiro Minami,
Takatsuki, Japan, Kazuhiro Nagao, Ryo
Inoue, Ube, Japan, Kiyoshi Takahara,
Takatsuki, Japan, Hideyasu Matsuyama, Ube,
Japan, Haruhito Azuma, Takatsuki, Japan
MP7-03
35
IS THERE A CORRELATION OF
HISTOPATHOLOGIC FEATURES WHICH
PREDICT UPPER TRACT UROTHELIAL
CYSTECTOMY?
Anvi Raina, Louis Krane*, Ahmed
Aboumohamed, Ashok K Hemal, Winston
Salem, NC
FRIDAY
MP6-16
MP7-04
PREOPERATIVE PREDICTIVE FACTORS
OF ENDOSCOPIC MANAGEMENT IN
UROTHELIAL CANCER
Jae yong Jeong, Young hyo Choi, Joon
hyung Park*, Sang eun Lee, Sin woo Lee,
Hyun hwan Sung, seoul, Korea, Republic of,
Jeong hee Hong, Cheonan, Korea, Republic
of, Hwang gyun Jeon, Byong chang Jeong,
Seong il Seo, Hyun moo Lee, Han yong Choi,
Seong soo Jeon, seoul, Korea, Republic of
MP7-05
PROGNOSTIC VALUE OF THE PT3
SUBCLASSIFICATION FOR UPPER TRACT
UROTHELIAL CARCINOMAS OF THE
RENAL PELVICALYCEAL SYSTEM
Thomas Seisen*, Eva Compérat, Paris,
Léon, Laurent Nison, Paris, France, Gregory
Bozzini, Lille, France, Christian Pfister,
Rouen, France, Laurent Guy, Clermont
Ferrand, France, Alain Ruffion, Lyon, France,
Jean Luc Descotes, Paris, France, Jacques
Irani, Poitiers, France, Alexandre De La
Taille, Créteil, France, Thierry Lebret,
Suresnes, France, Olivier Cussenot, Paris,
France, Shahrokh Shariat, Vienna, Austria,
Morgan Rouprêt, Paris, France
MP7-06
MP7-07
MP7-08
MULTICENTER EXTERNAL VALIDATION
OF A POST-OPERATIVE NOMOGRAM FOR
PREDICTING THE RISK OF
INTRAVESICAL RECURRENCE AFTER
RADICAL NEPHROURETERECTOMY FOR
Thomas Seisen*, Vincent Hupertan, Paris,
Léon, Gregory Bozzini, Paris, France, Laurent
Nison, Lille, France, Véronique Phé, François
Rozet, Pierre Mozer, Olivier Cussenot, Paris,
France, Shahrokh Shariat, Vienna, Austria,
Morgan Rouprêt, Paris, France
ENDOSCOPIC MANAGEMENT FOR UPPER
TRACT UROTHELIAL CANCER (UTUC)
COMPARED TO IMMEDIATE
NEPHROURETERECTOMY: SURVIVAL
OUTCOMES IN SEER DATABASE AND
CANCER CENTER COHORT
Katie Murray*, Andrew Winer, Aditya
Bagrodia, Samuel Kaffenberger, Michael
Vacchio, Alexander Sankin, Eugene Cha,
Nicole Benfante, Guido Dalbagni, New York,
NY, Joel Vetter, St. Louis, MO, Jonathan
Coleman, New York, NY, Seth Strope, St.
Louis, MO
THE COMPREHENSIVE COMPLICATION
INDEX (CCI) IS MORE ACCURATE THAN
THE CLAVIEN-DINDO GRADING SYSTEM
IN PREDICTING LENGTH OF STAY
FOLLOWING RADICAL
NEPHROURETERECTOMY
Rosa Park*, Chris Rjepaj, Jay D. Raman,
Hershey, PA
36
MP7-09
INCREASED EZH2 EXPRESSION IS
ASSOCIATED WITH ADVERSE
ONCOLOGIC OUTCOMES FOLLOWING
RADICAL NEPHROURETERECTOMY
Jay D. Raman*, Carla Caruso, Zhaohai Yang,
David DeGraff, Hershey, PA, Shahrokh
Shariat, Vienna, Austria, Jose Karam,
Christopher Wood, Houston, TX, Alon
Weizer, Ann Arbor, MI, Mesut Remzi, Andrea
Haitel, Vienna, Austria, Karim Bensalah,
Nathalie Rioux-Leclerq, Rennes, France,
Christian Bolenz, Mannheim, Germany,
Marco Roscigno, Bergamo, Italy, Laura-Maria
Krabbe, Payal Kapur, Yair Lotan, Vitaly
MP7-10
THE PROGNOSTIC IMPACT OF HISTONE
H3K27 TRIMETHYLATION REGULATED
BY EZH2 IN PATIENTS WITH UPPER
CARCINOMA
Yasumasa Miyazaki*, Takeo Kosaka, Shuji
Mikami, Eiji Kikuchi, Nobuyuki Tanaka, Yota
Yasumizu, Akira Miyajima, Yasunori Okada,
MP7-11
PROGNOSTIC IMPACT OF
NUCLEOPHOSMIN/B23 EXPRESSION IN
(UTUC) IN PATIENTS UNDERGOING
RADICAL NEPHROURETERECTOMY (RNU)
Harutake Sawazaki*, Keiichi Ito, Takako
Asano, Kenji Kuroda, Akinori Sato, Junichi
Asakuma, Akio Horiguchi, Kenji Seguchi,
Tomohiko Asano, Tokorozawa, Japan
MP7-12
DETECTION OF FGFR3 MUTATIONS FROM
URINE SEDIMENT DNA TO PREDICT THE
RISK OF INTRAVESICAL RECURRENCE
AFTER RADICAL
Thomas Seisen*, Morgan Rouprêt, Géraldine
Cancel-Tassin, Priscilla Léon, Eva Compérat,
Sarah Drouin, Véronique Phé, Raphaële
Renard-Penna, Pierre Mozer, Olivier
Cussenot, Paris, France
MP7-13
GENETIC SIGNATURES ARE ASSOCIATED
WITH ADVERSE PATHOLOGIC AND
CLINICAL OUTCOMES IN PATIENTS WITH
(UTUC)
Aditya Bagrodia*, Eugene Cha, New York,
NY, John Sfakianos, New, NY, Gopa Iyer,
Byron Lee, Sasinya Scott, Emily Zabor,
Ronak Shah, Qinghu Ren, Philip Kim, Ari
Hakimi, Irina Ostrovnaya, Jonathan
Rosenberg, Guido Dalbagni, Dean Bajorin,
Victor Reuter, Michael Berger, Bernard
Bochner, Hikmat Al-Ahmadie, David Solit,
Jonathan Coleman, New York, NY
MP7-15
EXPRESSION OF STEROID HORMONE
RECEPTORS AND ITS PROGNOSTIC
SIGNIFICANCE IN UROTHELIAL
CARCINOMA OF THE UPPER URINARY
TRACT (UCUUT)
Eiji Kashiwagi*, Baltimore, MD, Kazutoshi
Fujita, Suita, Japan, Seiji Yamaguchi, Hiroaki
Fushimi, Osaka, Japan, Leonardo Reis,
George Netto, Baltimore, MD, Norio
Nonomura, Suita, Japan, Hiroshi Miyamoto,
Baltimore, MD
SIMPLE PREDICTION OF
POSTOPERATIVE RENAL FUNCTION
WITH DYNAMIC CT BEFORE
NEPHROURETERECTOMY: THE RATIO OF
RENAL CORTEX ENHANCEMENT
BETWEEN DISEASED AND
CONTRALATERAL KIDNEY
Yuma Waseda*, Yudai Ishikawa, Keizou
Kawano, Ibaraki, Japan, Kazunori Kihara,
Tokyo, Japan, Shinji Morimoto, Ibaraki, Japan
MP7-16
MOLECULAR DIAGNOSIS OF LYMPH
NODE METASTASIS IN PATIENT WITH
UPPER URINARY TRACT CANCER WHO
HAD EXTENDED LYMPHADENECTOMY
Yoshiki Kodama*, Nagahide Matsumura,
Yasuo Kohjimoto, Isao Hara, Wakayama,
Japan, Tsunenori Kondo, Tokyo, Japan
MP7-17
HISTOLOGICAL VARIANTS OF UPPER
CARCINOMA: THE 18-YEAR MSKCC
EXPERIENCE
Andrew Winer*, Michael Vacchio, Katie
Murray, Samuel Kaffenberger, Aditya
Bagrodia, Eugene Cha, Alexander Sankin,
John Sfakianos, Guido Dalbagni, Jonathan
Coleman, New York, NY
MP7-18
EXTERNAL VALIDATION OF TALL SCORE
FOR PREDICTION OF ONCOLOGICAL
OUTCOMES OF HIGH GRADE UPPER
TRACT UROTHELIAL CARCINOMA AFTER
RADICAL NEPHROURETERECTOMY
Kyle Spradling*, Zhamshid Okhunov, Orange,
CA, Yair Lotan, Arthur Sagalowsky, Dallas,
TX, Shahrokh Shariat, Vienna, Austria, Jaime
Landman, Ramy Youssef, Orange, CA
MP7-19
EARLY REPEATED URETEROSCOPY
WITHIN 6-8 WEEKS AFTER A PRIMARY
ENDOSCOPIC TREATMENT IN PATIENTS
WITH UPPER TRACT UROTHELIAL CELL
CARCINOMA - PRELIMINARY FINDINGS
Luca Villa*, Jonathan Cloutier, Julien
Letendre, Achilles Ploumidis, Paris, France,
Andrea Salonia, Milan, Italy, Jean-Nicolas
Cornu, Paris, France, Francesco Montorsi,
Milan, Italy, Olivier Traxer, Paris, France
MP7-20
THE ASSOCIATION BETWEEN
RESECTION OF BLADDER CANCERS
AROUND URETERAL ORIFICES AND
UPPER TRACT UROTHELIAL CANCERS
Muammer Altok, Isparta, Turkey, Ali
Feyzullah şahin*, SItkI Ün, Osman Koca,
Rauf Taner Divrik, Izmir, Turkey
CREDITTM
1:00 pm - 3:00 pm
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: BASIC RESEARCH I
Moderators: Matthew Fraser and Karl-Dietrich Sievert
ABSTRACT
NUMBER TITLE
MP8-01 THE ESTABLISHMENT OF AN
UNDERACTIVE BLADDER MODEL
FOLLOWING A HYSTERECTOMY IN
MONKEY
Daisuke Wakamatsu*, Jun Kida, Takeya
Otsuki, Hiroki Okada, Hidekazu Matsuya,
Osaka, Japan, Noritoshi Sekido, Tokyo,
Japan
MP8-02
*Presenting author
ABSTRACT
NUMBER TITLE
MP8-03 SKELETAL MYOGENIC DIFFERENTIATION
OF URINE-DERIVED STEM CELLS,
ANGIOGENESIS AND INNERVATION
USING HYDROGEL LOADED WITH
GROWTH FACTORS FOR POTENTIAL IN
TREATMENT OF URINARY
INCONTINENCE
Guihua Liu, Rajesh Pareta, Rongpei Wu,
Yingai Shi, Chunhua Deng, Xiaobo Zhou,
Anthony Atala, Emmanuel Opara, Yuanyuan
Zhang*, Winston Salem, NC
CHARACTERIZATION OF THE MURINE
BLADDER RESPONSE TO SUBTOTAL
CYSTECTOMY: A MODEL OF MAMMALIAN
ORGAN REGENERATION
Grace Delos Santos*, Maywood, IL, Andrew
Flum, Natalie Kukulka, Robert Dettman,
Edward Gong, Chicago, IL
MP8-04
37
UNDERACTIVE BLADDER IN OBESEPRONE RATS FED A HIGH FAT DIET
Nazema Siddiqui*, Alexis Dieter, Cindy
Amundsen, Jillene Brooks, Danielle Degoski,
Matthew Fraser, Durham, NC
FRIDAY
MP7-14
MP8-05
OBESITY-INDUCED METABOLIC
SYNDROME PROMOTE LOWER URINARY
TRACT SYMPTOMS (LUTS) IN A MOUSE
MODEL
Qiqi He, Sanjeev Shukla, Cleveland, OH,
Zhiping Wang, Lanzhou, China, People’s
Republic of, Guiming Liu, Bernadette Erokwu,
Chris Flask, Lan Lu, Melissa Babcook, Firouz
Daneshgari, Sanjay Gupta*, Cleveland, OH
MP8-12
A NEUROTROPHIC AGENT, NHEXACOSANOL, PREVENTS THE
DEVELOPMENT OF BLADDER
HYPERACTIVITY IN A RAT MODEL OF
CHRONIC BLADDER ISCHEMIA
Masanori Nomiya*, Mozomu Miyazaki,
Kentaro Ikegami, Koriyama, Japan, Takahisa
Noma, Yukio Hayashi, Tsukuba, Japan,
Osamu Yamaguchi, Koriyama, Japan
MP8-06
PREVENTIVE EFFECTS OF CALORIC
RESTRICTION ON AGING-ASSOCIATED
BIOLOGICAL AND MOLECULAR CHANGES
IN THE RAT BLADDER AND DORSAL
ROOT GANGLIA
Hiroki Ito*, Naoki Aizawa, Rino Sugiyama,
Jun Kamei, Yoshiyuki Akiyama, Koji Ichihara,
Yasunori Fujita, Tokyo, Japan, Toshio
Kojima, Aichi, Japan, Yukio Homma, Tokyo,
Japan, Yoshinobu Kubota, Yokohama, Japan,
Masafumi Ito, Tokyo, Japan, Karl-Erik
Andersson, Aarhus, Denmark, Yasuhiko
Igawa, Tokyo, Japan
MP8-13
PLASMID-BASED CELL-SPECIFIC GENE
TRANSFER TO TREAT OVERACTIVE
BLADDER SYNDROME
Aryeh Keehn*, Moses Tar, Kelvin Davies,
Sylvia Suadicani, Arnold Melman, Bronx, NY
MP8-14
THE BENEFICIAL EFFECT OF
RESVERATROL ON BLADDER FUNCTION
IN A RAT MODEL OF CHRONIC BLADDER
ISCHEMIA
Norifumi Sawada*, Satoru Kira, Tatsuya
Ihara, Yuki Imai, Nobuhiro Takahashi,
Hidenori Zakohji, Chuo, Japan, Masanori
Nomiya, Koriyama, Japan, Masayuki Takeda,
Chuo, Japan
MP8-15
ELECTRICAL STIMULATION OF THE
SPINAL DORSAL ROOT INHIBITS REFLEX
BLADDER CONTRACTION AND
EXTERNAL URETHRA SPHINCTER
ACTIVITY: IS THIS HOW SACRAL
NEUROMODULATION WORKS?
Jian Ren*, Beijing, China, People’s Republic
of, Daniel Chew, Nikesh Thiruchelvam,
Cambridge, United Kingdom
MP8-16
CHRONIC BILATERAL PUDENDAL NERVE
ELECTRICAL STIMULATION IMPROVES
RECOVERY FROM SIMULATED
CHILDBIRTH INJURY IN A STRESS
URINARY INCONTINENCE MODEL
Kangli Deng*, Danli Lin, Brett Hanzlicek,
Qi-Xiang Song, Hui Zhu, Margot Damaser,
Cleveland, OH
MP8-17
HIPPOCAMPAL MICROSTIMULATION OR
MICROINJECTION OF NMDA IONOTROPIC
GLUTAMATE RECEPTOR ANTAGONIST
INHIBITS MICTURITION REFLEX IN
URETHANE-ANESTHETIZED RATS
Yosuke Matsuta*, Satoshi Yokoi, Fukui,
Japan, Bing Shen, James R. Roppolo,
William C. de Groat, Changfeng Tai,
Pittsburgh, PA, Osamu Yokoyama, Fukui,
Japan
MP8-18
THE ROLE OF THE BRAINSTEM IN TIBIAL
INHIBITION OF THE MICTURITION
REFLEX IN CATS
Matthew Ferroni*, Richard Slater, Bing Shen,
Zhiying Xiao, Jicheng Wang, Andy Lee,
James Roppolo, William de Groat, Changfeng
Tai, Pittsburgh, PA
MP8-07
MP8-08
MP8-09
MP8-10
MP8-11
HIGH FAT DIET IS RELATED TO BLADDER
DYSFUNCTION: AN URODYNAMICCONTROLLED EXPERIMENTAL STUDY
UM RATS
Andre Matos Oliveira*, Fernando F Fonseca,
Sabrina T Reis, Luiz O Leiria, Katia R Leite,
William C Nahas, Miguel Srougi, Alberto A
Antunes, Sao Paulo, Brazil
PROLONGED ISCHEMIA MEDIATES
OVERACTIVE BLADDER TRANSITION TO
UNDERACTIV BLADDER
Zuohui Zhao, Jing-Hua Yang, Portia
Thurmond, Kazem Azadzoi*, Boston, MA
A NEW MATERIAL TO BE USED AS A
URETHRAL COVERAGE LAYER DURING
THE IMPLANTATION OF ARTIFICIAL
DEVICES
Salvador Vilar Correia Lima*, Marcı́lio
Romero Machado, Flávia Cristina Pinto,
Mariana Montenegro de Melo Lira, Olávio
Campos Jr, Danielly Karla Leal de Lima, José
Lamartine de Andrade Andrade, Recife,
Brazil
REDUCTION IN PELVIC ORGAN
PROLAPSE IN LYSYL OXIDASE LIKE-1
(LOXL1) KNOCKOUT (KO) MICE USING A
CELL BASED THERAPY
Bruna M. Couri*, Brittaney Wilson-Harris,
Javier Pizarro-Berdichevsky, Ali Borazjani,
Samantha D. Gonzalez-Ramos, Geerke
Dijkema, Mei Kuang, Brian M. Balog, Margot
S. Damaser, Cleveland, OH
QUALITY, ACCESSIBILITY AND
READABILITY OF ONLINE HEALTH
INFORMATION ON URINARY
INCONTINENCE
Hendrik Borgmann*, Jan-Henning Wölm,
Michael Reiter, Kilian Gust, Stefan Vallo,
Georg Bartsch Jr, Roman Blaheta, Igor
Tsaur, Axel Haferkamp, Frankfurt, Germany
38
MP8-20
A NEW MECHANISM OF INFECTIONINDUCED BLADDER HYPERACTIVITY:
LIPOPOLYSACCHARIDE CAUSES RAPID
ATP RELEASE FROM UROTHELIUM AND
STIMULATES THE MECHANOSENSORY
AFFERENT PATHWAY
Kentaro Takezawa*, Makoto Kondo, Hiroshi
Kiuchi, Tetsuji Soda, Shinichiro Fukuhara,
Suita, Japan, Tetsuya Takao, Osaka, Japan,
Yasushi Miyagawa, Suita, Japan, Akira
Tsujimura, Tokyo, Japan, Kazumasa
Matsumoto-Miyai, Awaji, Japan, Shoichi
Shimada, Norio Nonomura, Suita, Japan
ONABOTULINUMTOXINA VERSUS
ABOBOTULINUMTOXINA: POTENCY AND
DIFFUSION CAPACITY ON THE BLADDER
WALL
Raquel Oliveira, Ana Coelho, Antonio
Avelino, Francisco Cruz*, Porto, Portugal
CREDITTM
1:00 pm - 3:00 pm
Podium Session 3
ADRENAL
Moderators: Rajeev Kumar and Howard Winfield
TIME
1:00
1:10
ABSTRACT
NUMBER TITLE
PD3-01 OPEN VERSUS ROBOTIC
ADRENALECTOMY – A MATCHED PAIR
ANALYSIS
Kai Probst*, Carsten Ohlmann, Stefan
Siemer, Michael Stöckle, Martin Janssen,
Homburg, Germany
PD3-02
IN PRIMARY ALDOSTERONISM WITH
BILATERAL ADRENAL ADNOMAS,
LAPAROSCOPIC BILATERAL ADRENAL
SURGERY COULD BE AN OPTIONAL
TREATMENT UNDER SELECTIVE
ADRENAL VENOUS SAMPLING
Yoshihide Kawasaki*, Shigeto Ishidoya,
Akihiro Ito, Yasuhiro Kaiho, Ryo Morimoto,
Kei Takase, Yoichi Arai, Sendai, Japan
1:20
PD3-03
RATIONALE FOR PARTIAL
ADRENALECTOMY: REVIEW OF DANGERS
TO ADRENAL GLAND
Alosh Madala*, Michael Daugherty, Gennady
Bratslavsky, Syracuse, NY
1:30
PD3-04
LESS POSTERIOR
RETROPERITONEOSCOPIC
ADRENALECTOMY: STEP-BY-STEP
TECHNIQUE DESCRIPTION AND
COMPARISON WITH 3-PORTS LATERAL
RETROPERITONEAL APPROACH
Marcos Tobias-Machado, Igor Nunes-Silva*,
Marcel A. Silveira, Oseas Castro Neves,
Alexandre Kyoshi Hidaka, Antonio Carlos
Lima Pompeo, São Paulo, Brazil
1:40
PD3-05
*Presenting author
ABSTRACT
TIME NUMBER TITLE
1:50
PD3-06 IMPACT OF PRIMARY HISTOLOGY ON
DISEASE FREE SURVIVAL AFTER
MINIMALLY INVASIVE ADRENALECTOMY
FOR METASTATIC CANCER
Mariaconsiglia Ferriero*, Rome, Italy,
Giuseppe Simone, Turin, Italy, Rocco
Papalia, Riccardo Mastroianni, Salvatore
Guaglianone, Michele Gallucci, Rome, Italy
RECURRENT SOMATIC MUTATIONS
UNDERLIE CORTICOTROPININDEPENDENT CUSHING’S SYNDROME
Shigekatsu Maekawa*, Tokyo, Japan, Yusuke
Sato, Kyoto, Japan, Toru Nakagawa, Haruki
Kume, Tokyo, Japan, Seishi Ogawa, Kyoto,
Japan, Yukio Homma, Tokyo, Japan
39
2:00
PD3-07
CONDITIONAL SURVIVAL ANALYSIS FOR
PATIENTS WITH ADRENAL CORTICAL
CARCINOMAS: RESULTS FROM
POPULATION-BASED DATA
Yuanyuan Qu*, Yao Zhu, Dingwei Ye,
2:10
PD3-08
IMPACT OF IMPAIRED GLUCOSE
TOLERANCE ON THE DEVELOPMENT OF
HYPOGLYCEMIA FOLLOWING REMOVAL
OF PHEOCHROMOCYTOMA
Manabu Tatokoro*, Yasukazu Nakanishi,
Yoshinobu Komai, Yoh Matsuoka, Junichiro
Ishioka, Noboru Numao, Takanobu
Yoshimoto, Kazutaka Saito, Yasuhisa Fujii,
Yoshihiro Ogawa, Kazunori Kihara, Tokyo,
Japan
2:20
PD3-09
PHEOCHROMOCYTOMA: A COMPARISON
OF PERIOPERATIVE MANAGEMENT WITH
CALCIUM CHANNEL BLOCKERS AND
SELECTIVE AND NON-SELECTIVE ALPHA
RECEPTOR BLOCKERS
Ryan W Zipper*, Clinton D Bahler, M
Francesca Monn, David Y Yang, Matthew J
Mellon, Chandru P Sundaram, Indianapolis,
IN
2:30
PD3-10
PREOPERATIVE BODY MASS INDEX
PREDICTS THE NEED OF
POSTOPERATIVE CATECHOLAMINE
SUPPORT IN PHEOCHROMOCYTOMA
PATIENTS
Takeshi Namekawa*, Nobushige Takeshita,
Ken Wakai, Miki Fuse, Shinichi Sakamoto,
Koji Kawamura, Takashi Imamoto, Tomohiko
Ichikawa, Chiba, Japan
FRIDAY
MP8-19
2:40
PD3-11
2:50
MARKER-NEGATIVE
PHEOCHROMOCYTOMA
Shira Winters, Louis Krane, Majid
Mirzazadeh*, Winston-Salem, NC
PD3-12
HEALTH RELATED QUALITY OF LIFE IN
PATIENTS UNDERGOING LAPAROSCOPIC
ADRENALECTOMY
Ostap Dovirak*, Jialin Mao, Catrina Crociani,
Kimberly Taylor, Peter Chang, Andrew
Wagner, Boston, MA
CREDITTM
1:00 pm - 3:00 pm
Podium Session 4
IMAGING/RADIOLOGY: URORADIOLOGY I
Moderator: Edouard Trabulsi
TIME
1:00
ABSTRACT
NUMBER TITLE
PD4-01 FOLLOW UP OF LOWER URETERAL
STONES: A PROSPECTIVE COMPARATIVE
STUDY BETWEEN NON-CONTRAST
COMPUTED TOMOGRAPHY AND COLOR
DOPPLER ULTRASOUND
Emad Elsobky*, Abu Dhabi, United Arab
Emirates, Ravi Kadasne, Chandrashekar
Anjikar, Mahmoud Abdel-Gawad, Al ain,
United Arab Emirates
1:10
PD4-02
SHOULD BONE MINERAL DENSITY (BMD)
BE INCLUDED IN THE METABOLIC
EVALUATION OF YOUNG ADULTS WITH
CALCIUM KIDNEY STONE DISEASE ?: A
PROSPECTIVE STUDY
Uttam Mete*, Prashant Raj Garg, Mahesh
Prakash, Pinaki Dutta, Chandigarh, India
1:20
PD4-03
A COMPARISON OF CALCULATED
ABSORBED RADIATION ORGAN DOSES
AND IMAGE QUALITY FOR ITERATIVE
VERSUS FILTERED BACK PROJECTION
CT IN KIDNEY STONE PATIENTS
Rishi Modh*, Akira Yamamoto, James
Mason, Elizabeth Vorhis, Lori Deitte, Cyrus
Monroe, Anna Mench, Rebecca H.
Lamoureux, Izabella Lipnharski, Jacob
Batson, Derek Lee, Carl Henriksen, Manuel
Arreola, Benjamin Canales, Gainesville, FL
1:30
1:40
PD4-04
PD4-05
ABSTRACT
TIME NUMBER TITLE
1:50
PD4-06 A RANDOMIZED CONTROL TRIAL
DEMONSTRATES THAT ULTRASOUNDGUIDED PERCUTANEOUS RENAL
ACCESS IS A TEACHABLE SKILL
Pauline Filippou*, Anobel Odisho, Krishna
Ramaswamy, San Francisco, CA, Weiguo
Hu, Jianxing Li, Beijing, China, People’s
Republic of, Thomas Chi, San Francisco, CA
USE OF FLUOROSCOPY AND POTENTIAL
LONG-TERM RADIATION EFFECTS ON
CATARACT FORMATION
Rutveej Patel*, Justin Dubin, Sammy
Elsamra, Ephrem Olweny, Robert Weiss,
New Brunswick, NJ
INCIDENCE OF CONTRAST REACTION
DURING NON-INTRAVENOUS URINARY
TRACT IMAGING
Robert Blackwell, Eric Kirshenbaum*,
Matthew Zapf, Anai Kothari, Paul Kuo, Robert
Flanigan, Gopal Gupta, Maywood, IL
40
2:00
PD4-07
PREOPERATIVE
FLUORODEOXYGLUCOSE POSITRON
EMISSION TOMOGRAPHY/COMPUTED
TOMOGRAPHY ON THE DIAGNOSIS IN
UPPER URINARY TRACT CANCER
Seiji Asai*, Toshio Kakuda, Kouji Hara,
Terutaka Noda, Kenichi Nishimura, Tetsuya
Fukumoto, Noriyoshi Miura, Yutaka
Yanagihara, Akitomi Shirato, Yuki Miyauchi,
Tadahiko Kikugawa, Masao Miyagawa,
Nozomu Tanji, Masayoshi Yokoyama, Toon,
Japan
2:10
PD4-08
PRE-TREATMENT CT TEXTURAL
ANALYSIS OF LARGE PRIMARY RENAL
CELL CARCINOMAS; TUMOR
HETEROGENEITY CORRELATES WITH
HISTOLOGY AND CLINICAL OUTCOMES
E. Jason Abel*, Meghan Lubner, Alejandro
Munoz Del Rio, Nicholas Stabo, Perry
Pickhardt, Madison, WI
2:20
PD4-09
VASOACTIVE INTESTINAL PEPTIDE AND
PITUITARY ADENYLATE CYCLASE
ACTIVATING PEPTIDE RECEPTOR 1
(VPAC1) TARGETED IMAGING OF
PROSTATE CANCER: A PILOT STUDY
Edouard Trabulsi*, Sushil Tripathi, Peter
McCue, Ruth Birbe, Eric Wickstrom, Leonard
Gomella, Sung Kim, Charles Intenzo,
Madhukar Thakur, Philadelphia, PA
2:40
PD4-10
PD4-11
2:50
REPRODUCIBILITY OF
MULTIPARAMETRIC MAGNETIC
RESONANCE IMAGING AND FUSIONGUIDED PROSTATE BIOPSY: MULTIINSTITUTIONAL EXTERNAL VALIDATION
BY A PROPENSITY SCORE MATCHED
COHORT
Steven F. Abboud*, Arvin K. George, Thomas
Frye, Bethesda, MD, Ardeshir R. Rastinehad,
New Hyde Park, NY, Richard Ho, Michele
Fascelli, Raju chelluri, Nabeel Shakir,
Annerleim Walton- Diaz, Sandeep Sankineni,
Baris Turkbey, Peter L. Choyke, Bradford J.
Wood, Maria J. Merino, Peter A. Pinto,
Bethesda, MD
PD4-12
3D ACOUSTIC RADIATION FORCE
IMPULSE (ARFI) ELASTICITY IMAGING OF
PROSTATE CANCER: CORRELATION
BETWEEN IN VIVO IMAGING AND WHOLE
MOUNT HISTOLOGY
Melissa Mendez*, Mark Palmeri, Zachary
Miller, Tyler Glass, Stephen Rosenzweig,
Andrew Buck, John Madden, Thomas
Polascik, Kathryn Nightingale, Durham, NC
CREDITTM
THE RELATIONSHIP OF INCREASING MRI
SUSPICION SCORE AND THE
IDENTIFICATION OF HIGH GRADE
PROSTATE CANCER ON MRI FUSION
TARGETED BIOPSY
Xiaosong Meng*, Andrew B. Rosenkrantz,
Michael Fenstermaker, Neil Mendhiratta,
Richard Huang, Fang-Ming Deng, Ming Zhou,
William C. Huang, Herbert Lepor, Samir S.
Taneja, New York, NY
1:00 pm - 3:00 pm
Podium Session 5
BENIGN PROSTATIC HYPERPLASIA: SURGICAL THERAPY & NEW TECHNOLOGY II
Moderator: Ricardo Gonzalez
TIME
1:00
1:10
ABSTRACT
NUMBER TITLE
PD5-01 THREE YEAR DURABILITY OF THE
PROSTATIC URETHRAL LIFT FOR BPH:
RESULTS OF A PROSPECTIVE, MULTICENTER, RANDOMIZED STUDY
Claus Roehrborn*, Dallas, TX, Steven Gange,
Salt Lake City, UT, Neal Shore, Myrtle
Beach, SC, Jonathan Giddens, Woodbridge,
Canada, Damien Bolton, Melbourne,
Australia, Barrett Cowan, Denver, CO,
Thomas Brown, Daytona Beach, FL, Kevin
McVary, Springfield, IL, Peter Chin, Figtree,
Australia, Alexis Te, New York, NY, Shahram
Gholami, San Jose, CA, Prem Rashid, Port
Macquarie, Australia, William Moseley, San
Diego, CA, Ronald Tutrone, Towson, MD,
Sheldon Freedman, Las Vegas, NV, Peter
Incze, Oakville,, Canada, K. Scott Coffield,
Temple,, TX, Fernando Borges, St.
Petersburg, FL, Daniel Rukstalis, WinstonSalem, NC
PD5-02
*Presenting author
ABSTRACT
TIME NUMBER TITLE
1:20
PD5-03 CLINICALLY AND STATISTICALLY
SIGNIFICANT CHANGES SEEN IN SHAM
SURGERY ARMS OF BENIGN PROSTATIC
HYPERPLASIA SURGERY TRIALS
Charles Welliver*, Albany, NY, Michael
Kottwitz, Kevin McVary, Springfield, IL
MULTICENTER EXPERIENCE OF A NOVEL
TREATMENT FOR BPH: AQUABLATION –
IMAGE GUIDED ROBOT-ASSISTED WATER
JET ABLATION OF THE PROSTATE
Peter Gilling*, Tauranga, New Zealand,
Andrew Tan, Perth, Australia, Paul Anderson,
Melbourne, Australia
41
1:30
PD5-04
CAN WE PREDICT WHICH PATIENTS WILL
PRESENT RESOLUTION OF
DETRUSOROVERACTIVITY (DO) AFTER
PROSTATE (TURP)?
Alexandre Iscaife*, Sabrina T Reis, Aline
Albertini, Marco A Nunes, Antonio M Lucon,
Willian C Nahas, Miguel Srougi, Alberto A
1:40
PD5-05
USE OF ADDITIONAL THERAPY FOR
BENIGN PROSTATIC HYPERPLASIA
AFTER TURP AND LASER VAPORIZATION
Niraj Badhiwala*, Adrienne Kuxhausen, Joel
Vetter, Seth Strope, St. Louis, MO
1:50
PD5-06
EVALUATION OF LASER ENUCLEATION
TECHNIQUES IN THE MANAGEMENT OF
BENIGN PROSTATIC HYPERPLASIA: A
SYSTEMATIC REVIEW AND METAANALYSIS
Sam Chopra*, Cindy Garcia, Venu Chalasani,
Henry Woo, Sydney, Australia
FRIDAY
2:30
2:00
PD5-07
COST-BENEFIT COMPARISON OF
ROBOTIC-ASSISTED SIMPLE
PROSTATECTOMY (RASP),
TRANSURETHRAL RESECTION (TURP),
AND PHOTOVAPORIZATION (PVP) FOR
BENIGN PROSTATIC HYPERPLASIA (BPH)
Andrew Eschenroeder*, Devin Haddad, Sij
Hemal, Gopal Badlani, Winston Salem, NC
2:10
PD5-08
24-MONTH RESULTS FOR A
PROSPECTIVE RANDOMIZED
CONTROLLED STUDY COMPARING
GREENLIGHT XPS TO TURP
DEMONSTRATE DURABILITY OF
RESPONSE AT 24-MONTHS
James Andrew Thomas*, Bridgend, Wales,
United Kingdom, Andrea Tubaro, Rome, Italy,
Neil Barber, Frimley, Camberley Surrey,
United Kingdom, Frank d’ Ancona, Nijmegen,
Netherlands, Gordon Muir, London, United
Kingdom, Ulrich Witzsch, Frankfurt, Germany,
Marc-Oliver Grimm, Jena, Germany, Joan
Benejam, Manacor, Spain, Jens-Uwe
Stolzenburg, Leipzig, Germany, Antony
Riddick, Edinburgh, Scotland, United
Kingdom, Sascha Pahernik, Heidelberg,
Germany, Johannes Roelink,
Almelo/Hengelo, Netherlands, Filip Ameye,
Gent, Belgium, Christian Saussine,
Strasbourg, France, Frank Bruyere, Tours,
France, Wolfgang Loidl, Linz, Austria, Tim
Larner, Brighton, United Kingdom, Nirjan
Gogoi, Wakefield, United Kingdom, Richard
Hindley, Hampshire, United Kingdom, Rolf
Muschter, Rotenburg, Germany, Andrew
Thorpe, Newcastle upon Tyne, United
Kingdom, Nitin Shrotri, Kent, United Kingdom,
Stuart Graham, London, United Kingdom,
Moritz Hamann, Kiel, Germany, Kurt Miller,
Berlin, Germany, Martin Schostak,
Magdeburg, Germany, Carlos Capitan,
Madrid, Spain, Helmut Knispel, Berlin,
Germany, Alexander Bachmann, Basel,
Switzerland
2:20
PD5-09
IMPACT OF PHOTOSELECTIVE
VAPORIZATION OF PROSTATE IN
MANAGEMENT OF PROSTATE CANCER
Pradère Benjamin*, Tours, France, Peyronnet
Benoit, Rennes, France, Brichart Nicolas,
Bruyère Franck, Tours, France
2:30
PD5-10
PROSTATE (GL-XPS OR TURP) DOES NOT
RESULT IN SIGNIFICANT IMPAIRMENT OF
ERECTILE FUNCTION
James Andrew Thomas*, Bridgend, Wales,
United Kingdom, Andrea Tubaro, Rome, Italy,
Neil Barber, Frimley, Camberley Surrey,
United Kingdom, Frank d’ Ancona, Nijmegen,
Netherlands, Gordon Muir, London, United
Kingdom, Ulrich Witzsch, Frankfurt, Germany,
Marc-Oliver Grimm, Jena, Germany, Joan
Benejam, Manacor, Spain, Jens-Uwe
Stolzenburg, Leipzig, Germany, Antony
Riddick, Edinburgh, Scotland, United
Kingdom, Sascha Pahernik, Heidelberg,
Germany, Johannes Roelink,
Almelo/Hengelo, Netherlands, Filip Ameye,
Gent, Belgium, Christian Saussine,
Strasbourg, France, Frank Bruyere, Tours,
France, Wolfgang Loidl, Linz, Austria, Tim
Larner, Brighton, United Kingdom, Nirjan
Gogoi, Wakefield, United Kingdom, Richard
Hindley, Hampshire, United Kingdom, Rolf
Muschter, Rotenburg, Germany, Andrew
Thorpe, Newcastle upon Tyne, United
Kingdom, Nitin Shrotri, Kent, United Kingdom,
Stuart Graham, London, United Kingdom,
Moritz Hamann, Kiel, Germany, Kurt Miller,
Berlin, Germany, Martin Schostak,
Magdeburg, Germany, Carlos Capitan,
Madrid, Spain, Helmut Knispel, Berlin,
Germany, Alexander Bachmann, Basel,
Switzerland
2:40
PD5-11
THE IMPACT OF TRAINING ON THE
PERIOPERATIVE AND INTERMEDIATE
FUNCTIONAL OUTCOMES AFTER
PROSTATE
Haidar Abdul-Muhsin*, Mark Tyson, Karen
Stern, Rafael Nuñez, Mitchell Humphreys,
Phoenix, AZ
2:50
PD5-12
SEXUAL FUNCTION CHANGES
FOLLOWING DIFFERENT
TRANSURETHRAL PROSTATE
SURGERIES: PROSPECTIVE SHAM
CONTROLLED STUDY
Ahmed Elshal*, Ramy Mekkawy, Ahmed ELAssmy, Diaa-Eldin Taha, Ahmed EL-Nahas,
Ahmed Mosbah, Hamdy El-Kappany, ElHousseiny Ibrahiem, Mansoura, Egypt
CREDITTM
42
1:00 pm - 3:00 pm
Video Session 2
FEMALE VOIDING DYSFUNCTION
Moderators: Toby Chai and Courtenay Moore
ABSTRACT
NUMBER TITLE
V2-01
TRANSABDOMINAL SACROCOLPOPEXY
WITH RECTUS FASCIA GRAFT
Adrienne Quirouet*, Cleveland, OH, Nitya
Abraham, New York, NY, Howard Goldman,
Cleveland, OH
V2-02
AUTOLOGOUS FASCIAL PUBOVAGINAL
SLING: CONTEMPORARY INDICATIONS,
TECHNIQUES, AND CHALLENGES
Lindsey Cox*, Anne Cameron, J. Quentin
Clemens, Ann Arbor, MI
V2-03
PUBOVAGINAL SLING WITH TENSOR
FASCIA LATA
Judy M. Choi*, Patkawat Ramart, Diana
Kang, Seth Cohen, Lenny Ackerman, Shlomo
Raz, Los Angeles, CA
V2-04
V2-05
RECTUS FASCIA SPIRAL SLING (RFSS)
TECHNIQUE FOR WOMEN WITH
MULTIPLE FAILED STRESS
INCONTINENCE SURGERY DUE TO
SEVERE INTRINSIC SPHINCTERIC
DEFICIENCY
Fikret Fatih Onol*, Sinasi Yavuz Onol,
Mehmet Cenk Gürbüz, Ahmet Tahra, Eyüp
Veli Küçük, Istanbul, Turkey
SURGICAL TECHNIQUE, SURGICAL
BENCHMARKS AND IMPACT OF TEAM
CONSTANCY ON SURGICAL DURATION IN
ROBOT-ASSISTED ISOLATED
SACROCOLPOPEXY AND
SACROCOLPOPEXY COMBINED WITH
MODIFIED BURCH COLPOSUSPENSION
PROCEDURE. EXPERIENCE IN ONE
INSTITUTION IN 120 CASES
Assen Alexandrov, Carolin Hach, Stephan
Buse*, Essen, Germany
V2-06
SKENE’S GLAND CYST EXCISION
Philippe Zimmern*, Gary Lemack, Dallas, TX
V2-07
ROBOTIC-ASSISTED VESICOVAGINAL
FISTULA REPAIR AND RIGHT URETERAL
REIMPLANT
Christopher Hartman*, Paras Shah,
Akinwunmi Carons, Michael Schwartz,
Farzeen Firoozi, New Hyde Park, NY
V2-08
ROBOTIC-ASSISTED LAPAROSCOPIC
REMOVAL OF EXTRUDED
SACROCOLPOPEXY MESH
Kai-wen Chuang*, Christopher Hartman, Akin
Carons, Manaf Alom, Paras Shah, Lee
Richstone, Farzeen Firoozi, New Hyde Park,
NY
*Presenting author
ABSTRACT
NUMBER TITLE
V2-09
ROBOTIC-ASSISTED MESH
EXPLANTATION AND BLADDER
RECONSTRUCTION
James Bienvenu*, Robert Elder, Wesley
White, Knoxville, TN
V2-10
IDENTIFICATION OF THE S3 FORAMEN
DURING TRANSFORAMINAL SACRAL
NEUROMODULATION LEAD PLACEMENT
– A NOVEL “ROLLING PEN” TECHNIQUE
Amanda Saltzman*, Kristi Hebert, Howard
Woo, Ryan Krlin, New Orleans, LA
V2-11
EXCISION OF URERTHRAL
DIVERTICULUM WITH RECTUS FASCIA
SLING
Mahmoud Mohamed*, Ayman Mahdy,
Cincinnati, OH
V2-12
TRANSVAGINAL APPROACH TO
URETHRAL RECONSTRUCTION AFTER
MIDURETHRAL SLING COMPLICATION
Tony Nimeh*, Chicago, IL, Elisabetta
Constantini, Perugia, Italy, Whitney
Halgrimson, Chicago, IL, Manuel Di Biase,
Perugia, Italy, Ervin Kocjancic, Chicago, IL
V2-13
LAPAROSCOPIC EXTRAVESICAL REPAIR
OF VESICOVAGINAL FISTULA
Xiao Han*, Ho Yee Tiong, David Consigliere,
Singapore, Singapore
V2-14
VAGINAL EXCISION OF PERIVESICAL
MASS
Mahmoud Mohamed*, Ayman Mahdy,
Cincinnati, OH
CREDITTM
43
FRIDAY
1:00 pm - 5:00 pm
CROSSFIRE: CONTROVERSIES IN UROLOGY
Hall B1 @ New Orleans Morial Convention Center
12:58
WELCOME AND ANNOUNCEMENTS
1:00
REVERSAL OF VASECTOMY IN THE ERA OF INTRACYTOPLASMIC SPERM INJECTION (ICSI) IS NOT WORTH
THE EFFORT
Moderator:
Harris Nagler
Debater - Pro: Gianpiero Palermo
Debater - Pro: Peter Schlegel
Debater - Con: Edmund Sabanegh
Debater - Con: Larry Lipshultz
1:30
SACROCOLPOPEXY
Moderator:
Debater - Pro:
Debater - Pro:
Debater - Con:
Debater - Con:
2:00
FOCAL THERAPY FOR PROSTATE CANCER: HOPE OR HYPE
Moderator:
Peter Scardino
Debater - Hope: Aaron Katz
Debater - Hope: Mark Emberton
Debater - Hype: Eric Klein
Debater - Hype: Mark Gonzalgo
2:30
BLADDER SPARING FOR INVASIVE BLADDER CANCER IS NOT CANCER SPARING
Moderator:
Urs Studer
Debater - Pro: Ashish Kamat
Debater - Pro: James Catto
Debater - Con: William Shipley
Debater - Con: Bernard Bochner
3:00
OTC ALPHA BLOCKER IS NOT IN THE BEST INTEREST OF PATIENTS
Moderator:
Claus Roehrborn
Debater - Pro: Kevin McVary
Debater - Pro: Christian Gratzke
Debater - Con: Marc Gittelman
Debater - Con: Franklin Lowe
3:30
SHOCK WAVE LITHOTRIPSY SHOULD BE RETIRED
Moderator:
Ralph Clayman
Debater - Pro: Olivier Traxer
Debater - Pro: Glenn Preminger
Debater - Con: Geert Tailly
Debater - Con: James Lingeman
4:00
NEUROMODULATION SHOULD BE THE FIRST CHOICE OVER BOTULINUM TOXIN FOR IDO
Moderator:
Dirk De Ridder
Debater - Pro: Steven Siegel
Debater - Pro: Anurag Das
Debater - Con: Christopher Smith
Debater - Con: Michael Chancellor
4:30
NO DEFLUX FOR REFLUX
Moderator:
Anthony Atala
Debater - Pro: Jonathan Routh
Debater - Pro: Alan Retik
Debater - Con: Jack Elder
Debater - Con: Stephane Bolduc
FOR APICAL PROLAPSE IS NOT THE GOLD STANDARD
J. Christian Winters
Philippe Zimmern
Saad Juma
Michael Albo
Nirit Rosenblum
44
3:30 pm - 5:30 pm
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: EVIDENCE-BASED MEDICINE & OUTCOMES II
Moderators: Gabriel Haas and Scott Delacroix
ABSTRACT
NUMBER TITLE
MP9-01 COMPARATIVE EFFECTIVENESS OF
AGGRESSIVE VS NON-AGGRESSIVE
TREATMENT FOR HIGH-GRADE
PROSTATE CANCER ACROSS DIFFERENT
COMORBIDITY LEVELS
Timothy Daskivich*, Los Angeles, CA, Julie
Lai, Andrew Dick, Claude Setodji, Janet
Hanley, Santa Monica, CA, Mark Litwin,
Christopher Saigal, Los Angeles, CA
MP9-02
OLDER AGE PREDICTS GLEASON SCORE
UPGRADING DURING LONG-TERM
MONITORING ON ACTIVE SURVEILLANCE
Jeffrey Tosoian*, Amar Srivastava, Max
Kates, Patricia Landis, Jonathan Epstein,
Mufaddal Mamawala, H. Ballentine Carter,
Bruce Trock, Baltimore, MD
MP9-03
THE EFFECT OF HEALTHCARE SYSTEM
ON APPROPRIATENESS OF PROSTATE
CANCER IMAGING: DO PATIENTS GET
BETTER CARE IN VA OR FEE-FORSERVICE MEDICARE?
Danil Makarov*, Heather Gold, Dawn Walter,
New York, NY, Evercita Eugenio, Seattle,
WA, Scott Sherman, New York, NY, Cary
Gross, New Haven, CT, Steven Zeliadt,
Seattle, WA
MP9-04
A NOVEL COMPREHENSIVE
COMPLICATION INDEX BY CLAVIEN IN
PATIENTS WITH RADICAL
PROSTATECTOMY
Burkhard Beyer*, Markus Graefen, Hartwig
Huland, Thomas Steuber, Hamburg,
Germany
MP9-05
INCIDENCE AND CHARACTERISTICS OF
UNCOMPLICATED RECURRENT URINARY
TRACT INFECTIONS IN A NATIONAL
SAMPLE OF COMMUNITY DWELLING
WOMEN
Anne M Suskind*, San Francisco, CA,
Christopher S Saigal, Los Angeles, CA, Janet
M Hanley, Julie Lai, Claude M Setodji, Santa
Monica, CA, J. Quentin Clemens, Ann Arbor,
MI, Urologic Diseases of America Project
UDA, Los Angeles, CA
MP9-06
*Presenting author
ABSTRACT
NUMBER TITLE
MP9-07 THE METHODOLOGICAL QUALITY AND
PUBLICATION OF INDUSTRY VERSUS
NON-INDUSTRY TRIALS FOR
TESTOSTERONE TREATMENT
Sean Skeldon*, Toronto, Canada, Larry
Goldenberg, Michael Law, Vancouver,
Canada
IMPACT OF COUNTY RURALITY AND
UROLOGIST DENSITY ON UROLOGIC
CANCER MORTALITY IN ILLINOIS
Daniel Sadowski*, Springfield, IL, Thomas
Frye, Bethesda, MD, Shaheen Alanee,
Whitney Zahnd, Wiley Jenkins, Danuta
Dynda, Georgia Mueller, Kevin McVary,
Springfield, IL
45
MP9-08
IMPACT OF SMOKING ON
PERIOPERATIVE OUTCOMES AFTER
MAJOR UROLOGIC SURGERY
Akshay Sood*, Detroit, MI, Marianne Schmid,
Boston, MA, Logan Campbell, Victor Kapoor,
Firas Abdollah, Dane Klett, Deepansh Dalela,
Detroit, MI, Steven Chang, Boston, MA, Felix
Chun, Hamburg, Germany, Adam Kibel,
Boston, MA, Jesse Sammon, James
Peabody, Mani Menon, Detroit, MI, Margit
Fisch, Hamburg, Germany, Quoc-Dien Trinh,
Boston, MA
MP9-09
PREDICTORS OF CONTINUED SMOKING
AFTER THE DIAGNOSIS OF A
GENITOURINARY MALIGNANCY
Stephen Hurley*, Saumya Easaw, Andrew
Drago, Christina Palmer, Tayna Uddin,
Thomas O’Grady, Mark Wille, Courtney
Hollowell, Chicago, IL
MP9-10
FACTORS ASSOCIATED WITH SUICIDE IN
PATIENTS WITH GENITOURINARY
MALIGNANCIES
Zachary Klaassen*, Rita P. Jen, Augusta,
GA, John M. DiBianco, Roseau, Dominica,
Lael Reinstatler, Qiang Li, Rabii Madi, Ronald
W. Lewis, Arthur M. Smith, Durwood E. Neal,
Jr., Augusta, GA, Kelvin A. Moses, Nashville,
TN, Martha K. Terris, Augusta, GA
MP9-11
LONG-TERM RISK OF UROLOGIC
COMPLICATIONS FOLLOWING CERVICAL
CANCER TREATMENT
Robert Goldfarb*, Yunhua Fan, Stephanie
Jarosek, Haitao Chu, Beth Virnig, Sean
Elliott, Minneapolis, MN
MP9-12
PATIENT-CENTERED TREATMENT
DECISIONS: USING CONJOINT ANALYSIS
AS AN AID FOR SHARED DECISIONMAKING FOR URETHRAL STRICTURE
TREATMENT
Lindsay Hampson*, Thomas Gaither, Leslie
Wilson, Jie Ting, Isabel Allen, Benjamin
Breyer, San Francisco, CA
MP9-13
IN PATIENTS WITH POST-OPERATIVE
VENOUS THROMBOEMBOLIC EVENTS,
PHARMACOLOGIC PROPHYLAXIS IS
FREQUENTLY UNDERDOSED
Raman Unnikrishnan*, Benjamin Cohen,
Michelle Ponziano, Venkatesh Krishnamurthi,
Cleveland, OH
FRIDAY
MP9-14
POSTOPERATIVE SEPSIS PREDICTION IN
PATIENTS UNDERGOING MAJOR
CANCER SURGERY
Akshay Sood*, Firas Abdollah, Jesse
Sammon, Dane Klett, Daniel Pucheril, Detroit,
MI, Kaustav Majumder, Marianne Schmid,
Adam Kibel, Boston, MA, Mani Menon,
Detroit, MI, Quoc-Dien Trinh, Boston, MA
MP9-15
IDENTIFYING RISK FACTORS FOR
READMISSION TO THE SURGICAL
INTENSIVE CARE UNIT FOLLOWING
MAJOR UROLOGICAL SURGERY: A 24MONTH EXPERIENCE
Mark Hockenberry*, Zachary Smith,
Philadelphia, PA, Kavita Gupta, District of
Columbia, DC, Matthew Robertson,
Charlottesville, VA, Niels Martin, Thomas
Guzzo, Philadelphia, PA
MP9-16
NATIONAL MULTI-INSTITUTIONAL
CAUSES AND PREDICTORS OF 30-DAY
UNPLANNED READMISSION AFTER
MAJOR UROLOGIC SURGERY USING THE
IMPROVEMENT PROGRAM
Raffaella DeRosa*, Alexander Ernest,
Michael Lustik, Joseph Sterbis, Leah
McMann, Honolulu, HI
MP9-17
UTILIZATION AND OUTCOMES OF
INPATIENT SURGERY AT SAFETY-NET
HOSPITALS
Lindsey Herrel*, Zaojun Ye, David Miller, Ann
Arbor, MI
MP9-18
ANTICIPATING THE IMPACT OF
ACCOUNTABLE CARE ORGANIZATIONS
ON THE COST AND QUALITY OF
UROLOGIC CANCER CARE
Lindsey Herrel*, Scott Hawken, Chandy
Ellimoottil, Zachary Montgomery, Zaojun Ye,
David Miller, Ann Arbor, MI
MP9-19
DO HOSPITAL RANKINGS CORRELATE
WITH ACTUAL OUTCOMES?
Joel Durinka*, Philadelphia, PA, Afshin
Parsikia, Ryan Flynn, Jorge Ortiz, Toledo, OH
MP9-20
BASELINE CLINICAL CARACHTERISTICS
AND PATHOLOGICAL OUTCOMES
FOLLOWING ROBOTIC-ASSISTED
LAPAROSCOPIC RADICAL
PROSTATECTOMY (RALP): A
POPULATION BASED PROSPECTIVE
SERIES
Lorenzo Tosco*, Leuven, Belgium, Filip
Ameye, Ghent, Belgium, Simone Albisinni,
Brussels, Belgium, Peter Dekuyper, Ghent,
Belgium, David Jegou, Thierry Quackels,
Thierry Roumeguere, Brussels, Belgium, Ben
Van Cleynenbreugel, Leuven, Belgium,
Nancy Van Damme, Liesbet Van Eycken,
Brussels, Belgium, Steven Joniau, Leuven,
Belgium
CREDITTM
3:30 pm - 5:30 pm
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: PENIS/TESTIS/URETHRA: MALIGNANT DISEASE
Moderator: Jeffrey Holzbeierlein
ABSTRACT
NUMBER TITLE
MP10-01 SURGICAL MANAGEMENT OF PATIENTS
WITH ADVANCED GERM CELL TUMORS
FOLLOWING SALVAGE CHEMOTHERAPY
WITH PACLITAXEL, IFOSFAMIDE AND
CISPLATIN (TIP) OR PACLITAXEL PLUS
IFOSFAMIDE FOLLOWED BY HIGH DOSE
CARBOPLATIN AND ETOPOSIDE WITH
STEM CELL SUPPORT (TICE): MEM
Mariam Imnadze*, Darren Feldman, Brett
Carver, George Bosl, Robert Motzer, Dean
Bajorin, Joel Sheinfeld, New York, NY
ABSTRACT
NUMBER TITLE
MP10-03 MODIFICATION OF N STAGING SYSTEMS
FOR PENILE CANCER¡A¡ABE MORE
PRECISELY PREDICATIVE OF
PROGNOSIS
Kai Yao, Zaishang Li, guangzhou, China,
People’s Republic of, Peng Chen, Urumchi,
China, People’s Republic of, Fangjian Zhou,
Zike Qin, Zhuowei Liu, Yonghong Li, Pei
Dong, Hui Han*, guangzhou, China, People’s
Republic of
MP10-04 LONG-TERM INCIDENCE OF
METACHRONOUS CONTRALATERAL
TESTIS CANCER: IMPACT OF HISTOLOGY
Farhang Rabbani*, Susan MacDonald, Bronx,
NY
MP10-02 RETROPERITONEAL LYMPH NODE
DISSECTION AS FIRST-LINE TREATMENT
FOR NODE POSITIVE SEMINOMA
Brian Hu*, Swar Shah, Sepehr Shojaei,
MP10-05 CLINICAL OUTCOME OF PATIENTS WITH
FIBROSIS/NECROSIS AT POSTCHEMOTHERAPY RETROPERITONEAL
LYMPH NODE DISSECTION FOR
ADVANCED GERM CELL TUMORS
Roy Mano*, Brett Carver, George Bosl,
Robert Motzer, Dean Bajorin, Darren
Feldman, Joel Sheinfeld, New York, NY
46
MP10-07 CURRENT TRENDS IN IMAGING PENILE
CANCER FOR DIAGNOSIS AND
SURVEILLANCE
Aaron Benham*, Jonathan Heinlein, Nabil
Bissada, Daniel Culkin, Oklahoma City, OK,
Sean Elliott, Oluwakayode Adejoro,
Minneapolis, MN, Joel Slaton, Oklahoma City,
OK
MP10-14 EFFICACY AND TOLERABILITY OF TIP
(PACLITAXEL, IFOSFAMIDE AND
CISPLATIN) INCORPORATED INTO
INDUCTION CHEMOTHERAPY FOR
PATIENTS WITH INTERMEDIATE- OR
POOR-RISK METASTATIC GERM CELL
TUMORS
Masatomo Nishikawa*, Hideaki Miyake,
Masato Fujisawa, Kobe, Japan
MP10-08 MODIFIED TEMPLATE
RETROPERITONEAL LYMPH NODE
DISSECTION FOR POSTCHEMOTHERAPY
RESIDUAL TUMOR: A LONG TERM
UPDATE
Jane S. Cho*, Hristos Kaimakliotis, Timothy
A. Masterson, K. Clint Cary, Richard Bihrle,
Richard S. Foster, Indianapolis, IN
MP10-15 PATTERNS OF CARE AND SURVIVAL
OUTCOMES FOR MALIGNANT SEX CORD
STROMAL TESTICULAR CANCER:
RESULTS FROM THE NATIONAL CANCER
DATA BASE
John S. Banerji*, Katherine Odem-Davis,
Erika M. Wolff, Khanh N. Pham, Craig R.
Nichols, Christopher R. Porter, Seattle, WA
MP10-09 CONTEMPORARY USE OF
DISSECTION FOR STAGE II NONSEMINOMATOUS GERM CELL TUMOR: A
POPULATION-BASED STUDY USING
SURVEILLANCE EPIDEMIOLOGY AND
END RESULTS
Eugene Pietzak, III*, Jeremy Bonzo, S. Bruce
Malkowicz, Alan Wein, Thomas Guzzo,
Philadelphia, PA
MP10-16 SUBSTITUTION URETHROPLASTY FOR
TREATMENT OF DISTAL URETHRAL
CARCINOMA AND CARCINOMA IN SITU
Meghana Kulkarni*, Mahua Sahu, Alberto
Coscione, Davendra Sharma, Benjamin
Ayres, Nicholas Watkin, London, United
Kingdom
MP10-10 OUTCOMES OF PROGRESSION ON
SURVEILLANCE FOR CLINICAL STAGE I
NONSEMINOMATOUS GERM CELL
TUMOURS
Madhur Nayan*, Michael AS Jewett, Lynn
Anson-Cartwright, Philippe Bedard, Malcolm
Moore, Peter Chung, Padraig Warde, Joan
Sweet, Martin O’Malley, Robert J Hamilton,
Toronto, Canada
MP10-17 MANAGEMENT OF CHYLOUS LEAK
AFTER RETROPERITONEAL LYMPH NODE
DISSECTION FOR ADVANCED
TESTICULAR CANCER
Jane S. Cho*, Hristos Kaimakliotis, K. Clint
Cary, Timothy A. Masterson, Richard Bihrle,
Richard S. Foster, Indianapolis, IN
MP10-18 PITUITARY-LEYDIG AXIS DYSFUNCTION
PRIOR TO ORCHIECTOMY IN
TESTICULAR GERM CELL CANCER
Claire Sadler, Daniel Shin, Kenneth Faber,
Hooman Djaladat, Siamak Daneshmand*, Los
Angeles, CA
MP10-11 PELVIC EXTRANODAL EXTENSION
LEADS TO WORSE OUTCOMES IN PENILE
CANCER PATIENTS WITH POSITIVE
PELVIC LYMPH NODES AND IS
ASSOCIATED WITH A SURVIVAL BENEFIT
AFTER ADJUVANT CHEMOTHERAPY: A
MULTI-INSTITUTIONAL STUDY
Pranav Sharma*, Tampa, FL, Rosa
Djajadiningrat, Amsterdam, Netherlands,
Kamran Zargar-Shoshtari, Tampa, FL, Mario
Catanzaro, Milan, Italy, Yao Zhu, Shanghai,
China, People’s Republic of, Nicola Nicolai,
Milan, Italy, Simon Horenblas, Amsterdam,
Netherlands, Philippe Spiess, Tampa, FL
MP10-19 OUTCOMES IN PATIENTS WITH VIABLE
CANCER AT POST-CHEMOTHERAPY
DISSECTION
John Musser*, Catherine Dowling, New York,
NY, Shilajit Kundu, Chicago, IL, Brett Carver,
George Bosl, Dean Bajorin, Darren Feldman,
Robert Motzer, Joel Sheinfeld, New York, NY
MP10-12 BILATERAL TESTICULAR GERM CELL
TUMORS IN THE ERA OF MULTIMODAL
THERAPY
Ryan Kopp*, Michael Chevinsky, Melanie
Bernstein, George Bosl, Robert Motzer, Dean
Bajorin, Darren Feldman, Brett Carver, Joel
Sheinfeld, New York, NY
*Presenting author
CREDITTM
47
FRIDAY
MP10-13 CLINICAL OUTCOME OF
DISSECTION AFTER CHEMOTHERAPY IN
PATIENTS WITH PURE EMBRYONAL
CARCINOMA IN THE ORCHIECTOMY
SPECIMEN
Catherine Dowling*, Melissa Assel, John
Musser, Joshua Meeks, Dan Sjoberg, George
Bosl, Robert Motzer, Dean Bajorin, Darren
Feldman, Brett Carver, Joel Sheinfeld, New
York, NY
MP10-06 SURGICAL TREATMENT OF PRIMARY
DISEASE FOR PENILE SQUAMOUS CELL
CARCINOMA: A SURVEILLANCE,
EPIDEMIOLOGY, AND END RESULTS
(SEER) DATABASE ANALYSIS
Gu Weijie*, Zhu Yao, Ye Dingwei, Shanghai,
3:30 pm - 5:30 pm
IMAGING/RADIOLOGY: URORADIOLOGY II
Moderators: Christopher Porter and Art Rastinehad
ABSTRACT
NUMBER TITLE
MP11-01 VALUE OF ULTRASOUND IN THE
DIAGNOSIS OF URETERIC STONE – A
SINGLE INSTITUTION STUDY
arun panackal*, santhosh kumar, muscat,
Oman
ABSTRACT
NUMBER TITLE
MP11-08 MANUALLY CONTROLLED TARGETED
BIOPSY WITH REAL-TIME FUSION IMAGE
OF MULTIPARAMETRIC MAGNETIC
RESONANCE IMAGE AND TRANSRECTAL
ULTRASOUND IMAGE FOR THE
DIAGNOSIS OF PROSTATE CANCER
BASED ON PROSTATE IMAGEREPORTING AND DATA SYSTEM
Sunao Shoji*, Shinichiro Hiraiwa, Akio
Hashimoto, Kazunobu Hashida, Jun Endo,
Tetsuro Tomonaga, Mayura Nakano, Takuma
Tajiri, Hachioji, Japan, Toshiro Terachi,
Shimokasuya, Japan, Toyoaki Uchida,
Hachioji, Japan
MP11-02 STONE DIMENSIONS, SKIN-TO-STONE
DISTANCE, HOUNSFIELD UNIT DENSITY,
AND VISCERAL FAT AREA ARE
PRESERVED EVEN WITH ULTRA-LOW
DOSE COMPUTERIZED TOMOGRAPHY IN
STONE PATIENTS
Jennifer E. Heckman*, Meghan G. Lubner,
Richard Bruce, Madison, WI, Ronald M.
Summers, Jiamin Liu, Bethesda, MD, Perry J.
Pickhardt, Stephen Y. Nakada, Madison, WI
MP11-09 TRANSPERINEAL TEMPLATE-GUIDED
PROSTATE BIOPSY IN PATIENTS
INITIATING ACTIVE SURVEILLANCE: A
MULTI-INSTITUTIONAL COMPARISON
Khanh Pham*, Katherine Odem-Davis,
Claudio Jeldres, Christopher Porter, Seattle,
WA, John Wei, Todd Morgan, Ann Arbor, MI
MP11-03 CONTEMPORARY IMAGING PRACTICE
PATTERNS AFTER URETEROSCOPY FOR
STONE DISEASE
Mohamed Omar, Hemant Chaparala, Manoj
Monga, Sri Sivalingam*, Cleveland, OH
MP11-04 NEW INSIGHTS INTO THE GENESIS AND
ADHERENCE OF URINARY CALCULI
USING HIGH RESOLUTION MICROSCOPY
Sunita Ho*, San Francisco, CA, Frances
Allen, Andrew Minor, Berkeley, CA, Sabra
Djomehri, Ling Chen, Thomas Chi, Krishna
Ramaswamy, Marshall Stoller, San
Francisco, CA
MP11-10 UTILITY OF MULTIPARAMETRIC
MAGNETIC RESONANCE IMAGING
(MPMRI) IN THE EVALUATION OF MEN
FOR ACTIVE SURVEILLANCE OF
PROSTATE CANCER
Simpa Salami*, Anna Marie Sonstegard,
Oksana Yaskiv, New Hyde Park, NY, Baris
Turkbey, Bethesda, MD, Robert Villani, Eran
Ben-Levi, Ardeshir Rastinehad, New Hyde
Park, NY
MP11-05 MR-US FUSION BIOPSY: IMPORTANCE OF
BOTH SYSTEMATIC AND TARGETED
SAMPLING TO DIAGNOSE PROSTATE
CANCER
Christopher Filson*, Daniel Margolis, Jiaoti
Huang, Shyam Natarajan, Patricia Lieu,
Frederick Dorey, Leonard Marks, Los
Angeles, CA
MP11-11 SARCOPENIA AS A PROGNOSTIC
BIOMARKER OF METASTATIC RENAL
CELL CARCINOMA: ITS EFFECT ON
SURVIVAL BENEFIT FROM
CYTOREDUCTIVE NEPHRECTOMY
Hiroshi Fukushima*, Fumitaka Koga,
Yasukazu Nakanishi, Kenichi Tobisu, Tokyo,
Japan
MP11-06 RESULTS OF TARGETED BIOPSY WITH
REAL-TIME BALLOON INFLATION
ELASTOGRAPHY OF PROSTATE
Masahiro Sumura*, Kouhei Ogawa, Taichi
Nagami, Haruki Anjiki, Chiaki Koike, Naoko
Arichi, Yozo Mitsui, Shigenobu Nakamura,
Takeo Hiraoka, Hiroaki Yasumoto, Shinji
Hara, Takeshi Yoshizako, Hiroaki Shiina,
Izumo, Shimane, Japan
MP11-12 DEVELOPMENT AND VALIDATION OF A
NOVEL PREDICTION MODEL FOR FATPOOR ANGIOMYOLIPOMA IN SMALL
RENAL MASSES BASED ON
RADIOLOGICAL AND CLINICAL
FEATURES
Hajime Tanaka*, Yasuhisa Fujii, Masaya Ito,
Manabu Tatokoro, Soichiro Yoshida, Minato
Yokoyama, Junichiro Ishioka, Yoh Matsuoka,
Noboru Numao, Kazutaka Saito, Junji
Yonese, Kazunori Kihara, Tokyo, Japan
MP11-07 T2-WEIGHTED/DIFFUSION-WEIGHTED
MAGNETIC RESONANCE IMAGING AS A
NOVEL SCORING MODE FOR THE EARLY
DETECTION OF PROSTATE CANCER
Xuan Wang*, Ming Liu, Jianye Wang, Min
Chen, Ben Wan, Chunmei Li, Gang Wan,
Wei Zhang, Yong Zhang, Beijing, China,
People’s Republic of, Yuanyuan Zhang,
Winston-Salem, NC
MP11-13 PREDICTORS OF VOLUME LOSS AFTER
ROBOTIC PARTIAL NEPHRECTOMY:
INFLUENCE OF TUMOR LOCATION
BASED ON VASCULAR ANATOMY
Clinton D Bahler*, Kevin J Flynn, David Y
Yang, Hitesh Dube, Chandru P Sundaram,
Indianapolis, IN
48
MP11-19 MAGNETIC RESONANCE VISIBILITY OF
IRON LABELED MESENCHYMAL STEM
CELLS FOR ENDOSCOPIC INJECTION
INTO THE PORCINE URETHRAL
SPHINCTER
Susanne Will, Tübingen, Germany, KarlDietrich Sievert*, Lübeck, Germany, Martin
Vaegler, Petros Martirosian, Frank Eibofner,
Fritz Schick, Jörg Schmehl, Gerd Grözinger,
Rüdiger Bantleon, Konstantin Nikolaou, Ulrich
Kramer, Tübingen, Germany
MP11-15 DEVELOPMENT OF A TARGETED
GADOLINIUM CONTRAST FOR
NONINVASIVE OF MAGNETIC
RESONANCE (MR) IMAGING OF NONMUSCLE INVASIVE BLADDER CANCER
Joel Slaton*, Carole Davis, Nataliya Smith,
Debbie Saunders, Paul Hauser, Robert Hurst,
Rheal Towner, Oklahoma City, OK
MP11-16 USE OF 18F-FLUORODEOXYGLUCOSE
POSITRON EMISSION
TOMOGRAPHY/COMPUTED
TOMOGRAPHY (FDG PET/CT) TO PREDICT
VIABLE LYMPH NODE METASTASES
FOLLOWING PREOPERATIVE
CHEMOTHERAPY FOR MUSCLE INVASIVE
AND ADVANCED-STAGE BLADDER
CANCER
Byron Lee*, Aditya Bagrodia, Timothy
Donahue, Guido Dalbagni, Jonathan
Rosenberg, Dean Bajorin, Hebert Alberto
Vargas, Bernard Bochner, New York, NY
MP11-20 DIFFUSION TENSOR IMAGING OF THE
NEURONAL NETWORK INNERVATING
THE LOWER URINARY TRACT
Jens Wöllner*, Peter Zweers, Jörg Krebs,
Juergen Pannek, Nottwil, Switzerland
CREDITTM
MP11-17 USING TRANSLABIAL ULTRASOUND AS
AN EFFECTIVE TOOL TO VISUALIZE
MESH EROSION INTO THE URETHRA AND
BLADDER
Seth A. Cohen*, Karoly A. Viragh, Leah Y.
Nakamura, Anne L. Ackerman, Patkawat
Ramart, Diana C. Kang, Judy M. Choi, JaHong Kim, Steven S. Raman, Shlomo Raz,
Los Angeles, CA
3:30 pm - 5:30 pm
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: BASIC RESEARCH II
Moderators: Larissa Rodriguez and Henry Lai
ABSTRACT
NUMBER TITLE
MP12-01 SPINAL METABOTROPIC GLUTAMATE
RECEPTOR 5 INVOLVEMENT IN
PUDENDAL INHIBITION OF NOCICEPTIVE
BLADDER REFLEX IN CATS
Jeremy Reese*, Marc Rogers, Zhiying Xiao,
Bing Shen, Jicheng Wang, Zayed Schwen,
James Roppolo, William DeGroat, Tai
Changfeng, Pittsburgh, PA
ABSTRACT
NUMBER TITLE
MP12-03 FUNCTIONAL CHANGES OF THE
BLADDER IN VIVO IN MICE LACKING
TRANSIENT RECEPTOR POTENTIAL
MELASTAIN 2 (TRPM2) CHANNELS
Jun Kamei*, Naoki Aizawa, Tokyo, Japan,
Takayuki Nakagawa, Kyoto, Japan, Hiroki Ito,
Rino Sugiyama, Yoshiyuki Akiyama, Koji
Ichihara, Tokyo, Japan, Shuji Kaneko, Kyoto,
Japan, Yukio Homma, Yasuhiko Igawa,
Tokyo, Japan
MP12-02 TRANSCRIPTIONAL REGULATION OF
CORTICOTROPIN RELEASING FACTOR
GENE EXPRESSION
Lizath Aguiniga*, Anthony Schaeffer, David
Klumpp, Chicago, IL
*Presenting author
49
FRIDAY
MP11-18 3D-ULTRASOUND ORIENTED
ADJUSTMENT FOR SPHINCTERIC
URETHRA PRIOR TO VELOCITY-FLOW
EVALUATION USING DOPPLER
ULTRASONOGRPAHY
Hideo Ozawa*, Okayama, Japan, Michael
Chancellor, Royal Oak, MI, Atsushi Nagai,
Kurashiki, Japan, Hiromi Kumon, Okayama,
Japan
MP11-14 QUANTITATIVE PERFUSION
MEASUREMENTS IN RENAL MASSES
WITH ASL AND DCE MRI AT 3T
CORRELATE WITH MICROVASCULAR
DENSITY AT HISTOPATHOLOGY
Yue Zhang, Payal Kapur, Qing Yuan, Ananth
Madhuranthakam, Dallas, TX, Ingrid Carvo,
Sabina Signoretti, Boston, MA, Ivan Dimitrov,
Yin Xi, Katherine Wicks, Vitaly Margulis,
Jeffrey Cadeddu, Aaron Lay, James
Brugarolas, Ivan Pedrosa*, Dallas, TX
MP12-13 COITAL URINARY INCONTINENCE IN
RATS
José Luis Palacios*, Margarita Juárez, Raúl
Juárez, Alfonso Medel, Yolanda Cruz,
Tlaxcala, Mexico
MP12-04 DETRUSOR OVERACTIVITY INDUCED BY
CEREBRAL INFARCTION MAY BE
ASSOCIATED WITH ENHANCED ACTIVITY
OF RHO-KINASE IN THE BLADDER
Hironobu Akino*, Keiko Nagase, Xinmin Zha,
Yoshitaka Aoki, Hideaki Ito, Nobuyuki
Oyama, Osamu Yokoyama, Fukui, Japan
MP12-14 INVESTIGATIONS INTO THE
MECHANISTIC LINK BETWEEN
ELEVATED URINE BDNF LEVELS AND
EXPRESSION OF CONNEXIN 43 IN
BLADDER BIOPSY OF OVERACTIVE
BLADDER PATIENTS
Mahendra Kashyap*, Subrata Pore, Willam C
Degroat, Christopher J Chermansky, Naoki
Yoshimura, Pradeep Tyagi, Pittsburgh, PA
MP12-05 LUMBAR TO SACRAL NERVE REROUTING
TO RESTORE VOIDING FUNCTION IN A
FELINE SPINAL CORD INJURY MODEL
Jacques Corcos*, Ornella Lam Van Ba,
Romain Caremel, Shachar Aharony, Oleg
Loutochin, Montreal, Canada, Mary Barbe,
Philadelphia, PA, Line Jacques, Montreal,
Canada, Gerald F. Tuite, Saint Petersburg,
FL, Michael R. Ruggieri, Sr, Philadelphia, PA
MP12-15 ACUTE LENGTH ADAPTATION AND
ADJUSTABLE PRELOAD TENSION IN THE
HUMAN DETRUSOR: THE CONCEPT OF A
DETRUSOR TENSION SENSOR
Andrew Colhoun*, John Speich, MaryEllen
Dolat, Joseph Habibi, R. Wayne Barbee, Paul
Ratz, Adam Klausner, Richmond, VA
MP12-06 SUPRASPINAL ACTIVITY TO
AUTOMATED, REPETITIVE BLADDER
FILLING - AN FMRI STUDY
Matthias Walter*, Lorenz Leitner, Lars
Michels, Spyros Kollias, Thomas M. Kessler,
Ulrich Mehnert, Zürich, Switzerland
MP12-16 DYNAMIC COMPLIANCE: A NOVEL
METRIC FOR THE URODYNAMIC FILLING
PHASE
Andrew Colhoun*, John Speich, Jay Sulek,
Paul Ratz, R. Wayne Barbee, J. Tyler
Roseman, Adam Klausner, Richmond, VA
MP12-07 THE ROLE OF GLYCINE IN PUDENDAL
NERVE STIMULATION AND BLADDER
OVERACTIVITY
Marc J. Rogers*, Jeremy N. Reese, Zhiying
Xiao, Bing Shen, Jicheng Wang, Zeyad
Schwen, James R. Roppolo, William C. de
Groat, Changfeng Tai, Pittsburgh, PA
MP12-17 PROTECTIVE EFFECT OF A RHO-KINASE
INHIBITOR ON CHRONIC ISCHEMIARELATED BLADDER DYSFUNCTION
Hidenori Akaihata*, Fukushima, Japan,
Masanori Nomiya, Koriyama, Japan,
Nobuhiro Haga, Nobuhiro Kushida, Kei
Ishibashi, Ken Aikawa, Fukushima, Japan,
Osamu Yamaguchi, Koriyama, Japan,
Yoshiyuki Kojima, Fukushima, Japan
MP12-08 NOXIOUS ELECTRICAL STIMULATION OF
PELVIC FLOOR INDUCES TRANSIENT
DYSFUNCTIONAL VOIDING IN RABBITS
Amy D. Dobberfuhl*, Sara Spettel, Catherine
Schuler, Robert M. Levin, Andrew H. Dubin,
Elise J.B. De, Albany, NY
MP12-09 A NOVEL INTRACEREBRAL
HEMORRHAGE-INDUCED RAT MODEL OF
NEUROGENIC VOIDING DYSFUNCTION:
ANALYSIS OF LOWER URINARY TRACT
FUNCTION
Young Sam Cho*, Kwan Joong Joo, Heung
Jae Park, Chil Hun Kwon, Seoul, Korea,
Republic of
MP12-18 EFFECTS OF LIPOSOME-BASED LOCAL
SUPPRESSION OF NERVE GROWTH
FACTOR IN THE BLADDER ON
AUTONOMIC DYSREFLEXIA DURING
URINARY BLADDER DISTENTION IN RATS
WITH SPINAL CORD INJURY
Katsumi Kadekawa*, Tsuyoshi Yoshizawa,
Pradeep Yyagi, Pittsburgh, PA, Kimio
Sugaya, Okinawa, Japan, Naoki Yoshimura,
Pittsburgh, PA
MP12-10 WHITE AND GRAY MATTER DAMAGE ARE
RELATED TO URGE INCONTINENCE
Becky Clarkson*, Stasa Tadic, Neil Resnick,
Derek Griffiths, Pittsburgh, PA
MP12-19 SPONTANEOUS MICTURITION BEHAVIOR
AND CYSTOMETRIC EVALUATION OF
BLADDER FUNCTION IN P2X7 RECEPTOR
DEFICIENT MICE
Hiromitsu Negoro*, Kyoto, Japan, Nuan Cui,
Bronx, NY, Osamu Ogawa, Kyoto, Japan,
Sylvia Suadicani, Bronx, NY
MP12-11 URODYNAMIC INVESTIGATION: A
SENSIBLE TOOL TO DEFINE NORMAL
LOWER URINARY TRACT FUNCTION?
Lorenz Leitner*, Matthias Walter, Ulrich
Mehnert, Thomas M. Kessler, Zürich,
Switzerland
MP12-20 SUPRASPINAL ACTIVITY TO BLADDER
COLD SENSATION IN HEALTHY
SUBJECTS - AN FMRI STUDY
Matthias Walter*, Lorenz Leitner, Lars
Michels, Spyros Kollias, Thomas M. Kessler,
Ulrich Mehnert, Zürich, Switzerland
MP12-12 ENHANCED SPINAL GLYCINERGIC
SYSTEM BY GLYCINE TRANSPORTER
TYPE 2 (GLYT2) INHIBITION REDUCES
NEUROGENIC DETRUSOR OVERACTIVITY
IN RATS WITH SPINAL CORD INJURY
Tsuyoshi Yoshizawa*, Satoru Yoshikawa,
Hiroki Okada, Pittsburgh, PA, Satoru
Takahashi, Tokyo, Japan, Naoki Yoshimura,
Pittsburgh, PA
CREDITTM
50
3:30 pm - 5:30 pm
BENIGN PROSTATIC HYPERPLASIA: SURGICAL THERAPY & NEW TECHNOLOGY III
Moderators: Andreas Gross and Giuseppe Carrieri
ABSTRACT
NUMBER TITLE
MP13-01 PATIENT’S PERCEPTIONS ABOUT
EJACULATORY VOLUME CHANGES
AFTER HOLMIUM LASER ENUCLEATION
OF THE PROSTATE
Jae-Seung Paick, Hyung Suk Kim*, Seoul,
Korea, Republic of, Min Chul Cho, Young Ju
Lee, Myong Kim, Min Yong Kang, Jeong
Kwon Kim, Ju Hyun Park, Seung Beom Ha,
ABSTRACT
NUMBER TITLE
MP13-07 CAN MEN WITH BOTH BENIGN
PROSTATIC OBSTRUCTION AND
BLADDER UNDERACTIVITY BENEFIT
FROM HOLMIUM LASER ENUCLEATION
OF THE PROSTATE (HOLEP) MORE THAN
FROM PHOTOSELECTIVE VAPORIZATION
OF THE PROSTATE (PVP)?
Min Chul Cho*, Goyang-si, Korea, Republic
of, Seung Beom Ha, Ju Hyun Park, Sung
Yong Cho, Seoul, Korea, Republic of, Seung
Baik, Gwangju, Korea, Republic of, Kwang
Ho You, Gwangmyeong, Korea, Republic of,
Ja Hyeon Ku, Seung-June Oh, Soo Woong
Kim, Seoul, Korea, Republic of, Kwang Soo
Lee, Goyang-si, Korea, Republic of, JaeSeung Paick, Seoul, Korea, Republic of
MP13-02 IMPACT OF PROSTATE VOLUME ON
SURGICAL EFFECTIVENESS AND SAFETY
WITH XPS GREENLIGHT LASER.
OUTCOMES OF A MULTICENTER
RETROSPECTIVE STUDY
Mahmood A. Hai*, Westland, MI, Ricardo R.
Gonzalez, Houston, TX, Gregg R. Eure,
Virginia Beach, VA, Lewis S. Kriteman,
Roswell, GA, Kevin C. Zorn, Montreal,
Canada
MP13-08 PROSPECTIVE EVALUATION OF LASER
PROSTATECTOMY USING A NEW 1.9␮M
THULIUM LASER: 1 YEAR FOLLOW-UP
David Zimmermann*, Patrick Honeck,
Thomas Knoll, Gunnar Wendt-Nordahl,
Sindelfingen, Germany
MP13-03 TOWARDS OPTIMIZING PROSTATE
TISSUE RETRIEVAL AFTER HOLMIUM
LASER ENUCLEATION OF THE
PROSTATE: PROSPECTIVE ASSESSMENT
OF DIFFERENT APPROACHES
Ahmed Elshal*, Ramy Mekkawy, Ahmed ELAssmy, Ahmed EL-Nahas, Mansoura, Egypt
MP13-09 DOES 5␣-REDUCTASE INHIBITIOR
AFFECT THE EFFICIENCY OF THULIUM:
YAG (REVOLIX®) VAPOENUCLEATION OF
THE PROSTATE FOR THE TREATMENT OF
BENIGN PROSTATIC HYPERPLASIA?
Jae Il Chung*, Jae Seung Chung, Won IK
Seo, Pil Moon Kang, Jang Ho Yoon, Wan
Seok Kim, Dong Il Kang, Kweon Sik Min,
Seong Cheol Kim, Cheol Kyu Oh, Sang Hyun
Park, Seok San Park, Busan, Korea,
Republic of
MP13-04 IS POWER EVERYTHING IN HOLMIUM
SURGERY? THE FIRST REPORTED 50
WATT HOLMIUM LASER ENUCLEATION
OF THE PROSTATE SERIES
Farooq Khan*, Mohamed Asad Saleemi,
Sanjeev Taneja, Asher Alam, Luton, United
Kingdom, Ian Nunney, Norwich, United
Kingdom, Michal Sut, Tevita Futo ’Aho,
Cambridge, United Kingdom
MP13-10 THULIUM VAPOENUCLEATION OF THE
PROSTATE (THUVEP): LONG-TERM
RESULTS DURING 6-YEAR FOLLOW-UP
OF 500 PROCEDURES
Christopher Netsch*, Daniela Jakobler,
Thorsten Bach, Andreas J. Gross, Hamburg,
Germany
MP13-05 PREDICTORS OF REOPERATION AFTER
PROSTATE FOR MANAGEMENT OF
SYMPTOMATIC BENIGN PROSTATE
HYPERPLASIA
Mohamed Elkoushy*, Ahmed Elshal, Mostafa
Elhilali, Montreal, Canada
MP13-11 THULIUM VAPOENUCLEATION OF THE
PROSTATE (THUVEP) FOR PROSTATES
LARGER THAN 80ML: LONG-TERM
DURABILITY OF THE PROCEDURE
Germany
MP13-06 IS THE CAPSULAR PERFORATION A
COMPLICATION OF HOLMIUM LASER
(HOLEP)?
José Placer*, Carlos Salvador, David Lorente,
Ana Celma, Jacques Planas, Enrique Trilla,
Miguel Ángel López Pacios, Christian Isalt,
Lucas Regis, Pol Servián, Juan Morote,
Barcelona, Spain
*Presenting author
MP13-12 AGE-STRATIFIED OUTCOMES OF
THULIUM VAPOENUCLEATION OF THE
PROSTATE (THUVEP)
Germany
51
FRIDAY
MP13-17 EN BLOC ENUCLEATION OF THE
PROSTATE USING A SURGICAL 532-NM
LASER (GREENLEP) TECHNIQUE: INITIAL
RESULTS
Vincent Misrai, Julien Guillotreau*, Benoit
Bordier, Toulouse, France, Henry Woo,
Sydney, Australia, Fernando Gomez-Sancha,
Madrid, Spain
MP13-13 FUNCTIONAL RESULTS AFTER
PHOTOVAPORISATION OF THE
PROSTATE (PVP) WITH GREENLIGHT XPS
LASER: A PROSPECTIVE MULTIINSTITUTIONAL STUDY
Maxime Thoulouzan*, Romain Huet, Romain
Mathieu, Karim Bensalah, Rennes, France,
Jehanne Calves, Brest, France, Pierre
Coeurdacier, Cesson-Sévigné, France, Luc
Corbel, Emmanuel Della Negra, Saint-Brieuc,
France, Alexandre Fourcade, Brest, France,
Benoit Gires, Vivien Grafeille, Rennes,
France, Marie-Aimée Perrouin-Verbe, Sophie
Serey-Eiffel, Antoine Valeri, Brest, France,
Grégory Verhoest, Sébastien Vincendeau,
Rennes, France, Georges Fournier, Brest,
France
MP13-18 GREENLIGHT XPS PHOTOVAPORIZATION
FOR LARGE PROSTATIC ADENOMAS (>80
ML): A PROSPECTIVE MULTIINSTITUTIONAL STUDY
Maxime Thoulouzan*, Romain Huet, Romain
Mathieu, Karim Bensalah, Rennes, France,
Jehanne Calves, Brest, France, Pierre
Coeurdacier, Cesson-Sévigné, France, Luc
Corbel, Emmanuel Della Negra, Saint-Brieuc,
France, Alexandre Fourcade, Brest, France,
Benoit Gires, Vivien Grafeille, Rennes,
France, Marie-Aimée Perrouin-Verbe, Sophie
Serey-Eiffel, Antoine Valeri, Brest, France,
Grégory Verhoest, Sébastien Vincendeau,
Rennes, France, Georges Fournier, Brest,
France
MP13-14 180W LBO LASER VAPORIZATION OF THE
PROSTATE FOR BENIGN PROSTATIC
HYPERPLASIA IN HIGH-RISK PATIENTS
Pierre-Alain Hueber*, Marc Nicolas Bienz,
Roger Valdivieso, Hugo Lavigueur-Blouin,
Montreal, Canada, Vincent Misrai, Toulouse,
France, Matthew Rutman, Alexis Te, Bilal
Chughtai, New York, NY, Neil Barber, Amr
Emara, Frimley, Surrey, United Kingdom,
Ravi Munver, Hackensack, NJ, Naeem
Bhojani, Kevin Zorn, Montreal, Canada
MP13-19 THE LEARNING CURVE OF MULTIPLE
OPERATORS FOR LASER ENUCLEATION
OF PROSTATE IN TREATMENT OF
BENIGN PROSTATE OBSTRUCTION
Jonathan Lopater*, Pierre Etienne
Theveniaud, Nauman Zafar, Walid Massoud,
Frederic Girard, Mohammed Fennouri,
Laurent Lamy, Hervé Baumert, Paris, France
MP13-15 DO ANTIPLATELET AND
ANTICOAGULANT INCREASE RISK OF
HAEMORRHAGIC COMPLICATIONS IN
PHOTOVAPORIZATION OF PROSTATE BY
GREENLIGHT® LASER
Pradère Benjamin*, Tours, France, Peyronnet
Benoit, Rennes, France, Brichart Nicolas,
Bruyère Franck, Tours, France
MP13-20 12-MONTH EVALUATION BY VALIDATED
QUESTIONNAIRES OF VOIDING AND
STORAGE SYMPTOMS AFTER SURGERY
FOR BLADDER OUTLET OBSTRUCTION
(PVP XPS 180W, HOLEP, TURP)
Borja Lopez*, Carlos Capitán, Isabel M.
Jiménez-Valladolid, Virginia Hernández,
Enrique De la Peña, Elia Pérez-Fernández,
Carlos Llorente, Madrid, Spain
MP13-16 EVALUATION OF SAFETY, EFFICIENCY
AND SURGICAL OUTCOMES BETWEEN
GREENLIGHT 180W-XPS TECHNIQUES:
COMPARISON OF PURE PHOTOVAPORIZATION AND VAPOR-INCISION
TECHNIQUES
Kevin C. Zorn*, Montreal, Canada, Ricardo R.
Gonzalez, Houston, TX, Greg R Eure,
Virginia Beach, VA, Lewis S. Kriteman,
Roswell, GA, Pierre-Alain Hueber, Abdullah
Alenizi, Marc Bienz, Khaled ElHosni, Malek
Meskawi, Montreal, Canada, Mahmood A.
Hai, Westland, MI
CREDITTM
52
3:30 pm - 5:30 pm
Podium Session 6
PROSTATE CANCER: EPIDEMIOLOGY & NATURAL HISTORY II
Moderators: Steven Joniau and Christopher Kane
TIME
3:30
ABSTRACT
NUMBER TITLE
PD6-01 ASPIRIN, NSAID AND RISK OF HIGHGRADE PROSTATE CANCER: RESULTS
FROM THE REDUCE STUDY
Adriana C. Vidal*, Lauren E. Howard,
Durham, NC, Daniel M. Moreira, Rochester,
MN, Ramiro Castro-Santamaria, King of
Prussia, PA, Gerald L. Andriole, St. Louis,
MO, Stephen J. Freedland, Durham, NC
3:40
PD6-02
5-ALPHA REDUCTASE INHIBITOR USE
AND PROSTATE CANCER SURVIVAL IN
THE FINNISH PROSTATE CANCER
SCREENING TRIAL
Teemu Murtola*, Elina Karppa, Tampere,
Finland, Kimmo Taari, Helsinki, Finland,
Teuvo Tammela, Anssi Auvinen, Tampere,
Finland
3:50
PD6-03
METFORMIN USE PREDICTS AN OVERALL
SURVIVAL ADVANTAGE IN DIABETIC
VETERANS WITH PROSTATE CANCER
Daniel Reznicek*, Elena Klyushnenkova,
Richard Alexander, Baltimore, MD
4:00
PD6-04
A PROSPECTIVE, LONGITUDINAL ACTIVE
SURVEILLANCE PROGRAM FOR
FAVORABLE-RISK PROSTATE CANCER:
LONG TERM OUTCOMES
Jeffrey Tosoian*, Mufaddal Mamawala,
Jonathan Epstein, Patricia Landis, Sacha
Wolf, Bruce Trock, H. Ballentine Carter,
Baltimore, MD
4:10
PD6-05
CHANGE IN PREDICTED PROGNOSIS
AFTER RADICAL PROSTATECTOMY
DURING FOLLOW-UP IN AN ACTIVE
SURVEILLANCE COHORT
John B. Eifler, Jr.*, Daren Diiorio, Chaochen
You, Nashville, TN, Vidhush Yarlagadda,
Birmingham, AL, David F. Penson, Joseph A.
Smith, Jr., Sam Chang, Nashville, TN,
Michael S. Cookson, Oklahoma City, OK,
Daniel A. Barocas, Nashville, TN
4:20
PD6-06
NATIONAL PROSTATE CANCER
PRACTICE TRENDS: EVOLVING TOWARD
EVIDENCE-BASED PRACTICE ACROSS
RISK STRATA
Matthew Cooperberg*, Peter Carroll, San
Francisco, CA
4:30
PD6-07
EJACULATION FREQUENCY AND RISK OF
PROSTATE CANCER: UPDATED RESULTS
FROM THE HEALTH PROFESSIONALS
FOLLOW-UP STUDY
Jennifer Rider*, Kathryn Wilson, Rachel Kelly,
Erika Ebot, Edward Giovannucci, Lorelei
Mucci, Boston, MA
*Presenting author
ABSTRACT
TIME NUMBER TITLE
4:40
PD6-08 HOSPITAL READMISSIONS AFTER
TRANSRECTAL ULTRASOUND GUIDED
PROSTATE BIOPSY IN THE VA MEDICAL
SYSTEM
Mark Garzotto*, James Edwards, Michael
Conlin, Portland, OR
4:50
PD6-09
POLYMORPHISMS IN GENES OF THE
GLUCOSE- AND ENERGY-METABOLISM
PATHWAYS AND PROSTATE CANCER:
INTERPLAY WITH METFORMIN
Teemu Murtola*, Tiina Wahlfors, Antti Haring,
Tampere, Finland, Kimmo Taari, Ulf-Håkan
Stenman, Helsinki, Finland, Teuvo Tammela,
Tampere, Finland, Johanna Schleutker,
Turku, Finland, Anssi Auvinen, Tampere,
Finland
5:00
PD6-10
ADVERSE EVENTS AFTER RADICAL
PROSTATECTOMY AND CURATIVE
RADIOTHERAPY. POPULATION-BASED
NATION-WIDE REGISTER STUDY
Jón Ö. Friðriksson, Umeå, Sweden, Yasin
Folkvaljon, Uppsala, Sweden, Per Nilsson,
Lund, Sweden, David Robinson, Jönköping,
Sweden, Ingela F. Frank Lissbrant,
Gothenburg, Sweden, Behfar Ehdaie*, James
A. Eastham, New York, NY, Anders Widmark,
Camilla Thellenberg, Pär Stattin, Umeå,
Sweden
5:10
PD6-11
OUTCOMES AND COSTS FOLLOWING
TREATMENT FOR LOCALLY ADVANCED
PROSTATE CANCER: RESULTS FROM
SEER-MEDICARE
Rachael Sussman*, Washington, DC, Andrew
Harbin, Philidelphia, PA, John Lynch,
Washington, DC, Jim Hu, Los Angeles, CA,
Keith Kowalczyk, Washington, DC
5:20
PD6-12
DIMINISHING RETURNS OF ROBOTIC
DIFFUSION: COMPLICATIONS
FOLLOWING ROBOT-ASSISTED RADICAL
PROSTATECTOMY
Jesse Sammon*, Firas Abdollah, Dane Klett,
Daniel Pucheril, Akshay Sood, Detroit, MI,
Quoc-Dien Trinh, Boston, MA, Mani Menon,
Detroit, MI
CREDITTM
53
FRIDAY
NOTES
7:00 am - 6:15 pm
7:00
BREAKFAST SYMPOSIUM (BREAKFAST
INCLUDED, ROOM 278-282, NON-CME)
8:00
(CME PORTION OF PROGRAM BEGINS)
PRESIDENTIAL WELCOME
Lawrence Hakim
8:05
CME ACTIVITY ANNOUNCEMENTS
Run Wang
8:10
SESSION 1 - PEYRONIE’S DISEASE MEDICAL
THERAPY
Moderators: Lawrence Hakim, Brian Christine
FROM BENCH RESEARCH TO MEANINGFUL
CLINICAL PREVENTION
Arthur Burnett
ISSM LECTURE: COLLAGENASE
CLOSTRIDUIM HISTOLYTICUM INJECTION:
UPDATE 2015
Wayne Hellstrom
11:15
MEDICAL INTERVENTION
Laurence Levine
11:25
SURGICAL THERAPY - THE PREFERRED
SHUNT PROCEDURE
Justin Parker
11:35
POINT/COUNTERPOINT: EARLY VS LATE
IMPLANTS
Allen Morey, David Ralph
11:55
Q&A
12:05
LUNCH SYMPOSIUM (LUNCH INCLUDED,
ROOM 278-282, NON-CME)
8:25
POINT/COUNTERPOINT: VERAPAMIL
INJECTION - STILL A VIABLE OPTION
Nelson Bennett, Chad Ritenour
8:45
POINT/COUNTERPOINT: INTERFERON ␣2B
INJECTION - STILL A VIABLE OPTION
Andrew McCullough, Mustafa Usta
9:05
Q&A
9:15
SESSION 2 - PEYRONIE’S DISEASE SURGICAL
THERAPY
Moderators: Serge Carrier, LeRoy Jones
1:15
FEMALE SEXUAL DYSFUNCTION: WHAT
UROLOGISTS SHOULD KNOW
Seth Cohen
PLICATION IS THE BEST OPTION
Anthony Bella
1:25
EXCISION AND GRAFTING: WHO SHOULD GET
IT?
Doron Stember
FEMALE SEXUAL DYSFUNCTION: WHAT
GYNECOLOGISTS SHOULD KNOW
Andrew Goldstein
1:35
Q&A
1:45
SESSION 6 - 2ND ANNUAL IRA D. SHARLIP
LECTURE AND AWARD
Moderators: Ira Sharlip, Ronald Lewis
9:25
9:35
PENILE IMPLANT SHOULD BE OFFERED
EARLY
Landon Trost
9:45
LENGTH AND GIRTH RESTORATION WITHOUT
GRAFT
9:55
Q&A
10:05
BREAK
10:20
SESSION 3 - JSM, ICSM AND SMSNA
Moderators: Run Wang, Luca Incrocci
(CME PORTION OF PROGRAM RESUMES IN
ROOM 265-268)
1:05
STATE OF ART IN FEMALE SEXUAL
DYSFUNCTION
Annamaria Giraldi
THE ROAD FROM UROLOGIST TO SEXUAL
MEDICINE SPECIALIST
Irwin Goldstein
2:00
Q&A
2:05
SESSION 7 - PENILE IMPLANT
Moderators: John Mulcahy, Andrew Kramer
POINT/COUNTERPOINT: TWO-PIECE
INFLATABLE IMPLANT HAS NO ROLE IN
MODERN ERA
Steven Wilson, Ashley Tapscott
JSM LECTURE: 2015 AND BEYOND- EDITORIN-CHIEF’S NOTE
John Mulhall
10:35
ICSM UPDATE
Gerald Brock
10:45
TESTOSTERONE REPLACEMENT PATTERN
AMONG SMSNA MEMBERS
10:55
Q&A
11:05
SESSION 4 - PRIAPISM
Moderators: Gregory Broderick, Trinity Bivalacqua
*Presenting author
SESSION 5 - FEMALE SEXUAL DYSFUNCTION
Moderators: Susan Goldstein, Noel Kim
55
2:25
SST: PREVENTION, IDENTIFICATION, INTRAOPERATIVE CORRECTION
Rafael Carrion
2:35
POST PENILE IMPLANT REHABILITATION:
WHAT AND WHEN
Gerard Henry
2:45
CODING FOR REIMBURSEMENT IN
PROSTHETIC UROLOGY
Edward Karpman
2:55
Q&A
SATURDAY
SEXUAL MEDICINE SOCIETY OF NORTH AMERICA (SMSNA)
3:05
BREAK
3:20
SESSION 8 - MALE ORGASM AND
EJACULATORY DISORDERS
Moderators: Stanley Althof, Christian Nelson
PSYCHOTHERAPY FOR DECREASED ORGASM
WITH NORMAL HORMONAL PROFILE
Michael Perelman
3:30
MEDICAL THERAPY FOR DECREASED
ORGASM WITH NORMAL HORMONAL
PROFILE
Tobias Kohler
4:35
SEXUAL DYSFUNCTION ASSOCIATED WITH
COLORECTAL CANCER TREATMENT: AN
IGNORED CONDITION
O. Lenaine Westney
4:45
SEXUAL BEHAVIOR AND PROSTATE CANCER
RISK
Marie-Elise Parent
4:55
Q&A
5:05
SESSION 11 - SEXUAL MEDICINE FOR LGBT
PERSONS
Moderators: Alan Shindel, Hui Jiang
ADDRESSING SEXUALITY AND SEXUAL
DYSFUNCTION IN LGBT PERSONS
Mohit Khera
3:40
TREATMENT OF PREMATURE EJACULATION:
UPDATE 2015
Ricardo Munarriz
3:50
Q&A
5:15
4:00
SESSION 9 - TRANSLATIONAL SEXUAL
MEDICINE
Moderators: Kelvin Davies, Michael DiSanto
PROSTATE CANCER AND SEXUALITY IN GAY
MEN
David Latini
5:25
LOW ENERGY SHOCK WAVE FOR ERECTILE
DYSFUNCTION: SCIENCE OR FICTION
Tom Lue
SEXUAL BEHAVIOR AND DYSFUNCTIONS IN
WOMEN WHO HAVE SEX WITH WOMEN
Vanessa Schick
5:35
Q&A
5:45
(NON-CME PORTION) SESSION 12 -THE
PIPELINE: DRUG DEVELOPMENT IN SEXUAL
HEALTH
Moderators: Gregory Broderick, Run Wang
Presenter: Andrew McCullough
6:00
SMSNA BUSINESS MEETING
4:10
NANOTECHNOLOGY FOR ERECTION
DYSFUNCTION: ARE WE READY FOR
CLINICAL TRIAL
Carol Podlasek
4:20
Q&A
4:25
SESSION 10 - SEXUAL DYSFUNCTION EXPANDED FIELD
Moderators: Chris McMahon, Kwangsung Park
CREDITTM
ASSOCIATION OF FERTILITY AND SEXUAL
DYSFUNCTION
Alexander Pastuszak
7:15 am - 4:30 pm
ENGINEERING AND UROLOGY SOCIETY (EUS) - SECTION OF THE ENDOUROLOGICAL SOCIETY
Napoleon Ballroom @ Hilton New Orleans Riverside
7:25
WELCOME
Program Chair: Peter Schulam, Jean Zheng
7:30
SESSION 1: ADVANCES IN URETERAL STENT
DEVELOPMENT
Moderator: Ravindra Kulkarni
8:20
UPDATE ON REGENERATIVE MEDICINE
Anthony Atala
BIODEGRADABLE MATERIALS IN UROLOGY
Ben Chew
7:40
ANTIMICROBIAL APPROACHES TO
RENDERING URINARY BIOMATERIAL
SURFACES STERILE
Dirk Lange
7:50
A NEW STENT
Ravindra Kulkarni
8:00
COMMERCIALIZING NEW STENT
TECHNLOGY: CHALLENGES &
OPPORTUNITIES
Tim Harrah
8:10
SESSION 2: REGENERATIVE MEDICINE
Moderator: Peter Schulam
8:50
ENGINEERING AN ILEAL CONDUIT
Deepak Jain
9:10
QUESTIONS
9:15
AWARDS PRESENTATION
Dan Stoianovici
9:30
SESSION 3: ESUT SESSION
Chairman: Alberto Breda
Moderators: Jens Rassweiler, Pilar Laguna Pes
DYNA-CT-NAVIGATED ROBOTIC SURGERY
Dogu Teber
9:45
QUESTIONS
56
NEW DEVELOPMENTS IN ROBOTIC FLEXIBLE
URETEROSCOPY
Jens Rassweiler
NOVEL USE OF ULTRASOUND FOR KIDNEY
STONE MANAGEMENT - FIRST CLINICAL
STUDY
Jonathan Harper
10:15
LATEST NEWS FROM THE IRCAD - NOTES,
LESS & MORE
Roland van Velthoven
10:30
SESSION 4: INTERVENTIONAL UROLOGIC
ONCOLOGY
1:30
LESS IN THE DEVELOPING WORLD
P. P. Rao
1:40
LESS DONOR NEPHRECTOMY
Ricardo Autorino
1:50
IS LESS HERE TO STAY
Lee Ponsky
2:00
INNOVATIONS IN UROLOGY (SCIENCE &
TECHNOLOGY HALL)
THE NEW FRONTIER OF PROSTATE CANCER
IMAGING, BEYOND MULTI-PARAMETRIC MRI
Peter Choyke
SESSION 6: IMAGED GUIDED WORKING
GROUP
Moderator: James Borin
10:45
LATEST ADVANCES IN PROSTATE FUSION
BIOPSY
Srinivas Vourganti
MRI/US FUSION FOR DIAGNOSIS AND
TREATMENT OF PROSTATE CANCER IN THE
OFFICE SETTING
Samir Taneja
11:00
THE CURRENT AND EMERGING ROLE OF
RENAL BIOPSY FOR THE RENAL MASS
Jaime Landman
11:15
RENAL TUMOR ABLATION: WHAT’S NEW ON
THE HORIZON
Brian Shuch
11:30
CURRENT AND EMERGING INDICATIONS FOR
PROSTATE EMBOLIZATION
Ardeshir Rastinehad
11:45
CURRENT STATUS OF FOCAL THERAPY
MODALITIES FOR PROSTATE CANCER
Peter Pinto
12:00
LUNCH
1:00
SESSION 5: LESS AND NOTES
Moderator: Abhay Rane
1:10
LESS AND NOTES PUBLICATIONS UPDATE
Brian Irwin
1:20
“NEW” ROBOTIC LESS IS THE WAY FORWARD
Jihad Kaouk
2:10
TECHNICAL SOLUTIONS TO IMPROVE THE
MANAGEMENT OF NON-MUSCLE INVASIVE
TRANSITIONAL CELL CARCINOMA
Evangelos Liatsikos
2:20
FIBEROPTIC CONFOCAL LASER
ENDOMICROSCOPY: OPTICAL TISSUE
CHARACTERIZATION OF RENAL TUMORS
Li-Ming Su
2:30
3D PRINTING OF UROLOGICAL
MALIGNANCIES
Jonathan Silberstein
2:40
LAPAROSCOPIC HIFU FOR THE TREATMENT
OF SMALL RENAL MASSES
Chandru Sundaram
2:50
NEW HORIZONS FOR IMAGING OF KIDNEY
STONES TO GUIDE THERAPY
Ojas Shah
CREDITTM
7:30 - 11:45 am
RESIDENTS FORUM
7:30
REGISTRATION
8:26
7:45
WELCOME AND INTRODUCTORY REMARKS
Residents Committee Chair: John Lacy
RESEARCH-ORIENTED
Doug Clayton
8:34
PRIVATE PRACTICE
Chris Schrepferman
8:45
ROUND TABLE Q&A
9:10
BUSINESS ASPECT WITH PANEL OF EXPERTS
7:50
PEARLS FOR CONTRACTS, INCOME CENTERS
AND ESTABLISHING A PROSTHETIC
UROLOGY PRACTICE
Gerard Henry
PRACTICE BUY-INS, HOW TO FIND BEST
UROLOGY POSITION FOR YOUR UROLOGY
CAREER AND PEACE OF MIND
Roger Bonds
AN EXPERT’S VIEW TO FINDING THE IDEAL
JOB
Moderator: Ben Ristau, Residents Committee Vice
Chair
8:10
CLINICAL ASPECT WITH PANEL OF EXPERTS
ACADEMICS
Gennady Bratslavsky
8:18
HOSPITAL-EMPLOYED
Richard Santucci
*Presenting author
57
9:20
CONTRACT PITFALLS, HOW TO NEGOTIATE
IDEAL CONTRACT
Thomas Crawford
9:30
DEBT MANAGEMENT/INVESTMENTS
Marshall Gifford
SATURDAY
10:00
11:00
9:40
ROUND TABLE Q&A
10:10
BREAK
10:20
CORE CURRICULUM SERIES
John Mulhall
10:30
TEACHING AWARD PRESENTATION
10:40
RAFFLE DRAWING/CLOSING REMARKS
10:45
FELLOWS INTRODUCTION
LUNCH WITH A FELLOW
SESSION A: QUESTION AND ANSWER
SESSION: IS PROSTHETIC UROLOGY
FELLOWSHIP A GOOD FIT FOR ME?
Gerard Henry, Michael Pryor, Martin Gross
SESSION B: QUESTION AND ANSWER
SESSION: CHOOSE YOUR FELLOWSHIP
7:30 am - 12:00 pm
Live Surgery Program
LIVE SURGERY I
Moderators: Ashok Hemal and James Porter
7:30
8:45
MICRO, ULTRA-MINI, AND SUPER
PERCUTANEOUS NEPHROLITHOTOMY
Surgeons: R.B. Sabnis, Janak Desai, Madhu
Agrawal, Kaushik Shah
Panelists: Mahesh Desai, Arthur Smith
9:45
ROBOTIC ASSISTED PARTIAL NEPHRECTOMY
Surgeon: Sam Bhayani
Panelists: Mahesh Desai, Arthur D. Smith
11:00
MALE STRESS URINARY INCONTINENCE
SLING SURGERY
Surgeon: Andrew Peterson
Panelist: Jaspreet Sandhu
SHOCK AND AWE-NEW PHYSICIAN
CONTROLLED PCNL LITHOTRIPSY WITH
SUPERIOR SPEED AND EFFICIENCY
Surgeon: Raju Thomas
Operating Room Monitor: Ben Chew
Panelists: Mahesh Desai, Arthur Smith
CREDITTM
7:30 am - 12:10 pm
ARAB ASSOCIATION OF UROLOGY (AAU)
7:30
BREAKFAST & REGISTRATION
9:25
COFFEE BREAK
7:50
WELCOME AND INTRODUCTIONS
Michael Blute, Hassan Abol-Enein, Gopal Badlani,
Raja Khauli
9:45
SESSION II: ADVANCED KIDNEY CANCER
Chairmen: Yasser Farahat, Abdul Naser Shunaigat
8:00
SESSION I: PROSTATE CANCER UPDATE
Chairmen: Abdou Khair Chamssuddin, Khalid Sayyid
STRATEGIES & TECHNICAL
CONSIDERATIONS IN SURGICAL TREATMENT
FOR ADVANCED RCC
Bradley Leibovich
CURRENT STATUS & INDICATIONS FOR
ACTIVE SURVEILLANCE IN PROSTATE
CANCER
Laurence Klotz
8:15
8:30
8:45
9:00
PRECISION MEDICINE IN PROSTATE CANCER
- THE DAWN OF THE GENOMIC ERA
Eric Klein
CLINICAL T3 DISEASE: IS THERE A ROLE OF
ROBOTIC RADICAL PROSTATECTOMY?
Stephen Boorjian
10:00
ROLE OF METASTECTOMY IN THE
MANAGEMENT OF RCC & INDICATIONS FOR
ADJUVANT THERAPY
Christopher Wood
10:15
CASE PRESENTATIONS & PANEL
DISCUSSION: RCC
Moderator: Michael Blute
Panelists: Christopher Wood, Bradley Leibovich
10:45
SESSION III: SUPERFICIAL BLADDER
CANCER/BPH/MEN’S HEALTH
Chairmen: Georges Nassar, Ahmed Shokeir
CONTROL OF THE PRIMARY TUMOR IN THE
SETTING OF ADVANCED PROSTATE CANCER
Brian Chapin
BCG ALTERNATIVE FOR NMIBC IN LIGHT OF
SHORTAGES
Badrinath Konety
PANEL DISCUSSION/DEBATE: DILEMMAS IN
PROSTATE CANCER SCREENING, DIAGNOSIS
& MANAGEMENT
Moderator: Raja Khauli
Panelists: Peter Albertsen, Stephen Boorjian,
Laurence Klotz, Brian Chapin
11:00
58
BPH: NEW TECHNOLOGY PVP RESULTS; IS
TURP STILL THE STANDARD?
Shahin Tabatabaei
12:10
11:15
MEDICAL STRATEGIES FOR BPH
Kevin McVary
11:30
MEN’S HEALTH UPDATE
Ajay Nehra
11:45
PANEL DISCUSSION/DEBATE:
Moderator: Hassan Abol-Enein
Panelists: Kevin McVary, Badrinath Konety, Shahin
Tabatabaei, Ates Kadioglu
ADJOURN
SATURDAY
CREDITTM
7:30 am - 5:30 pm
SOCIETY FOR PEDIATRIC UROLOGY - SATURDAY
Grand Ballroom BC @ Hilton New Orleans Riverside
7:30
SESSION 5: VOIDING DYSFUNCTION
Moderators: Paul Austin, C. K. Yeung
8:40
PANEL DISCUSSION: SOCIOECONOMICS
PANEL (SPU QUALITY INITIATIVE;
AFFORDABLE CARE ACT; FELLOWSHIP
TRAINING IN PEDIATRIC UROLOGY)
Moderator: Lane Palmer
Panelists: Barry Kogan, Douglas Husmann, Bradley
Kropp
12:00
LUNCH (ON OWN)
1:30
SESSION 6: NEUROPATHIC BLADDER
Moderators: John Wiener, Kourosh Afshar
2:30
PANEL DISCUSSION: “THE THREE WISE MEN”
Moderator: David Bloom
Panelists: Alan Retik, Stephen Koff, Edmond
Gonzalez
3:30
SESSION 7: TUMOR, TRAUMA AND
TRANSPLANTATION
Moderators: Israel Franco, Armando Lorenzo
9:45
BREAK
10:15
SPU LECTURE
4:00
BREAK
11:00
SPU PRESIDENTIAL ADDRESS
Society President: Barry Kogan
4:30
SESSION 8: DSD
Moderators: Joao Luiz Pippi Salle, David Diamond
11:15
SPU PRIZE AWARDS AND GRADUATING
FELLOWS
5:30
ADJOURN
11:30
SPU ANNUAL BUSINESS MEETING (SPU
MEMBERS ONLY)
CREDITTM
8:00 am - 10:00 am
PROSTATE CANCER: EPIDEMIOLOGY & NATURAL HISTORY III
Moderators: Francesco Montorsi and Scott Eggener
ABSTRACT
NUMBER TITLE
MP14-01 USING THE EPIC 26 QOL
QUESTIONNAIRE TO DETECT AND
ASSESS DEPRESSION IN PATIENTS WITH
PROSTATE CANCER
Patrick Kilday*, Peter Elliott, George
Abdelsayed, Jeff Slezak, Edward Rodriguez,
Teresa Harrison, Steven J Jacobsen, Gary W
Chien, LOS ANGELES, CA
ABSTRACT
NUMBER TITLE
MP14-03 SIMPLIFIED FRAILTY INDEX PREDICTS
ADVERSE SURGICAL OUTCOMES AND
INCREASED LENGTH OF STAY IN
RADICAL PROSTATECTOMY PATIENTS:
AN ANALYSIS OF THE ACS-NSQIP
DATABASE
Danny Lascano*, Jamie S Pak, Alexander C
Small, Mark V Silva, James M McKiernan, G.
Joel DeCastro, Sven Wenske, Mitchell C
Benson, New York, NY
MP14-02 PROSPECTIVE QUALITY OF LIFE IMPACT
ANALYSIS FOLLOWING LOCALIZED
PROSTATE CANCER TREATMENTS:
BRACHYTHERAPY, CRYOTHERAPY, AND
RADICAL PROSTATECTOMY LONG-TERM
FOLLOW-UP
Matthew Ingham*, Arjun Poddar, Mark
Shaves, Michael Fabrizio, Raymond Lance,
Robert Given, Kurt McCammon, Paul
Schellhammer, Michael Williams, Norfolk, VA
*Presenting author
MP14-04 DISSATISFACTION WITH INFORMATION
PROVISION AND PATIENT REPORTED
OUTCOMES IN PROSTATE CANCER
SURVIVORS
Paul Kil*, Romy Lamers, Maarten Cuypers,
Marieke De Vries, Tilburg, Netherlands, Ruud
Bosch, Utrecht, Netherlands, Lonneke vd
Poll-Franse, Tilburg, Netherlands
59
MP14-11 IS BMI THE BEST ADIPOSITY MEASURE
FOR PROSTATE CANCER RISK?
Lourdes Guerrios*, San Juan, PR, Lauren
Howard, Katherine Sourbeer, Evangeline
Arulraja, Devon Beverly, Delores J. Grant,
Catherine Hoyo, Steve Freedland, Durham,
NC
MP14-05 A PROSPECTIVE COHORT STUDY OF
TREATMENT DECISION-MAKING FOR
PROSTATE CANCER FOLLOWING
PARTICIPATION IN A MULTIDISCIPLINARY CLINIC
Lauren Hurwitz*, Jennifer Cullen, Sally
Elsamanoudi, Rockville, MD, Daniel Kim,
Jane Hudak, Maryellen Colston, Judith
Travis, Bethesda, MD, Huai-Ching Kuo,
Rockville, MD, Inger Rosner, Bethesda, MD
MP14-12 OBESE CASTRATION-RESISTANT
PROSTATE CANCER PATIENTS MAY BE
AT A LOWER RISK OF METASTASIS AND
ALL-CAUSE MORTALITY: RESULTS FROM
THE SEARCH DATABASE
Durham, NC, Christopher J. Kane, San
Diego, CA, Martha K. Terris, Augusta, GA,
William J. Aronson, Los Angeles, CA,
Matthew R. Cooperberg, San Francisco, CA,
Christopher L. Amling, Portland, OR, Stephen
J. Freedland, Durham, NC
MP14-06 SELF-REPORTED SEXUAL FUNCTION IS
ASSOCIATED WITH PROSTATE CANCER
RISK
Daniel Zapata*, Lauren E Howard, Jennifer
Frank, Simon Ross, Catherine Hoyo, Dolores
Grant, Stephen J Freedland, Adriana C Vidal,
Durham, NC
MP14-07 WHAT ARE WE MISSING? THE
PERSISTENCE OF VITALITY SYMPTOM
BURDEN IN LONG-TERM PROSTATE
CANCER SURVIVORS WITHOUT
RECURRENT DISEASE
Alexander M. Helfand*, Naveen Krishnan,
Daniela A. Wittmann, Sarah T. Hawley,
Chang He, Ann Arbor, MI, May DarwishYassine, Okemos, MI, Ted A. Skolarus, Ann
Arbor, MI
MP14-13 WEIGHING IN ON ACTIVE
SURVEILLANCE: IMPACT OF OBESITY ON
PATIENT COUNSELING
Melissa Mendez*, Mitchell Bassett, Durham,
NC, Michael Abern, Chicago, IL, Lionel
Banez, Michael Ferrandino, Cary Robertson,
Stephen Freedland, Brant Inman, Philip
Walther, Judd Moul, Thomas Polascik,
Durham, NC
MP14-08 THE INCIDENCE OF TREATMENTRELATED COMPLICATIONS WITH
CONTEMPORARY TREATMENT FOR
CLINICALLY-LOCALIZED PROSTATE
CANCER
Christopher Wallis*, Alyson Mahar, Patrick
Cheung, Sender Herschorn, Laurence Klotz,
Ashraf Al-Matar, Girish Kulkarni, Yuna Lee,
Ronald Kodama, Steven Narod, Robert Nam,
Toronto, Canada
MP14-14 EFFECT OF METFORMIN USE ON
PROSTATE CANCER
Abdo Kabarriti*, Ben Boursi, Ronac
Mamatani, Thomas Guzzo, Kevin Haynes,
Yu-Xiao Yang, S. Bruce Malkowicz,
Philadelphia, PA
MP14-15 METABOLIC SYNDROME AND
AGGRESSIVE PROSTATE CANCER AND
DEFINITIVE TREATMENT
Jennifer Beebe-Dimmer*, Lance Heilbrun,
Cathryn Bock, Daryn Smith, Izabela
Podgorski, Sue Bolton, Isaac Powell, Detroit,
MI
MP14-09 UNEXPECTED LONG-TERM
IMPROVEMENTS IN URINARY AND
ERECTILE FUNCTION IN A LARGE
COHORT OF MEN WITH SELF-REPORTED
OUTCOMES FOLLOWING RADICAL
PROSTATECTOMY
Justin K. Lee*, Daniel D. Sjoberg, Alan
Thong, John P. Mulhall, Jaspreet Sandhu,
Andrew J. Vickers, Behfar Ehdaie, New York,
NY
MP14-16 THE NATURAL HISTORY OF TARGETED
BIOPSY NEGATIVE LESIONS IDENTIFIED
ON MULTIPARAMETRIC PROSTATE
MAGNETIC RESONANCE IMAGING
Raju Chelluri*, Thomas Frye, Arvin K.
George, Michele Fascelli, Richard Ho, Steven
Abboud, Annerleim Walton-Diaz, Baris
Turkbey, Bradford J. Wood, Peter A. Pinto,
Peter L. Choyke, Bethesda, MD
MP14-10 THE ROLE OF PATIENT AND PROVIDER
CHARACTERISTICS IN RADICAL
PROSTATECTOMY UTILIZATION AND
QUALITY OF CARE – RESULTS FROM THE
CDC PROSTATE CANCER DATA QUALITY
AND PATTERNS OF CARE STUDY (CDC
POC-BP)
Raj Satkunasivam*, Mary Lo, Mariana Stern,
Inderbir Gill, Los Angeles, CA, Steven
Fleming, Lexington, KY, Xiao-Cheng Wu,
New Orleans, LA, Dian Wang, Milwaukee,
WI, Michael Goodman, Atlanta, GA, Roger
Anderson, Philadelphia, PA, Trevor
Thompson, Atlanta, GA, Ann Hamilton, Los
Angeles, CA
60
MP14-20 SHORT PEAK EXPOSURE TO AMBIENT
FINE PARTICULATE MATTER PROBABLY
CONTRIBUTED TO INCREASED
PROSTATE CANCER MORTALITY
Xiaojian Qin*, Fangning Wan, Hailiang
Zhang, Bo Dai, Guohai Shi, Yao Zhu,
Dingwei Ye, Shanghai, China, People’s
Republic of
MP14-18 VERY LOW RISK VS. LOW RISK
PROSTATE CANCER DESIGNATIONS IN
AN ACTIVE SURVEILLANCE COHORT
Andrew J. Cohen*, Joseph J. Pariser,
Chicago, IL, Brittany Lapin, Chi-Hsiung
Wang, Brian T. Helfand, Michael McGuire,
Evanston, IL
CREDITTM
8:00 am - 10:00 am
TRAUMA/RECONSTRUCTION: URETHRAL RECONSTRUCTION (INCLUDING STRICTURE) I
Moderator: Allen Morey
ABSTRACT
NUMBER TITLE
MP15-01 CHANGING PRACTICE PATTERNS IN THE
TREATMENT OF URETHRAL STRICTURE
AMONGST AMERICAN UROLOGISTS
Joceline S. Liu*, Matthias D. Hofer, Daniel T.
Oberlin, Jaclyn Milose, Sarah C. Flury,
Chicago, IL, Allen F. Morey, Dallas, TX, Chris
M. Gonzalez, Chicago, IL
ABSTRACT
NUMBER TITLE
MP15-04 ENDOSCOPIC TREATMENT OF
VESICOURETHRAL STENOSIS AFTER
RADICAL PROSTATECTOMY: OUTCOMES
AND PREDICTORS OF SUCCESS
Joseph LaBossiere*, Douglas Cheung, Keith
Rourke, Edmonton, Canada
MP15-05 EFFECTS OF PRIOR RADIATION ON
OUTCOMES FROM VESICAL NECK
INCISION WITH INTRALESIONAL
MITOMYCIN C FOR RECALCITRANT
BLADDER NECK CONTRACTURE
Ronak Gor*, Phillip Ginsberg, Michael Metro,
Philadelphia, PA
MP15-02 NATIONAL TRENDS IN THE
MANAGEMENT OF URETHRAL
STRICTURE DISEASE: A 14-YEAR
SURVEY OF THE NATIONWIDE INPATIENT
SAMPLE
Nishant Patel*, San Diego, CA, Michael Liss,
San Antonio, TX, Song Wang, La Jolla, CA,
Jill Buckley, San Diego, CA
MP15-06 BIPOLAR INCISION OF BLADDER NECK
CONTRACTURE WITH INTRALESIONAL
INJECTION OF MITOMYCIN C: A SINGLE
INSTITUTION EXPERIENCE
Timothy Lyon*, Matthew Ferroni, Kevin
Rycyna, Mang Chen, Pittsburgh, PA
MP15-03 NATIONAL VARIATION IN
URETHROPLASTY COST AND
PREDICTORS OF EXTREME COST: A
COST ANALYSIS WITH POLICY
IMPLICATIONS
Catherine Harris*, Amjad Alwaal, Jack
McAninch, Charles McCulloch, Benjamin
*Presenting author
MP15-07 URETHROTOMY AND HIGH DOSE
TRIAMCINOLONE INJECTIONS IN THE
TREATMENT OF POST-URETHROPLASTY
RECURRENT STRICTURES
Jennifer A. Robles*, St Louis, MO, Jairam R.
Eswara, Boston, MA, Joel Vetter, Kerry
Madison, Steven B. Brandes, St Louis, MO
61
SATURDAY
MP14-19 LYMPH NODE METASTASES IN GLEASON
ⱕ 6 PROSTATE CANCER: DATA FROM A
GERMAN MULTICENTER DATABASE
Daniel Schindele*, Daniel Baumunk, Simon
Blaschke, Magdeburg, Germany, Annette
Reinicke, Tom Fischer, Stefan Hinz, Berlin,
Germany, Alexander Winter, Oldenburg,
Germany, Mario Zacharias, Berlin, Germany,
Sebastian Schäfers, Lüdenscheid, Germany,
Ulrich Witzsch, Frankfurt, Germany, Robert
Kössler, Berlin, Germany, Jan Fichtner,
Oberhausen-Sterkrade, Germany, Steffen
Weikert, Kurt Miller, Berlin, Germany, Martin
Schostak, Magdeburg, Germany
MP14-17 IMMEDIATE REPEAT BIOPSY IS NOT
NECESSARY IN PATIENTS WITH
ATYPICAL SMALL ACINAR
PROLIFERATION (ASAP): A MULTIINSTITUTIONAL REVIEW
Andrew Leone*, Providence, RI, Boris
Gershman, Rochester, MN, Katherine Rotker,
Christi Butler, Providence, RI, Jennifer
Fantasia, Achankeng Afiadata, Worcester,
MA, Jianhong Li, Providence, RI, Thomas
Sebo, Rochester, MN, Amy Zhou, Zhong
Jiang, Worcester, MA, Ali Amin, Anthony
Mega, Stephen Schiff, Gyan Pareek, Dragan
Golijanin, Providence, RI, Jennifer Yates,
Worcester, MA, R. Jeffrey Karnes, Rochester,
MN, Joseph Renzulli, Providence, RI
MP15-15 REDO - BUCCAL MUCOSA GRAFT
URETHROPLASTY: SUCCES RATE AND
ORAL MORBIDITY
Clemens Rosenbaum*, Marianne Schmid,
Tim Ludwig, Luis Kluth, Philip Reiss, Armin
Soave, Roland Dahlem, Oliver Engel, Silke
Riechardt, Margit Fisch, Sascha Ahyai,
Hamburg, Germany
MP15-08 AN EX-VIVO ANALYSIS OF VARIOUS
SUTURE MATERIALS AND TECHNIQUES,
AND TYPES OF URINARY CATHETERS IN
VESICOURETHRAL ANASTOMOTIC
TENSILE STRENGTH AND CATHETER
DISLODGMENT: A PORCINE MODEL
Marlon Perera*, Pranav Divakaran, Matthew
Roberts, Mackay, Australia, Eric Chung,
Brisbane, Australia
MP15-16 REVISION URETHROPLASTY VS PRIMARY
URETHROPLASTY: ARE THEY REALLY
DIFFERENT?
Fabio Castiglione*, Pieter D’Hulst, Kathy
Vander Eeckt, Frank Van der Aa, Steven
Joniau, Leuven, Belgium
MP15-09 CRITICAL ANALYSIS OF
UROFLOWMETRY FOR URETHRAL
STRICTURE DISEASE SURVEILLANCE
Christopher A. Tam*, Iowa City, IA, Sean P.
Elliott, Minneapolis, MN, Jeremy B. Myers,
Salt Lake City, UT, Alex J. Vanni, Burlington,
MA, Bryan B. Voelzke, Seattle, WA, Bradley
A. Erickson, Iowa City, IA
MP15-17 ASSESSMENT OF THE LEARNING CURVE
FOR MALE URETHRAL
RECONSTRUCTION: DOES EXPERIENCE
MATTER?
Sarah Faris*, Christopher Tam, Iowa City, IA,
Bryan Voelzke, Seattle, WA, Jeremy Myers,
Salt Lake City, UT, Sean Elliott, Minneapolis,
MN, Alex Vanni, Burlington, MA, Thomas
Smith, III, Houston, TX, Benjamin Breyer,
Thomas Gaither, San Francisco, CA, Deep
Bhatt, Bradley Erickson, Iowa City, IA
MP15-10 VALSALVA VOIDING DISTINGUISHES
SLOW URINARY FLOW CAUSED BY
ANTERIOR URETHRAL STRICTURES
FROM PROSTATIC OBSTRUCTION
Rajveer Purohit*, Matthew Benedon, Gabriel
Mekel, New York, NY, James Weinberger,
Los Angeles, CA, Johnson Tsui, Jerry
Blaivas, New York, NY
MP15-18 PREDICTIVE VALUE OF POSTURETHROPLASTY VOIDING
CYSTOURETHROGRAM
Daniel Stein*, Ibraheem Malkawi, Richard
Santucci, Detroit, MI
MP15-11 OUTPATIENT ULTRASOUND
URETHROGRAM FOR ASSESSMENT OF
ANTERIOR URETHRAL STRICTURE
RENDERS RADIATION EXPOSURE
UNNECESSARY
Darren J Bryk*, Yuka Yamaguchi, Shpetim
Telegrafi, Mariana Kozirovsky, Lee C Zhao,
New York, NY
MP15-19 COLLAGENASE CLOSTRIDIUM
HISTOLYTICUM FOR TREATMENT OF
URETHRAL STRICTURE DISEASE IN A
RAT MODEL OF URETHRAL FIBROSIS
Premsant Sangkum*, Hogyoung Kim, New
Orleans, LA, Mostafa Bouljihad, Covington,
LA, Manish Ranjan, Amrita Datta, Sree
Mandava, Faysal Yafi, Suresh Sikka, Asim
Abdel-Mageed, Wayne Hellstrom, New
Orleans, LA
MP15-12 URETHRAL STRICTURE (US) AND
ARTIFICIAL URINARY SPHINCTER (AUS)
REINSERTION RATES AFTER URETHRAL
REPAIR AT THE TIME OF AUS
EXPLANTATION FOR EROSION
Stephen Mock*, Elizabeth T. Brown, W.
Stuart Reynolds, Melissa R. Kaufman,
Douglas F. Milam, Roger R. Dmochowski,
Nashville, TN
MP15-20 ROBOTIC UROLOGICAL SURGERY FOR
BENIGN INDICATIONS: THE USC
EXPERIENCE
Sameer Chopra*, Shalini Nagaraj, Carlee
Beckler, Andre Luis de Castro de Abreu, Raj
Satkunasivam, Raed A. Azhar, Charles
Metcalfe, Inderbir Gill, Monish Aron, Mihir
Desai, Andre K. Berger, Los Angeles, CA
MP15-13 ASSOCIATION BETWEEN TYPE OF
PERINEAL INCISION AND WOUND
COMPLICATIONS AFTER BULBAR
URETHROPLASTY
Alexandra Bascom*, Sunita Ghosh, Adrian
Fairey, Keith Rourke, Edmonton, Canada
MP15-14 DOUBLE TRANSECTION WITH INJURY AT
MEMBRANOBULBAR AND PROSTATE
BLADDER NECK AFTER PELVIC
FRACTURE URETHRAL INJURY
Craig Hunter*, Walid Shahrour, Pankaj Joshi,
Sandesh Surana, Vikram shah Batra, Sanjay
Kulkarni, Pune, India, India
CREDITTM
62
8:00 am - 10:00 am
ABSTRACT
NUMBER TITLE
MP16-01 TEAM STRATEGIES AND TOOLS TO
ENHANCE PERFORMANCE AND PATIENT
SAFETY (TEAMSTEPPS) IMPROVES
OPERATING ROOM EFFICIENCY
Matthew Stringer*, Lancaster Weld, James
Ebertowski, Timothy Baumgartner, Matthew
Kasprenski, Jeremy Kelley, Doug Cho, Erwin
Tieva, Kyle Weld, San Antonio, TX
ABSTRACT
NUMBER TITLE
MP16-08 ANTICIPATING THE IMPACT OF THE
AFFORDABLE CARE ACT ON UROLOGIC
CARE AT SAFETY-NET HOSPITALS
Lindsey Herrel*, Zaojun Ye, David Miller, Ann
Arbor, MI
MP16-09 LOW SELF-EFFICACY IS ASSOCIATED
WITH DECREASED EMERGENCY
DEPARTMENT USE IN UNDERSERVED
MEN WITH PROSTATE CANCER
Avi S. Baskin*, Lorna Kwan, Sarah E.
Connor, Sally L. Maliski, Mark S. Litwin, Los
Angeles, CA
MP16-02 INFLUENCE OF INTERDEPARTMENTAL
COLLABORATION ON UTILIZATION OF
NEOADJUVANT CHEMOTHERAPY PRIOR
TO CYSTECTOMY; A 14-YEAR
EXPERIENCE
Ashley Winter*, Bashir Awamleh, Sameer
Mittal, Shiyi Jin, Daniel Nguyen, Scott
Tagawa, Douglas Scherr, New York, NY
MP16-10 EQUITABLE COMMUNITY UTILIZATION
OF PARTIAL NEPHRECTOMY
NATIONALLY FOR MANAGEMENT OF T1A
RENAL TUMORS
Dhruti Patel*, Robert Abouassaly, Cleveland,
OH
MP16-03 STRATEGIC IMPROVEMENT IN
PROSTATE BIOPSY FIXATION; ROLE OF
INTERDISCIPLINARY QUALITY
COLLABORATION IN UROLOGIC
PRACTICE
Ashley Winter*, Paul DiMaggio, Brian
Robinson, New York, NY
MP16-11 ASSOCIATION BETWEEN THE SELFPERCEPTION PERIOD OF LOWER
URINARY TRACT SYMPTOMS
ASSOCIATED WITH BENIGN PROSTATIC
HYPERPLASIA AND THE INTERNATIONAL
PROSTATE SYMPTOM SCORE
Sungryul Shim*, Jaeheon Kim, Young-Ho
Kim, Wonjin Lee, Seoul, Korea, Republic of,
Sangjin Yoon, Incheon, Korea, Republic of,
Jaehyun Bae, 136-075, Korea, Republic of
MP16-04 USING LEAN / SIX-SIGMA METHODOLOGY
TO ACHIEVE IMPROVED ACCESS IN A
UROLOGY CLINIC
Bradford Stevenson*, Thomas Tieu, Teri
Baldini, Springfield, IL, Chris Gonzalez,
Chicago, IL, Tobias Kohler, Kevin McVary,
Springfield, IL
MP16-12 CORRELATION BETWEEN SURGEONS’
AND PATIENTS’ SUBJECTIVE AND
OBJECTIVE PERCEPTIONS OF FRAILTY
Daniel Canter*, Wynnewood, PA, Louis
Revenig, Yuan Liu, Sungjin Kim, Kenneth
Ogan, Viraj A Master, Atlanta, GA
MP16-05 TELEUROLOGY TO ENHANCE ACCESS
AND EXPEDITE CARE OF PATIENTS
REFERRED WITH HEMATURIA
Salil Gabale*, Ilan Safir, Catrina White, I.
Jane Kimberl, Debra Fabian, Muta M. Issa,
Atlanta, GA
MP16-13 SLOW GAIT SPEED PREDICT OF POSTOPERATIVE DELIRIUM IN ELDERLY
PATIENTS
Masaaki Oikawa*, Teppei Okamoto, Shingo
Hatakeyama, Hayato Yamamoto, Atsushi
Imai, Takahiro Yoneyama, Yasuhiro
Hashimoto, Takuya Koie, Chikara Ohyama,
Hirosaki, Japan
MP16-06 WHATSAPP DOC? EVALUATING A NOVEL
MODALITY OF COMMUNICATION
AMONGST UROLOGY TEAM MEMBERS TO
PROMOTE PATIENT SAFETY
Clarissa Martyn-Hemphill, Somita Sarkar,
John Withington, Ashoke Roy, Rosaline
Chisholm, Toby Newton, Diego Ottaviani,
Connie Pidgeon, Sonia Szamocki, Daniel
Cohen, James Green*, London, United
Kingdom
MP16-14 THE INFLUENCE OF THE USE MEDICAL
CLOWNS TO THE REDUCTION OF
PREOPERATIVE ANXIETY,
POSTOPERATIVE PAIN AND MEDICAL
COSTS IN CHILDREN UNDERGOING
OUTPATIENT PENILE SURGERY: A
RANDOMIZED CONTROLLED TRIAL
Stanislav Kocherov*, Yaniv Hen, Sol
Jaworowski, Israel Ostrovsky, Judith Gabay,
Genady Lev, Avraham Cohen, Ya’acov Shvili,
Arthur I. Edelman, Boris Chertin, Jerusalem,
Israel
MP16-07 IMPLICATIONS OF REGIONALIZING
FUSION MRI TECHNOLOGY
Karen Wheeler*, Jennifer Lobo, Drew Jensen,
Jules Manger, Shawnna Blanchard, Afshan
Ornan, Sebastian Feuerlain, Tracey Krupski,
Charlottesville, VA
*Presenting author
63
SATURDAY
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, COST EFFECTIVENESS I
Moderators: Matthew Resnick and Bradley Erickson
MP16-19 ADHERENCE RATES FOR SELECTIVE
MEDICAL THERAPY AMONG PATIENTS
WITH KIDNEY STONES
Yooni Yi*, Casey Dauw, Maggie Bierlein,
Abdul Alruwaily, Khurshid Ghani, Stuart Wolf,
John Hollingsworth, Ann Arbor, MI
MP16-15 CURRENT UROLOGY RESIDENT VIEWS
ON DESIRABLE CHARACTERISTICS FOR
FIRST TIME EMPLOYMENT
Jyoti Chouhan*, Katherine Fischer, Jeffrey
Weiss, Brooklyn, NY
MP16-16 THE FEMINIZATION OF THE WORKFORCE
IN UROLOGY: SOCIOECONOMIC,
WORKFORCE, AND QUALITY OF LIFE
ISSUES
Nicholas Pruthi, Sophie Spencer*, Matthew
Lyons, Peter Greene, Max McKibben, Chapel
Hill, NC, Christopher Gonzalez, Chicago, IL,
Patrick McKenna, Madison, WI, Matthew
Nielsen, Mathew Raynor, Angela Smith, Eric
Wallen, Michael Woods, Raj Pruthi, Chapel
Hill, NC
MP16-20 CHANGES IN PRIMARY CARE PROVIDER
PRACTICE PATTERNS SINCE 2012:
IMPACT OF THE USPSTF GUIDELINE
STATEMENT
Jennifer Yates*, Mitchell Sokoloff, Achankeng
Afiadata, Jennifer Fantasia, David Frendl,
Mara Epstein, Roger Luckmann, Worcester,
MA
MP16-17 THE VALUE OF PATHOLOGIC
EXAMINATION OF THE FORESKIN
FOLLOWING CIRCUMCISION
Ilan Safir*, Amar Patel, Brad Moore,
Dattatraya Patil, Gabriel Bellott-McGrath,
Adeboye Osunkoya, Muta Issa, Atlanta, GA
CREDITTM
MP16-18 PREDISPOSING FACTORS AND
OUTCOMES OF MALPRACTICE
LITIGATION FOR CASES OF TESTICULAR
TORSION: A LEGAL DATABASE REVIEW
Marc A Colaco*, Matthew G Heavner,
Winston-Salem, NC, Peter L Sunyaro,
Newark, NJ, Ryan P Terlecki, WinstonSalem, NC
8:00 am - 10:00 am
IMAGING/RADIOLOGY: URORADIOLOGY III
Moderators: Daniel Rukstalis and Pat Fulgham
ABSTRACT
NUMBER TITLE
MP17-01 THE POSTERIOR ACOUSTIC SHADOW:
EVALUATING STONE SIZE IN PEDIATRIC
STONE FORMERS
Franklin Lee*, Jonathan Harper, Thomas
Lendvay, Seattle, WA, Ziyue Liu,
Indianapolis, IN, Barbrina Dunmire, Jonathan
Swanson, Manjiri Dighe, Michael Bailey,
Mathew Sorensen, Seattle, WA
ABSTRACT
NUMBER TITLE
MP17-04 UROLOGIC IMAGING QUALITY USING A
PORTABLE ULTRASOUND WITH REGARD
TO THE OPERATOR AND THE DEVICE
Arnon Lavi*, Sharon Tzemach, Alon Masiach,
Genady Zelichenko, Michael Gross, Leonid
Cherbinsky, David Giser, Rafi Shoshana, Ziv
Neeman, Michael Cohen, Afula, Israel
MP17-05 PROSPECTIVE CLINICAL TRIAL
EVALUATING ANTEGRADE
NEPHROSTOGRAPHY TO ASSESS URINE
FLOW AFTER PERCUTANEOUS
NEPHROLITHOTOMY
Matthew Truesdale*, Molly Elmer-Dewitt,
Bogdana Schmidt, Ian Metzler, David Bayne,
Marco Sandri, Marshall Stoller, Thomas Chi,
San Francisco, CA
MP17-02 DEVELOPING A PROTOTYPE FOR AN
AUTOMATED, LOW-COST 3D
ULTRASOUND SCANNER FOR
DEDICATED UROLOGICAL APPLICATIONS
Ryan Gessner*, Lyle Baumgarten, Paul
Dayton, Robert Coward, Chapel Hill, NC
MP17-03 A MINIATURE FORWARD-VIEWING
ENDOSCOPIC OPTICAL COHERENCE
TOMOGRAPHY PROBE FOR RENAL
PELVIC IMAGING
Xiaoyong Fu, Dhruti Patel*, Hui Zhu, Gregory
Maclennan, Yves Wang, Michael Jenkins,
Andrew Rollins, Cleveland, OH
MP17-06 RADIATION DOSES IN PRONE VERSUS
SUPINE POSITION DURING
PERCUTANEOUS NEPHROLITHOTOMY,
RESULTS WITH AN ANTHROPOMORPHIC
MODEL
Jonathan Cloutier*, Jean-Baptiste Terrasa,
Luca Villa, Olivier Traxer, Paris, France
64
MP17-08 MRI-FUSION PROSTATE BIOPSY IN
FIRST-TIME BIOPSY COHORT YIELDS
INCREASED DETECTION OF CLINICALLY
SIGNIFICANT PROSTATE CANCER USING
A SIMPLIFIED MRI GRADING SCALE
Steven V. Kardos*, Shu Pan, Cayce B.
Nawaf, New Haven, CT, Richard Fan, Palo
Alto, CA, Daniel Cornfeld, Jeffrey Weinreb,
Peter G. Schulam, Preston C. Sprenkle, New
Haven, CT
MP17-15 EVALUATION OF TRANSRECTAL
ULTRASOUND IN PREOPERATIVE
STAGING OF PROSTATE CANCER:
CORRELATION WITH THE EXPERIENCE
OF THE UROLOGIST
Andreas Bannowsky*, Osnabrück, Germany,
Daniar Osmonov, Klaus-Peter Jünemann,
Kiel, Germany, Hermann van Ahlen,
Osnabrück, Germany
MP17-09 TRENDS IN CANCER DETECTION RATE
AND COMPLICATIONS AFTER MAGNETIC
RESONANCE IMAGING-ULTRASOUND
(MRI/US) FUSION-GUIDED PROSTATE
BIOPSIES
Simpa Salami*, Oksana Yaskiv, New Hyde
Park, NY, Baris Turkbey, Bethesda, MD,
Robert Villani, Eran Ben-Levi, Ardeshir
Rastinehad, New Hyde Park, NY
MP17-16 URETHRA-SPARING TREATMENT WITH
HIGH-INTENSITY FOCUSED
ULTRASOUND FOR LOCALIZED
PROSTATE CANCER
Sunao Shoji*, Mayura Nakano, Tetsuro
Tomonaga, Hiroshi Fujikawa, Kazuyuki Endo,
Akio Hashimoto, Toshiro Terachi, Toyoaki
Uchida, Hachioji, Japan
MP17-10 EVALUATION OF PI-RADS
CLASSIFICATION IN PREDICTION OF
TUMOUR AGGRESSIVENESS –
COMPARISON TO RADICAL
PROSTATECTOMY SPECIMEN
Angelika Borkowetz*, Ivan Platzek, Marieta
Toma, Stefan Zastrow, Michael Froehner,
Rainer Koch, Manfred Wirth, Dresden,
Germany
MP17-17 SIGNIFICANCE OF URETHRAL FIBROSIS
EVALUATED BY PREOPERATIVE
MAGNETIC RESONANCE IMAGING AS A
PREDICTOR OF CONTINENCE STATUS
AFTER ROBOT-ASSISTED RADICAL
PROSTATECTOMY
Hiroyuki Momozono*, Hideaki Miyake, Akira
Miyazaki, Masato Fujisawa, Kobe, Japan
MP17-11 COST EFFECTIVENESS OF
RESONANCE IMAGING FOR DETECTION
OF PROSTATE CANCER
Ahmed Q Haddad*, Daniel Costa, Ivan
Pedrosa, Neil Rofsky, Claus Roehrborn, Yair
Lotan, Dallas, TX
MP17-18 SUPERB MICROVASCULAR IMAGING FOR
THE EVALUATION OF PARENCHYMAL
PERFUSION IN THE UNDESCENDED
TESTES IN YOUNG CHILDREN
Yong Seung Lee*, Sang Won Han, MyungJoon Kim, Young Jae Im, Mi-Jung Lee,
MP17-12 MOLECULAR ALTERATIONS IN
PROSTATE CANCER AND ASSOCIATION
WITH MRI FEATURES
Daniel Lee*, Jacqueline Fontugne, Naveen
Gumpeni, Kyung Park, Theresa MacDonald,
Brian Robinson, Andrea Sboner, Juan Miguel
Mosquera, Mark Rubin, Christopher Barbieri,
New York, NY
MP17-19 QUANTITY ASSESSMENT OF
VESICOURETERAL REFLUX BY DIRECT
RADIONUCLIDE CYSTOGRAPHY
Zukhra Sabirzyanova*, Andrey Pavlov, Dmitry
Fomin, Gevorg Simonyan, Moscow, Russian
Federation
MP17-20 MAGNETIC RESONANCE IMAGING IN
PATIENTS WITH STRESS URINARY
INCONTINENCE - NEW EVALUATION
TOOL
George Kasyan*, Mariya Barinova, Nataliya
Tupikina, Mikhail Gvozdev, Boris Godunov,
Dmitry Pushkar, Moscow, Russian Federation
MP17-13 MULTIPARAMETRIC MAGNETIC
RESONANCE IMAGING AND
MRI/ULTRASOUND FUSION-GUIDED
BIOPSY PREDICTS TOTAL TUMOR
BURDEN CONFIRMED BY WHOLE MOUNT
PROSTATECTOMY
Richard Ho*, Arvin K. George, Thomas Frye,
Steven Abboud, Raju Chelluri, Michele
Fascelli, Chinonyerem Okoro, Nabeel Shakir,
Bethesda, MD, M. Minhaj Siddiqui, Baltimore,
MD, Vanessa Moreno, Annerleim WaltonDiaz, Sandeep Sankineni, Maria Merino,
Baris Turkbey, Peter Choyke, Bradford J.
Wood, Peter Pinto, Bethesda, MD
*Presenting author
CREDITTM
65
SATURDAY
MP17-14 UTILITY OF PREOPERATIVE 3 TESLA
MULTIPARAMETRIC PELVIC PHASEDARRAY MAGNETIC RESONANCE IMAGING
IN PREDICTION OF EXTRACAPSULAR
EXTENSION OF PROSTATE CANCER AND
ITS IMPACT ON SURGICAL MARGIN
STATUS: EXPERIENCE AT A CANADIAN
TERTIARY ACADEMIC HEALTH CENTER
Jen Hoogenes*, Ian Wright, Colm Boylan,
Bobby Shayegan, Hamilton, Canada
MP17-07 RAPID PRE-PROSTATE BIOPSY MRI,
RESULTS OF A CONTROLLED
PROSPECTIVE REGISTERED IMPRODTRIAL
Peter J. Bostrom*, Pekka Taimen, Kari
Syvänen, Esa Kähkönen, Markku Kallajoki,
Hannu Aronen, Ivan Jambor, Turku, Finland
8:00 am - 10:00 am
Podium Session 7
BLADDER AND URETHRA: ANATOMY, PHYSIOLOGY AND PHARMACOLOGY I
Moderators: Christopher Chapple and Arthur Mourtzinos
TIME
8:00
8:10
8:20
8:30
8:40
8:50
ABSTRACT
NUMBER TITLE
PD7-01 ONO-8055, A NOVEL AND POTENT
PROSTANOID EP2 AND EP3 RECEPTOR
DUAL AGONIST, IMPROVES VOIDING
DYSFUNCTION IN A MONKEY
UNDERACTIVE BLADDER MODEL
Hidekazu Matsuya*, Takeya Otsuki, Jun Kida,
Daisuke Wakamatsu, Hiroki Okada, Osaka,
Japan, Noritoshi Sekido, Tokyo, Japan
PD7-02
PD7-03
PD7-04
PD7-05
PD7-06
ABSTRACT
TIME NUMBER TITLE
9:00
PD7-07 A NOVEL TARGET FOR UNDERACTIVE
BLADDER DISEASE: TRPV4 CATION
CHANNEL ACTIVATION IMPROVES
BLADDER FUNCTION IN A RAT MODEL
FOR DETRUSOR UNDERACTIVITY
Yves Deruyver*, Emmanuel Weyne, Karel
Dewulf, Wouter Everaerts, Thomas Voets,
Dirk De Ridder, Leuven, Belgium
DELETION OF THE TRPV4 CATION
CHANNEL LEADS TO DECREASED
SENSORY INPUT INTO THE CENTRAL
NERVOUS SYSTEM DURING THE
MICTURITION CYCLE: A PET IMAGING
STUDY IN RATS
Yves Deruyver*, Roma Rietjens, Jan
Franken, Ann Van Santvoort, Cindy Casteels,
Thomas Voets, Dirk De Ridder, Leuven,
Belgium
IMPAIRED EXPRESSION AND FUNCTION
OF TREK-1, A STRETCH-ACTIVATED
TWO-PORE DOMAIN POTASSIUM
CHANNEL, UNDERLIES DETRUSOR
OVERACTIVITY IN HUMANS
Joseph Hypolite, Aurora, CO, Xiao-Qing Pan,
Philadelphia, PA, Shandra Wilson, Randall
Meacham, Anna Malykhina*, Aurora, CO
PRECISE CHARACTERIZATION OF
BLADDER NECK INNERVATION WITH
THREE-DIMENSIONAL IMAGE
RECONSTRUCTION
Kyle Spradling*, Cyrus Khoyilar, Garen Abedi,
Zhamshid Okhunov, Michael del Junco,
Renai Yoon, Nicholas Nguyen, Jamie
Wikenheiser, Orange, CA, Jiaoti Huang, Los
Angeles, CA, Ramy Youssef, Gamal
Ghoniem, Jaime Landman, Orange, CA
VIRAL CYSTITIS INDUCED BY CROSSINFECTION FROM THE COLON –
POTENTIAL MECHANISM FOR
INTERSTITIAL CYSTITIS
Youko Ikeda*, Irina Zabbarova, Sandra
Gomez-Amaya, Sunita Shinde, Lori Birder,
Anthony Kanai, Pittsburgh, PA
PUDENDAL NERVE STIMULATION
INHIBITS THE VISCEROMOTOR
RESPONSES TO URINARY BLADDER
DISTENSION IN A NON-OPIOID
DEPENDENT MANNER
Timothy Ness, Alan Randich, Julie Hill, Jamie
McNaught, Birmingham, AL, Dwight Nelson,
Xin Su*, Minneapolis, MN
9:10
PD7-08
A THREE DIMENSIONAL MAP OF HUMAN
BLADDER INNERVATION
J. Purves*, Mount Pleasant, SC, Laura
Spruill, Eric Rovner, Elyse Borisko, Alden
McCants, Elizabeth Mugo, Ashley Wingard,
Thierry Bacro, Thomas Trusk, Monty Hughes,
Charleston, SC
9:20
PD7-09
VOLTAGE-GATED KCNQ CHANNELS IN
HUMAN DETRUSOR SMOOTH MUSCLE
CONTRACTILITY: A NOVEL TARGET FOR
THE PHARMACOLOGICAL TREATMENT
OF OVERACTIVE BLADDER
Aaron Provence*, Kiril L. Hristov, Shankar P.
Parajuli, Columbia, SC, Eric S. Rovner,
Charleston, SC, Georgi V. Petkov, Columbia,
SC
9:30
PD7-10
TURBT OF THE INTRAMURAL PORTION
OF THE DISTAL URETER: PREDICTIVE
FACTORS FOR SECONDARY STENOSIS
AND DEVELOPMENT OF UPPER URINARY
TRACT TUMOURS
Oscar Rodrı́guez Faba*, Pablo Juárez del
Dago, Josep Maria Gaya, Joan Palou, Ferran
Algaba, Humberto Villavicencio, Barcelona,
Spain
9:40
PD7-11
SPONTANEOUS VOIDING IS
SURPRISINGLY RECOVERABLE VIA
OUTLET PROCEDURE AFTER
DOCUMENTED UNDERACTIVE BLADDER
ON URODYNAMICS
Ahmed Alkaram, Elise J.B. De, Amy D.
Dobberfuhl*, Albany, NY
9:50
PD7-12
HIGHLY COORDINATED DELIVERY OF
UROPLAKIN PROTEINS TO THE APICAL
UROTHELIAL CELL SURFACE
Jiangyong Ouyang, Xuemei Guo, Krassimira
Hadjiolova, Jeremy Miller, Iwona Gumper,
Jean-Pierre Simon, New York, NY, Tanya
Tolmachova, Miguel Seabra, London, United
Kingdom, Mitsunori Fukuda, Sendai, Miyagi,
Japan, Xue-Ru Wu, Michael Rindler*, Sun
Tung-Tien, Gert Kreibich, New York, NY
CREDITTM
66
8:00 am - 10:00 am
Podium Session 8
TIME
8:00
8:10
8:20
8:30
8:40
8:50
9:00
ABSTRACT
NUMBER TITLE
PD8-01 URINARY TRACT INFECTIONS,
RESISTANCE PATTERNS AND
EFFECTIVENESS OF ANTIMICROBIAL
PERIOPERATIVE PROPHYLAXIS AFTER
TRANSURETHRAL PROCEDURES
Ashkan Mortezavi*, Maryna Fröhlich, Jan
Fehr, Tullio Sulser, Daniel Eberli, Zurich,
Switzerland
PD8-02
PD8-03
PD8-04
PD8-05
PD8-06
PD8-07
*Presenting author
ABSTRACT
TIME NUMBER TITLE
9:10
PD8-08 RISK FACTORS FOR FEBRILE UTI IN
SPINAL CORD INJURY PATIENTS WITH
ROUTINE CONCOMITANT INTERMITTENT
CATHETERIZATION (CIC)
Fukashi Yamamichi, Amagasaki, Hyogo,
Japan, Katsumi Shigemura*, Shigeto Mukai,
Masashi Nomi, Akihiro Yanagiuchi, Atsushi
Sengoku, Kazushi Tanaka, Soichi Arakawa,
UPPER TRACT IMAGING ABNORMALITIES
RELATED TO RECURRENT URINARY
TRACT INFECTIONS RARELY FOUND IN
WOMEN
Lauren Rego*, Alana Christie, Philippe
Zimmern, Dallas, TX
PREDICTORS OF READMISSION FOR
INFECTIOUS COMPLICATIONS
FOLLOWING RADICAL CYSTECTOMY –
RESULTS FROM A MULTI INSTITUTIONAL
NATIONAL DATASET
Sij Hemal*, Louis Krane, Winston-Salem, NC,
Kyle A Richards, Madison, WI, Michael Liss,
San Antonio, TX, A Karim Kader, San Diego,
CA, Ronald Davis, Winston Salem, NC
TRANSMOGRIFYING INFECTION STONES:
ARE CALCIUM STONES NOW THE
COMMONER INFECTION STONES IN
PCNL?
Ivo Dukic*, Ayo Kalejaiye, Kim Jacobson,
Francis Keeley, Anthony Timoney, Joe Philip,
Bristol, United Kingdom
DOES STONE REMOVAL HELP PATIENTS
WITH RECURRENT URINARY TRACT
INFECTIONS?
Mohamed Omar*, Hemant Chaparala,
Abdullahi Ahmed, Manoj Monga, Cleveland,
OH
PERIOPERATIVE BLOOD TRANSFUSIONS
AS A RISK FACTOR FOR INFECTIOUS
COMPLICATIONS AFTER UROLOGIC
SURGERY
Richard Matulewicz*, Daniel Oberlin, Irene
Helenowski, Borko Jovanovic, Shilajit Kundu,
Chicago, IL
9:20
PD8-09
PAINFUL BLADDER FILLING AND
PAINFUL URGENCY ARE DISTINCT
CHARACTERISTICS IN MEN AND WOMEN
WITH UROLOGIC CHRONIC PELVIC PAIN
SYNDROMES (UCPPS) – A MAPP
RESEARCH NETWORK STUDY
H. Henry Lai*, St Louis, MO, John Krieger,
Seattle, WA, Michel Pontari, Philadelphia, PA,
Dedra Buchwald, Seattle, WA, Xiaoling Hou,
J. Richard Landis, Philadelphia, PA
9:30
PD8-10
ARE OUR DAILY CLINICS FOLLOWING
GUIDELINES FOR PREVENTION OF
SURGICAL SITE INFECTION?
Katsumi Shigemura*, Soichi Arakawa,
Fukashi Yamamichi, Hideaki Miyake, Kazushi
Tanaka, Masato Fujisawa, Kobe, Japan
9:40
PD8-11
THE CHARACTERISTICS OF WOMEN
TESTING POSITIVE FOR MYCOPLASMA
HOMINIS AND UREAPLASMA
UREALYTICUM IN THE URINARY TRACT
Jessie Liang*, Sarah Rentrop, Andrea
Balthazar, Clifton F. Frilot II, Alex Gomelsky,
Shreveport, LA
9:50
PD8-12
CHANGING TRENDS IN CAUSATION,
PRESENTATION AND MANAGEMENT OF
PSOAS ABSCESS
Tanvi Sood, Manasa T, Rajeev Sood*,
Raman Tanwar, New Delhi, India
CREDITTM
A PROSPECTIVE RANDOMIZED DOUBLEBLINDED PLACEBO CONTROL TRIAL ON
THE EFFECTS OF CRANBERRY
SUPPLEMENTATION ON BACTERIAL
COLONIZATION AND SYMPTOMATIC
URINARY TRACT INFECTIONS IN
FEMALES WITH NEUROGENIC BLADDER
DYSFUNCTION DEPENDENT ON SELF
CATHETERIZATION
Jason Scovell*, Houston, TX, Sophie
Fletcher, Santa Rosa, CA, Julie Stewart,
Rose Khavari, Houston, TX
67
SATURDAY
INFECTIONS/INFLAMMATION OF THE GENITOURINARY TRACT: KIDNEY & BLADDER I
Moderators: Robert Moldwin and Durwood Neal, Jr.
8:00 am - 10:00 am
Podium Session 9
URINARY DIVERSION: BLADDER RECONSTRUCTION, AUGMENTATION, SUBSTITUTION, DIVERSION I
Moderator: Arnulf Stenzl
TIME
8:00
8:10
8:20
ABSTRACT
NUMBER TITLE
PD9-01 CONTINENCE OUTCOMES FOLLOWING
RADICAL CYSTECTOMY AND
ORTHOTOPIC NEOBLADDER
Swar Shah*, Soroush Bazaragani, Gus
Miranda, Kevin Wayne, Hooman Djaladat,
Anne Schuckman, Siamak Daneshmand, Los
Angeles, CA
PD9-02
PD9-03
ABSTRACT
TIME NUMBER TITLE
9:00
PD9-07 EARLY AND LATE COMPLICATIONS OF
ROBOTIC RADICAL CYSTECTOMY AND
INTRA-CORPOREAL URINARY DIVERSION
Raed A Azhar, Andre Luis de Castro Abreu*,
Evren Suer, Jie Cai, Gus Miranda, Raj
Satkunasivam, Charles Metcalfe, Kelvin
Wong, Andre Berger, Monish Aron, Inderbir S
Gill, Mihir Desai, Los Angeles, CA
HEALTH RELATED QUALITY OF LIFE
AFTER RADICAL CYSTECTOMY IN
WOMEN: ORTHOTOPIC NEOBLADDER
VERSUS ILEAL LOOP CONDUIT AND
IMPACT OF INCONTINENCE
Mohamed Zahran, Diaa-eddin Taha,
Mohamed Tharwat, Essam M Zidan, Mona A
El-Bilsha, Ahmed Harraz, Bedeir Ali-El-Dein*,
Mansoura, Egypt
QUALITY OF LIFE IN 112 MEN AND 33
WOMEN WITH BLADDER CANCER
UNDERGOING ILEAL CONDUIT: A
MULTICENTRE STUDY AMONG LONGTERM SURVIVORS
Salvatore Siracusano*, Stefano Ciciliato,
Renato Talamini, Laura Toffoli, Francesco
Visalli, Tommaso Silvestri, Emanuele
Belgrano, Trieste, Italy, Mauro Niero, Cristina
Lonardi, Maria Angela Cerruto, Verona, Italy,
Ciro Imbimbo, Naples, Italy, Marco Racioppi,
Rome, Italy, Massimo Iafrate, Padua, Italy,
Carolina D’Elia, Giovanni Cacciamani, Davide
De Marchi, Verona, Italy, Paolo Verze,
Naples, Italy, Pierfrancesco Bassi, Rome,
Italy, Walter Artibani, Verona, Italy
8:30
PD9-04
QUALITY OF LIFE AFTER URINARY
DIVERSION WITH ORTHOTOPIC
NEOBLADDER
Alexander Kretschmer*, Tobias Grimm,
Alexander Buchner, Birte-Swantje
Schneevoigt, Maria Apfelbeck, Markus
Grabbert, Christian G. Stief, Alexander Karl,
Munich, Germany
8:40
PD9-05
ATTITUDES TOWARD THE USE OF
CONTINENT URINARY DIVERSIONS IN
PATIENTS UNDERGOING CYSTECTOMY:
A SURVEY OF THE SOCIETY OF
UROLOGIC ONCOLOGY
Adam Mellis*, Michael Cookson, Joel Slaton,
Oklahoma City, OK
8:50
PD9-06
LONG-TERM FUNCTIONAL OUTCOME
AND COMPLICATIONS AFTER RADICAL
CYSTECTOMY AND ORTHOTOPIC
NEOBLADDER DIVERSION
Michael Maidaa, Burbank, CA, Gus Miranda,
Inderbir Gill, Siamak Daneshmand, Hooman
Djaladat*, Los Angeles, CA
9:10
PD9-08
RISK ASSESSMENT OF LATE
COMPLICATIONS AFTER ROBOTIC
RADICAL CYSTECTOMY WITH TOTAL
INTRACORPOREAL URINARY DIVERSION
Mariaconsiglia Ferriero*, Rome, Italy,
Giuseppe Simone, Turin, Italy, Rocco
Papalia, Salvatore Guaglianone, Michele
Gallucci, Rome, Italy
9:20
PD9-09
ANALYSIS OF PERIOPERATIVE
OUTCOMES FOR PROCEDURES
INVOLVING URINARY DIVERSION USING
THE NATIONAL SURGICAL QUALITY
DATABASE
Robert C Kovell*, David C Brooks, Devin A.
Haddad, Ahmed A Aboumohamed, Ryan P
Terlecki, Winston Salem, NC
9:30
PD9-10
TIMING OF URETERAL STENT REMOVAL
AND POSTOPERATIVE COMPLICATIONS
WITH URINARY DIVERSION
Justin Matulay, Christopher Sayegh, Julia
Finkelstein, Mark Silva*, G. Joel DeCastro,
New York, NY
9:40
PD9-11
PREDICTORS OF SYMPTOMATIC
URETERO-ENTERIC ANASTOMOTIC
STRICTURES AFTER RADICAL
CYSTECTOMY AND URINARY DIVERSION
Katherine Brewer*, Gillian Stearns,
S. Machele Donat, Harry Herr, Bernard
Bochner, Guido Dalbagni, Jaspreet Sandhu,
New York, NY
9:50
PD9-12
VIDEOURODYNAMIC EVALUATION OF
INTRACORPOREALLY RECONSTRUCTED
ORTHOTOPIC U-SHAPED ILEAL
NEOBLADDERS
Antonio Luigi Pastore, Giovanni Palleschi*,
Luigi Silvestri, Andrea Ripoli, Antonio
Carbone, Latina, Italy
CREDITTM
68
8:00 am - 10:00 am
Podium Session 10
TIME
8:00
8:10
8:20
8:30
8:40
8:50
ABSTRACT
NUMBER TITLE
PD10-01 THE IMPACT OF PONTINE DISEASE ON
LOWER URINARY TRACT SYMPTOMS IN
PATIENTS WITH MULTIPLE SCLEROSIS
Steven Weissbart*, Philadelphia, PA, Anna
Malykhina, Denver, CO, Tom Bavaria, Alan
Wein, Ariana Smith, Philadelphia, PA
ABSTRACT
TIME NUMBER TITLE
9:00
PD10-07 THE SEVERITY OF BOWEL DYSFUNCTION
IN PATIENTS WITH NEUROGENIC
BLADDER
Anne P Cameron*, Gianna M Rodriguez,
Amy Gursky, Chang He, J Quentin Clemens,
John T Stoffel, Ann Arbor, MI
PD10-02 HIGHER NEURAL CORRELATES AT
INITIATION OF VOIDING IN PATIENTS
WITH MULTIPLE SCLEROSIS WITH
NEUROGENIC BLADDER DYSFUNCTION
VIA CONCURRENT FUNCTIONAL
MAGNETIC RESONANCE IMAGING (FMRI)
AND URODYNAMIC STUDIES
Michael Shy*, Christof Karmonik, Jeff
Anderson, Abdulaziz Alkattan, Timothy
Boone, Steve Fung, Houston, TX, Sophie
Fletcher, Santa Rosa, CA, Rose Khavari,
Houston, TX
PD10-03 EXTERNAL VALIDATION OF THE
NEUROGENIC BLADDER SYMPTOM
SCORE IN MULTIPLE SCLEROSIS
PATIENTS WITH LOWER URINARY TRACT
DYSFUNCTION
Giorgio Ivan Russo*, Tommaso Castelli,
Eugenia Fragalà, Alessandro Di Rosa,
Raimondo Giardina, Vincenzo Favilla,
Salvatore Privitera, Sebastiano Cimino,
Catania, Italy, Blayne Welk, London, Canada,
Giuseppe Morgia, Catania, Italy
PD10-04 CHANGES IN THE HOFFMANN REFLEX
DURING BLADDER FILLING PROVIDE
CLUES TO THE PATHOPHYSIOLOGY OF
BLADDER DYSFUNCTION IN PATIENTS
WITH MULTIPLE SCLEROSIS
Antonella Giannantoni, Perugia, Italy, Silvia
Proietti, Guido Giusti, Rozzano (MI), Italy,
Marilena Gubbiotti, Jacopo Adolfo Rossi de
Vermandois, Andrea Boni, Perugia, Italy,
Antonella Conte*, Rome, Italy
PD10-05 UTILIZING MORE RESTRICTIVE CRITERIA
FOR OBTAINING URODYNAMICS IN
WOMEN WITH MULTIPLE SCLEROSIS
DOES NOT RESULT IN MORE
WORRISOME FINDINGS
Himanshu AGGARWAL*, Rebecca Lavelle,
Louise Gliga, Alana Christie, Gary Lemack,
Dallas, TX
PD10-06 THE TENSION FREE VAGINAL TAPE
VERSUS THE PUBOVAGINAL SLINGS FOR
WOMEN WITH NEUROGENIC STRESS
URINARY INCONTINENCE
Ahmed El-Azab*, Asyut, Egypt, Sherif
El-Nashar, Rochester, MN
9:10
PD10-08 THE NATURAL HISTORY OF
NEUROGENIC BLADDER IN ADULTS WITH
SEVERE CEREBRAL PALSY
Robert Goldfarb*, Daniel Liberman, Yunhua
Fan, Andrew Pisansky, Sean Elliott,
Minneapolis, MN
9:20
PD10-09 GENTAMICIN INTRAVESICAL
INSTILLATIONS DECREASE
SYMPTOMATIC URINARY TRACT
INFECTIONS AND ORAL ANTIBIOTIC USE
IN PATIENTS WITH NEUROGENIC
BLADDER ON INTERMITTENT
CATHETERIZATION
Lindsey Cox*, J. Quentin Clemens, Anne
Cameron, Ann Arbor, MI
9:30
PD10-10 FOXP3 EXPRESSION SERVES AS A
MARKER OF SQUAMOUS CELL
DIFFERENTIATION AND AGGRESSIVE
PATHOLOGY OF UROTHELIAL
CARCINOMAS IN NEUROGENIC
PATIENTS
Véronique Phé*, Morgan Rouprêt, Olivier
Cussenot, Emmanuel Chartier-Kastler, Paris,
France, Xavier Gamé, Toulouse, France, Eva
Compérat, Paris, France
9:40
PD10-11 LONG-TERM FUNCTIONAL OUTCOMES
AFTER ARTIFICIAL URINARY SPHINCTER
(AMS 800®) IMPLANTATION IN FEMALE
NEUROGENIC PATIENTS WITH STRESS
Véronique Phé*, Priscilla Léon, Benjamin
Granger, Morgan Rouprêt, Paris, France,
Pierre Denys, Garches, France, Marc-Olivier
Bitker, Emmanuel Charttier-Kastler, Paris,
France
9:50
PD10-12 MEDICAL COMPLICATIONS AND
UROLOGICAL SURVEILLANCE IN THE
UNITED STATES ADULT SPINA BIFIDA
POPULATION
Yahir Santiago-Lastra*, Anne P Cameron,
Ann Arbor, MI, Julie Lai, Santa Monica, CA,
Christopher Saigal, Los Angeles, CA, J.
Quentin Clemens, Ann Arbor, MI, The NIDDK
Urologic Diseases in America Project, Los
Angeles, CA
CREDITTM
*Presenting author
69
SATURDAY
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: NEUROGENIC VOIDING DYSFUNCTION II
Moderators: Patrick Shenot and Alex Gomelsky
8:00 am - 11:30 am
SOCIETY FOR BASIC UROLOGIC RESEARCH/THE SOCIETY OF UROLOGIC ONCOLOGY (SBUR/SUO) JOINT SESSION
8:00
WELCOME
8:05
CHALLENGES FACED WITH RE-EMERGING
CANCERS
Michael Cher
8:15
TUMOR DORMANCY: THE HEMATOPOIETIC
STEM CELL NICHE REGULATES DORMANCY
Russell Taichman
8:40
MTOR INHIBITORS IN METASTATIC RENAL
CANCER - DO THEY WORK AND WHEN DO
THEY WORK?
Robert Figlin
9:00
EPITHELIAL-MESENCHYMAL-TRANSITION:
THE THERAPEUTIC POTENTIAL OF
TARGETING THE EPITHELIAL-MESENCHYMAL
TRANSITION IN CANCER
Fazlul Sarkar
9:20
BREAK
9:40
CIRCULATING TUMOR CELLS: TELLING THE
TRUTH ABOUT METASTASIS
Massimo Cristofanilli
10:00
PRE-METASTATIC NICHE: BREAST
FIBROBLASTS MODULATE EARLY
DISSEMINATION, TUMORIGENESIS, AND
METASTASIS THROUGH ALTERATION OF
EXTRACELLULAR MATRIX
CHARACTERISTICS
Thea Tlsty
10:25
DEBATE: THE CLONALITY OF PROSTATE
CANCER METASTASES - MULTIPLE OR
SINGLE ORIGINS?
Moderator: Natasha Kyprianou
Debaters: Francesca Demichelis, Srinivasan
Yegnasubramanian
10:55
DONALD S. COFFEY LECTURE: STEM CELLS
AND SIGNALING PATHWAYS IN UROLOGIC
REGENERATION AND MALIGNANCY
Philip Beachy
11:30
ADJOURN
CREDITTM
8:00 am - 2:00 pm
WORLD CHINESE UROLOGICAL SOCIETY (WCUS)
8:00
WELCOME
Society Chair: Tom Lue
8:05
SCIENTIFIC PROGRAM
Richard Lo
8:10
SESSION 1: LO PING-WAN MEMORIAL
LECTURE
Moderators: Henry Lai, Richard Lo
9:20
TARGETING NOVEL ANDROGEN AXIS
RESISTANCE MECHANISMS FOR
DEVELOPMENT OF NEXT GENERATION
TREATMENT STRATEGIES
Allen Gao
A 35 YEAR JOURNEY IN FEMALE PELVIS
REPAIR
Shlomo Raz
8:30
DISCUSSION
8:35
SESSION 2: PROSTATE CANCER
Moderators: Yinghao Sun, Teng Lung Lin
9:30
TARGETING PI3K-AR PATHWAYS FOR
PROSTATE CANCER MANAGEMENT
Benyi Li
9:40
DISCUSSION
9:45
WCUS AWARDS
9:55
SESSION 4: ADVANCE IN LAPAROSCOPY
Moderators: Yeh Tan, Peggy Chu, Ming-Tsun Chen
ADJUVANT THERAPY FOR PATHOLOGICAL T3
PROSTATE CANCER
Tony Wu
8:45
PROSTATE CANCER DETECTION PHI
C. F. Ng
8:55
UPDATE ON ROBOTIC-ASSISTED
LAPAROSCOPIC RADICAL PROSTATECTOMY
Yiu Ming Kwong
9:05
RADIAL PROSTATECTOMY WITH THE TRANSBLADDER NECK SLING TECHNIQUE
Tiejun Pan
9:15
DISCUSSION
SESSION 3: BASIC SCIENCE IN ONCOLOGY
Moderators: Liyan Zhuang, Chi-Rei Yang
RETROPERITONEAL LAPAROSCOPIC
SURGERY IN UROLOGY: THE IUPU
TECHNIQUES
Liqun Zhou
70
10:05
THE DEVELOPMENT AND APPLICATION OF
DR. SUN URETEROSCOPE
Xiaofeng Gao
10:15
THE CURRENT PRACTICE OF LAPAROSCOPIC
UROLOGY IN TAIWAN
Chia-Hsiang Lin
10:25
ROBOTIC PARTIAL NEPHRECTOMY
Fan Chi Wai
DISCUSSION
11:50
10:40
SESSION 5: AJA LECTURE
Moderators: Philip Li, Vitalino Carvalho
ED BASIC RESEARCH UPDATE IN CHINA
Yutian Dai
12:00
THULIUM LASER IN TREATMENT OF BENIGN
PROSTATE HYPERPLASIA
Shujie Xia
NOVEL THERAPEUTIC APPROACH FOR
URETHRAL CALCULI
Lili Liang
12:10
THE TREATMENT OF URINARY STONE BY
SOFT URETEROSCOPE
Wei Xue
12:20
DISCUSSION
12:25
SESSION 6: ADVANCE IN INFERTILITY
Moderators: Ronny Tan, Xuejun Shang
SESSION 8: BPH AND VOIDING DYSFUNCTION
Moderators: Shaw Zhou, Dominic Lee, Yiu Ming
Kwong
MALE INFERTILITY MICROSURGERIES
Peter Chan
ENDOSCOPIC OPTIONS FOR BPH
Liping Xie
10:55
11:05
11:15
HOW TO GET PERMISSIONS TO RE-USE
PUBLISHED TABLES/FIGURES IN YOUR NEW
MANUSCRIPT
Danqing Ren
THE APPLICATION OF DIAGNOSTIC
MICRODISSECTION TESTICULAR SPERM
EXTRACTION FOR INFERTILE MALE WITH
NON-OBSTRUCTIVE AZOOSPERMIA
William Huang
11:25
TREATMENT OF VARICOCELE
Xiangming Mao
11:35
DISCUSSION
11:40
SESSION 7: ED AND OTHERS
Moderators: George Chow, Lap Hong Ian, Lee Zhao
12:35
GREEN LIGHT LASER FOR BPH
Qiang Dong
12:45
SHOULD WE ARRANGE URODYNAMIC
TESTING BEFORE SURGERY FOR STRESS
INCONTINENCE?
Chieh-Lung Chou
12:55
DISCUSSION
1:00
SESSION 9: POSTER SESSION AND AWARDS
2:00
ADJOURN
A NEW THERAPEUTIC APPROACH FOR
ERECTILE DYSFUNCTION: ENDOGENOUS
STEM CELL
Zhongcheng Xin
8:00 am - 2:30 pm
INDIAN AMERICAN UROLOGICAL ASSOCIATION (IAUA)
8:00
INTRODUCTIONS
Program Chair: Anurag Das
10:00
COFFEE BREAK AND VISIT POSTERS &
EXHIBITS
8:10
SHOULD USE OF POLYPROPYLENE MESH IN
THE VAGINA BE ABANDONED? POINT /
COUNTERPOINT
Moderator: Gopal Badlani
Debaters: E. Ann Gormley, Eric Rovner
10:20
MANAGEMENT OF RENAL MASSES: EXPERT
CASE DISCUSSIONS
Moderator: Chandru Sundaram
Panelists: Ravi Munver, Ashok Hemal, Mihir Desai
10:50
QUESTIONS AND ARS
8:30
QUESTIONS AND ARS
11:00
8:40
OAB GUIDELINES UPDATE
E. Ann Gormley
9:00
BULBAR URETHRAL STRICTURESENDOSCOPIC MANAGEMENT VS.
URETHROPLASTY - A DEBATE
Moderator: Edward Wright
Debaters: Sanjay Kulkarni, Kennon Miller
MANAGEMENT OF BPH RELATED LUTS ROLE OF MINIMALLY INVASIVE PROCEDURES
Moderator: Raju Thomas
Discussants: Jaspreet Sandhu, Harcharan Gill,
Puneet Sindhwani
11:30
USI SESSION MANAGEMENT OF DIFFICULT
STONES: EXPERT CASES
Moderator: Mantu Gupta
Discussants: Ojas Shah, Percy Chibber, Mahesh
Desai
12:00
QUESTIONS AND ARS
12:10
ACADEMIA AND INDUSTRY SYNERGY - THE
NEW DRUG DEVELOPMENT ECOSYSTEM
Moderator: Anurag Das
Speakers: Grannum Sant, Deepak Kirpekar
9:20
QUESTIONS AND ARS
9:30
ARE ROUTINE MRI FUSION BIOPSIES USEFUL
OR WASTEFUL? A DEBATE
Moderator: Mani Menon
Debaters: Badrinath Konety, Ashutosh Tewari
9:50
QUESTIONS AND ARS
*Presenting author
71
SATURDAY
10:35
12:30
2:30
SPONSORED LUNCH PROGRAM AND
BUSINESS MEETING (NON-CME PORTION OF
PROGRAM)
1:30
IAUA BUSINESS MEETING-MEMBERS ONLY
(CME RESUMES)
2:00
POSTER PRESENTATIONS AND DISCUSSION
Moderators: D Ramesh, Ajay Singla, Ramasamy
Chettiar Meyyappan, Kim Mammen
ADJOURN
CREDITTM
8:00 am - 5:00 pm
AUA/CONFEDERACION AMERICANA DE UROLOGIA (CAU)
Great Hall @ New Orleans Morial Convention Center
8:00
MORNING SESSION
Moderator: Shlomo Raz
TREATMENT OF INFERTILITY
Jacob Rajfer
8:30
TREATMENT OF BPH
Claus Roehrborn
9:00
TREATMENT OF TESTICULAR CANCER
Joel Sheinfeld
9:30
TREATMENT OF KIDNEY STONES
Jorge Gutierrez-Aceves
10:00
WELCOMING REMARKS
Secretary General, CAU: Hugo Davila
2:00
COMPLICATIONS IN ROBOTIC KIDNEY
SURGERY
Michael Stifelman
2:15
BLADDER
ROBOTIC RADICAL CYSTECTOMY, HOW I DO
IT?
Erik Castle
2:30
DEBATE: RADICAL CYSTECTOMY - OPEN VS
ROBOTIC
Debaters: Harry Herr, Mihir Desai
3:00
VAGINAL PROLAPSE
DEBATE PELVIC ORGAN PROLAPSE REPAIR:
OPEN VS ROBOTIC
Debaters: Mauricio Plata, Ariel Kaufman
10:05
BREAK
10:30
TARGET BIOPSY IN CANCER OF PROSTATE
Leonard Marks
11:00
CARCINOMA OF BLADDER
Juan Palou
11:30
CARCINOMA OF PROSTATE
William Catalona
3:45
12:00
DEBATE: SURGERY FOR STRESS
INCONTINENCE – WITH VS WITHOUT MESH
Debaters: Shlomo Raz, Paulo Palma
RADICAL PROSTATECTOMY IN HIGH RISK
AND OLIGO METASTATIC DISEASE
Monish Aron
4:00
12:30
LUNCH
DEBATE: RADICAL PROSTATECTOMY - OPEN
VS ROBOTIC, WHAT’S THE EVIDENCE
Debaters: William Catalona, Rafael Coelho
4:30
COMPLICATIONS OF ROBOTIC RADICAL
PROSTATECTOMY
Rene Sotelo
5:00
ADJOURN
3:30
SURGICAL ANATOMY AND TECHNIQUE OF
NERVE PRESERVATION IN ROBOTIC RADICAL
PROSTATECTOMY
Mani Menon
AFTERNOON SESSION: SEMINAR ON
LAPAROSCOPIC AND ROBOTIC SURGERY IN
UROLOGY
Moderator: Rene Sotelo
1:30
PROSTATE
KIDNEY
LAPAROSCOPIC RADICAL NEPHRECTOMY
Camilo Giedelman
1:45
NEW FRONTIERS IN ROBOTIC KIDNEY
SURGERY
Inderbir Gill
8:00 am - 6:00 pm
AUA/AMERICAN COLLEGE OF OSTEOPATHIC SURGEONS (ACOS) UROLOGY PROGRAM
8:00
Program Chairs: Carolyn Langford, Marta JohnsonMitchell
72
CASTRATE RESISTANT PROSTATE CANCER
Gordon Brown
DEFINING THE OVERACTIVE BLADDER (OAB)
PATHWAY AND IMPROVING TECHNIQUES
FOR SNM THERAPY
Steven Siegel
9:30
MEN’S HEALTH: THINKING OUTSIDE THE BOX
Tarek Pacha
10:15
THE DO’S AND DON’TS OF ANDROLOGY 2015:
INFERTILITY, SEXUAL MEDICINE,
TESTOSTERONE, AND NEW TECHNOLOGIES
Michael Butcher
11:00
SUPERFICIAL BLADDER CANCER AND THE
BCG SHORTAGE
Edouard Trabulsi
11:45
UROLOGIC ONCOLOGY
Thomas Mueller
12:30
LUNCH
1:30
MATRISTEM - SITE SPECIFIC TISSUE
REGENERATION GRAFT
Carolyn Langford
2:15
URETHROPLASTY: WHAT TO DO AND HOW
TO DO IT
Richard Santucci
2:45
QUALITY OF LIFE OUTCOMES RESEARCH IN
UROLOGY
Daniel Stein
3:30
EVALUATION AND MANAGEMENT OF POSTPROSTATECTOMY INCONTINENCE
Frank Burks
4:15
ONCOLOGIC/ ROBOTIC CASE STUDIES
Ranko Miocinovic, Michael White, Gregory Weigler
5:00
OSTEOPATHIC RESIDENT PRESENTATIONS
6:00
ADJOURN
8:05 am - 12:05 pm
THE SCIENCE OF FEMALE PELVIC HEALTH
10:25
Program Chairs: Lori Birder, Toby Chai
8:05
PANEL 1: BIOMECHANICS AND BIOLOGY OF
PELVIC ORGAN SUPPORT
USE OF MESENCHYMAL STEM CELL TO
TREAT PELVIC FLOOR INJURY
Margot Damaser
MESH AND BIOMECHANICS
Pam Moalli
8:35
THE FIBULIN 5 STORY
Hiromi Yanagisawa
9:05
Q&A WITH THE PANEL
9:15
PANEL 2: PELVIC ULTRASOUND IMAGING OF
PELVIC FLOOR
IMAGING OF THE LEVATOR MUSCLE
Lieschen Quiroz
9:45
IMAGING OF IMPLANTED MESH
Larissa Rodriguez
10:15
Q&A WITH THE PANEL
PANEL 3: STEM CELLS OF PELVIC FLOOR
MEDICINE
10:50
HOPE AND REALITY OF TISSUE
ENGINEERING IN LOWER URINARY TRACT
J. Koudy Williams
11:25
DEVELOPING TISSUE ENGINEERING
SOLUTIONS FOR PELVIC ORGAN PROLAPSE
Sheila MacNeil
11:50
Q&A WITH THE PANEL
CREDITTM
10:30 am - 12:30 pm
TRAUMA/RECONSTRUCTION: URETER, BLADDER, EXTERNAL GENITALIA AND UROTRAUMA I
Moderators: Ryan Terlecki and Joel Gelman
ABSTRACT
NUMBER TITLE
MP18-01 THE IMPACT OF MASSIVE TRANSFUSION
PROTOCOL ON SIGNIFICANT
HEMORRHAGE DURING UROLOGIC
SURGERIES
Mathew Fakhoury*, Manaf Alom, Michael
Siev, Kai-Wen Chuang, Philip Zhao, Lee
Richstone, New Hyde Park, NY
ABSTRACT
NUMBER TITLE
MP18-03 PENILE FRACTURE: NATIONAL TRENDS
IN URETHRAL EVALUATION AND RISK
FACTORS FOR URETHRAL INJURY
Joseph J. Pariser*, Shane M. Pearce, Sanjay
G. Patel, Gregory T. Bales, Chicago, IL
MP18-02 WITHDRAWN
*Presenting author
73
SATURDAY
8:45
MP18-13 READMISSION AFTER TREATMENT OF
GRADE 3 AND 4 RENAL INJURIES AT A
LEVEL 1 TRAUMA CENTER: STATEWIDE
ASSESSMENT USING THE
COMPREHENSIVE HOSPITAL ABSTRACT
REPORTING SYSTEM
Brian Winters*, Hunter Wessells, Brian
Winters, Seattle, WA
MP18-04 HIGH-GRADE RENAL TRAUMA: DOES
MANAGEMENT PREDICT LENGTH OF
HOSPITAL STAY?
Lindsay Hampson*, Anobel Odisho, Benjamin
Breyer, Jack McAninch, San Francisco, CA
MP18-05 EPIDEMIOLOGY OF GENITOURINARY
TRAUMA IN SERVICE MEMBERS WITH
COLORECTAL INJURY WOUNDED
DURING OPERATION IRAQI FREEDOM
AND OPERATION ENDURING FREEDOM
Matthew Kasprenski*, San Antonio, TX, Sean
Glasgow, St. Louis, MO, Steven Hudak, San
Antonio, TX
MP18-14 UROLOGY CONSULTATION CAN
IMPROVE SURVIVAL RATES IN RENAL
TRAUMA PATIENTS
Rodrigo Donalisio da Silva*, Diedra
Gustafson, Leticia Nogueira, Wilson R.
Molina, Fernando J. Kim, Denver, CO
MP18-06 PREDICTING FACTORS FOR CONSERVATIVE
TREATMENT FAILURE IN GRADE IV
PEDIATRIC BLUNT RENAL TRAUMA
Jun Nyung Lee, Bum Soo Kim, Yun-Sok Ha,
Se Yun Kwon, Jae Young Choi, Seock Hwan
Choi, Daegu, Korea, Republic of, Deok-Hyun
Cho, Gumi-si, Korea, Republic of, Hyun Tae
Kim*, Tae-Hwan Kim, Eun Sang Yoo, Tae
Gyun Kwon, Sung Kwang Chung, Bup Wan
Kim, Daegu, Korea, Republic of
MP18-15 PENETRATING RENAL INJURIES:
FEASIBILITY OF NON-OPERATIVE
MANAGEMENT
Oussama Darwish*, Brian Dang, Prajakta
Adsul, Sameer Siddiqui, St. Louis, MO
MP18-16 COMPARISON OF NONOPERATIVE AND
SURGIAL MANAGEMENT OF RENAL
TRAUMA; CAN WE PREDICT WHEN
NONOPERATIVE MANAGEMENT FAILS?
Marc Bjurlin*, New York, NY, Richard Jacob
Fantus, Richard Joseph Fantus, Dana
Villines, Chicago, IL
MP18-07 CHANGING PATTERNS OF IATROGENIC
URETERIC AND BLADDER INJURIES IN
THE ERA OF LAPAROSCOPIC AND
ROBOTIC SURGERY: A REVIEW OF 114
CONSECUTIVE INJURIES
Sunu Philip*, Patrick Hurley, Southfield, MI
MP18-17 ARE ALL PEDIATRIC GRADE 4 RENAL
TRAUMAS THE SAME?
Christopher Long*, Sasha Tharakan, Dana
Weiss, David Chu, Aseem Shukla, Michael
Nance, Arun Srinivasan, Philadelphia, PA
MP18-08 ADRENAL INJURIES: A NATIONAL
TRAUMA DATA BANK ANALYSIS
Jairam R. Eswara*, Boston, MA, Valary T.
Raup, Julio Geminiani, Joel Vetter, Steven B.
Brandes, St Louis, MO
MP18-18 COMPARISON OF POLYPROPYLENE MESH
AND PRIMARY REPAIR IN THE TREATMENT
OF BLUNT TESTICULAR RUPTURE
Ibrahim Nüvit Tahtali*, Malatya, Turkey,
Turan Yildiz, zekeriya Ilce, sakarya, Turkey,
Mevlana Derya Balbay, istanbul, Turkey
MP18-09 IATROGENIC GENITOURINARY INJURIES
DURING COLORECTAL SURGERY:
CHARACTERIZATION AND LONG-TERM
OUTCOMES
Valary T. Raup*, St Louis, MO, Jairam R.
Eswara, Boston, MA, Steven B. Brandes, St
Louis, MO
MP18-19 DELAY OF SURGICAL TREATMENT OF
PENILE FRACTURE RESULTS IN POOR
FUNCTIONAL OUTCOME: RESULTS FROM
A LARGE RETROSPECTIVE
MULTICENTER EUROPEAN STUDY
Giorgio Bozzini*, Milan, Italy, Maarten Albersen,
Leuven, Belgium, Javier Romero Otero, Juan
Ignacio Martinez-Salamanca, Madrid, Spain,
Markus Margreiter, Wien, Austria, Christian
Gratzke, Munich, Germany, Eduardo Garcia
Cruz, Barcelona, Spain, Alex Mueller, Zurich,
Switzerland, Ege Can Serefoglu, Istanbul, Turkey,
Paolo Verze, Naples, Italy
MP18-10 LACTATE LEVELS AT ADMISSION CAN
PREDICT NEPHRECTOMY AND
MORTALITY IN PATIENTS WITH HIGH
GRADE RENAL TRAUMA (AAST III-V)
Rodrigo Donalsio da Silva*, Paulo Jaworski,
Diedra Gustafson, Leticia Nogueira, Denver, CO,
Nathalia Martins Lopes, Curitiba, Brazil, Wilson R.
Molina, Fernando J. Kim, Denver, CO
MP18-11 CYSTOSCOPY AT THE TIME OF
HYSTERECTOMY IMPROVES DETECTION
OF URETERAL INJURY: A POPULATION
BASED ANALYSIS
Robert Blackwell*, Elizabeth Dray, Matthew
Zapf, Anai Kothari, Paul Kuo, Robert
Flanigan, Gopal Gupta, Maywood, IL
MP18-20 ENDOSCOPIC RENDEZVOUS PROCEDURE
FOR URETERAL IATROGENIC
DETACHMENT: REPORT OF A CASE
SERIES WITH LONG-TERM OUTCOMES
Antonio Luigi Pastore*, Giovanni Palleschi, Luigi
Silvestri, Andrea Ripoli, Domenico Autieri, Yazan
Al Salhi, Antonio Carbone, Latina, Italy
MP18-12 BLUNT SCROTAL TRAUMA - IS SURGICAL
EXPLORATION NECESSARY?
Elaine Redmond*, Fergal MacNamara, Hugh
Flood, Limerick, Ireland
CREDITTM
74
10:30 am - 12:30 pm
ABSTRACT
NUMBER TITLE
MP19-01 FUNCTIONAL ANALYSIS OF CANCER
STEM-LIKE CELLS BY A NOVEL HSP40
FAMILY MEMBER PROTEIN
Hiroki Kusumoto*, Wakayama, Japan,
Satoshi Nishizawa, Izumisano, Japan,
Yoshihiko Hirohashi, Toshihiko Torigoe,
Sapporo, Japan, Nagahide Matsumura,
Yasuo Kohjimoto, Wakayama, Japan,
Noriyuki Sato, Sapporo, Japan, Isao Hara,
Wakayama, Japan
ABSTRACT
NUMBER TITLE
MP19-08 THE MURINE BLADDER SUPPORTS A
POPULATION OF STROMAL SCA-1ⴙ
SMOOTH MUSCLE PROGENITOR CELLS
Robert Dettman*, Meredith Lilly, Natalie
Kulkulna, Andrew Flum, Grace Delos Santos,
Edward Gong, Chicago, IL
MP19-09 NOVEL AND COST-EFFECTIVE
BIOREACTOR FOR MANUFACTURING
HUMAN MULTI-LAYERED UROTHELIAL
SHEETS IN TISSUE ENGINEERING
Leon Gustaffson, Martin Vaegler, Tubingen,
Germany, Karl-Dietrich Sievert*, TubingenLubeck, Germany
MP19-02 HUMAN RENAL PROXIMAL TUBULE
CELLS EXPRESSING FUNCTIONAL
CHARACTERISTICS WITH MEMBRANOUS
AND 3D TUBULAR CHITOSAN SCAFFOLD
INI CHIANG*, Taipei, Taiwan
MP19-10 SYNERGISTIC EFFECTS OF COMBINING
UNDIFFERENTIATED ADULT STEM CELLS
AND DIFFEREN-TIATED CELLS FOR THE
ENGINEERING OF FUNCTIONAL
BLADDER SMOOTH MUSCLE TISSUE
Souzan Salemi, Daniel Keller, Markus
Rottmar, Tullio Sulser, Daniel Eberli*, Zürich,
Switzerland
MP19-03 THE ANGIOGENIC SIGNALING MOLECULE
CYR61 INDUCES INCREASED NEOVASCULARIZATION IN REGENERATED
BLADDER TISSUE
Devon Snow-Lisy*, Edward Diaz, Chicago, IL,
Jessica Hannick, Maywood, IL, Matthew
Bury, Natalie Fuller, Chicago, IL, Nida
Ahmad, Maywood, IL, Arun Sharma, Chicago,
IL
MP19-11 WNT-5A OVEREXPRESSING
MESENCHYMAL STEM CELLS ENHANCE
BLADDER MUSCLE, VESSEL, NERVE, AND
UROTHELIUM REGENERATION IN A
MURINE MODEL OF BLADDER
AUGMENTATION
Jessica Hannick*, Maywood, IL, Edward Diaz,
Devon Snow-Lisy, Matt Bury, Natalie Fuller,
Nida Ahmad, Arun Sharma, Chicago, IL
MP19-04 IN-VIVO REGENERATION OF BLADDER
MUSCULAR WALL WITH
DECELLULARIZED COLON MATRIX: AN
EXPERIMENTAL STUDY
Abdol-Mohammad Kajbafzadeh, Reza
Khorramirouz, Shabnam Sabetkish, Nastaran
Sabetkish, Ahmad Masoumi, Sorena
Keihani*, Tehran, Islamic Republic of Iran
MP19-12 INJECTION OF MESENCHYMAL STEMS
CELLS IN RATS WITH CHRONIC CYSTITIS
IMPROVES DETRUSOR CONTRACTILITY
Jessica Hammett*, Orange, CA, Cody
Thorson, Irvine, CA, Felicia Lane, Gamal
Ghoniem, Orange, CA, Os Steward, Huiyi
Chang, Irvine, CA
MP19-05 THE HIPPO/MST PATHWAY IS A CRUCIAL
PART OF THE BLADDER SMC RESPONSE
TO INJURY
KJ Aitken, Martin Sidler, Alaleh Samiei, Paul
Delgado-Olguin, Darius Bagli*, Toronto,
Canada
MP19-13 DEVELOPMENT OF A LARGE XENOGRAFT
ANIMAL MODEL TO INVSTIGATE
EFFICACY OF CELL-BASED THERAPIES
TO TREAT STRESS URINARY
INCONTINENCE
Bastian Amend, Alexandra Kelp, Martin
Vaegler, Arnulf Stenzl, Tubingen, Germany,
Karl-Dietrich Sievert*, Tubingen-Lubeck,
Germany
MP19-06 MESENCHYMAL STEM-CELL THERAPY
ALLEVIATES INTERSTITIAL CYSTITIS BY
ACTIVATING WNT SIGNALING PATHWAY
miho song*, Junsoo Park, Myung-Soo Choo,
MP19-07 CAN WE USE HUMAN ADIPOSE-DERIVED
STEM CELLS (ADSCS) FROM UROLOGIC
CANCER PATIENTS FOR AUTOLOGOUS
CELL THERAPY?: A PILOT STUDY
Marta Garcia-Contreras, Valencia, Spain,
Cesar Vera-Donoso*, Paterna, Spain, José
Hernández-Andreu, Valencia, Spain, José
Garcı́a-Verdugo, Paterna, Spain, Elisa Oltra,
Valencia, Spain
*Presenting author
MP19-14 MAGNETIZATION TRANSFER (MT)-MRI
CHARACTERIZES IN VIVO MYOFIBER
FORMATION OF MUSCLE PRECURSOR
CELLS
Markus Rottmar, Andreas Boss, Daniel
Eberli*, Zurich, Switzerland
75
SATURDAY
STEM CELL RESEARCH
Moderators: Adonis Hijaz and Kazunori Hattori
MP19-18 INTRATUNICAL INJECTION OF ADIPOSE
STROMAL VASCULAR FRACTION (SVF)
PREVENTS FIBROSIS EXPRESSION IN A
RAT MODEL OF PEYRONIE’S DISEASE
Fabio Castiglione*, Maarten Albersen,
Leuven, Belgium, Ettore Di Trapani,
Francesco Montorsi, Milan, Italy, Trinity J.
Bivalacqua, Baltimore, MD, Steven Joniau,
Dirk De Ridder, Leuven, Belgium, Petter
Hedlund, Milan, Italy
MP19-15 COMPARATIVE ASSESSMENT OF ORAL
AND URETHRAL MUCOSA CELL
CULTURES AND IN VITRO ANALYSIS OF
THEIR REGENERATIVE AND
PROLIFERATIVE PROPERTIES FOR
TISSUE ENGINEERING URETHRAL
RECONSTRUCTION
Graziella Pellegrini*, Francesca Corradini,
Modena, Italy, Guido Barbagli, Arezzo, Italy,
Michela Zattoni, Michael Giovanardi,
Vincenzo Genna, Gianpaolo Bianchi,
Modena, Italy, Massimo Lazzeri, Arezzo, Italy
MP19-19 COMPARATIVE STUDY OF AUTOLOGOUS
STROMAL VASCULAR FRACTION AND
ADIPOSE-DERIVED STEM CELLS FOR
ERECTILE FUNCTION RECOVERY IN A
RAT MODEL OF CAVERNOUS NERVE
INJURY
Dalsan You*, Myoung Jin Jang, Bo Hyun
Kim, Geehyun Song, Chunwoo Lee, Nayoung
Suh, In Gab Jeong, Sang Hoon Song, Kun
Suk Kim, Tai Young Ahn, Choung-Soo Kim,
MP19-16 HUMAN ADIPOSE TISSUE DERIVED STEM
CELLS (HADSCS) PREVENTS FIBROSIS
AND BLADDER DYSFUNCTION IN A RAT
MODEL OF URETHRAL STRICTURE
Fabio Castiglione*, Maarten Albersen,
Leuven, Belgium, Andrea Russo, Milan, Italy,
Trinity J. Bivalacqua, Baltimore, MD,
Francesco Montorsi, Milan, Italy, Steven
Joniau, Dirk De Ridder, Leuven, Belgium,
Petter Hedlund, Milan, Italy
MP19-20 SURVIVIN MEDIATES INFLAMMATIONDRIVEN EXPANSION OF PROGENITOR
CELLS IN THE PROSTATE
Liang Wang, Edward Srour, Jian-Ting Zhang,
Hal Broxmeyer, Travis Jerde*, Indianapolis,
IN
MP19-17 HUMAN URETHRA-ENGINEERED WITH
HUMAN MESENCHYMAL STEM CELL
WITH MATURATION BY
REARRANGEMENT OF CELLS FOR SELFORGANIZATION - NEWLY DEVELOPED
SCAFFOLD-FREE THREE-DIMENSIONAL
BIO-PRINTER Tokunori Yamamoto*, Yasuto Funahashi,
Yoshihisa Mastukawa, Yoshikazu Tsuji,
Hideki Mizuno, Nagoya, Japan, Koichi
Nakayama, Saga, Japan, Momokazu Gotoh,
Nagoya, Japan
CREDITTM
10:30 am - 12:30 pm
INFECTIONS/INFLAMMATION OF THE GENITOURINARY TRACT: KIDNEY & BLADDER II
Moderators: Anthony Schaeffer and Claire Yang
ABSTRACT
NUMBER TITLE
MP20-01 CYTOTOXIC NECROTIZING FACTOR-1
(CNF-1) TOXIN IN UROPATHOGENIC E.
COLI: IS THERE A ROLE FOR VIRULENCE
IN URINARY TRACT INFECTION?
Jason Michaud*, William Harty, Kwang Sik
Kim, Ming-Hsien Wang, Baltimore, MD
ABSTRACT
NUMBER TITLE
MP20-04 DNA DAMAGE REPAIR GENES REGULATE
BLADDER INFLAMMATION
Christopher Dru*, Subhash Haldar, Neil
Bhowmick, Los Angeles, CA
MP20-05 BLADDER INSTILLATION THEARPY OF
MESENCYMAL STEM CELL AND THE
ADDITION OF MANNOSE IN A RAT
CYSTITIS MODEL- MULTIPLE
SUPPRESSIVE EFFECTS FOR EXCESS
CYTOKINES
Tokunori Yamamoto*, Yasuto Funahashi,
Majima Tsuyoshi, Takai Syun, Yoshihisa
Matsukawa, Hideki Mizuno, Momokazu
Gotoh, Nagoya, Japan
MP20-02 CONDITIONED MEDIA FROM INFECTED
UROTHELIAL CELLS CONTAIN
EXOSOMES WITH EPIGENETIC
POTENTIAL
Kenneth Ting, Alaleh Samiei, Karen J. Aitken,
Bryce Weber, Fadi Ibrahim, Akshita Kapila,
Frank J. Penna*, Cornelia Tolg, Darius Bagli,
Toronto, Canada
MP20-03 NLRP3 INFLAMMASOME PLAYS A KEY
ROLE IN UROTHELIAL DEFENSE
AGAINST UROPATHOGENIC E. COLI
Feng He, Yan Liu, Ellen Shapiro, Herbert
Lepor, Xue-Ru Wu*, New York, NY
76
MP20-07 ALL ASYMPTOMATIC BACTERIURIA, ALL
THE TIME
Suzanne Groah, Marcos Perez-Losada,
Ljubica Caldovic, Inger Ljungberg, Bruce
Sprague, Eduardo Castro-Nallar, Neel Shah,
Michael Hsieh, Hans Pohl*, Washington, DC
MP20-15 FIBRINOGEN RELEASE AND DEPOSITION
ON URINARY CATHETERS PLACED
DURING UROLOGIC PROCEDURES
Jeffrey Larson*, Aaron Potretzke, Jennifer
Walker, Ana Lidia Flores-Mireles, Scott
Hultgren, Alana Desai, St. Louis, MO
MP20-08 PYURIA AND ASYMPTOMATIC
BACTERIURIA IS ASSOCIATED WITH
NOVEL AND SPECIFIC URINE
MICROBIOMES
Suzanne Groah, Marcos Perez-Losada,
Ljubica Caldovic, Inger Ljungberg, Bruce
Sprague, Eduardo Castro-Nallar, Neel Shah,
Michael Hsieh, Hans Pohl*, Washington, DC
MP20-16 REDUCED BLADDER CAPACITY AND
INCREASED BLADDER SENSATION IS
ASSOCIATED WITH UROTHELIAL
DYSFUNCTION AND CHRONIC
INFLAMMATION IN PATIENTS WITH
CHRONIC KIDNEY DISEASE AND ENDSTAGE RENAL DISEASE
Jia-Fong Jhang*, Jing-Liang Chen, Jia-Hui
Chang, Hann-Chorng Kuo, Hualien, Taiwan
MP20-09 PREDICTIVE VALUE OF ROUTINE
URINALYSIS AND URINE MICROSCOPY
FOR THE DETECTION OF BACTERIURIA:
RESULTS FROM A VETERANS
ADMINISTRATION QUALITY ASSURANCE
INITIATIVE
Kyle Richards*, Stacy Cesario, Sara Best,
Susan Deeren, Granville Lloyd, Timothy
Moon, Madison, WI
MP20-17 INTRAVESICAL LIPOSOMAL
TACROLIMUS PROTECTS AGAINST
RADIATION CYSTITIS INDUCED BY 3BEAM TARGETED BLADDER RADIATION
Bharathi Raja Rajaganapathy*, Royal Oak,
MI, Joseph Janicki, Pittsburgh, PA, Peter
Levanovich, Royal Oak, MI, Pradeep Tyagi,
Pittsburgh, PA, Jason Hafron, Michael
Chancellor, Sarah Krueger, Brian Marples,
Royal Oak, MI
MP20-10 A BIOSENSOR FOR RAPID AND
SIMULTANEOUS UROPATHOGEN
IDENTIFICATION AND CIPROFLOXACIN
MINIMUM INHIBITORY CONCENTRATION
DETERMINATION
Emanuela Altobelli*, Ruchika Mohan,
Kathleen Mach, Mandy La Yi Sin, Victoria
Anikst, Stanford, CA, Maurizio Buscarini,
Rome, Italy, Pak Kin Wong, Tucson, AZ,
Vincent Gau, Irwindale, CA, Niaz Banaei,
Joseph C. Liao, Stanford, CA
MP20-18 GRADE 4 HEMORRHAGE RADIATION
CYSTITIS TREATED BY EARLY
TRANSURETHRAL FULGURATION
VERSUS CONSERVATIVE OBSERVATION
STRATEGY: OUTCOME COMPARISON
FROM 283 CASES
Toru Sugiahra*, Hideo Yasunaga, Jun Kamei,
Hiroki Matsui, Tohru Nakagawa, Tetsuya
Fujimura, Hiroshi Fukuhara, Haruki Kume,
Kiyohide Fushimi, Masaaki Tachibana, Yukio
Homma, Tokyo, Japan
MP20-11 ANTIMICROBIAL SUSCEPTIBILITIES OF
URINARY EXTENDED SPECTRUM BETALACTAMASE-PRODUCING ESCHERICHIA
COLI AND KLEBSIELLA PNEUMONIAE TO
FOSFOMYCIN IN HEALTH CARE
ASSOCIATED URINARY TRACT
INFECTION
Ho Seok Chung*, Je-Guk Ryu, Bosung Shin,
Deok Hyun Nam, Ho Song Yu, Eu Chang
Hwang, Sun-Ouck Kim, Seung Il Jung, Taek
Won Kang, Dongdeuk Kwon, Kwangsung
Park, Gwangju, Korea, Republic of
MP20-19 SAFETY AND EFFICACY OF
INTRAVESICAL ALUM FOR INTRACTABLE
HEMORRHAGIC CYSTITIS: A
CONTEMPORARY EVALUATION
Mary E. Westerman*, Stephen A. Boorjian,
Brian J. Linder, Rochester, MN
MP20-20 CYSTECTOMY FOR REFRACTORY
HEMORRHAGIC CYSTITIS:
CONTEMPORARY ETIOLOGY,
PRESENTATION AND OUTCOMES
Brian Linder*, Robert Tarrell, Stephen
Boorjian, Rochester, MN
MP20-12 RECENT ANTIBIOTIC TREATMENT AND
THE RISK OF POST-OUTPATIENT
CYSTOSCOPY URINARY TRACT
INFECTION
Justin R. Gregg*, Caroline M. Lai, Thomas R.
Talbot, Daniel A. Barocas, Nashville, TN
MP20-13 STENT COLONIZATION: DISCORDANCE
WITH URINE CULTURE
Jennifer Davila-Aponte*, Naveen Nandanan,
Sean Corbett, Noah Schenkman, Tracey
Krupski, Charlottesville, VA
*Presenting author
CREDITTM
77
SATURDAY
MP20-14 ANTIMICROBIAL UTILIZATION PRIOR TO
ENDOUROLOGICAL SURGERY FOR
UROLITHIASIS: ENDOUROLOGICAL
SOCIETY SURVEY RESULTS
Adam Kaplan*, Durham, NC, Ramy Yacoub,
Orange, CA, Richard Shin, Fernando
Cabrera, Durham, NC, Andreas Neisius,
Mainz, Germany, Charles Scales, Durham,
NC, Roger Sur, San Diego, CA, Anicka
Ackerman, Michael Ferrandino, Durham, NC,
Brian Eisner, Boston, MA, Glenn Preminger,
Michael Lipkin, Durham, NC
MP20-06 OPTICAL MONITORING OF DETRUSOR
TISSUE OXYGEN SATURATION IN ACUTE
LOWER URINARY TRACT INFECTION: A
CASE CONTROL COMPARISON
Babak Shadgan, Vancouer, Canada, Lynn
Stothers, Andrew Macnab*, Mark Nigro,
Vancouver, Canada, A Kajbafzadeh, Tehran,
Islamic Republic of Iran
10:30 am - 12:30 pm
BLADDER AND URETHRA: ANATOMY, PHYSIOLOGY AND PHARMACOLOGY II
Moderators: Karl-Erik Andersson and Michael Ruggieri
ABSTRACT
NUMBER TITLE
MP21-01 HYDROGEN SULFIDE IS A POTENT
RELAXING FACTOR IN THE RAT
BLADDER AND PROSTATE
Takahiro Shimizu*, Shogo Shimizu, Kumiko
Nakamura, Nankoku, Japan, Masashi Honda,
Yonago, Japan, Keiji Inoue, Motoaki Saito,
Nankoku, Japan
ABSTRACT
NUMBER TITLE
MP21-08 SKELETAL MYOGENIC DIFFERENTIATION
OF HUMAN URINE-DERIVED CELLS AS A
POTENTIAL SOURCE OF CELL THERAPY
FOR URETHRAL SPHINCTER MUSCLE
DYSFUNCTION
Wei Chen, Chongqing, China, People’s
Republic of, M Xie, Bin Yang, S Bharadwaj,
Song Li, Guihua Liu, Anthony Atala,
Yuanyuan Zhang*, Winston Salem, NC
MP21-02 TRANSLOCATION OF NUCLEAR FACTOR
KAPPA B AND EXPRESSION OF
CYCLOOXYGENASE-2 IS ENHANCED BY
KETAMINE-INDUCED ULCERATIVE
CYSTITIS IN RAT BLADDER
Yung-Shun Juan*, Yi-Lun Lee, Mei-Yu Jang,
Wen-Jeng Wu, Su-E Chen, Kaohsiung,
Taiwan, Wei-Chiao Chang, Taipei, Taiwan,
Shu-Mien Chuang, Kaohsiung, Taiwan
MP21-09 CYSTOMETRIC EFFECTS OF ANDROGEN
DEPRIVATION AND DAILY TADALAFIL
ADMINISTRATION IN MICE WITH
DETRUSOR OVERACTIVITY INDUCED BY
NITRIC OXIDE CHRONIC DEFICIENCY
Raphael Farias Carvalho*, Ricardo Reges,
Patrı́cia Gaspar, Lucas Marinho, João Batista
Cerqueira, Lúcio Flávio Gonzaga-Silva,
Fortaleza, Brazil
MP21-03 CLINICAL PREDICTORS OF NOCTURIA IN
THE SLEEP APNEA POPULATION
Omer Raheem*, Ryan Orosco, Terence
Davidson, Charles Lakin, San Diego, CA
MP21-10 PHYSICAL ACTIVITY MAY PREVENT
BLADDER DYSFUNCTION IN OBESE RATS
THROUGH OVER-EXPRESSION OF
INSULIN SIGNALING RELATED GENES
Andre Matos Oliveira*, Fernando F Fonseca,
Sabrina T Reis, Vanessa Guimaraes, Katia R
Leite, William C Nahas, Miguel Srougi,
Alberto A Antunes, Sao Paulo, Brazil
MP21-04 UROTHELIAL EPAC: NOVEL MEDIATOR IN
THE REGULATION OF BLADDER
CAPACITY
Hiroshi Nakagomi*, F.Aura Kullmann, Wily
G.Ruiz, Amanda Wolf-Johnston, Gerard
Apodaca, Lori A. Birder, Pittsburgh, PA
MP21-11 CLARITY ILLUMINATES THE
STRUCTURAL AND MOLECULAR
CHARACTERISTICS OF MOUSE
GENITOURINARY TISSUES — OVER AND
OVER AGAIN
Yan Liu, Herbert Lepor, Xue-Ru Wu, Ellen
Shapiro*, New York, NY
MP21-05 THE ASSOCIATION BETWEEN IMPAIRED
URINARY CONTINENCE MECHANISMS
AND AGE-RELATED INFLAMMATION IN
FEMALE RATS
Yasuhiro Sumino*, Oita, Japan, Satoru
Yoshikawa, Pittsburgh, PA, Mayuka
Shinohara, Ken-ichi Mori, Fuminori Satoh,
Hiromitsu Mimata, Oita, Japan, Naoki
Yoshimura, Pittsburgh, PA
MP21-12 TREATMENT OF RADIATION CYSTITIS
VIA P75 RECEPTOR BLOCKADE
Youko Ikeda*, Irina Zabbarova, Kathryn
Lemon, Neil Lamarre, Michael Epperly,
Anthony Kanai, Pittsburgh, PA
MP21-06 BLADDER SMOOTH MUSCLE CELLS
UNDERGO A SYNTHETIC PHENOTYPE
SWITCH IN A RAT MODEL OF
NEUROGENIC UNDERACTIVE BLADDER
DISEASE
Emmanuel Weyne*, Yves Deruyver, Karel
Dewulf, Roma Rietjens, Leuven, Belgium,
Trinity J Bivalacqua, Baltimore, MD, Dirk De
Ridder, Frank Van der Aa, Maarten Albersen,
Leuven, Belgium
MP21-13 FUNCTIONAL ROLES OF METABOTROPIC
GLUTAMATE RECEPTOR SUBTYPE 1A IN
CONTROL OF LOWER URINARY TRACT
ACTIVITY IN MICE
Mitsuharu Yoshiyama*, Tsutomu Mochizuki,
Masayuki Takeda, Chuo, Japan
MP21-14 UROTHELIAL DYSFUNCTION IN DIABETIC
PATIENTS WITH OVERACTIVE BLADDER
Chung-Cheng Wang*, New Taipei City,
Taiwan, Jing-Hui Lin, Hann-Chorng Kuo,
Hualien, Taiwan
MP21-07 SAFETY, TOLERABILITY AND
PHARMACOKINETICS OF SINGLE AND
MULTIPLE ASCENDING DOSES OF THE
EP2/EP3 RECEPTOR AGONIST ONO-8055,
A POTENTIAL NEW THERAPY FOR
UNDERACTIVE BLADDER, IN HEALTHY
SUBJECTS
Christopher Chapple*, Sheffield, United
Kingdom, Mark Bruce, Tomoya Ohno,
Tomohiro Kuwayama, Stephen Deacon,
London, United Kingdom
MP21-15 IMPORTANCE OF DNA-METHYLATION IN
PARTIAL BLADDER OUTLET
OBSTRUCTION
Martin Sidler*, Karen Aitken, Rosanna
Weksberg, Darius Bägli, Toronto, Canada
78
MP21-20 INTRAVESICAL INHIBITION OF P2X3
RECEPTORS IMPROVES BLADDER
DYSFUNCTION DEPENDING ON
UROTHELIAL EXPRESSION LEVELS FOR
THE RECEPTOR IN SCI RATS
Jorge Tovar-Perez, Broderick Sutton, Timothy
Boone, Alvaro Munoz*, Houston, TX
MP21-17 MACROPHAGE MIGRATION INHIBITORY
FACTOR MEDIATES PROTEASE
ACTIVATED RECEPTOR-INDUCED
BLADDER PAIN
Dimitrios E. Kouzoukas*, Lexington, KY,
Katherine L. Meyer-Siegler, St. Petersburg,
FL, Fei Ma, Karin N. Westlund, David E.
Hunt, Pedro L. Vera, Lexington, KY
CREDITTM
MP21-18 CONDITIONAL DELETION OF
MANGANESE SUPEROXIDE DISMUTASE
IN DETRUSOR SMOOTH MUSCLE IS
ASSOCIATED WITH BLADDER
OVERACTIVITY IN MICE
Rania Elrashidy*, Guiming Liu, Nan Xiao,
Michael Kavran, Yexiang Huang, Mingfang
Tao, Cleveland, OH, Hoda Mohammad,
Zagazig, Egypt, C Thomas Powell, Firouz
Daneshgari, Cleveland, OH
10:30 am - 12:30 pm
TECHNOLOGY & INSTRUMENTS: SURGICAL EDUCATION & SKILLS ASSESSMENT I
Moderators: James Borin and Mahesh Desai
ABSTRACT
NUMBER TITLE
MP22-01 JOURNAL CLUBS VIA MICROBLOGGING
ARE GLOBALIZING CONTINUING
MEDICAL EDUCATION: A SYSTEMATIC
REVIEW
Matthew Roberts*, Brisbane, Australia,
Marlon Perera, Mackay, Australia, Nathan
Lawrentschuk, Diana Romanic, Nathan Papa,
Damien Bolton, Melbourne, Australia
ABSTRACT
NUMBER TITLE
MP22-04 EVOLUTION OF 3-D PHYSICAL MODELS
OF RENAL MALIGNANCIES USING MULTIMATERIAL 3-D PRINTERS
Michael Maddox*, Allison Feibus, Benjamin
Lee, Julie Wang, Raju Thomas, Jonathan
Silberstein, New Orleans, LA
MP22-05 EVALUATION OF TECHNICAL LEARNINGCURVES FOR ROBOT ASSISTED RADICAL
PROSTATECTOMY - A MULTIINSTITUTIONAL STUDY
Catherine Lovegrove*, London, United
Kingdom, Giacomo Novara, Padua, Italy,
Khurshid Guru, Buffalo, NY, Alex Mottrie,
Aalst, Italy, Ben Challacombe, London,
United Kingdom, Johar Raza, Buffalo, NY,
Henk Van der Poel, Amsterdam, Netherlands,
James Peabody, Detroit, MI, Rick Popert,
Prokar Dasgupta, Kamran Ahmed, London,
United Kingdom
MP22-02 APPLICATION OF SIMULATED PATIENTSPECIFIC 3D PRINTED KIDNEY MODEL
FABRICATED BY COLOR MULTIMATERIAL 3D PRINTER FROM
VOLUMETRIC CT TO AID PARTIAL
NEPHRECTOMY
Yoon Soo Kyung*, Namkug Kim, Dalsan You,
Jeong In Gab, Jun Hyuk Hong, Choung-Soo
Kim, Myungchan Park, Chanwoo Lee,
Sangjun Yoo, Seoul, Korea, Republic of
MP22-03 MALLEABLE PHYSICAL MODELS OF
RENAL MALIGNANCIES CONSTRUCTED
FROM 3-D PRINTERS TO ALLOW
SURGICAL RESECTION FOR
INDIVIDUALIZED PRE-SURGICAL
SIMULATION
*Presenting author
MP22-06 PRELIMINARY EVALUATION OF THE
SIMPORTAL MAJOR VESSEL INJURY
(MVI) REPAIR MODEL
Domenico Veneziano*, Lauren Poniatowski,
Troy Reihsen, Robert Sweet, Minneapolis,
MN
79
SATURDAY
MP21-19 THE IMPACT OF AUTHOPHAGY IN
NEUROPATHIC BLADDER REMODELING
Souzan Salemi, Ashkan Mortezavi, Maya
Horst, Rita Gobet, Tullio Sulser, Daniel
Eberli*, Zürich, Switzerland
MP21-16 ROLE OF TRPM4 ON MORPHOLOGICAL
AND FUNCTIONAL CHANGES IN THE
NEUROGENIC BLADDER
F. Aura Kullmann*, Jonathan Beckel, Hiroshi
Nakagomi, Amanda Wolf-Johnston, Christian
Gauthier, Anthony Kanai, Lori Birder,
Pittsburgh, PA
MP22-14 EVALUATION OF IGNITION AND BURN
RISK ASSOCIATED WITH
CONTEMPORARY FIBEROPTIC AND
DISTAL SENSOR ENDOSCOPIC
TECHNOLOGY
Kyle Spradling*, Brittany Uribe, Zhamshid
Okhunov, Martin Hofmann, Michael del
Junco, Christina Hwang, Caden Gruber,
Ramy Youssef, Jaime Landman, Orange, CA
MP22-07 LAPAROSCOPIC IVC INJURY
MANAGEMENT TRAINING – PREDICTING
TECHNICAL & NON-TECHNICAL SKILLS
Jason Lee*, Udi Blankstein, Richard Hoang,
Michael Ordon, Kenneth Pace, Toronto,
Canada
MP22-08 INTRAOPERATIVE MRI-GUIDED
NAVIGATION OF THE PELVIC FLOOR
DURING CLASSIC BLADDER EXSTROPHY
AND CLOACAL EXSTROPHY CLOSURE CUTTING EDGE TECHNOLOGY FOR
SURGICAL SKILL EDUCATION
Heather Di Carlo*, Baltimore, MD, Eric
Massanyi, Akron, OH, Bhavik Shah, Tampa,
FL, Aylin Tekes, John Gearhart, Baltimore,
MD
MP22-15 PRELIMINARY EVALUATION OF A NOVEL
PCNL TRAINER
Ashish Rawandale*, lokesh patni, yaser
ahmad, pramod patil, Dhule, India
MP22-16 DELIVERY OF A UROLOGY ONLINE
COURSE USING MOODLE VERSUS
DIDACTIC LECTURES
Leonardo O. Reis*, Osamu Ikari, Khaled
Ahmed Taha-Neto, Bruno D.B. Carneiro,
Gustavo Mendonça, Antonio Gugliotta,
Fernandes Denardi, Campinas, Brazil
MP22-09 DEVELOPMENT AND VALIDATION OF AN
INTEGRATED SKILLS CURRICULUM
WITHIN URETEROSCOPY– A
RANDOMISED CONTROLLED TRIAL
Oliver Brunckhorst*, Shahab Shahid,
Abdullatif Aydin, London, United Kingdom,
Craig McIlhenny, Larbet, United Kingdom,
Shahid Khan, Redhill, United Kingdom, Syed
Raza, Buffalo, NY, Arun Sahai, James
Brewin, Fernando Bello, Roger Kneebone,
Muhammad Khan, Prokar Dasgupta, Kamran
Ahmed, London, United Kingdom
MP22-17 IMPACT OF SPATIAL COGNITIVE ABILITY
ON THE PROFICIENCY OF UROLOGICAL
SURGEONS IN ROBOT-ASSISTED
SURGERY USING MIMIC DV-TRAINER
Jun Teishima*, Minoru Hattori, Shogo Inoue,
Keisuke Hieda, Shunsuke Shinmei, Hiroyuki
Egi, Hideki Ohdan, Akio Matsubara,
Hiroshima, Japan
MP22-10 IMPACT OF MATCHING EDUCATIONAL
MATERIALS TO LEARNING STYLE ON
ROBOTIC SURGICAL SKILLS TRAINING
Daniel Ballow, Justin Fang*, Christopher
Kosarek, Travis Green, William Tarry, Susan
Tarry, Galveston, TX
MP22-18 EFFECTS OF RESIDENCY TRAINING ON
PROSTATE BIOPSY EFFICACY: A REVIEW
OF PROSTATE BIOPSIES IN A RESIDENTRUN CLINIC AT AN INNER-CITY
HOSPITAL
Allison Polland*, John Griffith, Kathleen Kan,
New York, NY, Egor Parkhomenko, True
Blue, Grenada, John Sfakianos, New York,
NY, Alfred Winkler, Queens, NY
MP22-11 UNDERSTANDING SURGICAL
PERFORMANCE DURING ROBOTASSISTED SURGERY: PIERCING THE
HORNET’S NEST
Khurshid Guru*, Somayeh Shafiei, Atif Khan,
Mohamed Sharif, Syed Johar Raza, Thomas
Fiorica, Mohammad M Durrani, Ehsan
Esfahani, Buffalo, NY
MP22-19 INNOVATION, CONSTRUCTION AND
ASSESSMENT OF A NOVEL SEAMLESS
LAPAROSOPIC PORT PLACEMENT
SYSTEM
Ashish Rawandale*, lokesh patni, yaser
ahmad, Dhule, India
MP22-12 UROLOGY CORE QUESTION
CURRICULUM: UNIVERSITY OF
WASHINGTON RESIDENCY
EDUCATIONAL TOOL
Ryan Hsi*, Byron Joyner, Jonathan Harper,
Seattle, WA
MP22-20 PARENTAL STATUS AMONG
SUCCESSFUL APPLICANTS TO UROLOGY
RESIDENCY
Ariella A. Friedman*, Lane S. Palmer, New
Hyde Park, NY
MP22-13 TRENDS IN MESH USAGE AND RESIDENT
INVOLVEMENT FOR VAGINAL SURGERY
FROM THE NATIONAL SURGICAL
QUALITY IMPROVEMENT PROGRAM
Devin Haddad*, Louis Krane, Majid
Mirzazadeh, Gopal Badlani, Winston-Salem,
NC
CREDITTM
80
10:30 am - 12:30 pm
Podium Session 11
ABSTRACT
TIME NUMBER TITLE
10:30 PD11-01 PELVIC RADIATION IS ASSOCIATED WITH
URINARY FISTULAE REPAIR FAILURE
AND NEED FOR PERMANENT URINARY
DIVERSION
Eswara, Boston, MA, Avory M. Heningburg,
Steven B. Brandes, St Louis, MO
10:40
10:50
11:00
ABSTRACT
TIME NUMBER TITLE
11:30 PD11-07 SLOW WAVE CONDUCTION
DISTURBANCES PROXIMAL AND DISTAL
TO ILEAL END-TO-END ANASTOMOSIS
FOLLOWING ILEOCYSTOPLASTY
Fayez Hammad*, Wim Lammers, Al Ain,
United Arab Emirates, John Rietbergen,
Rotterdam, Netherlands, Betty Stephen, Loay
Lubbad, Al Ain, United Arab Emirates
PD11-02 URINARY DIVERSION FOR
COMPLICATIONS OF PROSTATE CANCER
RADIATION TREATMENT
Mitchell Bassett*, Darshan Patel, Salt Lake
City, UT, Benjamin Breyer, San Francisco,
CA, Jonathan Tward, Cameron Thorpe, Salt
Lake City, UT, Thomas Gaither, San
Francisco, CA, James Hotaling, William
Brant, Jeremy Myers, Salt Lake City, UT
PD11-03 FOLLOW-UP SURGICAL INTERVENTIONS
IN PATIENTS WITH URINARY DIVERSION:
A COMPARISON BETWEEN ORTHOTOPIC
NEOBLADDERS AND ILEAL CONDUITS
David Flores*, Katie Murray, William Parker,
Daniel Zainfeld, Moben Mirza, Jeffrey
Holzbeierlein, Kansas City, KS
PD11-04 TEMPORAL TRENDS IN CONCOMITANT
CYSTECTOMY WITH URINARY
DIVERSION FOR BENIGN INDICATIONS IN
THE NATIONWIDE INPATIENT SAMPLE
Elizabeth T. Brown*, David Osborn, Stephen
Mock, Amy Graves, Laurel Milam, Douglas
Milam, Melissa Kaufman, Roger Dmochowski,
W. Stuart Reynolds, Nashville, TN
11:10
PD11-05 UNDIVERSION OF THE URINARY TRACT:
RESULTS FROM A LARGE CYSTECTOMY
SERIES (Nⴝ1616)
Richard Hautmann*, Robert de Petriconi,
Ulm, Germany, Juliane Schwarz, Bjoern
Volkmer, Kassel, Germany
11:20
PD11-06 DURABILITY OF REVISION SURGERY FOR
STENOSIS OF CATHETERIZABLE
CHANNELS IN ADULTS
Travis Pagliara*, Daniel Liberman,
Minneapolis, MN, Jeremy Myers, Salt Lake
City, UT, John Stoffel, Ann Arbor, MI, Sean
11:40
PD11-08 CONTEMPORARY INDICATIONS FOR
ENTEROCYSTOPLASTY IN ADULTS
Darshan Patel*, James Hotaling, William
Brant, Jeremy Myers, Salt Lake City, UT
11:50
PD11-09 LONG-TERM FUNCTIONAL OUTCOMES OF
AUGMENTATION CYSTOPLASTY IN
ADULT SPINA BIFIDA PATIENTS: A
SINGLE-CENTER EXPERIENCE IN A
MULTIDISCIPLINARY TEAM
Priscilla Léon*, Emmanuel Chartier-Kastler,
Morgan Rouprêt, Paris, France, Pierre Denys,
Garches, France, Gilberte Robain, Pierre
Montgiat-Artus, Véronique Phé, Paris, France
12:00
PD11-10 AUGMENTATION ENTEROCYSTOPLASTY
WITH CONTINENT ILEAL CONDUIT.
SURGICAL TECHNIQUE AND OUTCOMES
Matias I Gonzalez, Gabriel A Favre, Maria E
Zubieta*, Lucas Britez, Oscar H Damia, Juan
C Tejerizo, Buenos Aires, Argentina
12:10
PD11-11 PSYCHOLOGICAL AND SEXUOLOGICAL
ASPECTS IN YOUNG ADULTS WITH
EXSTROPHY-EPISPADIAS COMPLEX:
SIMILARITIES AND DIFFERENCES
BETWEEN MALE AND FEMALE
Massimo Di Grazia*, Sandra Pellizzoni,
Michele Rizzo, Paolo Umari, Giovanni
Chiriacò, Carlo Trombetta, Waifro Rigamonti,
Trieste, Italy
12:20
PD11-12 URINARY TRACT INFECTION AFTER
URINARY DIVERSION – DIFFERENT
PATTERNS OF OCCURRENCE IN
PATIENTS WITH ILEAL CONDUIT AND
ORTHOTOPIC NEOBLADDER
Roy Mano*, Hanan Goldberg, Yariv Stabholz,
Danny Hazan, Daniel Kedar, Jack Baniel,
Ofer Yossepowitch, Petach Tikva, Israel
CREDITTM
*Presenting author
81
SATURDAY
URINARY DIVERSION: BLADDER RECONSTRUCTION, AUGMENTATION, SUBSTITUTION, DIVERSION II
Moderator: Richard Hautmann
10:30 am - 12:30 pm
Podium Session 12
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, COST EFFECTIVENESS II
Moderators: Christopher Saigal and Ted Skolarus
ABSTRACT
TIME NUMBER TITLE
10:30 PD12-01 COST-EFFECTIVENESS OF MRI
TARGETED BIOPSY OF THE PROSTATE
yannick Cerantola, Alice Dragomir*, Simon
Tanguay, Franck Bladou, Armen Aprikian,
Wassim Kassouf, Montreal, Canada
10:40
PD12-02 UTILIZATION AND OUTCOMES OF
REPEAT PROSTATE BIOPSY IN A
STATEWIDE QUALITY IMPROVEMENT
COLLABORATIVE
Dinesh Telang*, Roseville, MI, Alice Liu,
Yuqing Gao, Susan Linsell, Ann Arbor, MI,
Frank Burks, Royal Oak, MI, James Montie,
David Miller, Khurshid Ghani, Ann Arbor, MI
10:50
PD12-03 IMPACT OF ADHERENCE TO QUALITY
MEASURES FOR LOCALIZED PROSTATE
CANCER ON HEALTH-RELATED QUALITY
OF LIFE OUTCOMES
William Sohn*, Sharon Phillips, Brock O’neil,
Matthew Resnick, Tatsuki Koyama, David
Penson, Daniel Barocas, CEASAR
Investigators, Nashville, TN
11:00
PD12-04 TRENDS IN UTILIZATION OF PRIMARY
ANDROGEN DEPRIVATION THERAPY FOR
Mohammed Haseebuddin*, Elizabeth
Handorf, Yu-Ning Wong, Philadelphia, PA,
Simon Kim, Cleveland, OH, Nikhil
Wainganker, Alexander Kutikov, Justin
Bekelman, Robert Uzzo, Marc Smaldone,
Philadelphia, PA
11:10
11:20
ABSTRACT
TIME NUMBER TITLE
11:30 PD12-07 DECLINE IN THE USE OF RADIATION FOR
STAGE I SEMINOMA: ANALYSIS OF THE
NATIONAL CANCER DATABASE
Nikhil Waingankar*, Elizabeth Handorf, Marc
Smaldone, Elizabeth Plimack, Yu-Ning Wong,
Mohammed Haseebuddin, Eric Horwitz,
Robert Uzzo, Alexander Kutikov,
Philadelphia, PA
PD12-05 DEFINING THE EXTENT AND NATURE OF
OVERTREATMENT OF PROSTATE
CANCER IN OLDER MEN
Daniel Frendl*, Jennifer Yates, Mara Epstein,
Robert Blute, Jr, Mitchell Sokoloff, John
Ware, Jr, Worcester, MA
PD12-06 INCREASED PAYMENT FOR OFFICEBASED MANAGEMENT OF BLADDER
CANCER: UNINTENDED CONSEQUENCES
IN A FEE-FOR-SERVICE ENVIRONMENT
Brock O’Neil*, Amy Graves, Daniel Barocas,
William Sohn, Sam Chang, David Penson,
Matthew Resnick, Nashville, TN
11:40
PD12-08 LIFE EXPECTANCY AND VARIATION IN
TREATMENT FOR EARLY-STAGE KIDNEY
CANCER
Timothy Daskivich*, Hung-Jui Tan, Mark
Litwin, Jim Hu, Los Angeles, CA
11:50
PD12-09 EFFICIENCY AND SATISFACTION OF
VIDEO-VISITS IS EQUIVALENT TO AN
OFFICE VISIT: A PROSPECTIVE
RANDOMIZED CONTROLLED STUDY IN
UROLOGY
Boyd Viers*, Marcelino Rivera, Igor Frank,
Matthew Tollefson, R. Houston Thompson, R.
Jeffrey Karnes, Stephen Boorjian, Daniel
O’Neil, Matthew Gardner, Sarah Jenkins,
Deborah Lightner, Matthew Gettman,
Rochester, MN
12:00
PD12-10 RACIAL DISPARITIES IN PAIN
MEDICATION FOR STONES: RESULTS OF
A NATIONWIDE HOSPITAL DATABASE
ANALYSIS
Courtney K. Rowe*, Deborah S. Hess, James
S. Hwong, Francisco J. GelpiHammerschmidt, Boston, MA, Benjamin I.
Chung, Palo Alto, CA, Steven L. Chang,
Boston, MA
12:10
PD12-11 SURGEON VARIATION IN SURGICAL
CASE COSTS
Lindsay Hampson*, Anobel Odisho, Peter
Carroll, Maxwell Meng, San Francisco, CA
12:20
PD12-12 30-YEAR NEW YORK STATE INPATIENT
UROLOGY PRACTICE TRENDS
Mark Finkelstein*, Khawaja H Bilal, Rajiv
Jayadevan, New York City, NY, Kristian
Stensland, Burlington, MA, Michael Palese,
New York City, NY
CREDITTM
82
10:30 am - 12:30 pm
Podium Session 13
ABSTRACT
TIME NUMBER TITLE
10:30 PD13-01 DUSTING VS BASKETING DURING
URETEROSCOPIC LITHOTRIPSY—WHAT
IS MORE EFFICACIOUS? INTERIM
ANALYSIS FROM A MULTI-CENTRE
PROSPECTIVE TRIAL FROM THE EDGE
RESEARCH CONSORTIUM
Ben H. Chew, Vancouver, Canada, Ojas
Shah, New York City, NY, Roger L. Sur, San
Diego, CA, Bodo E. Knudsen, Columbus, OH,
Brian R. Matlaga, Baltimore, MD, Amy E.
Krambeck, Rochester, MN, Nicole L. Miller,
Nashville, TN, Manoj Monga, Cleveland, OH,
Mitchell R. Humphreys*, Phoenix, AZ
10:40
PD13-02 CAN LOW-DOSAGE, DIGITAL X-RAY
SCANNING (LODOX) REPLACE
COMPUTED TOMOGRAPHY (CT) AND
CONVENTIONAL RADIOGRAPHY (CR) IN
THE DIAGNOSTICS OF URETERAL
STONES?
Beat Roth*, Stefanie Hnilicka, Susan D.
Meierhans Ruf, Andreas Christe, George N.
Thalmann, Bern, Switzerland
10:50
PD13-03 ROBOTIC ANATROPHIC
NEPHROLITHOTOMY: IDEA,
DEVELOPMENT, EXPLORATION,
ASSESSMENT AND LONG-TERM
MONITORING (IDEAL) PHASE 0 STUDY
Akshay Sood*, Detroit, MI, Jay Rohde,
Michael Van Winkle, Atlanta, GA, Dean
Assimos, Birmingham, AL, Ashok Hemal,
Salem, NC, James Peabody, Mani Menon,
Detroit, MI, Khurshid Ghani, Ann Arbor, MI
11:00
11:10
ABSTRACT
TIME NUMBER TITLE
11:20 PD13-06 RETROPERITONEAL LAPAROSCOPIC
TECHNIQUE IN TREATMENT OF
COMPLEX RENAL STONES: 104 CASES
Qiang Lu*, Pengchao Li, Jun Tao, Chao Qin,
Changjun Yin, Nanjing, China, People’s
Republic of
PD13-04 COMPARISON OF FLOW
CHARACTERISTICS OF NOVEL THREEDIMENSIONALLY PRINTED URETERAL
STENTS VS. STANDARD URETERAL
STENTS IN A PORCINE MODEL
Zhamshid Okhunov*, Michael Del Junco,
Renai Yoon, Garen Abedi, Christopher
Pulford, Christina Hwang, Jaime Landman,
Orange, CA
PD13-05 PRESTENTING IN URETERORENOSCOPY:
MULTICENTER EVALUATION BY THE
INTERNATIONAL COLLABORATION IN
ENDOUROLOGY (UROICE)
Jan Jessen*, Sindelfingen, Germany, Alberto
Breda, Barcelona, Spain, Marianne Brehmer,
Aarhus, Denmark, Evangelos Liatsikos,
Patras, Greece, Felix Millan Rodriguez,
Barcelona, Spain, Palle Osther, Fredericia,
Denmark, Cesare Scoffone, Torino, Italy,
Thomas Knoll, Sindelfingen, Germany
*Presenting author
83
11:30
PD13-07 NATURAL HISTORY, COMPLICATIONS,
AND RE-INTERVENTION RATES OF
ASYMPTOMATIC RESIDUAL STONE
FRAGMENTS POST-URETEROSCOPY: A
REPORT FROM THE EDGE RESEARCH
CONSORTIUM
Ben H. Chew*, Hilary Brotherhood,
Vancouver, Canada, Roger L. Sur, San
Diego, CA, Bodo E. Knudsen, Columbus, OH,
Nicole L. Miller, Nashville, TN, Courtney
Yong, Columbus, OH, Tracy Marien,
Nashville, TN, An-Qi Wang, San Diego, CA,
Cameron Charchenko, Rochester, MN,
Mitchell R. Humphreys, Phoenix, AZ, Amy E.
Krambeck, Rochester, MN
11:40
PD13-08 CHANGING PATIENT POSITION CAN
ELIMINATE ARRHYTHMIAS DEVELOPING
DURING SHOCK WAVE LITHOTRIPSY (SWL)
Tarek Alzahrani*, Daniela Ghiculete, Kenneth
Pace, R.J. D’A. Honey, Toronto, Canada
11:50
PD13-09 MICRO VERSUS MINI PERCUTANEOUS
NEPHROLITHOTOMY FOR THE TREATMENT
OF PEDIATRIC KIDNEY STONE DISEASE
Tuna Karatag, Konya, Turkey, Abdulkadir
Tepeler, Mesrur Selcuk Silay, Istanbul,
Turkey, Mehmet Nuri Bodakci, Diyarbakir,
Turkey, Ibrahim Buldu, Mansur Daggulli,
Namik Kemal Hatipoglu, Mustafa Okan
Istanbulluoglu*, Abdullah Armagan, Konya,
Turkey
12:00
PD13-10 UPPER CALYX APPROACHABILITY USING
RIGID NEPHROSCOPES THROUGH A
LOWER CALYX ACCESS: COMPARISON
BETWEEN PRONE AND SUPINE PCNL
AND ASSESSMENT OF ANATOMICAL
FACTORS THAT MAY INFLUENCE THIS
APPROACH AS MEASURED BY
MULTIDETECTOR CT WITH 3D
RECONSTRUCTIONS
Mario Sofer*, Tel Aviv, Israel, Silvia Proietti,
Rozano (MI), Italy, Maharan Kabha, Tel Aviv,
Israel, Guido Giusti, Rozano (MI), Italy, Haim
Matzkin, Galit Aviram, Tel Aviv, Israel
SATURDAY
STONE DISEASE: SURGICAL THERAPY I
Moderators: David Duchene and Ali Riza Kural
12:10
12:20
PD13-11 A MULTICENTER EVALUATION OF ZEROFRAGMENT NEPHROLITHOTOMY:
ROBOTIC PYELOLITHOTOMY AND
NEPHROLITHOTOMY FOR TREATING
RENAL STONES
Ryan Swearingen*, Ann Arbor, MI, Rabii
Madi, Zachary Klaassen, Augusta, GA, Ketan
Badani, New York, NY, Akshay Sood, Jack
Elder, Detroit, MI, Kyle Wood, Ashok Hemal,
Winston-Salem, NC, Khurshid Ghani, Ann
Arbor, MI
PD13-12 USING AN ELECTRONIC MEDICAL
RECORD TO ASSESS PATIENTREPORTED MORBIDITY AFTER
URETEROSCOPY
Monica S.C. Morgan*, Jodi A. Antonelli,
Nicholas Kavoussi, Niccolo M. Passoni,
Adam Cohen, Margaret S. Pearle, Dallas, TX
CREDITTM
12:30 pm - 4:30 pm
THE SOCIETY OF URODYNAMICS, FEMALE PELVIC MEDICINE AND UROGENITAL RECONSTRUCTION (SUFU)
12:30
WELCOME AND INTRODUCTION
Program Chair: Alexander Gomelsky
3:00
BIOLOGICS IN POP SURGERY
Una Lee
12:40
PREOP WORK-UP OF POP
Moderator: Tracey Wilson
Panelists: Anne Pelletier Cameron, Priya
Padmanabhan, Christopher Wolter
3:15
ROLE OF UTERUS SPARING SURGERY
Nirit Rosenblum
3:30
Q&A
1:05
Q&A
3:40
1:15
NON-SURGICAL TREATMENT OF POP
(OBSERVATION, PESSARY, BIOFEEDBACK)
Harriette Scarpero, Ariana Smith, Joanna Togami
INCONTINENCE PROCEDURE DURING POP
REPAIR
Moderator: Donna Deng
Panelists: Jason Gilleran, Elizabeth Mueller
4:05
Q&A
1:45
Q&A
4:10
1:55
SURGERY OF THE APEX (TRANSVAGINAL
REPAIR, OPEN/ROBOTIC SACRAL
COLPOPEXY, COLPOCLEISIS)
Sandip Vasavada, Jennifer Anger, J. Christian
Winters
STATUS OF MESH IN 2015
Victor Nitti
4:25
Q&A
4:30
ADJOURN
2:35
Q&A
2:45
BREAK
CREDITTM
12:30 pm - 5:00 pm
SOCIETY OF UROLOGIC ONCOLOGY (SUO)
12:30
David Jarrard
12:40
WHITMORE LECTURE – THE EMPEROR’S NEW
CLOTHES: BIAS IN UROLOGIC SCIENCE
Introduction: J. Brantley Thrasher
Speaker: Ian Thompson
1:00
EVALUATING THE RISK OF LOCALLY
ADVANCED AND MICROMETASTATIC
BLADDER CANCER PRIOR TO CYSTECTOMY
Moderator: Tracy Downs
ROLE CONTEMPORARY PRE-CYSTECTOMY
NOMOGRAMS AT PREDICTING LOCALLY
ADVANCED AND METASTATIC UROTHELIAL
BLADDER CANCER
Wes Kassouf
84
1:10
PATHOLOGIC ASSESSMENT AT THE TIME OF
TURBT: CAN YOUR INITIAL PATHOLOGY
REPORT BE TRUSTED WHEN MAKING
TREATMENT DECISIONS
Donna Hansel
1:20
OPPORTUNITIES IN PET AND PET/MRI FOR
BLADDER CANCER
Steven Cho
1:30
LIQUID BIOPSY: CIRCULATING TUMOR CELLS
AS BIOMAKERS FOR ADVANCED
Trinity Bivalacqua
1:40
CASE DISCUSSION: ASSESSING THE HIGH
RISK PATIENT
Moderator: Tracy Downs
Speakers: Wes Kassouf, Urs Studer, Trinity
Bivalacqua, Donna Hansel
PERSONALIZED MEDICINE APPROACH TO
THE TREATMENT OF ADVANCED PROSTATE
CANCER
APPLICATION OF PERSONALIZED MEDICINE
TO PROSTATE CANCER
Ganesh Palapattu
3:40
DEBATE: NEOADJUVANT VS. ADJUVANT
SYSTEMIC CHEMOTHERAPY FOR PENILE
CANCER PATIENTS WITH BULKY INGUINAL
ADENOPATHY (CN2/3) IN THE ABSENCE OF
OCCULT SITES OF METASTASES)
Debaters: Lance Pagliaro, Mayer Fishman
3:55
QUESTIONS AND DISCUSSION
4:00
ENHANCING POST-OPERATIVE RECOVERY
AFTER CYSTECTOMY FOR BLADDER CANCER
Moderator: Badrinath Konety
2:00
WHAT GENOMIC RESEARCH TELLS US
ABOUT TREATING PROSTATE CANCER
James Brooks
2:10
AR SPLICE VARIANTS AS PREDICTION TOOLS
IN ADVANCED PROSTATE CANCER
Emmanuel Antonarakis
2:20
PROSTATE CANCER BIOMARKERS FOR
TAILORED THERAPY: VALUE ADDED OR
ONLY COST
David Jarrard
4:10
PATTERNS OF TOBACCO USE AND
OUTCOMES FROM BLADDER CANCER POLICY IMPLICATIONS
John Gore
2:30
THE CHANGING FACE OF PROSTATE CANCER
TREATMENT: ADT AND EARLY
CHEMOTHERAPY
Christopher Sweeney
4:20
2:40
PANEL DISCUSSION: ARE WE READY FOR
MOLECULAR CLASSIFICATION OF ALL
TUMORS PRIOR TO TREATMENT?
Panelists: Christopher Sweeney, David Jarrard,
James Brooks, Emmanuel Antonarakis
GUIDELINES FOR PERIOPERATIVE CARE
AFTER RADICAL CYSTECTOMY FOR
BLADDER CANCER: ENHANCED RECOVERY
AFTER SURGERY (ERAS) SOCIETY
RECOMMENDATIONS
Jay Shah
4:30
INTRA-OPERATIVE TECHNIQUES TO
ENHANCE POST-OPERATIVE OUTCOMES
George Thalmann
4:40
PREVENTING READMISSIONS FOLLOWING
CYSTECTOMY
Ted Skolarus
4:50
QUESTIONS
5:00
ADJOURN
2:55
BREAK
3:10
PENILE CANCER: NEW APPROACHES AND
GUIDELINES
Moderator: Philippe Spiess
QUITTING THE RIGHT WAY: EVIDENCE
BASED TOBACCO USE PREVENTION
Dorothy Hatsukami
UPDATED NCCN GUIDELINES ON PENILE
CANCER AND TRIALS
Moderator: Philippe Spiess
3:20
PRIMARY PENILE SPARING TREATMENT
APPROACHES
Adam Feldman
3:30
MANAGEMENT OF INGUINAL LYMPH NODES
IN PATIENTS WITH HIGH-RISK PRIMARY
PENILE TUMORS AND NO PALPABLE
ADENOPATHY OR NON-BULKY LYMPH NODES
Viraj Master
CREDITTM
1:00 pm - 3:00 pm
BANGLADESH ASSOCIATION OF UROLOGICAL SURGEONS (BAUS)
1:35
MINI PERC OUR EXPERIENCE / OUR
EXPERIENCE IN BANGLADESH
Tohid Mohammad Saiful Hossain
1:42
SESSION 2: UROONCOLOGY
FLEXIBLE URETEROSCOPY: TECHNIQUE AND
TRICKS OF THE TRADE
John Denstedt
1:42
SURGERY FOR MUSCLE INVASIVE BLADDER
CANCER
Mohammad Hooda
OPTIMIZING THE OUTCOME OF RENAL
TRANSPLANT IN BANGLADESH
AKM Anwarul Islam
1:49
LAPAROSCOPIC NEPHRECTOMY
EXPERIENCE IN BANGLADESH
S A Khan
1:00
WELCOME ADDRESS
Society President: M A Salam
1:03
SESSION 1: URINARY STONE DISEASE &
RENAL TRANSPLANT
1:28
*Presenting author
85
SATURDAY
1:50
1:56
SESSION 3: PEDIATRIC & RECONSTRUCTIVE
UROLOGY
MANAGEMENT OF POSTERIOR URETHRAL
VALVE
Lane Palmer
2:16
MANAGEMENT OF GENITOURINARY FISTULA
M W Islam
2:23
LONG-TERM RESULT OF SUBSTITUTION
URETHROPLASTY
C Dixon
2:48
MANAGEMENT OF COMPLEX URETHRAL
STRICTURE
F Islam
2:55
DISCUSSION & CLOSING REMARKS
3:00
ADJOURN
1:00 pm - 3:00 pm
TECHNOLOGY & INSTRUMENTS: SURGICAL EDUCATION & SKILLS ASSESSMENT II
Moderators: Robert Sweet and Tadashi Matsuda
ABSTRACT
NUMBER TITLE
MP23-01 USING ANDROID SMARTPHONES TO
TAKE CYSTOSCOPIC AND
URETEROSOPIC IMAGES FOR EXCLUSIVE
ONLINE INTERNET REFERRALS
Ernesto III Arada*, Luis Florencio, Michael
Macalalag, Frederick Mendiola, Jun Dy,
Ceasar Ballesteros, Jeremiah Mangahas,
Quezon City, Philippines
ABSTRACT
NUMBER TITLE
MP23-05 IS THERE A CORRELATION BETWEEN
TECHNICAL SKILLS AND NONTECHNICAL SKILLS PERFORMANCE
WITHIN URETEROSCOPY?
Oliver Brunckhorst*, Shahab Shahid,
Abdullatif Aydin, London, United Kingdom,
Craig McIlhenny, Larbet, United Kingdom,
Shahid Khan, Redhill, United Kingdom, Arun
Sahai, James Brewin, Fernando Bello, Roger
Kneebone, Muhammad Khan, Prokar
Dasgupta, Kamran Ahmed, London, United
Kingdom
MP23-02 DEVELOPMENT AND CONTENT
VALIDATION OF A SAFETY CHECKLIST
FOR ROBOT-ASSISTED RADICAL
PROSTATECTOMY
Catherine Lovegrove*, London, United
Kingdom, Giacomo Novara, Padua, Italy,
Khurshid Guru, Buffalo, NY, Alex Mottrie,
Aalst, Italy, Ben Challacombe, London,
United Kingdom, Johar Raza, Buffalo, NY,
Henk Van der Poel, Amsterdam, Netherlands,
James Peabody, Detroit, MI, Rick Popert,
Prokar Dasgupta, Kamran Ahmed, London,
United Kingdom
MP23-06 BATTLE OF THE BOTS: A COMPARISON
OF THE STANDARD DA VINCI AND THE
DA VINCI SURGICAL SKILLS SIMULATOR
IN SURGICAL SKILLS ACQUISITION
Kevin Brown, Natalie Mosley*, Elise Drake,
Asmita Modak, Marian Campbell, James
Tierney, Charleston, WV
MP23-07 VASECTOMY SIMULATION MODULE:
DIDACTIC, AUDIO-VISUAL, AND LIVESIMULATION EXPERIENCE
Ram Pathak*, Scott Alford, Todd Igel,
Jacksonville, FL
MP23-03 NEW INSIGHTS INTO THE PERFORMANCE
OF JUNIOR AND SENIOR RESIDENTS ON
BASIC UROLOGICAL PROCEDURES
Anna Helena de Vries*, Eindhoven,
Netherlands, Maaike Boute, Hoorn,
Netherlands, Malou Kuppen, Eindhoven,
Netherlands, Jeroen van Merriënboer,
Maastricht, Netherlands, Evert Koldewijn,
Eindhoven, Netherlands, Rob Pelger, Leiden,
Netherlands, Barbara Schout, Alkmaar,
Netherlands, Cordula Wagner, Amsterdam,
Netherlands
MP23-08 INITIAL VALIDATION DURING
DEVELOPMENT OF LOW COST
ALTERNATIVE TO THE DV-TRAINER
USING THE HYDRA SYSTEM
Swar Shah*, Eric Hwang, Inderbir Gill,
Andrew Hung, Los Angeles, CA
MP23-09 A NOVEL TECHNIQUE FOR SIMULATED
SURGICAL PROCEDURES USING 3D
PRINTING TECHNOLOGY
Jonathan Stone*, Braden Candela, Vincent
Alleluia, Anees Fazili, Michael Richards,
Changyong Feng, Sarah Peyre, Jean Joseph,
Ahmed Ghazi, Rochester, NY
MP23-04 VALIDATION OF A NOVEL ROBOTIC
SKILLS LAB URETHROVESICAL
ANASTOMOSIS SIMULATOR
Daniel Parisi*, Gregory Murphy, Joseph
Wagner, Steven Shichman, Ryan Dorin,
Hartford, CT
86
MP23-16 THE ROLE OF HUMAN CADAVERIC
PROCEDURAL SIMULATION IN UROLOGY
TRAINING
Abdullatif Aydin*, Kamran Ahmed,
Muhammad Shamim Khan, Prokar Dasgupta,
London, United Kingdom, John McCabe,
Merseyside, United Kingdom
MP23-11 AUGMENTED REALITY ASSISTED
UROLOGIC SURGERY (ARAUS): A
SURGICAL TRAINING TOOL
Tariq Hakky*, Houston, TX, Daniel, R.
Martinez, Tampa, FL, Larry, I. Lipshultz,
Houston, TX, Philippe, E. Spiess, Rafael, E.
Carrion, Tampa, FL
MP23-17 LACK OF AN EXPERIENCED BEDSIDE
ASSISTANT MAY ADVERSELY AFFECT
OUTCOMES DURING ROBOTIC
PROSTATECTOMY
Ilana Jacobs*, Aaron Lay, Jeffrey Gahan,
Dallas, TX
MP23-18 FACE AND CONTENT VALIDATION OF A
VASECTOMY SIMULATOR
Sangtae Park*, Natalie Fahey, Alex Wind,
Omar Farhat, Evanston, IL
MP23-12 ACCELERATED SKILLS ACQUISITION
PROTOCOL (ASAP): AN EFFECTIVE TIMEEFFICIENT APPROACH TO VIRTUAL
REALITY BASIC TASK SIMULATION
TRAINING
Ahmed Ghazi*, Aisha Siebert, Changyong
feng, Sarah Peyre, Rochester, NY
MP23-19 THE SIMPORTAL FLUORO-LESS C-ARM
TRAINER (CAT): PRELIMINARY TRAINING
RESULTS
Domenico Veneziano*, Minneapolis, MN,
Arthur Smith, New York, NY, David Hananel,
Troy Reihsen, Jack Stubbs, Jason Speich,
Robert Sweet, Minneapolis, MN
MP23-13 MEDICAL STUDENT DELIBERATE
PRACTICE ON A VIRTUAL-REALITY
CURRICULUM CAN ACHIEVE
EQUIVALENCY TO SENIOR UROLOGY
RESIDENT REAL-TIME TRAINING
Ahmed Ghazi*, Aisha Siebert, Anees Fazili,
Vineet Agrawal, Changyong feng, Sarah
Peyre, Rochester, NY
MP23-20 LIVE SURGICAL DEMONSTRATIONS IN
UROLOGY: A SYSTEMATIC REVIEW
Oliver Brunckhorst*, Ben Challacombe,
Hamid Abboudi, Muhammad Khan, Prokar
Dasgupta, Kamran Ahmed, London, United
Kingdom
MP23-14 WORKPLACE DANGERS AND SAFETY
FOR THE UROLOGIST
Kelly A. Healy*, Demetrius H. Bagley,
Philadelphia, PA
CREDITTM
MP23-15 COMPARATIVE EVALUATION OF 2D AND
NOVEL 3D ROBOTIC SURGERY
MENTORING TOOLS
Swar Shah*, Los Angeles, CA, Anthony Jarc,
Sunnyvale, CA, Eric Hwang, Los Angeles,
CA, Joey Chau, Sunnyvale, CA, JeanChristophe Bernhard, Inderbir Gill, Monish
Aron, Andrew Hung, Los Angeles, CA
1:00 pm - 3:00 pm
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, COST EFFECTIVENESS III
Moderators: Mark Litwin and Bruce Jacobs
ABSTRACT
NUMBER TITLE
MP24-01 SECOND PRIMARY MALIGNANCIES: AN
ANALYSIS OF SEER DATA
Christopher Filson*, Alex Castillo, Lorna
Kwan, Mark Litwin, Karim Chamie, Los
Angeles, CA
ABSTRACT
NUMBER TITLE
MP24-03 RECEIPT OF INGUINAL LYMPH NODE
DISSECTION IN PATIENTS WITH T2
PENILE CANCER: RESULTS FROM THE
Mohammed Haseebuddin*, Elizabeth
Handorf, Nikhil Wainganker, Rosalia Viterbo,
Richard Greenberg, Robert Uzzo, Alexander
Kutikov, Marc Smaldone, David Chen,
Philadelphia, PA
MP24-02 GEOGRAPHIC VARIATION OF PROSTATE
CANCER INCIDENCE RATE: AN
ECOLOGICAL STUDY
Matthew Lyons*, Tzy-Mey Kuo, Anne-Marie
Meyer, E.Sophie Spencer, Peter Greene,
Angela Smith, Michael Woods, Eric Wallen,
Raj Pruthi, Matthew Nielsen, Chapel Hill, NC
*Presenting author
87
SATURDAY
MP23-10 CURRENT OPINIONS OF PROGRAM
DIRECTORS ON THE ROLE OF
SIMULATION IN UROLOGICAL
RESIDENCY TRAINING
Ehab Eltahawy, Renee Powell*, Carol
Thrush, Katherine Berry, Evan Lacefield,
Mohamed Kamel, Little Rock, AR
MP24-11 TESTOSTERONE REPLACEMENT
THERAPY USE AMONG YOUNG
PRIVATELY INSURED U.S. MEN, 20032012
Pravin Rao*, Baltimore, MD, Sheree Boulet,
Akanksha Mehta, Atlanta, GA, James
Hotaling, Salt Lake City, UT, Michael
Eisenberg, Palo Alto, CA, Stanton Honig,
New Haven, CT, Lee Warner, Dmitry Kissin,
Atlanta, GA, Ajay Nangia, Kansas City, KS,
Lawrence Ross, Chicago, IL
MP24-04 USE OF RPLND IN TESTICULAR CANCER
IN THE UNITED STATES: RESULTS FROM
THE NATIONAL CANCER DATA BASE
(1998-2011)
Brian Hu*, Los Angeles, CA, Claudio Jeldres,
Katherine Odem-Davis, Seattle, WA, Claire
Sadler, Los Angeles, CA, Craig Nichols,
Christopher Porter, Seattle, WA, Siamak
Daneshmand, Los Angeles, CA
MP24-05 TREATMENT DELAYS IN THE
MANAGEMENT OF MUSCLE INVASIVE
BLADDER CANCER: ANALYSIS OF THE
Nikhil Waingankar*, Thomas Churilla,
Elizabeth Handorf, Mohammed Haseebuddin,
Philadelphia, PA, Jeffrey Tomaszewski,
Camden, NJ, Daniel Canter, Alexander
Kutikov, Eric Horwitz, Richard Greenberg,
David Chen, Rosalia Viterbo, Robert Uzzo,
Marc Smaldone, Philadelphia, PA
MP24-12 MULTILEVEL PREDICTORS OF BPH
MEDICATION INITIATION IN PRIMARY
CARE AND UROLOGY
Seth A. Strope*, Saint Louis, MO, Adriennne
Kuxhausen, Joel Vetter, Jeff Gill, St. Louis,
MO
MP24-13 PATTERNS OF NON-SURGICAL
MANAGEMENT OF BENIGN PROSTATIC
HYPERPLASIA (BPH) IN THE UNITED
STATES
Jennifer T. Anger*, Beverly Hills, CA, Howard
B. Goldman, Cleveland, OH, Kelly H. Zou,
Xuemei Luo, David J. Russell, Doug
Chapman, Canan Esinduy, New York, NY, J
Quentin Clemens, Ann Arbor, MI
MP24-06 THE IMPACT OF INSURANCE STATUS ON
TUMOR CHARACTERISTICS AND
TREATMENT SELECTION IN
CONTEMPORARY PROSTATE CANCER
PATIENTS
Nicola Fossati, New York, NY, Daniel P.
Nguyen*, New York, Italy, Quoc-Dien Trinh,
Boston, MA, Jesse Sammon, Akshay Sood,
Detroit, MI, Alessandro Larcher, Giorgio
Guazzoni, Milan, Italy, Pierre I Karakiewicz,
Montreal, Canada, Shahrokh F. Shariat,
Vienna, Austria, Francesco Montorsi, Alberto
Briganti, Milan, Italy, Mani Menon, Firas
Abdollah, Detroit, MI
MP24-14 DIFFERENCES IN TREATMENT OF
BENIGN PROSTATIC HYPERPLASIA BY
THE UROLOGIST AND PRIMARY-CARE
PHYSICIAN
Adam Rensing*, Adrienne Kuxhausen, Joel
Vetter, Seth Strope, Saint Louis, MO
MP24-15 PREOPERATIVE TESTING FOR STRESS
URINARY INCONTINENCE AND
PROLAPSE SURGERY: OVERUSE,
UNDERUSE, AND COST IMPLICATIONS
Tom Feng*, Colby Perkins, Lauren Wood,
Jerome Wang, Jenna Borok, Alex
Hannemann, Catherine Bresee, Los Angeles,
CA, Karyn Eilber, Los Angeles, MS, Jennifer
Anger, Los Angeles, CA
MP24-07 TIME TRENDS IN THE USE OF
SECONDARY TREATMENTS FOR
Daniel Moreira*, Boris Gershman, Stephen
Boorjian, R. Houston Thompson, Igor Frank,
Matthew Tollefson, Matthew Gettman, Eric
Bergstralh, R. Jeffrey Karnes, Rochester, MN
MP24-16 VARIABILITY IN MEDICARE UTILIZATION
AND PAYMENT AMONG UROLOGISTS
Joan Ko*, Heather Chalfin, Bruce Trock,
Zhaoyong Feng, Elizabeth Humphreys, SungWoo Park, H. Ballentine Carter, Kevin Frick,
Misop Han, Baltimore, MD
MP24-08 SURGEON VARIATION IN THE COST OF
LAPAROSCOPIC NEPHRECTOMY
Lindsay Hampson*, Anobel Odisho, Peter
Carroll, Maxwell Meng, San Francisco, CA
MP24-09 INSURANCE COVERAGE AND
DISPARITIES IN KIDNEY CANCER CARE:
IMPLICATIONS FOR THE AFFORDABLE
CARE ACT
Hung-Jui Tan*, Ryan J. Chuang, Aaron A.
Laviana, Jim C. Hu, Los Angeles, CA
MP24-17 PHYSICIAN-OWNED AMBULATORY
SURGERY CENTERS AND UTILIZATION
OF DISCRETIONARY UROLOGICAL
PROCEDURES
Chandy Ellimoottil*, Rodney Dunn, Brent
Hollenbeck, Ann Arbor, MI
MP24-10 DECLINING USE OF URINARY HERBAL
AND VITAMIN SUPPLEMENTS AMONG
U.S. MEN IN LONGITUDINAL NATIONAL
PROSTATE CANCER SCREENING
COHORTS
Michael Leapman*, San Francisco, CA, David
Crawford, Wendy Poage, Aurora, CO, Nelson
Stone, New York, NY
MP24-18 THE IMPACT OF READMISSIONS TO
SECONDARY HOSPITALS ON FAILURETO-RESCUE RATES FOLLOWING MAJOR
UROLOGIC CANCER SURGERY
Jasmir Nayak*, Sarah Holt, Jonathan Wright,
Atreya Dash, John Gore, Seattle, WA
88
CREDITTM
1:00 pm - 3:00 pm
INFECTIONS/INFLAMMATION OF THE GENITOURINARY TRACT: PROSTATE & GENITALIA
Moderators: Michel Pontari and Jordan Dimitrakoff
ABSTRACT
NUMBER TITLE
MP25-01 RELATIONSHIP BETWEEN
TESTOSTERONE AND PROSTATITIS-LIKE
SYMPTOMS ASSESSED BY THE
NATIONAL INSTITUTES OF HEALTH
CHRONIC PROSTATITIS SYMPTOM INDEX
Gyeong Eun Min*, Jun Ho Lee, Koo Han
Yoo, Dong-Gi Lee, Hyung-Lae Lee, Seoul,
Korea, Republic of
ABSTRACT
NUMBER TITLE
MP25-06 MODELS OF LOWER URINARY TRACT
SYMPTOMS IN THE PRESENCE AND
ABSENCE OF PAIN
Daniel J. Mazur*, Anthony J. Schaeffer,
Praveen Thumbikat, Chicago, IL
MP25-07 PROSTATIC INFLAMMATION EVOKES
UPREGULATION OF NEUROTROPHINS IN
SENSORY GANGLIA: POSSIBLE
CONTRIBUTION TO DYSFUNCTIONAL
VOIDING
Pradeep Tyagi*, Mahendra Kashyap, Subrata
Pore, Zhou Wang, Naoki Yoshimura,
Pittsburgh, PA
MP25-02 TESTOSTERONE REPLACEMENT
THERAPY FOR HYPOGONADAL PATIENTS
WITH CHRONIC PROSTATITIS / CHRONIC
PELVIC PAIN SYNDROME
Ran Pang*, Jianxin Lu, Xinyao Zhou,
Xiaosong Gao, Yaqiang Zhang, Beijing,
MP25-08 EVALUATION OF THE UTILITY OF
DIFFERENT SCORING SYSTEMS (FGSI,
LRINEC AND NLR) IN THE MANAGEMENT
OF FOURNIER’S GANGRENE
Ozan Bozkurt, Volkan Sen, Omer Demir, Adil
Esen*, Izmir, Turkey
MP25-03 FOSFOMYCIN FOR ANTIBIOTIC
PROPHYLAXIS PRIOR TO TRANSRECTAL
ULTRASOUND-GUIDED PROSTATE
BIOPSY
Andrew Colhoun*, Jay Sulek, Zachary
McDowell, Michael Climo, B. Mayer Grob,
Richmond, VA
MP25-09 RISK FACTORS FOR SELECTIVE
SCREENING OF MALE GENITAL
CHLAMYDIAL INFECTION
Gilho Lee*, Cheonan, Korea, Republic of,
Duk Kim, Gyeongsan-Si, Korea, Republic of
MP25-04 TRANSUTRICULAR SEMINALVESICULOSCOPY IN THE MANAGEMENT
OF SYMPTOMATIC MIDLINE CYSTS OF
THE PROSTATE
Pil Moon Kang*, Won Ik Seo, Wan Suk Kim,
Jang Ho Yoon, Dong Il Kang, Kweon Sik Min,
Jae Il Chung, Busan, Korea, Republic of
MP25-10 ETIOLOGY OF SYMPTOMATIC
URETHRITIS IN MEN ACCORDING TO
SEXUAL BEHAVIORS
Hari T. Vigneswaran*, Kathleen Hwang,
Joseph F. II Renzulli, Philip A. Chan,
Providence, RI
MP25-05 ENHANCED BLADDER PAIN SENSITIVITY
DUE TO THE PROSTATE-TO-BLADDER
AFFERENT CROSS SENSITIZATION IN A
RAT MODEL OF PROSTATITIS
Tsuyoshi Majima*, Pittsburgh, PA, Yasuhito
Funahashi, Nagoya, Japan, Katsumi
Kadekawa, Pittsburgh, PA, Momokazu Gotoh,
Nagoya, Japan, Naoki Yoshimura, Pittsburgh,
PA
*Presenting author
MP25-11 NEED FOR URETHROPLASTY IS RARE IN
PATIENTS WITH BIOPSY PROVEN LICHEN
SCLEROSUS WHO ARE TREATED WITH
MULTIMODAL THERAPY
Bradley Potts, Michael Belsante*, Ramiro
Madden-Fuentes, John Patrick Selph, Andrew
Peterson, Durham, NC
89
SATURDAY
MP24-20 CAUSES OF HOSPITAL READMISSIONS
AFTER UROLOGIC CANCER SURGERY
Marianne Schmid*, Hamburg, Germany,
Abraham Chiang, Boston, MA, Akshay Sood,
Logan Campbell, Detroit, MI, Felix Chun,
Hamburg, Germany, Deepansh Dalela,
Detroit, MI, James Okwara, Boston, MA,
Jesse Sammon, Detroit, MI, Adam Kibel,
Boston, MA, Mani Menon, Detroit, MI, Margit
Fisch, Hamburg, Germany, Quoc-Dien Trinh,
Boston, MA
MP24-19 PATTERNS OF CARE FOR READMISSION
FOLLOWING RADICAL CYSTECTOMY IN
NEW YORK STATE: DOES THE HOSPITAL
MATTER?
Jamie S Pak*, Danny Lascano, Daniel Kabat,
Julia B Finkelstein, Mark V Silva, G Joel
DeCastro, William Gold, James M McKiernan,
New York, NY
MP25-12 EVALUATION OF PROGNOSTIC FACTORS
AND DEFINITION OF NEW PROGNOSTIC
PARAMETER IN FOURNIER’S GANGRENE
Bulent Erol*, Istanbul, Turkey, Altug Tuncel,
Ankara, Turkey, Adem Tok, Zonguldak,
Turkey, Utku Sari, Istanbul, Turkey, Volkan
Hanci, izmir, Turkey, Furkan Sendogan,
Turhan Caskurlu, Istanbul, Turkey
MP25-17 RAPID QPCR TO IDENTIFY MULTI-DRUG
RESISTANT E. COLI PRIOR TO PROSTATE
BIOPSY
Michael Liss*, San Antonio, TX, Linda Otelly,
San Diego, CA, Veronika Tchesnokova,
Seattle, WA, Kyoko Sakamoto, Joshua Fierer,
San Diego, CA, Evgeni Sokurenko, Seattle,
WA
MP25-13 MICROSURGICAL DENERVATION OF THE
SPERMATIC CORD FOR ORCHIALGIA:
RESULTS AND PHENOTYPIC ANALYSIS
OF TREATMENT FAILURES
Daniel Shoskes*, Scott Polackwich,
Cleveland, OH
MP25-18 UTILITY OF ENEMAS BEFORE
TRANSRECTAL PROSTATE BIOPSIES:
PRELIMINARY REPORT
Jaime O. Herrera-Caceres*, Sergio Del
Moral, Christian Villeda-Sandoval, Benjamin
Montaño, Ricardo A. Castillejos-Molina,
Carlos E. Mendez-Probst, Mexico City,
Mexico
MP25-14 THE TREATMENT OF CHRONIC
ORCHALGIA WITH TMRTM: SUBSTANTIAL
PAIN REDUCTION WITH DURABLE
RESULTS
Daniel H. Shin*, Los Angeles, CA, Aaron
Spitz, Laguna Hills, CA
MP25-19 EFFICACY OF RECTAL POVIDONE-IODINE
SWABS IN DECREASING INFECTIOUS
COMPLICATIONS AFTER TRANSRECTAL
PROSTATE BIOPSY
Jennifer J Ahn*, Jason P Van Batavia,
Mitchell C Benson, New York, NY
MP25-15 IMPACT OF ROUTINE SCREENING FOR
FLUOROQUINOLINE RESISTANT ENTERIC
BACTERIA ON INCIDENCE OF POST
TRANSRECTAL PROSTATE BIOPSY
SEPSIS
John Farrell, Jennifer Hicks*, Stephanie
Wallace, Peoria, IL, Allen Seftel, Camden,
NJ, Thomas Rashid, Peoria, IL
MP25-20 A PERI-PROCEDURAL POVIDONE IODINE
RECTAL PREPARATION DECREASES
BACTERIURIA AND BACTEREMIA
FOLLOWING PROSTATE NEEDLE BIOPSY
Jay D. Raman*, Kathleen Lehman, Chris
Rjepaj, Hershey, PA, Kalyan Dewan, Girish
Kirimanjeswara, University Park, PA
MP25-16 IMPACT OF RECTAL SWABS ON
INFECTIOUS COMPLICATIONS AFTER
TRANSRECTAL PROSTATE BIOPSY
Carlos Gustavo Trujillo*, Mauricio Plata, Juan
Ignacio Caicedo, Juan Guillermo Cataño,
Diana Castelblanco, Angela Marcela Mariño,
Bogotá, Colombia
CREDITTM
1:00 pm - 3:00 pm
BLADDER CANCER: NON-INVASIVE I
Moderators: Stanley Malkowicz and Matthew Tollefson
ABSTRACT
NUMBER TITLE
MP26-01 A PHASE II RANDOMIZED, PRESURGICAL
PLACEBO-CONTROLLED TRIAL OF
POLYPHENON E IN BLADDER CANCER
PATIENTS TO EVALUATE BLADDER
TISSUE LEVELS OF EGCG AND
BIOMARKERS OF GROWTH AND
APOPTOSIS
Jason Gee*, Burlington, MA, Daniel
Saltzstein, KyungMann Kim, Jill Kolesar, Wei
Huang, Tom Havighurst, Barbara Wollmer,
Jeanne Stublaski, Tracy Downs, Hasan
Mukhtar, Madison, WI, Margaret House,
Howard Parnes, Bethesda, MD, Howard
Bailey, Madison, WI
ABSTRACT
NUMBER TITLE
MP26-03 SINGLE INSTILLATION OF MITOMYCIN C
(MMC) PLUS BACILLUS CALMETTEGUÉRIN (BCG) VERSUS BCG ALONE IN
HIGH GRADE NON-MUSCLE INVASIVE
BLADDER CANCER (NMIBC)
Brian Weiss*, New York, NY, Alan Wein, S.
Bruce Malkowicz, Thomas Guzzo,
Philadelphia, PA
MP26-02 A MANAGEMENT ALGORITHM FOR
MITOMYCIN-C (MMC)
Amy Luckenbaugh*, David Miller, Alon
Weizer, John Stoffel, Jeffrey Montgomery,
Ann Arbor, MI
90
MP26-11 THE TIMING OF RADICAL CYSTECTOMY
FOR BCG FAILURE: COMPARISON OF
OUTCOMES AND RISK FACTORS FOR
PROGNOSIS
Christopher Haas*, LaMont Barlow, G Joel
DeCastro, James McKiernan, New York, NY
MP26-12 INCIDENCE AND MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER
RECURRENCES AFTER COMPLETE
RESPONSE TO COMBINED-MODALITY
ORGAN-PRESERVING THERAPY FOR
MUSCLE-INVASIVE BLADDER CANCER
Alejandro Sanchez*, Matthew F. Wszolek,
Rebecca H. Clayman, Dayron Rodriguez,
Andrzej Niemierko, Francis J. McGovern,
Anthony L. Zietman, Niall M. Heney, W. Scott
McDougal, William U. Shipley, Jason A.
Efstathiou, Boston, MA
MP26-05 ACTIVE SURVEILLANCE PROGRAM IN
RECURRENT NMIBC
Rodolfo Fausto Hurle, Luigi Castaldo,
Taverna Gianluigi, Matteo Ferro, Ottavio
DeCobelli, Danilo Bottero, Milan, Italy,
Daniela Terraciano, Naples, Italy, Luisa
Pasini*, Milan, Italy
MP26-06 NEUTROPHIL TO LYMPHOCYTE RATIO
PREDICTS RECURRENCE OF NONMUSCLE INVASIVE BLADDER CANCER
Emrah Yuruk, Istanbul, Turkey, Theodore R.
Saitz*, Portland, OR, Serkan Gonultas, Ege
Can Serefoglu, Ahmet Yaser Muslumanoglu,
Istanbul, Turkey
MP26-13 PREDICTING PATHOLOGIC AND
SURVIVAL OUTCOMES AFTER MULTIPLE
SALVAGE INTRAVESICAL THERAPIES
FOLLOWED BY RADICAL CYSTECTOMY
FOR PERSISTENT NON-MUSCLEINVASIVE BLADDER CANCER
Christopher Haas*, LaMont Barlow, G Joel
DeCastro, James McKiernan, New York, NY
MP26-07 THE EFFICACY AND LIMITATIONS OF
EORTC RISK STRATIFICATION FOR THE
PREDICTION OF RECURRENCE AND
PROGRESSION OF 1,024 JAPANESE NONMUSCLE INVASIVE BLADDER CANCERS
Takeshi Ieda*, Satoru Muto, Yoshiro
Sakamoto, Sohei Takahata, Toshiyuki China,
Shinji Shiozawa, Kazutaka Terai, Fumitaka
Shimizu, Shin-ichi Hisasue, Yoshiaki
Wakumoto, Shigeo Horie, Tokyo, Japan
MP26-14 MEASURING SUCCESS AFTER RADICAL
CYSTECTOMY: FEASIBILITY OF A NOVEL
COMPOSITE ENDPOINT (“POOR
RECOVERY”) TO QUANTIFY OUTCOMES
AFTER SURGERY
Erika L. Wood*, Houston, TX, Janet E. Baack
Krukreja, Rochester, NY, Sima Porten, San
Francisco, CA, Wei Qiao, Raphael Ezeagu,
Neema Navai, Ashish M. Kamat, Colin P.
Dinney, Jay B. Shah, Houston, TX
MP26-08 RENIN-ANGIOTENSIN INHIBITORS
DECREASE RECURRENCE AFTER TURBT
IN NON-MUSCLE INVASIVE BLADDER
CANCER
Michael L. Blute, Jr.*, Timothy J. Rushmer,
Fangfang Shi, Benjamin Fuller, E. Jason
Abel, David F. Jarrard, Tracy M. Downs,
Madison, WI
MP26-15 TREND IN TA STAGE UROTHELIAL
CARCINOMA OF THE BLADDER: SHIFT TO
HIGHER GRADING?
Shane Barney*, George Wayne, Elizabeth
Nagoda, Mark Soloway, Juan Acuna, Miami,
FL
MP26-09 MODERATE CHRONIC KIDNEY DISEASE
(EGFR < 60 ML/MIN) PREDICTS
RECURRENCE AND PROGRESSION IN
BLADDER CANCER PATIENTS TREATED
WITH TRANSURETHRAL RESECTION
Michael L. Blute, Jr.*, Timothy J. Rushmer,
Fangfang Shi, Benjamin Fuller, E. Jason
Abel, David F. Jarrard, Tracy M. Downs,
Madison, WI
*Presenting author
MP26-16 NEUTROPHIL TO LYMPHOCYTE RATIO, A
NEW PROGNOSTIC FACTOR IN NON
MUSCLE INVASIVE BLADDER CANCER
Vincenzo Favilla, Tommaso Castelli, Daniele
Urzı̀, Sebastiano Cimino, Salvatore Privitera,
Eugenia Fragalà, Giorgio Ivan Russo*,
Giuseppe Morgia, Catania, Italy
91
SATURDAY
MP26-10 A PROSPECTIVE RANDOMIZED TRIAL OF
INTRAVESICAL BACILLUS CALMETTEGUERIN THERAPY WITH THE TOKYO172
VERSUS CONNAUGHT STRAIN FOR NONMUSCLE INVASIVE BLADDER CANCER
Tatsuro Hayashi*, Takeshi Yuasa, Masayuki
Sano, Sho Uehara, Mutsushi Yamasaki,
Kiichi Hagiwara, Mizuaki Sakura, Hitoshi
Masuda, Shinya Yamamoto, Shinji Urakami,
Iwao Fukui, Jyunji Yonese, Tokyo, Japan
MP26-04 SAFETY, EFFICACY AND 12-MONTHS
RECURRENCE RATE OF LASER VS.
ELECTRICAL EN BLOC RESECTION OF
UROTHELIUM CARCINOMA OF THE
BLADDER: RESULTS OF THE EBRUC
TRIAL
Mario W. Kramer*, Hannover, Germany, Jens
J. Rassweiler, Jan Klein, Heilbronn,
Germany, Alexey Martov, Nikolay Baykov,
Moscow, Russian Federation, Rodolfo Hurle,
Milan, Italy, Guenter Janetschek, Lukas
Lusuardi, Salzburg, Austria, Mathias Wolters,
Mahmoud Abbas, Hannover, Germany, Armin
Leitenberger, Markus Riedl, Wolfsburg,
Germany, Udo Nagele, Hall, Austria, Axel S.
Merseburger, Markus A. Kuczyk, Hannover,
Germany, Marko Babjuk, Prague, Czech
Republic, Thomas R.W. Herrmann,
Hannover, Germany
MP26-19 A PROSPECTIVE STUDY ON THE
INFLUENCE ON RECURRENCE OF
QUITTING CIGARETTE SMOKING AT
DIAGNOSIS OF PRIMARY NON MUSCLE
INVASIVE BLADDER CANCER
Cristina Scalici Gesolfo*, Francesco D’Amato,
Dario Fontana, Francesco Sommatino,
Palermo, Italy, Lorenzo Rocchini, Marco
Moschini, Renzo Colombo, Andrea Gallina,
Milan, Italy, Vincenzo Serretta, Palermo, Italy
MP26-17 T1 HIGH-GRADE (G3) TRANSITIONAL
CELL CARCINOMA OF THE URINARY
BLADDER: DELAYED RADICAL
CYSTECTOMY IS CORRELATED TO A
WORSENED OUTCOME
Birte-Swantje Schneevoigt*, Tobias Grimm,
Alexander Buchner, Alexander Kretschmer,
Maria Apfelbeck, Markus Grabbert, Christian
Stief, Alexander Karl, Munich, Germany
MP26-18 MULTI-ISTITUTIONAL CONTROLLED
STUDIES DO NO REFLECT THE
PATIENT’S COMPLIANCE TO BCG
ENCOUNTERED IN CLINICAL PRACTICE.
RESULTS ON 411 PATIENTS
Vincenzo Serretta*, Cristina Scalici Gesolfo,
Vincenza Alonge, Fabrizio Di Maida,
Palermo, Italy, Lorenzo Rocchini, Marco
Moschini, Andrea Gallina, Renzo Colombo,
Milan, Italy
MP26-20 SEQUENTIAL INTRAVESICAL
GEMCITABINE AND DOCETAXEL FOR
THE SALVAGE TREATMENT OF NONMUSCLE INVASIVE BLADDER CANCER
Ryan Steinberg*, Lewis Thomas, Michael
O’Donnell, Kenneth Nepple, Iowa City, IA
CREDITTM
1:00 pm - 3:00 pm
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: QUALITY OF LIFE
Moderators: Quoc-Dien Trinh and Timothy Daskivich
ABSTRACT
NUMBER TITLE
MP27-01 A RANDOMIZED CONTROLLED TRIAL
COMPARING ALPHA BLOCKER
(TAMSULOSIN) AND ANTICHOLINERGIC
(SOLIFENACIN) IN TREATMENT OF
URETERAL STENT RELATED SYMPTOMS
Ahmed EL-Nahas*, Mohamed Tharwat,
Mohamed Elsaadany, Ahmed Mosbah,
Mohamed Gaballah, Mansoura, Egypt
ABSTRACT
NUMBER TITLE
MP27-04 A PSYCHOMETRIC ANALYSIS OF PAIN
AND URINARY SYMPTOMS IN PATIENTS
WITH INTERSTITIAL CYSTITIS/BLADDER
PAIN SYNDROME AND CHRONIC
PROSTATITIS/CHRONIC PELVIC PAIN
SYNDROME: FINDINGS FROM MAPP
RESEARCH NETWORK
James Griffith*, Chicago, IL, Todd Edwards,
Seattle, WA, Barry Hong, Siobhan Sutcliffe,
St Louis, MO, Michel Pontari, Philadelphia,
PA, Niloofar Afari, San Diego, CA, John
Krieger, Seattle, WA, Robert Lloyd, Chicago,
IL, Frank Tu, Evanston, IL, David Williams,
Ann Arbor, MI, Donald Patrick, Seattle, WA,
Jayoung Kim, Bruce Naliboff, Los Angeles,
CA, Henry Lai, St Louis, MO, Catherine
Bradley, Iowa City, IA, Chris Mullins,
Bethesda, MD, Richard Landis, Philadelphia,
PA
MP27-02 THE ASSOCIATION BETWEEN VASCULAR
RISK FACTORS AND OVER ACTIVE
BLADDER
Teruhiko Tsuru*, Isao Araki, Sayaka
Kadowaki, Takashi Hisamatsu, Akira
Fujiyoshi, Akihiro Kawauchi, Katsuyuki Miura,
Hirotsugu Ueshima, Otsu, Japan
MP27-03 EFFECTS OF CONTINUOUS LONG-TERM
THERAPY (TRT) UP TO 11 YEARS IN 115
HYPOGONADAL ELDERLY MEN ON
ANTHROPOMETRIC, ENDOCRINE AND
METABOLIC PARAMETERS: REAL-LIFE
EXPERIENCE FROM AN OBSERVATIONAL
REGISTRY STUDY
Aksam Yassin*, Yousef Al Mehmadi,
Norderstedt-Hamburg, Germany, Dany-Jan
Yassin, Braunschweig, Germany, Gheorghe
Doros, Abdul Traish, Boston, MA
MP27-05 SEVERE WAR-RELATED GENITOURINARY
INJURIES AMONG MALE SERVICE
MEMBERS IN OPERATIONS ENDURING
FREEDOM AND IRAQI FREEDOM
Jud Janak*, Steven Hudak, Douglas
Soderdahl, Jean Orman, JBSA Fort Sam
Houston, TX, Kristy Pottol, Wendy Dean, Fort
Detrick, MD
MP27-06 RESIDENT IMPACT ON PATIENT &
SURGEON SATISFACTION AND
OUTCOMES: EVIDENCE FOR HEALTH
SYSTEM SUPPORT FOR UROLOGY
EDUCATION
Bradford Stevenson*, Jessica Healey, William
Severino, Thomas Baron, David Roszhart,
David Lieber, Kevin McVary, Tobias Kohler,
Springfield, IL
92
MP27-16 EFFECT OF EXERCISE ON QUALITY OF
LIFE AND PSYCHOLOGICAL FUNCTION IN
MEN WITH PROSTATE CANCER: METAANALYSES OF >600 MEN FROM 7
RANDOMIZED CLINICAL TRIALS
Dharam Kaushik*, San Antonio, TX,
Balwinder Singh, Fargo, ND
MP27-08 THE IMPORTANCE OF GRAPHIC
LITERACY IN PATIENT-CENTERED
COMMUNICATION
Jasmir Nayak*, Andrea Hartzler, Seattle, WA,
Jason Izard, Kingston, Canada, Bruce Dalkin,
John Gore, Seattle, WA
MP27-17 DOMAIN-SPECIFIC SYMPTOM BURDEN
AND INFORMATION NEEDS IN PROSTATE
CANCER SURVIVORS: A CASE FOR
TAILORED LONG-TERM SURVIVORSHIP
CARE
Jennifer Bernat*, Indianapolis, IN, Daniela
Wittmann, Sarah Hawley, Ann Arbor, MI,
David Haggstrom, Indianapolis, IN, May
Darwish-Yassine, Boston, MA, Ted Skolarus,
Ann Arbor, MI
MP27-09 “I SAW IT ON TV, DOC!” DIRECT-TOCONSUMER TELEVISION ADVERTISING
FOR UROLOGICAL PHARMACEUTICAL
PRODUCTS, 2010 –2013
Kevin Koo*, Lebanon, NH, Ronald Yap,
Concord, NH
MP27-10 POST-OPERATIVE PAIN MANAGEMENT
AFTER RADICAL CYSTECTOMY:
COMPARING TRADITIONAL AND
ENHANCED RECOVERY AFTER SURGERY
PROTOCOL AT USC
Weichen Xu*, Hamed Ahmadi, Jie Cai, Gus
Miranda, Anne Shuckman, Siamak
Daneshmand, Hooman Djaladat, Los
Angeles, CA
MP27-18 BLADDER OUTLET OBSTRUCTION AFTER
PROSTATE CANCER TREATMENT: A
POPULATION-BASED ANALYSIS
Daniel Liberman*, Stephanie Jarosek, Beth
Virnig, Sean Elliott, Minneapolis, MN
MP27-19 QUALITY OF LIFE AND FUNCTIONAL
RESULTS AFTER ROBOTIC ASSISTED
PROSTATECTOMY (RALP): A
PROSPECTIVE POPULATION-BASED
SERIES
Lorenzo Tosco*, Leuven, Belgium, Filip
Ameye, Ghent, Belgium, Simone Albisinni,
Brussels, Belgium, Peter Dekuyper, Ghent,
Belgium, David Jegou, Thierry Quackels,
Thierry Roumeguere, Brussels, Belgium, Ben
Van Cleynenbreugel, Leuven, Belgium,
Nancy Van Damme, Liesbet Van Eycken,
Brussels, Belgium, Steven Joniau, Leuven,
Belgium
MP27-11 DISTINCT SIDE EFFECT PROFILES AFTER
CONTEMPORARY TREATMENT OF
Karen Hoffman*, Houston, TX, JoAnn
Alvarez, Daniel Barocas, Tatsuki Koyama,
Alicia Morgans, Sharon Phillips, Matthew
Resnick, David Penson, CEASAR
Investigators, Nashville, TN
MP27-12 DETERMINANTS OF INFORMATION
NEEDS IN LONG-TERM PROSTATE
CANCER SURVIVORS
Jennifer Bernat*, Indianapolis, IN, Daniela
Wittmann, Sarah Hawley, Ann Arbor, MI,
David Haggstrom, Indianapolis, IN, May
Darwish-Yassine, Boston, MA, Ted Skolarus,
Ann Arbor, MI
MP27-20 IMPACT ON HEALTH RELATED QUALITY
OF LIFE FOLLOWING TREATMENT OF
UROLOGIC CANCERS: RESULTS OF A
PROSPECTIVE STUDY
John Oliver DeLancey*, Gregory Auffenberg,
David Victorson, Shilajit Kundu, Chicago, IL
MP27-13 AGREEMENT BETWEEN PATIENT AND
PHYSICIAN REPORTED OUTCOMES
Alan Thong*, Bing Ying Poon, Justin Lee,
Daniel Sjoberg, Andrew Vickers, Behfar
Ehdaie, New York, NY
CREDITTM
MP27-14 A CROSS-SECTIONAL COMPARISON
STUDY OF SELF-HELP FOR PROSTATE
CANCER: HOW DO ONLINE AND FACE-TOFACE SUPPORT GROUPS DIFFER?
Johannes Huber*, Tanja Muck, Philipp Maatz,
Dresden, Germany, Anette Brechtel, Andreas
Ihrig, Heidelberg, Germany
*Presenting author
93
SATURDAY
MP27-15 INTOLERANCE OF UNCERTAINTY AND
URINARY SYMPTOMS PREDICT ANXIETY
FOR MEN ON ACTIVE SURVEILLANCE
FOR LOW-RISK PROSTATE CANCER
Hung-Jui Tan*, Leonard S. Marks, Los
Angeles, CA, Michael Hoyt, New York, NY,
Lorna Kwan, Christopher P. Filson, Malu
Macairan, Patricia Lieu, Mark S. Litwin,
Annette L. Stanton, Los Angeles, CA
MP27-07 THE WISCONSIN STONE QUALITY OF
LIFE QUESTIONNAIRE: BASELINE
RESULTS FROM A PROSPECTIVE,
LONGITUDINAL, MULTI-CENTER
VALIDATION STUDY
Kristina L Penniston*, Madison, WI, Jodi A
Antonelli, Dallas, TX, Timothy D Averch,
Pittsburgh, PA, Davis P Viprakasit, Chapel
Hill, NC, Roger L Sur, San Diego, CA,
Vincent G Bird, Gainesville, FL, Stephen Y
Nakada, Madison, WI
1:00 pm - 3:00 pm
STONE DISEASE: SURGICAL THERAPY II
Moderators: Ashish Rawandale and Brian Auge
ABSTRACT
NUMBER TITLE
MP28-01 EXTERANAL VALIDATION OF S-RESC-R
TO PREDICT STONE-FREE RATE AFTER
RIRS
Juhyun Park*, Minyong Kang, Songzhe Piao,
Jeong Woo Lee, Chang Wook Jeong, Seung
Bae Lee, Hwancheol Son, Hyeon Jeong,
Sung Yong Cho, Seoul, Korea, Republic of
ABSTRACT
NUMBER TITLE
MP28-08 THE OUTCOME OF USING A PREOPERATIVE J STENT IN URETEROSCOPY:
RESULTS FROM THE CLINICAL
RESEARCH OFFICE OF
ENDOUROLOGICAL SOCIETY URS
GLOBAL STUDY
Dean Assimos*, Birmingham, AL, Alfonso
Crisci, Florence, Italy, Daniel Culkin,
Oklahoma City, OK, Wei Xue, Shanghai,
China, People’s Republic of, Anita Roelofs,
Arnhem, Netherlands, Mordechai Duvdevani,
Jerusalem, Israel, Mahesh Desai, Nadiad,
India, Jean de la Rosette, Amsterdam,
Netherlands
MP28-02 FLEXIBLE URETEROSCOPE REPAIRS
USING ORIGINAL MANUFACTURER
VERSUS THIRD-PARTY COMPANY
Kyle Wood*, Marc Colaco, Ilya Gorbachinsky,
Amanda Hughes, Jorge Gutierrez-Aceves,
Winston-Salem, NC
MP28-03 WILL THE RISKS OF POSTOPERATIVE
INFECTION BE INCREASED AFTER
URETEROSCOPIC LITHOTRIPSY FOR
PATIENTS WITH MILD PYURIA BEFORE
THE OPERATION?
Hung Keng Li*, New Taipei City, Taiwan, Eric
Y. Huang, Alex T.L. Lin, Taipei, Taiwan
MP28-09 BALLOON DILATION OF THE URETER: A
CONTEMPORARY REVIEW OF OUTCOMES
AND COMPLICATIONS
Nicholas Kuntz*, Durham, NC, Andreas
Neisius, Mainz, Germany, Matvey Tsivian
Tsivian, Momin Ghaffar, Fernando Cabrera,
Ramy Youssef, Michael Ferrandino, Durham,
NC, Nishant Patel, Roger Sur, San Diego,
CA, Glenn Preminger, Michael Lipkin,
Durham, NC
MP28-04 FLEXIBLE URS HOLMIUM LASER STONE
DUSTING VS FRAGMENTAION FOR 2 CM
SINGLE RENAL STONE
Wael Gamal*, Soahg, Egypt, Ahmed
Mmdouh, Sohag, Egypt
MP28-10 EVIDENCE FOR FLEXIBLE
URETERORENOSCOPY (FURS) FOR
LARGE RENAL STONES IN THE MODERN
ERA: A SYSTEMATIC REVIEW
Robert Geraghty, Southampton, United
Kingdom, Omar Aboumarzouk, Cardiff, United
Kingdom, Bhavan Rai, Dundee, United
Kingdom, Chandra shekhar Biyani, Yorkshire,
United Kingdom, Nick Rukin, Wolverhampton,
United Kingdom, Bhaskar Somani*,
Southampton, United Kingdom
MP28-05 URETEROSCOPIC REMOVAL OF
CALCULUS IN POORLY FUNCTIONING
(<10%) KIDNEYS DUE TO URETERIC
STONE: A PROSPECTIVE OUTCOME
ANALYSIS
Prem Nath Dogra*, Rajan Gupta, Prabhjot
Singh, Ashish Kumar Saini, Rajeev Kumar,
Amlesh Seth, New Delhi, India
MP28-06 COST ANALYSIS OF FLEXIBILE
URETEROSOPE REPAIRS: EVALUATION
OF 655 PROCEDURES IN A COMMUNITYBASED PRACTICE EXPERIENCE
Eugene Kramolowsky*, Zachary McDowell,
Blake Moore, David Rapp, Nada Wood,
Richmond, VA
MP28-11 FEASIBILITY AND OUTCOME OF
EMERGENCY URETEROSCOPIC
REMOVAL OF LOWER URETERAL STONE
UNDER INTRAVENOUS SEDATION: A
PROSPECTIVE STUDY
Waleed Shabana, Mohamed Teleb, Tamer
Dawod*, Zagazig, Egypt
MP28-07 FLEXIBLE URETEROSCOPY TRAINING.
NEW TOOL OF TWO-PART SILICONE
MOLD (CAVITIES) BASED ON REAL
HUMAN KIDNEYS ENDOCASTS
Bruno Marroig*, Marco Pereira Sampaio,
Luciano Favorito, Francisco Sampaio, Rio de
Janeiro, Brazil
MP28-12 EMERGENCY VERSUS ELECTIVE
URETEROSCOPIC TREATMENT : WHAT
ROLE OF THE EMERGENCY
URETEROSCOPY APPROCH IN THE
DEFINITIVE TREATMENT OF URETERIC
STONES ?
BENRABAH Rabah*, azli mohcine, nechiche
farid, boumelit samir, souid M Bachir, lounici
mustapha, algiers, Algeria
MP28-13 LEAVE NO STONE UNTURNED? NEGATIVE URETEROSCOPY RATES
Remy Lamberts*, Simon Conti, Stanford, CA,
Rajesh Shinghal, San Jose, CA, John
Leppert, Stanford, CA, Christopher Elliott,
San Jose, CA
94
MP28-18 PREDICTING RADIATION EXPOSURE IN
URETERORENOSCOPY AND LASER
LITHOTRIPSY: AN ANALYSIS OF PATIENT
AND STONE CHARACTERISTICS
Marios Hadjipavlou*, Portsmouth, United
Kingdom, Vincent Lam, Jai Seth, Faqar
Anjum, Sri Sriprasad, Dartford, Kent, United
Kingdom
MP28-15 THE EFFECT OF LASER FIBER TIP
CLEAVING TECHNIQUE UPON RISK FOR
URETEROSCOPE DAMAGE OR URETERAL
INJURY
Daniel Faaborg*, Edna Miao, Herbert
Hodgson, Brandon Peplinski, Kristene
Myklak, Muhannad Alsyouf, D. Duane
Baldwin, Loma Linda, CA
MP28-19 RELATIVE COST COMPARISON OF
STANDARD SURGICAL TREATMENTS
FOR MEDIUM-SIZED RENAL STONES
Blake Hamilton*, Joel Hancock, Salt Lake
City, UT
MP28-20 COMPARISON OF FLEXIBLE
URETERORENOSCOPY AND MINI
PERCUTANEOUS NEPHROLITHOTOMY IN
TREATMENT OF LOWER CALYCEAL
STONES SMALLER THAN 2 CM
Mehmet Fatih Akbulut*, Onur Kucuktopcu,
Emre Kandemir, Erkan Sonmezay,
Abdulmuttalip Simsek, Faruk Ozgor, Murat
Binbay, Ahmet Yaser Muslumanoglu, Zafer
Gokhan Gurbuz, Istanbul, Turkey
MP28-16 THE EFFECT OF FLEXIBLE
URETERORENOSCOPY ON RENAL
HEMODYNAMICS
Vahit Guzelburc*, Rukiye Kilicarslan, Istanbul,
Turkey, Caner Baran, Adana, Turkey, Murat
Can Kiremit, Mustafa Yucel Boz, Mustafa
Soytas, Rahim Horuz, Selami Albayrak,
Istanbul, Turkey
MP28-17 LUBRIGLIDE SEQUENTIAL URETERAL
DILATORS®: A SAFE AND EFFECTIVE
METHOD OF URETERAL DILATION TO
FACILITATE PRIMARY URETEROSCOPIC
INTERVENTION
Christopher Mitchell*, Benjamin McCormick,
Tracy Marien, Nicole Miller, Nashville, TN
CREDITTM
1:00 pm - 3:00 pm
Podium Session 14
TRAUMA/RECONSTRUCTION: URETHRAL RECONSTRUCTION (INCLUDING STRICTURE) II
Moderators: Jill Buckley and Ramón Virasoro
TIME
1:00
1:10
1:20
ABSTRACT
NUMBER TITLE
PD14-01 PATIENT AGE RATHER THAN URETHRAL
TRANSECTION INFLUENCES ERECTILE
FUNCTION AFTER URETHROPLASTY: A
PROSPECTIVE ANALYSIS
Keith Rourke, Trevor Haines*, Edmonton,
Canada
ABSTRACT
TIME NUMBER TITLE
1:30
PD14-04 REPEAT ENDOSCOPIC MANIPULATION
FOR BULBAR URETHRAL STRICTURES
INCREASES STRICTURE LENGTH AND
URETHROPLASTY COMPLEXITY BUT
DOES NOT AFFECT URETHROPLASTY
OUTCOMES
David W Chapman*, Abhaya Prasad, Adam
Kinnaird, Keith Rourke, Edmonton, Canada
PD14-02 RECTOURETHRAL FISTULA REPAIR:
EXPERIENCE OF VARIOUS APPROACHES
OVER 30 YEARS
Christopher Zappavigna*, Sender Herschorn,
Toronto, Canada
PD14-03 OPEN SURGICAL RECONSTRUCTION FOR
RECALCITRANT BLADDER NECK
CONTRACTURES – FUNCTIONAL
OUTCOME AFTER IMPLANTATION OF AN
ARTIFICIAL URINARY SPHINCTER
Simon Bugeja*, Anastasia Frost, Enrique Fes,
Stella Ivaz, Daniela E Andrich, Anthony R
Mundy, London, United Kingdom
*Presenting author
95
1:40
PD14-05 OUTCOME OF DIRECT VISUAL INTERNAL
URETHROTOMY (DVIU) FOR POSTURETHROPLASTY STRICTURES
Stephen Mock*, Elizabeth T. Brown, W.
Stuart Reynolds, Melissa R. Kaufman,
Douglas F. Milam, Roger R. Dmochowski,
Nashville, TN
1:50
PD14-06 VALIDATION OF A NON-INVASIVE
URETHRAL MONITORING PROTOCOL
AFTER URETHRAL RECONSTRUCTION
Bradley A. Erickson*, Christopher A. Tam,
Iowa City, IA, Sean P. Elliott, Minneapolis,
MN, Jeremy B. Myers, Salt Lake City, UT,
Alex J. Vanni, Burlington, MA, Bryan B.
Voelzke, Seattle, WA
SATURDAY
MP28-14 THE RESULTS OF RETROGRADE
INTRARENAL SURGERY (RIRS) IN THE
TREATMENT OF RENAL STONES LARGER
THAN 15 MM. A COMPARATIVE STUDY
Hanan Goldberg*, Dor Golomb, Shlomi
Tapiero, Yariv Shtabholtz, Avi Shariv, Ronen
Holland, Jack Baniel, David Lifshitz, Petach
Tiqva, Israel
2:00
PD14-07 PHASE I DEVELOPMENT OF A PATIENT
REPORTED OUTCOME MEASURE FOR
MALE URETHRAL STRICTURE DISEASE
Benjamin Breyer*, San Francisco, CA, Todd
Edwards, Donald Patrick, Bryan Voelzke,
Seattle, WA
2:10
PD14-08 SEXUAL FUNCTIONAL OUTCOMES WITH
DORSAL VS. VENTRAL SUBSTITUTION
BULBAR URETHROPLASTY
Daniel Liberman*, Minneapolis, MN, Joshua
Broghammer, Kansas City, KS, Thomas
Smith III, Houston, TX, Bryan Voelzke,
Seattle, WA, Bradley Erickson, Iowa City, IA,
Christopher McClung, Columbus, OH, Nejd
Alsikafi, Gurney, IL, Alex Vanni, Burlington,
MA, Jeremy Myers, Salt Lake City, UT, Sean
2:20
PD14-09 MOST EFFECTIVE METHOD OF USING
BUCCAL GRAFT IN STAGED
URETHROPLASTY FOR HYPOSPADIAS
CRIPPLE
Pankaj Joshi*, Craig Hunter, Walid Shahrour,
Kulkarni, Pune, India
2:30
PD14-10 A MULITINSTITUTIONAL EVALUATION OF
THE MANAGEMENT AND OUTCOMES OF
LONG SEGMENT AND PANURETHRAL
STRICTURES
Jonathan Warner*, Ann Arbor, MI, Ibraheem
Malkawi, Detroit, MI, Panjak Joshi, Sanjay
Kulkarni, Pune, India, Guido Barbagli, Arezzo,
Italy, Massimo Lazzeri, Milan, Italy, Ryan
Mori, Kenneth Angermeier, Cleveland, OH,
Justin Han, Christopher Gonzalez, Chicago,
IL, Fransisco Martins, Lisbon, Portugal,
Reynaldo Gomez, Santiago, Chile, Richard
Santucci, Detroit, MI
2:40
PD14-11 SINGLE STAGE VERSUS CLASSICAL
STAGED APPROACH FOR PENILE
URETHRAL STRICTURES
Felix Campos*, Simon Bugeja, Anastasia
Frost, Enrique Fes, Stella Ivaz, Daniela E
Andrich, Anthony R Mundy, London, United
Kingdom
2:50
PD14-12 HETEROGENOUS DISEASE
CHARACTERISTICS IN PATIENTS WITH
THE CLINICAL DIAGNOSIS OF LICHEN
SCLEROSUS
Peter Kirk, Heather Crossley, Miriam HadjMoussa, Bahaa Malaeb*, Ann Arbor, MI
CREDITTM
1:00 pm - 3:00 pm
Podium Session 15
TECHNOLOGY & INSTRUMENTS: LAPAROSCOPY AND ROBOTICS: MALIGNANT DISEASE I
Moderators: Dipen Parekh and Jeffrey Cadeddu
TIME
1:00
1:10
ABSTRACT
NUMBER TITLE
PD15-01 VIDEO-RATE STRUCTURED
ILLUMINATION MICROSCOPY FOR RAPID
ASSESSMENT OF SURGICAL MARGINS
DURING RADICAL PROSTATECTOMY
J. Quincy Brown, Michael Maddox*, Mei
Wang, Hillary Kimbrell, David Tulman, Tyler
Schlichenmeyer, Sree Mandava, Benjamin
Lee, New Orleans, LA
ABSTRACT
TIME NUMBER TITLE
1:20
PD15-03 RANDOMIZED CLINICAL TRIAL
EXAMINING THE RETURN OF URINARY
CONTINENCE AFTER ROBOT-ASSISTED
RADICAL PROSTATECTOMY WITH OR
WITHOUT A BLADDER NECK SLING
Chandru P Sundaram*, Clinton D Bahler,
Indianapolis, IN, Steven M Lucas, Detroit, MI,
Naveen Kella, San Antonio, TX, Thomas A
Gardner, Michael O Koch, Indianapolis, IN
PD15-02 DEVELOPMENT OF NEW THREEDIMENSIONAL IMAGE SYSTEM FOR
TRANSURETHRAL SURGERY
Soichiro Yoshida*, Tsuneo Fukuyo, Masaya
Ito, Manabu Tatokoro, Junichiro Ishioka, Yoh
Matsuoka, Noboru Numao, Kazutaka Saito,
Yasuhisa Fujii, Kazunori Kihara, Bunkyo-ku,
Tokyo, Japan
96
1:30
PD15-04 COMPARISON OF EARLY ONCOLOGIC
OUTCOMES IN OPEN VERSUS ROBOTICASSISTED LAPAROSCOPIC
PROSTATECTOMY IN A LARGE
POPULATION-BASED US COHORT
Shane Pearce*, Joseph Pariser, Theodore
Karrison, Sanjay Patel, Scott Eggener,
Chicago, IL
1:40
PD15-05 COMPARISON OF PERIOPERATIVE
COMPLICATIONS FOLLOWING OPEN
VERSUS MINIMALLY INVASIVE
NEPHROURETERECTOMY
Eric DeRoo*, Francesca Monn, Clint Bahler,
Chandru Sundaram, Indianapolis, IN
PD15-06 NOVEL IMAGE MONITORING SYSTEM
USING A HEAD-MOUNTED DISPLAY FOR
ASSISTANTS IN DA VINCI SURGERY
Soichiro Yoshida*, Bunkyo-ku, Tokyo, Japan,
Shohei Fukuda, Toshihiro Kanda, Naotaka
Fukui, Kita-Adachi-gun, Saitama, Japan,
Kazutaka Saito, Yasuhisa Fujii, Bunkyo-ku,
Tokyo, Japan, Yukio Kageyama, Kita-Adachigun, Saitama, Japan, Kazunori Kihara,
Bunkyo-ku, Tokyo, Japan
2:00
PD15-07 OPTICAL BIOPSY OF SUSPECTED PENILE
CANCER USING CONFOCAL LASER
ENDOMICROSCOPY: INITIAL FEASIBILITY
STUDY
Dimitar V. Zlatev*, Aristeo Lopez, Kathleen E.
Mach, Robert V. Rouse, John T. Leppert,
2:10
PD15-08 OPEN VERSUS ROBOTIC-ASSISTED
LAPAROSCOPIC RETROPERITONEAL
LYMPH NODE DISSECTION FOR
TESTICULAR CANCER
Kimberly Fischer*, Michael Santomauro, Eric
Biewenga, Justin Nork, Patrick Scarborough,
Ithaar Derweesh, Sean Stroup, San Diego,
CA, Erik Castle, Phoenix, AZ, James Porter,
Seattle, WA, James L’Esperance, San Diego,
CA
2:20
2:30
PD15-10 FEASIBILITY OF HIFU-TRIGGERED
SORAFENIB-LOADED LIPOSOME
NANOPARTICLES FOR TARGETED DRUG
THERAPY IN RENAL CELL CARCINOMA
Caleb Abshire*, James Liu, Jaspreet Arora,
Hakm Murad, Sree Harsha Mandava, Michael
Maddox, Cameron Callaghan, Damir
Khismatullin, Vijay John, Benjamin Lee, New
Orleans, LA
2:40
PD15-11 INSTRUMENT LIFE FOR ROBOT
ASSISTED LAPAROSCOPIC RADICAL
PROSTATECTOMY: ARE TEN LIVES FOR
MOST INSTRUMENTS JUSTIFIED?
Wesley Ludwig, Michael Gorin, Mark Ball,
Edward Schaeffer, Misop Han, Mohamad
Allaf*, Baltimore, MD
2:50
PD15-12 DESIGN AND EARLY CLINICAL
EXPERIENCE WITH A TACTILE
FEEDBACK DRIVEN PELVIC FLOOR
MUSCLE TRAINING SMARTPHONE APP
Maurice Garcia*, Michael Leapman, Jonathan
Brajtbord, Peter Carroll, San Francisco, CA
CREDITTM
PD15-09 EFFECT OF RENAL VASCULAR CLAMP
TYPE AND POSITION UPON LEAK POINT
PRESSURE IN HUMAN RENAL ARTERIES
David Tryon, Kristene Myklak*, Muhannad
Alsyouf, Brandon Peplinski, Javier L. Arenas,
Daniel Faaborg, Carol Conceicao, Herbert C.
Ruckle, D. Duane Baldwin, Loma Linda, CA
1:00 pm - 3:00 pm
Podium Session 16
BENIGN PROSTATIC HYPERPLASIA: MEDICAL & NON-SURGICAL THERAPY
Moderators: Li-Ping Xie and Steve Kaplan
TIME
1:00
1:10
1:20
ABSTRACT
NUMBER TITLE
PD16-01 NEW INSIGHT OF PSA REDUCTION
DURING FINASTERIDE THERAPY
Ding Xu*, Jie Ding, Jun Qi, Shanghai, China,
ABSTRACT
TIME NUMBER TITLE
1:30
PD16-04 ALTERATIONS OF HEMATOGENESIS AND
BONE MINERAL DENSITY AFTER
DUTASTERIDE TREATMENT IN AGED
PATIENTS WITH BENIGN PROSTATIC
HYPERPLASIA
Kenichi Mori*, Shinsuke Mizoguchi, Yasuhiro
Sumino, Fuminori Sato, Yufu, Japan, Naoki
Yoshimura, Pittsburgh, PA, Hiromitsu Mimata,
Yufu, Japan
PD16-02 INVESTIGATION OF PATIENTS
DIAGNOSED WITH PROSTATE CANCER
DURING DUTASTERIDE TREATMENT
Shoichiro Sugiura*, Hisamitsu Ide, Kosuke
Kitamura, Satoru Muto, Raizo Yamaguchi,
Shigeo Horie, Tokyo, Japan
1:40
PD16-03 A PROSPECTIVE STUDY OF SILODOSIN
IN COMPARISION WITH TAMSULOSIN IN
THE MANAGEMENT OF PATIENTS IN
ACUTE URINARY RETENTION DUE TO
BENIGN HYPERPLASIA OF PROSTATE
bhavani ginka*, Tirupati, India
*Presenting author
97
PD16-05 EFFICACY AND SAFETY OF SILODOSIN
AND DUTASTERIDE COMBINATION
THERAPY IN ACUTE URINARY
RETENTION DUE TO BENIGN PROSTATIC
HYPERPLASIA: A SINGLE-ARM
PROSPECTIVE STUDY
Atsushi Imai*, Hayato Yamamoto, Shingo
Hatakeyama, Takahiro Yoneyama, Yasuhiro
Hashimoto, Takuya Koie, Noritaka Kamimura,
Kazuaki Yoshikawa, Atsushi Kyan, Toshiaki
Kawaguchi, Yasuo Kusumi, Yuji Yagihashi,
Chikara Ohyama, Hirosaki, Japan
SATURDAY
1:50
1:50
PD16-06 A PROSPECTIVE RANDOMIZED STUDY TO
EVALUATE THE OUTCOME OF
ALPHABLOCKERS AND THE
COMPINATION WITH TADALAFILE IN
TREATING LUTS/BPH AND ERECTILE
DYSFUNCTION
Dawod*, Zagazig, Egypt
2:00
PD16-07 ANALYSIS OF CAUSES OF FAILURE OF
MEDICAL TREATMENT IN PATIENTS
UNDERGOING SURGERY FOR BENIGN
ENLARGEMENT OF PROSTATE
Ajay Anand*, Jammu, India, Narmada P
Gupta, P N Dogra, Amlesh Seth, New Delhi,
India
2:10
PD16-08 EVOLUTION: A EUROPEAN REGISTRY
EVALUATING MANAGEMENT PRACTICES
OF PHARMACOLOGICALLY TREATED
PATIENTS WITH LUTS ASSOCIATED WITH
BPH. SYMPTOMATIC IMPROVEMENT,
PROGRESSION AND TREATMENT
DISCONTINUATION RESULTS. A
COMPARISON BETWEEN EUROPEAN
COUNTRIES
Andrea Tubaro*, Rome, Italy, Richard
Berges, Cologne, Germany, Mark Speakman,
Taunton, United Kingdom, Alexandre de la
Taille, Creteil, France, Luis Martı́nez-Piñeiro,
Madrid, Spain, Anup Patel, London, United
Kingdom, Christien Caris, Wim Witjes,
Arnhem, Netherlands
2:20
2:30
PD16-10 THE EFFECT OF COMBINED
SYSTEMATIZED BEHAVIORAL
MODIFICATION EDUCATION PROGRAM
(SBMP) WITH DDAVP IN PATIENTS WITH
NOCTURIA: A PROSPECTIVE,
MULTICENTER, RANDOMIZED, AND
PARALLEL STUDY
Sung Yong Cho*, Juhyun Park, Songzhe
Piao, Seung Bae Lee, Hyeon Jeong,
Hwancheol Son, Jang Hwan Kim, JJi-Youn
Chun, Miho Song, Myung-Soo Choo, KyuSung Lee, Joon Chul Kim, Seoul, Korea,
Republic of, Jong Bo Choi, Suwon, Korea,
Republic of, Ju Tae Seo, Seung-June Oh,
2:40
PD16-11 DUTASTERIDE IMPROVES BONE
MINERAL DENSITY IN AGING MALE: A
PRELIMINARY STUDY
Naoki Wada*, Kazumi Hashizume, Seiji
Matsumoto, Hidehiro Kakizaki, Asahikawa,
Japan
2:50
PD16-12 SWITCH OF MEDICAL TREATMENT IN
SYMPTOMS SUGGESTIVE OF BENIGN
PROSTATIC HYPERPLASIA OVER 10YEAR FOLLOW-UP
Wonho Jung*, Ji Yong Ha, Byung Hoon Kim,
Choal Hee Park, Chun Il Kim, Daegu, Korea,
Republic of
PD16-09 HEALTHCARE COSTS FOR OFFICE
BASED BENIGN PROSTATIC
HYPERPLASIA THERAPIES
Craig Smith*, Naperville, IL, Robert Pugach,
Los Alamitos, CA
CREDITTM
1:00 pm - 3:00 pm
Video Session 3
MALE VOIDING/SEXUAL DYSFUNCTION/BPH/ INCONTINENCE/INFECTION/INFERTILITY
Moderators: Jaspreet Sandhu and Tobias Kohler
ABSTRACT
NUMBER TITLE
V3-01
USE OF THE OHMMETER TO IDENTIFY
THE SITE OF FLUID LEAK DURING
REVISION SURGERY
Michael Belsante*, John Patrick Selph,
Jessica Lloyd, Divya Ajay, George Webster,
Ngoc-Bich Le, Andrew Peterson, Durham, NC
V3-02
ABSTRACT
NUMBER TITLE
V3-03
SINGLE PERINEAL INCISION: A NOVEL
TECHNIQUE FOR ARTIFICIAL URINARY
SPHINCTER PLACEMENT
Cooper Benson*, Hajar Ayoub, O. Lenaine
Westney, Houston, TX
PLACEMENT OF BLADDER NECK
ARTIFICIAL URINARY SPHINCTER IN A
MALE
Stephen Blakely*, Henry Okafor, Gennady
Bratslavsky, Dimitriy Nikolavsky, Syracuse,
NY
98
V3-04
SIMPLE MALE URETHRAL SLING
REVISION TECHNIQUE
James H. Masterson, Yokosuka, Japan,
Eugene Y. Rhee*, San Diego, CA
V3-05
REMOVAL AND REPLACEMENT WITH
CORPORAL RECONSTRUCTION
Robert Kovell*, Ahmed Aboumohamed,
Patrick McKenzie, Ryan Terlecki, WinstonSalem, NC
A NEW TECHNIQUE FOR REMOVAL OF
CHRONICALLY IMPLANTED
NEUROMODULATOR LEADS
Christopher Pulford*, Zhamshid Okhunov,
Gamal Ghoniem, Orange, CA
V3-07
POVIDONE IODINE RECTAL
PREPARATION AT TIME OF PROSTATE
NEEDLE BIOPSY IS A SIMPLE AND
REPRODUCIBLE MEANS TO REDUCE
RISK OF PROCEDURAL INFECTION
Mikhail Regelman*, Jay Raman, Hershey, PA
V3-08
A SIMPLIFIED NO-FLIP SHANG RING
CIRCUMCISION TECHNIQUE WITH
TOPICAL (EMLA) ANESTHESIA IN
ADOLESCENTS AND ADULTS
Aaron Bernie*, New York, NY, Yifeng Peng,
Wuhu, China, People’s Republic of, Philip Li,
Richard Lee, New York, NY, Chao Jia,
Benhai Yang, Wuhu, China, People’s
Republic of, Quentin Awori, New York, NY,
Nian Qing Lu, Nanjing, China, People’s
Republic of, Mark Barone, Marc Goldstein,
New York, NY
V3-09
EPIDIDYMOVASOSTOMY: A TWO-SUTURE
INTUSSUSCEPTION APPROACH
Tariq, S. Hakky*, Gavin Langille, Aravind
Chandrashekar, Alexander,W. Pastuszak,
Ranjith Ramasamy, Larry,I. Lipshultz,
Houston, TX
V3-10
LESS GONADECTOMY FOR ANDROGEN
INSENSITIVITY SYNDROME (AIS)
Anibal W.Branco*, Luciano C.Stunitz, Sandro
Nichele, Julio C. Foiatto, Juliano D. Scheffer,
Marcio Gatti, Kleber Stelmasuk, Curitiba,
Brazil
V3-11
V3-12
COMPARISON OF THE DIFFERENT
TECHNIQUES FOR LASER ENUCLEATION
OF THE PROSTATE: PVEP, HOLEP,
THUVEP
David Leavitt*, New Hyde Park, NY,
Christopher Netsch, Hamburg, Germany,
Marawan El Tayeb, Michael Borofsky,
Indianapolis, IN, Christian Tiburtius,
Hamburg, Germany, Bilal Chughtai, New
York, NY, Arthur Smith, New Hyde Park, NY,
Alexis Te, New York, NY, James Lingeman,
Indianapolis, IN, Andreas Gross, Hamburg,
Germany, Zeph Okeke, New Hyde Park, NY
V3-13
THULIUM VAPOENUCLEATION OF THE
PROSTATE: SURGICAL TECHNIQUE
FROM VAPORIZATION TO
VAPOENUCLEATION
David Leavitt*, New Hyde Park, NY, Christian
Tiburtius, Christopher Netsch, Hamburg,
Germany, Zeph Okeke, New Hyde Park, NY,
Thomas Herrmann, Hannover, Germany,
Arthur Smith, New Hyde Park, NY, Andreas
Gross, Hamburg, Germany
V3-14
TRANSURETHRAL BIPOLAR
ENUCLEATION OF THE PROSTATE, A
NOVEL TECHNIQUE FOR BLADDER
OUTLET OBSTRUCTION
James M Tracey*, Jonathan N Warner, Ann
Arbor, MI
CREDITTM
ROBOTIC-ASSISTED EPIGASTRIC
ARTERY HARVEST: A NOVEL APPROACH
TO PENILE REVASCULARIZATION
Michael Aberger*, Katie Murray, Joshua
Broghammer, David Duchene, Kansas City,
KS
1:00 pm - 3:30 pm
SOCIETY FOR BASIC UROLOGIC RESEARCH (SBUR)
1:00
INTRODUCTION
Donald Vander Griend, Susan Kasper
2:25
PROSTATE EPITHELIAL LINEAGE HIERARCHY
Li Xin
1:10
PENILE STEM-PROGENITOR CELLS:
EFFICACY FOR ERECTILE DYSFUNCTION
THERAPY
Tom Lue
2:50
CONTROL OF HUMAN PROSTATE CANCER
STEM CELL PROLIFERATION AND
DIFFERENTIATION
Susan Kasper
1:35
INDUCTION OF HUMAN EMBRYONIC AND
INDUCED PLURIPOTENT STEM CELLS INTO
UROTHELIUM
Eric Kurzrock
3:15
OPEN DISCUSSION AND CONCLUDING
REMARKS
3:30
ADJOURN
2:00
CREDITTM
MESENCHYMAL STEM CELLS AS A VECTOR
FOR THE INFLAMMATORY PROSTATE
MICROENVIRONMENT
John Isaacs
*Presenting author
99
SATURDAY
V3-06
1:00 pm - 5:00 pm
SECOND OPINION CASES
Moderators: Gopal Badlani and Steven Campbell
12:55
INTRODUCTIONS
3:00
1:00
NON-INVASIVE BLADDER CANCER
Panel Leader: Mark Soloway
Discussants: Yair Lotan, Mark Schoenberg
DIFFICULT STONE CASES
Panel Leader: Dean Assimos
Discussants: Michael Wong, Margaret Pearle
3:30
SMALL RENAL MASSES
Panel Leader: Steven Campbell
Discussants: Brian Lane, David Canes
PROSTATE CANCER
Panel Leader: Peter Carroll
Discussants: Howard Scher, Anthony D’Amico
4:00
CHRONIC PELVIC PAIN SYNDROME
Panel Leader: J. Curtis Nickel
Discussants: Michel Pontari, Daniel Shoskes
4:30
MALE INCONTINENCE
Panel Leader: Craig Comiter
Discussants: Eugene Rhee, Ajay Singla
1:30
2:00
2:30
PENILE RECONSTRUCTION, ERECTILE
DYSFUNCTION, IMPLANTS
Panel Leader: Tom Lue
Discussants: Gerard Henry, Yoram Vardi
REFRACTORY OVERACTIVE BLADDER AND
FEMALE INCONTINENCE
Panel Leader: Gary Lemack
Discussants: Ariana Smith, David Ginsberg
CREDITTM
1:00 pm - 5:30 pm
UROLOGY CARE BY THE APN/PA: MAXIMIZING PATIENT OUTCOMES
1:00
Director: Susan Flick
1:05
UROLOGIC CANCER SCREENING
RECOMMENDATIONS FOR 2015
3:05
BREAK
3:30
OUTPATIENT UROLOGIC ONCOLOGY: PRIMER
Anne Calvaresi, Edouard Trabulsi
CREDITTM
USE OF GENETIC TESTING
MRI IMAGING PRIOR TO AND AFTER
DIAGNOSING PROSTATE CANCER (NCCN
GUIDELINE CHANGES)
Robert Abouassaly, Lee Ponsky
2:05
PANEL DISCUSSION - MALE URINARY
INCONTINENCE AND SEXUAL
REHABILITATION PROGRAM
Todd Doran, Allen Seftel
2:00 pm - 4:00 pm
INNOVATIONS IN UROLOGY - AUA AND THE ENDOUROLOGICAL SOCIETY
Science & Technology Hall Booth 1043 @ New Orleans Morial Convention Center
2:45
KEYNOTE LECTURE: THE COLLABORATION
PARADOX, INVENTING SOLUTIONS IN A
HYPER-CONNECTED ENVIRONMENT
John Abele
3:05
SBIR GRANT AND HOW HE
BENEFITTED/USED IT
Hassan Razvi
CORPORATE VIEW ON PATENTS
Robert Behl
3:20
TALK ON STARTUPS, LESSONS LEARNED,
AND ALTERNATIVES TO SBIR
Errol Singh
ABSTRACTS HIGHLIGHTING INNOVATION
PROJECTS FROM ENGINEERING AND
UROLOGY
3:30
PANEL DISCUSSION
Moderator: Christopher Loose
Panelists: Maurice Garcia, Errol Singh, Hassan
Razvi, Ziya Kirkali, William Roberts
2:00
Moderator: Bodo Knudsen
2:05
LECTURE ON GRANTS PROCESS AND
AVAILABILITY
Ziya Kirkali
2:15
2:30
100
2:55 pm - 7:30 pm
2:55
OPENING REMARKS
Society Chair: Ates Kadioglu
3:00
URO-ONCOLOGY SESSION
Moderators: Mevlana Derya Balbay, Bulent Semerci
4:45
STANDARD TO MICRO PERC - HAS THE
MINIATURIZATION COME TO AN END
Thomas Knoll
5:00
CASE DISCUSSIONS ON URINARY STONE
DISEASE
Moderator: Murat Binbay
Panelists: Sulcek Guven, Stephen Nakada, Thomas
Knoll
5:30
ROBOTIC UROLOGIC SURGERY SESSION
TO SCREEN OR NOT TO SCREEN IN
PROSTATE CANCER
Douglas Scherr
3:20
3:40
4:00
4:15
4:30
CASTRATE RESISTANT PROSTATE CANCER:
AN UPDATE
Laurence Klotz
CHALLENGING SITUATIONS DURING
ROBOTIC PROSTATECTOMY: TIPS & TRICKS
Vipul Patel
CASE DISCUSSIONS ON PROSTATE CANCER
Moderator: Oner Sanli
Panelists: Laurence Klotz, Fatih Atug, Raja Khauli,
Douglas Scherr
5:40
ENDOUROLOGY SESSION
Moderator: Burak Turna
COMPLICATIONS: MALFUNCTION, BLEEDING,
VASCULAR INJURY, ETC
Mohamad Allaf
5:50
NEW CONCEPTS IN THE PATHOPHYSIOLOGY
OF STONE DISEASE
Stephen Nakada
NEW ROBOTIC SYSTEMS AND DEVELOPING
SURGICAL TECHNIQUES
Volkan Tugcu
6:00
AUA-TURKISH ASSOCIATION OF UROLOGYPOSTER SESSION
7:30
ADJOURN
ESWL IS NOT DEAD; HOW TO IMPROVE THE
SUCCESS RATE
James Lingeman
CREDITTM
RESIDUAL FRAGMENTS: SURVEILLANCE OR
TREATMENT
Kemal Sarica
3:00 pm - 5:30 pm
JOINT PROGRAM OF THE HUNGARIAN (HUA) AND POLISH (PTU) UROLOGICAL ASSOCIATIONS
3:00
Peter Tenke
3:05
NEUROSTIMULATION IN UROLOGY
Jerzy B. Gajewski
3:15
PROSTATE CANCER MARKER PANEL WITH
SINGLE CELL SENSITIVITY IN URINE
Gyorgy Petrovics
3:25
TARGETING GASTRIN-RELEASING PEPTIDE
RECEPTORS IN PROSTATE CANCER - FROM
BASIC RESEARCH TO CLINICAL
APPLICATION
Ferenc Rick
3:35
NEW DEVELOPMENTS IN GENETIC
PROFILING OF PROSTATE CANCER – NEW
CLINICAL APPLICATIONS FOR THE OCOTYPE
DX ASSAY
Bela Denes
3:45
FREQUENT OVEREXPRESSION OF ETSRELATED GENE-1 (ERG1) IN PROSTATE
CANCER TRANSCRIPTOME: THE DECADE IN
REVIEW
Albert Dobi
*Presenting author
101
3:55
THE ROLE OF INTRAOPERATIVE FROZEN
SECTION DURING LAPAROSCOPIC RADICAL
PROSTATECTOMY
Péter Tenke
4:05
HEALTH-RELATED QUALITY OF LIFE IN BPH/
LUTS: A CROSS-SECTIONAL STUDY FROM
HUNGARY
Ágnes Kovács, Fanni Rencz, Valentin Brodszky
4:15
SUCCESSFUL TREATMENT OF
INCONTINENCE WITH PROLAPSE: WHY
LAPAROSCOPY?
Zsolt Domján
4:25
PROGNOSTIC AND PREDICTIVE BIOMARKERS
FOR DEXRYPTION OF TUMOR
HETEROGENEITY IN URINARY BLADDER
CANCER
Péter Nyirády
4:35
QUESTION OF MASCULINITY OR JUST A
PRISON COURAGE?
Zoltán Bajory
SATURDAY
AUA-EURASIAN UROLOGY PLATFORM (EUP) JOINT MEETING PROGRAM
4:45
POLISH UROLOGICAL ASSOCIATION ON
THEIR WAY TO COOPERATE WITH HUA AND
AUA
Piotr L. Chlosta
4:55
LAPAROSCOPIC RADICAL CYSTECTOMY:
TECHNIQUE, RESULTS AND LIMITATIONS
Piotr L. Chlosta
5:05
CLINICAL VALUE OF EXTENDED LND DURING
ENDOSCOPIC RADICAL PROSTATECTOMY
Jakub Dobruch
5:15
TISSUE ENGINEERING IN RECONSTRUCTIVE
UROLOGY
Tomasz Drewa
5:25
CLOSING REMARKS
5:30
ADJOURN
3:30 pm - 5:30 pm
TRAUMA/RECONSTRUCTION: URETER, BLADDER, EXTERNAL GENITALIA AND UROTRAUMA II
Moderators: Sean Elliott and Jerilyn Latini
MP29-07 COMPLICATIONS ASSOCIATED WITH
CLEAN INTERMITTENT SELF
CATHETERISATION IN PATIENTS WITH
ARTIFICIAL URINARY SPHINCTER FOR
THE TREATMENT OF NEUROPATHIC
BLADDER DYSFUNCTION
Anastasia Frost*, Andrew Cole, Michael
Fadel, Simon Bugeja, Daniela Andrich,
Anthony Mundy, London, United Kingdom
MP29-01 MULTI-INSTITUTIONAL STUDY OF
ROBOTIC BUCCAL MUCOSA GRAFT
URETEROPLASTY: INITAL RESULTS
Lee C Zhao*, Yuka Yamaguchi, Darren J
Bryk, New York, NY, Michael M Maddox,
Mary K Powers, New Orleans, LA, Andrew
Harbin, Ziho Lee, Laura Giusto, Philadelphia,
PA, Benjamin R Lee, New Orleans, LA,
Daniel D Eun, Philadelphia, PA, Michael D
Stifelman, New York, NY
MP29-08 INDICATIONS AND TIMING OF REVISION
SURGERY IN PATIENTS HAVING HAD
MULTIPLE ARTIFICIAL URINARY
SPHINCTERS
Anastasia Frost*, Simon Bugeja, Daniela
Andrich, Anthony Mundy, London, United
Kingdom
MP29-02 PREOPERATIVE PAD USAGE AND
ELEVATED BMI ARE INDEPENDENTLY
ASSOCIATED WITH FAILURE OF MALE
TRANSOBTURATOR SLINGS IN
OTHERWISE WELL SELECTED PATIENTS
Logan Zemp*, Nathan Hoy, Keith Rourke,
Edmonton, Canada
MP29-09 VESICOVAGINAL FISTULA REPAIR – 27
YEAR EXPERIENCE
Christopher Zappavigna*, Sender Herschorn,
Toronto, Canada
MP29-03 PENILE PROSTHESIS PLACEMENT IN
PATIENTS WITH A HISTORY OF TOTAL
PHALLIC CONSTRUCTION
Jack Zuckerman*, Kate Smentkowski, Dave
Gilbert, Ramon Virasoro, Jeremy Tonkin,
Gerald Jordan, Kurt McCammon, Norfolk, VA
MP29-10 RHABDOMYOLYSIS AFTER MAJOR
UROLOGIC SURGERY: INCIDENCE, RISK
FACTORS AND OUTCOMES
Joseph J. Pariser*, Shane M. Pearce, Sanjay
G. Patel, Vignesh T. Packiam, Blake B.
Anderson, Arieh L. Shalhav, Gregory T.
Bales, Norm D. Smith, Chicago, IL
MP29-04 THE LOSS OF PTEN CONSEQUENT TO
URETERAL OBSTRUCTION
CONTRIBUTES TO RENAL FIBROSIS
Sevann Helo*, Rohan Samarakoon, Amy
Dobberfuhl, Paul Higgins, Albany, NY
MP29-11 URETERAL RECONSTRUCTION WITH
ILEUM: LONG TERM FOLLOW-UP OF
RENAL FUNCTION
Joshua Roth*, Richard Bihrle, Matthew
Mellon, Indianapolis, IN
MP29-05 GRACILIS MUSCLE INTERPOSITION FLAP
REPAIR OF URINARY FISTULAE: PELVIC
RADIATION IS ASSOCIATED WITH
PERSISTENT URINARY INCONTINENCE
AND DECREASED QUALITY OF LIFE
Eswara, Boston, MA, Kerry Madison, Julio
Geminiani, Avory M. Heningburg, Steven B.
Brandes, St Louis, MO
MP29-12 USE OF THE ILEAL URETER FOR
RADIATION-INDUCED URETERAL
STRICTURES
Joshua Roth*, Richard Bihrle, Matthew
Mellon, Indianapolis, IN
MP29-06 RECONSTRUCTIVE SURGERY FOR URORECTAL AND PERINEAL FISTULAE
Simon Bugeja*, Anastasia Frost, Enrique Fes,
Stella Ivaz, Daniela E Andrich, Anthony R
Mundy, London, United Kingdom
MP29-13 CORPOROPLASTY WITH SMALL
INTESTINE SUBMUCOSA IN PATIENTS
WITH PEYRONIE’S DISEASE
Ramon Virasoro, Oscar A. Storme*, Kenneth
J. Delay, Jeremy B. Tonkin, Jack M.
Zuckerman, Kurt A. Mccammon, Gerald H.
Jordan, Norfolk, VA
102
MP29-15 CLINICAL OUTCOMES OF URETEROILEAL
ANASTOMOTIC STRICTURE
MANAGEMENT
Marcelino Rivera*, Boyd Viers, Patrick
Cockerill, Robert Tarrell, Prabin Thapa, Igor
Frank, Stephen Boorjian, Amy Krambeck,
Rochester, MN
MP29-19 BUILDING VIABLE TISSUES USING A 3-D
BIOPRINTER FOR SURGICAL
RECONSTRUCTION
Hyun-Wook Kang, Sang Jin Lee*, John
Jackson, James Yoo, Anthony Atala, Winston
Salem, NC
MP29-20 PERIOPERATIVE OUTCOMES FOLLOWING
OPEN AND MINIMALLY INVASIVE
SACRAL COLPOPEXY. ANALYSIS OF THE
DATABASE
Ahmed Sarhan*, Ahmad Shabsigh, Ketul
Shah, Columbus, OH
MP29-16 INCIDENCE AND RISK FACTORS OF
URETEROENTERIC ANASTOMOTIC
STRICTURE FOLLOWING RADICAL
CYSTECTOMY WITH URINARY
DIVERSION
Boyd Viers*, Amy Krambeck, Marcelino
Rivera, R. Jeffrey Karnes, Robert Tarrell,
Prabin Thapa, R. Houston Thompson,
Matthew Tollefson, Stephen Boorjian,
Rochester, MN
MP29-17 LONG-TERM OUTCOMES IN THE
MANAGEMENT OF TRAUMATIC
URETHRAL DISRUPTION INJURIES
Niels V Johnsen*, Stephen Mock, W Stuart
Reynolds, Roger R Dmochowski, Douglas F
Milam, Melissa R Kaufman, Nashville, TN
*Presenting author
CREDITTM
103
SATURDAY
MP29-18 PREFABRICATION OF NEUROMUSCULAR
JUNCTION FOR ACCELERATED
RECOVERY OF MUSCLE FUNCTION
In Kap Ko, Sang Jin Lee*, John Jackson,
Anthony Atala, James Yoo, Winston Salem,
NC
MP29-14 MANAGEMENT OF PUBIC
OSTEOMYELITIS FOLLOWING RADIATION
THERAPY FOR PROSTATE CANCER
McCabe C. Kenny*, Andrew P. Windsperger,
Brian J. Flynn, Ty T. Higuchi, Aurora, CO
3:30 pm - 5:30 pm
STONE DISEASE: SURGICAL THERAPY III
Moderators: Ben Chew and Michael Ferrandino
ABSTRACT
NUMBER TITLE
MP30-01 PATIENTS ARE AT RISK FOR
PYELOVENOUS BACKFLOW DURING
PERCUTANEOUS
NEPHROSTOLITHOTOMY
Muhannad Alsyouf*, Roger Li, Michelle
Lightfoot, Herbert Hodgson, Nigel Gillespie,
Kristene Myklak, Daniel Faaborg, Javier L.
Arenas, Gaudencio Olgin, D. Duane Baldwin,
Loma Linda, CA
ABSTRACT
NUMBER TITLE
MP30-07 ASSESSMENT OF STONE COMPLEXITY
FOR PCNL: A SYSTEMATIC REVIEW OF
THE EVIDENCE
John Withington*, London, United Kingdom,
James Armitage, Cambridge, United
Kingdom, Will Finch, Norwich, United
Kingdom, Stuart Irving, Norfolk, United
Kingdom, Oliver Wiseman, Cambridge,
United Kingdom, Jonathan Glass, London,
United Kingdom, Neil Burgess, Norwich,
United Kingdom
MP30-02 A NOVEL DOSIMETER FOR MEASURING
THE AMOUNT OF RADIATION EXPOSURE
DURING PERCUTANEOUS
NEPHROLITHOTOMY: INSTADOSE™
Emrah Yuruk*, Istanbul, Turkey, Gokhan
Gureser, Ankara, Turkey, Murat Tuken,
Kasim Ertas, Ege Can Serefoglu, Istanbul,
Turkey
MP30-08 CAN ACTIVITIES OF DAILY LIVING
PREDICT FOR COMPLICATIONS
FOLLOWING PERCUTANEOUS
NEPHROLITHOTOMY?
David Leavitt*, Shamus Moran, Piruz
Motamedinia, Michael Siev, Mathew
Fakhoury, Manaf Alom, David Hoenig, Arthur
Smith, Zeph Okeke, New Hyde Park, NY
MP30-03 IS PREOPERATIVE ANTIBIOTIC
PROPHYLAXIS FOR HIGH-RISK PATIENTS
NECESSARY BEFORE PERCUTANEOUS
NEPHROLITHOTOMY? A RETROSPECTIVE
REVIEW OF 7 VS 2 VS 0 DAY THERAPY
Jeffrey Larson*, Aaron Potretzke, Alana
Desai, Brian Benway, St. Louis, MO
MP30-09 URETERIC STENT VERSUS
PERCUTANEOUS NEPHROSTOMY FOR
ACUTE URETERAL OBSTRUCTION CLINICAL OUTCOME AND QUALITY OF
LIFE: A BI-CENTER PROSPECTIVE STUDY
Tomer Erlich*, Ramat gan, Israel, Ohad
Shoshany, Shay Golan, Pinhas Livne, David
Lifshitz, Petach Tikva, Israel, Barak
Rosenzweig, Alon Eisner, Nir Kleinman,
Yoram Mor, Jacob Ramon, Harry Winkler,
Ramat gan, Israel
MP30-04 X-RAY FREE DOPPLER ULTRASOUND
GUIDED PERCUTANEOUS
NEPHROLITHOTOMY: THE LARGEST
SAMPLE CASES EXPERIENCE FROM
CHINA
Bo Xiao, Jianxing Li*, Weiguo Hu, Bo Yang,
Liang Chen, Beijing, China, People’s
Republic of
MP30-10 INTRAOPERATIVE NOISE POLLUTION
AND ITS EFFECT UPON COMMUNICATION
DURING PERCUTANEOUS
NEPHROSTOLITHOTOMY
Kristene Myklak*, Hayley Mowery, Muhannad
Alsyouf, Roger Li, Michelle Lightfoot, Chase
Atiga, David Tryon, Herbert Hodgson, Carol
Conceicao, Daniel Faaborg, Javier L. Arenas,
Nazih Khater, Herbert C. Ruckle, D. Daniel
Baldwin, D. Duane Baldwin, Loma Linda, CA
MP30-05 A PROSPECTIVE EVALUATION OF THE
SURGEON PERSPECTIVE FOR
DETERMINING STONE-FREE STATUS
AFTER PERCUTANEOUS
NEPHROLITHOTOMY
Ahmed Harraz*, Yasser Osman, Osama
Mahmoud, Amr Elsawy, Islam Fakhreldin,
Ahmed El-Nahas, Ahmed Shoma, Ahmed
Shokeir, Mansoura, Egypt
MP30-11 PERINEPHRIC FAT DISTRIBUTION AND
ANATOMICAL CONSIDERATIONS WHEN
PERFORMING PERCUTANEOUS
NEPHROLITHOTOMY IN OBESE
PATIENTS
TAREK ALZAHRANI*, Daniela Ghiculete,
Alaina Garbens, Kenneth Pace, R.J. D’A.
Honey, Toronto, Canada
MP30-06 ACUTE KIDNEY INJURY AFTER
FOR STONES IN A SOLITARY KIDNEY
Ahmed EL-Nahas, Diaa-Eldin Taha*, Hussien
Ali, Mohamed Zahran, Mahmoud Othman,
Ahmed Harraz, Ahmed Mosbah, Ahmed
Shokeir, Mansoura, Egypt
MP30-12 POST PERCUTANEOUS
NEPHROLITHOTOMY, WHAT DEFINES
CLINICAL INSIGINIFICANT RESIDUAL
FRAGMENTS
Tze Ying, Benjamin Lim*, Wai Loon Yam,
Sey Kiat Lim, Foo Cheong Ng, Kok Kit Ng,
104
MP30-17 NATURAL HISTORY OF RESIDUAL
FRAGMENTS FOLLOWING
PERCUTANEOUS
NEPHROSTOLITHOTOMY
Kyle Wood*, Marc Colaco, Juan Mainez, Ilya
Gorbachinsky, Miguel Osorio, Eliud Sanchez,
Majid Mirzazadeh, Winston-Salem, NC, Dean
Assimos, Birmingham, AL, Jorge GutierrezAceves, Winston-Salem, NC
MP30-18 COMPLIANCE WITH GUIDELINES FOR
ANTIBIOTICS AFTER PERCUTANEOUS
NEPHROLITHOTOMY DOES NOT
INCREASE INFECTIOUS
COMPLICATIONS: A RETROSPECTIVE
COHORT STUDY
Sameer Deshmukh*, Seth Bechis, Boston,
MA, Kevan Sternberg, Benjamin King,
Burlington, VT, Brian Eisner, Boston, MA
MP30-19 IMPACT OF THE GUY’S STONE SCORE ON
SUCESS RATES FOR PERCUTANEOUS
NEPHROLITHOTOMY
Fabio C Vicentini*, Carlos Watanabe-Silva,
Thiago Ac Ferreira, Claudio B Murta,
Joaquim F A Claro, São Paulo, Brazil
MP30-14 UPPER POLE UROLOGIST-OBTAINTED
PERCUTANEOUS RENAL ACCESS FOR
PCNL IS SAFE AND EFFICACIOUS
Amar Patel*, Don Bui, John Pattaras,
Kenneth Ogan, Atlanta, GA
MP30-15 PREDICTORS OF HOSPITAL
READMISSION AFTER PERCUTANEOUS
NEPHROLITHOTOMY: ANALYSIS OF
MORE THAN 700 CONSECUTIVE
PATIENTS FROM A TERTIARY REFERRAL
CENTER
Yasser Osman, Ahmed Harraz, Diaa-Eldin
Taha*, Amr Elsawy, Nasr El-Tabey, Ahmed
El-Nahas, Ahmed Shoma, Ahmed Shokeir,
Mansoura, Egypt
MP30-20 MAJOR POSTOPERATIVE
COMPLICATIONS AFTER
(PCNL) IN A SINGLE TERTIARY
REFERRAL CENTRE
Daniel Olvera-Posada*, Thomas Tailly,
Philippe Violette, Husain Alenezi, John
Denstedt, Hassan Razvi, London, Canada
CREDITTM
3:30 pm - 5:30 pm
BENIGN PROSTATIC HYPERPLASIA: BASIC RESEARCH
Moderator: Robert Getzenberg
ABSTRACT
NUMBER TITLE
MP31-01 FUNCTIONAL MRNA - MICRORNA
REGULATORY MODULES IDENTIFIED
USING COMPREHENSIVE MOLECULAR
CHARACTERIZATION OF BLADDER
OUTLET OBSTRUCTION
Katia Monastyrskaya*, Ali Hashemi Gheinani,
Bern, Switzerland, Hubert Rehrauer,
Catharine Aquino Fournier, Zurich,
Switzerland, Irene Keller, Rémy Bruggmann,
Fiona C. Burkhard, Bern, Switzerland
*Presenting author
ABSTRACT
NUMBER TITLE
MP31-02 SELECTIVE ␣1A-ADRENOCEPTOR BLOCKER
SILODOSIN AMELIORATES VENTRAL
PROSTATIC ENLARGEMENT IN THE
SPONTANEOUSLY HYPERTENSIVE RAT :
POSSIBLE ROLE OF THE PROSTATIC
BLOOD FLOW
Shogo Shimizu*, Nankoku, Japan, Panagiota
Tsounapi, Yonago, Japan, Takahiro Shimizu,
Youichirou Higashi, Kumiko Nakamura, Felix
Holmstrom, Nankoku, Japan, Masashi Honda,
Yonago, Japan, Keiji Inoue, Motoaki Saito,
Nankoku, Japan
105
SATURDAY
MP30-16 PROGNOSTIC FACTORS OF
POSTOPERATIVE COMPLICATIONS IN
Fabio C Vicentini*, Carlos H Watanabe-Silva,
Vinicius Meneguete, Rodrigo Perrela, Claudio B
Murta, Joaquim F A Claro, São Paulo, Brazil
MP30-13 PREOPERATIVE FACTORS AFFECTING
RADIATION TIME DURING
PERCUTANEOUS NEPHROLITHOTOMY: A
MULTI-INSTITUTIONAL ANALYSIS
Zhamshid Okhunov*, Orange, CA, Vincent
Bird, Arash Akhavein, Gainesville, FL, Daniel
Moreira, Arvin George, Sammy Elsamra,
Hempstead, NY, Brian Duty, Portland, OR,
Michael Del Junco, Orange, CA, Fotima
Asquarova, Michael Rothberg, Mantu Gupta,
New York, NY, Chad Tracy, Mark Newton,
Iowa City, IA, Kevan Sternberg, Benjamin
King, Burlington, VT, Edan Shapiro, New
York, NY, Jorge Moreno, Mexico City,
Mexico, Christopher Pulford, Orange, CA,
Juan Carlos Rosales, Caracas, Venezuela,
Arun Srinivasan, Philadelphia, PA, Yasser
Noureldin, Sero Andonian, Montreal, Canada,
Nazih Khater, Duane Baldwin, Loma Linda,
CA, Khurshid Ghani, Maksim Shlykov, Ann
Arbor, MI, Ramy Youssef, Orange, CA, Brian
Shinsky, Madison, WI, Justin Friedlander,
Philadelphia, PA, Steven Nakada, Madison,
WI, Stuart Wolf Jr., Ann Arbor, MI, Arthur D.
Smith, Zeph Okeke, Hempstead, NY, Jaime
Landman, Orange, CA
MP31-10 ADDITIVE CONTRACTIONS BY
THROMBOXANE A2 AND ENDOTHELIN-1
ARE STRONGER THAN
NOREPINEPHRINE-INDUCED
CONTRACTIONS IN HUMAN PROSTATE
SMOOTH MUSCLE
Martin Hennenberg*, Alice C. Acevedo,
Alexander Tamalunas, Yiming Wang, Beata
Rutz, Frank Strittmatter, Raphaela Waidelich,
Christian G. Stief, Christian Gratzke, Munich,
Germany
MP31-03 DIFFERENCES IN THE CONTRACTILITY
OF HUMAN ISOLATED PROSTATIC
URETHRA TO OXYTOCIN AND
NOREPINEPHRINE IN BENIGN
PROSTATIC HYPERPLASIA: POTENTIAL
ROLE OF OXYTOCIN IN BPH
Stewart McCallum, Collegeville, PA, Celine
Rouget, Moez Rekik, TOULOUSE, France,
Philippe Camparo, Henry Botto, Suresnes,
France, Pascal Rischmann, Philippe Lluel,
Stefano Palea, Timothy Westfall*,
TOULOUSE, France
MP31-11 IMPACT OF TESTOSTERONE DEFICIENCY
ON BLADDER SMOOTH MUSCLE
FUNCTION IN MALE RATS WITH
BLADDER OUTLET OBSTRUCTION
Masafumi Kita*, Kazumi Hashizume, Naoki
Wada, Seiji Matsumoto, Hidehiro Kakizaki,
Asahikawa, Japan
MP31-04 CD8ⴙ T CELLS PROMOTE
PROLIFERATION OF BENIGN PROSTATIC
HYPERPLASIA EPITHELIAL CELLS IN THE
CONDITION OF LOW ANDROGEN
Yang Yang*, Shuai Hu, Yu Fan, Yun Cui,
Mengkui Sun, Jie Jin, Beijing, China,
MP31-12 TAMSULOSIN IMPROVES MEMORY
FUNCTION BY ACTIVATING NMDA
RECEPTORS IN RAT HIPPOCAMPUS
Kyung Jin Chung*, Chang Hee Kim, Kwang
Taek Kim, Jin Gyu Oh, Tae Beom Kim, Han
Jung, Incheon, Korea, Republic of, Kwang Ho
You, GwangMyeong, Korea, Republic of,
Young Sam Cho, Sung Tae Cho, Seoul,
Korea, Republic of, Sang Jin Yoon, Khae
Hawn Kim, Incheon, Korea, Republic of
MP31-05 UROTHELIAL DYSFUNCTION AND
CHRONIC INFLAMMATION IN PATIENTS
WITH BLADDER OUTLET OBSTRUCTION
AND DIFFERENT BLADDER
DYSFUNCTION AND DIFFERENT
BLADDER OUTLET OBSTRUCTION
DEGREE
Chung-Cheng Wang*, New Taipei City,
Taiwan, Jia-Hui Chang, Hann-Chorng Kuo,
Hualien, Taiwan
MP31-13 UPREGULATED EXPRESSION OF NLRP1
AND DOWNSTREAM CYTOKINES
SUPPORT A ROLE OF INFLAMMASOME
PATHWAY IN PROSTATIC INFLAMMATION
ASSOCIATED WITH BPH
Pradeep Tyagi*, Mahendra Kashyap, Subrata
Pore, Zhou Wang, Naoki Yoshimura,
Pittsburgh, PA
MP31-06 UPREGULATION OF
PHOSPHODIESTERASE TYPE 5 IN THE
HYPERPLASTIC PROSTATE: A RAT
MODEL STUDY
Wenhao Zhang, Ping Chen, Devendra Singh
Negi, Zhuo Li, Keke Zhao, Qi Mao, Xinhua
Zhang*, Wuhan, China, People’s Republic of
MP31-14 CHANGES IN APOPTOSIS RELATED
PROTEINS IN THE BLADDER AFTER
PARTIAL BLADDER OUTLET
OBSTRUCTION RELIEF
Ki Hak Song, Chong koo Sul, Yong gil Na,
Jae sung Lim, Ju Hyun Shin, Jong mok
Park*, Daejeon, Korea, Republic of
MP31-07 EFFECT OF DUTASTERIDE ON
INTRAPROSTATIC LEVELS OF
ESTROGENS AND ANDROGENS IN MEN
WITH BENIGN PROSTATIC HYPERPLASIA
Itsuhiro Takizawa*, Niigata, Japan, Fumio
Ishizaki, Nagaoka, Japan, Yoshimichi
Miyashiro, Kawasaki, Japan, Takeshi
Komeyama, Hideo Morishita, Nagaoka,
Japan, Tsutomu Nishiyama, Niigata, Japan
MP31-15 GENE EXPRESSION PROFILING REVEALS
MOLECULAR SUBTYPES OF BENIGN
PROSTATIC HYPERPLASIA
Keyan Salari*, Seth Bechis, Rongbin Ge, Jian
Hong, Aleksander Otsetov, Zongwei Wang,
Shahin Tabatabaei, Aria Olumi, Boston, MA
MP31-08 A TISSUE SPECIFIC ROLE FOR LIGAND
INDEPENDENT ARV7 SIGNALING IN
BENIGN PROSTATE PATHOGENESIS
Tyler M. Bauman*, Emily A. Ricke, Wei
Huang, William A. Ricke, Madison, WI
MP31-16 SEROTONIN INHIBITS PROSTATE
GROWTH DOWN REGULATING
ANDROGEN RECEPTORS: EVIDENCE FOR
A NOVEL THEORY FOR BPH
Emanuel Carvalho-Dias*, Olga Martinho,
Paulo Mota, Estêvão Lima, Jorge CorreiaPinto, Braga, Portugal
MP31-09 THE EFFECTS OF CURRENTLY USED
ANTI-HYPERTENSIVES ON THE
CONTRACTILITY OF THE HUMAN
PROSTATE GLAND
Betty Exintaris*, Basu Chakrabarty, Brad
Wittmer, Melissa Papargiris, Sarah Wilkinson,
Mark Frydenberg, Nathan Lawrentschuk,
John Pedersen, Tim Nottle, Andrew Ryan,
Sam Norden, Gail Risbridger, Melbourne,
Australia
MP31-17 ROLE OF PHYSICAL ACTIVITY IN THE
PREVENTION OF BPH THROUGH
INHIBITION OF PROSTATIC IGF1/AKT
PROLIFERATIVE AXIS: AN
EXPERIMENTAL STUDY IN RATS
Fernando Fróes Fonseca*, André M Oliveira,
Sabrina T Reis, Kátia R Leite, William C
Nahas, Miguel Srougi, Alberto A Antunes,
São Paulo, Brazil
106
MP31-19 ESTROGEN RECEPTOR-ALPHA IS
NECESSARY FOR HORMONAL
INDUCTION OF PROSTATE GROWTH IN
MALE MICE
Tristan Nicholson*, Jalissa Wynder, William
Ricke, Madison, WI
CREDITTM
3:30 pm - 5:30 pm
GENERAL & EPIDEMIOLOGICAL TRENDS & SOCIOECONOMICS: PRACTICE PATTERNS, COST EFFECTIVENESS IV
Moderator: David Miller
ABSTRACT
NUMBER TITLE
MP32-01 VALIDATION OF NATURAL-LANGUAGEPROCESSING AS AN AUTOMATED
METHOD FOR IDENTIFYING RADICAL
CYSTECTOMIES PERFORMED FOR
BLADDER CANCER
Hung-Jui Tan*, Robin Clarke, Arnold I. Chin,
Alan L. Kaplan, Mark S. Litwin, Christopher
S. Saigal, Karim Chamie, Andrew D.
Hackbarth, Los Angeles, CA
ABSTRACT
NUMBER TITLE
MP32-06 DOES THE OWNERSHIP OF RADIATION
ONCOLOGY SERVICES AFFECT
UROLOGISTS’ PRACTICE PATTERNS FOR
THE TREATMENT OF PROSTATE
CANCER?
Deborah Kaye*, Theodore DeWeese, Heather
Chalfin, Bruce Trock, Zhaoyong Feng, Misop
Han, Baltimore, MD
MP32-07 THE DRIVING FORCES AND COST OF
READMISSIONS AND DEATHS IN POSTOPERATIVE RADICAL CYSTECTOMY
PATIENTS AT 30 DAY AND 90 DAY
READMISSIONS
Danny Lascano*, Jamie S Pak, Daniel Kabat,
LaMont J Barlow, G. Joel DeCastro, William
Gold, James M McKiernan, New York, NY
MP32-02 BASELINE UTILIZATION AND OUTCOMES
OF INPATIENT SURGICAL CARE FOR
HOSPITALS PARTICIPATING IN
ACCOUNTABLE CARE ORGANIZATIONS
Scott Hawken*, Lindsey Herrel, Chandy
Ellimoottil, Zachary Montgomery, Zaojun Ye,
MP32-08 READMISSIONS AFTER MAJOR
UROLOGIC CANCER SURGERY
Jeffrey Leow*, Julian Hanske, Christian
Meyer, Boston, MA, Giorgio Gandaglia, Milan,
Italy, Marianne Schmid, Hamburg, Germany,
Jesse Sammon, Firas Abdollah, Mani Menon,
Detroit, MI, Maxine Sun, Montreal, Canada,
Joachim Noldus, Herne, Germany, Adam
Kibel, Quoc-Dien Trinh, Boston, MA
MP32-03 TRENDS IN THE DELIVERY OF UROLOGIC
PROCEDURAL CARE BY ADVANCED
PRACTICE PROVIDERS
Matthew Uhlman*, Thomas Gruca, Bradley
Erickson, Iowa City, IA
MP32-04 EMERGENCY DEPARTMENT REVISITS
FOR PATIENTS WITH KIDNEY STONES
Charles Scales, Jr.*, Li Lin, Durham, NC,
Christopher Saigal, Carol Bennett, Ninez
Ponce, Carol Mangione, Mark Litwin, Los
Angeles, CA
MP32-09 USING LEAN METHODOLOGY FOR
UROLOGY PATIENT CALL CENTER
IMPROVEMENT AT A SINGLE ACADEMIC
INSTITUTION
Thomas Tieu*, Bradford Stevenson, Teri
Baldini, Tobias S. Kohler, Springfield, IL,
Christopher Gonzalez, Chicago, IL, Kevin T.
McVary, Springfield, IL
MP32-05 SOCIETAL COSTS AFTER UPPER TRACT
UROLOGIC SURGERY
Peter Chang*, Peter R Renehan, Kimberly
Taylor, Ostap Dovirak, Arie Carneiro, Kyle
McAnally, Catrina Crociani, Boston, MA,
Andrew Percy, Richmond, VA, Andrew A
Wagner, Boston, MA
*Presenting author
MP32-10 MEASURING THE TRUE COST OF
TREATING SMALL RENAL MASSES: AN
ASSESSMENT OF TIME-DRIVEN
ACTIVITY-BASED-COSTING
Aaron Laviana*, Chandan Kundavaram,
Hung-Jui Tan, Michael Burke, Douglas
Niedzwiecki, Nisheeta Setlur, Christopher
Saigal, Jim Hu, Los Angeles, CA
107
SATURDAY
MP31-20 THE EFFECT OF SYSTEMIC
INFLAMMATION ON PROSTATE VOLUME:
A STUDY OF SERUM MAKERS
Ryan Werntz*, Wesley Stoller, Brittany
Holzhammer, Jackilen Shannon, Mark
Garzotto, Portland, OR
MP31-18 TESTOSTERONE MODIFIES
ALTERATIONS TO DETRUSOR MUSCLE
AFTER PARTIAL BLADDER OUTLET
OBSTRUCTION IN MICE
Andrew Flum*, Diana Bowen, Grace Delos
Santos, Natalie Kukulka, Paula Firmiss,
Robert Dettman, Edward Gong, Chicago, IL
MP32-17 “CHOOSING WISELY” – PROSTATE
CANCER SCREENING, DIAGNOSIS, AND
TREATMENT AMONG THE ELDERLY MEN
IN ISRAEL
Liat Shavit Grievink*, Petah Tikva, Israel,
Moshe Hoshen, Becca Feldman, Ran Balicer,
Tel Aviv, Israel, Jack Baniel, Eli Rosenbaum,
David Margel, Petah Tikva, Israel
MP32-11 THE DIFFERENCE A YEAR CAN MAKE:
ACADEMIC PRODUCTIVITY OF
RESIDENTS IN 5 VERSUS 6-YEAR
UROLOGY PROGRAMS
Julia B Finkelstein*, Jason P Van Batavia,
New York, NY, James S Rosoff, New Haven,
CT
MP32-12 HOW SURGEONS EARN THEIR KEEP:
DATA FROM THE CMS DATA RELEASE
Aaron Laviana*, Jim Hu, Steven Lerman,
Kwan Lorna, William Aronson, Carol Bennett,
Jonathan Bergman, Los Angeles, CA
MP32-18 A COMPARISON BETWEEN UROLOGY
AND OTHER SPECIALITIES IN THE
UTILIZATION OF TWITTER AT
INTERNATIONAL CONFERENCES
Amanda S Chung*, Kit H Lee, Henry H Woo,
Sydney, Australia
MP32-13 FREQUENCY OF UTILIZATION AND
REIMBURSEMENT OF VARIOUS
DIAGNOSTIC TESTS AND TREATMENTS
FOR TESTICULAR CANCER
Austin Barber*, Mohamed Kamel, Ehab
Eltahawy, Rodney Davis, Little Rock, AR
MP32-19 HOSPITAL UTILIZATION & TRAVEL
PATTERNS OF INPATIENT UROLOGICAL
SURGERY PATIENTS IN NEW YORK
STATE: HAVE TRAVEL PATTERNS
CHANGED SINCE 1982?
Khawaja Bilal*, New York, NY, Mark
Finkelstein, New York City, NY, Rajiv
Jeyadevan, New York, NY, Michael Palese,
New York City, NY
MP32-14 OBSERVING SHARED DECISION-MAKING
IN THE UROLOGY CLINIC: A PILOT
STUDY AMONG MEN WITH PROSTATE
CANCER
Alan L Kaplan*, Josemanuel D Saucedo, Los
Angeles, CA, Glyn Elwyn, Hanover, NH,
Catherine M Crespi, Los Angeles, CA,
Masahito Jimbo, Ann Arbor, CA, Christopher
S Saigal, Los Angeles, CA
MP32-20 TAKING THE PROCEDURE TO THE
PATIENT: INCREASING ACCESS TO
UROLOGIC PROCEDURAL CARE
THROUGH OUTREACH
Matthew Uhlman*, Thomas Gruca, Bradley
Erickson, Iowa City, IA
MP32-15 READMISSION INTENSITY AFTER HIGHRISK SURGERY
Bruce Jacobs*, Pittsburgh, PA, Chang He,
Benjamin Li, Michael Hu, Alex Helfand,
Naveen Krishnan, Brent Hollenbeck, Ann
Arbor, MI, Jonathan Helm, Bloomington, IN,
Mariel Lavieri, Ted Skolarus, Ann Arbor, MI
CREDITTM
MP32-16 TRENDS IN MESH USE IN PELVIC ORGAN
PROLAPSE REPAIR
Lily Wang*, Bashir Al Hussein Al Awamlh,
Tina Schubert, Melissa Laudano, Daniel Lee,
Wesley Davidson, Michael Schulster, Fujun
Zhao, Bilal Chughtai, Richard Lee, New York,
NY
3:30 pm - 5:30 pm
STONE DISEASE: BASIC RESEARCH I
Moderators: John Denstedt and Saeed Khan
ABSTRACT
NUMBER TITLE
MP33-01 MINERAL GRADIENTS IN HUMAN RENAL
PAPILLAE WITH AND WITHOUT
RANDALL’S PLAQUE
Sunita Ho*, San Francisco, CA, Frances
Allen, Andrew Minor, Berkeley, CA, Sabra
Djomehri, Ling Chen, Thomas Chi, Krishna
Ramaswamy, Marshall Stoller, San
Francisco, CA
ABSTRACT
NUMBER TITLE
MP33-02 TRANSCRIPTOME OF TAMM-HORSFALL
PROTEIN-DEFICIENT KIDNEYS REVEALS
SECONDARY EVENTS THAT MAY
CONTRIBUTE TO INTRA-RENAL
CALCINOSIS
Yan Liu, Ellen Shapiro, Herbert Lepor, XueRu Wu*, New York, NY
MP33-03 OXALOBACTER FORMIGENES
COLONIZATION NORMALIZES OXALATE
EXCRETION IN A GASTRIC BYPASS
MODEL OF HYPEROXALURIA
Benjamin Canales*, Marguerite Hatch,
Gainesville, FL
108
MP33-05 IN VITRO STUDY ON URETERAL SMOOTH
MUSCLE CONTRACTILITY WITH
TAMSULOSIN, NIFEDIPINE, AND
TERPENE MIXTURE (ROWATINEX¢Ç)
jea whan Lee*, Tae Hoon Oh, Whi-An Kwon,
Seung Chol Park, Hee Jong Jeong, Ill Young
Seo, Iksan city, Korea, Republic of
MP33-13 HYPERCALCIURIA AND MIGRATION OF
INFLAMMATORY MACROPHAGES PLAY
KEY ROLES FOR KIDNEY STONE
FORMATION IN METABOLIC SYNDROME
Kazumi Taguchi*, Nagoya, Japan, Rei Unno,
Naogya, Japan, Yasuhiro Fujii, Shuzo
Hamamoto, Ryosuke Ando, Atsushi Okada,
Takahiro Yasui, Keiji Fujita, Keiichi Tozawa,
Yutaro Hayashi, Kenjiro Kohri, Nagoya,
Japan
MP33-06 A NEW PORCINE MODEL OF ENTERIC
HYPEROXALURIA MIMICS EFFECTS OF
HIGH OXALATE ABSORPTION IN
HUMANS
Kristina L Penniston*, David A Bennett,
Leema M John, Elizabeth L Zars, Thomas D
Crenshaw, Madison, WI
MP33-14 SEASONAL VARIATION OF 25HYDROXYCHOLECALCIFEROL AND
SERUM AND URINE ELECTROLYTES IN A
POPULATION OF PATIENTS WITH STONE
DISEASE
David Crawley*, David Chalmers, Farmington,
CT, David O’Sullivan, Plainville, CT, Wilner
Samson, Hartford, CT, Edward Myer,
Middletown, CT
MP33-07 CLINICAL AND METABOLIC RISK
FACTORS FOR PLUG FORMATION
AMONG IDIOPATHIC CALCIUM OXALATE
STONE FORMERS
Marcelino Rivera*, Patrick Cockerill, Eric
Bergstralh, Ramila Mehta, Lisa Vaughan,
John Lieske, Amy Krambeck, Rochester, MN
MP33-15 MITOCHONDRIAL COLLAPSE DEPENDS
ON CYCLOPHILIN D IN RENAL TUBULAR
CELLS PROMOTES KIDNEY STONE
FORMATION
Yasuhiko Ito*, Takahiro Yasui, Kazuhiro
Niimi, Shoichiro Iwatsuki, Takashi
Hamakawa, Kazumi Taguchi, Yasuhiro Fujii,
Yasuhiko Hirose, Shuzo Hamamoto, Atsushi
Okada, Yukihiro Umemoto, Keiichi Tozawa,
Kenjiro Kohri, Nagoya, Japan
MP33-08 PROGESTERONE SURGE DECREASES
THE SEVERITY OF URETERAL STENT
RELATED SYMPTOMS IN FEMALE
PATIENTS
Emrah Yuruk*, Aykut Colakerol, Ege Can
Serefoglu, Istanbul, Turkey
MP33-09 HUMAN MONOCYTE-DERIVED
MACROPHAGES ARE ABLE TO DESTROY
KIDNEY STONES
Sergei Kusmartsev*, Paul Dominguez
Gutierrez, Benjamin Canales, Johannes
Vieweg, Saeed Khan, Gainesville, FL
MP33-16 ARE SPOT URINARY DIPSTICK PH
VALUES RELIABLY COMPARABLE TO
COMMERCIAL 24-HOUR URINARY PH?
William Shi*, Daniel L Miller, David L
Wenzler, Angela Wang, Roger L Sur, San
Diego, CA
MP33-10 QUANTITATIVE INVESTIGATION OF ZINC,
SELENIUM, STRONTIUM AND LEAD IN
HUMAN URINARY CALCULI BY USING
INDUCTIVELY COUPLED PLASMA
OPTICAL EMISSION SPECTROMETRY
Mahmoud El-Naggar*, Al Ain, United Arab
Emirates, Bedeir Ali-El-Dein, Mansoura,
Egypt, Sanjeev Mehta, Ahmedabad, India,
Naimat Alsaigh, Al ain, United Arab Emirates,
Manoj Monga, Ohio, OH
MP33-17 THE PREVENTIVE EFFECTS OF OXALATEDEGRADING ENZYME ON THE OXALATE
KIDNEY STONES IN INTESTINAL
HYPEROXALURIA RAT
Qiangqiang Ge, Zhong Chen*, Zhangqun Ye,
Wuhan, China, People’s Republic of
MP33-18 “THE ROLE OF RENAL TUBULAR CELL
INJURY IN THE EARLY PERIOD OF RENAL
CRYSTAL FORMATION” IDENTIFIED
FROM THE CELL INJURY-INHIBITING
EFFECT OF GREEN TEA
Masahito Hirose*, Konan, Japan, Rika Banno,
Kazuhiro Kanemoto, Konan City, Japan,
Atsushi Okada, Takahiro Yasui, Nagoya City,
Japan, Takeshi Sakakura, Konan City, Japan,
Keiichi Tozawa, Kenjiro Kohri, Nagoya City,
Japan
MP33-11 CALCIUM IS MORE EFFECTIVE THAN
VITAMIN B6 AT REDUCING OXALATE
EXCRETION IN A GASTRIC BYPASS
MODEL OF HYPEROXALURIA
Christopher Monsour*, Jesse Gregory,
Marguerite Hatch, Saeed Khan, Benjamin
Canales, Gainesville, FL
*Presenting author
109
SATURDAY
MP33-12 A NOVEL WET COUPLING DESIGN FOR
CONTEMPORARY ELECTROMAGNETIC
LITHOTRIPTERS: ELIMINATION OF
COUPLING DEFECTS AND IMPROVEMENT
OF COMMINUTION EFFICIENCY
Fernando Cabrera*, Richard Shin, Daniel
Concha, Jaclyn Lautz, Georgy Sankin,
Durham, NC, Ramy Youseff, Irvine, CA,
Charles Scales, Michael Lipkin, Glenn
Preminger, F. Hadley Cocks, Walter
Simmons, Pei Zhong, Durham, NC
MP33-04 HETEROGENEOUS NUCLEATION DRIVES
THE FORMATION OF NON-CALCIUM
URINARY STONES IN HUMANS AND
DROSOPHILA MELANOGASTER
Thomas Chi*, San Francisco, CA, Gregory
Tasian, Philadelphia, PA, Tiffany Zee, Sven
Lang, Gulinuer Muteliefu, Novato, CA, David
Killilea, Oakland, CA, Arnold Kahn, Pankaj
Kapahi, Novato, CA, Marshall Stoller, San
Francisco, CA
CREDITTM
MP33-19 THE RELATION BETWEEN CALCIUM
OXALATE STONE DISEASE AND SERUM
ANTIOXIDANT ENZYME LEVELS
Omer Cakir*, Damla Arisan, Serdar Arisan,
Ahmet Muslumanoglu, Istanbul, Turkey
3:30 pm - 5:30 pm
Podium Session 17
BLADDER CANCER: NON-INVASIVE II
Moderators: Gary Steinberg and Brant Inman
TIME
3:30
ABSTRACT
NUMBER TITLE
PD17-01 NATURAL RESISTANCE-ASSOCIATED
MACROPHAGE PROTEIN 1 (NRAMP1)
GENE POLYMORPHISMS AND RESPONSE
TO BACILLUS CALMETTE-GUERIN
THERAPY IN ASIAN NON-MUSCLE
INVASIVE BLADDER CANCER PATIENTS
Jen-Hwei Sng, Yew Koon Lim, Zi Ting Wang,
Lata Raman Nee Mani, Yiong Huak Chan,
Ma Thin Mar Win, Ratha Mahendran,
Edmund Chiong*, Singapore, Singapore
3:40
PD17-02 IS INTRAVESICAL BCG ALONE STILL THE
ONLY TRULY EFFECTIVE INTRAVESICAL
THERAPY FOR NON-MUSCLE INVASIVE
BLADDER CANCER?
Savino Mauro Di Stasi*, Rome, Italy, Claus
Riedl, Baden, Austria, Antonella Giannantoni,
Perugia, Italy, Cristian Verri, Francesco
Celestino, Francesco De Carlo, Rome, Italy,
Francesco Masedu, Marco Valenti, L’Aquila,
Italy
3:50
PD17-03 “TUMOR BUDDING”, A NOVEL
PROGNOSTIC INDICATOR FOR
PREDICTING STAGE PROGRESSION IN T1
BLADDER TUMORS
Keishiro Fukumoto*, Eiji Kikuchi, Shuji
Mikami, Kazuyuki Yuge, Ogihara Koichiro,
Kazuhiro Matsumoto, Shinya Morita,
Kazunobu Shinoda, Takeo Kosaka, Ryuichi
Mizuno, Toshiaki Shinojima, Hiroshi
Asanuma, Akira Miyajima, Mototsugu Oya,
Tokyo, Japan
4:00
PD17-04 MOST PATIENTS WITH CARCINOMA IN
SITU OF THE BLADDER ARE NOT
RECEIVING INTRAVESICAL BACILLE
CALMETTE-GUERIN (BCG)
Phillipe Nabbout*, Oklahoma City, OK, Sean
Elliott, Oluwakayode Adejoro, Minneapolis,
MN, Joel Slaton, Oklahoma City, OK
4:10
PD17-05 BACILLUS CALMETTE-GUERIN
INTRAVESICAL INSTILLATION THERAPY
IS NECESSARY FOR PATIENTS WITH A
SECOND TRANSURETHRAL RESECTION
PATHOLOGY OF PT0
Keitaro Iida*, Etani Toshiki, Taku Naiki,
Ryosuke Ando, Noriyasu Kawai, Keiichi
Tozawa, Kenjiro Kohri, Nagoya, Aichi, Japan
ABSTRACT
TIME NUMBER TITLE
4:20
PD17-06 RANDOMIZED PHASE II TRIAL OF
INTRAVESICAL ADENOVIRAL MEDIATED
INTERFERON-␣ GENE THERAPY WITH
THE EXCIPIENT SYN3 (RAD-IFN␣/SYN3)
IN PATIENTS WITH BCG REFRACTORY
OR RELAPSING HIGH GRADE (HG) NON
(NMIBC)
Daniel Canter*, Elkins Park, PA, Stephen
Boorjian, Rochester, MN, Kenneth Ogan,
Atlanta, GA, Neal Shore, Myrtle Beach, SC,
Trinity Bivalacqua, Baltimore, MD, Bernard
Bochner, New York City, NY, Tracy Downs,
Madison, WI, Leonard Gomella, Philadelphia,
PA, Robert Grubb III, St. Louis, MO, Brant
Inman, Durham, NC, Ashish Kamat, Houston,
TX, Larry Karsh, Denver, CO, Tracey
Krupski, Charlottesville, VA, Seth Lerner,
Houston, TX, Yair Lotan, Dallas, TX, Matthew
Milowsky, Chapel Hill, NC, Mark Schoenberg,
Bronx, NY, Robert Svatek, San Antonio, TX,
Michael Woods, Chapel Hill, NC, Colin
Dinney, Houston, TX
110
4:30
PD17-07 IMPACT OF BLADDER NECK
INVOLVEMENT ON PROGRESSION IN
PATIENTS WITH PRIMARY NON-MUSCLEINVASIVE BLADDER CANCER: A
MULTICENTER VALIDATION STUDY
Yasuhisa Fujii*, Shingo Moriyama, Minato
Yokoyama, Junji Yonese, Tokyo, Japan,
Akira Noro, Saitama, Japan, Chizuru Arisawa,
Tokyo, Japan, Shinji Morimoto, Tsuchiura,
Japan, Tetsuo Okuno, Toride, Japan, Satoshi
Kitahara, Tama, Japan, Fumitaka Koga,
Tokyo, Japan, Yasuyuki Sakai, Masahito
Suzuki, Kashiwa, Japan, Katsushi
Nagahama, Ichikawa, Japan, Toshifumi
Izutani, Mishima, Japan, Kazutaka Saito,
Kazunori Kihara, Tokyo, Japan
4:40
PD17-08 REFRAINING FROM SMOKING FOR 15
YEARS OR MORE REDUCED THE RISK OF
TUMOR RECURRENCE IN NON-MUSCLE
INVASIVE BLADDER CANCER PATIENTS
Koichiro Ogihara*, Eiji Kikuchi, Kazuyuki
Yuge, Nobuyuki Tanaka, Kazuhiro
Matsumoto, Akira Miyajima, Mototsugu Oya,
Tokyo, Japan
PD17-09 DECADE-LONG EXPERIENCE WITH
INTRAVESICAL DOCETAXEL IN THE
MANAGEMENT OF NON-MUSCLEINVASIVE BLADDER CANCER (NMIBC)
REFRACTORY TO BCG THERAPY
LaMont Barlow*, Danny Lascano, James
McKiernan, Mitchell Benson, New York, NY
5:00
PD17-10 MONOPOLAR VERSUS BIPOLAR
TRANSURETHRAL RESECTION OF NONMUSCLE INVASIVE BLADDER CANCER: A
SINGLE CENTER RANDOMIZED
CONTROLLED TRIAL
Ahmed M. Mansour*, Ahmed A. Shokeir,
Mohammed Tharwat, Bedeir Ali-El-Dein,
Yasser Osman, Mansoura, Egypt
5:10
5:20
PD17-12 PATIENT COMPLIANCE WITH
INTRAVESICAL MAINTENANCE
PROTOCOLS FOR NON-MUSCLE
Alex Helfand*, Tel Aviv, Israel, Liat Shavit
Grievink, Daniel Kedar, Ofer Yossepowitch,
Andrei Nadu, Eli Rosenbaum, Jack Baniel,
David Margel, Petah Tikva, Israel
CREDITTM
PD17-11 THE IMPACT OF DIFFERENT BCG
STRAINS ON OUTCOME IN A LARGE
COHORT OF T1G3 PATIENTS TREATED
WITH BCG
Paolo Gontero*, turin, Italy, Richard
Sylvester, Bruxelles, Belgium, Francesca
Pisano, Turin, Italy, Guido Dalbagni, New
York, NY, Sharok Shariat, Vienna, Austria,
Jeffrey Karnes, rochester, NY, Steven joniau,
leuven, Belgium, Vincenzo Serretta, Palermo,
Italy, Jouan Palou, Barcelona, Spain, Savino
Di Stasi, Rome, Italy, Stephane Larrè,
Oxford, United Kingdom, Renzo Colombo,
Milan, Italy, Marek Babjuk, Praga, Czech
Republic, Per Uno Malmstrom, Uppsala,
Sweden, Jaques Irani, Poitiers, France, Nuria
Malats, madrid, Spain, Jack Baniel, Tel Aviv,
Israel, Tommaso Cai, Trento, Italy, Eugene
Cha, New York, NY, Petere Ardelt, Freiburg,
Germany, Jhon varkarakis, Atene, Greece,
Riccardo Bartoletti, Florence, Italy, Marthin
Sphan, Wurtzburg, Germany, J Alfred Witjes,
Nijmegen, Netherlands
3:30 pm - 5:30 pm
Podium Session 18
TECHNOLOGY & INSTRUMENTS: LAPAROSCOPY AND ROBOTICS: MALIGNANT DISEASE II
Moderators: Ravi Munver and Gunter Janetschek
TIME
3:30
3:40
ABSTRACT
NUMBER TITLE
PD18-01 IMPROVEMENT IN CONTINENCE AND
QUALITY OF LIFE IN MEN WITH SEVERE
LUTS VIA HYPOTHERMIC COOLING
Adam Gordon, Cody Arbuckle, Douglas
Skarecky, Blanca Morales, Thomas Ahlering*,
Orange, CA
ABSTRACT
TIME NUMBER TITLE
3:50
PD18-03 CONSOLE-INTEGRATED REAL-TIME
THREE-DIMENSIONAL IMAGE OVERLAY
NAVIGATION FOR ROBOT-ASSISTED
PARTIAL NEPHRECTOMY WITH
SELECTIVE ARTERIAL CLAMPING: EARLY
SINGLE-CENTER EXPERIENCE WITH 25
CASES
Junya Furukawa*, Hideaki Miyake, Kazushi
Tanaka, Masato Fujisawa, Kobe, Japan
PD18-02 SURGEON HUMAN CAPITAL
DEPRECIATION: THE IMPACT OF DAYS
OFF BETWEEN CASES ON
PERIOPERATIVE AND FUNCTIONAL
OUTCOMES FOR ROBOTIC-ASSISTED
LAPAROSCOPIC PROSTATECTOMY
Shane Pearce*, Joseph Pariser, Sanjay
Patel, Blake Anderson, Scott Eggener,
Gregory Zagaja, Chicago, IL
*Presenting author
111
SATURDAY
4:50
4:00
4:10
4:20
PD18-04 DEVELOPMENT OF AN ARM SUPPORT
SYSTEM TO IMPROVE ERGONOMICS IN
LAPAROSCOPIC SURGERY – STUDY
DESIGN AND PROVISIONAL RESULTS
Benjamin Steinhilber, Sascha Hoffmann,
Tubingen, Germany, Kristian Karlovic, Stefan
Pfeffer, Thomas Maier, Stuttgart, Germany,
Omar Hallasheh, Stefan Kruck, Robert Seibt,
Monika Rieger, Tubingen, Germany, Michael
Heidingsfeld, Ronny Feuer, Oliver Sawodny,
Stuttgart, Germany, Ralf Rothmund,
Tubingen, Germany, Karl-Dietrich Sievert*,
Tubingen-Lubeck, Germany
PD18-05 ROBOTIC NEPHRECTOMY IS NOT
COSTLIER THAN STANDARD
LAPAROSCOPY WHEN A ROBOT IS
AVAILABLE
Ronney Abaza*, Dublin, OH, Iahn
Gonsenhauser, Geoffrey Box, David Sharp,
Ahmad Shabsigh, Columbus, OH
PD18-06 APPLYING CLINICAL PATHWAY TO
ROBOTIC CYSTECTOMY ALLOWS
SHORTEST POSSIBLE LENGTH OF STAY
Ronney Abaza*, Dublin, OH
4:30
PD18-07 FLOW DYNAMICS IN A DRAINED
URETERAL BIOMIMETIC MODEL
miki Haifler*, Jacob Ramon, Harry Winkler,
Nir Kleinmann, Ramat gan, Israel
4:40
PD18-08 ROBOTIC VERSUS LAPAROSCOPIC
PARTIAL NEPHRECTOMY: A SYSTEMATIC
REVIEW AND META-ANALYSIS
Jeffrey Leow*, Yew Lam Chong, Keng Siang
Png, Singapore, Singapore
4:50
PD18-09 THE ROLE OF THE ASSISTANT DURING
ROBOT-ASSISTED PARTIAL
NEPHRECTOMY: DOES EXPERIENCE
MATTER?
John A. Brockman*, Aaron M. Potretzke,
Jeffrey A. Larson, Joel Vetter, R. Sherburne
Figenshau, Samuel B Bhayani, Brian M.
Benway, Saint Louis, MO
5:00
PD18-10 DRAINING URETERS OBSTRUCTED BY
MALIGNANT DISEASES WITH TANDEM
STIFF URETERAL STENTS – INITIAL
CLINICAL EXPERIENCE
miki Haifler*, Jacob Ramon, Harry Winkler,
Nir Kleinmann, Ramat gan, Israel
5:10
PD18-11 A LAPAROSCOPIC COMBINATION WITH
COMPARABLE ERGONOMIC RESULTS TO
ROBOTIC SURGERY, TESTED IN AN
EXPERIMENTAL LAPAROSCOPIC
RADICAL PROSTATECTOMY SETTING
Theodoros Tokas*, Ali Serdar Gözen,
Alexandra Tschada, Jens Rassweiler,
Heilbronn, Germany
5:20
PD18-12 USE OF HYALURONIC ACIDCARBOXYMETHYLCELLULOSE
ADHESION BARRIER ON THE
NEUROVASCULAR BUNDLE DURING
ROBOT-ASSISTED RADICAL
PROSTATECTOMY: LONG TERM
OUTCOMES
Rutveej Patel*, Parth Modi, Isaac Kim, New
Brunswick, NJ
CREDITTM
3:30 pm - 5:30 pm
Podium Session 19
TECHNOLOGY & INSTRUMENTS: SURGICAL EDUCATION & SKILLS ASSESSMENT III
Moderators: Lee Richstone and Cassio Andreoni
TIME
3:30
ABSTRACT
NUMBER TITLE
PD19-01 THE VALUE OF OPEN CONVERSION
SIMULATIONS DURING ROBOT-ASSISTED
RADICAL PROSTATECTOMY:
IMPLICATIONS FOR ROBOTIC TRAINING
CURRICULUMS
Fabio Zattoni*, Padua, Italy, Vidit Sharma,
Rochester, MN, Andrea Guttilla, Alessandro
Crestani, Francesco Cattaneo, Fabrizio Dal
Moro, Filiberto Zattoni, Padua, Italy
ABSTRACT
TIME NUMBER TITLE
3:40
PD19-02 USING THE WISDOM OF CROWDS:
VALIDATION THROUGH THE BASIC
LAPAROSCOPIC UROLOGIC SURGERY
(BLUS) CURRICULUM
Thomas Lendvay*, Seattle, WA, Timothy
Kowalewski, Robert Sweet, Minneapolis, MN,
Ashleigh Menhadji, Boston, MA, Timothy
Averch, Pittsburgh, PA, Geoffrey Box,
Columbus, OH, Timothy Brand, Tacoma, WA,
Michael Fearrandino, Durham, NC, Jihad
Kaouk, Cleveland, OH, Bodo Knudsen,
Columbus, OH, Jamie Landman, Orange, CA,
Benjamin Lee, New Orleans, LA, Bradley
Schwartz, Springfield, IL, Bryan Comstock,
Seattle, WA, Elspeth McDougall, Vancouver,
Canada
112
4:00
4:10
4:20
PD19-03 LARGE-SCALE EVIDENCE OF
CONSTRUCT VALIDITY: THE BASIC
LAPAROSCOPIC UROLOGIC SKILLS
(BLUS) INITIATIVE
Timothy Kowalewski, Robert Sweet,
Minneapolis, MN, Ashleigh Menhadji, Boston,
MA, Timothy Averch, Pittsburgh, PA, Geoffrey
Box, Columbus, OH, Timothy Brand, Tacoma,
WA, Michael Fearrandino, Durham, NC, Jihad
Seattle, WA, Cory Schaffhausen,
Minneapolis, MN, Elspeth McDougall,
Vancouver, Canada, Thomas Lendvay*,
Seattle, WA
PD19-04 VALIDATION OF LAPAROSCOPIC
TRAINING CURRICULUM: THE BASIC
(BLUS) INITIATIVE
Schwartz, Springfield, IL, Elspeth McDougall,
Vancouver, Canada, Thomas Lendvay*,
Seattle, WA
PD19-05 HIGH-VOLUME ASSESSMENT OF
SURGICAL VIDEOS VIA
CROWD-SOURCING: THE BASIC
(BLUS) INITIATIVE
Seattle, WA, Cory Schaffhausen, Minneapolis,
MN, Elspeth McDougall, Vancouver, Canada,
Thomas Lendvay*, Seattle, WA
PD19-07 VALIDATION OF A TRAINING MODEL FOR
INTRACORPOREAL BOWEL ANASTOMOSIS
IN ROBOTIC SURGERY (BARS)
Friedrich-Carl von Rundstedt*, Selcuk Silay,
Monty Aghazadeh, Alvin Goh, Houston, TX
4:40
PD19-08 PROFICIENCY-BASED ROBOTIC
TRAINING CURRICULUM YIELDS
IMPROVEMENTS IN ROBOTIC CLINICAL
PERFORMANCE: A RANDOMIZED
CONTROLLED STUDY
Monty Aghazadeh, Miguel Mercado, Michael
Pan, Neel Srikishen*, Brian Miles, Richard
Link, Brian Dunkin, Alvin Goh, Houston, TX
4:50
PD19-09 INTERNATIONAL UROLOGY JOURNAL
CLUB ON TWITTER- A GROWING
EDUCATIONAL FORUM
Isaac Thangasamy*, Brisbane, Australia,
Michael Leveridge, Kingston, Canada,
Benjamin Davies, Pittsburgh, PA, Brian Stork,
Muskegon, MI, Stacy Loeb, New York, NY,
Henry Woo, Sydney, Australia
5:00
PD19-10 IMPLEMENTATION OF A WEB-BASED,
PROCEDURE-SPECIFIC, ROBOTIC
TRAINING EXPERIENCE LOG WITH
FEEDBACK AND LONGITUDINAL
REPORTING FEATURES
Ryan Thorwarth*, Maywood, IL, Marcus Quek,
Mawyood, IL, Gopal Gupta, Maywood, IL
5:10
PD19-11 SURGEON PERFORMANCE AND
DISTRACTIONS IN THE OPERATING
ROOM: A RANDOMIZED, CONTROLLED,
CROSSOVER TRIAL
Ryan Speir*, Timothy Brand, Tacoma, WA,
Richard Greene, El Paso, TX
5:20
PD19-12 THE IMPACT OF REMOTE MONITORING
AND SUPERVISION ON RESIDENT
TRAINING USING NEW ACGME & ABU
UROLOGY MILESTONE CRITERIA
Ilan Safir*, Adam Shrewsberry, Kenneth Ogan,
Chad Ritenour, Catrina White, Jane Kimberl,
Jerry Sullivan, Muta Issa, Atlanta, GA
CREDITTM
PD19-06 VIDEO-BASED PEER REVIEW OF ROBOTASSISTED RADICAL PROSTATECTOMY IN
A STATEWIDE QUALITY IMPROVEMENT
COLLABORATIVE
Khurshid Ghani*, David Miller, Ann Arbor, MI,
Brian Lane, Grand Rapids, MI, Richard Sarle,
Dearborn, MI, Andrew Brachulis, Susan
Linsell, Tae-Kyung Kim, Ann Arbor, MI,
Deepansh Dalela, Detroit, MI, James Montie,
Ann Arbor, MI, Bryan Comstock, Tom
Lendvay, Seattle, MI, James Peabody,
Detroit, MI
*Presenting author
4:30
113
SATURDAY
3:50
3:30 pm - 5:30 pm
Podium Session 20
INFECTIONS/INFLAMMATION OF THE GENITOURINARY TRACT: INTERSTITIAL CYSTITIS
Moderators: Robert Evans and John Krieger
TIME
3:30
3:40
3:50
4:00
4:10
ABSTRACT
NUMBER TITLE
PD20-01 TANEZUMAB REDUCES PAIN IN WOMEN
WITH INTERSTITIAL CYSTITIS/BLADDER
PAIN SYNDROME
J. Curtis Nickel*, Kingston, Canada, John
Krieger, Seattle, WA, Ian Mills, Tim Crook,
Tadworth, United Kingdom, Anamaria Jorga,
New York, NY, Gary Atkinson, Tadworth,
United Kingdom, Michael Smith, Northbrook, IL
ABSTRACT
TIME NUMBER TITLE
4:20
PD20-06 COMPARATIVE PILOT STUDY OF
IMPLANTATION TECHNIQUES FOR
PUDENDAL NEUROMODULATION:
TECHNICAL AND CLINICAL OUTCOME IN
FIRST 20 PATIENTS WITH CHRONIC
PELVIC PAIN
Arndt van Ophoven*, Kai Heinze, Herne,
Germany, Romed Hoermann, Helga Fritsch,
Innsbruck, Austria, Rolf Dermietzel, Bochum,
Germany
PD20-02 INTRAVESICAL BOTULINUM TOXIN A
SINGLE INJECTIONS CAN REDUCE
BLADDER PAIN IN TREATMENT OF
INTERSTITIAL CYSTITIS / BLADDER PAIN
SYNDROME REFRACTORY TO
CONVENTIONAL TREATMENT - A
PROSPECTIVE, MULTICENTER,
RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED CLINICAL
Jia-Fong Jhang*, Hui-Ling Tseng, HannChorng Kuo, Hualien, Taiwan, Yuh-Chen
Kuo, Taipei, Taiwan, Yao-Chou Tsai, New
Taipei City, Taiwan
PD20-03 PILOT STUDY EVALUATING SAFETY AND
FEASIBILITY OF INTRAVESICAL
INSTILLATION OF BOTULINUM TOXIN IN
HYDROGEL-BASED SLOW RELEASE
DELIVERY SYSTEM IN PBS/IC PATIENTS
Kobi Stav, Zeriffin, Israel, Yuri Vinshtok,
Michal Jeshurun, Neely Ivgy-May, Tami
Gerassi, Raanana, Israel, Amnon Zisman*,
Zeriffin, Israel
PD20-04 ROLE OF SPINAL ASTROCYTIC
ACTIVATION IN PAIN PATHOGENESIS IN
RATS WITH CYCLOPHOSPHAMIDEINDUCED CYSTITIS
Xiangfu Zhou, Bolong Liu*, Wenbiao Li,
Guangzhou, China, People’s Republic of,
Shaojun Tang, Galveston, TX, Minzhi Su,
Guangzhou, China, People’s Republic of
4:30
PD20-07 ALTERATIONS IN CONNECTIVITY ON
FMRI WITH PROVOCATION OF LOWER
URINARY TRACT SYMPTOMS IN
UROLOGIC CHRONIC PELVIC PAIN
SYNDROMES
Natalia Kleinhans, Claire Yang*, Eric
Strachan, Dedra Buchwald, Kenneth
Maravilla, Seattle, WA
4:40
PD20-08 THE IMPACT OF COMORBID CHRONIC
PAIN SYNDROMES ON SEXUAL ACTIVITY
AND DYSPAREUNIA AFTER PELVIC
ORGAN PROLAPSE REPAIR
Priyanka Gupta*, Michael Ehlert, Royal Oak,
MI, James Payne, Rochester, MI, Kim A.
Killinger, Judith A. Boura, Melissa Fischer,
Larry T. Sirls, Royal Oak, MI
4:50
PD20-09 ALTERED MICROBIOME IN CHRONIC
PELVIC PAIN PATIENTS
David Klumpp*, Chicago, IL, Andrea BraudmeierFleming, Springfield, IL, Ryan Yaggie, Laurie
Bachrack, Sarah Flury, Darlene Marko, Chicago,
IL, Matthew Berry, Michael Welge, Colleen
Bushell, Bryan White, Urbana-Champaign, IL,
Anthony Schaeffer, Chicago, IL
5:00
PD20-10 PROSPECTIVE, MULTICENTER,
RANDOMIZED CLINICAL TRIAL COMPARING
THE EFFECT OF HYDRODISTENTION AND
TRANSURTHRAL FULGURATION OF
BLADDER IN INTERSTITIAL
CYSTITIS/BLADDER PAIN SYNDROME
PATIENTS
Jang Hwan Kim*, Sang Woon Kim, Sang
Hyun Jee, Kyu Sung Lee, Myung Soo Choo,
Seoul, Korea, Republic of, Joon Chul Kim,
Buchan, Korea, Republic of, Sung Yong Cho,
Ju Tae Seo, Seoul, Korea, Republic of, Jong
Bo Choi, Suwon, Korea, Republic of, Seung
June Oh, Seoul, Korea, Republic of
5:10
PD20-11 ENDOSCOPIC INJECTION OF
TRIAMCINOLONE – A SIMPLE, MINIMALLY
INVASIVE, AND EFFECTIVE THERAPY
FOR HUNNER’S LESIONS
Sonia Bahlani*, Alexandra King, Robert
Moldwin, New Hyde Park, NY
PD20-05 HERPES SIMPLEX VIRUS (HSV) VECTORMEDIATED GENE DELIVERY OF PROTEIN
PHOSPHATASE 1␣ REDUCES BLADDER
OVERACTIVITY AND
Tsuyoshi Majima*, Hiroki Okada, Katsumi
Kadekawa, Kenichi Mori, Naoki Kawamorita,
Pittsburgh, PA, Momokazu Gotoh, Nagoya,
Japan, William Goins, Joseph Glorioso,
Justus Cohen, Naoki Yoshimura, Pittsburgh,
PA
114
CREDITTM
PD20-12 MICROVASCULAR INJURY IN KETAMINEINDUCED BLADDER DYSFUNCTION
Chih-Chieh Lin*, An-Hang Yang, Alex T.L.
Lin, Kuang-Kuo Chen, Taipei, Taiwan
3:30 pm - 5:30 pm
Video Session 4
ROBOTICS – PROSTATE/NOVEL IMAGING
Moderators: Misop Han and J. Kellogg Parsons
ABSTRACT
NUMBER TITLE
V4-01
PERINEAL ROBOT ASSISTED
PROSTATECTOMY (P-RALP)
Oktay Akca*, Peter Caputo, Humberto
Laydner, Homayoun Zargar, Daniel Ramirez,
Juan Jimenez, Hiury Andrade, Robert J Stein,
Cleveland, OH, Selami Albayrak, Istanbul,
Turkey, Kenneth Angermeier, Jihad H Kaouk,
Cleveland, OH
V4-02
PROSTATECTOMY IN INTERMEDIATE
AND HIGH RISK PROSTATE CANCER.
INDOCYANINE GREEN-GUIDED PELVIC
LYMPH NODE DISSECTION
Sebastián Valverde Martı́nez, Salamanca,
Spain, Miguel Ramı́rez Backhaus*, José
Rubio Briones, José Luis Domı́nguez Escrig,
Juan Casanova, Alvaro Gómez Ferrer,
Solsona Narbón Eduardo, Valencia, Spain
V4-03
TECHNIQUE AND OUTCOMES OF
BLADDER NECK INTUSSUSCEPTION
DURING ROBOTIC-ASSISTED RADICAL
PROSTATECTOMY: A PARALLEL
COMPARATIVE TRIAL
Aaron Laviana*, Hung-Jui Tan, Siwei Xiong,
Ryan Chuang, Eric Treat, Los Angeles, CA,
Patrick Walsh, Baltimore, MD, Jim Hu, Los
Angeles, CA
V4-04
TECHNICAL ASPECTS OF ROBOTASSISTED LAPAROSCOPIC
PROSTATECTOMY IN LARGE PROSTATES
(>75G)
Everaerts Wouter*, Ken Chow, Melbourne,
Australia, Hans Pottel, Leuven, Belgium,
Andrew Ryan, Marni Basto, Justin Peters,
Daniel Moon, Anthony Costello, Declan
Murphy, Melbourne, Australia
V4-05
*Presenting author
ABSTRACT
NUMBER TITLE
V4-06
ANTERIOR SUSPENSION OF POSTERIOR
RECONSTRUCTION SUTURE- A NOVEL
TECHNIQUE TO IMPROVE EARLY
RETURN OF URINARY CONTINENCE
FOLLOWING ROBOT-ASSISTED RADICAL
PROSTATECTOMY
Vineet Agrawal*, Ahmed Ghazi, Jean Joseph,
Rochester, NY
ROBOTIC ASSISTED RADICAL
PROSTATECTOMY BLADDER NECK
RECONSTRUCTION WITH ANTERIOR AND
POSTERIOR INTUSSUSCEPTION
Fernando Bianco*, igor kislinger, Isabel
Lopez, Marilin Nicholson, Hialeah, FL
115
V4-07
USE OF INTRA-OPERATIVE INDOCYANINE
GREEN AND FIREFLY® TECHNOLOGY TO
VISUALIZE THE “LANDMARK ARTERY”
FOR NERVE SPARING ROBOT ASSISTED
Anup Kumar*, Srinivas Samavedi, Anthony
Bates, Rafael Coelho, Bernardo Rocco, Jeff
Marquinez, Cathy Jenson, Kenneth Palmer,
Vipul Patel, Celebration, FL
V4-08
DEHYDRATED HUMAN AMNIOTIC
MEMBRANE ALLOGRAFT NERVE WRAP
AROUND THE PROSTATIC
NEUROVASCULAR BUNDLE
ACCELERATES EARLY RETURN TO
CONTINENCE AND POTENCY
FOLLOWING RADICAL ROBOT ASSISTED
RADICAL PROSTATECTOMY : A
PROPENSITY SCORE MATCHED
ANALYSIS
Anup Kumar*, Srinivas Samavedi, Anthony
Bates, Rafael Coelho, Bernardo Rocco, Jeff
Marquinez, Ignacio Camacho, Cathy Jenson,
Kenneth Palmer, Vipul Patel, Celebration, FL
V4-09
TRANSPERINEAL PROSTATE BIOPSY
WITH NEW MAPPING SOFTWARE
Nelson Stone*, New York, NY, Vassilios
Skouteris, Athens, Greece, Paul Arangua, E.
David Crawford, Aurora, CO
V4-10
URETERAL REIMPLANTATION: OUR
TECNIQUE AND OUTCOMES
Daniel Zainfeld*, Andrew Windsperger,
Moben Mirza, David Duchene, Kansas City,
KS
SATURDAY
5:20
V4-11
V4-12
STEP-BY-STEP ROBOTIC
URETEROURETEROSTOMY: TIPS AND
TRICKS TO OPTIMIZE OUTCOMES
Hiury Andrade*, Jihad Kaouk, Homayoun
Zargar, Peter Caputo, Cleveland, OH, Jayram
Krishnan, Las Vegas, NV, Oktay Akca, Daniel
Ramirez, Luis Felipe Brandao, GeorgesPascal Haber, Robert Stein, Cleveland, OH
ROBOTIC REPAIR FOR RECTOURETHRAL
FISTULA: A NEW TECHNIQUE
Rene Sotelo*, Oswaldo Carmona, Robert De
Andrade, Caracas, Venezuela, David Canes,
Burlington, MA, Victor Machuca, Luciano
Nuñez, Eric Saenz, Luis Medina, Carlos
Marrugo, Marino Cabrera, Caracas,
Venezuela
116
V4-13
POSTERIOR APPROACH TO ROBOTIC
SIMPLE PROSTATECTOMY
Brian Cronson*, Andrew Harbin, Laura
Giusto, Anuj Desai, Ziho Lee, Joshua Kaplan,
Blake Moore, Daniel Eun, Philadelphia, PA
V4-14
ROBOT ASSISTED MILLIN
PROSTATECTOMY
Giuseppe Simone*, Rocco Papalia,
Mariaconsiglia Ferriero, Riccardo Mastroianni,
Salvatore Guaglianone, Michele Gallucci,
Rome, Italy
Plenary Session
7:30 am - 12:00 pm
7:25
AUA Secretary: Gopal Badlani
7:30
HIGHLIGHTS: ONCOLOGY RESEARCH PROGRAM
Johannes Vieweg
7:40
HIGHLIGHTS: RESEARCH IN BENIGN DISEASES PROGRAM
George Christ
7:50
STATE-OF-THE-ART LECTURE: HORMONE THERAPY FOR MEN WITH INFERTILITY
Craig Niederberger
8:05
CRITICAL DISCUSSION: FERTILITY PRESERVATION IN CANCER PATIENTS
Critical Discussant: Jay Sandlow
Presenters:
Robert Brannigan
Kirk Lo
8:25
PANEL DISCUSSION: OPTIMAL MANAGEMENT OF ISCHEMIC PRIAPISM
Moderator:
Ira Sharlip
Panelists:
Ricardo Munarriz
David Ralph
Arthur Burnett
8:50
STATE-OF-THE-ART LECTURE: PDE5 INHIBITORS SIDE AFFECTS: MYTHS VS. REALITY
Gregory Broderick
9:05
JOHN K. LATTIMER LECTURE: INTEGRATING THE DIGITAL UNIVERSE OF DATA TO BUILD MORE PREDICTIVE
MODELS OF CANCER
Eric Schadt
9:25
STATE-OF-THE-ART LECTURE: MANAGEMENT OF URINARY INCONTINENCE POST PROSTATE CANCER
TREATMENT & URETHROPLASTY
Kurt McCammon
9:40
STATE-OF-THE-ART LECTURE: SURGICAL MANAGEMENT OF ADULT BURIED PENIS
Richard Santucci
9:55
AUA GUIDELINE: PEYRONIE’S DISEASE
Ajay Nehra
10:05
BEST ABSTRACT: PI-01: RECTOURETHRAL FISTULAS SECONDARY TO PROSTATE CANCER TREATMENT:
MANAGEMENT AND OUTCOMES
Catherine Harris*, Benjamin Breyer, San Francisco, CA, Ramon Virasoro, Virginia Beach, VA, Alex Vanni, Burlington,
MA, Daniela Andrich, London, United Kingdom, Gerald Jordan, Virginia Beach, VA, Leonard Zinman, Burlington, MA,
Anthony Mundy, London, United Kingdom, Jack McAninch, San Francisco, CA
10:13
BEST ABSTRACT: PI-02: AGE AND OBESITY PROMOTE METHYLATION AND SUPPRESSION OF 5-ALPHA
REDUCTASE 2—IMPLICATIONS FOR PERSONALIZED THERAPY IN BPH
Seth Bechis*, Alexander Otsetov, Rongbin Ge, Zongwei Wang, Mark Vangel, Chin-Lee Wu, Shahin Tabatabaei, Aria
Olumi, Boston, MA
10:21
BEST ABSTRACT: PI-03: SCROTAL ULTRASOUND FOR PAIN: LOW FREQUENCY OF ABSOLUTE SURGICAL
INDICATIONS
James Kashanian, Christopher D. Morrison*, Daniel J. Mazur, Chicago, IL, Marah C. Hehemann, Maywood, IL, Daniel
T. Oberlin, Mohammed Said, Chicago, IL, Valary Raup, St. Louis, MO, Brian Trinh, Andrew Choi, Robert E. Brannigan,
Chicago, IL
10:30
HIGHLIGHTS: SOCIETY FOR PEDIATRIC UROLOGY (SPU) PROGRAM
Martin A. Koyle
10:40
JOHN DUCKETT MEMORIAL LECTURE: MINIMALLY INVASIVE SURGERY IN PEDIATRIC UROLOGY: PRESENT &
FUTURE
Chung Kwong Yeung
11:00
PANEL DISCUSSION: SIMULATION IN SURGICAL EDUCATION
Moderator:
Elspeth McDougall
Panelists:
Patrick McKenna
Max Maizels
Thomas Lendvay
*Presenting author
117
SUNDAY
PLENARY I - SUNDAY
11:25
STATE-OF-THE-ART LECTURE: MODERN MANAGEMENT OF THE NEWBORN WITH DISORDERS OF SEXUAL
DEVELOPMENT (DSD)
David Diamond
11:40
POINT-COUNTERPOINT: RECENT RANDOMIZED CONTROLLED TRIALS HAVE CHANGED MY PRACTICE
Moderator:
Steven Skoog
Debaters:
Antoine Khoury (Pro)
Anthony Caldamone (Con)
12:00
SESSION CONCLUDES
Plenary Session
10:00 am - 12:20 pm
PLENARY II - SUNDAY
9:55
10:00
AMERICAN BOARD OF UROLOGY UPDATE
Ian Thompson
10:10
JOURNAL OF UROLOGY LECTURE: USING NEW KNOWLEDGE TO CHANGE CLINICAL PRACTICE
Introduction:
William Bohnert
Presenter:
Joseph Smith
10:30
RISING STAR REPORT: OPTIMIZING SURVIVORSHIP AND DECISION-MAKING IN LOW RISK BLADDER CANCER
Introduction:
Carolyn Best
Presenter:
Matthew Nielsen
LATE BREAKING ABSTRACTS
10:45
PII-LBA1: USING THE THERMAL ENERGY OF CONVECTIVELY DELIVERED WATER VAPOR FOR THE TREATMENT OF
LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA: THE REZUM II STUDY
Kevin McVary*, Springfield, IL, Lance Mynderse, Rochester, MN, Steven Gange, Salt Lake City, UT, Marc Gittelman,
Aventura, FL, Kenneth Goldberg, Lewisville, TX, Kalpesh Patel, Tucson, AZ, Neal Shore, Myrtle Beach, SC, Richard
Levin, Baltimore, MD, Michael Rousseau, Cincinnati, OH, Randolf Beahrs, Woodbury, MN, Jed Kaminetsky, New York,
NY, Barrett Cowan, Denver, CO, Christopher Cantrill, San Antonio, TX, James Ulchaker, Cleveland, OH, Claus
Roehrborn, Dallas, TX
10:52
PII-LBA2: VALIDATION OF A NOVEL NON-INVASIVE URINE EXOSOME GENE EXPRESSION ASSAY TO PREDICT
HIGH-GRADE PROSTATE CANCER IN PATIENTS UNDERGOING INITIAL BIOPSY WITH AN EQUIVOCAL PSA
James McKiernan*, Michael Donovan, New York, NY, Vince O’Neill, Cambridge, MA, Stefan Bentink, Mikkel Noerholm,
Martinsried, Germany, Susan Belzer, St. Paul, MN, Johan Skog, Cambridge, MA, Alan Partin, Baltimore, MD, Gerald
Andriole, St. Louis, MO, Gordon Brown, Vorhees, NJ, James Cochran, Dallas, TX, John Wei, Livonia, MI, Ian
Thompson, San Antonio, TX, Peter Carroll, San Francisco, CA
10:59
PII-LBA3: GLYPICAN-1 AS A BIOMARKER FOR PROSTATE CANCER
Neal Shore*, Myrtle Beach, SC, Raoul Concepcion, Nashville, TN, Daniel Saltzstein, San Antonio, TX, Thomas Paivanas,
Annandale, VA, Jennifer Beebe-Dimmer, Julie Ruterbusch, Detroit, MI, Irene Justiniano, Hubert Mazure, Aline Nocon, Julie
Soon, Quach Truong, Sandra Wissmueller, Douglas Campbell, Bradley Walsh, Macquarie Park, Australia
11:06
PII-LBA4: TERRAIN TRIAL: PROSTATE-SPECIFIC ANTIGEN KINETICS AND QUALITY OF LIFE RESULTS OF
ENZALUTAMIDE VERSUS BICALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Neal Shore*, Myrtle Beach, SC, Axel Heidenreich, Aachen, Germany, Arnauld Villers, Lille, France, Laurence Klotz,
Toronto, Canada, Maha Hussain, Ann Arbor, MI, Lawrence Karsh, Denver, CO, Steve van Os, Benoit Baron, Leiden,
Netherlands, Fong Wang, David Forer, San Francisco, CA, Simon Chowdhury, London, United Kingdon, Robert D.
Siemens, Kingston, Canada
11:13
PII-LBA5: EVIDENCE OF SUPERIOR QUALITY OF LIFE AFTER ROBOTIC PROSTATECTOMY: RESULTS FROM A
Brock O’Neil*, Tatsuki Koyama, JoAnn Rudd, Nashville, TN, Peter Albertsen, Farmington, CT, Matthew Cooperberg,
San Francisco, CA, Michael Goodman, Atlanta, GA, Sheldon Greenfield, Irvine, CA, Ann Hamilton, Los Angeles, CA,
Karen Hoffman, Houston, TX, Richard Hoffman, Albuquerque, NM, Sherrie Kaplan, Irvine, CA, Janet Stanford, Seattle,
WA, Antoinette Stroup, New Brunswick, NJ, Xiao-Cheng Wu, New Orleans, LA, Matthew Resnick, Daniel Barocas,
David Penson, Nashville, TN
118
PII-LBA6: EFFECT OF TESTOSTERONE SOLUTION ON TOTAL TESTOSTERONE, SEX DRIVE AND ENERGY IN
HYPOGONADAL MEN
Gerald Brock*, London, Canada, Darell Heiselman, Indianapolis, IN, Mario Maggi, Florence, Italy, Sae Woong Kim,
Seoul, Korea, Republic of, José Maria Rodrı́guez Vallejo, Madrid, Spain, Hermann Behre, Halle, Germany, John
McGettigan, Tucson, AZ, Sherie Dowsett, Jack Knorr, Xiao Ni, Kraig Kinchen, Indianapolis, IN
11:27
PII-LBA7: IN TWO PHASE III STUDIES, ENDROXAL™ (ENCLOMIPHENE CITRATE) SIGNIFICANTLY IMPROVES
TOTAL TESTOSTERONE LEVELS COMPARED TO ANDROGEL 1.62%, WITHOUT SUPPRESSION OF
SPERMATOGENESIS AND TESTICULAR FUNCTION IN OVERWEIGHT MALES WITH SECONDARY
HYPOGONADISM
Andrew McCullough*, Albany, NY, Edward Kim, Knoxville, TN, Michael Wyllie, Banbury, United Kingdom
11:34
PII-LBA8: USE OF LINEAR DISCRIMINANT ANALYSIS IN A URINE-BASED TEST FOR BLADDER CANCER
DIAGNOSIS
Ellen Wallace, Sunnyvale, CA, Kathleen E. Mach, Stanford, CA, Leena McCann, Sunnyvale, CA, Lai Yi Mandy Sin*,
Ruchika Mohan, Stanford, CA, Malini Satya, Huilin Wei, Jun Zhang, Chris Lykke, Russell Higuchi, Sunnyvale, CA,
11:41
PII-LBA9: EFFICACY AND SAFETY OF MIRABEGRON ADD-ON TREATMENT TO SOLIFENACIN IN INCONTINENT
OAB SUBJECTS WITH AN INADEQUATE RESPONSE TO INITIAL 4-WEEK SOLIFENACIN MONOTHERAPY
Marcus Drake*, Bristol, UK, Ahmet Adil Esen, Izmir, Turkey, Stavros Athanasiou, Athens, Greece, Claire Herholdt,
Surrey, UK, Roberta Baronio, Leiden, Netherlands, Tahir Saleem, Moses Huang, Emad Siddiqui, Surrey, UK, Scott
MacDiarmid, Greensboro, NC
11:48
PII-LBA10: A MULTICENTER PHASE 2 STUDY OF ENZALUTAMIDE (ENZA) VERSUS BICALUTAMIDE (BIC) IN
MEN WITH NONMETASTATIC (M0) OR METASTATIC (M1) CASTRATION-RESISTANT PROSTATE CANCER
(CRPC): THE STRIVE TRIAL
David Penson, Nashville, TN, Andrew Armstrong, Durham, NC, Raoul Concepcion, Nashville, TN, Neeraj Agarwal, Salt
Lake City, UT, Fong Wang, Kenneth Wu, San Francisco, CA, Andree Amelsberg, Northbrook, IL, De Phung, Leiden,
The Netherlands, Celestia Higano*, Seattle, WA
11:55
PANEL DISCUSSION: AUA, OBAMACARE AND THE PAYER: CURRENT EFFORTS AND FUTURE CHALLENGES
Moderator:
David Penson
Panelists:
Norm Smith
Christopher Gonzalez
Martin Dineen
12:20
SESSION CONCLUDES
6:30 am - 9:00 am
SWIU ANNUAL BREAKFAST MEETING
6:30
BREAKFAST BUFFET
8:00
SWIU AWARD PRESENTATIONS
6:45
PRESIDENT’S WELCOME
Leslie Rickey
8:20
ANNUAL BUSINESS MEETING
8:45
NETWORKING
6:50
AUA UPDATE
William Gee
9:00
ADJOURN
7:00
ACHIEVING LEADERSHIP ROLES
Tonette Krousel-Wood
*Presenting author
CREDITTM
119
SUNDAY
11:20
8:00 am - 10:00 am
STONE DISEASE: BASIC RESEARCH II
Moderators: Erdal Erturk and Evangelos Liatsikos
ABSTRACT
NUMBER TITLE
MP34-01 RENAL HISTOPATHOLOGY AFTER
CALCIUM OXALATE STONE INDUCTION:
CRYSTALLURIC AND TUBULAR EFFECTS
OF HIGH URINARY OXALATE EXCRETION
IN A SWINE MODEL
Kristina L Penniston*, Denise J Schwahn,
Thomas D Crenshaw, Stephen Y Nakada,
Madison, WI
ABSTRACT
NUMBER TITLE
MP34-07 INTRAVITAL IMAGING OF THE
DROSOPHILA MELANOGASTER MODEL
OF HUMAN NEPHROLITHIASIS
Sohrab Naushad Ali*, Dajung Kim, Thomas
Tailly, Hassan Razvi, Hon Leong, London,
Canada
MP34-08 LITHOTRIPSY PERFORMANCE OF
TRADITIONAL AND SPECIAL DESIGNED
LASER FIBERS
Peter Kronenberg*, Amadora, Portugal,
Olivier Traxer, Paris, France
MP34-02 GENE EXPRESSION PROFILE OF RANDALL’S
PLAQUE IN IDIOPATHIC CAOX STONE
FORMERS SUGGESTS DYSREGULATION OF
M⌽-RELATED GENES
Naogya, Japan, Yasuhiro Fujii, Taku Naiki, Shuzo
Hamamoto, Ryosuke Ando, Kazuhiro Kanemoto,
Atsushi Okada, Takahiro Yasui, Keiichi Tozawa,
Yutaro Hayashi, Kenjiro Kohri, Nagoya, Japan
MP34-09 OXALOBACTER FORMIGENES
COLONIZATION IN A HYPEROXALURIC
RAT MODEL OF GASTRIC BYPASS
INCREASES BENEFICIAL GUT BACTERIA
AND ACTS AS A KEYSTONE SPECIES
Ryan Chastain-Gross*, Gary Wang, Eric Li,
Marguerite Hatch, Benjamin Canales,
Gainesville, FL
MP34-03 CAN STATIN USE REDUCE THE RISK OF
UPPER URINARY TRACT STONE IN
PATIENTS WITH DYSLIPIDEMIA? A
NATION-WIDE POPULATION-BASED AND
WITH AN 8-YEAR FOLLOW-UP STUDY
Hsiao-Jen Chung*, Alex T.L. Lin, Yi-Hsiu
Huang, Chih-Chieh Lin, Yu-Hua Fan, TzengJi Chen, Kuang-Kuo Chen, Taipei, Taiwan
MP34-10 THE EFFECT OF INSULIN USE IN TYPE II
DIABETES ON 24 HOUR URINE
PARAMETERS
Ethan B Fram, Saman Moazami*, Bronx, NY,
David M Hoenig, New Hyde Park, NY,
Joshua M Stern, Bronx, NY
MP34-04 INHIBITION OF GLYCOLATE OXIDASE
REDUCES URINARY OXALATE
EXCRETION IN A MOUSE MODEL OF
PRIMARY HYPEROXALURIA TYPE 1
Xingsheng Li, John Knight*, Sonia Fargue,
Birmingham, AL, William Querbes, Kevin
Fitzgerald, Boston, MA, Ross P Holmes,
Birmingham, AL
MP34-11 EXPRESSION OF NNT APPEARS
TO SUPPRESS KIDNEY STONE
FORMATION IN C57BL/6 MOUSE
SUBSTRAINS
Masayuki Usami*, Rei Unno, Shoichiro
Iwatsuki, Takashi Hamakawa, Yasuhiro Fujii,
Kazumi Taguchi, Yasuhiko Hirose, Shuzo
Hamamoto, Ryosuke Ando, Atsushi Okada,
Takahiro Yasui, Keiichi Tozawa, Kenjiro
Kohri, Nagoya, Japan
MP34-05 N-METHYL-4-ISOLEUCINE
CYCLOSPORINE, AN INHIBITOR OF
MITOCHONDRIAL CYCLOPHILIN D
ACTIVATION, PREVENTS KIDNEY STONE
FORMATION BY ALLEVIATING OXIDATIVE
STRESS IN RENAL TUBULAR CELLS
Takahiro Yasui*, Kazuhiro Niimi, Atsushi
Okada, Kazumi Taguchi, Yasuhiro Fujii,
Yasuhiko Hirose, Yasuhiko Ito, Shuzo
Hamamoto, Masahito Hirose, Keiichi Tozawa,
Shoichi Sasaki, Yutaro Hayashi, Kenjiro
MP34-12 SERUM PARAOXANASE-1 GENE
POLYMORPHISM AND ENZYME
ACTIVITY IN PATIENTS WITH
UROLITHIASIS
Asuman Gedikbasi, Arda Atar*, Erkan
Sonmezay, Zeynep Kusku Kiraz, Semra
Abbasoglu, Ali Ihsan Tasci, Volkan Tugcu,
Istanbul, Turkey
MP34-13 PPAR-␣/␥ AGONISTS HAVE DIFFERENT
EFFECTS ON RENAL CRYSTAL
FORMATION IN HYPEROXALURIC ANIMAL
MODELS
Naogya, Japan, Yasuhiro Hirose, Shuzo
Hamamoto, Takahiro Kobayashi, Ryosuke
Ando, Atsushi Okada, Yasunori Itoh, Takahiro
Yasui, Keiichi Tozawa, Yutaro Hayashi,
Kenjiro Kohri, Nagoya, Japan
MP34-06 INHIBITION OF NUCLEATION AND
GROWTH OF CYSTINE CRYSTALS IN
URINE
Daryl Chrzan, Berkeley, CA, Krishna
Ramaswamy*, San Francisco, CA, David
Killilea, Oakland, CA, Tiffany Zee, Novato,
CA, Thomas Chi, San Francisco, CA, Pankaj
Kapahi, Arnold Kahn, Novato, CA, Marshall
Stoller, San Francisco, CA
120
MP34-19 SURGICAL FACTORS CONTRIBUTING TO
THE ACUTE REDUCTION IN RENAL
FUNCTION AFTER PERCUTANEOUS
NEPHROLITHOTOMY
Rajash Handa*, Cynthia Johnson, Bret
Connors, Jessica Mandeville, Ehud Gnessin,
Amy Krambeck, Naeem Bhojani, Marawan El
Tayeb, Andrew Evan, James Lingeman,
Indianapolis, IN
MP34-15 INCREASED RISK FOR CHRONIC
KIDNEY DISEASE IN KIDNEY STONE
FORMERS: A FOLLOW-UP STUDY IN
JAPANESE MEN
Ryosuke Ando*, Teruo Nagaya, Sadao
Suzuki, Kazumi Taguchi, Atsushi Okada,
Takahiro Yasui, Keiichi Tozawa, Kenjiro
MP34-20 TRANSIENT RECEPTOR POTENTIAL A1
ION CHANNEL ANTAGONISM ABOLISHES
INCREASED URETER IN VIVO
PERISTALSIS CAUSED BY UROTHELIAL
DAMAGE IN RATS
Philipp Weinhold*, Munich, Germany, Luca
Villa, Milan, Italy, Frank Strittmatter, Christian
G. Stief, Christian Gratzke, Munich, Germany,
Francesco Montorsi, Fabio Benigni, Petter
Hedlund, Milan, Italy
MP34-16 PATIENTS WITH CYSTINURIA HAVE
ALKALINE URINE DUE TO RENAL LOSS
OF SULFATE PRECURSORS
Daniel Wollin*, David Goldfarb, New York,
NY, John Asplin, Chicago, IL
MP34-17 OXALATE CONCENTRATIONS IN HUMAN
GASTROINTESTINAL FLUID
Thanmaya Reddy*, John Knight, Ross P
Holmes, Lisa Harvey, April LE Mitchem,
Charles Mel Wilcox, Klaus Monkemuller,
Dean G Assimos, Birmingham, AL
CREDITTM
8:00 am - 10:00 am
KIDNEY CANCER: EVALUATION AND STAGING I
Moderators: Allan Pantuck and Li-Ming Su
ABSTRACT
NUMBER TITLE
MP35-01 PROTEOMIC STRATIFICATION OF CLEAR
CELL RENAL CELL CARCINOMA
UTILIZING THE CANCER GENOME ATLAS
(TCGA) WITH EXTERNAL VALIDATION
Samuel Kaffenberger*, Giovanni Ciriello,
Andrew Winer, Martin Voss, New York, NY,
Jodi Maranchie, Pittsburgh, PA, Pheroze
Tamboli, Houston, TX, Kimryn Rathmell,
Chapel Hill, NC, Toni Choueiri, Boston, MA,
Robert Motzer, Jonathan Coleman, Paul
Russo, Chris Sander, James Hsieh, Ari
Hakimi, New York, NY
ABSTRACT
NUMBER TITLE
MP35-03 RADIOGENOMICS OF CLEAR CELL RENAL
CELL CARCINOMA: ASSOCIATIONS
BETWEEN IMAGING, MOLECULAR
ALTERATIONS AND PATHOLOGIC
FEATURES
Andrew G. Winer, Andreas Hoetker, Michael
J. Vacchio*, Emily C. Zabor, Irina
Ostravnaya, Paul Russo, James J. Hsieh,
Oguz Akin, A. Ari Hakimi, New York, NY
MP35-04 FIBEROPTIC CONFOCAL LASER
ENDOMICROSCOPY OF SMALL RENAL
MASSES: TOWARDS REAL TIME OPTICAL
DIAGNOSTIC BIOPSY
Li-Ming Su*, Robert Allan, Kellie Ritari,
Patrick Tomeny, Christopher Carter,
Gainesville, FL
MP35-02 PRETREATMENT NEUTROPHIL-TOLYMPHOCYTE RATIO CAN PREDICT
TUMOR AGGRESSIVENESS IN NEWLY
DIAGNOSED RENAL LESIONS
Boyd Viers*, R. Houston Thompson, Stephen
Boorjian, Christine Lohse, Bradley Leibovich,
Matthew Tollefson, Rochester, MN
*Presenting author
MP35-05 IN-VIVO, PERCUTANEOUS, NEEDLE
BASED, OPTICAL COHERENCE
TOMOGRAPHY OF RENAL MASSES
Peter Wagstaff*, Daniel de Bruin, Alexandre
Ingels, Patricia Zondervan, Otto van Delden,
Ton van Leeuwen, Jeroen van Moorselaar,
Jean de la Rosette, Pilar Laguna,
Amsterdam, Netherlands
121
SUNDAY
MP34-18 IN VITRO STUDY, THE ROLE OF RHOKINASE IN URETERAL SMOOTH MUSCLE
RELAXATION WITH TAMSULOSIN AND
TERPENE MIXURE (ROWATINEX¢Ç)
jea whan Lee*, Tae Hoon Oh, Whi-An Kwon,
Seung Chol Park, Hee Jong Jeong, Ill Young
Seo, Iksan city, Korea, Republic of
MP34-14 INHIBITION OF CALCIUM OXALATE
CRYSTALLIZATION AND DIMINUTION
OF OXALATE INDUCED RENAL
TUBULAR EPITHELIAL CELL INJURY IN
VITRO BY TERMINALIA ARJUNA
Amisha Mittal*, Simran Tandon, Solan, India,
Surender K. Singla, Chandigarh, India,
Chanderdeep Tandon, Noida, India
MP35-06 ESTABLISHMENT OF A FISH BASED
ANALYSIS FOR INDIVIDUAL RISK
ASSESSMENT OF CCRCC PATIENTS ON
TISSUE MICRO ARRAYS
Julia Grimm, Homburg, Germany, Arndt
Hartmann, Erlangen, Germany, Martin Janssen,
Homburg, Germany, Christine Stoehr, Frank
Kunath, Erlangen, Germany, Michael Stöckle,
Kerstin Junker*, Homburg, Germany
MP35-14 COMMONLY-USED COST-EFFECTIVE PREOPERATIVE INFLAMMATORY MARKERS
PROVIDE PROGNOSTIC INFORMATION IN
PATIENTS WITH LOCALIZED CLEAR CELL
RENAL CELL CARCINOMA
Yoram Baum*, Claire De la Calle, Dattatraya
Patil, Anna Bausum, Jonathan Huang, Mehrdad
Alemozaffar, John Pattaras, Peter Nieh,
Kenneth Ogan, Viraj Master, Atlanta, GA
MP35-07 THE EFFECTS OF NON-NEOPLASTIC
RENAL PARENCHYMAL ABNORMALITIES
ON RENAL FUNCTIONAL OUTCOMES
AFTER PARTIAL NEPHRECTOMY
Oktay Akca*, Homayoun Zargar, Hiury
Andrade, Daniel Ramirez, Peter Caputo,
Khaled Fareed, Robert J Stein, Jihad H
Kaouk, Cleveland, OH
MP35-15 PRETHERAPEUTIC PLASMA FIBRINOGEN
LEVEL IS AN INDEPENDENT SURVIVAL
PREDICTOR IN RENAL CELL CARCINOMA
Takeshi Sasaki*, Tsu, Mie, Japan, Takehisa
Onishi, Ise, Mie, Japan, Yoshiki Sugimura,
Tsu, Mie, Japan
MP35-16 PILOT STUDY EVALUATING 99MTCSESTAMIBI SPECT/CT FOR THE
DIFFERENTIATION OF ONCOCYTOMA
FROM RENAL CELL CARCINOMA
Michael Gorin*, Steven Rowe, Jennifer
Gordetsky, Mark Ball, Phillip Pierorazio,
Jonathan Epstein, Mehrbod Javadi, Mohamad
Allaf, Baltimore, MD
MP35-08 HISTOPATHOLOGICAL EVALUATION OF
NON-NEOPLASTIC RENAL PARENCHYMA
IS MORE PROMISING THAN
SOPHISTICATED FILM TECHNOLOGY FOR
THE PREDICTION OF POST-PARTIAL
NEPHRECTOMY RENAL FUNCTION
Takehiro Sejima*, Noriya Yamaguchi, Hideto
Iwamoto, Toshihiko Masago, Shuichi
Morizane, Masashi Honda, Atsushi Takenaka,
Yonago, Japan
MP35-17 MULTI-QUADRANT BIOPSY TECHNIQUE
DECREASES SAMPLING ERROR IN LARGE
HETEROGENEOUS RENAL TUMORS
Jennifer E. Heckman*, Timothy Ziemlewicz,
Sara Best, Meghan Lubner, Louis Hinshaw,
David F. Jarrard, Tracy Downs, Wei Huang,
Fred T. Lee, Jr, Stephen Y. Nakada, E.
Jason Abel, Madison, WI
MP35-09 MANAGEMENT OF SUSPICIOUS LIPID
POOR RENAL MASSES IN THE
TUBEROUS SCLEROSIS COMPLEX
PATIENT WITH MULTIPLE RENAL
LESIONS
Adam Feldman*, Michael Kurtz, Michael Blute,
Elizabeth Thiele, Chin-Lee Wu, Michael Gee,
Gregory Walker, Elahna Paul, Boston, MA
MP35-18 SARCOPENIA IS INDEPENDENTLY
ASSOCIATED WITH INCREASED
MORTALITY FOLLOWING RADICAL
NEPHRECTOMY FOR LOCALIZED RENAL
CELL CARCINOMA
Sarah Psutka*, Michael Moynagh, Grant
Schmit, R. Houston Thompson, Stephen
Boorjian, Suzanne Stewart, Christine Lohse,
John Cheville, Bradley Leibovich, Matthew
Tollefson, Rochester, MN
MP35-10 TUMOR CAPSULE PROPERTIES OF
PAPILLARY RENAL CELL CARCINOMA
Chandra K. Flack*, Dibson D. Gondim, Adam
C. Calaway, Joseph M. Jacob, Muhammad T.
Idrees, Ronald S. Boris, Indianapolis, IN
MP35-11 SIGNIFICANT ELEVATION AND SUBTYPE
DIFFERENCES OF PLASMATIC
KISSPEPTIN IN PATIENTS WITH SMALL
RENAL TUMOURS
Marcus Horstmann*, Felix Krause, Daniel
Steinbach, Martina Walter, Marc-Oliver
Grimm, Jena, Germany
MP35-19 THE IMPACT OF EXCESS FAT MASS ON
MORTALITY AFTER RADICAL
NEPHRECTOMY FOR RENAL CELL
CARCINOMA: BEYOND BODY MASS
INDEX
Sarah Psutka*, Michael Moynagh, Grant
Schmit, R. Houston Thompson, Stephen
Boorjian, Suzanne Stewart, Christine Lohse,
John Cheville, Bradley Leibovich, Matthew
Tollefson, Rochester, MN
MP35-12 A NOVEL APPROACH FOR IDENTIFYING
AGGRESSIVE CYSTIC RENAL CELL
CARCINOMA USING SOLID VOLUME
SCORE AND ENHANCEMENT
Shervin Badkhshan*, Chirag Doshi, Brian
Quaranto, Jay Amin, Nicholas Georgalas,
Michael Mungillo, Terrence Creighton, Thomas
Schwaab, Eric Kauffman, Buffalo, NY
MP35-20 PLASMA FIBRINOGEN LEVEL
INDEPENDENTLY PREDICTS THE
PROGNOSIS OF PATIENTS WITH NONMETASTATIC RENAL CELL CARCINOMA
Jun Obata*, Nobuyuki Tanaka, Ryuichi
Mizuno, Shinya Morita, Kazunobu Shinoda,
Takeo Kosaka, Toshiaki Shinojima, Eiji
Kikuchi, Hiroshi Asanuma, Akira Miyajima,
MP35-13 UTILITY OF A VOLUMETRIC COMPUTER
AIDED DIAGNOSTIC (CAD) BASED
ALGORITHM ASSESSING RELATIVE
LESION ENHANCEMENT TO DISCRIMINATE
MALIGNANT AND BENIGN SMALL RENAL
MASSES ON FOUR-PHASE MDCT
Heidi Coy*, Jonathan Young, Michael Douek,
Moe Moe Ko, War War Ko, Pechin Lo,
Matthew Brown, Jonathan Goldin, Steven
Raman, Los Angeles, CA
CREDITTM
122
8:00 am - 10:00 am
ABSTRACT
NUMBER TITLE
MP36-01 MITOCHONDRIAL DNA CONTENT AS RISK
FACTOR FOR BLADDER CANCER AND ITS
ASSOCIATION WITH MITOCHONDRIAL
DNA POLYMORPHISMS
Stephen Williams*, Yanquing Ye, Maosheng
Huang, David Cheng, Ashish Kamat, Xia Pu,
Colin Dinney, Xifeng Wu, Houston, TX
ABSTRACT
NUMBER TITLE
MP36-08 MICRORNA-144-5P FUNCTIONS AS
TUMOUR SUPPRESSOR THROUGH
TARGETING CYCLIN E1 AND CYCLIN E2
THAT ARE POTENTIAL PROGNOSTIC
MARKERS IN BLADDER CANCER
Ryosuke Matsushita*, Kagoshima city, Japan,
Naohiko Seki, Chiba city, Japan, Takeshi
Chiyomaru, Satoru Inoguchi, Tomoaki
Ishihara, Toshihiko Itesako, Shuichi Tatarano,
Hirofumi Yoshino, Kagoshima city, Japan,
Yusuke Goto, Rika Nishikawa, Chiba city,
Japan, Hideki Enokida, Masayuki Nakagawa,
Kagoshima city, Japan
MP36-02 POLYMORPHISMS OF MEMBRANE
TRANSPORTING GENE SLCO1B3 AND
DETOXIFICATION ENZYME NAT2
ASSOCIATE WITH BLADDER CANCER
SUSCEPTIBILITY IN SMOKERS
Naohiro Fujimoto*, Hoai Bui, Tatsuhiko Kubo,
Kitakyushu, Japan, Hisato Inatomi, Fukutsu,
Japan, Ryoichi Hamasuna, Kitakyushu, Japan
MP36-09 SCHISTOSOMA HAEMATOBIUM EGGINDUCED BLADDER UROTHELIAL
ABNORMALITIES ARE MODULATED BY
P53 IN A GENDER-DEPENDENT FASHION
Jared Honeycutt, Stanford, CA, Olfat
Hammam, Giza, Egypt, Michael Hsieh*,
Washington, DC
MP36-03 PLECTIN ANCHORING INVADOPODIA TO
VIMENTIN INTERMEDIATE FILAMENT IS A
CRITICAL MOLECULAR STEP FOR
BLADDER CANCER CELL INVASION AND
EXTRAVASATION FOR METASTASIS
Mihoko Sutoh Yoneyama*, Shingo
Hatakeyama, Hirosaki, Japan, Tomonori
Habuchi, Takamitsu Inoue, Akita, Japan,
Toshiya Nakamura, Tomihisa Funyu,
Hirosaki, Japan, Gerhard Wiche, Vienna,
Austria, Chikara Ohyama, Shigeru Tsuboi,
Hirosaki, Japan
MP36-10 MIR-99A ACTS AS TUMOR SUPPRESSOR
VIA TARGETING TO MTOR IN HUMAN
BLADDER CANCER CELLS
Te-Fu Tsai*, Ji-Fan Lin, Yi-Chia Lin, KuangYu Chou, Hung-En Chen, Thomas I.S.
Hwang, Taipei, Taiwan
MP36-11 AUTOPHAGY IS ACTIVATED IN HUMAN
BLADDER CANCER AND REQUIRED FOR
CANCER CELL GROWTH
Thomas I.S. Hwang*, Ji-Fan Lin, Yi-Chia Lin,
Te-Fu Tsai, Hung-En Chen, Kuang-Yu Chou,
Taipei, Taiwan
MP36-04 GENE AMPLIFICATION AND
OVEREXPRESSION OF CYP2A6 IN EARLY
STAGE OF INVASIVE BLADDER CANCER
Kazuhiro Kanemoto*, Katsuhiro Fukuta,
Noriyasu Kawai, Keiichi Tozawa, Nagoya,
Japan, Masako Ochiai, Koji Okamoto, Hiromi
Sakamoto, Teruhiko Yoshida, Yae Kanai,
Masaru Katoh, Hitoshi Nakagama, Tokyo,
Japan, Kenjiro Kohri, Nagoya, Japan
MP36-12 CLONALITY OF BLADDER TUMORS
FOLLOWING RADICAL
NEPHROURETERECTOMY – AGAINST THE
FIELD DEFECT HYPOTHESIS
Eugene Cha*, John Sfakianos, Sasinya Scott,
Paari Murugan, Gopa Iyer, Ronak Shah,
Aditya Bagrodia, Neil Desai, Dean Bajorin,
Jonathan Rosenberg, Michael Berger, Hikmat
Al-Ahmadie, Bernard Bochner, Jonathan
Coleman, David Solit, New York, NY
MP36-05 OVEREXPRESSION OF THE LONG
NONCODING RNA LOC572558 IMPAIRS IN
VITRO BLADDER CANCER CELL
PROLIFERATION BY REGULATING P53
yiping zhu*, hailiang zhang, dingwei ye,
shanghai, China, People’s Republic of
MP36-13 DEEP SEQUENCING OF MICRORNA
EXPRESSION SIGNATURE OF BLADDER
CANCER: THE FUNCTIONAL
SIGNIFICANCE OF MIR-145/145* AND ITS
REGULATED MOLECULAR PATHWAYS
Satoru Inoguchi*, Kagoshima, Japan,
Naohiko Seki, Chiba, Japan, Takeshi
Chiyomaru, Ryosuke Matsushita, Tomoaki
Ishihara, Hirofumi Yoshino, Kagoshima,
Japan, Yusuke Goto, Rika Nishikawa, Chiba,
Japan, Hideki Enokida, Masayuki Nakagawa,
Kagoshima, Japan
MP36-06 P63 EXPRESSION IN BLADDER CANCER
VERSUS CHRONIC BILHARZIAL BLADDER
Khaled Mursi*, Ayman Agag, Olfat Hammam,
Essam Riad, Mahmoud Daw, Cairo, Egypt
MP36-07 ROLE OF ADIPOSE TISSUE IN BLADDER
CANCER PROGRESSION
Nisha Hariharan*, Teresa Johnson-Pais,
Robert Svatek, Keith Ashcraft, Robin Leach,
San Antonio, TX
*Presenting author
123
SUNDAY
BLADDER CANCER: BASIC RESEARCH I
Moderators: Vinata Lokeshwar and Jay Shah
MP36-18 TOBACCO SMOKE NITROSAMINE
BLADDER CARCINOGENIC MECHANISMS:
INDUCING MUTAGENIC DNA ADDUCTS
INHIBITING DNA REPAIR AND
ENHANCING MUTATION SUSCEPTIBILITY
hyun-wook lee*, Tuxedo Park, NY
MP36-14 TOLL-LIKE RECEPTOR 4-DEPENDENT,
URINE-INDUCED ACTIVATION OF THE
STRESS SENSOR INOSITOL-REQUIRING
PROTEIN 1 (IRE1) PATHWAY IN BLADDER
CANCER
Daniel Nguyen*, Huixian Liu, James Chrystal,
Thomas Flynn, Douglas Scherr, New York, NY
MP36-19 RAS ACTIVATION SYNERGIZES WITH P53
DEFICIENCY TO PROVOKE EPITHELIALMESENCHYMAL TRANSITION FORMING
CANCER PROGENITOR CELLS AND
TRIGGERING BASAL SUBTYPE MUSCLE
Feng He, Yan Liu, Jonathan Melamed,
Herbert Lepor, Moon-shong Tang, Chuanshu
Huang, Xue-Ru Wu*, New York, NY
MP36-15 MICRORNA-218 INHIBITS BLADDER
CANCER CELL PROLIFERATION,
MIGRATION AND INVASION BY
TARGETING BMI-1
Pengchao Li*, Qiang Lu, Jun Tao, Chao Qin,
MP36-16 THE ROLE OF P63 AND P53MUTANT IN
THE REGULATION OF DNA REPAIR,
MUTATOR AND INVASIVE PHENOTYPE
OF BLADDER CANCER CELLS
Mao-wen Weng*, Hsiang-Tsui Wang, HyunWook Lee, Tuxedo Park, NY, William C.
Huang, Herbert Lepor, Xue-Ru Wu, New York
City, NY, Moon-shong Tang, Tuxedo Park, NY
MP36-20 DEFINING THE MOLECULAR DRIVERS OF
HIGH-GRADE NON-INVASIVE
BLADDER
Haiping Zhou, Yan Liu, Herbert Lepor, Moonshong Tang, Chuanshu Huang, Xue-Ru Wu*,
New York, NY
MP36-17 CANONICAL NOTCH2 SIGNALING
PROMOTES TUMOR GROWTH AND
METASTASIS IN BLADDER CANCER
THROUGH CELL CYCLE PROGRESSION,
DEDIFFERENTIATION AND EMT
Tetsutaro Hayashi*, Kilian Gust, Wolfgang
Jäger, Shannon Awrey, Na Li, Manuel
Altamirano-Dimas, Ralph Buttyan, Ladan
Fazli, vancouver, Canada, Akio Matsubara,
Hiroshima, Japan, Peter Black, Vancouver,
Canada
CREDITTM
8:00 am - 10:00 am
PROSTATE CANCER: BASIC RESEARCH I
Moderators: Ralph Buttyan and Natasha Kyprianou
ABSTRACT
NUMBER TITLE
MP37-01 GLI3 EXPRESSION INFLUENCES
ANDROGEN RECEPTOR ACTIVITY AND
FUNCTION IN ANDROGEN GROWTHINDEPENDENT PROSTATE CANCER
Na Li, Sarah Truong, Mannan Nouri, Ralph
Buttyan*, Vancouver, Canada
ABSTRACT
NUMBER TITLE
MP37-03 INFILTRATING NEUTROPHILS PROMOTE
PROSTATE CANCER PROLIFERATION VIA
ALTERATION OF IL8-ANDROGEN
RECEPTOR SIGNALING
Shuai Hu*, Yun Cui, Xin Li, Beijing, China,
People’s Republic of, Shuyuan Yeh,
Rochester, NY, Jie Jin, Yinglu Guo, Beijing,
China, People’s Republic of, Chawnshang
Chang, Rochester, NY
MP37-02 ERG/AKR1C3/AR CONSTITUTES A FEEDFORWARD LOOP FOR AR SIGNALING IN
PROSTATE CANCER CELLS
Katelyn Powell, Louie Semaan, Mary ConleyLaComb, Detroit, MI, Irfan Asangani, Yi-Mi
Wu, Ann Arbor, MI, Julia Williams, Kingston,
Canada, Jeremy Squire, Sao Paolo, Brazil,
Krishna Maddipati, Michael Cher*, Sreenivasa
Chinni, Detroit, MI
MP37-04 ANDROGEN RECEPTOR POSITIVE
STROMAL CELLS REGULATE PROSTATE
CANCER PROLIFERATION THROUGH
NON-CANONICAL WNT SIGNALING
Sayuri Takahashi*, Ichiro Takada, Tokyo,
Japan, Naoki Terada, Kyoto, Japan, Yukio
Homma, Tokyo, Japan, Robert H.
Getzenberg, Memphis, TN
MP37-05 ERP46 MEDIATES PROSTATE CANCER
TUMORIGENESIS
Wilhelmina Duivenvoorden, Stephanie
Federov, Sarah Hopmans, Jehonathan
Pinthus*, Hamilton, Canada
124
MP37-13 ACCELERATED CELL PROLIFERATION
AND ENHANCED RESISTANCE TO
DOCETAXEL BY INHIBITION OF 4EBINDING PROTEIN 1 EXPRESSION IN
HUMAN CASTRATION-RESISTANT
PROSTATE CANCER PC3 CELLS
Hiromoto Tei*, Hideaki Miyake, Masato
Fujisawa, Kobe, Japan
MP37-07 UP REGULATION OF AMINOACID
TRANSPORTER LAT1 DURING
ANDROGEN DEPRIVATION THERAPY
CONTRIBUTES TO ACQUISITION OF
CASTRATION RESISTANCE IN PROSTATE
CANCER CELLS
Min Hui Xu*, Shinichi Sakamoto, Shuhei
Kamda, Mayuko Kato, Akira Kurozumi, Rika
Nishikawa, Yusuke Goto, Miki Fuse,
Yoshikatu Kanai, Naohiko Seki, Tomohiko
Ichikawa, Chiba, Japan
MP37-14 RNA INTERFERENCE-MEDIATED
KNOCKDOWN OF CHD1 IN HUMAN
PROSTATE XENOGRAFT TUMORS
ALTERS TUMOR GROWTH AND
METASTATIC BEHAVIOR
Su Jung Oh*, Derya Tilki, Hüseyin Sirma,
Ronald Simon, Tobias Lange, Hamburg,
Germany
MP37-08 USING THE CLINICO-GENETIC MODEL
FOR PREDICTING LYMPH NODE
INVASION BY GENOME-BASED
BIOMARKERS FROM EXOME ARRAY
AMONG PROSTATE CANCER PATIENTS
Jong Jin Oh*, Seongnam-si, Korea, Republic
of, Seunghyun Park, Seoul, Korea, Republic
of, Sang Eun Lee, Sung Kyu Hong, Sangchul
Lee, Hak Min Lee, Jeung Geun Lee,
Seongnam-si, Korea, Republic of, Sungroh
Yoon, Seoul, Korea, Republic of, Seok-soo
Byun, Seongnam-si, Korea, Republic of
MP37-15 THE CARDIOVASCULAR SERUM MARKER
OX-LDL MAY PROMOTE METASTASIS IN
PROSTATE CANCER
Xiaojian Qin*, Fangning Wan, Yao Zhu,
Hailiang Zhang, Bo Dai, Guohai Shi, Dingwei
Ye, Shanghai, China, People’s Republic of
MP37-16 A NKX3.1 BINDING SITE POLYMORPHISM
IN THE L-PLASTIN PROMOTER LEADS TO
DIFFERENTIAL GENE EXPRESSION IN
HUMAN PROSTATE CANCER
Jian Huang, Changhao Chen*, Tianxin Lin,
Wang He, Xu Chen, guangzhou, China,
MP37-09 A MULTIPARAMETRIC MOLECULAR
CLASSIFIER FOR IMPROVED PREDICTION
OF PROSTATE CANCER PROGNOSIS
Raisa Pompe*, Stefan Kraft, Philipp Gild,
Martina Kluth, Ronald Simon, Pierre
Tennstedt, Markus Graefen, Guido Sauter,
Thorsten Schlomm, Hamburg, Germany
MP37-17 DISTINCT EXPRESSION FEATURES OF
PMEPA1 AND ITS ISOFORM STAG1 IN
PROSTATE CANCER
Hua Li*, Lakshmi Ravindranath, Yongmei
Chen, Rockville, MD, David McLeod,
Bethesda, MD, Isabell Sesterhenn, Silver
Spring, MD, Albert Dobi, Shiv Srivastava,
Gyorgy Petrovics, Rockville, MD
MP37-10 11B6 MAB: APPLICATIONS FOR
PROSTATE CANCER STAGING, INTRAOPERATIVE GUIDANCE AND
EVALUATION OF TREATMENT BY IN VIVO
IMAGING OF HK2
Daniel Thorek, Baltimore, MD, Katharina
Braun, Herne, Germany, Jason Lewis, Peter
Scardino, Hans Lilja, Steven Larson, David
Ulmert*, New York, NY
MP37-18 SOX2 IS ASSOCIATED WITH
EXTRACAPSULAR EXTENSION
FOR PROSTATE CANCER
Blake Anderson*, Steven Kregel, Gladell
Paner, Gregory Zagaja, Donald Vander
Griend, Chicago, IL
MP37-11 TERT PROMOTER METHYLATION IS A
PAN-CANCER BIOMARKER WITH
PROGNOSTIC SIGNIFICANCE IN
PROSTATE CANCER PATIENTS
Ricardo Leao*, Toronto, Canada, Pedro
Castelo-Branco, Faro, Portugal, Tatiana
Lipman, Brittany Campbell, Aryeh Price, Cindy
Zhang, Toronto, Canada, Ana Gomes, Hugo
Coelho, Coimbra, Portugal, Robert G. Bristow,
Toronto, Canada, Michal Schweiger, Berlin,
Germany, Robert J. Hamilton, Alexandre R.
Zlotta, Toronto, Canada, Arnaldo Figueiredo,
Coimbra, Portugal, Helmut Klocker, Innsbruck,
Austria, Holger Sulttmann, Heidelberg,
Germany, Uri Tabori, Toronto, Canada
*Presenting author
MP37-19 AXIN2 EXPRESSION PREDICTS
PROSTATE CANCER RECURRENCE AND
MEDIATES AN INVASIVE, TUMORIGENIC
PHENOTYPE
Brian Hu*, Los Angeles, CA, Adrian Fairey,
Edmonton, Canada, Anisha Madhav,
Dongyun Yang, Meng Li, Susan Groshen,
Craig Stephens, Philip Kim, Navneet Virk,
Lina Wang, Sue Ellen Martin, Los Angeles,
CA, Nicholas Erho, Elai Davicioni, San Diego,
CA, Robert Jenkins, Rochester, MN, Robert
Den, Philadelphia, PA, Tong Xu, Yucheng
Xu, Inderbir Gill, David Quinn, Amir Goldkorn,
Los Angeles, CA
125
SUNDAY
MP37-12 INSULIN-LIKE GROWTH FACTOR-I
INDUCES CLU EXPRESSION THROUGH
TWIST1 TO PROMOTE PROSTATE
CANCER GROWTH
Ario Takeuchi*, Masaki Shiota, Seiji Naito,
Fukuoka, Japan, Michael Cox, Martin Gleave,
Amina Zoubeidi, Vancouver, Canada
MP37-06 TARGETED SEQUENCING OF PROSTATE
CANCER CIRCULATING TUMOR CELLS
AND COMPARISON WITH MATCHED CELL
FREE DNA AND PROSTATE TUMORS
Brian Hu*, Los Angeles, CA, Stephen Liu,
Washington, DC, Yucheng Xu, Los Angeles,
CA, Paul Dempsey, William Strauss, Westlake
Village, CA, Kristopher Wentzel, Tong Xu,
Jacek Pinski, Tanya Dorff, Timothy Triche, Los
Angeles, CA, Jessamine Winer Jones,
Westlake Village, CA, Inderbir Gill, David
Quinn, Amir Goldkorn, Los Angeles, CA
CREDITTM
MP37-20 NEOADJUVANT ANDROGEN
DEPRIVATION THERAPY INDUCES
SENESCENCE IN RADICAL
PROSTATECTOMY SPECIMENS
Michael L. Blute, Jr.*, Jennifer Wagner,
Nathan Damaschke, Bing Yang, Madison, WI,
Martin Gleave, Ladan Fazli, Vancouver,
Canada, Wei Huang, David F. Jarrard,
Madison, WI
8:00 am - 10:00 am
STONE DISEASE: SURGICAL THERAPY IV
Moderators: Mantu Gupta and R. John Honey
ABSTRACT
NUMBER TITLE
MP38-01 UROLITHIASIS IN PREGNANCY: A COSTEFFECTIVENESS ANALYSIS OF
URETEROSCOPIC MANAGEMENT
VERSUS SERIAL URETERAL STENTING
Kevin Wymer*, Chicago, IL, Beth Plunkett,
Sangtae Park, Evanston, IL
ABSTRACT
NUMBER TITLE
MP38-07 COMPARISON OF FLEXIBLE
URETERORENOSCOPIC LITHOTRIPSY
AND RETROPERITONEAL
LAPAROSCOPIC URETEROLITHOTOMY
FOR TREATMENT OF UNILATERAL
LARGE (>15 MM) UPPER URETERAL
STONE: A SIX YEAR RETROSPECTIVE
STUDY
Volkan Tugcu, Selcuk Sahin, Arda Atar*,
Ramazan Kocakaya, Mithat Eksi, Ali Tasci,
Istanbul, Turkey
MP38-02 WITHDRAWN
MP38-03 EFFECT OF STEP-WISE VOLTAGE
RAMPING ON RENAL DAMAGE AND
TREATMENT OUTCOME FOLLOWING
EXTRACORPOREAL SHOCKWAVE
LITHOTRIPSY (ESWL) OF KIDNEY
STONES: RESULTS OF A PROSPECTIVE
RANDOMIZED TRIAL
Veronika Skuginna*, Daniel P. Nguyen,
Roland Seiler, George N. Thalmann, Beat
Roth, Bern, Switzerland
MP38-08 DETERMINANTS OF HEALTH-RELATED
QUALITY OF LIFE FOR PATIENTS AFTER
URINARY LITHOTRIPSY:
URETEROSCOPIC VERSUS SHOCK WAVE
LITHOTRIPSY
Shuzo Hamamoto*, Takahiro Yasui, Nagoya,
Japan, Naoko Okuda, Satoshi Koiwa, Toyota,
Japan, Atsushi Okada, Nagoya, Japan,
Hiroyuki Kamiya, Yoshihiro Hashimoto,
Toyota, Japan, Keiichi Tozawa, Nagoya,
Japan, Yutaka Iwase, Toyota, Japan, Kenjiro
MP38-04 IMPACTED STONE MODEL USED TO
COMPARE HYDROPHILIC GUIDEWIRE
EFFICACY
Daniel Faaborg*, Jacob Khouri, Kristene
Myklak, Muhannad Alsyouf, Duane Baldwin,
Loma Linda, CA
MP38-09 EXCELLENT TREATMENT OUTCOMES
CAN BE ACHIEVED FOR URETERAL
STONES BY OPTIMIZING
EXTRACORPOREAL SHOCK WAVE
LITHOTRIPSY (ESWL) PARAMETERS.
RESULTS OF A PROSPECTIVE,
RANDOMIZED TRIAL
Stefanie Hnilicka*, Daniel P. Nguyen, Rolf
Schmutz, Bernhard Kiss, Roland Seiler,
George N. Thalmann, Beat Roth, Bern,
Switzerland
MP38-05 THE MODERN ERA STRUVITE STONE:
PATTERNS OF URINARY INFECTION AND
COLONIZATION
Adam De Fazio*, Haresh Thummar, Michael
Rothberg, Piruz Motamedinia, Gina Badalato,
Mantu Gupta, New York, NY
MP38-06 ULTRA LOW DOSE CT-KUB TO DETECT
KIDNEY STONES WITH 44% LESS
RADIATION: IS THE PLAIN RADIOGRAPH
OBSOLETE?
Ben H. Chew*, Patrick McLaughlin, Ryan F.
Paterson, Elspeth M. McDougall, James
Nugent, Allen V. Rowley, Jean Buckley,
Charles Zwirewich, Vancouver, Canada
MP38-10 EXTRACORPOREAL SHOCKWAVE
LITHOTRIPSY VERSUS FLEXIBLE
URETEROSCOPY FOR THE
MANAGEMENT OF UPPER TRACT
URINARY STONES IN CHILDREN:A CASECONTROL NON RANDOMIZED STUDY
benoit peyronnet*, alexis arnaud, lauranne
tondut, lucas freton, gaetan berquet, gregory
verhoest, olivier azzis, benjamin fremond,
karim bensalah, Rennes, France
126
MP38-16 OUTCOMES OF UROLITHIASIS
TREATMENT IN PATIENTS WITH RENAL
INSUFFICIENCY
Haresh Thummar*, Usama Khater, New York,
NY, V Joshi, P Kansagra, Rajkot, India,
mantu gupta, new York, NY
MP38-11 IS AN INCREASE IN THE NUMBER OF
SHOCK WAVES PER SESSION EFFECTIVE
AND SAFE IN EXTRACORPOREAL
LITHOTRIPSY? A RANDOMIZED,
PROSPECTIVE AND COMPARATIVE
STUDY
Alberto Budı́a*, José Daniel López-Acón,
Marta Trassierra, Pilar Bahı́lo, Ariana Álvarez,
Francisco Boronat, Valencia, Spain
MP38-12 EFFECTS OF ENDOUROLOGICAL
PROCEDURES ON ERECTILE FUNCTION:
A PROSPECTIVE COHORT STUDY
Ashraf Mosharafa*, Mohammed Tawfik,
Mahmoud Abdelhamid, Omar Abdelrazzak,
Cairo, Egypt
MP38-18 PROSPECTIVE EVALUATION OF THE
SAFETY AND EFFICACY OF SPINAL
ANESTHESIA VS. GENERAL ANESTHESIA
FOR PERCUTANEOUS
NEPHROLITHOTOMY (PCNL)
Haresh Thummar*, New York, NY, Usama
Khater, Nw York, NY, Rachael Shapiro, New
Yorkk, NY, Balaji reddy, Mantu Gupta, new
York, NY
MP38-13 FACTORS ASSOCIATED WITH NEED FOR
RETREATMENT FOLLOWING
SHOCKWAVE LITHOTRIPSY: A LARGE
MULTI-INSTITUTIONAL COHORT STUDY
Jonathan Witten*, Solange MongoueTchokote, Brian Duty, Portland, OR
MP38-14 IMPACT OF COLIC PAIN AS A
SIGNIFICANT FACTOR FOR PREDICTING
THE STONE FREE RATE OF ONE-SESSION
SHOCK WAVE LITHOTRIPSY FOR
TREATING URETER STONES: A
BAYESIAN LOGISTIC REGRESSION
MODEL ANALYSIS
Hae Do Jung*, , Korea, Republic of, Doo
Yong Chung, Kang Su Cho, Dae Hun Lee,
Seoul, Korea, Republic of, Ki Soo Lee, Tae
Nam Kim, Korea, Republic of, Young Deuk
Choi, Joo Yong Lee, Seoul, Korea, Republic
of, Dong Hyuk Kang, Yangpyeong, Korea,
Republic of, Jang Hee Han, Ho Won Kang,
MP38-19 EFFECTS OF SEDATION ON KIDNEY
POSITION IN THE SUPINE AND PRONE
POSITIONS
Natalia Hernandez*, Florian Fintelmann,
Hosam Attaya, Yan Song, Brian Eisner,
Boston, MA
MP38-20 MICRO-PERCUTANEOUS
NEPHROLITHOTOMY FOR THE
TREATMENT OF MODERATE SIZED
KIDNEY STONES; OUR CLINICAL
EXPERIENCES IN FIRST 100 CASES
FROM A SINGLE CENTER
Tuna Karatag, Ibrahim Buldu, Ramazan Inan,
Mustafa Okan Istanbulluoglu*, Konya, Turkey
MP38-15 THE NOVEL K.U.B GRADING SYSTEM
FOR STRATIFYING SURGICAL
COMPLEXITY IN PATIENTS WITH
ENTOMBED JJ STENTS
Javier L. Arenas*, Albert Lee, Phillip Stokes,
Roger Li, Muhannad Alsyouf, Michelle
Lightfoot, D. Duane Baldwin, Loma Linda, CA
CREDITTM
8:00 am - 10:00 am
KIDNEY CANCER: BASIC RESEARCH I
Moderators: Gopal Gupta and Hari Koul
ABSTRACT
NUMBER TITLE
MP39-01 IN VITRO PERFORMANCE OF
SORAFENIB-LOADED PLGA AND
LIPOSOME NANOPARTICLES AS A
DELIVERY SYSTEM IN THE TREATMENT
OF RENAL CELL CARCINOMA
James Liu*, Benjawan Boonkaew, Sree
Harsha Mandava, Jaspreet Arora, Michael
Maddox, Srinivas Chava, Cameron
Callaghan, Srikanta Dash, Vijay John,
Benjamin Lee, New Orleans, LA
*Presenting author
ABSTRACT
NUMBER TITLE
MP39-02 OVEREXPRESSION OF MPS1 IN CLEAR
CELL RENAL CELL CARCINOMA (CCRCC)
CONFERS TUMOR SELECTIVITY ON HEAT
SHOCK PROTEIN-90 (HSP90) INHIBITORS
Mourad Abouelleil, Diana Dunn, Mark
Woodford, Syracuse, NY, Sandra Jensen,
Gaithersburg, MD, Mahmoud Chehab, Alosh
Madala, Tiffany Caza, Steve Landas,
Syracuse, NY, William G. Stetler-Stevenson,
Gaithersburg, MD, Len Neckers, Bethesda,
MD, Dimitra Bourboulia, Gennady
Bratslavsky, Mehdi Mollapour*, Syracuse, NY
127
SUNDAY
MP38-17 LAPAROASSISTED PERCUTANEOUS
NEPHROLITHOTOMY: EXPERIENCE AND
OUTCOMES
Helena Vila Reyes*, Carlos Torrecilla Ortiz,
Miguel Angel Lopez Costea, Sergi Colom
Feixas, Francesc Vigues Julia, Eladio Franco
Miranda, Barcelona, Spain
MP39-10 EFFECT OF OBESITY AND ADIPONECTIN
SIGNALING IN PATIENTS WITH RENAL
CELL CARCINOMA TREATED WITH
SURGERY
Ryuichi Itoh*, Akita, Japan, Shintaro Narita,
Akita, Akita, Japan, Mingguo Huang,
Hiroshi Tsuruta, Susumu Akihama, Mitsuru
Saito, Takamitsu Inoue, Norihiko Tsuchiya,
Shigeru Satoh, Tomonori Habuchi, Akita,
Japan
MP39-03 WITHDRAWN
MP39-04 IL-6 RECEPTOR ANTIBODY ENHANCES
THE EFFECT OF TKI AGAINST RENAL
CELL CARCINOMA
Kei Ishibashi*, Hitoshi Kubo, Yoshiyuki
Kojima, Fukushima, Japan, Tobias Haber,
Joachim W Thüroff, Walburgis Brenner,
Mainz, Germany
MP39-05 INHIBITION OF CARBONIC ANHYDRASE
IX CONFERS RADIATION SENSITIVITY TO
Jehonathan Pinthus*, Sarah Hopmans, Daniel
Gallino, Carrie Gerdes, Diana Glennie,
Thomas Farrell, Hamilton, Canada
MP39-11 DECREASING SURVIVIN BY YM155
REVERSES RAPAMYCIN RESISTANCE IN
RENAL CANCER
Hidekazu Koike*, Takashi Nitta, Yoshitaka
Sekine, Yoshiyuki Miyazawa, Haruo Kato,
Yosuke Furuya, Yasuhiro Shibata, Kazuto
Ito, Kazuhiro Suzuki, Maebashi, Japan
MP39-06 ENHANCED CELL PROLIFERATION AND
INCREASED RESISTANCE TO
MAMMALIAN TARGET OF RAPAMYCIN
INHIBITORS BY INHIBITION OF 4EBINDING PROTEIN 1 EXPRESSION IN
HUMAN RENAL CELL CARCINOMA ACHN
CELLS
Akira Miyazaki*, Hideaki Miyake, Masato
MP39-12 CARBONIC ANHYDRASE X, A NOVEL
PUTATIVE TUMOR SUPPRESSOR
SILENCED BY PROMOTER CPG
METHYLATION, SUPPRESSES GROWTH
AND INVASIVENESS OF RENAL CELL
CARCINOMA
Lian Zhang*, Yu Fan, Lu Wang, Qian Zhang,
Jie Jin, Beijing, China, People’s Republic of
MP39-07 ACCELERATION OF PROTEINURIA
WITHOUT SIGNIFICANT IMPACT ON
RENAL FUNCTION AND ITS PROTECTION
BY ANGIOTENSIN II RECEPTOR
BLOCKER IN RATS TREATED WITH
AXITINIB
Satoshi Imai*, Hideaki Miyake, Masato
MP39-13 DEVELOPMENT OF A NOVEL METHOD
FOR DETECTING RENAL CELL
CARCINOMA CIRCULATING TUMOR
CELLS
Michael Gorin*, Mark Ball, Baltimore, MD,
Darren Davis, Houston, TX, Phillip Pierorazio,
Hans Hammers, Kenneth Pienta, Mohamad
Allaf, Baltimore, MD
MP39-08 CLUSTERIN INHIBITION USING OGX-011
SYNERGISTICALLY ENHANCES
ANTITUMOR ACTIVITY OF
TEMSIROLIMUS IN A HUMAN RENAL
CELL CARCINOMA MODEL
Masatomo Nishikawa*, Hideaki Miyake, Kobe,
Japan, Martin Gleave, Vancouver, Canada,
MP39-14 BOILING HISTOTRIPSY ABLATION OF IN
VIVO RENAL CARCINOMA IN THE EKER
RAT
George R. Schade*, Yak-Nam Wang,
Samantha D’Andrea, Joo Ha Hwang, Daniel
W. Lin, Michael R. Bailey, Tatiana D.
Khokhlova, Seattle, WA
MP39-09 RAPAMYCIN INHIBITS FLCN-DEFICIENT
RENAL TUMOR GROWTH IN MICE
Jindong Chen*, Shuhui Si, Rochester, NY,
Xueying Li, Zunyi, China, People’s Republic
of, Yan Li, Beijing, China, People’s
Republic of, Susan Schoen, Rochester, NY,
Bin Tean Teh, Singapore, Singapore, Guan
Wu, Rochester, NY
MP39-15 NEOVASCULARITY IS A PROGNOSTIC
MARKER IN RENAL CELL CARCINOMA
Tyler Bauman*, Wei Huang, E. Jason Abel,
Madison, WI
MP39-16 ATTRACTIVE STRATEGY FOR
TREATMENT OF ADVANCED RENAL
CELL CARCINOMA BASED ON
VERSICAN EXPRESSION
Yozo Mitsui*, San Francisco, CA, Inik
Chang, Seoul, Korea, Republic of, Naoko
Arichi, Miho Hiraki, Hiroaki Yasumoto,
Izumo, Japan, Shinichiro Fukuhara, Hiroshi
Hirata, Soichiro Yamamura, Varahram
Shahryari, Guoren Deng, Ruzhu Lan,
Sharanjot Saini, Shahana Majid, San
Francisco, CA, Hiroaki Shiina, Izumo,
Japan, Rajvir Dahiya, Tanaka Yuichirio,
San Francisco, CA
128
MP39-19 INHIBITION OF TELOMERE REPEAT
BINDING FACTORS INDUCE APOPTOSIS
AND REDUCES PROLIFERATION IN
Deeksha Pal, Shrawan K Singh*, Rajendra
Prasad, Chandigarh, India
MP39-17 A NOVEL COMBINATORIAL THERAPY IN
RENAL CELL CARCINOMA: SILENCING
SEMAPHORIN 3C IN COMBINATION WITH
SUNITINIB
Takashi Dejima*, Vancouver, Canada, Ario
Takeuchi, Fukuoka, Japan, Tabitha Tombe,
Kevin Tam, Vancouver, Canada, Seiji Naito,
Fukuoka, Japan, Martin Gleave, Christopher
Ong, Vancouver, Canada
MP39-18 EFFECT OF OBESITY ON THE
PERIPHERAL IMMUNE SIGNATURE IN
Laura Bertrand*, Lewis J. Thomas, Megan T.
Bing, Gal Wald, Kenneth G. Nepple, James
A. Brown, Lyse A. Norian, Iowa City, IA
CREDITTM
8:00 am - 10:00 am
PEDIATRICS: TESTIS & VARICOCELES, STONES
Moderators: Christopher Cooper and Walid Farhat
ABSTRACT
NUMBER TITLE
MP40-01 IS TAMSULOSIN EFFECTIVE AFTER
SHOCKWAVE LITHOTRIPSY FOR
PEDIATRIC RENAL STONES? A
RANDOMIZED CONTROLLED STUDY
Ahmed Shahat, Ahmad Elderwy, Ahmed
Safwat*, Ahmed Badawy, Yasser
Abdelsalam, Mohamed Sayed, Hisham
Hammouda, Assiut, Egypt
ABSTRACT
NUMBER TITLE
MP40-05 DOES NEAR INFRARED SPECTROSCOPY
IMPROVE TWIST SCORE IN THE
DIAGNOSIS OF TESTICULAR TORSION?
Kunj R. Sheth*, Dallas, TX, Melise Keays,
Ottawa, Canada, Gwen Grimsby, Dallas, TX,
Candice Granbery, Rochester, MN, Daniel G.
DaJusta, Columbus, OH, Lauren Ostrov,
Martinez Hill, Emma Sanchez, Clanton
Harrison, Micah Jacobs, Rong Huang, Dallas,
TX, Berk Burgu, Ankara, Turkey, Halim
Hennes, Bruce Schlomer, LA Baker, Dallas,
TX
MP40-02 IDENTIFICATION OF NATURALLY
OCCURRING CALCIUM-OXALATE
BINDING PROTEINS IN HUMAN URINE
THAT PREVENT CRYSTAL ADHESION IN
AN IN VITRO MODEL OF KIDNEY STONE
FORMATION
Joel Koenig*, Scott Manson, Qiusha Guo,
Katelynn Moore, Paul Austin, Saint Louis, MO
MP40-06 THE IMPACT OF VARICOCELE
CORRECTION ON SEMEN ANALYSIS IN
THE ADOLESCENT
Casey Seideman*, Ricardo Palmerola,
Ronnie Fine, Jordan Gitlin, Lane Palmer,
Lake Success, NY
MP40-03 TRANS-SCROTAL NEAR INFRARED
SPECTROSCOPY IN THE EMERGENCY
DEPARTMENT TO DIAGNOSE
TESTICULAR TORSION IN PEDIATRIC
PATIENTS PRESENTING WITH ACUTE
SCROTUM
Bruce Schlomer*, Dallas, TX, Melise Keays,
Ottowa, Canada, Gwen Grimsby, Dallas, TX,
Candace Granberg, Rochester, MN, Daniel
DaJusta, Columbus, OH, Berk Bergu, Ankar,
Turkey, Lauren Ostrov, Kunj Sheth, Martinez
Hill, Emma Sanchez, Rong Huang, Clanton
Harrison, Micah Jacobs, Helim Hennes, Linda
Baker, Dallas, TX
MP40-07 RECURRENCE OF SYMPTOMATIC KIDNEY
STONES DIAGNOSED DURING
CHILDHOOD
Gregory Tasian*, Angela Kalmus, Susan
Furth, Philadelphia, PA
MP40-08 MEDICAL EXPULSIVE THERAPY FOR
PEDIATRIC UROLITHIASIS: SYSTEMATIC
REVIEW AND META-ANALYSIS
Nermarie Velasquez, Daniel Zapata, HsinHsiao Wang, John Wiener, Michael Lipkin,
Jonathan Routh*, Durham, NC
MP40-09 SURGICAL OUTCOMES FOR PEDIATRIC
UROLITHIASIS: INCREASED
RETREATMENT RATES WITH
SHOCKWAVE LITHOTRIPSY COMPARED
TO URETEROSCOPY
Hsin-Hsiao Wang*, Rohit Tejwani, John
Wiener, Jonathan Routh, Durham, NC
MP40-04 EMBRYONIC TESTIS CONTAINS
VASCULAR ENDOTHELIAL PRECURSOR
CELLS- A NEW INSIGHT
Pankaj Dangle*, Elina Mukherjee, Sunder
Sims-Lucas, Pittsburgh, PA
*Presenting author
129
SUNDAY
MP39-20 MOLECULAR MECHANISM UNDERLYING
CYTOTOXIC ACTIVITY OF AXITINIB IN
SUNITINIB-RESISTANT HUMAN RENAL
CELL CARCINOMA ACHN CELLS
Akira Miyazaki*, Hideaki Miyake, Masato
MP40-15 RENAL TUBULAR INJURY IN PEDIATRIC
NEPHROLITHIASIS: PROTEOMIC
EVIDENCE
Larisa Kovacevic*, Hong Lu, Joseph A.
Caruso, Yegappan Lakshmanan, Detroit, MI
MP40-10 COMPLETE BLOOD COUNT PARAMETERS
AS A PREDICTOR OF TESTICULAR
SURVIVAL FOLLOWING ACUTE
TESTICULAR TORSION IN CHILDREN
Cagatay E. Afsarlar*, Engin Yilmaz, Yilmaz
Aslan, Jason Au, Irina Stanasel, David Roth,
Chester J. Koh, Houston, TX
MP40-16 DOES EXTRACORPOREAL SHOCK WAVE
LITHOTRIPSY CAUSE HEARING
IMPAIRMENT IN CHILDREN?
Murat Tuncer*, Cahit Sahin, Ozgur Yazici,
Alper Kafkasli, Ýstanbul, Turkey, Akif Turk,
Konya, Turkey, Banu A. Erdogan, Gokhan
Faydaci, Kemal Sarica, Ýstanbul, Turkey
MP40-11 PROSPECTIVE ASSESSMENT OF
PEDIATRIC RADIATION EXPOSURE: THE
PEDIATRIC UROLOGY RADIATION
SAFETY EVALUATION (PURSE) STUDY
Anne Dudley*, Moira Dwyer, Pankaj Dangle,
Omaya Banihani, Heidi Stephany, Glenn
Cannon, Francis Schneck, Michael Ost,
Pittsburgh, PA
MP40-17 INCIDENCE AND RISK FACTORS OF
RECURRENCE AFTER HYDROCELE
REPAIR IN CHILDREN
Jae Min Chung*, Ja Yoon Ku, Yangsan-si,
Gyeongsangnam-do, Korea, Republic of, Ho
Kyung Seo, Jeong Zoo Lee, Moon Kee
Chung, Korea, Republic of, Sang Don Lee,
Yangsan-si, Gyeongsangnam-do, Korea,
Republic of
MP40-12 THE EFFECT OF RACE AND SKIN COLOR
ON NEAR-INFRARED SPECTROSCOPY
READINGS IN PEDIATRIC PATIENTS WITH
UNILATERAL ACUTE SCROTUM
Lauren Ostrov*, Gwen Grimsby, Vani Menon,
Dallas, TX, Melise Keays, Ottawa, Canada,
Kunj Sheth, Dallas, TX, Candace Granberg,
Rochester, MN, Daniel DaJusta, Columbus,
OH, Martinez Hill, Emma Sanchez, Rong
Huang, Dallas, TX, Berk Burgu, Ankara,
Turkey, Clanton Harrison, Micah Jacobs,
Halim Hennes, Bruce Schlomer, Linda Baker,
Dallas, TX
MP40-18 OUTCOME ANALYSIS OF LOWER POLE
STONES IN CHILDREN
Joana Dos Santos*, Paul Bowlin, Fahad
Alyami, Walid Farhat, Toronto, Canada
MP40-19 METABOLIC STONE WORK-UP IN
CHILDREN: WHAT DOES IT TELL US AND
HOW IS IT UTILIZED?
Douglas Storm*, Ambika Kattula, Kathleen
Kieran, Cooper Christopher, Iowa City, IA
MP40-13 LAPAROSCOPIC INTRA-ABDOMINAL
PATENT PROCESS VAGINALIS LIGATION
IN PEDIATRIC UROLOGY PRACTICE
Nima Baradaran*, Case Wood, Michaella
Prasad, Andrew Stec, Charleston, SC
MP40-20 TESTICULAR MICROLITHIASIS IN
ASYMTOMATIC BOYS. WHAT IS THE
APPROPRIATE FOLLOW-UP?
Alison Keenan*, Aaron Carroll, Richard Rink,
Mark Cain, Benjamin Whittam, William
Bennett, Indianapolis, IN
MP40-14 ACHIEVING A STONE-FREE PEDIATRIC
PERCUTANEOUS NEPHROLITHOTRIPSY:
DOES AGE MATTER?
jonathan riddell*, Syracuse, NY, gerald
mingin, benjamin king, burlington, VT, devin
halleran, Syracuse, NY, nazih khater, loma
linda, CA, hassan razvi, london, Canada
CREDITTM
8:00 am - 10:00 am
Podium Session 21
TECHNOLOGY & INSTRUMENTS: LAPAROSCOPY AND ROBOTICS: BENIGN DISEASE
Moderators: Jaime Landman and Monish Aron
TIME
8:00
ABSTRACT
NUMBER TITLE
PD21-01 INTELLIGENT PERCUTANEOUS
NEPHROSTOMY (PCN) INSERTION
SYSTEM WHICH CAN DETECT THE
NEEDLE’S PENETRATION OF LUNG OR
INTESTINE: IN VITRO STUDY
Chang Hee Kim*, Incheon, Korea, Republic
of, Kwon Soo Chun, Houston, TX, Kwang
Taek Kim, Kyung Jin Chung, Incheon, Korea,
Republic of, Kwang Ho You, , Korea,
Republic of, Khae Hawn Kim, Sang Jin Yoon,
ABSTRACT
TIME NUMBER TITLE
8:10
PD21-02 SURGICAL CRISIS: IS THE ROBOT
FRIEND OR FOE?
Courtney K. Rowe*, Jeffrey J. Leow, Ye
Wang, Boston, MA, Benjamin I. Chung, Palo
Alto, CA, Quoc D. Trinh, Adam S. Kibel,
Richard N. Yu, Steven L. Chang, Boston, MA
130
PD21-03 COSMETIC IMPACT OF PORT VERSUS
PORTLESS NEEEDLESCOPIC SURGERY-A
PROSPECTIVE, RANDOMIZED, SINGLEBLINDED STUDY
Javier L. Arenas*, Janna Vassantachart,
Jacob Martin, Jonathan Maldonado, Michael
Lee, Alexander Yeo, Albert Lee, Muhannad
Alsyouf, Steven Engebretsen, Michael E. Hill,
Gaudencio Olgin, Michelle Lightfoot, Roger
Li, D. Duane Baldwin, Loma Linda, CA
8:30
PD21-04 MATCHED COMPARISON OF PRIMARY
VERSUS SALVAGE LAPAROSCOPIC
PYELOPLASTY (LP)
Sapan Ambani*, Ann Arbor, MI, David Yang,
Indianapolis, IN, J. Stuart Wolf, Jr., Ann
Arbor, MI
8:40
PD21-05 COMPLICATIONS OF TRANSVAGINAL
NATURAL ORIFICE TRANSLUMINAL
ENDOSCOPIC SURGERY (NOTES) IN
UROLOGY
Zhang Guoxi, Liu Quanliang, Zou xiaofeng*,
Yuan Yuanhu, Xiao Rihai, Liu Folin, Xue
Yijun, Ganzhou, China, People’s Republic of
8:50
9:00
9:10
PD21-06 PERIOPERATIVE OUTCOMES,
COMPLICATIONS, AND EFFICACY OF
ROBOTIC ASSISTED PROLAPSE REPAIR
Michael Ehlert*, Priyanka Gupta, Jamie
Bartley, Kim A. Killinger, Jason Gilleran,
Melissa Fischer, Royal Oak, MI
9:20
PD21-09 PRACTICE PATTERNS OF
LAPAROSCOPIC PYELOPLASTY AMONG
AMERICAN UROLOGISTS
Matthias D Hofer*, Joceline S Liu, Daniel T
Oberlin, Jaclyn Milose, Sarah C Flury,
Chicago, IL, Allen F Morey, Dallas, TX, Chris
M Gonzalez, Chicago, IL
9:30
PD21-10 A RANDOMIZED CONTROLLED TRIAL FOR
PAIN CONTROL IN LAPAROSCOPIC
UROLOGIC SURGERY: 0.25%
BUPIVACAINE VERSUS LONG-ACTING
LIPOSOMAL BUPIVACAINE
Richard Knight*, APO, —, Paul Walker, Baton
Rouge, LA, Kirk Keegan, Stephen
Overholser, Timothy Baumgartner, James
Ebertowski, James Aden, Michael White, San
Antonio, TX
9:40
PD21-11 THE DYNAMIC URINE VIBRATION
HALTER: A NEW OUTPATIENT DEVICE
FOR REMOTE PATIENT MONITORING OF
UROFLOW
Jerry Blaivas, Matthew Benedon, New York,
NY, James Weinberger, Los Angeles, CA,
Yosi Rozenberg, Lior Ravid, Herzliya, Israel,
Jonathan Vapnek*, New York, NY
9:50
PD21-12 LONG-TERM OUTCOMES OF ROBOTASSISTED LAPAROSCOPIC
PYELOPLASTY FOR URETEROPELVIC
JUNCTION OBSTRUCTION
Heather L Hopf*, Clinton D Bahler, Chandru
P Sundaram, Indianapolis, IN
PD21-07 FACTORS AFFECTING ROBOTIC
OPERATIVE TIMES IN A LARGE COHORT
OF PATIENTS AT A SINGLE INSTITUTION
Juzar Jamnagerwalla*, Lauren Wood, Ken
Catchpole, Catherine Bresee, Los Angeles, CA,
Bruno Gross, Bryan, TX, Stephanie Chu, Karyn
Eilber, Jennifer Anger, Los Angeles, CA
CREDITTM
PD21-08 ADVANTAGES AND TECHNICAL
CHALLENGES OF LIGHTED URETERAL
STENTS DURING LAPAROSCOPIC BOWEL
SURGERY
Danny Huynh*, Lucas Hockman, Jerry
Trulson, Mark Wakefield, Columbia, MO
8:00 am - 10:00 am
Podium Session 22
TRAUMA/RECONSTRUCTION: URETHRAL RECONSTRUCTION (INCLUDING STRICTURE) III
Moderators: John Spirnak and Alex Vanni
TIME
8:00
ABSTRACT
NUMBER TITLE
PD22-01 THE NON-TRANSECTING TECHNIQUE
FOR BULBAR URETHRAL STRICTURES
Simon Bugeja*, Felix Campos, Anastasia
Frost, Enrique Fes, Daniela E Andrich,
Anthony R Mundy, London, United Kingdom
*Presenting author
ABSTRACT
TIME NUMBER TITLE
8:10
PD22-02 TRANSECTED VS NON-TRANSECTED
BULBAR URETHROPLASTY RESULTS IN
SIMILAR STRICTURE RESOLUTION RATE
IN PRIMARY REPAIR OF BULBAR
URETHRAL STRICTURES
Kirk Anderson*, Catherine Cooper, Aurora,
CO, Dmitriy Nikolavsky, Syracuse, NY, Brian
Flynn, Aurora, CO
131
SUNDAY
8:20
8:20
8:30
PD22-03 HOW DIMINISHED CAVERNOSAL
ARTERIAL BLOOD FLOW AFFECTS THE
SUCCESS OF ANASTAMOTIC
URETHROPLASTY AFTER PELVIC
FRACTURE URETHRAL INJURY
Kulkarni, Pune, India
PD22-04 SALVAGE OF RECURRENT BULBAR
URETHRAL STRICTURE BY REPEAT
EXCISION AND PRIMARY ANASTOMOTIC
URETHROPLASTY
Jordan Siegel*, Arabind Panda, Timothy
Tausch, Matthew Meissner, Alexandra Klein,
Allen Morey, Dallas, TX
8:40
PD22-05 PERINEAL URETHROSTOMY: A
DEFINITIVE CURE FOR ADVANCED
URETHRAL STRICTURE DISEASE
Michael Belsante*, George Webster, John
Patrick Selph, Michael Granieri, Divya Ajay,
Andrew Peterson, Durham, NC
8:50
PD22-06 RE-OPERATIVE ABDOMINO-PERINEAL
RECONSTRUCTIVE SURGERY
Simon Bugeja*, Anastasia Frost, Daniela E
Andrich, Anthony R Mundy, London, United
Kingdom
9:00
9:10
PD22-08 MALE ANTERIOR URETHRAL
STRICTURES ARE COMMONLY TREATED
WITHOUT IMAGING OR BEING OFFERED
URETHROPLASTY
Justin De Grado*, Rachel Quinn, Joel
Gelman, Orange, CA
9:20
PD22-09 RESURFACING THE PENIS OF THE
HYPOSPADIAS CRIPPLE
Mina Fam*, Newark, NJ, Moneer Hanna, New
York, NY
9:30
PD22-10 HYPOSPADIAS REPAIR OF 223
ADOLSCENTS AND ADULTS: LESSONS
LEARNED
Moneer Hanna*, Great Neck, NY, Gina
Cambareri, Sa Diego, CA
9:40
PD22-11 DONOR SITE COMPLICATIONS
FOLLOWING URETHROPLASTY WITH
ORAL MUCOSAL GRAFT: ANALYSIS OF
442 PATIENTS WITH URETHRAL
STRICTURE
Abhishek Pandey*, Cristina Raita, Jörn Beier,
Hansjörg Keller, Hof, Germany
9:50
PD22-12 A RANDOMIZED TRIAL ON
PERIOPERATIVE PAIN AND MORBIDITY:
NON-CLOSURE VERSUS CLOSURE OF
THE BUCCAL MUCOSA HARVEST SITE
DURING URETHROPLASTY
Armin Soave*, Roland Dahlem, Jessica
Langetepe, Phillip Reiss, Matthias Müller,
Katharina Kuhlencord, Malte Vetterlein, Marie
Kuhl, Clemens Rosenbaum, Phillip Marks,
Michael Rink, Oliver Engel, Silke Riechardt,
Margit Fisch, Sascha Ahyai, Hamburg, Germany
PD22-07 INCIDENCE, TIMING, AND MANAGEMENT
OF URETHRAL STRICTURE FOLLOWING
PRIMARY RADIATION THERAPY FOR
PROSTATE CANCER
Timothy Baumgartner*, James Ebertowski,
Edith Canby-Hagino, Steven Hudak, San
Antonio, TX
CREDITTM
8:00 am - 10:00 am
Podium Session 23
BLADDER CANCER: DETECTION AND SCREENING I
Moderators: Daniel Canter and Robert Grubb
TIME
8:00
8:10
ABSTRACT
NUMBER TITLE
PD23-01 ASSESSMENT OF A MULTIPLEX URINARY
PROTEIN PANEL FOR THE DETECTION OF
UROTHELIAL AND SQUAMOUS CELL
CARCINOMA OF THE URINARY BLADDER
Ahmed M. Mansour*, Amr Elsawy, Amira
Awadallah, Nehal Elsherbiny, Ahmed A.
Shokeir, Hassan Abol-Enein, Mansoura,
Egypt, Charles J Rosser, Hawaii, HI
ABSTRACT
TIME NUMBER TITLE
8:20
PD23-03 A NOVEL URINE CYTOLOGY STAIN FOR
THE DETECTION AND MONITORING OF
Ofer Yossepowitch*, Petach Tikva, Israel,
Yoram Mor, Ramat Gan, Israel, Ofer Nativ,
Haifa, Israel, Ilan Leibovitch, Kfar Sava,
Israel, Ofer Gofrit, Jerusalem, Israel, Haim
Matzkin, Tel Aviv, Israel, Uri Lindner,
Rehovot, Israel, Ami Sidi, Holon, Israel,
Michael Cohen, Afula, Israel
PD23-02 LONG-TERM OUTCOMES OF HIGH RISK
BLADDER CANCER SCREENING COHORT
Nathan Starke*, Nirmish Singla, Ahmed Q
Haddad, Yair Lotan, Dallas, TX
8:30
132
PD23-04 THE POTENTIAL UTILITY OF CHEMOKINE
CXCL1 (GRO␣) AS A NOVEL DIAGNOSTIC
AND PROGNOSTIC MARKER FOR
BLADDER CANCER
Takashi Kobayashi*, Yoshiyuki Matsui,
Takuro Sunada, Takahiro Inoue, Tomomi
Kamba, Osamu Ogawa, Kyoto, Japan
8:50
9:00
9:10
PD23-05 CIRCULATING TUMOR CELLS IN
BLADDER CANCER: OPTIMIZATION OF
DETECTION AND INVESTIGATION OF
THEIR DIAGNOSTIC AND PROGNOSTIC
ROLES
Bedeir Ali-El-Dein*, Mahmoud Laymon,
Mahmoud Zakaria, Romayla Abdel-Raouf,
Hekmat El-Naggar, Nasr El-Tabey, Ahmed
El-Hefnawy, Tamer S Barakat, Samer ElHalwagy, Mona A Abdel-Rahim, Mohamed
Abdel-Hamid, Zakaria Lotfy, El-Houssiny I
Ibrahiem, Atallah A Shaaban, Mansoura,
Egypt
PD23-06 ROGNOSTIC VALUE OF SERUM CYFRA
21-1 IN PATIENTS WITH T1G3 OR
Akihiro Yano*, Hironori Sugiyama, Eiken Cho,
Hideki Takeshita, Yohei Okada, Hideki
Nagamatsu, Makoto Morozumi, Satoru
Kawakami, Takumi Yamada, Kawagoe,
Japan
PD23-07 A PROSPECTIVE TRANSLATIONAL
STUDY OF MICRORNA-519A DETECTION
AS A URINE MARKER IN OUTPATIENTS
WITH MACROSCOPIC HEMATURIA: A
PROMISING CANDIDATE MICRORNA
FROM DEEP SEQUENCING SIGNATURE
OF UROTHELIAL CARCINOMA
Hideki Enokida*, Yasutoshi Yamada, Satoru
Inoguchi, Tomoaki Ishihara, Shuichi Tatarano,
Toshihiko Itesako, Kagoshima, Japan,
Naohiko Seki, Chiba, Japan, Masayuki
Nakagawa, Kagoshima, Japan
9:20
PD23-09 EPITHELIAL TUMOR MARKERS (CA 125,
CA 19-9 AND CEA) TRENDS IN PATIENTS
UNDERGOING TREATMENT FOR
Soroush T.Bazargani*, Swar Shah, Los
Angeles, CA, Hamed Ahmadi, Portland, OR,
Anne Schuckman, Jie Cai, gus miranda,
tanya Dorff, sarmad sadeghi, David Quinn,
Hooman Djaladat, Siamak Daneshmand, Los
Angeles, CA
9:30
PD23-10 URINARY TRACT INFECTION IS
ASSOCIATED WITH WORSE BLADDER
CANCER OUTCOMES IN THE MEDICARE
POPULATION: IMPLICATIONS FOR SEX
DISPARITIES
Kyle Richards*, Madison, WI, Sandra Ham,
Joshua Cohn, Gary Steinberg, Chicago, IL
9:40
PD23-11 VARIATION IN EVALUATION OF
HEMATURIA BY GENDER, RACE, AND
RISK FACTORS FOR BLADDER CANCER
Jacob Ark*, JoAnn Alvarez, Nashville, TN,
Jeffrey Bassett, Anaheim, CA, Tatsuki
Koyama, Chaochen You, Shenghua Ni,
William Blot, David Penson, Daniel Barocas,
Nashville, TN
9:50
PD23-12 HEMATURIA PRACTICE PATTERNS IN
THE PRIMARY CARE SETTING
Lisa Parrillo*, Justin Ziemba, Matthew
Sterling, Alida Gertz, Phillip Mucksavage,
Thomas Guzzo, Philadelphia, PA
CREDITTM
PD23-08 POTENTIAL BLOOD-BASED TUMOR
MARKERS FOR NON-MUSCLE-INVASIVE
UROTHELIAL BLADDER CARCINOMA
Daher Chade*, Leopoldo Ribeiro-Filho,
Mauricio Cordeiro, Pedro Filipecki, Claudio
Murta, Miguel Srougi, William Nahas, Sao
Paulo, Brazil
8:00 am - 10:00 am
Podium Session 24
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: INCONTINENCE: EVALUATION (URODYNAMIC TESTING)
Moderator: Donna Deng
TIME
8:00
ABSTRACT
NUMBER TITLE
PD24-01 PROOF-OF-CONCEPT FOR DATA FUSION
OF URETHRAL PRESSURE DATA AND MRI
Mario Klünder, Stuttgart, Germany, Susanne
Will, Tuebingen, Germany, Karl-Dietrich
Sievert*, Luebeck, Germany, Bastian Amend,
Tuebingen, Germany, Ronny Feuer, Oliver
Sawodny, Stuttgart, Germany, Ulrich Kramer,
Arnulf Stenzl, Tuebingen, Germany, Michael
Ederer, Stuttgart, Germany
*Presenting author
ABSTRACT
TIME NUMBER TITLE
8:10
PD24-02 EVALUATION OF SYMPTOM SCORE AND
IN VITRO CONTRACTILE PROPERTIES OF
DETRUSOR IN WOMAN WITH LOWER
URINARY TRACT SYMPTOMS (LUTS) /
COMPARISON OF SCORES AND
CONTRACTILE PROPERTIES WITH OR
WITHOUT DETRUSOR OVERACTIVITY
(DO)
Nobuhiro Kushida*, Fukushima, Japan,
Osamu Yamaguchi, Koriyama, Japan,
Yoshiyuki Kojima, Fukushima, Japan, Fry
Christopher, Guildford, United Kingdom
133
SUNDAY
8:40
8:20
8:30
PD24-03 IDENTIFICATION OF INNERVATION
ZONES OF THE PELVIC FLOOR MUSCLE
FROM NONINVASIVE HIGH-DENSITY
INTRA-VAGINAL/RECTAL SURFACE EMG
RECORDINGS
Yun Peng, Houston, TX, Jinbao He, Ningbo,
China, People’s Republic of, Rose Khavari,
Timothy Boone, Yingchun Zhang*, Houston,
TX
PD24-04 NON INVASIVE VELOCITY-FLOW
VIDEOURODYNAMICS USING DOPPLER
ULTRASONOGRAPHY DETECTION OF
PERIODIC DETRUSOR ARREST DURING
MICTURITION IN MEN UNDERACTIVE
BLADDER SYNDROME
Hideo Ozawa*, Okayama, Japan, Michael
Chancellor, Royal Oak, MI, Atsushi Nagai,
Kurashiki, Japan, Hiromi Kumon, Okayama,
Japan
8:40
PD24-05 THE INTERACTION BETWEEN URINARY
INCONTINENCE (UI), RECURRENT LOWER
URINARY TRACT INFECTION (UTI), AND
AGING IN MICE
Zhina Sadeghi*, Johnathan Kenyon, Albert
Park, Michael Kavran, Adonis Hijaz,
Cleveland, OH, Thomas Hannan, St. Louis,
MO, Firouz Daneshgari, Cleveland, OH
8:50
PD24-06 PLUNG AS A SURROGATE MEASURE FOR
ABDOMINAL PRESSURE IN
URODYNAMICS FOR PATIENTS WITH
STRESS URINARY INCONTINENCE –
PRELIMINARY DATA
Harpreet Wadhwa*, Whitney Halgrimson,
Chicago, IL, Francesco Marson, Torino, Italy,
William Kobak, Ervin Kocjancic, Chicago, IL
9:00
PD24-07 DOES A POSITIVE URINE DIPSTICK OR
URINE CULTURE AT THE TIME OF
URODYNAMIC EVALUATION PREDICT
POST-PROCEDURAL FEBRILE URINARY
TRACT INFECTION?
Lynne Lapicz, Stephen Canon, Ashay Patel,
Ismael Zamilpa*, Little Rock, AR
9:10
PD24-08 WIRELESS IMPLANTABLE
RECHARGEABLE BLADDER PRESSURE
SENSOR: CYSTOSCOPIC IMPLANTATION
AND AMBULATORY DATA COLLECTION
Iryna Makovey*, Steve Majerus, Robert
Karam, Brett Hanzlicek, Matthew Streicher,
Hui Zhu, Margot Damaser, Cleveland, OH
9:20
PD24-09 ASSOCIATION BETWEEN OVERACTIVE
BLADDER AND RISK OF FALLS AMONG
MEDICARE ELDERLY FEE-FOR-SERVICE
PATIENTS
Ravishankar Jayadevappa*, Sumedha
Chhatre, Diane Newman, Alan Wein,
Philadelphia, PA
9:30
PD24-10 INVESTIGATION OF TYPES OF
SITUATIONS THAT TRIGGER URGE
Becky Clarkson*, Neil Resnick, Pittsburgh,
PA, Kathleen O’Connell, New York, NY
9:40
PD24-11 THE ARTIFICIAL URINARY SPHINCTER IS
SUPERIOR TO A SECONDARY
TRANSOBTURATOR MALE SLING IN
CASES OF A PRIMARY SLING FAILURE
Divya Ajay*, John Selph, Michael Belsante,
Ngoc-Bich Le, Durham, NC, Aaron Lentz,
Raleigh, NC, George Webster, Andrew
9:50
PD24-12 LOW CYSTOMETRIC CAPACITY IS
ASSOCIATED WITH MALE
TRANSOBTURATOR SLING FAILURE AND
DOES NOT CORRELATE WITH THE VOIDING
DIARY; PRE-OPERATIVE URODYNAMICS
ARE HELPFUL IN THE EVALUATION OF
Haijing Zhang, Durham, NC, Aaron Lentz,
Raleigh, NC, Ngoc-Bich Le, George Webster,
Andrew Peterson, Durham, NC
CREDITTM
8:00 am - 10:00 am
Video Session 5
RENAL ONCOLOGY
Moderators: Jay Raman and Timothy Masterson
ABSTRACT
NUMBER TITLE
V5-01
TOTALLY LAPAROSCOPIC RADICAL
NEPHRECTOMY WITH THROMBECTOMY
LEVEL IV
Cesar Britto*, Christophe Anselmo, Paulo Renato
Costa, Daniel Oliveira, Ronnie Lima, Thiago
Grossi, Hernani Gadelha Jr, Stefferson Duarte,
Rafael Coelho, Paulo Medeiros, NATAL, Brazil
ABSTRACT
NUMBER TITLE
V5-02
ROBOTIC-ASSISTED RADICAL
NEPHRECTOMY FOR 12 CM TUMOUR
WITH INFERIOR VENA CAVA THROMBUS
EXTENSION
Marco Puglisi*, Kamran Ahmed, Ben
Challacombe, London, United Kingdom
134
HAND-ASSISTED LAPAROSCOPIC
CARCINOMA WITH LEVEL ONE RENAL
VEIN THROMBOSIS
Daniel Yong*, Keng-Siang Png, Singapore,
Singapore
V5-04
RESECTABLE PHYSICAL 3-D MODELS
UTILIZING 3-D PRINTER TECHNOLOGY
FOR ROBOTIC PARTIAL NEPHRECTOMY
V5-05
V5-06
V5-07
V5-08
3D LAPAROSCOPIC PARTIAL
NEPHRECTOMY FOR COMPLEX RENAL
MASS
George Abraham*, Kerala, India, Datson
George P, Vijay Radhakrishnan, Krishanu
Das, cochin, India
3 MM OFF-CLAMP PARTIAL
NEPHRECTOMY: PROS, CONS, TIPS AND
TRICKS
Juan Antonio Peña, Nicolás Nervo, Esteban
Emiliani, Pavel Gavrilov, Ivan Schwartzmann,
Alberto Breda, Juan Palou, Humberto
Villavicencio, Oscar Rodrı́guez Faba*,
Barcelona, Spain
OFF-CLAMP LAPAROSCOPIC PARTIAL
NEPHRECTOMY IN A HORSESHOE
KIDNEY
Juan Antonio Peña, Mario Oliveira, Pavel
Gavrilov, Oscar Rodrı́guez Faba*, Nicolás
Nervo, Ivan Schwartzmann, Juan Palou,
Humberto Villavicencio, Barcelona, Spain
ZERO—ISCHEMIA LAPAROSCOPIC
PARTIAL NEPHRECTOMY FOR T2 KIDNEY
CANCER USING A SALINE-JET
DISSECTOR
Andrew Kennedy-Smith*, Stephanie Manning,
Wellington, New Zealand
V5-09
3-MM LAPAROSCOPIC OFF-CLAMP
RENAL TUMORECTOMY USING
HYDRODISSECTION
Juan Antonio Peña, Ivan Schwartzmann,
Pavel Gavrilov, Pablo Juárez del Dago,
Oscar Rodrı́guez Faba*, Alberto Breda, Juan
Palou, Humberto Villavicencio, Barcelona,
Spain
V5-10
SELECTIVE RENAL ARTERY CLAMPING:
RIGHT ROBOTIC ASSISTED HEMINEPHRECTOMY AND EN BLOC
ANDRENALECTOMY IN A DUPLICATED
SYSTEM
Mark Ferretti*, John Phillips, Valhalla, NY
V5-11
OFF-CLAMP PARTIAL NEPHRECTOMY
Jeffrey Larson*, Aaron Potretzke, Sam
Bhayani, Robert Figenshau, St. Louis, MO
V5-12
CALIBRATION OF NOVEL 12MM
LAPAROSCOPIC HIGH INTENSITY
ULTRASOUND PROBE FOR ABLATION OF
RENAL NEOPLASMS
Jason C Sea*, Orlando, FL, Clinton D Bahler,
Naren Sanghvi, Chandru P Sundaram,
Indianapolis, IN
V5-13
THE USE OF ARGON BEAM
COAGULATION DURING ROBOTIC
PARTIAL NEPHRECTOMY IN AN ANIMAL
MODEL
Andrew Harbin*, Kumar Nadhan, James
Mooney, Daniel Eun, Philadelphia, PA
V5-14
INTRAMURAL TUNNEL URETERECTOMY
FOR TREATMENT OF UPPER TRACT
UROTHELIAL TUMOR
Alexander Tsivian, Yury Stanevsky*, Holon,
Israel, Matvey Tsivian, Durham, NC, Shalva
Benjamin, Ami Sidi, Holon, Israel
CREDITTM
8:00 am - 5:00 pm
UROLOGIC CARE FOR THE ALLIED HEALTH PROFESSIONAL
1:00
ANDROGEN DEPRIVATION THERAPY AND
BONE HEALTH
Tracey Krupski
AUA CONSENSUS STATEMENT ON
ADVANCED PRACTICE PROVIDERS
Timothy Brand
2:00
PEELING BACK THE ONION: INTERSTITIAL
CYSTITIS AND PELVIC PAIN
Marina Ruzimovsky
CODING: ICD-10 AND COMMON CODING
PROBLEMS
Mark Painter
3:00
OVERACTIVE BLADDER AND INCONTINENCE
Kathleen Kobashi
8:00
Director: Louis Koncz
8:05
9:00
10:00
FEMALE SEXUAL DYSFUNCTION
Tricia Zubert
4:00
MANAGEMENT OF SMALL RENAL MASSES
Jaime Landman
11:00
TESTOSTERONE REPLACEMENT THERAPY
Jacob Rajfer
4:50
CLOSING REMARKS
Director: Louis Koncz
12:00
BREAK
*Presenting author
CREDITTM
135
SUNDAY
V5-03
10:00 am - 1:30 pm
UROLOGIC ONCOLOGY FORUM: “DEVELOPMENT OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN UROLOGIC ONCOLOGY”
10:00
Peter Clark
10:05
MICRORNAS: BIOMARKERS AND THERAPEUTIC
TARGETS IN PROSTATE CANCER
Fazlul Sarkar
10:20
PROTEOMIC PROFILING IN PROSTATE CANCER
Andrei Drabovich
10:35
DTC AND CTC —THE LIQUID BIOPSY —
SUCCESSES AND CHALLENGES
Robert Vesella
10:50
USING ORGANOID TECHNOLOGY TO
GENERATE PATIENT-DERIVED IN VITRO
MODELS
Yu Chen
11:05
Q&A
11:10
SCREENING FOR LETHAL PROSTATE
CANCER USING PSA AND RELATED BLOOD
BIOMARKERS
Hans Lilja
11:25
EXPLOITING THE EPIGENETIC FIELD EFFECT
TO IMPROVE PROSTATE CANCER DIAGNOSIS
David Jarrard
11:40
HISTOLOGIC APPROACHES TO
PERSONALIZING PROSTATE CANCER
PROGNOSIS
Michael Donovan
11:55
12:00
PERSONALIZING PROSTATE CANCER
TREATMENT
Tomasz Beer
12:15
BIOMARKERS IN DRUG DEVELOPMENT:
VALIDATION AND UTILITY FOR
PROGNOSTICATION AND PREDICTION
Howard Scher
12:30
Q&A
12:35
THE RAPID EVOLUTION OF TISSUE-BASED
RNA EXPRESSION ASSAYS TO IMPROVE
PROSTATE CANCER PROGNOSIS AND
DECISION MAKING
Matthew Cooperberg
12:50
THE USE OF CURRENTLY AVAILABLE BLOOD
BIOMARKERS TO ACCURATELY IDENTIFY
THE RISK OF AGGRESSIVE PROSTATE
CANCER
Mitchell Steiner
1:05
THE CHALLENGES AND OPPORTUNITIES FOR
GENOMIC TESTING FOR MEN WITH
P. George Febbo
1:20
Q&A
1:30
ADJOURN
CREDITTM
Q&A
10:00 am - 4:00 pm
INTERNATIONAL PROSTATE FORUM
Program Chairs: John Davis, Neal Shore
10:15
IPF2015 PROSTATE CANCER
CONTROVERSIES
John Davis, Neal Shore
10:30
SESSION I: WHAT IS CLINICALLY
SIGNIFICANT PROSTATE CANCER? OPTIMAL
DETECTION AND RISK ASSESSMENT
STRATEGIES
Moderators: Richard Babaian, Arturo
Mendoza-Valdes
WHOM TO BIOPSY: THE ROLE FOR PSA AND
NOVEL BIOMARKERS
Stacy Loeb
10:45
11:00
NEWLY DIAGNOSED PROSTATE CANCER:
THE ROLE OF GENOMIC ASSAYS
Peter Carroll
11:15
MEN’S HEALTH CLINIC: PROSTATE AND
MALE HEALTH EVALUATION IN THE
UROLOGY CLINIC
S. Larry Goldenberg
11:30
DISCUSSION
11:45
LUNCH BREAK
1:00
SESSION II: KEYNOTE SPEAKER: PROSTATE
CANCER IMPACTFUL RESEARCH - HOW
SHOULD YOUR CLINIC ADAPT?
Moderator: Tsuneharu Miki
Presenter: Peter Albertsen
1:30
SESSION III: WORKSHOP - IMPROVING YOUR
INTERVENTIONAL PARADIGM
Moderator: Badar Mian
ROBOTIC RADICAL PROSTATECTOMY MAXIMIZING EFFICACY AND QUALITY
Moderator: M. Derya Balbay
Presenter: Vipul Patel
THE ROLE FOR MULTI-PARAMETRIC MRI:
INDICATIONS AND IMPLEMENTATION?
Samir Taneja
136
SELECTION FOR NERVE SPARING
CANDIDATES - NOMOGRAMS, IMAGING, OR
FROZEN SECTION?
Markus Graefen
3:00
THE ANDROGEN-ANDROGEN RECEPTOR
PATHWAY – RECENT PROGRESS AND
FUTURE GOALS
Martin Gleave
2:00
OLIGOMETASTASES & LYMPH NODE
MANAGEMENT: LESSONS LEARNED FROM
TEMPLATES, LYMPHOSCINTIGRAPHY, AND
SALVAGE STRATEGIES
George Thalmann
3:20
KEY CLINICAL TRIAL UPDATES IN
CASTRATION RESISTANT PROSTATE
CANCER – WHAT SHOULD I KNOW?
Noel Clarke
3:40
DISCUSSION
2:15
DISCUSSION
4:00
ADJOURN
2:25
SESSION IV: ADVANCES IN SYSTEMIC
THERAPY
Moderators: Satoru Takahashi, Ziya Kirkali
CREDITTM
PROSTATE CANCER IMMUNOTHERAPY - WHY
NOW?
Charles Drake
2:40
TECHNOLOGY UPDATE FOR IMAGING IN
ADVANCED PROSTATE CANCER: ARE THERE
GLOBAL VARIATIONS?
Bertrand Tombal
10:30 am - 12:30 pm
STONE DISEASE: MEDICAL THERAPY
Moderators: Kenneth Pace and Stephen Nakada
ABSTRACT
NUMBER TITLE
MP41-01 A RANDOMIZED DOUBLE-BLINDED
PLACEBO CONTROLLED STUDY
EVALUATING THE EFFICACY OF INTRA
NASAL KETOROLAC IN TREATING POSTOPERATIVE PAIN IN AMBULATORY
URETEROSCOPIC SURGERY
Kara L Watts*, Nair Singh, Amaresh
Vydynathan, Irene Kho, Zhenmei Zhang,
Bronx, NY, David M Hoenig, New Hyde Park,
NY, Joshua Stern, Bronx, NY
ABSTRACT
NUMBER TITLE
MP41-04 CONSEQUENCES OF NON-ADHERENCE
TO SELECTIVE MEDICAL THERAPY
AMONG PATIENTS WITH KIDNEY STONES
Casey Dauw, Yooni Yi*, Maggie Bierlein,
Abdul Alruwaily, Khurshid Ghani, J. Stuart
Wolf, Jr., John Hollingsworth, Ann Arbor, MI
MP41-05 PERINATAL OUTCOMES WITH
TAMSULOSIN THERAPY FOR
SYMPTOMATIC UROLITHIASIS
George Bailey*, Lisa Vaughan, Eric
Bergstralh, Carl Rose, Amy Krambeck,
Rochester, MN
MP41-02 INFERENCE OF SHOCK RATE AND
POWER ON EFFECTIVE AND EFFICIENT
KIDNEY STONE FRAGMENTATION WITH
EXTRACORPOREAL SHOCKWAVE
LITHOTRIPSY (ESWL)
James Hayes*, Ray Kirk, Ann Richardson,
Christchurch, New Zealand
MP41-06 ADMINISTRATION OF THE SELECTIVE
ALPHA 1A ADRENOCEPTOR
ANTAGONIST SILODOSIN FACILITATES
EXPULSION OF SIZE 5 - 10 MM DISTAL
URETERAL STONES, AS COMPARED TO
CONTROL
Yasunori Itoh*, Atsushi Okada, Kazumi
Taguchi, Yasuhiko Hirose, Yasuhiro Fujii,
Takahiro Kobayashi, Masayuki Usami, Shuzo
Hamamoto, Masahito Hirose, Takahiro Yasui,
Keiichi Tozawa, Shoichi Sasaki, Yutaro
Hayashi, Kenjiro Kohri, Nagoya, Japan
MP41-03 ALENDRONATE HAS A PREVENTIVE
EFFECT FOR UROLITHIASIS
RECURRENCE IN MEN AND
POSTMENOPAUSAL WOMEN WITH
OSTEOPOROSIS
Takahiro Yasui*, Atsushi Okada, Kazumi
Taguchi, Masayuki Usami, Yasuhiro Fujii,
Kazuhiro Niimi, Shuzo Hamamoto, Masahito
Hirose, Ryosuke Ando, Yasunori Itoh, Keiichi
Tozawa, Yutaro Hayashi, Kenjiro Kohri,
Nagoya, Japan
*Presenting author
MP41-07 TRENDS IN UROLOGICAL INTERVENTION
FOR RENAL STONE DISEASE IN
ENGLAND: EVIDENCE FROM HOSPITAL
EPISODES STATISTICS (HES) DATABASE
Bhaskar Kumar Somani*, Ed Chegdy,
Southampton, United Kingdom, Ghulam Nabi,
Dundee, United Kingdom
137
SUNDAY
1:45
MP41-15 FLUID BOLUS FOR RENAL COLIC:
CURRENT PRACTICE
Sarah Tarplin*, Benjamin Larson, Michael
Byrne, Manoj Monga, Cleveland, OH
MP41-08 RANDOMIZED CONTROLLED TRIAL OF
TWO VITAMIN D REPLETION PROTOCOLS
TO ASSESS IMPACT ON CALCIUM
EXCRETION IN STONE FORMERS
Matthew Ferroni*, Kevin Rycyna, Timothy
Averch, Michelle Semins, Pittsburgh, PA
MP41-16 PREDICTORS OF URINARY TRACT
INFECTION IN PATIENTS WITH
URETERAL STENTS TREATED WITH
URETEROSCOPY
Amihay Nevo*, Lifshitsz David, Jack Baniel,
Petach Tikva, Israel
MP41-09 A PROSPECTIVE RANDOMIZED STUDY TO
EVALUATE THE OUTCOME OF ALPHA
BLOCKERS AND THE COMBINATION
WITH METHYLPREDNISOLONE IN
MEDICAL EXPULSIVE THERAPY FOR LOW
ER URETERAL STONES
Dawod, Mahmoud Eladl*, Zagazig, Egypt
MP41-17 EFFECTS OF TAMSULOSIN, SOLIFENACIN
MONOTHERAPY AND COMBINATION
THERAPY FOR THE RELIEF OF
URETERAL STENT-RELATED SYMPTOMS:
AN OPEN-LABEL RANDOMIZED
CONTROLLED TRIAL
Jinsung Park*, Daejeon, Korea, Republic of,
Changhee You, Chuncheon, Korea, Republic
of, Deok Hyun Han, Dong Wook Shin, Seoul,
Korea, Republic of
MP41-10 QUALITY OF ACUTE CARE FOR PATIENTS
WITH UPPER TRACT STONES IN THE
UNITED STATES
Charles Scales, Durham, NC, Jonathan
Bergman, Stacey Carter, Greg Jack, Christopher
Saigal, Mark Litwin, Los Angeles, CA
MP41-18 RELATIONSHIP BETWEEN DIETARY
PROTEIN INTAKE AND URINE OXALATE
Jonathan Shoag*, New York, NY, Yan Song,
Natalia Hernandez, Boston, MA, Joshua
Halpern, Sameer Mittal, New York, NY, Brian
Eisner, Boston, MA
MP41-11 NSAIDS FOR ACUTE UROLITHIASIS:
UNDERUTILIZED ANALGESICS WITH
POTENTIAL FOR COST SAVINGS
Courtney K. Rowe*, Deborah S. Hess, James
S. Hwong, Francisco J. GelpiHammerschmidt, Boston, MA, Benjamin I.
Chung, Palo Alto, CA, Steven L. Chang,
Boston, MA
MP41-19 CONTEMPORARY SURVEY OF
ENDOUROLOGISTS’ PRACTICES OF
ASSESSMENT AND MEDICAL
MANAGEMENT OF STONE DISEASE
Richard Matulewicz, Barry McGuire*, Rian
Zuccarino-Crowe, Robert Nadler, Kent Perry,
Chicago, IL
MP41-12 DIPSTICK SPOT URINE PH DOES NOT
ACCURATELY REPRESENT 24 HOUR
URINE PH MEASURED BY AN
ELECTRODE
Mohamed Omar*, Carl Sarkissian, li Jianbo,
Manoj Monga, Cleveland, OH
MP41-20 DO PATIENTS REMEMBER DIETARY
RECOMMENDATIONS FOR STONE
PREVENTION?
Margaret L Wertheim*, R Allan Jhagroo,
Kristina L Penniston, Madison, WI
MP41-13 VITAMIN D REPLACEMENT IN
RECURRENT RENAL STONE FORMERS
WITH HYPERCALCIURIA DOES NOT
INCREASE URINE CALCIUM EXCRETION
OR RENAL STONE GROWTH
Luke McGuinness*, Robert Calvert, Vinita
Mishra, Liverpool, United Kingdom
CREDITTM
MP41-14 IMPACT OF URINE PH ON URINARY
SUPERSATUATION OF CALCIUM
OXALATE
Jodi A. Antonelli, Naim Maalouf*, Jodi A.
Antonelli, Monica S.C. Morgan, Adam Cohen,
John Pointdexter, Beverley Adams-Huet,
Khashayar Sakhaee, Margaret S. Pearle,
Dallas, TX
138
10:30 am - 12:30 pm
ABSTRACT
NUMBER TITLE
MP42-01 NO SIGNIFICANT IMPROVEMENT IN
PATIENT OUTCOMES WHEN STRICTER
ACTIVE SURVEILLANCE CRITERIA ARE
APPLIED: A COMPARISON OF
CONTEMPORARY ACTIVE
SURVEILLANCE PROTOCOLS
Maria Komisarenko*, Narhari Timilshina,
Shabbir Alibhai, Neil Fleshner, Alexandre
Zlotta, Robert Hamilton, Girish Kulkarni,
Antonio Finelli, Toronto, Canada
ABSTRACT
NUMBER TITLE
MP42-08 INSTITUTION OF A WEB-BASED PATIENTREPORTED OUTCOMES (PRO) SYSTEM FOR
RADICAL PROSTATECTOMY IN A
COLLABORATIVE
Khurshid Ghani*, Tae-Kyung Kim, Ann Arbor, MI,
Patrick Hurley, Southfield, MI, Jay Starr, Traverse
City, MI, Susan Linsell, Ann Arbor, MI, James
Peabody, Detroit, MI, James Montie, David Miller,
Ann Arbor, MI, Michael Cher, Detroit, MI
MP42-02 EXTENSION OF BASELINE PROSTATE
ACUTE AND CHRONIC INFLAMMATION IS
ASSOCIATED WITH LOWER INCIDENCE OF
PROSTATE CANCER ON REPEAT BIOPSY
Daniel Moreira*, Rochester, MN, Gerald
Andriole, St Louis, MO, Ramiro CastroSantamaria, King of Prussia, PA, Stephen
MP42-09 SHOULD INCLUSION CRITERIA FOR
ACTIVE SURVEILLANCE FOR LOW-RISK
PROSTATE CANCER BE MORE
STRINGENT? : FROM AN INTERIM
ANALYSIS OF PRIAS-JAPAN
Mikio Sugimoto*, Hiromi Hirama, Yoshiyuki
Kakehi, Kagawa, Japan, Prias-Japan Study
Group -, -, Japan
MP42-03 UTILITY OF ANTERIOR ZONE BIOPSY IN
ACTIVE SURVEILLANCE OF PROSTATE
CANCER
Allison Glass*, Neil Pugashetti, Marc A.
Dall’Era, Christopher P. Evans, Stanley A.
Yap, Sacramento, CA
MP42-10 EXPANDING USE OF ACTIVE
SURVEILLANCE: DATA FROM THE
NATIONAL PROSTATE CANCER
REGISTER (NPCR) OF SWEDEN
Stacy Loeb*, New York, NY, Yasin
Folkvaljon, Uppsala, Sweden, Ola Bratt,
Helsingborg, Sweden, David Robinson, Pär
Stattin, Umeå, Sweden
MP42-04 ACTIVE SURVEILLANCE: WHEN CAN
PATIENTS STOP WORRYING?
Ridwan Alam*, H. Ballentine Carter, Patricia
Landis, Jonathan I. Epstein, Mufaddal
Mamawala, Baltimore, MD
MP42-11 ACTIVE SURVEILLANCE ACCEPTANCE
RATE AMONG AFRICAN AMERICAN MEN
WITH LOW RISK PROSTATE CANCER AT
A TERTIARY CARE CENTER
Ibraheem Malkawi*, Scott Hughes, Roy Miller,
Ranko Miocinovic, detroit, MI
MP42-05 A STATEWIDE INTERVENTION TO
REDUCE HOSPITALIZATIONS AFTER
PROSTATE BIOPSY
Paul R Womble*, Susan M. Linsell, Yuqing Gao,
Zaojun Ye, James E. Montie, Ann Arbor, MI,
Brian R. Lane, Grand Rapids, MI, Frank N. Burks,
Royal Oak, MI, David C. Miller, Ann Arbor, MI
MP42-12 CANCER OF THE PROSTATE RISK
ASSESSMENT SCORE FOLLOWING
BIOPSY GLEASON UPGRADE DURING
PROSTATE CANCER ACTIVE
SURVEILLANCE IS ASSOCIATED WITH
ADVERSE PATHOLOGY AT
PROSTATECTOMY
Michael Leapman*, Niloufar Ameli, Carissa
Chu, Ahmed Hussein, Christopher Welty,
Matthew Cooperberg, Peter Carroll, San
Francisco, CA
MP42-06 THE UPTAKE OF ACTIVE SURVEILLANCE
IN PROSTATE CANCER: RESULTS OF A
POPULATION BASED-STUDY
Patrick O. Richard*, Shabbir Alibhai, David
Urbach, Neil E. Fleshner, Narhari Timilshina,
Laurence Klotz, Antonio Finelli, Toronto, Canada
MP42-07 IMPACT OF SURGICAL APPROACH ON
ERECTILE FUNCTION RECOVERY
FOLLOWING BILATERAL NERVE
SPARING-RADICAL PROSTATECTOMY:
RESULTS FROM A RANDOMIZED
CONTROLLED TRIAL OF TADALAFIL
VERSUS PLACEBO (REACTT)
Martin Schostak*, Magdeburg, Germany, Markus
Graefen, Hamburg, Germany, Christian Kriegel,
Leipzig, Germany, Uwe Michl, Hamburg,
Germany, Antonio Martin Morales, Malaga, Spain,
Peter J. Pommerville, Vancouver, Canada,
Martina Manning, Hartwig Büttner, Carsten
Henneges, Bad Homburg, Germany, Jens-Uwe
Stolzenburg, Leipzig, Germany
*Presenting author
MP42-13 A PROSPECTIVE STUDY OF HEALTHRELATED QUALITY OF LIFE OUTCOMES
FOR LOW-RISK PROSTATE CANCER
PATIENTS MANAGED BY ACTIVE
SURVEILLANCE OR RADIATION THERAPY
John S. Banerji*, Seattle, WA, Lauren M.
Hurwitz, Jennifer Cullen, Rockville, MD,
Katherine Odem-Davis, Erika M. Wolff,
Katherine Levie, Khanh N. Pham, Christopher
R. Porter, Seattle, WA
139
SUNDAY
PROSTATE CANCER: LOCALIZED I
Moderators: Gerald Andriole, Jr. and Damien Bolton
MP42-19 DECISION AIDS FOR LOCALIZED
PROSTATE CANCER TREATMENT
CHOICE: SYSTEMATIC REVIEW AND
META-ANALYSIS
Philippe D Violette*, Woodstock, Canada,
Thomas Agoritsas, Hamilton, Canada, Jarno
Riikonen, Tampere, Finland, Henrikki Santti,
Helsinki, Finland, Paul Alexander, Hamilton,
Canada, Arnav Agarwal, Toronto, Canada,
Neera Bhatnagar, Hamilton, Canada, Philipp
Dahm, Minneapolis, MN, Victor Montori,
Rochester, MN, Gordon H Guyatt, Hamilton,
Canada, Kari Tikkinen, Helsinki, Finland
MP42-14 FAIR AND BALANCED? HOW THE MEDIA
REPORTED THE PIVOT AND SPCG-4
PROSTATE CANCER TREATMENT TRIALS
Joseph Yared*, Kevin Koo, Elias Hyams,
Lebanon, NH
MP42-15 IMPACT OF RACE ON SELECTING
APPROPRIATE PATIENTS FOR ACTIVE
SURVEILLANCE WITH SEEMINGLY LOW
RISK PROSTATE CANCER
Eugene J. Pietzak, III*, Keith Van Arsdalen,
Kinnari Patel, S. Bruce Malkowicz, Alan J.
Wein, Thomas J. Guzzo, Philadelphia, PA
MP42-16 CONTEMPORARY PATIENTS WITH
BIOPSY GLEASON 3ⴙ4 PROSTATE
CANCER: ELIGIBILITY FOR ACTIVE
SURVEILLANCE
Ohseong Kwon*, Hakmin Lee, Jung Ki Jo,
Young Ik Lee, Jong Jin Oh, Sangchul Lee,
Seong Jin Jeong, Seok-Soo Byun, Sang Eun
Lee, Sung Kyu Hong, Seongnam, Korea,
Republic of
MP42-20 PATHOLOGIC OUTCOMES OF CANDIDATES
FOR ACTIVE SURVEILLANCE UNDERGOING
RADICAL PROSTATECTOMY: RESULTS
FROM A CONTEMPORARY TURKISH
PATIENT COHORT
Ilker Tinay*, Istanbul, Turkey, Guven Aslan, Izmir,
Turkey, Ali Riza Kural, Istanbul, Turkey, Haluk
Ozen, , Turkey, Bulent Akdogan, Ankara, Turkey,
Asif Yildirim, Istanbul, Turkey, Ozdal Dillioglugil,
Kocaeli, Turkey, Tarik Esen, Istanbul, Turkey,
Ferruh Zorlu, Izmir, Turkey, Levent Turkeri,
Istanbul, Turkey
MP42-17 PREDICTORS OF PATHOLOGICAL
UPGRADING AND UPSTAGING IN
PATIENTS ELIGIBLE FOR ACTIVE
SURVEILLANCE SUBMITTED TO RADICAL
PROSTATECTOMY
Ana Maria Autran-Gomez*, Paris, France,
Fernando P Secin, Buenos Aires, Argentina,
Arjun Sivaraman, Rafael Sanchez Salas,
Paris, France, Juan I Monzo, Buenos Aires,
Argentina, Dominique Prapotnich, Eric Barret,
Francois Rozet, Marc Galiano, Annick
Mombet, Nathalia Cathala, Xavier
Cathelineau, Paris, France
CREDITTM
MP42-18 PATIENTS ELIGIBLE FOR ACTIVE
SURVEILLANCE WHO CHOSE TO
UNDERGO PROSTATECTOMY: THE
DIFFERENCE BETWEEN PROSTATE
CANCER FEATURES ON BIOPSY AND
FINAL PATHOLOGIC REPORT
Benjamin Katz*, Sue-Jean Yu, Elton Llukani,
Andrew Lightfoot, Kelly Monahan, Alice
McGill, David Lee, Philadelphia, PA
10:30 am - 12:30 pm
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: EVALUATION I
Moderators: Allen Seftel and Raphael Carrion
ABSTRACT
NUMBER TITLE
MP43-01 REAL AND PERCEIVED MAGNITUDE OF
CURVATURE AMONG PATIENTS
AFFECTED BY PENILE CURVATURE:
ACQUIRED PENILE CURVATURE (APC) VS
CONGENITAL PENILE CURVATURE (CPC)
ARE THERE ANY DIFFERENCES?
Giovanni Chiriacò, Nicola Pavan*, Michele
Rizzo, Paolo Umari, Gaetano Chiapparrone,
Giovanni Liguori, Carlo Trombetta, Trieste,
Italy
ABSTRACT
NUMBER TITLE
MP43-02 ANATOMIC LOCATION OF CAVERNOSAL
ARTERY IMAGING DURING DOPPLER
PENILE ULTRASOUND IMPACTS
VASCULAR DIAGNOSIS
Matthew Pagano*, Peter Stahl, New York, NY
MP43-03 ENDOTHELIAL DYSFUNCTION DETECTED
BY PERIPHERAL ARTERIAL TONOMETRY
IS MORE PREVALENT IN MEN WITH
Charles Peyton*, Robert Kovell, Jung Kim,
Ryan Terlecki, Winston Salem, NC
140
MP43-14 STUDY OF THE RISK FACTORS
ASSOCIATED WITH PREMATURE
EJACULATION
Seong Hyun Lee, See Min Choi*, Sol Yoon,
Jae Hwi Choi, Sung Chul Kam, Jeong Seok
Hwa, Ky Hyun Chung, Jae Seog Hyun, Jinju,
Korea, Republic of
MP43-05 SEXUAL AND GENITAL HEALTH
AWARENESS AMONG MALES ATTENDING
YOUTH HEALTH CLINICS
Alexander W. Pastuszak*, Peggy B. Smith,
Allyssa Abacan, Larry I. Lipshultz, Dolores J.
Lamb, Ruth Buzi, Houston, TX
MP43-15 OUTCOMES OF FOR CAUSE PROSTATE
BIOPSY IN MEN WITH HYPOGONADISM
Daniel Shoskes*, Yagil Barazani, Khaled
Fareed, Edmund Sabanegh, Cleveland, OH
MP43-06 SEXUAL FUNCTION CHANGES IN
BLADDER CANCER PATIENTS
UNDERGOING CYSTECTOMY
Lindsey Herrel*, Rujuta Umarji, Cheryl Lee,
Ann Arbor, MI, Heather Goltz, David Latini,
Houston, TX, Daniela Wittmann, Ann Arbor,
MI
MP43-16 PREVALENCE AND PREDICTORS OF
EJACULATORY DYSFUNCTION IN MEN
PRESENTING FOR ANDROLOGICAL
EVALUATION
Matthew Pagano*, Alison Levy, Adam De
Fazio, Peter Stahl, New York, NY
MP43-07 VASCULAR RISK FACTORS DO NOT
PREDICT PENILE DOPPLER DUPLEX
ULTRASOUND RESULTS IN OLDER MEN
Kelly A. Chiles*, Christian J. Nelson, John P.
Mulhall, New York, NY
MP43-17 ASSESSMENT OF THE MALE SEXUAL
QUOTIENT SCALE RELIABILITY TO
EVALUATE SEXUAL FUNCTION OF MEN
WITH SPINAL CORD INJURY
Eduardo Miranda*, Cristiano Gomes, Jose de
Bessa Júnior, Jose de Castro Filho, Carlos
Bellucci, Linamara Battistella, Tarcisio Barros
Filho, Fabricio Carvalho, Carmita Abdo,
Homero Bruschini, William Nahas, Miguel
Srougi, Sao Paulo, Brazil
MP43-08 THE RELATIONSHIP BETWEEN
VASECTOMY AND SEXUAL FREQUENCY
David Guo*, Shufeng Li, Michael Eisenberg,
Palo Alto, CA
MP43-09 FAILURE TO ATTAIN STRETCHED PENILE
LENGTH AFTER INTRACAVERNOSAL
INJECTION OF A VASODILATOR AGENT
IS PREDICTIVE OF VENO-OCCLUSIVE
DYSFUNCTION ON PENILE DUPLEX
DOPPLER ULTRASONOGRAPHY
Faysal A Yafi*, Ian R McCoslin, Russell P
Libby, Carrie A Stewart, Premsant Sangkum,
Suresh Sikka, Wayne JG Hellstrom, New
Orleans, LA
MP43-18 ASSESSING THE IMPACT OF AUDIOVISUAL SEXUAL STIMULATION (AVSS)
ON THE NEED FOR REPEAT VASOACTIVE
AGENT INJECTION DURING PENILE
DUPLEX DOPPLER ULTRASONOGRAPHY
Lawrence C. Jenkins*, Joseph Narus,
Amparo Camacho, Christian J. Nelson, John
P. Mulhall, New York, NY
MP43-19 HOW IS DELAYED EJACULATION
TREATED IN NORTH AMERICA?
Michael Butcher*, Springfield, IL, Charles
Welliver, Albany, NY, Daniel Sadowski,
Botchway Albert, Tobias Köhler, Springfield,
IL
MP43-10 HIGH-PRECISION EVALUATION OF
SYSTEMIC ENDOTHELIAL FUNCTION IN
THE COMPLEX DIAGNOSIS OF ERECTILE
DISORDERS
Oleg Apolikhin, Evgeny Efremov, Yaroslav
Melnik, Stepan Krasnyak*, Moscow, Russian
Federation
MP43-20 ENDOTHELIAL DYSFUNCTION IN
PATIENTS OF ERECTILE DYSFUNCTION
USING SHORT-TERM LOW DOSE
TADALAFIL : A DOUBLE BLIND
RANDOMIZED CONTROL TRIAL
Ravimohan Mavuduru*, Pawan Kundal, Smita
Pattanaik, Shrawan Singh, Arup Mandal,
Chandigarh, India
MP43-11 A NOVEL AND CHEAP VASOACTIVE
DRUG COMBINATION FOR
PHARMACOLOGICAL ERECTION
Shivam Priyadarshi*, Jaipur, India
MP43-12 FACTORS CAUSING EJACULATION
PROBLEMS: ANALYSES FROM THE
TURKISH SOCIETY OF ANDROLOGY,
MALE SEXUAL HEALTH STUDY GROUP
murat dincer*, Istanbul, Turkey, selahittin
cayan, Mersin, Turkey, Ramazan Asci,
Samsun, Turkey, Onder Yaman, Ankara,
Turkey, Ege Can Serefoglu, Ates Kadioglu,
Istanbul, Turkey
*Presenting author
CREDITTM
141
SUNDAY
MP43-13 ERECTILE FUNCTION IN PATIENTS
AFTER RADICAL PROSTATECTOMY IN
HIGH-RISK PROSTATE CANCER:
RECOVERY AND OUTCOME ANALYSIS
Ashwin Sridhar, Tet Yap, John Hines, Senthil
Nathan, Tim Briggs, John Kelly, Paul
Cathcart*, Suks Minhas, London, United
Kingdom
MP43-04 UROFLOW STOP TEST AT TIME OF
CATHETER REMOVAL IS A NOVEL AND
STRONG PREDICTOR OF EARLY
RECOVERY OF ERECTILE FUNCTION
FOLLOWING ROBOTIC-ASSISTED
RADICAL PROSTATECTOMY (RARP): A
PILOT STUDY
Abdullah Alenizi*, Marc Bienz, Anwar
Alesawi, Naif Al-Hathal, Serge Benayoun,
Thierry Lebeau, Kevin c Zorn, Assaad ElHakim, Montreal, Canada
10:30 am - 12:30 pm
KIDNEY CANCER: EVALUATION AND STAGING II
Moderators: J. Stuart Wolf, Jr. and John Libertino
ABSTRACT
NUMBER TITLE
MP44-01 A PROGNOSTIC MODEL FOR OVERALL
SURVIVAL IN PATIENTS WITH
METASTATIC CLEAR CELL RENAL
CARCINOMA: RESULTS FROM CALGB
90206 (ALLIANCE)
Hyung Kim*, Los Angeles, CA, Susan Halabi,
Durham, NC, Ping Li, Los Angeles, CA, Greg
Mayhew, Durham, NC, Jeff Simko, San
Francisco, CA, Andrew Nixon, Durham, NC,
Eric Small, San Francisco, CA, Brian Rini,
Cleveland, OH, Michael Morris, New York,
NY, Mary-Ellen Taplin, Boston, MA, Daniel
George, Durham, NC
ABSTRACT
NUMBER TITLE
MP44-06 CAN PROTEINURIA ON A SIMPLE
PREOPERATIVE URINARY DIPSTICK
PREDICT LONG TERM RENAL
FUNCTIONAL CHANGES IN PATIENTS
UNDERGOING PARTIAL NEPHRECTOMY?
Louis Krane*, Matt Heavner, James T Rague,
Ahmed Aboumohamed, Ashok K Hemal,
Winston Salem, NC
MP44-07 A CRITICAL ANALYSIS AND VALIDATION
OF THE RENAL CELL CARCINOMA
BIOMARKER LITERATURE USING THE
CANCER GENOME ATLAS (TCGA)
Samuel Kaffenberger*, Irina Ostrovnaya,
Andrew Winer, Victor Reuter, Jonathan
Coleman, Paul Russo, James Hsieh, Ari
MP44-02 IS GFR ENOUGH TO DEFINE CHRONIC
KIDNEY DISEASE IN KIDNEY CANCER
PATIENTS?
Kelly O’Donnell*, Conrad Tobert, Brad
Boelkins, Sabrina Noyes, Samer Kirmiz,
Mwafa Tourojman, George Ghareeb, Joseph
Giovanucci, Grand Rapids, MI, Sevag
Demirjian, Cleveland, OH, Brian Lane, Grand
Rapids, MI
MP44-08 PRE-OPERATIVE MODIFIED GLASGOW
PROGNOSTIC SCORE AS AN
INDEPENDENT PROGNOSIS FACTOR IN A
LARGE U.S. POPULATION
Yoram Baum*, Claire De la Calle, Dattatraya
Patil, Rachel Schwartz, Jonathan Huang,
Kenneth Ogan, Mehrdad Alemozaffar, John
Pattaras, Peter Nieh, Viraj Master, Atlanta, GA
MP44-03 IS THE ASSOCIATION BETWEEN KIDNEY
CANCER AND HEMODIALYSIS DIFFERENT
FROM PERITONEAL DIALYSIS? - A
NATIONWIDE POPULATION-BASED
STUDY
Eric Yi-Hsiu Huang*, Hsiao-Jen Chung, YuHua Fan, Ruo-Shin Peng, Yen-Hwa Chang,
Alex T.L. Lin, Kuang-Kuo Chen, Taipei,
Taiwan
MP44-09 DOES WARM ISCHEMIC TIME REALLY
AFFECT THE LATE KIDNEY FUNCTION
AND OVERALL SURVIVAL AFTER
PARTIAL NEPHRECTOMY ?
Jae Seung Chung*, Busan, Korea, Republic
of, Seok-Soo Byun, Sang Eun Lee, Sung Kyu
Hong, Sang Chul Lee, Seongnam, Korea,
Republic of, Cheol Kwak, Sung Hoo Hong,
Seoul, Korea, Republic of, Yong June Kim,
Chungbuk National University Hospital,
Korea, Republic of, Seok-Ho Kang, Seoul,
Korea, Republic of
MP44-04 NEPHRON-SPARING SURGERY
PROTECTS FROM CHRONIC KIDNEY
DISEASE RELATIVE TO RADICAL
NEPHRECTOMY BUT DOES NOT IMPACT
ON OTHER-CAUSES MORTALITY: LONGTERM (MORE THAN 10 YEARS) SURVIVAL
AND FUNCTIONAL OUTCOMES IN
PATIENTS WITH A T1A-T1B RENAL MASS
Umberto Capitanio*, Milan, Italy, Carlo
Terrone, Novara, Italy, Alessandro Antonelli,
Brescia, Italy, Andrea Minervini, Florence,
Italy, Cristian Fiori, Turin, Italy, Luisa Zegna,
Novara, Italy, Maria Furlan, Brescia, Italy,
Giorgio Gandaglia, Paolo Capogrosso, Milan,
Italy, Carini Marco, Florence, Italy, Claudio
Simeone, Brescia, Italy, Roberto Bertini,
Francesco Montorsi, Milan, Italy
MP44-10 TREATMENT TRENDS OF SMALL RENAL
MASSES IN PATIENTS OF ADVANCED
AGE
Shan Dong*, Jonathan E. Kiechle, Simon P.
Kim, Robert Abouassaly, Edward E. Cherullo,
Lee Ponsky, Cleveland, OH, Cary P. Gross,
New Haven, CT, Nilay D. Shah, Rochester,
MN, Hui Zhu, Cleveland, OH
MP44-11 PROGNOSTIC SIGNIFICANCE OF DEGREE
OF RENAL VEIN INVOLVEMENT IN
PATIENTS WITH PATHOLOGIC T3A
Myungsun Shim*, Myungchan Park, Aram
Kim, Mooyoung Sohn, Jaeyoon Jung, In Gab
Jeong, Cheryn Song, Choung-Soo Kim,
Hanjong Ahn, Seoul, Korea, Republic of
MP44-05 EXPLORATION OF PREDICTIVE FACTORS
OF POST-PARTIAL NEPHRECTOMY
RENAL FUNCTION: HOST FACTORS,
RATHER THAN SURGICAL FACTORS,
MAY BE USEFUL PREDICTORS IN THE
POST-OPERATIVE STABLE PERIOD
Takehiro Sejima*, Noriya Yamaguchi, Hideto
Iwamoto, Toshihiko Masago, Shuichi
Morizane, Masashi Honda, Atsushi Takenaka,
Yonago, Japan
142
MP44-13 OUTCOMES OF SURGICALLY TREATED
T4M0, T4M1, AND M1 PATIENTS WITH
Michael Daugherty*, Gennady Bratslavsky,
Syracuse, NY
MP44-14 PARANEOPLASTIC SYNDROMES ARE
ASSOCIATED WITH ADVERSE
PROGNOSIS AMONG PATIENTS WITH
RENAL CELL CARCINOMA UNDERGOING
NEPHRECTOMY
Daniel Moreira*, Boris Gershman, Christine
Lohse, Stephen Boorjian, John Cheville,
Bradley Leibovich, R. Houston Thompson,
Rochester, MN
MP44-15 ANATOMICAL SCORING SYSTEM FOR
ASSESSING PARTIAL NEPHRECTOMY
TECHNICAL COMPLEXITY
Massimiliano Spaliviero*, Bing Ying Poon,
Christoph A. Karlo, Giuliano B. Guglielmetti,
Pier Luigi Di Paolo, Felix Campos-Juanatey,
Melanie L. Bernstein, Daniel D. Sjoberg, Paul
Russo, Jonathan A. Coleman, Oguz Akin,
Karim A. Touijer, New York, NY
MP44-16 PREDICTORS OF NON-DIAGNOSTIC
RENAL MASS BIOPSY
Michael Blute*, Joel Prince, Eric Bultman,
Louis Hinshaw, Anna Drewry, Sara Best,
Fred T. Lee, Jr, Timothy Ziemlewicz, Meghan
Lubner, Fangfang Shi, Stephen Y. Nakada,
E. Jason Abel, Madison, WI
MP44-18 CLINICAL SIGNIFICANCE OF
NUTRITIONAL PROGNOSTIC INDEX IN
PATIENTS WITH CLEAR CELL RENAL
CELL CARCINOMA
Yoshio Ohno*, Jun Nakashima, Makoto
Ohori, Naoya Satake, Takeshi Kashima,
Tatsuo Gondo, Yoshihiro Nakagami, Masaaki
Tachibana, Tokyo, Japan
MP44-19 IMPACT OF REDUCED GFR AND
PROTEINURIA ON OVERALL SURVIVAL
OF RENAL CANCER PATIENTS
Mwafa Tourojman*, Sabrina Noyes, Kelly
O’Donnell, Samer Kirmiz, Conrad Tobert,
Brad Boelkins, George Ghareeb, Joseph
Giovanucci, Brian Lane, Grand Rapids, MI
MP44-20 CAN MORPHOLOGIC FEATURES OF VENA
CAVAL TUMOR THROMBUS ON CT OR
MRI BE A PROGNOSTIC FACTOR AFTER
SURGICAL TREATMENT OF RENAL CELL
CARCINOMA WITH IVC THROMBUS?
Don kyoung Choi*, Hwang Gyun Jeon, Byong
Chang Jeong, Seong Soo Jeon, Hyun Moo
Lee, Han-Yong Choi, Chang Wook Jeong,
Cheol Kwak, Cheryn Song, Jinsoo Chung,
Sung Kyu Hong, Sung-Hoo Hong, Seong Il
Seo, Seoul, Korea, Republic of
CREDITTM
*Presenting author
143
SUNDAY
MP44-17 THE SIGNIFICANCE OF
SYMPTOMATOLOGY: ANALYSIS FROM
THE INTERNATIONAL RENAL CELL
CARCINOMA-VENOUS THROMBUS
CONSORTIUM (IRCC-VTC)
Jamie S Pak*, Danny Lascano, Julia B
Finkelstein, James M McKiernan, G Joel
DeCastro, New York, NY, Umberto Capitanio,
Milan, Italy, Joaquı́n A Carballido, Madrid, Spain,
Venancio Chantada, Coruña, Spain, Thomas
Chromecki, Graz, Austria, Gaetano Ciancio,
Miami, FL, Siamak Daneshmand, Los Angeles,
CA, Christopher P Evans, Sacramento, CA,
Paolo Gontero, Turin, Italy, Javier González,
Madrid, Spain, Axel Haferkamp, Frankfurt,
Germany, Markus Hohenfellner, Heidelberg,
Germany, William C Huang, New York, NY,
Theresa M Koppie, Portland, OR, Estefanı́a L
Espinós, Madrid, Spain, Adam Lorentz, Atlanta,
GA, Juan I Martı́nez-Salamanca, Madrid, Spain,
Dario Martul, Coruña, Spain, Alon Y Mass, New
York, NY, Viraj A Master, Atlanta, GA, Carmen
Mir, Miami, FL, Francesco Montorsi, Milan, Italy,
Giacomo Novara, Padua, Italy, Padraic O’Malley,
New York, NY, Sascha Pahernik, Heidelberg,
Germany, Juan Palou, Barcelona, Spain, José LP
Moreno, Valencia, Spain, Raj S Pruthi, Chapel
Hill, NC, Oscar R Faba, Barcelona, Spain, Paul
Russo, Douglas S Scherr, New York, NY,
Shahrokh F Shariat, Vienna, Austria, Martin
Spahn, Würzburg, Germany, Carlo Terrone,
Novara, Italy, Derya Tilki, Sacramento, CA, Cesar
V Donoso, Valencia, Spain, Daniel Vergho,
Würzburg, Germany, Eric M Wallen, Chapel Hill,
NC, Richard Zigeuner, Graz, Austria, John A
Libertino, Burlington, MA
MP44-12 ENUCLEO-RESECTION VERSUS WEDGE
RESECTION FOR SMALL RENAL MASSES:
COMPARATIVE ANALYSIS OF VOLUME
PRESERVATION AND CHANGES IN
RENAL FUNCTION
Adam Kadlec*, Robert Blackwell, Timothy
Durso, Marcus Quek, Gopal Gupta,
Maywood, IL
10:30 am - 12:30 pm
BLADDER CANCER: BASIC RESEARCH II
Moderators: Piyush Agarwal and Jason Gee
ABSTRACT
NUMBER TITLE
MP45-01 HIGH ALDO-KETO REDUCTASE 1C1
EXPRESSION IN METASTATIC BLADDER
CANCER CELLS ASSOCIATED WITH
INVASIVE POTENTIAL AND DRUG
RESISTANCE
Ryuji Matsumoto*, Masumi Tsuda, Takashige
Abe, Satoru Maruyama, Kunihiko Tsuchiya,
Naoto Miyajima, Nobuo Shinohara, Shinya
Tanaka, Sapporo, Japan
ABSTRACT
NUMBER TITLE
MP45-07 SYNTHETIC INTRAVESICAL
IMMUNOMODULATORY MOLECULES AS
POTENTIAL ALTERNATIVES TO
BACILLUS CALMETTE-GUERIN (BCG)
AGAINST NON-MUSCLE-INVASIVE
BLADDER CANCER
Gabriela R. Passos, Karen L. Ferrari, Isadora
O. Gilli, Juliana A. de Camargo, Mariana A.
Davi, Mariana F. G. Fazuoli, Athanase Billis,
Leonardo O. Reis*, Campinas, Brazil
MP45-02 INVESTIGATION OF A NON-INVASIVE
DIAGNOSTIC ASSAY TO DETECT
ALTERED EXPRESSION OF MICRORNA IN
EXFOLIATED UROTHELIAL CARCINOMA
CELLS
Gabriel B. Saltzman*, Chicago, IL, Travis B.
Sullivan, Dylan Lavery, Jason R. Gee, John
A. Libertino, Kimberly M. Rieger-Christ,
Burlington, MA
MP45-08 GMCSF AND IFN␣ GENE THERAPY
IMPROVED RESPONSE TO BCG
IMMUNOTHERAPY IN A MURINE MODEL
OF BLADDER CANCER
Sin Mun Tham*, Abirami R, Kesavan
Esuvaranathan, Ratha Mahendran,
MP45-09 EMETINE DIHYDROCHLORIDE
PREFERENTIALLY INHIBITS HIF1␣ AND
HIF2␣ EXPRESSION IN BLADDER
CANCER CELLS
Kimberly E Foreman, Deval Patel, Valerie
Davidson, Paul Kuo, Robert Flanigan, Gopal
N Gupta*, Maywood, IL
MP45-03 TARGETING OF BIOMARKERS OF
BLADDER CANCER METASTASIS BY
4-METHYLUMBELLIFERONE
Juan Chipollini*, Ronny Racine, Luis Lopez,
Soum Lokeshwar, Travis Yates, Vinata
Lokeshwar, Miami, FL
MP45-04 ANDROGEN DEPRIVATION THERAPY
PREVENTS RECURRENCE OF BLADDER
CANCER
Koji Izumi*, Mastaka Taguri, Yokohama,
Japan, Hiroshi Miyamoto, Baltimore, MD,
Yusuke Ito, Yasuhide Miyoshi, Masatoshi
Moriyama, Tetsuo Murai, Hiroyuki Hayashi,
Yoshiaki Inayama, Yokohama, Japan, Yoji
Nagashima, Tokyo, Japan, Satoshi Morita,
Kyoto, Japan, Hiroji Uemura, Yokohama,
Japan
MP45-10 CORRELATION BETWEEN FIBRONECTIN
GENE EXPRESSION AND LOCAL
TOXICITY INDUCED BY ADJUVANT
INTRAVESICAL THERAPY
Vincenza Alonge, Cristina Scalici Gesolfo,
Fabrizio Di Maida, Giuseppe Cicero, Palermo,
Italy, Antonina Graziella Cangemi, Palermo⶿,
Italy, Antonio Russo, Michele D’Arienzo,
Rosalinda Allegro, Vincenzo Serretta*,
Palermo, Italy
MP45-11 PHARMACOGENETIC ASSOCIATION
BETWEEN COMBINED EFFECTS OF
GSTP1 AND GSTO1 GENETIC
POLYMORPHISMS AND INTRAVESICAL
INSTILLATION SENSITIVENESS OF
MP45-05 T0 DISEASE: THE POTENTIAL OF
AVOIDING CYSTECTOMIES THROUGH
MIRNA PROFILES IN CELL-FREE URINE
Chintan Patel*, Shiv Patel, Travis Sullivan,
Burlington, MA, Alexa Meyer, James
McKiernan, New York, NY, John Libertino,
Kimberly Christ, Burlington, MA
MP45-06 COMPARISON BETWEEN WHOLE MOUNT
TISSUE PREPARATIONS AND VIRTUAL
TISSUE MICROARRAY SAMPLES FOR
MEASUREMENT OF KI-67 AND
APOPTOSIS INDICES IN HUMAN
BLADDER CANCERS
Hisashi Oshiro*, Tokyo, Japan, Bogdan
Czerniak, Houston, Armenia, Kentaro
Sakamaki, Yokohama, Japan, Koji Tsuta,
Tokyo, Japan, Jolanta Bondaruk, Afsaneh
Keyhani, Colin Dinney, Houston, Armenia,
Takeshi Nagai, Tokyo, Japan, Ashish Kamat,
Houston, Armenia
MP45-12 PROGNOSTIC IMPACT OF TUMOR
ASSOCIATED MACROPHAGES IN
PATIENTS WITH TRANSITIONAL CELL
BLADDER CANCER
Bo Wang, Shaoxu Wu, Zhuowei Liu, Wen
Dong, Wang He, Xiaoliang Dong, Tianxin Lin,
Jian Huang*, Guangzhou, China, People’s
Republic of
144
MP45-18 EXPRESSION OF FOXP3⌬ 2 IN BLADDER
CANCER EPITHELIAL CELLS IMPARTS
RESISTANCE TO CHEMOTHERAPY AND
INVERSELY CORRELATES TO SURVIVAL
Hanwei Zhang, Elizabeth Peek, Jane Lee,
Kelvin Zhang, Xiaoyan Wang, Jiaoti Huang,
Gang Li, Matteo Pellegrini, Arnold Chin*, Los
Angeles, CA
MP45-14 COMPARISON OF DIFFERENT
ANALYTICAL PLATFORMS FOR THE
IDENTIFICATION OF TUMOR DNA IN THE
URINE OF BLADDER CANCER PATIENTS
Matthew J Resnick*, Nashville, TN, Richard D
Abramson, Carl Yoshizawa, Redwood City,
CA, Po N Lam, Syracuse, NY, Neal Shore,
Myrtle Beach, SC, Haluk Tezcan, Redwood
City, CA
MP45-19 UPREGULATION OF ISOENZYME M2 OF
PYRUVATE KINASE IN BLADDER
CANCER: IMPLICATION IN TUMOR
INITIATION, PROGRESSION AND
THERAPEUTIC TARGETING
Haiping Zhou, Kuo-How Huang, Yan Liu,
Feng He, Xing Wang, Lan Mo, Herbert Lepor,
Moon-shong Tang, Chuanshu Huang, Xue-Ru
Wu*, New York, NY
MP45-15 MIR-137 INHIBITED SP1 PROTEIN
TRANSLATION AND MEDIATED ANTICANCER ACTIVITY OF
ISORHAPONTIGENIN (ISO)
Dongyun Zhang*, Chuanshu Huang, Xingruo
Zeng, Zhou Xu, Tuxedo, NY, Xue-ru Wu,
New York, NY, Moon-Shong Tang, Tuxedo,
NY
MP45-20 PDK4 – A POSSIBLE THERAPEUTIC
TARGET FOR HIGH GRADE BLADDER
CANCER
Andrew Mikhalyuk*, Dharamainder
Choudhary, Carol Pilbeam, John Taylor, III,
Farmington, CT
MP45-16 NON-MUSCLE INVASIVE BALDDER
CANCER: CIRCULATING TUMOR CELLS
AND PROGNOSTIC SIGNIFICANCE
Gian Maria Busetto*, Riccardo Giovannone,
Gabriele Antonini, Paola Gazzaniga,
Vincenzo Gentile, Ettore De Berardinis,
Roma, Italy
CREDITTM
MP45-17 COMPARISON OF THE PROGNOSTIC AND
PREDICTIVE VALUE OF THE
BIOMARKERS ERCC1 AND KI67 IN
PATIENTS ENROLLED IN TWO
RANDOMIZED STUDIES OF
NEOADJUVANT CHEMOTHERAPY WITH
OR WITHOUT CYSTECTOMY
Tammer Hemdan*, Ulrika Segersten, Per-Uno
Malmström, Uppsala, Sweden
10:30 am - 12:30 pm
PROSTATE CANCER: BASIC RESEARCH II
Moderators: Christopher Evans and K. C. Balaji
ABSTRACT
NUMBER TITLE
MP46-01 AKR1C3 ACTIVATION AND INTRACRINE
ANDROGENS CONFER RESISTANCE TO
ENZALUTAMIDE
Chengfei Liu, Wei Lou, Yezi Zhu, Joy Yang,
Christopher Evans, Allen Gao*, Sacramento,
CA
ABSTRACT
NUMBER TITLE
MP46-03 NF-KAPPAB2/P52:C-MYC:HNRNPA1
REGULATORY PATHWAY CONTROLS
EXPRESSION OF ANDROGEN RECEPTOR
SPLICE VARIANTS AND ENZALUTAMIDE
SENSITIVITY IN PROSTATE CANCER
Nagalakshmi Nadiminty*, Ramakumar
Tummala, Chengfei Liu, Wei Lou, Christopher
Evans, Allen Gao, Sacramento, CA
MP46-02 UP-REGULATION OF GLUCOSE
METABOLISM BY NF-␬B2/P52 MEDIATES
ENZALUTAMIDE RESISTANCE IN
PROSTATE CANCER CELLS
Yuanyuan Cui, Nagalakshmi Nadiminty,
Chengfei Liu, Wei Lou, Allen Gao*,
Sacramento, CA
*Presenting author
145
SUNDAY
MP45-13 N-ACETYLCYSTEINE-MEDIATED
AUTOPHAGY INHIBITION LEADS TO
CYTOCHROME-C INDEPENDENT
CASPASE-9 ACTIVATION DURING
OXIDATIVE STRESS IN UROTHELIAL
CARCINOMA OF URINARY BLADDER
Rani Ojha, Shrawan K Singh*, Vivekanand
Jha, Chandigarh, India
MP46-12 USING THE NOVEL SELECTIVE LYSINESPECIFIC DEMETHYLASE 1 INHIBITOR
NCL1 TO IMPAIR PROSTATE CANCER
GROWTH
Toshiki Etani*, Taku Naiki, Keitaroh Iida,
Ryosuke Ando, Daichi Kobayashi, Noriyasu
Kawai, Keiichi Tozawa, Kenjiro Kohri,
Nagoya, Japan
MP46-04 REAL TIME IN VIVO MOLECULAR
IMAGING OF NF-␬B IN PROSTATE
CANCER: ROLE AS PROGNOSTIC
BIOMARKER AND THERAPEUTIC TARGET
Eugene Vykhovanets, Sanjeev Shukla, Eswar
Shankar, Olena Vykhovanets, Gregory
MacLennan, Sanjay Gupta*, Cleveland, OH
MP46-05 INHIBITION OF CONSTITUTIVELY ACTIVE
STAT3 AND AR VARIANTS REVERSES
ENZALUTAMIDE RESISTANCE IN
ADVANCED PROSTATE CANCER CELLS
Chengfei Liu*, Wei Lou, Yezi Zhu,
Christopher Evans, Allen Gao, Sacramento,
CA
MP46-13 NITRONE-BASED THERAPY FOR
TREATMENT OF A MURINE MODEL OF
HUMAN CASTRATION RESISTANT
PROSTATE CANCER
Joel Slaton*, Carole Davis, Nataliya Smith,
Debbie Saunders, Rober Hurst, Rheal
Towner, Oklahoma City, OK
MP46-06 ABLATION OF INTRATUMORAL
ANDROGENESIS IN PROSTATE TUMOR
CELL XENOGRAFTS BY A HEDGEHOG
SIGNALING INHIBITOR
Amy A Lubik, Mazyar Ghaffari, Hans Adomat,
Vancouver, Canada, Eva Corey, Seattle, WA,
Emma Guns, Michael E Cox, Ralph Buttyan*,
Vancouver, Canada
MP46-14 CAPSAICIN REDUCES THE METASTATIC
BURDEN IN THE TRANSGENIC
ADENOCARCINOMA OF THE MOUSE
PROSTATE (TRAMP) MODEL
Natalie Venier, Toshihiro Yamamoto*, Linda
Sugar, Toronto, Canada, Hans Adomat,
Vancouver, Canada, Neil Fleshner,
Vasundara Venkateswaran, Laurence Klotz,
Toronto, Canada
MP46-07 EFFECT OF A HISTONE DNA
DEMETHYLASE ON CRPC CELL LINES, A
POTENTIAL THERAPEUTIC APPLICATION
Thenappan Chandrasekar*, Joy C. Yang,
Sacramento, CA, Min Xie, Sheng Ding, San
Francisco, CA, Michael G. Rosenfeld, La
Jolla, CA, Christopher P. Evans, Sacramento,
CA
MP46-15 LIPID NANOPARTICLE SIRNA POTENTLY
SILENCES CLUSTERIN AND DELAYS
PROGRESSION WHEN COMBINED WITH
ANDROGEN RECEPTOR CO-TARGETING
IN ENZALUTAMIDE RESISTANT
PROSTATE CANCER
Yoshiaki Yamamoto*, Paulo Lin, Fan Zhang,
Eliana Beraldi, Yoshihisa Kawai, Jeffrey
Leong, Vancouver, Canada, Hideyasu
Matsuyama, Ube, Japan, Pieter Cullis, Martin
Gleave, Vancouver, Canada
MP46-08 THE TYRPHOSTIN, NT157, SUPPRESSES
INSULIN RECEPTOR SUBSTRATES AND
AUGMENTS THERAPEUTIC RESPONSE
OF PROSTATE CANCER
Naokazu Ibuki*, Hirakata, Japan, Mazyar
Ghaffari, Vancouver, Canada, Hadas
Reuveni, Jerusalem, Israel, Mitaly Pandey,
Ladan Fazli, Vancouver, Canada, Haruhito
Azuma, Takatsuki, Japan, Martin Gleave,
Vancouver, Canada, Alexander Levitzki,
Jerusalem, Israel, Michael Cox, Vancouver,
Canada
MP46-16 CASTRATION-INDUCED ACCELERATION
OF BONE METASTASIS PREVENTED BY
RANK INHIBITOR OSTEOPROTEGERIN IN
MURINE CASTRATION-RESISTANT
PROSTATE CANCER MODEL
Koichiro Takayama*, Takamitsu Inoue,
Shintaro Narita, Mingguo Huang, Yoko
Mitobe, Hiroshi Tsuruta, Susumu Akihama,
Mitsuru Saito, Norihiko Tsuchiya, Tomonori
Habuchi, Akita, Japan
MP46-09 METFORMIN INDUCES ER STRESSDEPENDENT APOPTOSIS THROUGH MIR708-5P/NNAT PATHWAY IN PROSTATE
CANCER
Jian Yang, Yuqi Guo, Xin Li*, New York, NY
MP46-17 TARGETING MULTIPLE FUNCTIONS OF
E3 UBIQUITIN LIGASE-1 (WWP1)
SIGNALING BY MIR-452 INHIBITS
CANCER CELL MIGRATION AND
INVASION IN PROSTATE CANCER
Yusuke Goto*, Akira Kurozumi, Rika
Nishikawa, Mayuko Kato, Shinichi Sakamoto,
Chiba, Japan, Satoko Kojima, Yukio Naya,
Ichihara, Japan, Hideki Enokida, Masayuki
Nakagawa, Kagoshima, Japan, Tomohiko
Ichikawa, Naohiko Seki, Chiba, Japan
MP46-10 UTILIZING INSULIN IN THE TREATMENT
OF PROSTATE CANCER WITH BKM120
ABROGATES THE THERAPEUTIC EFFECT
OF PI3K PATHWAY INHIBITION
Lily Wang*, David Nanus, Lewis Cantley,
New York, NY
MP46-11 TARGETING RIBOSOMAL S6 KINASES/YBOX BINDING PROTEIN-1 SIGNALING
IMPROVES CELLULAR SENSITIVITY TO
TAXANE IN PROSTATE CANCER
Masaki Shiota*, Momoe Itsumi, Akira
Yokomizo, Ario Takeuchi, Kenjiro Imada, Eiji
Kashiwagi, Junichi Inokuchi, Katsunori
Tatsugami, Takeshi Uchiumi, Seiji Naito,
Fukuoka, Japan
MP46-18 CD8 T CELLS INHIBIT THE INTERLEUKIN15 (IL-15) INDUCED CYTOTOXIC ACTIVITY
OF NK AND NKT CELLS TOWARD
TUMOUR CELLS IN THE PROSTATE
CANCER MICROENVIRONMENT
Oussama Elhage*, Christina Sakellariou,
Richard A Smith, Christine Galustian, Prokar
Dasgupta, London, United Kingdom
146
MP46-20 CARMUSTINE AND SELENITE
COMBINATION THERAPY EFFECTIVELY
INHIBITS CASTRATION RESISTANT
PROSTATE CANCER IN PRECLINICAL
MODELS
Vijayalakshmi Thamilselvan*, Mani Menon,
Sivagnanam Thamilselvan, Detroit, MI
MP46-19 MICRODISTRIBUTION OF ALPHA
PARTICLE EMITTING RADIUM-223
DICHLORIDE IN MODELS OF PROSTATE
CANCER BONE METASTASIS
Diane Abou, Baltimore, MD, David Ulmert,
New York, NY, Robert Hobbs, Ryan Riddle,
Daniel Thorek*, Baltimore, MD
10:30 am - 12:30 pm
KIDNEY CANCER: BASIC RESEARCH II
Moderator: W. Marston Linehan
ABSTRACT
NUMBER TITLE
MP47-01 OVEREXPRESSED MIR-27A-3P IS AS
INDEPENDENT PROGNOSTIC FACTOR
FOR RECURRENCE IN CLEAR CELL
Wataru Nakata*, Motohide Uemura, Toshiro
Kinouchi, Takuji Hayashi, Kyosuke Matsuzaki,
Norihiko Kawamura, Atsunari Kawashima,
Takeshi Ujike, Akira Nagahara, Kazutoshi
Fujita, Kentaro Jingushi, Kazutake Tsujikawa,
Norio Nonomura, Suita, Japan
ABSTRACT
NUMBER TITLE
MP47-05 ANDROGEN RECEPTOR MRNA
EXPRESSION IS ASSOCIATED WITH
PROGNOSIS IN LOCALIZED RENAL CELL
CARCINOMA
Parth Modi*, Yun-Sok Ha, Geuntaek Lee,
New Brunswick, NJ, Han-Jong Ahn, Seoul,
Korea, Republic of, Wun-Jae Kim, Cheongju,
Korea, Republic of, Isaac Kim, New
Brunswick, NJ
MP47-06 BRCA1 ASSOCIATED PROTEIN-1 (BAP-1)
LOSS IN CCRCC: MOLECULAR
CORRELATIONS AND VALIDATION AS A
PROGNOSTIC FACTOR
Nils Kroeger*, Greifswald, Germany, Payal
Kapur, Dallas, TX, Jiaoti Huang, Arie
Belldegrun, Los Angeles, CA, James
Brugarolas, Dallas, TX, Allan Pantuck, Los
Angeles, CA
MP47-02 MICRORNA MIR-200B IS DOWNREGULATED AND SUPPRESSES
METASTASIS BY TARGETING LAMA4 IN
Zhong yuan Zhang*, Xue song Li, Wei Zhao,
Bo xing Su, Xiao chun Zhang, Li qun Zhou,
Zhi qian Zhang, Beijing, China, People’s
Republic of
MP47-07 OVEREXPRESSION OF SIRT7 EXHIBITS
ONCOGENIC PROPERTY AND SERVES AS
A PROGNOSTIC FACTOR IN CLEAR CELL
Xue Yijun, Zou xiaofeng*, Zhang Guoxi, Yuan
Yuanhu, Xiao Rihai, Wu Gengqing, Wang
Xiaoning, Ganzhou, Jiangxi Province, China,
MP47-03 ADIPOQ GENE POLYMORPHISM IS
ASSOCIATED WITH CLEAR CELL RENAL
CELL CARCINOMA
Guiming Zhang*, Chengyuan Gu, Yao Zhu,
Shanghai, China, People’s Republic of, Lei
Luo, Dahai Dong, Qingdao, China, People’s
Republic of, Fangning Wan, Xiaojian Qin,
Hailiang Zhang, Guohai Shi, Bo Dai,
Shanghai, China, People’s Republic of,
Lijiang Sun, Qingdao, China, People’s
Republic of, Dingwei Ye, Shanghai, China,
MP47-08 THE METHYLATION OF SOX7 AND ITS
FUNCTION AS A TUMOR SUPPRESSOR IN
RENAL CELL CANCER
Lu Wang*, Qian Zhang, Lian Zhang, beijing,
China, People’s Republic of, Tingxiu Xiang,
chongqing, China, People’s Republic of, Yu
Fan, beijing, China, People’s Republic of,
Ben Xu, beijng, China, People’s Republic of,
Qian Tao, hongkng, China, People’s Republic
of, Jie Jin, beijing, China, People’s Republic
of
MP47-04 EXAMINATION OF GENOMIC COPY
NUMBER ALTERATIONS IN RENAL CELL
CARCINOMA WITH SARCOMATOID
FEATURES
Timothy Ito*, Jianming Pei, Essel Dulaimi,
Craig Menges, Philip Abbosh, Marc
Smaldone, David Chen, Richard Greenberg,
Alexander Kutikov, Rosalia Viterbo, Robert
Uzzo, Joseph Testa, Philadelphia, PA
*Presenting author
147
SUNDAY
CREDITTM
MP47-09 MOLECULAR CHARACTERIZATION OF
SARCOMATOID CLEAR CELL RENAL
CELL CARCINOMA
Roy Mano*, William Lee, Alexander Sankin,
Michael Chevinsky, Patricia Wang, Almedina
Djesevic, Robert Motzer, Emily Cheng, Paul
Russo, Dayna Oschwald, Umeshkumar
Bhanot, Satish Tickoo, A Ari Hakimi, James
Hsieh, New York, NY
MP47-16 PRETREATMENT PERIPHERAL BLOOD
MONOCYTE SUBSET SIGNATURE IN
STAGE IV RENAL CELL CARCINOMA
PATIENTS PREDICTS OUTCOME TO
DENDRITIC CELL VACCINATION
Jason Muhitch*, Alexander Wald, Mohammad
Habiby Kermany, Joseph Tario, Anand
Sharda, Buffalo, NY, Marc Ernstoff, Hanover,
NH, Thomas Schwaab, Buffalo, NY
MP47-10 MICRORNA EXPRESSION PROFILES FOR
RENAL MASS BIOPSY: A NOVEL TOOL TO
AID IN THE STRATIFICATION OF
PATIENTS WITH CLEAR CELL RENAL
CELL CARCINOMA
Drew Palmer*, Casey Kowalik, Patrick
Teebagy, Kari Bailey, Shiv Patel, Travis
Sullivan, John Dugan, John Libertino,
Kimberly Rieger-Christ, Burlington, MA
MP47-17 REDUCED TERE1 (UBIAD1) PROTEIN
EXPRESSION ASSOCIATES WITH
MALIGNANT BUT NOT BENIGN RENAL
CANCERS. ECTOPIC TERE1 EXPRESSION
INDUCES SXR TARGET GENES
REGULATING BONE REMODELING:
RELEVANCE TO BONE METASTASIS
William Fredericks*, Frank Rauscher III, Priti
Lal, S. Bruce Malkowicz, Philadelphia, PA
MP47-11 CANDIDATE BIOMARKER FOR BONE
MORPHOGENETIC PROTEIN 2 PREDICTS
RENAL CELL CARCINOMA PROGRESSION
VIA ITS PROMOTER CPG
HYPERMETHYLATION
Yozo Mitsui*, San Francisco, CA, Naoko
Arichi, Miho Hiraki, Hiroaki Yasumoto, Izumo,
Japan, Shinichiro Fukuhara, San Francisco,
CA, Inik Chang, Seoul, Korea, Republic of,
Hiroshi Hirata, Soichiro Yamamura, Varahram
Shahryari, Guoren Deng, Ruzhu Lan,
Sharanjot Saini, Shahana Majid, Rajvir
Dahiya, Tanaka Yuichirio, San Francisco, CA,
Hiroaki Shiina, Izumo, Japan
MP47-18 LYMPH NODE STROMAL CELLS
ENHANCE RENAL CELL CARCINOMA
GROWTH, TRANSMIGRATION, AND
METASTASIS IN AN ORTHOTOPIC
XENOGRAFT MODEL
John Nelson*, Jessie Gills, Ravan Moret, Xin
Zhang, Grace Maresh, Ashley Richman,
M’Liss Hudson, Marc Matrana, Ryan
Hedgepeth, Shams Halat, Stephen Bardot, Li
Li, New Orleans, LA, Christudas Morais,
Glenda Gobe, David Johnson, Brisbane,
Australia
MP47-19 URINE AND SERUM METABOLOMICS
ANALYSES MAY DISTINGUISH BENIGN
AND MALIGNANT RENAL NEOPLASMS
Oluyemia Falegan, Calgary, Canada, Mark
Ball, Baltimore, MD, Rustem Shaykhutdinov,
Calgary, Canada, Michael Gorin, Phillip
Pierorazio, George Netto, Mohamad Allaf*,
Baltimore, MD, Hans Vogel, Eric Hyndman,
Calgary, Canada
MP47-12 MIR-646 IN CLEAR CELL RENAL
CARCINOMA CORRELATED WITH
TUMOUR METASTASIS BY TARGETING
THE NIN ONE BINDING PROTEIN
Wei Li*, Shanghai, China, People’s Republic
of, Yuanyuan Zhang, Winston Salem, NC,
Min Liu, Jianping Che, Junhua Zheng,
MP47-20 IDENTIFICATION OF ACTIONABLE
TARGETS IN CHROMOPHOBE RENAL
CELL CARCINOMA DETECTED BY
MULTIPLATFORM MOLECULAR
ANALYSIS
Philip Abbosh*, Philadelphia, PA, Sherri
Millis, Nancy Doll, Adam Hauben, Sandeep
Reddy, Phoenix, AZ, Daniel Geynisman,
Robert Uzzo, Philadelphia, PA
MP47-13 MUTATIONAL AND PROGNOSTIC
ASSOCIATIONS OF IMMUNE CELL
SIGNATURES IN CLEAR CELL RENAL
CELL CARCINOMA
Andrew Winer*, Yasin Senbabaoglu, Samuel
Kaffenberger, Jonathan Coleman, Paul
Russo, Chris Sander, James Hsieh, Ari
MP47-14 MUTATION ANALYSIS OF AGGRESSIVE
CHROMOPHOBE RENAL CELL CANCER
PATIENTS
Jozefina Casuscelli*, William Lee, Patricia
Wang, Paul Russo, Jonathan A. Coleman,
New York, NY, Allan Pantuck, Los Angeles,
CA, R. Houston Thompson, Rochester, MN,
Victor E. Reuter, A. Ari Hakimi, James J
Hsieh, New York, NY
CREDITTM
MP47-15 A NOVEL ELISA FOR THE QUANTITATIVE
MEASUREMENT OF URINARY
AQUAPORIN-1 IN PATIENTS WITH RENAL
CANCER
Jaime H Noguez*, Cleveland, OH, Shilpa
Sreedharan, Fei Lian, Viraj Master, Kenneth
Ogan, John Pattaras, Rebecca S Arnold,
John A Petros, James C Ritchie, Atlanta, GA
148
10:30 am - 12:30 pm
Podium Session 25
ABSTRACT
TIME NUMBER TITLE
10:30 PD25-01 MOLECULAR IMAGING OF ORTHOTOPIC
MOUSE BLADDER CANCER MODEL
USING A CD47 ANTIBODY
Dimitar V. Zlatev*, Lei Kang, Mark Hsu, Ying
Pan, Kathleen E. Mach, Jens-Peter Volkmer,
Irving L. Weissman, Joseph C. Liao,
Stanford, CA
10:40
10:50
11:00
11:10
11:20
11:30
ABSTRACT
TIME NUMBER TITLE
11:40 PD25-08 A MODEL TO OPTIMIZE FOLLOW-UP
CARE AND REDUCE HOSPITAL
READMISSIONS AFTER RADICAL
CYSTECTOMY
Naveen Krishnan*, Xiang Liu, Michael Hu, Kedi
Wu, Ann Arbor, MI, Jonathan Helm, Bloomington,
IN, Alex Helfand, Benjamin Li, Alexandra
Zalewski, Chang He, Ann Arbor, MI, Bruce
Jacobs, Pittsburgh, PA, Brent Hollenbeck, Mariel
Lavieri, Ted Skolarus, Ann Arbor, MI
PD25-02 DIAGNOSTIC ACCURACY OF PROBE
BASED CONFOCAL LASER
ENDOMICROSCOPY IN BLADDER
CANCER
Seong Uk Jeh, Hae Do Jung*, Jong Kyou
Kwon, Ho Won Kang, Joo Yong Lee, Kang
Su Cho, Won Sik Ham, Yong Jin Kang,
Young Deuk Choi, seoul, Korea, Republic of
PD25-03 AN ELECTRONIC NOSE SYSTEM
DETECTS BLADDER CANCER IN URINE
SPECIMEN: FIRST RESULTS OF A PILOT
STUDY
Marcus Horstmann*, Daniel Steinbach,
Claudia Fischer, Astrid Enkelmann, MarcOliver Grimm, Andreas Voss, Jena, Germany
PD25-04 VIRTUAL 3D BLADDER
RECONSTRUCTION FROM WHITE LIGHT
CYSTOSCOPY
Kristen L. Lurie*, Dimitar V. Zlatev, Roland
Angst, Stanford, CA, Jiyang Gao, Bejing,
China, People’s Republic of, Sydney Li,
Kathleen E. Mach, Audrey K. Ellerbee,
PD25-05 CLINICAL CORRELATIONBETWEEN
INCIDENTALLY DETECTED BLADDER
WALL THICKENING ON COMPUTED
TOMOGRAPHY SCAN AND CYSTOSCOPY
Sin Woo Lee*, Joon Hyung Park, Sang Eun
Lee, Yong Hyo Choi, Jae Yong Jeong, Sae
Bin Jung, Don Kyoung Choi, Hyun Hwan
Sung, hwang Gyun Jeon, Byong Chang
Jeong, Seong Il Seo, Seong Soo Jeon, HanYong Choi, Hyun Moo Lee, Seoul, Korea,
Republic of
PD25-06 PRE-OPERATIVE INCIDENCE OF DEEP
VENOUS THROMBOSIS IN BLADDER
CANCER PATIENTS PRIOR TO
John Schomburg*, Ayman Soubra, Badrinath
Konety, Minneapolis, MN
PD25-09 CAN WE PREVENT READMISSIONS
FOLLOWING TRANSURETHRAL
RESECTION OF BLADDER TUMOR? A
MULTIVARIATE ANALYSIS OF A LARGE
SINGLE INSTITUTION’S EXPERIENCE
Rachel Moses*, Eric Raffin, Faddy Ghali,
Margaret Menkov, Elias Hyams, Lebanon, NH
12:00
PD25-10 RESIDENT INVOLVEMENT IN
ENDOSCOPIC BLADDER CANCER
SURGERY IS ASSOCIATED WITH
INADEQUATE PATHOLOGY SPECIMENS
AND PROLONGED TIME TO CYSTECTOMY
Derek Bos*, Hamilton, Canada, Christopher
Allard, Boston, MA, Shawn Dason, Vladimir
Ruzhynsky, Anil Kapoor, Bobby Shayegan,
Hamilton, Canada
12:10
PD25-11 TURBT: THE EFFECT OF OPERATIVE
DURATION ON POST-OPERATIVE
COMPLICATIONS IN 10,526 PATIENTS
Richard Matulewicz*, Vidit Sharma, Barry
McGuire, Daniel Oberlin, John Kim, Kent
Perry, Robert Nadler, Chicago, IL
12:20
PD25-12 PREDICTING RISK OF BCG RELATED
SIDE EFFECTS USING URINARY
CYTOKINES COMBINED WITH PREEXISTING URINARY SYMPTOMS
Hajar I. Ayoub*, Ashish M. Kamat, Colin P.
Dinney, H. Barton Grossman, Ferran Prat,
Houston, TX, Joseph Briggman, waltham,
MA, Bryan Fellman, Diana Urbauer,
Roosevelt Anderson, Shanna Pretzsch, O.
Lenaine Westney, Houston, TX
CREDITTM
PD25-07 SIGNIFICANTLY INCREASED LONG-TERM
RISK OF BLADDER CANCER AFTER
SOLID ORGAN TRANSPLANTATION
Kara L Watts*, Ethan B Fram, Mark
Schoenberg, Farhang Rabbani, Bronx, NY
*Presenting author
11:50
149
SUNDAY
BLADDER CANCER: DETECTION AND SCREENING II
Moderators: Edward Messing and Joseph Liao
10:30 am - 12:30 pm
Podium Session 26
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: SURGICAL THERAPY I
Moderators: TBD
ABSTRACT
TIME NUMBER TITLE
10:30 PD26-01 INCREASED PENILE LENGTH AFTER
REPLACEMENT
Paul Chung*, Jordan Siegel, R. Carrington
Mason, Timothy Tausch, Allen Morey, Dallas,
TX
10:40
PD26-02 A REVIEW OF MICROORGANISMS
ISOLATED AT SALVAGE OR EXPLANT OF
IPPS: ARE WE COVERING THE CORRECT
BUGS?
Martin Gross*, Boston, MA, Francois Eid,
New York City, NY, Christopher Yang, Ross
Simon, Daniel Martinez, Rafael Carrion,
Tampa, FL, Paul Perito, Coral Gables, FL,
Nelson Bennett, Burlington, MA, Laurence
Levine, Chicago, IL, Jason Greenfield,
Arlington, TX, Ricardo Munarriz, Boston, MA
10:50
PD26-03 BEYOND THE PUMP: USE OF MAGNETIC
INDUCTION TO ACTIVATE A PENILE
PROSTHESIS
Alberto Colombo, Springfield, IL, Brian Le*,
Madison, WI, Kevin McVary, Springfield, IL
11:00
PD26-04 IMPROVED INFECTION OUTCOMES
AFTER MULCAHY SALVAGE PROCEDURE
AND REPLACEMENT OF INFECTED IPP
WITH MALLEABLE PROSTHESIS
Martin Gross*, Boston, MA, Francois Eid,
New York City, NY, Christopher Yang, Ross
Simon, Daniel Martinez, Rafael Carrion,
Tampa, FL, Paul Perito, Coral Gables, FL,
Laurence Levine, Chicago, IL, Jason
Greenfield, Arlington, TX, Ricardo Munarriz,
Boston, MA
11:10
PD26-05 THE DECLINE OF INPATIENT PENILE
PROSTHESIS: ANALYSIS OF THE TRENDS
AND COMPLICATIONS OF INPATIENT
PENILE PROSTHESIS IMPLANTATION
USING NATIONAL INPATIENT SAMPLE
FROM 2000-2010
Amjad Alwaal*, Catherine Harris, Ahmed
Hussein, Thomas Sanford, Charles
McCulloch, Jack McAninch, Benjamin Breyer,
San Francisco, CA
11:20
ABSTRACT
TIME NUMBER TITLE
11:30 PD26-07 RACIAL AND AGE DIFFERENCES IN
IMPLANTATION OF INFLATABLE PENILE
PROSTHESIS FOR ERECTILE
DYSFUNCTION (ED) IN THE PROSTATE
CANCER SURVIVOR
Divya Ajay*, Durham, NC, Shubham Gupta,
Lexington, KY, John Selph, Michael Belsante,
Ngoc-Bich Le, Andrew Peterson, Durham, NC
PD26-06 IMPLANT LENGTH – BASELINE
CHARACTERISTIC CORRELATIONS
Nelson Bennett*, Burlington, MA, Anthony
Bella, Ottawa, Canada, Gerard Henry,
Shreveport, LA, Edward Karpman, Mountain
View, CA, Will Brant, Salt Lake City, UT,
LeRoy Jones, San Antonio, TX, Bryan
Kansas, Austin, TX, Tobias Kohler,
Springfield, IL, Mohit Khera, Houston, TX
11:40
PD26-08 SCROTOPLASTY AT TIME OF PENILE
IMPLANT IS AT HIGH RISK FOR
DEHISCENCE IN DIABETICS
Randy Sulaver, II*, Springfield, IL, Robert
Welliver, Albany, NY, Michael Kottwitz, Luke
Frederick, Brittney Hanerhoff, Danuta Dynda,
Tobias Kohler, Springfield, IL
11:50
PD26-09 FACTORS INVOLVED IN THE REMOVAL
OR REPLACEMENT OF PENILE
PROSTHESES
Bobby Najari*, Daniel Lee, Wesley Davison,
Bashir Al Hussein Al Awamlh, Fujun Zhao,
John Mulhall, Darius Paduch, Bilal Chughtai,
Richard Lee, New York, NY
12:00
PD26-10 OUTCOMES OF IPP PLACEMENT BY
SURGICAL APPROACH, PENOSCROTAL
VS INFRAPUBIC, RESULTS FROM A
PROSPECTIVE MULTICENTER STUDY
Edward Karpman*, Mountain View, CA,
Anthony Bella, Ottawa, Canada, William
Brant, Salt Lake City, UT, Brian Christine,
Homewood, AL, Bryan Kansas, Austin, TX,
LeRoy Jones, Sa Antonio, TX, Tobias Kohler,
Springfield, IL, Nelson Bennett, Burlington,
MA, Mohit Khera, Houston, TX, Gerard
Henry, Shreveport, LA
12:10
PD26-11 DEFINING THE UTILITY OF SALVAGE
SURGERY FOR INFECTED PENILE
IMPLANTS
Raanan Tal*, Kazuhito Matsushita, Nelson
Bennett, John P. Mulhall, New York, NY
12:20
PD26-12 PENILE PROSTHESIS INSERTION AFTER
RADIAL FOREARM FREE FLAP
NEOPHALLUS
Joseph J. Pariser*, Rena D. Malik, Lawrence
J. Gottlieb, Gregory T. Bales, Chicago, IL
CREDITTM
150
10:30 am - 12:30 pm
Podium Session 27
ABSTRACT
TIME NUMBER TITLE
10:30 PD27-01 ADVANCING CARE FOR OVERACTIVE
BLADDER: A TAILORED LEARNING
APPROACH TO IMPROVE CLINICAL
DECISION-MAKING
Simi Hurst*, New York, NY, Justin Barnes,
Evan Rhodes, Birmingham, AL
10:40
PD27-02 DOES PATIENT AGE AFFECT THE
OUTCOMES AND PATIENT REPORTED
HEALTH RELATED QUALITY OF LIFE
(HRQOL) AFTER SACRAL
NEUROMODULATION?
Tyler Lu, Jaspreet Singh Parihar*, Bianca
Chendrimada, Hari SGR Tunuguntla, New
Brunswick, NJ
10:50
PD27-03 COMPARATIVE EFFECTIVENESS OF
THREE DIFFERENT TEACHING METHODS
IN BEHAVIORAL THERAPY PROGRAM
FOR FEMALE OVERACTIVE BLADDER: A
Elif Gezginci, Emine Iyigun, Sercan Yilmaz*,
Emin Aydur, Ankara, Turkey
11:00
PD27-04 OUTCOMES OF BILATERAL LEAD
PLACEMENT FOR STAGE I OF SACRAL
NEUROMODULATION TRIAL
Adrienne Quirouet*, Ashley King, Howard
Goldman, Raymond Rackley, Courtenay
Moore, Sandip Vasavada, Cleveland, OH
11:10
PD27-05 THE USE OF ONABOTULINUMTOXINA
FOR TREATMENT OF OVERACTIVE
BLADDER IN OLDER PATIENTS
Anne Sammarco*, Elizabeth Ferry, Dhruti
Patel, Penny Benchek, Elias Kikano, Adonis
Hijaz, Sangeeta Mahajan, Cleveland, OH
11:20
ABSTRACT
TIME NUMBER TITLE
11:30 PD27-07 EVALUATION OF QUALITY OF LIFE
IMPROVEMENTS AT 36 MONTHS IN
SUBJECTS WITH OVERACTIVE BLADDER
TREATED WITH SACRAL
NEUROMODULATION USING THE
INTERSTIM® SYSTEM
Steven Siegel*, Woodbury, MN, Jason
Bennett, Grand Rapids, MI, Jeffrey Mangel,
Cleveland, OH, Craig Comiter, Stanford, CA,
Samuel Zylstra, Whitinsville, MA, Erin Bird,
Temple, TX, Tomas L. Griebling, Kansas
City, KS, Suzette E. Sutherland, Seattle, WA,
Daniel Culkin, Oklahoma City, OK, Karen
Noblett, Riverside, CA, Fangyu Kan, Lindsey
Guanella, Minneapolis, MN
PD27-06 REAL-WORLD PATTERNS OF
OVERACTIVE BLADDER (OAB) CARE IN
THE UNITED STATES (US) BASED ON AN
OBSERVATIONAL STUDY
Howard Goldman*, Cleveland, OH, Jennifer
Anger, Beverly Hills, CA, Canan Esinduy,
Kelly Zou, David Russell, Xuemei Luo, Fady
Ntanios, Martin Carlsson, New York, NY, J.
Quentin Clemens, Ann Arbor, MI
11:40
PD27-08 REAL WORLD RETENTION RATES AFTER
INTRAVESICAL ONABOTULINUMTOXINA
FOR IDIOPATHIC OVERACTIVE BLADDER
Olufenwa Milhouse*, Marta Johnson, Leah
Gross, Steven Siegel, Woodbury, MN
11:50
PD27-09 DOES THE USE OF A DEDICATED
OPERATING SPACE AND SURGICAL
TEAM REDUCE INFECTION RATES FOR
FIRST STAGE SACRAL
NEUROMODULATION?
Julie Jenks*, Eskinder Solomon, Bashir
Mukhtar, Mahreen Pakzad, Rizwan Hamid,
Tamsin Greenwell, Jeremy Ockrim, London,
United Kingdom
12:00
PD27-10 IMPACT OF NUMBER OF ACTIVE
ELECTRODES AT TIME OF SACRAL TINED
LEAD PLACEMENT ON VOLTAGE
THRESHOLDS AND CLINICAL OUTCOMES
Jason Gilleran*, Kim Killinger, Judith Boura,
Michael Ehlert, Priyanka Gupta, Cheryl
Wolfert, Jamie Bartley, Kenneth Peters, Royal
Oak, MI
12:10
PD27-11 THERAPEUTIC EFFECTS OF A SELECTIVE
ANDROGEN RECEPTOR MODULATOR,
GSK2849466A ON STRESS URINARY
INCONTINENCE IN OVARIECTOMIZED
RATS
Katsumi Kadekawa*, Pittsburgh, PA, Naoki
Kawamorita, Sendai, Japan, Philip Turnbull, Alan
Russell, Sundeep Chandra, Joanna Barton,
Durham, NC, Naoki Yoshimura, Pittsburgh, PA
12:20
PD27-12 MIRABEGRON DOES NOT DECREASE
URINARY NEUROTROPHINS’ LEVELS IN
OVERACTIVE BLADDER PATIENTS
DESPITE SYMPTOMATIC IMPROVEMENT
Tiago Antunes-Lopes*, Ana Ferreira,
Carvalho-Barros Sérgio, Daniel Costa, Rui
Pinto, João Silva, Silva Carlos, Francisco
Cruz, Porto, Portugal
CREDITTM
*Presenting author
151
SUNDAY
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: FEMALE INCONTINENCE - THERAPY I
Moderators: TBD
10:30 am - 12:30 pm
Video Session 6
UROLITHIASIS
Moderators: Altan Ilkay and Roger Low
ABSTRACT
NUMBER TITLE
V6-01
ROBOT ASSISTED FLEXIBLE
URETEROSCOPIC LASER LITHOTRIPSY,
WITH AVICENNA ROBOFLEX
Jens Rassweiler*, Heillbronn, Germany,
Remzi Saglam, ANKARA, Turkey, Olivier
Traxer, Paris, France, A. Sinan Kabakci,
Zafer Tokatli, Abdurrahim Imamoglu, Ankara,
Turkey, Glenn Preminger, Durham, NC
V6-02
ROBOTIC PYELOLITHOTOMY IN ECTOPIC
PELVIC KIDNEY: SIDE DOCKING IN SUPINE
POSITION AND A FOUR-ARM APPROACH
Ahmad Al-Marzouq*, Rawan Al-Yousef, Saad
Aldousari, Kuwait City, Kuwait
V6-03
LAPAROSCOPIC ROBOT-ASSISTED
PYELOLITHOTOMY IN AN ECTOPIC RIGHT
PELVIC KIDNEY
Dorit Zilberman*, Nir Kleinmann, Assaf Barel,
Harry Winkler, Jacob Ramon, Ramat-Gan, Israel
V6-04
THE SIMPORTAL FLUORO-LESS C-ARM
TRAINER (CAT): AN INNOVATIVE
TRAINING DEVICE FOR PERCUTANEOUS
KIDNEY ACCESS
Domenico Veneziano*, Minneapolis, MN,
Arthur Smith, New York, NY, Troy Reihsen,
David Hananel, Jack Stubbs, Jason Speich,
Robert Sweet, Minneapolis, MN
V6-05
ABSTRACT
NUMBER TITLE
V6-08
LARGE UPPER-CALYX STONE: CAN
SUPRA-TWELFTH PCNL APPROACH BE
AVOIDED?
Jose Agudelo*, Euro Arias, Nasser Ktech,
Jhonan Chirinos, Manuel Riveros, Luis
Sanchez, Eduardo Pena, Ricardo Montiel,
Maracaibo, Venezuela
CAPSULE TO CALCULUS OPTICAL
DISSECTION FOR TRACT CREATION
DURING DIFFICULT PERCUATANEOUS
NEPHROLITHOTOMY (PCNL)
Haresh Thummar*, new york, NY, Usama
Khater, ne york, NY, Kasmira Gupta,
Larchmont, NY, Mantu Gupta, New York, NY
V6-06
FLUOROSCOPIC ROADMAPPING FOR
ENDOUROLOGY
Jared Wachterman*, Kevan Sternberg,
Burlington, VT
V6-07
RETROGRADE PERCUTANEOUS
NEPHROSTOMY¡aESTABLISHMENT OF
PERCUTANEOUS RENAL CHANNEL
HOLMIUM LASER WIRE PUNCTURE FROM
RENAL CALYX TO THE SKIN UNDER
VISUALIZED OF FLEXIBLE URETEROSCOPE
(A REPORT OF 12 CASES AND TYPICAL
MEDICAL SURGERY VIDEO)
Zhao-kui Qu*, Yancheng, China, People’s
Republic of, Ming Chen, Nanjing, China, People’s
Republic of, Xiao-jun Jin, Jing Zhou, Yu-mei Pan,
Quan Wang, Shao-bo Xu, Jian-bo Ji, Feng
Wang, Bo Jiang, Hai-yan Chen, Xiang-liang Yin,
Yancheng, China, People’s Republic of
V6-09
TECHNIQUE FOR ENDOSCOPIC REMOVAL
OF CALCIFIED PERMANENT SUTURE
AFTER PYELOPLASTY
Sean McAdams*, Robert Sweet, Kyle
Anderson, Minneapolis, MN
V6-10
ULTRASOUND-GUIDED PERCUTANEOUS
NEPHROLITHOTOMY FOR STAGHORN
STONE IN CROSSED-FUSED ECTOPIC
PELVIC KIDNEY
Haresh Thummar*, Usama Khater, New York,
NY, v Joshi, rajkot, India, Mantu Gupta, New
York, NY
V6-11
THE CIRCLE NEPHROSTOMY TUBE: AN
ATTRACTIVE NEPHROSTOMY DRAINAGE
SYSTEM FOLLOWING COMPLEX
Marawan El Tayeb*, Michael S. Borofsky,
James E. Lingeman, Indianapolis, IN
V6-12
THE NEW STONE AGE: URETEROSCOPIC
STONE “DUSTING” WITH A 120-WATT
HOLMIUM LASER
Duncan R. Morhardt*, James Tracey, J.
Stuart Wolf, Jr., Khurshid R. Ghani, Ann
Arbor, MI
V6-13
MICROURETEROSCOPY:
MINIATURIZATION FOR THE TREATMENT
OF URETERAL STONES
Juan-Pablo Caballero-Romeu*, Juan-Antonio
Galán-Llopis, Alejandro Garcia-Segui,
Aleixandre Verges, Araceli Amorós-Torres,
Elche, Spain
V6-14
STRIPPERS, SCISSORS AND LASER
FIBER TIPS
CREDITTM
152
12:00 pm - 5:00 pm
SOCIETY FOR THE STUDY OF MALE REPRODUCTION (SSMR)
REPROS SPONSORED LUNCH SYMPOSIUM:
CLOMIPHENE - A NEW TWIST (NON-CME)
1:50
TESTICULAR VS. EJACULATED, FRESH VS.
FROZEN: SPERM AND MALE FACTORS THAT
IMPACT IVF SUCCESS
Peter Schlegel
2:10
Q&A
2:20
IVF: RISKS TO THE MOTHER
Sissy Sartor
2:40
IVF: RISKS TO OFFSPRING
James Smith
3:00
Q&A
3:10
BREAK
3:25
MALE REJUVENATION: WHAT IS IT AND WHO
MAY BENEFIT
Thomas Walsh
3:45
DANGERS OF MALE REJUVENATION: IT’S
NOT A FOUNTAIN OF YOUTH
Robert Oates
4:05
Q&A
4:20
CHALLENGING CASES
Sheldon Marks, Edmund Sabanegh, Eric Seaman
5:00
ADJOURN
INTRODUCTION
Society President: Edward Kim
12:05
CLOMIPHENE: BACKGROUND AND USE IN
INFERTILE MEN
Wayne Hellstrom
12:20
ENCLOMIPHENE: EFFECT ON HORMONAL
PROFILES AND METABOLIC PARAMETERS
Andrew McCullough
12:40
ENCLOMIPHENE: SAFETY AND SPERM
STUDIES
Edward Kim
12:55
Q&A
(CME PORTION OF PROGRAM BEGINS)
1:00
INTRODUCTION: ACHIEVING, MAINTAINING
AND USING HEALTHY SPERM: ALPHA TO
OMEGA
Michael Eisenberg
1:10
WHAT’S MALE GOT TO DO WITH IT: MALE
CONTRIBUTION TO EMBRYO DEVELOPMENT
Douglas Carrell
1:30
RECURRENT PREGNANCY LOSS: MALE
CONTRIBUTIONS TO A COUPLE’S PROBLEM
Kathleen Hwang
SUNDAY
12:00
CREDITTM
12:45 pm - 5:00 pm
SOCIETY OF UROLOGIC ROBOTIC SURGERY (SURS)
Napoleon Ballroom @ Hilton New Orleans Riverside
12:45
WELCOME AND INTRODUCTION OF
PROGRAM
Society Chair: James Porter
2:10
POSTERIOR APPROACH FOR ROBOTIC
PROSTATECTOMY
Vito Pansadoro
1:00
SESSION I: ROBOTIC TRAINING AND
PROGRAM DEVELOPMENT
SURGICAL SKILLS ASSESSMENT: USING THE
WISDOM OF CROWDS
Thomas Lendvay
2:25
ROBOTIC VS. LAPAROSCOPIC
PROSTATECTOMY DEBATE
1:15
SUCCESSFUL DEVELOPMENT OF HIGH
QUALITY ROBOTIC PROGRAMS: PLANNING,
TRAINING, CREDENTIALING STANDARDS AT
KAISER PERMANENTE
1:30
QUALITY OUTCOMES IN ROBOTIC SURGERY
Jay Bishoff
1:45
1:55
LAPAROSCOPIC PROSTATECTOMYOUTCOMES AND ADVANTAGES
Douglas Dahl
2:35
ROBOTIC PROSTATECTOMY
Thomas Ahlering
2:45
REBUTTAL-LAPAROSCOPIC
PROSTATECTOMY
Douglas Dahl
2:50
REBUTTAL-ROBOTIC PROSTATECTOMY
Thomas Ahlering
SESSION II: ROBOTIC SURGERY-PROSTATE
CANCER
2:55
3:05
SESSION III: ROBOTIC SURGERY-KIDNEY
CANCER
INTRAOPERATIVE EVALUATION OF
SURGICAL MARGINS DURING ROBOTIC
PROSTATECTOMY
Nicolo Buffi
*Presenting author
153
ROBOTIC CYSTECTOMY AND DIVERSION
Monish Aron
OBJECTIFYING DECISION-MAKING IN THE
PATIENT WITH RENAL MASS
Alexander Kutikov
3:20
CONTEMPORARY OPEN PARTIAL
NEPHRECTOMY
Paul Russo
3:35
Michael Stifelman
3:50
4:00
SESSION IV: ROBOTIC SURGERY-BLADDER
AND TESTIS CANCER
4:15
WHY USE A ROBOT FOR LAPAROSCOPIC
NEPHRECTOMY?
Ronney Abaza
4:30
SURS BUSINESS MEETING
5:00
ADJOURN
CREDITTM
1:00 pm - 3:00 pm
AUA/AACU HEALTH POLICY FORUM
1:00
AUA HEALTH POLICY LECTURE: FUTURE OF
PAYMENT POLICY
Barbara Levy
2:00
AACU HOFFMAN LECTURE
2:45
Q&A
1:00 pm - 3:00 pm
PROSTATE CANCER: DETECTION AND SCREENING I
Moderator: Kevin Loughlin
ABSTRACT
NUMBER TITLE
MP48-01 PREVALENCE OF ANTIBIOTIC
RESISTANCE IN FECAL FLORA BEFORE
TRANSRECTAL ULTRASOUND-GUIDED
PROSTATE BIOPSY AND CLINICAL
IMPACT OF TARGETED ANTIBIOTIC
PROPHYLAXIS
Turhan Caskurlu, Ozgur Arikan, Asif Yildirim*,
Berrin Tanidir, Cengiz Canakci, Yavuz Onur
Danacioglu, Ramazan Gokhan Atis, Cenk
Gurbuz, Bulent Erol, Haluk Vahaboglu,
Istanbul, Turkey
ABSTRACT
NUMBER TITLE
MP48-04 HOW RELIABLE IS A NEGATIVE MRI/TRUS
FUSION BIOPSY? THE NEGATIVE
PREDICTIVE VALUE OF TARGETED
BIOPSY FOR PROSTATE CANCER
Rachael Sussman*, Washington, DC, Michele
Fascelli, Thomas Frye, Arvin George, Steven
Abboud, Raju Chelluri, Richard Ho, Anna
Brown, Sandeep Sankineni, Maria Merino,
Ismail Turkbey, Peter Choyke, Bradford
Wood, Peter Pinto, Bethesda, MD
MP48-05 ASSESSMENT OF TUMOUR
AGGRESSIVENESS IN TRANPERINEAL
MRI/ULTRASOUND-FUSION BIOPSY IN
COMPARISON TO TRANSRECTAL
SYSTEMATIC PROSTATE BIOPSY
Angelika Borkowetz*, Stefan Zastrow, Ivan
Platzek, Marieta Toma, Michael Froehner,
Rainer Koch, Manfred Wirth, Dresden,
Germany
MP48-02 FLUORESCENCE SPECTROSCOPY CAN
INCREASE DIAGNOSTIC YIELD OF
PROSTATE BIOPSIES
E. David Crawford*, Edward A. Jasion,
Yongjun Liu, Aurora, CO, John Daily,
Boulder, CO, Paul Arangua, Clifford Jones,
Aurora, CO, S. Russell Nash, Centennial,
CO, Priya Werahera, Aurora, CO
MP48-06 COMPARATIVE ASSESSMENT OF
GLEASON SCORING OF PROSTATE
BIOPSIES OBTAINED BY STANDARD
TRUS AND MRI-TRUS AT FOLLOW UP IN
ACTIVE SURVEILLANCE PATIENTS
Max Jackson, Peter Haddock, Ilene Staff,
Ryan Dorin, Stuart Kesler, Michael
O’Loughlin, Anoop Meraney, Joseph
Wagner*, Hartford, CT
MP48-03 CONTRAST ENHANCED ULTRASOUND
WITH PARAMETRIC MAPS FOR THE
DETECTION OF PROSTATE CANCER
Arnoud Postema*, Amsterdam, Netherlands,
Peter Frinking, Plan-les-Ouates, Switzerland,
Martijn Smeenge, Theo De Reijke, Jean De
la Rosette, Amsterdam, Netherlands,
Francois Tranquart, Plan-les-Ouates,
Switzerland, Hessel Wijkstra, Amsterdam,
Netherlands
154
MP48-08 EARLY OUTCOMES OF COMBINATION
MRI-TARGETED AND SATURATION
TRANS-PERINEAL BIOPSY IN RESTAGING
LOW-RISK PROSTATE CANCER FOR
ACTIVE SURVEILLANCE
Kae Jack Tay*, Kenneth Chen, Yan Mee
Law, Henry Ho, John Yuen, Christopher
Cheng, Singapore, Singapore
MP48-15 EVALUATING THE CLINICAL UTILITY OF
TRANSPERINEAL TEMPLATE PROSTATE
MAPPING BIOPSY
Yaalini Shanmugabavan*, Alex Freeman,
Charles Jameson, Massimo Valerio, Mark
Emberton, Hashim Uddin Ahmed, London,
United Kingdom
MP48-16 CLINICAL UTILITY OF TRANSPERINEAL
TEMPLATE GUIDED MAPPING BIOPSY OF
PROSTATE AFTER NEGATIVE MAGNETIC
RESONANCE IMAGING GUIDED
TRANSRECTAL BIOPSY
Arjun Sivaraman*, Rafael Sanchez Salas,
Eric Barret, Marc Galiano, Francois Rozet,
Dominique Prapotnich, Nathalia Cathala,
Annick Mombet, Facundo Uriburu Pizarro,
Arie Carneiro, Steeve Doizi, Xavier
Cathelineau, Paris, France
MP48-09 RESULTS OF TRANSPERINEAL MAPPING
BIOPSY OF THE PROSTATE
Vasileios Skouteris*, Marios Metsinis,
Athanassios Dounis, Thomas Georgiadis,
Ioulia Evangelou, Dimitrios Papaioannou,
Savvas Papadopoulos, Michael Skouteris,
Spyros Yarmenitis, Georgios Zacharopoulos,
Athens, Greece, Nelson Stone, New York,
NY
MP48-10 INCLUSION OF THE “EXTREME”
ANTERIOR APICAL NEEDLE BIOPSIES IN
THE STANDARD 12 CORE BIOPSY
TEMPLATE AT THE INITIAL DETECTION
OF PROSTATE CANCER
Ayman S. Moussa*, Giza, Egypt, Ahmed ElShafei, Cairo, Egypt, Ahmad Aref AlDessoukey, Ahmed Abdel-bary, Amr Masoud,
Giza, Egypt, Amr Abd El-Hakium, Cairo,
Egypt
MP48-17 ANTERIOR PROSTATE CANCER:
CLINICOPATHOLOGIC
CHARACTERIZATION WITH BIOPSY
CORRELATION
Martin Magers*, Tianyu Zhan, Aaron Udager,
Brent Hollenbeck, John Wei, David Miller,
Jeffrey Montgomery, Javed Siddiqui, Felix
Feng, Daniel Hamstra, Alon Weizer, Todd
Morgan, Arul Chinnaiyan, Ganesh Palapattu,
Hui Jiang, Rohit Mehra, Ann Arbor, MI
MP48-11 PROSPECTIVE RANDOMIZED
CONTROLLED STUDY TO ASSESS THE
EFFECT OF PERINEAL REGION
CLEANSING WITH POVIDONE IODINE
BEFORE TRANSRECTAL NEEDLE BIOPSY
OF THE PROSTATE ON INFECTIOUS
COMPLICATIONS
Younis Taher*, haluk ozen, bulent akdogan,
serhat unal, serkan dogan, Ankara, Turkey
MP48-18 DIAGNOSTIC PERFORMANCE OF
MULTIPARAMETRIC MRI IN PROSTATE
CANCER: PER CORE ANALYSIS OF TWO
PROSPECTIVE ULTRASOUND/MRI
FUSION BIOPSY DATASETS
Giuseppe Simone*, Rome, Italy, Alessandro
Giacobbe, Devis Collura, Turin, Italy, Rocco
Papalia, Salvatore Guaglianone, Gian Luca Muto,
Michele Gallucci, Rome, Italy, Giovanni Muto,
Turin, Italy, Mariaconsiglia Ferriero, Rome, Italy
MP48-12 MULTIPARAMETRIC MRI INCREASES THE
EFFICIENCY OF THE STANDARD 12-CORE
TRUS-GUIDED REPEATED BIOPSIES
Lucas Regis*, Pol Servian, Ana Celma,
Ricardo Lopez, S Roche, Jacques Planas,
Jose Placer, Ines DeTorres, Juan Morote,
Barcelona, Spain
MP48-19 COGNITIVE MRI-ECHO FUSION BIOPSY OF
THE PROSTATE IS A VALUABLE FIRST STEP
IN DIAGNOSING PROSTATE CANCER
Paul Westerveld, Jessica Vriesema, Huib van
den Hout, Jeroen Veltman, Erik Cornel*,
Hengelo, Netherlands
MP48-13 IDENTIFICATION OF PATHOLOGICALLY
FAVORABLE DISEASE IN INTERMEDIATE
RISK PROSTATE CANCER PATIENTS:
IMPLICATIONS FOR SELECTION OF
ACTIVE SURVEILLANCE CANDIDATES
Giorgio Gandaglia*, Nazareno Suardi, Marco
Bianchi, Nicola Fossati, Federico Dehò,
Giuseppe Zanni, Milan, Italy, Firas Abdollah,
Detroit, MI, Umberto Capitanio, Emanuele
Zaffuto, Milan, Italy, Shahrokh F. Shariat,
Vienna, Austria, Pierre Karakiewicz, Montreal,
Canada, Francesco Montorsi, Alberto
*Presenting author
MP48-20 WEIGHTED GLEASON SCORES DO NOT
OUTPERFORM STANDARD CLINICAL
GLEASON SCORES IN PREDICTING
PATHOLOGIC GLEASON SCORE, MARGIN
STATUS AND RECURRENCE IN PATIENTS
WITH DISCORDANT PROSTATE BIOPSIES
Max Jackson, Peter Haddock, Antonio
Cusano, Ilene Staff, Joseph Wagner*,
Hartford, CT
CREDITTM
155
SUNDAY
MP48-14 TRANSRECTRAL ULTRASOUND GUIDED
BIOPSY VERSUS TRANSPERINEAL
TEMPLATE PROSTATE BIOPSIES IN
DIAGNOSIS OF PROSTATE CANCER IN MEN
WITH PREVIOUS NEGATIVE
TRANSRECTRAL ULTRASOUND GUIDED
BIOPSY
Shady Nafie*, John Dormer, Masood Khan,
Leicester, United Kingdom
MP48-07 RACIAL VARIATION IN POSITIVE
PROSTATE NEEDLE BIOPSIES WITH
TEMPLATES THAT INCLUDE THE
TRANSITION ZONE
Justin Levy*, Allison H. Feibus, Krishnarao
Moparty, Ian McCaslin, Michael M. Maddox,
Oliver Sartor, Jonathan L. Silberstein, New
Orleans, LA
1:00 pm - 3:00 pm
BLADDER CANCER: BASIC RESEARCH III
Moderators: Jeffrey Gingrich and Leonardo Reis
ABSTRACT
NUMBER TITLE
MP49-01 FOXA1 LOSS IS ASSOCIATED WITH POOR
PROGNOSIS AND SEX-DEPENDENT
PHENOTYPES FOLLOWING GENETIC
INACTIVATION
Opal Lin-Tsai Reddy, Justin Cates, Lan
Gellert, Nashville, TN, Hironobu Yamashita*,
Hershey, PA, John Taylor III, Farmington, CT,
Joseph Smith Jr., Sam Chang, Nashville, TN,
Michael Cookson, Oklahoma City, OK, Daniel
Barocas, Magdalena Grabowska, Magdalena
Grabowska, Fei Ye, Nashville, TN, Xue-Ru
Wu, New York, NY, Yajun Yi, Robert Matusik,
Nashville, TN, Klaus Kaestner, Philadelphia,
PA, Peter Clark, Nashville, TN, David
DeGraff, Hershey, PA
ABSTRACT
NUMBER TITLE
MP49-07 CANONICAL WNT PATHWAY TUMOR
PROGRESSION IS MEDIATED BY THE
LONG NON-CODING RNA HOTAIR IN
BLADDER CANCER
Claudia Berrondo*, Jonathan Flax, Edward
Messing, Carla Beckham, Rochester, NY
MP49-08 UROTHELIAL CELLS UNDERGO
EPITHELIAL TO MESENCHYMAL
TRANSITION AFTER EXPOSURE TO
EXOSOMES
Carrie Franzen*, Kristin Greco, Robert
Blackwell, Kimberly Foreman, Gopal Gupta,
Maywood, IL
MP49-09 ACTIVATION OF IFN/STAT1 SIGNALING IN
CISPLATIN/GEMCITABINE RESISTANT
BLADDER CANCER
Tetsutaro Hayashi*, Roland Seiler, Robert H
Bell, Susan Ettinger, Kendric Wang, Shannon
Awrey, Kilian Gust, Wolfgang Jäger, Tilman
Todenhoefer, Manuel Altamirano-Dimas,
Vancouver, Canada, Akio Matsubara,
Hiroshima, Japan, Colin Collins, Peter Black,
Vancouver, Canada
MP49-02 RELATIONSHIPS BETWEEN C-FES
EXPRESSION AND MALIGNANT
AGGRESSIVENESS IN BLADDER CANCER
IN VIVO AND IN VITRO
Akihiro Asai*, Yasuyoshi Miyata, Kensuke
Mitsunari, Tomohiro Matsuo, Kojiro Ohba,
Hideki Sakai, Nagasaki, Japan
MP49-03 RELATIONSHIP BETWEEN INCREASED
EXPRESSION OF AXL-GAS6 SIGNAL
CASCADE AND PROGNOSIS IN UPPER
CARCINOMA
Seiya Hattori*, Eiji Kikuchi, Takeo Kosaka,
Akira Miyajima, Shuji Mikami, Mototsugu Oya,
Tokyo, Japan
MP49-10 KNOCKDOWN OF GLYCOPROTEIN-130
INHIBITS BLADDER CANCER
PROGRESSION AND MIGRATION
Darryl T. Martin*, New Haven, CT, Jill M.
Steinbach, Louisville, KY, Marcia A. Wheeler,
Cayce B. Nawaf, W. Mark Saltzman, Robert
M. Weiss, New Haven, CT
MP49-04 CRITICAL ROLES OF A NUCLEOLAR
PROTEIN DDX31 IN BLADDER
CARCINOGENESIS DEPENDING ON P53
MUTATION STATUS
Kei Daizumoto*, Tomoya Fukawa, Hisanori
Uehara, Toyomasa Katagiri, Hiro-omi
Kanayama, Tokushima, Japan
MP49-11 TREHALOSE 6,6 DIMYCOLATE
CYTOTOXICITY IN BOTH BCG SENSITIVE
AND BCG RESISTANT CELL LINES
OCCURS VIA A “BCG DISTINCT”
PATHWAY
Gopitkumar Shah*, Justin Benabdallah,
Fanghong Chen, Guangjian Zhang,
Balaraman Kalyanaraman, William See,
Milwaukee, WI
MP49-05 A NOVEL LONG NONCODING RNA
CONTRIBUTES TO THE MAINTENANCE
OF SELF-RENEWAL IN BLADDER CANCER
STEM-LIKE CELLS
Tianxin Lin*, Guangzheng Zhong, Yang
Peng, Guangzhou, China, People’s Republic
of
MP49-12 EFFECT OF BCG EXPOSURE ON
ENZYMATIC REGULATORS OF CELLULAR
OXIDATIVE STRESS IN UROTHELIAL
CARCINOMA CELLS
Gopitkumar Shah*, Fanghong Chen,
Guangjian Zhang, Balaraman Kalyanaraman,
William See, Milwaukee, WI
MP49-06 STAT3 ACTIVATION STATUS
CONTRIBUTES TO THE DIFFERENTIAL
RESPONSES OF METASTATIC AND NOMETASTATIC HUMAN BLADDER CANCER
CELLS TO MIR-145 INHIBITION OF
ANCHORAGE-INDEPENDENT GROWTH
THROUGH REGULATION OF FOXO1
EXPRESSION
guosong jiang*, Jingxia Li, Moon-Shong
Tang, Tuxedo, NY, Xue-Ru Wu, New York,
NY, Chuanshu Huang, Tuxedo, NY
156
MP49-18 IDENTIFICATION OF EXTRACELLULAR
VESICLE PERIOSTIN AS A URINARY
BIOMARKER OF MUSCLE INVASIVE
BLADDER CANCER
Christopher Silvers, Rochester, NY, Miyamoto
Hiroshi, Baltimore, MD, Chia-Hao Wu,
Edward Messing, Yi-Fen Lee*, Rochester, NY
MP49-14 SYSTEMIC TRANSDUCTION OF P16INK4A
ANTITUMOR PEPTIDE INHIBITS LUNG
METASTASIS OF MBT-2 BLADDER TUMOR
CELL LINE IN MICE
Toru Shimazui*, Kasama, Japan, Kazuhiro
Yoshikawa, Nagakute, Japan, Jun Miyazaki,
Kazuhiko Uchida, Tsukuba, Japan, Atsushi
Yamauchi, Mikinobu Ohtani, Kasama, Japan,
Hiroyuki Nishiyama, Tsukuba, Japan
MP49-19 EMP2 AS A NOVEL TARGET OF BLADDER
CANCER IMMUNOTHERAPY
wujiang liu*, jie jin, liqun Zhou, Yinglu Guo,
beijing, China, People’s Republic of
MP49-20 SYNERGISTIC EFFECT OF TARGETED
COMBINATION THERAPY IN BLADDER
CANCER MODEL USING HSP90
INHIBITORS
Raju Chelluri*, Piyush K. Agarwal, Leonard
M. Neckers, Armine K. Smith, Bethesda, MD
MP49-15 LOSS OF ZKSCAN3 IN BLADDER CANCER
PROMOTES CELL PROLIFERATION,
MIGRATION, AND INVASION
Takashi Kawahara, Eiji Kashiwagi*,
Baltimore, MD, Yi Li, Rochester, NY, Yichun
Zheng, George Netto, Hitoshi Ishiguro,
Hiroshi Miyamoto, Baltimore, MD
CREDITTM
MP49-16 ENZALUTAMIDE INHIBITS ANDROGEN
RECEPTOR-POSITIVE BLADDER CANCER
CELL GROWTH
Takashi Kawahara, Hiroki Ide*, Eiji
Kashiwagi, Leonardo Reis, Yichun Zheng,
Hiroshi Miyamoto, Baltimore, MD
1:00 pm - 3:00 pm
KIDNEY CANCER: EVALUATION AND STAGING III
Moderators: Pilar Laguna Pes and Michael Blute, Sr.
ABSTRACT
NUMBER TITLE
MP50-01 RESULTS FROM A MULTIINSTITUTIONAL, PROSPECTIVE CLINICAL
TRIAL OF DELAYED INTERVENTION AND
SURVEILLANCE FOR SMALL RENAL
MASSES: THE DISSRM REGISTRY
Phillip Pierorazio*, Michael Johnson, Mark
Ball, Michael Gorin, Baltimore, MD, Peter
Chang, Andrew Wagner, Boston, MA, James
McKiernan, New York, NY, Bruce Trock,
Mohamad Allaf, Baltimore, MD
ABSTRACT
NUMBER TITLE
MP50-03 HYBRID KIDNEY TUMOR PATHOLOGY IS
ASSOCIATED WITH INCREASING TUMOR
STAGE AND GRADE
Neil J. Kocher*, Chris Rjepaj, Erik Lehman,
Jay D. Raman, Hershey, PA
MP50-04 HYPERTENSION IS THE PRIMARY
COMPONENT OF METABOLIC SYNDROME
ASSOCIATED WITH RENAL TUMOR
PATHOLOGY
Neil J. Kocher*, Chris Rjepaj, Erik Lehman,
Jay D. Raman, Hershey, PA
MP50-02 IS FOLLOW UP BEYOND 2 YEARS
NECESSARY FOR PT1A RENAL CELL
CARCINOMA TREATED WITH NEPHRON
SPARING SURGERY? AN ASSESSMENT
OF LATE RECURRENCES AND
SURVEILLANCE COSTS
Kamran Zargar-Shoshtari*, Tim Kim, Ross
Simon, Pranav Sharma, Binglin Yue, Hui-Yi
Lin, Julio M Pow-Sang, Michael Poch,
Philippe E Spiess, Wade J Sexton, Tampa,
FL
*Presenting author
MP50-05 VOLUMETRIC MEASUREMENT OF
COMPENSATORY HYPERTROPHY IN THE
CONTRALATERAL NORMAL KIDNEY BY
THE TUMOR GROWTH
Bong Hee Park*, Uijeongbu, Korea, Republic
of, Byong Chang Jeong, Seong Soo Jeon,
Seong Il Seo, Hyun Moo Lee, Han Yong
Choi, Hwang Gyun Jeon, Seoul, Korea,
Republic of
157
SUNDAY
MP49-17 NEURAL STEM CELLS AND GOLD
NANOPARTICLES AS NOVEL TREATMENT
FOR BLADDER CANCER – EARLY IN
VITRO STUDIES
Ali Zhumkhawala*, Revathi TirughanaSambandan, Rachael Mooney, Jacob Berlin,
Karen Aboody, Jonathan Yamzon, Duarte,
CA
MP49-13 LIM-SH3 DOMAIN PROTEIN 1
KNOCKDOWN INHIBITS CELL GROWTH
AND ENHANCES ACTIVITY OF CISPLATIN
IN BLADDER CANCER
Takeuchi, Fukuoka, Japan, Tetsutaro
Hayashi, Jeffrey Leong, Tabitha Tombe,
Kevin Tam, Htoo Oo, Peter Black,
Vancouver, Canada, Seiji Naito, Fukuoka,
Japan, Martin Gleave, Christopher Ong,
Vancouver, Canada
MP50-12 THE USE OF RENAL NEPHROMETRY
SCORES FOR PREDICTING TUMOR
UPGRADING BETWEEN CORE BIOPSIES
AND SURGICAL SPECIMENS: A
PROSPECTIVE EX VIVO STUDY
Guiming Zhang*, Yao Zhu, Hualei Gan,
Hongkai Wang, Guohai Shi, Hailiang Zhang,
Bo Dai, Chaofu Wang, Dingwei Ye,
MP50-06 COMPARATIVE ANALYSIS OF SMOKING
AS A RISK FACTOR AMONG RENAL CELL
CARCINOMA HISTOLOGIC SUBTYPES
Neel Patel*, Kristopher Attwood, Terrance
Creighton, Diana Mehedint, Michael Hanzly,
Thomas Schwaab, Eric Kauffman, Buffalo,
NY
MP50-07 THE ASSOCIATION BETWEEN OBESITY
AND INCIDENCE OF TOTAL AND FATAL
RENAL CELL CARCINOMA IN TWO
PROSPECTIVE COHORTS
Mark A Preston*, Jed-Sian Cheng, Alejandro
Sanchez, Boston, MA, Rebecca E Graff, San
Francisco, CA, Dayron Rodriguez, Adam S
Feldman, Glen W Barrisford, Seth Bechis,
Michael L Blute, Meir Stampfer, Steven L
Chang, Edward Giovannucci, Laurence
Albiges, Toni K Choueiri, Eunyoung Cho,
Kathryn M Wilson, Boston, MA
MP50-13 CAN ONCOCYTOMAS BE SAFELY
MONITORED BY SURVEILLANCE?
Patrick O. Richard*, Michael A.S. Jewett,
Jaimin R. Bhatt, Narhari Timilshina, Andrew
J. Evans, Antonio Finelli, Toronto, Canada
MP50-14 CLINICAL STAGE I RENAL MASS
UPSTAGING TO PATHOLOGICAL T3A
DISEASE PORTENDS A WORSE
PROGNOSIS ONLY WHEN SINUS FAT
INVASION IS PRESENT
Sumit De*, Robert Uzzo, Elizabeth Handorf,
David Chen, Rosalia Viterbo, Richard
Greenberg, Nikhil Waingankar, Mohammed
Haseebuddin, Marc Smaldone, Alexander
Kutikov, Philadelphia, PA
MP50-08 DIAGNOSTIC SUCCESS AND PREDICTION
OF TUMOR SUBTYPE OF RENAL MASS
BIOPSY IMPROVES WITH EXPERIENCE:
LONGITUDINAL RESULTS IN A SINGLE
SERIES COHORT OF 1233 TUMORS
David Kuppermann*, Christopher B. Allard,
Manish Dhyani, Dayron Rodriguez, Alejandro
Sanchez, Sameer Deshmukh, Francis J.
McGovern, Matthew Wszolek, Michael L.
Blute, Rosemary Tambouret, Chin-Lee Wu,
Anthony Samir, Adam S. Feldman, Boston,
MA
MP50-15 EVALUATION OF DE NOVO
HYPERTENSION AFTER ROBOTIC
PARTIAL NEPHRECTOMY: A SINGLE
CENTER ANALYSES
Oktay Akca*, Homayoun Zargar, Peter
Caputo, Daniel Ramirez, Riccardo Autorino,
Luis Felipe Brandao, Humberto Laydner,
Hiury Andrade, Robert J Stein, Jihad H
MP50-09 ROLE OF REPEAT BIOPSY IN THE
FOLLOW-UP OF RENAL LESIONS WITH A
PRIOR NON-DIAGNOSTIC BIOPSY OF THE
SAME MASS
David Kuppermann*, Manish Dhyani, Dayron
Rodriguez, Sameer Deshmukh, Francis J.
McGovern, Michael L. Blute, Rosemary
Tambouret, Chin-Lee Wu, Ronald S.
Arellano, Anthony Samir, Adam S. Feldman,
Boston, MA
MP50-16 MULTIPLE PRIMARY MALIGNANCIES IN
RENAL CORTICAL NEOPLASMS: AN
UPDATED EVALUATION
Katie S. Murray*, Emily C. Zabor,
Massimiliano Spaliviero, Paul Russo, Wassim
M. Bazzi, John E. Musser, A. Ari Hakimi,
Melanie L. Bernstein, Guido Dalbagni,
Jonathan A. Coleman, Helena Furberg, New
York, NY
MP50-10 INCIDENCE AND RISK FACTORS FOR
PERIOPERATIVE THROMBOEMBOLIC
EVENTS AMONG PATIENTS WITH RENAL
CELL CARCINOMA AND INFERIOR VENA
CAVA TUMOR THROMBUS
Boyd Viers*, Stephen Boorjian, Christine
Lohse, Sarah Psutka, Griffin Morrisson,
Bradley Leibovich, R. Houston Thompson,
Rochester, MN
MP50-17 INCIDENCE OF HYBRID TUMORS FOUND
IN EXCISED RENAL MASSES: A MULTIINSTITUTIONAL ANALYSIS
David Fumo*, Khaled Shahrour, Toledo, OH,
Ravi Munver, Hackensack, NJ, Samay Jain,
Toledo, OH
MP50-18 OBSTRUCTIVE SLEEP APNEA AND HIGH
FUHRMAN GRADE IN PATIENTS WITH
CLEAR CELL RENAL CELL CARCINOMA
TREATED WITH NEPHRECTOMY
Antoni Vilaseca Cabo*, Emily A. Vertosick,
Daniel P. Nguyen, Renato B. Corradi, New
York, NY, Mireia Musquera, Meritxell Pérez
Márquez, Barcelona, Spain, Nicola Fossati,
Daniel D. Sjoberg, New York, NY, Ramón
Farré, Josep M. Montserrat, Barcelona,
Spain, Nicole E. Benfante, Paul Russo, New
York, NY, Antonio Alcaraz Asensio,
Barcelona, Spain, Karim A. Touijer, New
York, NY
MP50-11 LOW-YIELD OF SURVEILLANCE IMAGING
AFTER SURGERY FOR T1 KIDNEY
CANCER
Michael Feuerstein*, John Musser, Matthew
Kent, Michael Chevinsky, Eugene Cha,
Simon Kimm, William Hilton, Timothy
Donahue, Jonathan Coleman, Sherri Donat,
Paul Russo, New York, NY
158
MP50-20 INCREASED THYROID CANCER RISK IN
PATIENTS WITH KIDNEY CANCERS
Emrullah Yilmaz*, Tejas Suresh, Benjamin
Gartrell, Bronx, NY, Ashutossh Naaraayan,
New Rochelle, NY, Antonio Di Cristofano,
Eric Epstein, Howard Strickler, Bronx, NY,
Marston Linehan, Bethesda, MD, Steven
Libutti, Missak Haigentz, Reza Ghavamian,
Bronx, NY
MP50-19 CONTRAST-ENHANCED ULTRASOUND
FOR SURVEILLANCE OF
RADIOFREQUENCY-ABLATED RENAL
TUMORS: RESULTS FROM A
PROSPECTIVE PILOT STUDY
Christopher Allard*, Boston, MA, Andu Coret,
Shawn Dason, Anil Kapoor, Hamilton,
Canada
1:00 pm - 3:00 pm
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: EVALUATION II
Moderators: Hossein Sadeghi-Nejad and Irwin Goldstein
ABSTRACT
NUMBER TITLE
MP51-01 LH SUPPRESSION AND SERUM
TESTOSTERONE IS POSITIVELY
ASSOCIATED WITH FEWER
HYPOGONADAL SYMPTOMS IN MEN ON
TESTOSTERONE SUPPLEMENTATION
Jason Scovell*, Christina Mai, Michael
Mederos, Ranjith Ramasamy, Dolores Lamb,
Larry Lipshultz, Houston, TX
ABSTRACT
NUMBER TITLE
MP51-06 INCREASED PREVALENCE OF
HYPOPROLACTINEMIA IN MEN TAKING
TESTOSTERONE SUPPLEMENTATION
THERAPY
Aravind Chandrashekar*, Tariq Hakky, Jason
Scovell, Ranjith Ramasamy, Alexander
Pastuszak, Dolores Lamb, Larry Lipshultz,
Houston, TX
MP51-07 DEVELOPMENT OF DE NOVO
HYPOGONADISM IN PATIENTS
UNDERGOING RENAL SURGERY FOR
CORTICAL NEOPLASM: A MULTICENTER
ANALYSIS
Omer Raheem*, Song Wang, Hak Lee, Jason
Woo, San Diego, CA, Reza Mehrazin, Jim
Wan, Anthony Patterson, Tennessee, TN,
Ithaar Derweesh, San Diego, CA
MP51-02 PREVALENCE OF LOW TESTOSTERONE
IN A POPULATION BASED, NATIONALLY
REPRESENTATIVE SURVEY
James Dupree*, Chang He, Dana Ohl, Ann
Arbor, MI, Larry Lipshultz, Houston, TX,
Aruna Sarma, Ann Arbor, MI
MP51-03 TESTOSTERONE STUDIES: REAL-WORLD
METHODOLOGICAL CHALLENGES
Kelly A. Chiles*, Christian J. Nelson, Keith
O’Brien, John P. Mulhall, New York, NY
MP51-08 CURRENT PRACTICES OF MEASURING
AND REFERENCE RANGE REPORTING OF
FREE AND TOTAL TESTOSTERONE IN
THE UNITED STATES
Margaret Le*, David Flores, Eric Gourley,
Danica May, Ajay Nangia, Kansas City, KS
MP51-04 ASSOCIATION BETWEEN
TESTOSTERONE, VITAMIN D AND
CARDIOVASCULAR RISK
Rupa Iyengar*, Cynara Maceda, Heather
Beebe, Laura Crowley, New York, NY, Mark
Woodward, Oxford, United Kingdom, Natan
Bar-chama, Mary Ann McLaughlin, New York,
NY
MP51-09 CHARACTERIZING TESTOSTERONE AND
BONE DENSITY PROFILES OF MEN
AFTER STEM CELL TRANSPLANT
Kelly A. Chiles*, Molly Maloy, Kara Mosesso,
Christian J. Nelson, Ann Jakubowski, John P.
Mulhall, New York, NY
MP51-05 DEFINING THE INCIDENCE OF
POLYCYTHEMIA IN MEN USING
INTRAMUSCULAR TESTOSTERONE
SUPPLEMENTATION
Serkan Deveci*, Patrick Teloken, Keith
O’Brien, Patricia Guhring, Marilyn Parker,
Joseph Narus, John P. Mulhall, New York,
NY
*Presenting author
MP51-10 DYSLIPIDEMIA AND OTHER METABOLIC
SYNDROME TRAITS ARE ASSOCIATED
WITH LOW TESTOSTERONE LEVEL IN
MEN REGARDLESS THEIR AGE
Amanda Soares, Feira de Santana, Brazil,
Fabio Torricelli, Sao Paulo, Brazil, Ricardo
Tiraboschi*, Victor Paschoalin, Carlos
Belucci, Jose Murillo Bastos-Netto, Feira de
Santana, Brazil, Cristiano Gomes, Sao Paulo,
Brazil, Jose Bessa, Jr., Feira de Santana,
Brazil
159
SUNDAY
CREDITTM
MP51-17 ORGASMIC FUNCTION RELIES ON
TESTOSTERONE LEVELS - RESULTS OF A
CROSS-SECTIONAL STUDY IN MEN
SEEKING MEDICAL HELP FOR ERECTILE
DYSFUNCTION
Eugenio Ventimiglia*, Paolo Capogrosso,
Luca Boeri, Alessandro Serino, Giovanni La
Croce, Giulia Castagna, Angela Pecoraro,
Marco Paciotti, Roberta Scano, Dana
Kuefner, Milan, Italy, Rocco Damiano,
Catanzaro, Italy, Francesco Montorsi, Andrea
Salonia, Milan, Italy
MP51-11 DOES HYPOGONADISM (OR LOW T)
PRESENT DIFFERENTLY IN THE
INFERTILE MALE?
Helen R Levey*, Janet E Kukreja, Rochester,
NY, Ranjith Ramasamay, Houston, TX, Victor
Kucherov, Justin Budnik, Chunkit Fung, David
Gentile, Jeanne Obrien, Rochester, NY
MP51-12 LOW SERUM TESTOSTERONE LEVEL IS
ASSOCIATED WITH BRACHIAL-ANKLE
PULSE WAVE VELOCITY IN PATIENTS
WITH SYMPTOM OF LATEONSET
HYPOGONADISM
Akira Tsujimura*, Shin-ichi Hisasue, BunkyoKu, Tokyo, Japan, Yoshiaki Kumamoto,
Kazuhiro Kobayashi, Tokyo, Japan, Shigeo
Horie, Bunkyo-Ku, Tokyo, Japan
MP51-18 ONE OUT OF TEN PATIENTS SUBMITTED
TO RADICAL PROSTATECTOMY
COMPLAINS OF POSTOPERATIVE
PAINFUL ORGASM
Paolo Capogrosso*, Alessandro Serino, Luca
Boeri, Giovanni La Croce, Eugenio
Ventimiglia, Angela Pecoraro, Marco Paciotti,
Giulia Castagna, Elena Farina, Giorgio
Gandaglia, Alberto Briganti, Milan, Italy,
Rocco Damiano, Catanzaro, Italy, Francesco
Montorsi, Andrea Salonia, Milan, Italy
MP51-13 BULBOCAVERNOSUS MUSCLE AREA AS
A MARKER OF ANDROGENIZATION
Nikhil Gupta*, New Hyde Park, NY, Amin
Herati, New York, NY, Yuki Yamashita, New
Hyde Park, NJ, Bruce Gilbert, New Hyde
Park, NY
MP51-14 CONTEMPORARY PRESCRIBING
PATTERNS OF TESTOSTERONE
REPLACEMENT THERAPY IN
HYPOGONADAL PATIENTS WITH A
HISTORY OF PROSTATE CANCER
Victor Lizarraga*, Mohit Khera, Houston, TX
MP51-19 COLOR DUPLEX DOPPLER ULTRASOUND
(CDDU): CAN WE CATEGORIZE
CAVERNOUS VENOUS OCCLUSIVE
DISEASE (CVOD) AS MILD, MODERATE
AND SEVERE?
Ram Pathak*, Russell Chavers, Bhupendra
Rawal, Gregory Broderick, Jacksonville, FL
MP51-15 LARGE PROSTATIC CALCULI MAY
WORSEN ERECTILE DYSFUNCTION AND
MIDDLE AGED MEN
Sung Dae Kim*, Jung-Sik Huh, Young Joo
Kim, Kyung Kgi Park, Jeju, Korea, Republic
of, Dong Wan Sohn, Seoul, Korea, Republic
of, Hee Jong Kim, Jeju, Korea, Republic of
MP51-20 AN ENHANCED ULTRASOUND
TECHNIQUE FOR FUNCTIONAL
EVALUATION OF SPERMATOGENESIS
Yuki Yamashita*, Amin S. Herati, Gideon
Richards, Oksana Yaskiv, Sleiman R.
Ghorayeb, Bruce R. Gilbert, New Hyde Park,
NY
MP51-16 ABNORMAL CALCULATED FREE
TESTOSTERONE DOES NOT PREDICT
EJACULATORY DYSFUNCTION OR
SEXUAL SATISFACTION
Michael Kottwitz*, Springfield, IL, Joel F
Koenig, St. Louis, MO, Bradford Stevenson,
Randy Sulaver, Georgia Mueller, Tobias S
Kohler, Springfield, IL
CREDITTM
1:00 pm - 3:00 pm
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: BASIC RESEARCH I
Moderators: Trinity Bivalacqua and Run Wang
ABSTRACT
NUMBER TITLE
MP52-01 NANOTECHNOLOGY IMPROVED ADIPOSE
DERIVED STEM CELL THERAPY IN
ERECTILE DYSFUNCTION IN POST
RADICAL PROSTATECTOMY ANIMAL
MODEL
Haocheng Lin*, Nadeem Dhanani, Hubert
Tseng, Glauco Souza, Run wang, Houston,
TX
ABSTRACT
NUMBER TITLE
MP52-02 REGENERATION OF RAT CORPUS
CAVERNOSA TISSUE AFTER
TRANSPLANTATION OF CD 133ⴙ CELLS
DERIVED FROM HUMAN BONE MARROW
AND PLACEMENT OF BIODEGRADABLE
GEL SPONGE SHEET
Shogo Inoue*, Shunsuke Shinmei, Koichi
Shoji, Mitsuru Kajiwara, Jun Teishima, Akio
Matsubara, Hiroshima, Japan
160
MP52-09 HUMAN TISSUE KALLIKREIN 1
IMPROVES ERECTILE FUNCTION OF
AGED RAT BY ACTIVATION OF NITRIC
OXIDE/CYCLIC GUANOSINE
MONOPHOSPHATE AND INHIBITION OF
RHO-KINASE SIGNALINGS IN THE
CORPUS CAVERNOSUM
Yang Luan, Tao Wang, Ya Ruan*, Yan
Zhang, Jun Yang, Ming Li, Rui Chen, Shao
Wang, Ji Liu, Zhang Ye, Wuhan, China,
MP52-04 SELECTIVE ␣ 1A-ADRENERGIC
MODULATION ENHANCES ERECTILE
RESPONSES IN RATS AFTER
CAVERNOUS NERVE INJURY AND
IMPROVES NEUROGENIC AND PDE5
INHIBITOR RESPONSES IN HUMAN AND
RAT CAVERNOSAL TISSUE
Juan Ignacio Martı́nez-Salamanca*, Madrid,
Spain, José M La Fuente, Porto, Portugal,
Eduardo Martı́nez-Salamanca, Argentina
Fernández, Madrid, Spain, Augusto J PepeCardoso, Amadora, Portugal, Joaquı́n
Carballido, Javier Angulo, Madrid, Spain
MP52-10 GENOME-WIDE PROFILING OF
LONGNONCODING RIBONUCLEIC ACID
EXPRESSION PATTERNS IN CORPUS
CAVERNOSUM OF DIABETIC RATS WITH
ERECTILE DYSFUNCTION BY
MICROARRAY
Wen Song, Yang Luan*, Jun Yang, Rui Chen,
Qing Ling, Ming Li, Tao Wang, Shao Wang,
Ji Liu, Zhang Ye, Wuhan, China, People’s
Republic of
MP52-11 ASSOCIATION OF URINARY PTHALATE
METABOLITES WITH ERECTILE
DYSFUNCTION IN DIFFERENT RACIAL
AND ETHNIC GROUPS IN THE NATIONAL
HEALTH AND NUTRITION EXAMINATION
SURVEY (NHANES) 2001-2004
David S. Lopez*, Houston, TX, Konstantinos
T. Tsilidis, Ioannina, Greece, Shailesh
Advani, Run Wang, Mike Hernandez, Elaine
Symanski, Steven Canfield, Houston, TX
MP52-05 BILATERAL CAVERNOUS NERVE INJURY
INDUCES TEMPORAL INCREASE OF TNF␣ AND RECRUITMENT OF MACROPHAGES
IN THE MAJOR PELVIC GANGLION IN
VIVO
Hotaka Matsui*, Johanna L. Hannan,
Baltimore, MD, Maarten Albersen, Emmanuel
Weyne, Leuven, Belgium, Xiaopu Liu, Arthur
L. Burnett, Ahmet Hoke, Trinity J. Bivalacqua,
Baltimore, MD
MP52-12 MECHANISM OF CAVERNOUS NERVE
REGENERATION BY SONIC HEDGEHOG
Christopher Bond, Chicago, IL, Daniel
Harrington, Houston, TX, Samuel Stupp,
Carol Podlasek*, Chicago, IL
MP52-06 LOW INTENSITY EXTRACORPORAL
SHOCK WAVES THERAPY IMPROVES
ERECTILE FUNCTION IN DIABETIC TYPE
II RATS INDEPENDENTLY OF NO/CGMP
PATHWAY
Rana Assaly, Miguel Laurin, Diane Gorny,
Montigny-le-Bretonneux, France, Micheline
Kergoat, Chilly Mazarin, France, Jacques
Bernabé, Montigny-Le-Bretonneux, France,
Yoram Vardi, Haifa, Israel, Francois Giuliano,
Garches, France, Delphine Behr-Roussel*,
Montigny-Le-Bretonneux, France
MP52-13 THE EFFECT OF PARTIAL BLADDER
OUTLET OBSTRUCTION (PBOO)
SEVERITY AND
HYPERCHOLESTEROLEMIA ON ERECTILE
FUNCTION IN RATS
Serap Gur*, Nur Bayatli, Didem Yilmaz,
Ankara, Turkey
MP52-14 EXPRESSIONS OF VAGINAL
PHOSPHODIESTERASE 5 AND NITRIC
OXIDE SYNTHASE IN FEMALE SEXUAL
DYSFUNCTION
Kang Jun Cho*, Jang Hwan Kim, Seoul, Korea,
Republic of, Jong Bo Choi, Suwon, Korea,
Republic of, Seung-June Oh, Kyu-Sung Lee,
Myung-Soo Choo, Seoul, Korea, Republic of,
Young Ho Kim, Bucheon, Korea, Republic of,
Joon Chul Kim, Seoul, Korea, Republic of
MP52-07 EXPRESSION AND DISTRIBUTION OF
CANNABINOID RECEPTORS IN THE
HUMAN SEMINAL VESICLES
Giovanni la Croce, Ariana Bettiga, Massimo
Freschi, Francesco Montorsi, Milano, Italy,
Markus Kuczyk, Stefan Ückert*, Hannover,
Germany, Petter Hedlund, Milano, Italy
MP52-08 SAC-1004, A VASCULAR LEAKAGE
BLOCKER, RESTORES ERECTILE
FUNCTION BY ENHANCING HEALTHY
ANGIOGENESIS IN THE
STREPTOZOTOCIN-INDUCED DIABETIC
MOUSE
Kang-Moon Song, Dulguun Batbold, SooHwan Park*, Jin-Mi Park, Mi-Hye Kwon, Anita
Limanjaya, Kalyan Ghatak, Jiyeon Ock, Guo
Nan Yin, Ji-Kan Ryu, Jun-Kyu Suh, Incheon,
Korea, Republic of
*Presenting author
MP52-15 MICROSCOPIC EVALUATION OF TISSUE
REMODELING AFTER PENILE GIRTH
ENHANCEMENT USING BIODEGRADABLE
SCAFFOLDS
Miroslav Djordjevic*, Uros Bumbasirevic,
Tamara Kravic, Tamara Martinovic, Marta
Bizic, Vladimir Kojovic, Marko Majstorovic,
Borko Stojanovic, Belgrade, Serbia
161
SUNDAY
MP52-03 THE PERICYTES AS A CELLULAR
REGULATOR OF PENILE ERECTION AND
A NOVEL THERAPEUTIC TARGET FOR
Guo Nan Yin, Nando Dulal Das, Min Ji Choi,
Kang-Moon Song, Mi-Hye Kwon, Jiyeon Ock,
Anita Limanjaya, Kalyan Ghatak, Woo Jean
Kim, Soo-Hwan Park, Incheon, Korea,
Republic of, Jae Seog Hyun, Jinju, Korea,
Republic of, Ji-Kan Ryu*, Jun-Kyu Suh,
MP52-16 TESTOSTERONE REGULATES THE
EXPRESSION AND FUNCTIONAL
ACTIVITY OF SPHINGOSINE-1PHOSPHATE RECEPTORS IN THE RAT
CORPUS CAVERNOSUM
Xinhua Zhang*, Wuhan, China, People’s
Republic of, Michael DiSanto, Camden, NJ,
Wenhao Zhang, Ping Chen, Wuhan, China,
MP52-19 NOVEL MUTATIONS OF THE CYSTIC
FIBROSIS TRANSMEMBRANE
CONDUCTANCE REGULATOR GENE IN
CHINESE PATIENTS WITH CONGENITAL
ABSENCE OF VAS DEFERENS
Yan Zhang*, Ping Yuan, Xiaojian Yang,
Qipeng Sun, Xiao Wu, Hao Zhang, Bin
Zhang, Xin Gao, Guangzhou, China, People’s
Republic of
MP52-17 EXPRESSION AND DISTRIBUTION OF THE
TRANSIENT RECEPTOR POTENTIAL
CATIONIC CHANNEL A1 (TRPA1) IN
HUMAN PENILE ERECTILE TISSUE AND
THE SEMINAL VESICLES
Stefan Ückert*, Hannover, Germany, Andreas
Bannowsky, Osnabrück, Germany, Markus
Kuczyk, Hannover, Germany, Petter Hedlund,
Milano, Italy
MP52-20 EFFECTS OF VITAMIN D RESTRICTION
DURING PERI AND POSTNATAL LIFE ON
PENIS MORPHOLOGY IN WISTAR RATS’
OFFSPRING
Flavia Fernandes-Lima, Pamella CamposSilva, Diogo B. De Souza, Waldemar S.
Costa, Francisco J. B. Sampaio, Bianca M.
Gregorio*, Rio de Janeiro, Brazil, Fernanda
A. M. Nascimento, MACAÉ, Brazil
MP52-18 ROLE OF FIBROBLAST GROWTH FACTOR
RECEPTORS IN LEYDIG CELL
DEVELOPMENT
Andres Correa*, Kenneth Walker, Daniel
Bushnel, Caitlin Schaefer, Julia Schaffer,
Carlton Bates, Pittsburgh, PA
CREDITTM
1:00 pm - 3:00 pm
PROSTATE CANCER: STAGING I
Moderators: Murugesan Manoharan and Steven Canfield
ABSTRACT
NUMBER TITLE
MP53-01 THE RELATIONSHIP OF OBESITY,
PATHOLOGIC GLEASON GRADE AND
PROSTATE CANCER TUMOR VOLUME AT
THE TIME OF RADICAL
PROSTATECTOMY—RESULTS FROM THE
SEARCH DATABASE
Zachary Klaassen*, Augusta, GA, Lauren E.
Howard, Durham, NC, Martha K. Terris,
Augusta, GA, William J. Aronson, Los
Angeles, CA, Matthew R. Cooperberg, San
Francisco, CA, Christopher L. Amling,
Portland, OR, Christopher J. Kane, San
Diego, CA, Stephen J. Freedland, Durham,
NC
ABSTRACT
NUMBER TITLE
MP53-03 MULTIPARAMETRIC MRI IMPROVES
PREDICTIVE ACCURACY OF CLINICAL
NOMOGRAMS FOR EXTRACAPSULAR
EXTENSION OF PROSTATE CANCER
Tom Feng*, Ali Afshar, Los Angeles, CA,
Steven Smith, Richmond, VA, Jonathan Wu,
Daniel Luthringer, Rola Saouaf, Hyung Kim,
Los Angeles, CA
MP53-04 SIGNIFICANT INTER-INSTITUTIONAL
VARIATIONS IN RACIAL DISPARITIES
AMONG AFRICAN-AMERICAN MEN
ELIGIBLE FOR PROSTATE CANCER
ACTIVE SURVEILLANCE
Michael Dinizo*, Weichung Shih, Amirali
Salmasi, Izak Faiena, Parth Modi, New
Brunswick, NJ, Misop Han, Alan W. Partin,
Baltimore, MD, Daniel Eun, Adam Reese,
Elton Llukani, Laura Giosto, Sean Wessel,
Edourad Trabulsi, Costas Lallas,
Philadelphia, PA, Bertram Yuh, Timothy
Wilson, Duarte, CA, Daniel Marchalik,
Jonathan Hwang, Washington, DC, Shilajit
Kundu, William Catalona, Drew Flum, Scott
Eggener, Edris Negron, Chicago, IL, Isaac Yi
Kim, New Brunswick NJ, NJ
MP53-02 IS CLINICAL STAGE T2C PROSTATE
CANCER INTERMEDIATE OR HIGH-RISK
DISEASE?
Zachary Klaassen*, Augusta, GA, Abhay A.
Singh, Lauren E. Howard, Durham, NC,
Zhaoyong Feng, Bruce Trock, Baltimore, MD,
Martha K. Terris, Augusta, GA, William J.
Aronson, Los Angeles, CA, Matthew R.
Cooperberg, San Francisco, CA, Christopher
L. Amling, Portland, OR, Christopher J. Kane,
San Diego, CA, Alan Partin, Misop Han,
Baltimore, MD, Stephen J. Freedland,
Durham, NC
162
MP53-06 DOES PATHOLOGIC UPSTAGING FROM
CLINICAL LOW-RISK PROSTATE CANCER
CONFER WORSE SURVIVAL?
Evan Kovac*, Chad Reichard, Andrew
Stephenson, Cleveland, OH
MP53-13 IS DOMINANT TUMOR NODULE SIZE A
SIGNIFICANT PREDICTOR OF ADVERSE
OUTCOME IN PROSTATE CANCER? A
STUDY OF 487 WHOLE MOUNT RADICAL
PROSTATECTOMY CASES
Laura Favazza*, Alpa Shah, Sean
Williamson, Mireya Diaz-Insua, Craig Rogers,
Hans Stricker, James Peabody, Mani Menon,
Nilesh Gupta, Detroit, MI
MP53-07 NEED FOR A SURGICAL TEMPLATE IN
SALVAGE LYMPHADENECTOMY FOR
NODAL RECURRENCE OF PROSTATE
CANCER: IS PELVIC INVOLVEMENT
PREDICTIVE OF RETROPERITONEAL
POSITIVITY?
Guglielmo Melloni, Marco Oderda, Marco
Falcone, Stefania Munegato, Turin, Italy,
Hannes Van De Bosche, Steven Deconinck,
Leuven, Belgium, Fabio Zattoni, Robert
Jeffrey Karnes, Rochester, MN, Steven
Joniau, Leuven, Belgium, Paolo Gontero*,
Turin, Italy
MP53-14 VITAMIN D DEFICIENCY PREDICTS
ADVERSE PATHOLOGY AT TIME OF
Diana K. Bowen*, Gregory A. Jordan, Tyler J.
Maiers, Chicago, IL, Rick A. Kittles, Tucson,
AZ, Adam B. Murphy, Chicago, IL
MP53-08 THE DIAGNOSTIC VALUE OF 68GALABELLED PSMA-LIGAND PET/CT IN MEN
WITH RECURRENT PROSTATE CANCER
Boris Hadaschik*, Ali Afshar-Oromieh, Jan
Radtke, Silvan Boxler, Matthias Eder, Klaus
Kopka, Jürgen Debus, Markus Hohenfellner,
Uwe Haberkorn, Heidelberg, Germany
MP53-15 BIOPSY RESULTS AMONG MEN
UNDERGOING REPEAT MRIULTRASOUND FUSION TARGETED
BIOPSIES
Michael Fenstermaker*, Neil Mendhiratta,
Xiaosong Meng, Andrew B. Rosenkrantz,
MP53-09 A SIMPLER MODIFIED GLEASON SCORE
PERFORMS SLIGHTLY BETTER THAN
THE STANDARD ONE
Domenico Gabriele, Torino, Italy, Enrico
Bollito, Orbassano, Italy, Carlo Terrone,
Paolo De Angelis, Novara, Italy, Alessandro
Giacobbe*, Torino, Italy, Luca Bellei, Ivrea,
Italy, Manuela Graziano, Asti, Italy, Patrizia
Gamba, Torino, Italy, Pietro Gabriele,
Candiolo, Italy
MP53-16 ONCOLOGIC OUTCOMES IN MEN WITH
METASTASIS TO THE PROSTATIC
ANTERIOR FAT PAD LYMPH NODES: A
MULTI-INSTITUTION INTERNATIONAL
STUDY
Isaac Kim*, New Brunswick, NJ, Yun-Sok Ha,
Daegu, Korea, Republic of, Parth Modi, Amirali
Salmasi, Jaspreet Parihar, Neal Patel, Izak
Faiena, Michael May, New Brunswick, NJ,
Daivd Lee, Elton Llukani, Philadelphia, PA,
Tuliao Patrick, Koon Ho Rha, Seoul, Korea,
Republic of, Thomas Ahlering, Douglas
Skarecky, Orange, CA, Hanjong Ahn, SeungKwon Choi, Seoul, Korea, Republic of, Sejun
Park, Ulsan, Korea, Republic of, Seong Soo
Jeon, Seoul, Korea, Republic of, Yen-Chuan
Ou, Taichung, Taiwan, Daniel Eun, Varsha
Manucha, Philadelphia, PA, David Albala,
Syracuse, NY, Ketan Badani, New York, NY,
Bertram Yuh, Nora Ruel, Duarte, CA, Tae
Gyun Kwon, Daegu, Korea, Republic of, Daniel
Marchalik, Jonathan Hwang, Washington, DC,
Wun-Jae Kim, Cheongju, Korea, Republic of
MP53-10 PREOPERATIVE MP-MRI IN PATIENTS
WITH LOCALIZED PROSTATE CANCER: IS
THERE A ROLE IN THE BEST CHOICE OF
THERAPEUTIC APPROACH?
Francesco Porpiglia, Matteo Manfredi*,
Fabrizio Mele, Orbassano (Turin), Italy,
Filippo Russo, Daniele Regge, Candiolo
(Turin), Italy, Agostino De Pascale,
Orbassano (Turin), Italy, Stefano Cirillo,
Torino, Italy, Enrico Bollito, Mauro Papotti,
Cristian Fiori, Orbassano (Turin), Italy
MP53-11 CLOSE SURGICAL MARGINS AFTER
RADICAL PROSTATECTOMY MIMIC
BIOCHEMICAL RECURRENCE RATES OF
POSITIVE MARGINS
Edan Shapiro, Michael Whalen*, New York,
NY, William Berg, Stony Brook, NY, Michael
Rothberg, Valhalla, NY, Solomon Woldu,
Arindam RoyChoudhury, Ari Bergman, New
York, NY, Trushar Patel, Tampa, FL, Ketan
Badani, New York, NY
*Presenting author
163
SUNDAY
MP53-12 LONG TERM ONCOLOGICAL OUTCOMES
OF APICAL POSITIVE SURGICAL
MARGINS AT RADICAL PROSTATECTOMY
IN THE SHARED EQUAL ACCESS
REGIONAL CANCER HOSPITAL (SEARCH)
COHORT
Harpreet Wadhwa*, Chicago, IL, Martha
Terris, Augusta, GA, William Aronson, Los
Angeles, CA, Christopher Kane, La Jolla, CA,
Christopher Amling, Portland, OR, Matthew
Cooperberg, San Francisco, CA, Stephen
Freedland, Durham, NC, Michael Abern,
Chicago, IL
MP53-05 PREDICTIVE VALUE OF TERTIARY
GLEASON SCORE
Domenico Gabriele, Torino, Italy, Enrico
Bollito, Francesco Porpiglia, Orbassano, Italy,
Paolo Gontero, Torino, Italy, Fabio Venzano,
Cuneo, Italy, Delia Genesi, Cirié, Italy, Marco
Manzo, Alessandro Giacobbe*, Caterina
Guiot, Torino, Italy
MP53-19 GENETIC BASIS FOR A GREATER
PROGRESSION RATE TO A HIGHER
GRADE OF LOW RISK PROSTATE
CANCER AMONG AFRICAN AMERICANS
COMPARED TO EUROPEAN AMERICANS:
IMPACT ON ACTIVE SURVEILLANCE
RECOMMENDATIONS
Isaac Powell*, Greg Dyson, Aliccia BolligFischer, Detroit, MI
MP53-17 CLINICAL VALIDATION OF THE 2005 ISUP
GLEASON GRADING SYSTEM IN A
COHORT OF INTERMEDIATE AND HIGH
RISK MEN UNDERGOING RADICAL
PROSTATECTOMY
Ashley Ross, Stephania Bezerra, Sheila
Faraj, Baltimore, MD, Kasra Yousefi,
Vancouver, Canada, Helen Fedor, Stephanie
Glavaris, Misop Han, Alan Partin, Elizabeth
Humphreys, Jeffrey Tosoian, Michael H.
Johnson, Baltimore, MD, Elai Davicioni,
Vancouver, Canada, Bruce Trock, Edward
Schaeffer, George Netto*, Baltimore, MD
MP53-20 ACCURACY OF MRI-TARGETED BIOPSY
TO RECLASSIFY GLEASON GRADE IN
MEN ON ACTIVE SURVEILLANCE
Pedro Recabal*, Melissa Assel, Dan Lee,
Oguz Akin, Jonathan Coleman, Alan Thong,
Justin Lee, James Eastham, Evis Salas,
Peter Scardino, Alberto Vargas, Behfar
Ehdaie, New YOrk, NY
MP53-18 ASSOCIATION BETWEEN A 17-GENE
GENOMIC PROSTATE SCORE AND MULTIPARAMETRIC PROSTATE MRI IN MEN
WITH LOW AND INTERMEDIATE RISK
PROSTATE CANCER (PCA)
Michael Leapman*, Antonio Westphalen,
Niloufar Ameli, San Francisco, CA, Jeffrey
Lawrence, Phillip Febbo, Redwood City, CA,
Matthew Cooperberg, Peter Carroll, San
Francisco, CA
CREDITTM
1:00 pm - 3:00 pm
Podium Session 28
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: FEMALE INCONTINENCE - THERAPY II
Moderators: Jerry Blaivas and Angelo Gousse
TIME
1:00
1:10
ABSTRACT
NUMBER TITLE
PD28-01 STILL DRY! LONGEVITY OF DEFLUX
URETHRAL BULKING INJECTIONS FOR
URINARY STRESS INCONTINENCE
Catherine Hobbs*, Steve Foley, Reading,
United Kingdom
ABSTRACT
TIME NUMBER TITLE
1:40
PD28-05 LONG-TERM OUTCOMES OF
MIDURETHRAL AND PUBOVAGINAL
SLINGS FOR STRESS URINARY
INCONTINENCE IN A TERTIARY
REFERRAL SETTING
Kevin Gioia*, Katherine Odem-Davis, John
Massman III, Erika Wolff, Alvaro Lucioni, Una
Lee, Kathleen Kobashi, Seattle, WA
PD28-02 MANAGEMENT OF URINARY
INCONTINENCE IN WOMEN AFTER
ORTHOTOPIC NEOBLADDER DIVERSION
George Bailey*, Andrew Blackburne, Deborah
Lightner, Rochester, MN
1:20
PD28-03 TEACHING MID-URETHRAL SLING
SURGERY TO RESIDENTS: IS IT SLOWING
US DOWN?
Ali Reza Sharif Afshar*, Lauren Wood, Los
Angeles, CA, Jennifer Anger, Beverly Hills, CA,
Catherine Bresee, Los Angeles, CA, Bruno
Gross, Bryan, TX, Eugene Shkolyar, Los
Angeles, CA, Karyn Eilber, Beverly Hills, CA
1:30
PD28-04 MANAGEMENT OF COMPLICATIONS IN
USE OF URETHRAL BULKING AGENTS IN
WOMEN FOR STRESS URINARY
INCONTINENCE – A SYSTEMATICANALYSIS
Majdee Islam, Columbia, MO, Harpreet
Wadhwa*, Ryan Dobbs, Ervin Kocjancic,
Chicago, IL
164
1:50
PD28-06 OUTCOMES OF AUTOLOGOUS RECTUS
FASCIA PUBOVAGINAL SLING FOR
SEVERE INTRINSIC SPHINCTER
DEFICIENCY AND/OR RECURRENT
STRESS URINARY INCONTINENCE: UP TO
11-YEAR FOLLOW-UP
Eugene W. Lee*, Seattle, WA, Andrew Chang,
Stony Brook, NY, Una J. Lee, Alvaro Lucioni,
John D. Massman, Erika M. Wolff, Fred E.
Govier, Kathleen C. Kobashi, Seattle, WA
2:00
PD28-07 THE IMPACT OF OBESITY ON OUTCOMES
AFTER RETROPUBIC MIDURETHRAL
SLING FOR FEMALE STRESS URINARY
INCONTINENCE
Umar Karaman*, Kevin Campbell, Clifton F.
Frilot II, Alex Gomelsky, Shreveport, LA
2:10
PD28-08 THE EFFECT OF TIME TO REVISION OF
AN OBSTRUCTING SYNTHETIC MIDURETHRAL SLING ON REOPERATION
FOR STRESS URINARY INCONTINENCE
Nitya Abraham*, Bronx, NY, Iryna Makovey,
Ashley King, Howard B. Goldman, Sandip
Vasavada, Cleveland, OH
2:20
PD28-09 A POPULATION BASED ASSESSMENT OF
THE RISK FACTORS FOR MESH
REMOVAL OR REVISION AFTER FEMALE
INCONTINENCE PROCEDURES
Blayne Welk*, London, Canada, Hana’a AlHothi, Doha, Qatar, Jennifer Winick-Ng,
London, Canada
2:30
PD28-10 SUCCESS AND COMPLICATIONS OF
PUBOVAGINAL SLING WITH HUMAN
CADAVERIC DERMAL TISSUE AND WITH
A MINIMUM 10-YEAR FOLLOW-UP
Serge Marinkovic*, Detroit, MI
PD28-12 HOLMIUM LASER EXCISON OF
GENITOURINARY MESH EXPOSURE
FOLLOWING ANTI⫺INCONTINENCE
SURGERY: MINIMUM 6 MONTH
FOLLOW⫺UP
Christina Ogle*, Brian Linder, Daniel Elliott,
Rochester, MN
CREDITTM
PD28-11 CHANGES IN URINARY STORAGE
SYMPTOMS FOLLOWING SURGICAL
TREATMENT FOR FEMALE STRESS
Zachary Panfili, William Parker*, Kansas City,
KS, Alexander Gomelsky, Shreveport, LA,
Priya Padmanabhan, Kansas City, KS
SUNDAY
2:40
2:50
1:00 pm - 3:00 pm
Podium Session 29
KIDNEY CANCER: SURGICAL THERAPY I
Moderators: Rene Sotelo and Abhay Rane
TIME
1:00
ABSTRACT
NUMBER TITLE
PD29-01 PREDICTING RENAL PARENCHYMAL
LOSS FOLLOWING NEPHRON SPARING
SURGERY
Solomon Woldu*, Alexa Meyer, Aaron
Weinberg, Justin Matulay, New York, NY,
Gregory Thoreson, Dallas, TX, Phillip
Pierorazio, Baltimore, MD, Mitchell Benson,
G. Joel DeCastro, James McKiernan, New
York, NY
1:10
PD29-02 SURGICAL MANAGEMENT OF RENAL
CELL CARCINOMA IN OCTOGENARIANS
AND NONAGENARIANS: DEFINING
APPROPRIATE TREATMENT STANDARDS
Zachary Klaassen*, Rita P. Jen, Augusta,
GA, John M. DiBianco, Roseau, Dominica,
Lael Reinstatler, Daniel Belew, Qiang Li,
Rabii Madi, Martha K. Terris, Augusta, GA
1:20
PD29-03 NEPHROMETRY SCORES AND THEIR
RELATION TO PERI-OPERATIVE AND
POST-OPERATIVE OUTCOMES AFTER
Renato B Corradi, Emily Vertosick, Daniel P
Nguyen, Antoni Vilaseca, Daniel D Sjoberg,
Maximiliano Spaliviero, Karim A Touijier, Paul
Russo, Jonathan A Coleman, Renato
Corradi*, New York, NY
ABSTRACT
TIME NUMBER TITLE
1:30
PD29-04 HISPANO-AMERICAN EXPERIENCE IN
MINIMALLY INVASIVE PARTIAL
NEPHRECTOMY
Fernando Pablo Secin*, Buenos Aires,
Argentina, Octavio Castillo Cadiz, Santiago
de Chile, Chile, Patricio Aitor Garcı́a
Marchiñena, Alberto Jurado Navarro, Agustin
Rovegno, Anamaria Autran, Buenos Aires,
Argentina, Oscar Rodriguez Faba, Joan
Palou Redorta, Barcelona, Spain, Jose
Rozanec, Marcelo Featherstone, Pablo Holst,
Buenos Aires, Argentina, Luciano Nuñez
Bragayrac, Rene Sotelo, Caracas,
Venezuela, Ricardo Faveretto, Stenio Zequi,
San Pablo, Brazil, Mario Álvarez Maestro,
Luis Martinez Piñeiro, Madrid, Spain, Gustavo
Villoldo, Alberto Villaronga, Buenos Aires,
Argentina, Diego Abreu Clavijo, Montevideo,
Uruguay, Ivar Vidal Mora, Santiago de Chile,
Chile, Diana Finkelstein, Juan Ignacio Monzo
Gardiner, Buenos Aires, Argentina, Oscar
Schatloff, Santiago de Chile, Chile, Andres
Hernandez Porras, Tijuana, Mexico, Félix
Santaella Torres, Distrito Federal, Mexico,
Rodolfo Sanchez Salas, Hugo Alberto Davila,
Caracas, Venezuela, Humberto Villavicencio
Mavrich, Barcelona, Spain
1:40
*Presenting author
165
PD29-05 MAJOR UROLOGIC PROCEDURES IN
JEHOVAH’S WITNESS POPULATION: A
STUDY OF SAFETY AND FEASIBILITY
Siamak Daneshmand*, Los Angeles, CA,
Antoin Douglawi, Alhambra, CA
1:50
PD29-06 ONCOLOGIC SURVEILLANCE FOLLOWING
SURGICAL RESECTION FOR RENAL CELL
CARCINOMA: A NOVEL RISK-BASED
APPROACH
Suzanne Stewart*, R. Houston Thompson,
Stephen Boorjian, Sarah Psutka, Christine
Lohse, John Cheville, Bradley Leibovich, Igor
Frank, Rochester, MN
2:00
PD29-07 AGE IS THE PRIMARY PREDICTOR OF
RENAL MASS OBSERVATION
Matthew Maurice*, Robert Abouassaly, Simon
Kim, Hui Zhu, Cleveland, OH
2:10
2:20
PD29-08 PREDICTIVE FACTORS FOR THE
DEVELOPMENT OF RENAL
INSUFFICIENCY FOLLOWING PARTIAL
NEPHRECTOMY AND SUBSEQUENT
RENAL FUNCTION RECOVERY
Kyo Chul Koo, Dae Keun Kim*, Sang Un
Park, Kwang Hyun Kim, Seoul, Korea,
Republic of, Woo Jin Bang, Chuncheon,
Korea, Republic of, Hyung Joon Kim,
Daejeon, Korea, Republic of, Sung Yul Park,
Seoul, Korea, Republic of, Changhee Yoo,
Chuncheon, Korea, Republic of, Byung Ha
Chung, Seoul, Korea, Republic of, Jin Seon
Cho, Chuncheon, Korea, Republic of, Koon
Ho Rha, Seoul, Korea, Republic of
2:30
PD29-10 ONCOLOGIC OUTCOMES AFTER PARTIAL
NEPHRECTOMY WITHOUT HILAR
CLAMPING
Rocco Papalia*, Giuseppe Simone,
Costantini Manuela, Del Giudice Francesco,
Rome, Italy, Al-Rawashdah Samer Fathi,
Maw’tah, Jordan, Pompeo Vincenzo,
Salvatore Guaglianone, Gallucci Michele,
Rome, Italy
2:40
PD29-11 RELATIONSHIP BETWEEN RENAL
OXYGENATION AND FUNCTION AFTER
PARTIAL NEPHRECTOMY
Satoshi Inoue*, Yasuhito Funahashi, Naoto
Sassa, Yasushi Yoshino, Ryohei Hattori,
Momokazu Gotoh, Nagoya, Japan
2:50
PD29-12 COMPARISON OF ONCOLOGICAL
OUTCOMES OF DISTAL URETERAL ⱕPT2
UROTHELIAL CARCINOMA MANAGED BY
NEPHROURETERECTOMY, SEGMENTAL
URETERECTOMY OR ENDOSCOPIC
SURGERY
Laurent Nison*, Pierre Colin, Lille, France,
Mesut Remzi, Korneuburg, Austria, Shahrokh
F. Shariat, Tobias Klatte, Vienna, Austria,
Rachid Yakoubi, Gregory Bozzini, Lille,
France, Umberto Capitanio, Milan, Italy,
Marek Babjuk, Prague, Czech Republic, Axel.
S Merseburger, Hanover, Germany, Eugene
Cha, New York, NY, Hans Martin Fritsche,
Regensburg, Germany, Giacomo Novara,
Padua, Italy, Francesco Montorsi, Milan, Italy,
Milan Hora, Prague, Czech Republic, Morgan
Rouprêt, Paris, France
PD29-09 EXTENDED FOLLOW-UP OF CHRONIC
KIDNEY DISEASE DUE TO SURGICAL
REMOVAL OF NEPHRONS: IMPACT ON
SURVIVAL AND FUNCTIONAL STABILITY
Sevag Demirjian*, Cleveland, OH, Brian
Lane, Grand Rapids, MI, Ithar Derweesh, La
Jolla, CA, Toshio Takagi, Zhiling Zhang, Liliya
Velet, Cesar Ercole, Amr Fergany, Steven
Campbell, Cleveland, OH
CREDITTM
1:00 pm - 3:00 pm
Podium Session 30
PROSTATE CANCER: LOCALIZED II
Moderators: Thomas Ahlering and Kevin Zorn
TIME
1:00
1:10
ABSTRACT
NUMBER TITLE
PD30-01 MR-US FUSION BIOPSY TO DIAGNOSE
PROSTATE CANCER: FIRST 1000 MEN AT
UCLA
Frederick Dorey, Robert Reiter, Leonard
Marks, Los Angeles, CA
ABSTRACT
TIME NUMBER TITLE
1:20
PD30-03 PREDICTING UNFAVORABLE PROSTATE
CANCER IN ACTIVE SURVEILLANCE
CANDIDATES TREATED WITH RADICAL
PROSTATECTOMY: A POPULATIONBASED STUDY
Nicola Fossati, Justin K. Lee, New York, NY,
Quoc-Dien Trinh, Boston, MA, Jesse
Sammon, Akshay Sood, Detroit, MI,
Alessandro Larcher, Marco Bianchi, Giorgio
Guazzoni*, Milan, Italy, Pierre I Karakiewicz,
Montreal, Canada, Shahrokh F. Shariat,
Briganti, Milan, Italy, Mani Menon, Firas
Abdollah, Detroit, MI
PD30-02 MRI-TRUS GUIDED FUSION BIOPSY TO
DETECT PROGRESSION ON ACTIVE
SURVEILLANCE FOR LOW AND
INTERMEDIATE RISK PROSTATE CANCER
Thomas P. Frye*, Nabeel Shakir, Steven
Abboud, Arvin K. George, Maria Merino,
Peter Choyke, Baris Turkbey, Bradford Wood,
Peter A. Pinto, Bethesda, MD
166
PD30-04 COMPARING ONCOLOGIC OUTCOMES OF
DIFFERENT DEFINITIVE TREATMENTS
FOR PROSTATE CANCER AFTER A
PERIOD OF ACTIVE SURVEILLANCE
Michael Whalen*, Danny Lascano, Jamie
Pak, David Ahlborn, Justin Matulay, James
McKiernan, Mitchell Benson, Sven Wenske,
New York, NY
1:40
PD30-05 WISDOM OF THE CROWDS: USE OF
CROWDSOURCING TO ASSESS
SURGICAL SKILL OF ROBOT-ASSISTED
RADICAL PROSTATECTOMY IN A
STATEWIDE SURGICAL COLLABORATIVE
James Peabody*, Detroit, MI, David Miller,
Ann Arbor, MI, Brian Lane, Grand Rapids, MI,
Richard Sarle, Dearborn, MI, Andrew
Brachulis, Susan Linsell, Tae-Kyung Kim,
Ann Arbor, MI, Deepansh Dalela, Mani
Menon, Detroit, MI, James Montie, Ann
Arbor, MI, Bryan Comstock, Tom Lendvay,
Seattle, MI, Khurshid Ghani, Ann Arbor, MI
1:50
2:00
2:10
PD30-06 MORTALITY RISK FACTORS IN
EUROPEAN PROSTATE CANCER
PATIENTS TREATED WITH RADICAL
PROSTATECTOMY. COMPETING RISK
ANALYSIS WITH 15-YEARS FOLLOW UP
Katharina Boehm*, Burkhard Beyer,
Hamburg, Germany, Alessandro Larcher,
Milan, Italy, Jonas Schiffmann, Hamburg,
Germany, Pierre Karakiewicz, Montreal,
Canada, Georg Salomon, Hartwig Huland,
Hamburg, Germany
PD30-07 ADHERENCE TO EUROPEAN
ASSOCIATION OF UROLOGY GUIDELINE
RECOMMENDATION FOR PELVIC LYMPH
NODE DISSECTION IN AN EUROPEAN
HIGH-VOLUME CENTER
Sami-Ramzi Leyh-Bannurah*, Jonas
Schiffman, Alexander Haese, Georg
Salomon, Thomas Steuber, Thorsten
Schlomm, Burkhard Beyer, Uwe Michl, Hans
Heinzer, Hartwig Huland, Markus Graefen,
Lars Budäus, Hamburg, Germany, Pierre
Karakiewicz, Montreal, Canada
PD30-08 CANCER-CONTROL OUTCOMES IN
PATIENTS WITH CLINICALLY HIGH-RISK
PROSTATE CANCER (PCA) TREATED
WITH ROBOTIC-ASSISTED
PROSTATECTOMY (RALP): A MULTIINSTITUTIONAL DATABASE ANALYSIS
Firas Abdollah*, Akshay Sood, Jesse
Sammon, Dane Klett, Daniel Pucheril, Detroit,
MI, Burkhard Beyer, Hamburg, Germany,
Nicola Fossati, Giorgio Gandaglia, Milan,
Italy, Craig Rogers, Hans Stricker, Wooju
Jeong, James Peabody, Detroit, MI,
Alexander Haese, Hamburg, Germany,
Francesco Montorsi, Milan, Italy, Markus
Graefen, Hamburg, Germany, Alberto
Briganti, Milan, Italy, Mani Menon, Detroit, MI
*Presenting author
2:20
PD30-09 THE EFFECT OF ANDROGEN
DEPRIVATION THERAPY FOR LOCALIZED
PROSTATE CANCER ON
CARDIOVASCULAR MORBIDITY
ACCORDING TO LIFE EXPECTANCY
Jesse Sammon, Detroit, MI, Gally Reznor,
Boston, MA, Victor Kapoor, Detroit, MI,
Jaqueline Speed, Boston, MA, Firas
Abdollah, Akshay Sood, Detroit, MI, Felix
Boston, MA, Mani Menon, Detroit, MI, Margit
Fisch, Hamburg, Germany, Maxine Sun,
Montreal, Canada, Quoc-Dien Trinh, Boston,
MA
2:30
PD30-10 EXTERNAL VALIDATION OF THE CAPRAS SCORE TO PREDICT BIOCHEMICAL
RECURRENCE, METASTASIS AND
MORTALITY AFTER RADICAL
PROSTATECTOMY IN A EUROPEAN
COHORT
Philipp Mandel*, Burkhard Beyer, Dirk
Pehrke, Thorsten Schlomm, Hartwig Huland,
Markus Graefen, Derya Tilki, Hamburg,
Germany
2:40
PD30-11 FATAL FAMILY HISTORY OF PROSTATE
CANCER AND APPARENT MODE OF
DISEASE TRANSMISSION: INDEPENDENT
PREDICTORS OF RADICAL
PROSTATECTOMY OUTCOMES?
Kathleen Herkommer*, Simon Heister,
Juergen Gschwend, Munich, Germany,
Martina Kron, Ulm, Germany
2:50
PD30-12 RACIAL DISPARITIES IN THE SURGICAL
CARE OF LOCALIZED PROSTATE
CANCER
Christian Meyer, Gally Reznor, Julian
Hanske, Boston, MA, Jesse Sammon, Firas
Abdollah, Akshay Sood, Deepansh Dalela,
Detroit, MI, Brandon Mahal, Adam Kibel,
Boston, MA, Felix Chun, Hamburg, Germany,
Paul Nguyen, Boston, MA, Mani Menon,
Detroit, MI, Margit Fisch, Hamburg, Germany,
Quoc-Dien Trinh, Boston, MA
CREDITTM
167
SUNDAY
1:30
1:00 pm - 3:00 pm
Video Session 7
PEDIATRICS
Moderators: Mohan Gundeti and Richard Schlussel
ABSTRACT
NUMBER TITLE
V7-01
BLADDER TRAINING FOR KIDS
Mandy Rickard*, Natasha Brownrigg, Jennifer
DCruz, Jorge DeMaria, Luis Braga, Hamilton,
Canada
V7-02
V7-03
V7-04
V7-05
ROBOTIC PARTIAL NEPHRECTOMY FOR
A COMPLEX HILAR MASS IN A 14 YEAR
OLD BOY
Abhishek Srivastava*, Aryeh Keehn, Amanda
North, Reza Ghavamian, Bronx, NY
V7-10
COMBINED LAPAROSCOPIC
PYELOLITHOTOMY AND
CYSTOLITHOTOMY IN A PEDIATRIC
PATIENT
Paul Bowlin*, Fahad Alyami, Walid Farhat,
Toronto, Canada
V7-11
MULTI-INSTITUTIONAL BLADDER
EXSTROPHY CONSORTIUM: COMPLETE
PRIMARY REPAIR OF EXSTROPHY
Joseph G. Borer*, Evalynn Vasquez, Anthony
J. Schaeffer, Boston, MA, Douglas A.
Canning, Philadelphia, PA, John V. Kryger,
Michael E. Mitchell, Milwaukee, WI
ROBOT-ASSISTED REPAIR OF A
CIRCUMCAVAL URETER IN A CHILD
Hubert Swana, Celebration, FL, Diego
Aguilar*, Orlando, FL, Alberto DuBoy, Tampa,
FL, Mark Rich, Orlando, FL
V7-12
IMMEDIATE LAPAROSCOPIC
RECONSTRUCTION OF AN ACUTE
IATROGENIC VESICO-VAGINAL FISTULA
BY A NEO-VAGINAL DILATOR IN A
PATIENT WITH MAYER-ROKITANSKYKÜSTER-HAUSER-SYNDROME
Wael Khoder*, Christian Stief, Maximiliane
Burgmann, Alexander Burges, Munich,
Germany
A NOVEL LAPAROSCOPIC SURGICAL
METHOD FOR COEXISTENCE OF
TESTICULAR VARICOCELE AND
IPSILATERAL HYDROCELE
Nobuhiro Takahashi*, Shoji Kudo, Hideki
Kobayashi, Satoshi Azuma, Tatsuya
Miyamoto, Hidenori Zakohji, Masayuki
Takeda, Chuo, Japan
V7-13
ROBOTIC ASSISTED LAPAROSCOPIC
ORCHIOPEXY: PRELIMINARY RESULTS
OF AN INITIAL CASE SERIES
Dana Point*, John Michael DiBianco, Osama
Al-Omar, Morgantown, WV
V7-14
ROBOT-ASSISTED LAPAROSCOPIC
NEPHROURETERECTOMY IN A 9-YEAROLD GIRL WITH OBSTRUCTED
HEMIVAGINA IPISILATERAL RENAL
ANOMALY
Amanda Saltzman*, Christopher Roth, New
Orleans, LA
ROBOT ASSISTED LAPAROSCOPIC
RENAL CALYCEAL DIVERTICULECTOMY
Joel Koenig*, Saint Louis, MO, Gino Vricella,
St. Louis, MO
V7-06
ROBOTIC CONVERSION OF CECOSTOMY
TUBE TO MALONE ANTEGRADE
CONTINENCE ENEMA (ACE), SURGICAL
TECHNIQUE
Mourad Abouelleil*, Raju Chelluri, Jonathan
Riddell, Syracuse, NY
V7-07
COMBINED ROBOTIC AND OPEN
APPROACH TO EXCISION OF
ACCESSORY BLADDER AND URETHRAL
TRIPLICATION
Diana K. Bowen, Alex P. Glaser*, Jonathan
W. Bush, Earl Y. Cheng, Edward M. Gong,
Chicago, IL
V7-08
ABSTRACT
NUMBER TITLE
V7-09
URETEROCALICOSTOMY IN THE
PEDIATRIC PATIENT
Ashley Wietsma*, Patricia Cho, Richard Yu,
Boston, MA
CREDITTM
LOWER TO UPPER
PYELOURETEROSTOMY IN THE
PEDIATRIC PATIENT
Ashley Wietsma*, Patricia Cho, Richard Yu,
Boston, MA
168
1:00 pm - 3:00 pm
RESEARCH FORUM: SESSION I
“FUNDING OPPORTUNITIES AND GRANTWRITING GUIDANCE FOR EARLY-CAREER INVESTIGATORS”
NIDDK TRAINING & RESEARCH MECHANISMS
Tracy Rankin
PERSPECTIVES FROM AN EARLY-CAREER
INVESTIGATOR
William Roberts
2:17
DOD/CDMRP FUNDING OPPORTUNITIES FOR
UROLOGIC RESEARCH AND TRAINING
Melissa Cunningham
PERSPECTIVES FROM A SENIOR
INVESTIGATOR
Peter Clark
2:29
Q&A
2:55
CLOSING REMARKS
Carolyn Best
3:00
ADJOURN
COURSE OVERVIEW AND GOALS
Carolyn Best
1:05
1:17
1:29
AUA AND UROLOGY CARE FOUNDATION
OPPORTUNITIES
Carolyn Best
1:41
OTHER EXTERNAL FUNDING SOURCES
1:53
STRATEGIES FOR OBTAINING FUNDING
WHEN FUNDS ARE TIGHT/BRIDGE FUNDING
Matthew Fraser
SUNDAY
2:05
1:00
CREDIT TM
3:00 pm - 5:30 pm
RESEARCH FORUM: SESSION II
“EARLY CAREER INVESTIGATOR SHOWCASE”
4:25
LOW OSTEOCALCIN LEVELS IS AN
INDEPENDENT FACTOR ASSOCIATED WITH
ANDROGEN DEFICIENCY
Brian Le
4:35
BASELINE PROSTATE SPECIFIC ANTIGEN
(PSA) LEVEL IN MIDLIFE PREDICTS LETHAL
PROSTATE CANCER
Mark Preston
A NEWLY IDENTIFIED ROLE FOR
INTERLEUKIN-22 IN BLADDER IMMUNITY
Michael Hsieh
4:45
RESTORING FERTILITY FOR MEN AND BOYS
FACING STERILIZING CANCER THERAPY
James Smith
3:55
THE CUPID STUDY: CARDIO-UROLOGIC
PATHOLOGY/PREVALENCE INTERPLAY
DETERMINATION STUDY
Tobias Kohler
4:55
DEVELOPMENTAL TRANSCRIPTION FACTORS
AND PROSTATE CANCER PROGRESSION
Donald Vander Griend
4:05
DEVELOPMENT AND VALIDATION OF THE
BLADDER UTILITY SYMPTOM SCALE (BUSS)
Girish Kulkarni
5:05
AUA/UROLOGY CARE FOUNDATION
RESEARCH ACTIVITIES
Carolyn Best
4:15
ACCELERATING RECOVERY OF NORMAL
URETERAL FUNCTION FOLLOWING
OBSTRUCTIVE UROPATHY
Dirk Lange
5:20
PRESENTATION OF AWARDS
5:30
ADJOURN
3:00
EARLY CAREER INVESTIGATORS POSTER
VIEWING
3:30
PROGRAM INTRODUCTION
Carolyn Best
3:35
THE IMPACT OF CARE COORDINATION ON
RADICAL PROSTATECTOMY OUTCOMES
John Hollingsworth
3:45
CREDIT TM
1:00 pm - 4:30 pm
SOCIETY FOR INFECTION AND INFLAMMATION IN UROLOGY (SIIU)
1:00
OPENING COMMENTS
Society Chair: Dean Tripp
1:10
TALKS FROM THE FLOOR
*Presenting author
2:10
169
INTRO OF SIIU INVITED SPEAKERS
2:15
2:35
2:55
THE URINARY TRACT MICROBIOME: WHAT
WE THINK WE KNOW
Michael Freeman
3:10
DEBATE/ QUESTIONS FROM THE FLOOR
3:35
SIIU GENERAL MEETING
THE URINARY TRACT MICROBIOME: WHAT
WE’RE LEARNING FROM NEXT GENERATION
TECHNOLOGIES
Jennifer Anger
4:30
ADJOURN
CREDITTM
PRESENTATION OVERVIEW AND
REFLECTIONS
J. Curtis Nickel
1:00 pm - 4:30 pm
Live Surgery Program
LIVE SURGERY II
Moderators: Amy Krambeck and Nicole Miller
3:30
1:00
PROSTATIC URETHRAL LIFT FOR BPH
Surgeon: Daniel Rukstalis
Panelist: Eugene Rhee
1:30
PLASMA BUTTON BIPOLAR (BIPOLAR TURBT
WITH NBI IMAGING)
Surgeons: Raju Thomas, Jonathan Silberstein
Panelists: Harry Herr, Mark Soloway
2:30
MINI INVASIVE PERCUTANEOUS
NEPHROLITHOTOMY
Surgeon: Jorge Gutierrez-Aceves
Panelists: Amy Krambeck, Nicole Miller
CREDITTM
PDD CYSTOSCOPY AND RESECTION OF
BLADDER TUMORS
Surgeon: Anne Schuckman
Panelists: Harry Herr, Mark Soloway
1:00 pm - 4:40 pm
History Forum I
HISTORY OF UROLOGY I (PODIUM)
TIME
1:00
1:10
1:20
1:30
1:40
ABSTRACT
NUMBER TITLE
FRI-01
LIGHTS, CAMERA, ACTION: WIRT DAKIN
AND THE INTRODUCTION OF FILM AS A
UROLOGIC TRAINING TOOL
Unwanaobong Nseyo*, San Diego, CA,
Leonard Marks, Los Angeles, CA
FRI-02
FRI-03
FRI-04
FRI-05
ABSTRACT
TIME NUMBER TITLE
1:50
FRI-06
GENITAL BEADING: A HISTORICAL
“SPEED BUMP” ON THE ROAD TO
SEXUAL SATISFACTION
Casey McCraw*, John DiBianco, Zachary
Klaassen, Ronald Lewis, Martha Terris,
Augusta, GA
FOREIGN BODIES IN THE BLADDERMEDICAL CURIOSITIES THROUGH THE
AGES
Friedrich Moll*, Thorsten Halling, Heiner
Fangerau, Cologne, Germany
CANDIRU: THE URETHRAL INVADER’
FISH - MYTHS AND FACTS
Marios Hadjipavlou*, Portsmouth, United
Kingdom, June Tay, London, United
Kingdom, Yiannis Philippou, Basildon, United
Kingdom
CLOACAL EXSTROPHY: A HISTORY OF
GENDER REASSIGNMENT
Jennifer Gordetsky*, David Joseph,
Birmingham, AL
CURIOSITY OR CURE? THE CASE OF
SURGICAL CASTRATION
Barbara Chubak*, Paul Gittens, Bronx, NY
170
2:00
FRI-07
HOW A RECORDING COMPANY, A BAND
AND A NOBEL LAUREATE DEVELOPED
COMPUTED TOMOGRAPHY
Sutchin R. Patel*, Madison, WI, Nicholas A.
Rotker, Anthony A. Caldamone, Providence,
RI
2:10
FRI-08
ERECTILE DYSFUNCTION: A HISTORICAL
REVIEW OF TREATMENT OPTIONS WITH
A FOCUS ON THE DEVELOPMENT OF THE
Amanda Saltzman, Kristi L. Hebert*, Kristen
Gurtner, Eric Laborde, New Orleans, LA
2:20
FRI-09
THE CURIOUS CASE OF DR. LEVI
HAMMOND: TRANSPLANTATION GALORE
OF 1911
Pamela Baron*, David Schulsinger, Yefim
Sheynkin, Stony Brook, NY
FRI-10
MITOMYCIN-C: HISTORICAL ASPECTS OF
THE DISCOVERY OF MOST COMMONLY
USED CHEMOTHERAPY AGENT IN
UROLOGY
Hemant Nemade*, Hussein Tukmatchy,
Basildon, United Kingdom, Peter Thompson,
4:00
FRI-15
A HISTORY OF TRADITIONAL CHINESE
MEDICINE (TCM) AND ITS CURRENT
ROLE IN UROLITHAISIS
Li June Tay*, London, United Kingdom, Di
Gu, Guangzhou, Guangdong, China, People’s
Republic of, Robert Gray, Peter Thompson,
2:40
FRI-11
THE UROLOGICAL DRAWINGS OF
LEONARDO DA VINCI
Giorgio Bozzini*, Dario Ratti, Carlo Marenghi,
Elisabetta Finkelberg, Luca Carmignani,
Milano San Donato M.se, Italy
4:10
FRI-16
WERNER FORSSMANN – A NOBEL PRIZE
WINNER AND HIS POLITICAL ATTITUDE
BEFORE AND AFTER 1945
Lisa-Maria Packy*, Matthis Krischel, Dominik
Groß, Aachen, Germany
2:50
THE 2014 AUA EARL NATION
RETROSPECTROSCOPE AWARD
Effie Poulakou-Rebelakou for “Syphilis’ Impact
On Late Works of Classical Music Composers”
4:20
FRI-17
FRACTURED FAIRY TALES- UROLOGIST
IN THE MIDDLE
Michael Moran*, McComb, MS
4:30
FRI-18
3:00
BICKNELL LECTURE
David K.C. Cooper, MD, PHD, FRCS: “CrossSpecies Kidney Transplantation – History,
Experimental Progress, and Clinical Potential”
ROBERT BENJAMIN GREENBLATT AND
HIS MANY PURSUITS: AN UNLIKELY
FOUNDER OF THE TESTOSTERONE
PELLET
Zachary Klaassen*, Lael Reinstatler, Casey
O. McCraw, Roger Chen, Martha K. Terris,
Durwood E. Neal, Jr, Ronald W. Lewis,
Arthur M. Smith, Augusta, GA
3:30
FRI-12
THE FAULT IN OUR PVRS
Lawrence Wyner*, Huntington, WV
3:40
FRI-13
THE BURDEN OF SEGREGATION, FROM
THE MISSOURI COMPROMISE TO THE
PROTESTS IN FERGUSON, MO OBSTACLES TO BECOMING A BLACK
SURGEON/ UROLOGIST
Steven Brandes*, Saint Louis, MO, Julio
Geminiani, Stephen Marshall, St. Louis, MO
3:50
FRI-14
ERASTUS B WOLCOTT: A PIONEER IN
RENAL SURGERY AND WISCONSIN
MEDICINE
Sara Best*, Madison, WI
CREDITTM
4:40 pm - 5:30 pm
History Forum II
HISTORY OF UROLOGY II (POSTER)
TIME
4:40
4:43
4:46
4:49
ABSTRACT
NUMBER TITLE
FRII-01 BEHIND THE NAME: THE HISTORICAL
PERSPECTIVE OF THE PATHOLOGIZING
OF ATYPICAL SEXUAL DEVELOPMENT
Matthew Truesdale*, Hillary Copp, San
Francisco, CA
FRII-02
FRII-03
FRII-04
*Presenting author
ABSTRACT
TIME NUMBER TITLE
4:52
FRII-05 THE OLDEST RETAINED URETERAL
STENT: A HISTORY OF THE URETERAL
STENT
Rishi Modh*, James Mason, Akira
Yamamoto, Thomas Stringer, Vincent Bird,
Gainesville, FL
PEARLS OF WISDOM: A HISTORY OF
MALE GENITAL ORNAMENTATION
Justina Tam*, Wai Lee, Howard L. Adler,
Stony Brook, NY
CASTRATION OF SEXUAL OFFENDERS IN
THE UNITED STATES
Ariel Schulman*, Ruben Pinkhasov, Ciril
Godec, David Silver, Brooklyn, NY
SIR PERCIVALL POTT AND SOOT WART:
THE EFFECTS OF SCROTAL CANCER ON
CHILD LABOR LAWS IN THE BRITISH
EMPIRE
Drew Palmer*, Kari Bailey, Shiv Patel,
Burlington, MA
171
4:55
FRII-06
THE LIFE AND CONTRIBUTIONS OF
JOAQUÍN MARÍA ALBARRÁN Y
DOMÍNGUEZ
Ricardo Palmerola*, Richard Ashley, New
Hyde Park, NY
4:58
FRII-07
THE HISTORY OF PELVIC ORGAN
PROLAPSE FROM ANTIQUITY TO
PRESENT DAY
John Mattimore*, Stony Brook, NY, Philippa
Cheetham, Aaron Katz, Garden City, NY
5:01
FRII-08
EDWARD CANNY RYALL: THE LOST
UROLOGIST
William Gallagher*, Emma Sabin, Jonathen
Goddard, Leicester, United Kingdom
SUNDAY
2:30
5:04
FRII-09
FROM ULTRASOUND TO ‘HIGH
INTENSITY FOCUSSED ULTRASOUND’: A
BRIEF HISTORY OF ULTRASOUND AS A
THERAPEUTIC MODALITY
Michael Wanis*, Marios Hadjipavlou,
Portsmouth, United Kingdom
5:16
FRII-13
NOT LACKING IN TESTICULAR
FORTITUDE: THE EUNUCHS OF IMPERIAL
CHINA
Roger Chen*, Zachary Klaassen, Casey
McCraw, Durwood Neal, Martha Terris, Arthur
Smith, Ronald Lewis, Augusta, GA
5:07
FRII-10
A TRIBUTE TO SIR DAVID INNES
WILLIAMS: THE FOUNDER OF PEDIATRIC
UROLOGY
Mohit Sirohi*, New York, NY, Aizid Hashmat,
Brooklyn, NY, Harris Nagler, Zafar Khan,
New York, NY
5:19
FRII-14
SEXUAL MEDICINE AND THE “SIXTH
SENSE”: EVOLUTION OF THE MALE
SEXUAL CASE HISTORY
Susanne Quallich*, Dana Ohl, David Bloom,
Ann Arbor, MI
5:10
FRII-11
A HISTORICAL PERSPECTIVE ON THE
DISCOVERY OF THE PROSTATE
Alberto Coscione*, Michalis Varnavas, Arun
Sujenthiran, Samer Katmawi-Sabbagh,
5:13
FRII-12
HISTORY OF THE TRANSURETHRAL
RESECTION OF THE PROSTATE: THE
GOLD STANDARD AND ITS ROLE IN THE
21ST CENTURY
Marcus Austenfeld*, Ajay Nangia, Kansas
City, KS
CREDITTM
1:00 pm - 5:00 pm
KOREAN WORLD UROLOGIC CONGRESS (KWUC)
1:00
OPENING REMARKS
Society President: Myung-Soo Choo
1:10
MANAGEMENT OF MUSCLE-INVASIVE
BLADDER CANCER
Moderator: Hong-Sup Kim
CURRENT TREATMENT OF VARIANT
HISTOLOGY
Ashish Kamat
1:25
KOREAN CONTEMPORARY MULTIINSTITUTIONAL DATA ON TREATMENT
OUTCOME AFTER RADICAL CYSTECTOMY IN
Sun Il Kim
1:40
ROBOTIC INTRA-CORPOREAL DIVERSION
Mihir Desai
1:55
CASE DISCUSSION: HIGH RISK BLADDER
CANCER
Presenter: Seok-Ho Kang
Panelists: Ho Kyung Seo, Byong Chang Jeong
2:20
COFFEE BREAK
2:40
MANAGEMENT OF PROSTATE CANCER
Moderator: Hanjong Ahn
PATHOLOGIC FINDINGS OF MULTIINSTITUTIONAL DATA IN KOREA
Jun Cheon
3:25
CASE DISCUSSION: LOCALLY ADVANCED
PROSTATE CANCER
Presenter: Dong-Deuk Kwon
Panelists: Hong Koo Ha, Sang-Heon Cheon
3:50
PEDIATRIC UROLOGY
Moderator: Sang Won Han
RECONSTRUCTIVE SURGICAL OPTIONS IN
PEDIATRIC NEUROGENIC BLADDER
Barry Kogan
MANAGEMENT OF POSITIVE SURGICAL
MARGIN AFTER RADICAL PROSTATECTOMY
Arieh Shalhav
2:55
3:10
4:05
ANTIMICROBIAL PROPHYLAXIS FOR
CHILDREN WITH VESICO-URETERAL REFLUX
Antoine Khoury
4:20
LONG-TERM OUTCOME OF PEDIATRIC
PYELOPLASTY
Kwanjin Park
4:35
CASE DISCUSSION: OPTIMAL MANAGEMENT
OF VESICO-URETERAL REFLUX IN THE ERA
OF DELAYED VCUG
Presenter: Yong Seung Lee
Panelists: Sang Don Lee, Kun Kim
5:00
CLOSING REMARKS
ADJOURN
CYTOREDUCTIVE PROSTATECTOMY IN
Isaac Kim
CREDITTM
172
1:00 pm - 5:30 pm
1:00
Society Chair: Tomas Griebling
1:05
STATE-OF-THE-ART PLENARY PANEL:
CONSIDERATIONS FOR RECONSTRUCTIVE
UROLOGY IN GERIATRIC PATIENTS
(INCLUDING URINARY INCONTINENCE,
PELVIC ORGAN PROLAPSE, URETHRAL
DISEASE, AND TRAUMA)
Moderator: Tomas Griebling
Panelists: Theodore Johnson, J. Christian Winters,
Joshua Broghammer, Allen Morey, Tracey Wilson
2:30
CASE PRESENTATIONS, QUESTIONS AND
DISCUSSION
3:15
BREAK
3:30
INTERNATIONAL ROUNDTABLE: GERIATRIC
UROLOGY IN GLOBAL CONTEXT
Moderator: Ananias Diokno
4:15
4:30
PAPERS SUBMITTED FOR PRESENTATION AT
THE GERIATRIC UROLOGICAL SOCIETY
Moderator: Ananias Diokno
5:15
5:30
ADJOURN
CREDITTM
2:00 pm - 5:00 pm
BRITISH ASSOCIATION OF UROLOGICAL SURGEONS (BAUS) / BJU INTERNATIONAL (BJUI) / UROLOGICAL SOCIETY OF
AUSTRALIA AND NEW ZEALAND (USANZ)
2:00
URO-ONCOLOGY
Chairman: Mark Frydenberg
3:30
AFTERNOON TEA
4:00
TECHNOLOGICAL ADVANCES
Chairman: Mark Speakman
UPDATE IN THE CONTEMPORARY
MANAGEMENT OF UPPER TRACT TCC
Stephen Boorjian
2:15
2:30
ADVANCES IN THE MANAGEMENT OF LUTS/
BPH
Henry Woo
THE ROLE OF FOCAL THERAPY IN
LOCALISED PROSTATE CANCER,
PRELIMINARY AUSTRALIAN RESULTS
Phillip Stricker
4:15
THE ROLE OF PET PSMA IN THE STAGING
AND RE-STAGING OF MEN WITH PROSTATE
CANCER
Declan Murphy
BJUI GUEST SPEAKER: THE EVIDENCE FOR
PARTIAL NEPHRECTOMY FOR THE
MANAGEMENT OF RCC
Ben Challacombe
4:30
WHAT IS THE EVIDENCE TO SUPPORT
ROBOTIC CYSTECTOMY FOR TCC BLADDER?
Prokar Dasgupta
4:45
THE ROLE OF MINIMALLY INVASIVE
SURGERY FOR RETROPERITONEAL LYMPH
NODE DISSECTION
David Nicol
5:00
ADJOURN
2:45
BRCA 1/2 MUTATIONS, EVIDENCE BASED
IMPLICATIONS FOR SCREENING AND ACTIVE
SURVEILLANCE
Damien Bolton
3:00
SURGERY FOR HIGH RISK PROSTATE
CANCER INCLUDING METASTATIC DISEASE
Daniel Moon
3:15
RESULTS FROM THE VICTORIAN TRANSPERINEAL PROSTATE BIOPSY
COLLABORATIVE GROUP
Jeremy Grummet
BJUI RECEPTION
2:00 pm - 5:00 pm
JAPANESE UROLOGICAL ASSOCIATION (JUA)
2:00
OPENING REMARKS
AUA Secretary: Gopal Badlani
*Presenting author
2:05
173
PROSTATE CANCER - PARADIGM SHIFT IN
THE TREATMENT OF CASTRATION
RESISTANT PROSTATE CANCER
Moderators: Hirotsugu Uemura, Robert Reiter
SUNDAY
GERIATRIC UROLOGICAL SOCIETY (GUS)
LECTURE 1: IMMUNOTHERAPY OF
CASTRATE-RESISTANT PROSTATE CANCER:
PROGRESS AND NEW PARADIGMS
Takahiro Kimura
3:50
BREAK
4:05
AGING MALE
Moderators: Yoshiyuki Kakehi, Tomas Griebling
2:15
LECTURE 2: EMERGING NEW DRUGS AND
REGIMENS FOR CASTRATE RESISTANT
PROSTATE CANCER (CRPC)
A. Oliver Sartor
4:05
LECTURE 1: TESTOSTERONE LEVELS,
DEPRESSIVE SYMPTOMS, AND FALLS IN
OLDER MEN
Shigeo Horie
2:30
PANEL DISCUSSION: TREATMENT OF CRPCWHAT IS THE BEST MANAGEMENT
Panelists: Natasha Kyprianou, Shinichi Sakamoto,
Teruo Inamoto, A. Oliver Sartor
4:15
LECTURE 2: METABOLIC SYNDROME AND
LOWER URINARY TRACT SYMPTOMS (LUTS)
Kevin McVary
4:25
3:00
Moderators: Masatoshi Eto, Robert Flanigan
PANEL DISCUSSION: APPROACHES TO
COMPLICATED CASES OF MALE LUTS
Panelists: Koji Shiraishi, Ajay Singla, Eiji Kikuchi,
Tomas Griebling
4:55
CLOSING REMARKS
Seiji Naito
5:00
ADJOURN
LECTURE 1: PREDICTING OCCULT
MULTIFOCALITY OF RENAL CELL
CARCINOMA
Dipen Parekh
3:10
LECTURE 2: HOW TO ASSESS THE RESPONSE
TO TARGETED THERAPIES IN PATIENTS
WITH METASTATIC RENAL CELL CARCINOMA
Nobuo Shinohara
3:20
PANEL DISCUSSION: WHAT IS YOUR CHOICE
OF TREATMENT FOR THIS SITUATION
Panelists: Robert Flanigan, Dipen Parekh, Kazutaka
Saito, Motohide Uemura, Katsunori Tatsugami
CREDITTM
2:00 pm - 6:00 pm
AUA/FDA/SUO WORKSHOP
3:27
FDA REGULATORY ISSUES IN PARTIAL
GLAND ABLATION
Jonathan Jarow
PERFORMANCE CHARACTERISTICS OF
MPMRI AT CENTERS OF EXCELLENCE
Peter Choyke
3:34
SESSION 1: PARTIAL GLAND ABLATION FOR
PROSTATE CANCER
Moderators: Peter Scardino, Peter Carroll
PATHOLOGIC CONSIDERATIONS IN PARTIAL
GLAND ABLATION
Jonathan Epstein
3:41
SUMMARY OF CONSENSUS REPORTS ON
PARTIAL GLAND ABLATION IN PROSTATE
CANCER: THE ROLE OF IMAGING IN PARTIAL
GLAND ABLATION AND OPTIMAL BIOPSY
TECHNIQUES
Leonard Marks
3:48
PANEL DISCUSSION: ROLE OF MRI IN
PATIENT SELECTION AND ENDPOINT
DETERMINATION
Panelists: Behfar Ehdaie, Peter Pinto, Hebert Vargas
4:23
BREAK
4:33
SESSION 3: DESIGNING CLINICAL TRIALS TO
MEASURE OUTCOMES IN PARTIAL GLAND
ABLATION
Moderators: Samir Taneja, Laurence Klotz
4:35
MEASURING CANCER-SPECIFIC OUTCOMES:
DEFINING VALID SHORT-TERM AND
INTERMEDIATE ENDPOINTS IN PARTIAL
GLAND ABLATION?
Scott Eggener
2:00
INTRODUCTION AND WELCOME
Co-Chairs: Jonathan Jarow, Peter Scardino
2:05
2:20
2:25
OVERVIEW OF TECHNOLOGY USED IN
CANCER
Jonathan Coleman
2:32
CANCER: INDICATIONS
Hashim Ahmed
2:39
PANEL DISCUSSION: THE BENEFITS AND
RISKS OF PARTIAL GLAND ABLATION IN
PROSTATE CANCER FOR VARIOUS PATIENT
GROUPS
Panelists: James Kiefert, Peter Kellogg, Eric Klein,
Mark Emberton, Adam Kibel
3:25
SESSION 2: IMAGING TO AID PATIENT
SELECTION AND GUIDE TREATMENT
Moderators: Mark Emberton, Gerald Andriole
174
4:42
MEASURING PATIENT-CENTERED OUTCOMES
IN PARTIAL GLAND ABLATION: DEFINING A
MINIMUM SET
Martin Sanda
4:49
CANCER: CLINICAL TRIAL DESIGNS (PART)
Freddie Hamdy
4:56
PANEL DISCUSSION: HOW TO ASSESS THIS
TECHNOLOGY FOR CLINICAL ADOPTION AND
REGULATORY APPROVAL
Panelists: Thomas Polascik, Howard Sandler,
Michael Cookson, Craig Pynn, Terrance Kungel
5:55
CONCLUSION
6:00
ADJOURN
2:00 pm - 6:00 pm
UROLOGICAL CONGENITALISM FORUM
Grand Salon 21 & 24 @ Hilton New Orleans Riverside
2:00
INTRODUCTIONS AND WELCOME
2:10
OVERVIEW OF OUTCOMES OF NIDDK
WORKSHOP: RESEARCH NEEDS FOR
EFFECTIVE TRANSITION IN LIFELONG CARE
OF CONGENITAL GENITOURINARY
CONDITIONS
Tamara Bavendam
2:30
3:30
CASE 2: MALE WITH MYELOMENINGOCELE
MANAGED WITH ILEAL CONDUIT SEEKING
CONTINENT DIVERSION
Case Presenter: Stephanie Kielb
Panelists: John Thomas, Jeremy Myers
4:30
CASE 3: FEMALE WITH BLADDER
EXSTROPHY PRESENTS 6 WEEKS PREGNANT
Case Presenter: Dan Wood
Panelists: John Gearhart, Margit Fisch
5:30
SUMMARY AND TAKE-HOME MESSAGES
CASE PRESENTATIONS
CASE 1: FEMALE WITH RECURRENT CYSTITIS
AND VESICOURETERAL REFLUX IN
CHILDHOOD SEEKING CONSULTATION FOR
PREGNANCY MANAGEMENT
Case Presenter: Martin A. Koyle
Panelists: Ariella Friedman, David Ginsberg
CREDITTM
2:00 pm - 7:45 pm
R. FRANK JONES UROLOGICAL SOCIETY
2:00
WELCOME AND PRESIDENT’S UPDATE
Society President: Kevin Billups
2:10
IMPLICATIONS OF CHRONIC SLEEP
DISORDERS ON MEN’S HEALTH
Charlene Gamaldo
4:00
BREAK
4:15
MINORITY MEN’S HEALTH SYMPOSIUM
Moderator: Charles Modlin
INTRODUCTION
Charles Modlin
2:35
AUDIENCE RESPONSE/QUESTIONS AND
ANSWERS
4:25
MEDICAL ASPECTS OF MEN’S HEALTH
Kevin Billups
2:40
UPDATE FROM THE AUA EDUCATION
COUNCIL
Cheryl Lee
4:55
IMPACT OF SOCIAL DETERMINANTS ON
MEN’S HEALTH
Roland Thorpe
2:50
REPORT: AUA LEGISLATIVE AFFAIRS
COMMITTEE UPDATE
Brian Stone, Chiledum Ahaghotu
5:15
MASCULINITY AND ITS IMPACT ON HEALTH
BEHAVIORS
Derek Griffith
3:10
NEW PARADIGMS FOR EARLY DETECTION OF
CARDIOMETABOLIC RISK IN MEN: EMERGING
ROLE OF ED AND TRT
Martin Miner
5:35
IMPLICATIONS OF POLICY & PROGRAM
REFORM
April Young
3:25
ANSWERS
5:55
Q & A/PANEL DISCUSSION: IMPLEMENTING
MINORITY MEN’S HEALTH AT THE
COMMUNITY LEVEL
3:30
HEPATITIS C INFECTION AMONG AFRICAN
AMERICAN MEN: REVISITING STD’S AS AN
EMERGING PARADIGM IN MEN’S HEALTH
R. Douglas Bruce
6:30
CONCLUDING REMARKS
6:45
RECEPTION
3:55
CREDITTM
ANSWER
*Presenting author
175
SUNDAY
2:55 pm - 6:00 pm
SOCIEDAD ARGENTINA DE UROLOGIA (SAU)
2:55
APERTURA DEL SIMPOSIO (INTRODUCTION)
3:00
LOS RESULTADOS ECONÓMICOS DEL
TRATAMIENTO DE LA LITIASIS URINARIA
(ECONOMIC OUTCOMES OF TREATMENT OF
UROLITHIASIS)
Speaker: Norberto Bernardo
Moderators: Alejandro Nolazco, Miguel Rivero
3:15
ESTENOSIS DE LA URETRA SECUNDARIAS A
LA CIRUGÍA DESOBSTRUCTIVA POR HPB
(URETHRAL STRICTURES SECONDARY TO
BPH-LUTS SURGERY)
Speaker: Carlos Giudice
Moderators: Claudio Koren, Norberto Lafos
3:30
3:45
4:00
LAS ESTRATEGIAS Y LAS CONSIDERACIONES
EN LA PLANIFICACIÓN Y LA REALIZACIÓN DE
LA NEFRECTOMÍA PARCIAL (STRATEGIES
AND CONSIDERATIONS IN PLANNING AND
PERFORMING PARTIAL NEPHRECTOMY)
Speaker: Jose Juan Rozanec
Moderators: Adrian Momesso, Angel Martin Piana
LAS COMPLICACIONES EN LA
PROSTATECTOMIA RADICAL
LAPAROSCÓPICA: CÓMO EVITARLAS Y CÓMO
RESOLVERLAS (COMPLICATIONS IN
LAPAROSCOPIC RADICAL PROSTATECTOMY:
HOW TO AVOID AND HOW TO RESOLVE
THEM)
Speaker: Gonzalo Vitagliano
Moderators: Carlos Ameri, Martin Del Sordo
LAS COMPLICACIONES CON LA CIRUGÍA
ROBÓTICA: CÓMO EVITARLAS Y CÓMO
RESOLVERLAS (ROBOTIC SURGERY
COMPLICATIONS: HOW TO AVOID AND
MANAGE THEM)
Speaker: Antonio Villamil
Moderators: Fernando Secin, Juan Carlos Tejerizo
4:30
LA TERAPIA MULTIFOCAL PARA MEJORAR
LA CALIDAD DE VIDA EN LOS PACIENTES
CON LUTS (MULTIFOCAL THERAPY TO
IMPROVE THE QUALITY OF LIFE IN PATIENTS
WITH LUTS)
Speaker: Osvaldo Mazza
Moderator: Miguel Costa
5:00
MESA REDONDA: CÁNCER DE PRÓSTATA
AVANZADO (ROUND TABLE: ADVANCED
PROSTATE CANCER)
INTRODUCIÓN (INTRODUCTION)
Miguel Costa
5:10
ACTUALIZACIONES CLAVE EN CPRCM: DE
ESMO A ASCO GU (KEY UPDATES IN MCRPC:
FROM ESMO TO ASCO GU)
Speaker: Antonio Alcaraz
5:30
PUNTO Y CONTRAPUNTO: “TERAPIAS
NOVELES VS TERAPIAS TRADICIONALES
COMO TRATAMIENTO HORMONAL DE
ELECCIÓN AL DIAGNÓSTICO DE CPRC”
(POINT - COUNTER-POINT: “NEW THERAPIES
VS TRADITIONAL THERAPIES AS HORMONAL
TREATMENT OF CHOICE FOR MCRPC”)
Speakers: Antonio Alcaraz, Claudio Alberto
Graziano, Ricardo Nardone, Carlos Scorticati
5:50
CONCLUSIONES (CONCLUSIONS)
Moderators: Antonio Alcaraz, Miguel Costa
6:00
ADJOURN
3:30 pm - 5:30 pm
ASSOCIATION FRANCAISE D’UROLOGIE (AFU)
3:30
WELCOME BY THE AFU DELEGATE
Emmanuel Chartier-Kastler
3:35
LOW RISK PROSTATE CANCER DIAGNOSIS
AND MANAGEMENT
Laurence Klotz, Guillaume Ploussard
4:30
MALE URINARY INCONTINENCE
MANAGEMENT
Daniel Elliott, Xavier Game
176
5:25
CONCLUSION OF THE MEETING AND
SUMMARY BY THE PRESIDENT OF AFU
Jean-Luc Descotes
5:30
ADJOURN
3:30 pm - 5:30 pm
PEDIATRICS: URINARY TRACT INFECTIONS/VESICOURETERAL REFLUX
Moderators: Joseph Ortenberg and Abhishek Seth
ABSTRACT
NUMBER TITLE
MP54-08 INCIDENCE AND RISK FACTORS FOR
POSITIVE URINE CULTURE AT THE TIME
OF PEDIATRIC UROLOGIC SURGERY
Michael A Maccini*, David Chalmers, Jeffrey
B Campbell, Aurora, CO
MP54-09 ANTIMICROBIAL EXPOSURE AND
UROPATHOGEN RESISTANCE: AN
ANALYSIS OF INDIVIDUAL PATIENT DATA
FROM RCTS ON ANTIBIOTIC
PROPHYLAXIS AND THE PREVENTION OF
UTI
Rachel Sharon Selekman*, Daniel J Shapiro,
Hillary L Copp, San Francisco, CA
MP54-02 MULTI-INSTITUTIONAL ANALYSIS AND
VALIDATION OF THE VESICOURETERAL
REFLUX INDEX (VURX)
Angela M. Arlen*, Iowa City, IA, Aaron D.
Weiss, Michael Garcia-Roig, Traci Leong,
Atlanta, GA, Christopher S. Cooper, Iowa
City, IA, Andrew J. Kirsch, Atlanta, GA
MP54-10 THE IMPACT OF OBESITY ON FEBRILE
URINARY TRACT INFECTION AND RENAL
SCARRING IN CHILDREN WITH
VESICOURETERAL REFLUX
Ji Yong Ha*, Hye Jin Byun, Wonho Jung,
Byung Hoon Kim, Chol Hee Park, Chun Il
Kim, Daegu, Korea, Republic of, Kyung Seop
Lee, Gyeongju, Korea, Republic of, Jae Ho
Kim, , Korea, Republic of
MP54-03 COST EFFECTIVENESS OF
ANTIMICROBIAL PROPHYLAXIS FOR
CHILDREN IN THE RIVUR TRIAL
Casey Seideman*, Lake Success, NY, Yair
Lotan, Dallas, TX, Lane Palmer, Lake
Success, NY
MP54-04 THE NEW DIAGNOSTIC APPROACH
USING URETERAL JET ANGLE
MEASUREMENT IN CHILDREN WITH
URINARY TRACT INFECTION
Zenichi Matsui*, Hiroshi Asanuma, Hiroyuki
Satoh, Yujiro Aoki, Kei Sakurabayashi,
Ryuichi Mizuno, Mototsugu Oya, Tokyo,
Japan
MP54-11 READMISSION, UNPLANNED
EMERGENCY ROOM VISITS, AND
SURGICAL RETREATMENT RATES AFTER
PROCEDURES
Hsin-Hsiao Wang*, Rohit Tejwani, John
Wiener, Jonathan Routh, Durham, NC
MP54-05 THE FATE OF PRIMARY OBSTRUCTIVE
MEGAURETER (POM): A PROSPECTIVE
OUTCOME ANALYSIS OF 72 INFANTS
Luis Braga*, Jennifer DCruz, Forough
Farrokhyar, Mandy Rickard, Hamilton,
Canada, Armando Lorenzo, Toronto, Canada
MP54-12 DETERMINANTS OF PRACTICE
PATTERNS IN PEDIATRIC UTI
MANAGEMENT
Rachel Sharon Selekman*, Hillary L Copp,
San Francisco, CA
MP54-06 RISK FACTORS FOR CATHETERASSOCIATED URINARY TRACT
INFECTION IN A PEDIATRIC INSTITUTION
Nora Lee, Daniel Marchalik*, Washington,
DC, Andrew Lipsky, New York, NY, H. Gil
Rushton, Hans Pohl, Xiaoyan Song,
Washington, DC
MP54-13 DOES PERCEPTION OF
CATHETERIZATION LIMIT ITS USE IN
PEDIATRIC UTI?
Rachel Sharon Selekman*, Melissa T
Sanford, San Francisco, CA, Lauren N Ko,
Boston, MA, Hillary L Copp, San Francisco,
CA
MP54-07 INCIDENCE, ADMISSION RATES AND
ECONOMIC BURDEN OF PEDIATRIC
EMERGENCY DEPARTMENT VISITS FOR
URINARY TRACT INFECTION
Akshay Sood*, Frank Penna, Sriram
Eleswarapu, Daniel Pucheril, Dane Klett,
Abd-El-Rahman Abd-El-Barr, Firas Abdollah,
Yegappan Lakshmanan, Mani Menon, Detroit,
MI, Quoc-Dien Trinh, Boston, MA, Jesse
Sammon, Jack Elder, Detroit, MI
MP54-14 WHAT DO PREOPERATIVE AND
INTRAOPERATIVE URINE CULTURES
PROVIDE FOR PEDIATRIC PATIENTS
UNDERGOING URETERAL
REIMPLANTATION FOR
VESICOURETERAL REFLUX?
Daniel Hettel*, Bradley Gill, Audrey Rhee,
Cleveland, OH
*Presenting author
MP54-15 WHAT IS THE INCIDENCE OF DEFLUX
CALCIFICATION ON ULTRASOUND?
Julia B Finkelstein*, Mark V Silva, Jennifer J
Ahn, Jason P Van Batavia, Shumyle Alam,
Pasquale Casale, New York, NY
177
SUNDAY
ABSTRACT
NUMBER TITLE
MP54-01 SIGNIFICANT PREDICTORS OF CHRONIC
KIDNEY DISEASE DURING POSTPUBERTAL PERIODS IN PATIENTS WITH
Minyong Kang, Seoul, Korea, Republic of,
Hae Won Lee, , Korea, Republic of, Kwanjin
Park*, Seoul, Korea, Republic of
MP54-19 COMPARISON OF COST AND
COMPLICATIONS IN OPEN VERSUS
ROBOTIC URETERAL REIMPLANTATION
IN AMERICAN CHILDREN’S HOSPITALS
Benjamin Whittam*, William Bennett, Alison
Keenan, Konrad Szymanski, Aaron Carroll,
Richard Rink, Mark Cain, Indianapolis, IN
MP54-16 DOES ENDOSCOPIC PUNCTURE OF
URETEROCELE PROVIDE NOT ONLY AN
INITIAL SOLUTION, BUT ALSO A
DEFINITE TREATMENT IN ALL
CHILDREN? OVER THE 25 YEARS OF
EXPERIENCE
Stanislav Kocherov*, Shahar Rotem, Amicur
Farkas, Boris Chertin, Jerusalem, Israel
MP54-20 INCIDENCE OF DEXTRANOMERHYALURONIC ACID SITE CALCIFICATION
IS GREATER THAN EXPECTED
Tyler Kern, Steven Lerman, Bernard
Churchill, Jennifer Singer*, Los Angeles, CA
MP54-17 BEYOND VUR GRADING AND SURGICAL
TECHNIQUE: PATIENT-BASED
PARAMETERS SIGNIFICANT FOR
SUCCESS OF ENDOSCOPIC ANTIREFLUX
SURGERY
Gina Cambareri*, George Chiang, Madhu
Alagiri, San Diego, CA
CREDITTM
MP54-18 THE ROLE OF PROPHYLACTIC
ANTIBIOTICS AFTER LAPAROSCOPIC
PYELOPLASTY WITH URETERAL STENT
PLACEMENT IN CHILDREN
Matthew Ferroni*, Kevin Rycyna, Moira
Dwyer, Francis Schneck, Michael Ost, Steven
Docimo, Heidi Stephany, Glenn Cannon,
Pittsburgh, PA
3:30 pm - 5:30 pm
PROSTATE CANCER: BASIC RESEARCH III
Moderators: David Jarrard and Jill Macoska
ABSTRACT
NUMBER TITLE
MP55-01 CYTOPLASMIC FOXO1 NEGATIVELY
REGULATES ERK TO OVERCOME TAXOL
RESISTANCE IN PROSTATE CANCER
Chunwu Pan*, Shanghai, China, People’s
Republic of, Jian An, Yunqian Pan, Liguo
Wang, Jun Zhang, Rochester, MN, Jun Qi,
Haojie Huang, Rochester, MN
ABSTRACT
NUMBER TITLE
MP55-05 CHARACTERISATION OF IMMUNE
INFILTRATES IN MALIGNANT AND
BENIGN PROSTATE TISSUES
Dixon (Teck Sing) Woon*, Genevieve Whitty,
Manvendra Saxena, Damien Bolton, Ian
Davis, Heidelberg, Australia
MP55-06 GALECTIN-3 IS A THERAPEUTIC TARGET
FOR CASTRATION-RESISTANT
PROSTATE CANCER
Tomoharu Fukumori*, Tsogt-Ochir Dondoo,
Kei Daizumoto, Tomoya Fukawa, Yasuyo
Yamamoto, Kunihisa Yamaguchi, Masayuki
Takahashi, Hiro-omi Kanayama, Tokushima,
Japan
MP55-02 PROSTATE ADENOCARCINOMAS
COMPARED WITH NON-TUMOR
PROSTATE TISSUE. EXPRESSION OF
COLLAGEN, ELASTIC SYSTEM FIBERS,
SMOOTH MUSCLE CELLS AND VESSELS,
ACCORDING TO THE GLEASON SCORE
Carla Gallo, Waldemar Costa*, Francisco
Sampaio, Clarice Osorio, Rio de Janeiro,
Brazil
MP55-07 FLAVONOIDS ENHANCE TRAIL
SENSITIVITY IN PROSTATE CANCER
CELLS BY TARGETING ADENINE
NUCLEOTIDE TRANSLOCASE-2
masakatsu oishi*, takashi ueda, terukazu
nakamura, yoshio naya, fumiya hongo,
kazumi kamoi, koji okihara, tsuneharu miki,
kyoto, Japan
MP55-03 PATHOLOGICAL ROLES OF HUR
EXPRESSION IN PROSTATE CANCER
Kensuke Mitsunari*, Yasuyoshi Miyata,
Akihiro Asai, Tomohiro Matsuo, Kojiro Ohba,
Kosuke Takehara, Hideki Sakai, Nagasaki,
Japan
MP55-08 GENOMIC DELETION OF CHROMOSOME
12P IS AN INDEPENDENT PROGNOSTIC
MARKER IN PROSTATE CANCER
Raisa Pompe*, Martina Kluth, Sarah Minner,
Philipp Gild, Ronald Simon, Pierre Tennstedt,
Markus Graefen, Guido Sauter, Thorsten
Schlomm, Hamburg, Germany
MP55-04 THERMOTHERAPY WITH MAGNETIC
CATIONIC LIPOSOMES POWERFULLY
SUPPRESSES PROSTATE CANCER BONE
METASTASIS IN A NOVEL RAT MODEL
Daichi Kobayashi*, Noriyasu Kawai, Keitaro
Iida, Toshiki Etani, Taku Naiki, Ryosuke
Ando, Keiichi Tozawa, Tohru Mogami, Kenjiro
178
MP55-10 EPIGENETIC REGULATION OF THE 3P22
TUMOR SUPPRESSOR DLEC1 IN HUMAN
PROSTATE CANCER ASSOCIATED WITH
ITS PROGNOSIS
Lian Zhang, Yu Fan*, Beijing, China, People’s
Republic of, Lili Li, Zhaohui Wang, Hong
Kong, China, People’s Republic of, Qian
Zhang, Beijing, China, People’s Republic of,
Qian Tao, Hong Kong, China, People’s
Republic of, Jie Jin, Beijing, China, People’s
Republic of
MP55-17 EFFECT OF EPIGENETIC MODIFICATION
AND IMMUNOMODULATION ON MURINE
PROSTATE CANCER AND DENDRITIC
CELLS
Jay Sulek*, Shaoqing Zhou, Albert
Petrossian, Samuel Robinson, Ekaterine
Goliadze, Georgi Guruli, Richmond, VA
MP55-18 RACE IMPACTS ETS FAMILY
TRANSCRIPTION FACTOR EXPRESSION
IN PROSTATE CANCER: DATA FROM A
MULTI-INSTITUTIONAL COHORT
Farzana Faisal*, Debasish Sundi, Ashley
Ross, Baltimore, MD, Eric Klein, Cleveland,
OH, Robert Den, Adam Dicker, Philadelphia,
PA, Voleak Choeurng, Nicholas Erho,
Mohammed Alshalalfa, Elai Davicioni,
Vancouver, Canada, Tamara Lotan, Edward
Schaeffer, Baltimore, MD
MP55-11 SYNTHETIC LETHAL METABOLIC
TARGETING OF CELLULAR SENESCENCE
IN PROSTATE CANCER WITH METFORMIN
Michael L. Blute, Jr.*, Bing Yang, Nathan
Damaschke, Dudley Lamming, F. Michael
Hoffman, David F. Jarrard, Madison, WI
MP55-12 THE PROTON-ASSISTED AMINO ACID
TRANSPORTER 4 (PAT4/SLC36A4) IS UPREGULATED IN PROSTATE CANCER
Daniel Stevens*, Claire Verrill, Richard
Bryant, Chad McKee, Helen Turley, ShihJung Fan, Sumeth Perera, Clive Wilson,
Adrian L Harris, Freddie C Hamdy, Deborah
CI Goberdhan, Oxford, United Kingdom
MP55-19 SUPPRESSION OF AUTOPHAGY BY
CHLOROQUINE POTENTIATES THE ANTICANCER EFFECT OF DOCETAXEL ON
CASTRATION-RESISTANT PROSTATE
CANCER CELLS
Wen Song, Jun Yang*, Yang Cai, Yang Luan,
Li Wu, Xia Liu, Tao Wang, Shao Wang, Ji
Liu, Zhang Ye, Wuhan, China, People’s
Republic of
MP55-13 TRIPTOLIDE INHIBIT CASTRATE
RESISTANT AND ENZALUTAMIDE
GROWTH BY DECREASING ANDROGEN
RECEPTOR FULL LENGTH AND SPLICE
VARIANTS EXPRESSION
Sumit Isharwal*, Shrey Modi, Usman Barlass,
Minneapolis, MN, Rohit Chugh, Mineapolis,
MN, Sulagna Banerjee, Vikas Dudeja, Ashok
Saluja, Badrinath Konety, Minneapolis, MN
MP55-20 ESTABLISHMENT OF LUCAP CELL LINES
BY “ORGANOID” IN VITRO CULTURE
TECHNOLOGY
Catherine Dowling*, Dong Gao, Samuel
Kaffenberger, Youxin Guan, Qi Fan Zhang,
Devan Murphy, New York, NY, Holly Nguyen,
Eva Corey, Seattle, WA, Yu Chen, New York,
NY
MP55-14 METFORMIN USE AND METABOLIC
SIGNALING IN MEN UNDERGOING
PROSTATE NEEDLE BIOPSY
Brian Winters*, Sarah Holt, Xiaotun Zhang,
Colm Morrissey, Daniel Lin, Stephen
Plymate, Jonathan Wright, Seattle, WA
CREDITTM
MP55-15 INVOLVEMENT OF MIR-181B-MEDIATED
EZH2/IGF-1R SIGNALLING PATHWAY IN
THE GROWTH AND ENERGY
METABOLISM OF PROSTATE CANCER
Tao Tao*, Chunhui Liu, Yeqing Huang, Han
Guan, Ming Chen, Nanjing, China, People’s
Republic of
*Presenting author
179
SUNDAY
MP55-16 BLOCKING THE INTRACRINE BACKCONVERSION PATHWAY WITH
ABIRATERONE IN PROSTATE CANCER
CELLS
Takashi Ando*, Itsuhiro Takizawa, Fumio
Ishizaki, Keisuke Takeda, Niigata City, Japan,
Yoshimichi Miyashiro, Kawasaki City, Japan,
Noboru Hara, Tsutomu Nishiyama, Niigata
City, Japan
MP55-09 PRE-CLINICAL EVALUATION OF THE
NOVEL THERAPIES OF THE
CANCER
David Charbit, Ihsan El Sayed, Alexandra
Masson-Lecomte, Carolina Saldana, Laurent
Salomon, Francis Vacherot, Alexandre De La
Taille*, Creteil, France
3:30 pm - 5:30 pm
PROSTATE CANCER: LOCALIZED III
Moderators: Thomas Guzzo and Joel Nelson
ABSTRACT
NUMBER TITLE
MP56-01 SIZE-ADJUSTED QUANTITATIVE
GLEASON SCORE AS A PREDICTOR OF
Nicholas Donin, Fang-Ming Deng, Ruth Pe
Benito, Jinhua Wang, Jonathan Melamed,
Ming Zhou, Herbert Lepor*, New York, NY
ABSTRACT
NUMBER TITLE
MP56-06 ASSOCIATION BETWEEN PROVIDERLEVEL FACTORS AND LYMPH NODE
DISSECTION OUTCOMES DURING
RADICAL PROSTATECTOMY: A
ANALYSIS
Jonathan E Kiechle*, Cleveland, OH, Elyn
Wang, James B Yu, Cary P Gross, New
Haven, CT, Robert Abouassaly, Edward E
Cherullo, Cleveland, OH, Marc C Smaldone,
Philadelphia, PA, Nilay D Shah, Rochester,
MN, Quoc-Dien Trinh, Boston, MA, Maxine
Sun, Montreal, Canada, Simon P Kim,
Cleveland, OH
MP56-02 HEAD TO HEAD COMPARISON OF
CONDITIONAL ONCOLOGICAL
OUTCOMES AFTER RADICAL
PROSTATECTOMY IN PATIENTS WITH
INTERMEDIATE AND HIGH RISK
PROSTATE CANCER
Marco Bianchi*, Nicola Fossati, Giorgio
Gandaglia, Rayan Matloob, Milan, Italy, Firas
Abdollah, Detroit, MI, Umberto Capitanio,
Federico Dehò, Vincenzo Scattoni, Milan,
Italy, Shahrokh F. Shariat, Vienna, Austria,
Pierre Karakiewicz, Montreal, Canada,
Francesco Montorsi, Alberto Briganti, Milan,
Italy
MP56-07 ONCOLOGICAL OUTCOMES IN HIGH-RISK
PROSTATE CANCER AFTER RADICAL
PROSTATECTOMY: COMPARING
GLEASON 8 VERSUS 9,10 DISEASE
Weichen Xu*, Jie Cai, Gary Lieskovsky,
Siamak Daneshmand, Hooman Djaladat, Los
Angeles, CA
MP56-08 IMPACT OF INTRAOPERATIVE FROZEN
SECTIONS OF THE URETHRA ON
SURGICAL MARGINS AND ONCOLOGIC
OUTCOME IN PATIENTS UNDERGOING
Georgios Hatzichristodoulou*, Munich,
Germany, Stefan Wagenpfeil, Homburg,
Germany, Kathleen Herkommer, Jürgen
Gschwend, Hubert Kübler, Munich, Germany
MP56-03 NUMBER OF LYMPH NODES REMOVED
AT RADICAL PROSTATECTOMY FOR
NODE NEGATIVE PROSTATE CANCER: A
POTENTIAL MARKER OF DISEASE
PERSISTENCE IN PATIENTS WITH EARLY
BIOCHEMICAL FAILURE
Marco Bianchi*, Nicola Fossati, Nazareno
Suardi, Giorgio Gandaglia, Paolo Dell’Oglio,
Umberto Capitanio, Milan, Italy, Firas Abdollah,
Detroit, MI, Andrea Gallina, Milan, Italy,
Shahrokh F. Shariat, Vienna, Austria, Federico
Dehò, Andrea Salonia, Milan, Italy, Pierre
Karakiewicz, Montreal, Canada, Francesco
Montorsi, Alberto Briganti, Milan, Italy
MP56-09 EXPRESSION PROFILE OF CD44S,
CD44V6, AND CD44V10 IN LOCALIZED
PROSTATE CANCER: IMPACT ON
PROGNOSTIC OUTCOMES FOLLOWING
MP56-04 RECURRENCE PATTERN IN LYMPH NODE
POSITIVE PROSTATE CANCER PATIENTS
AFTER EXTENDED PELVIC
LYMPHADENECTOMY AND RADICAL
PROSTATECTOMY – THE NATURAL
COURSE OF DISEASE
Silvan Boxler*, Tobias Gross, George N.
Thalmann, Urs E. Studer, Martin Spahn,
Bern, Switzerland
MP56-10 LONG-TERM SURVIVAL PATTERNS OF
YOUNG PATIENTS WITH HIGH RISK
PROSTATE CANCER TREATED WITH
RADICAL PROSTATECTOMY. RESULTS
OF A MULTI INSTITUTIONAL,
CONDITIONAL SURVIVAL ANALYSIS
Marco Bianchi*, Milan, Italy, R. Jeffrey
Karnes, Rochester, MN, Steven Joniau,
Leuven, Belgium, Giorgio Gandaglia, Milan,
Italy, Martin Spahn, Bern, Switzerland, Paolo
Gontero, Turin, Italy, Lorenzo Tosco, Leuven,
Belgium, Rafael Sanchez Salas, Xavier
Cathelineau, Paris, France, Burkhard Kneitz,
Wurzburg, Germany, Felix K. H. Chun,
Hamburg, Germany, Pierre Karakiewicz,
Montreal, Canada, Markus Graefen,
Hamburg, Germany, Piotr Chlosta, Krakow,
Poland, Giansilvio Marchioro, Novara, Italy,
Detlef Frohneberg, Karlsruhe, Germany, Hein
Van Poppel, Leuven, Belgium, Francesco
MP56-05 EARLY POST-OPERATIVE PSA AFTER
RADICAL PROSTATECTOMY IS A MAJOR
PREDICTOR OF PROGRESSION AND
DEATH IN PATIENTS WITH LYMPH NODE
METASTASES. RESULTS FROM A
TERTIARY CARE CENTER
Alessandro Nini*, Marco Bianchi, Nazareno
Suardi, Giorgio Gandaglia, Paolo Dell’Oglio,
Renzo Colombo, Milan, Italy, Firas Abdollah,
Detroit, MI, Vito Cucchiara, Milan, Italy,
Shahrokh F. Shariat, Vienna, Austria, Pierre
Karakiewicz, Montreal, Canada, Francesco
180
MP56-12 THE ROLE OF PERINEURAL INVASION AS
A PROGNOSTIC TOOL IN PROSTATE
CANCER
Udit Singhal*, Louis Lu, Ted Skolarus,
Ganesh Palapattu, Jeffrey Montgomery, Alon
Weizer, Brent Hollenbeck, David Miller, Jason
Chan, Rohit Mehra, Scott Tomlins, Daniel
Hamstra, Felix Feng, Todd Morgan, Ann
Arbor, MI
MP56-17 UNDERTREATMENT OF MEN IN THEIR
SEVENTIES WITH HIGH RISK, NONMETASTATIC PROSTATE CANCER
Pär Stattin*, Umeå, Sweden, Marie Hjälm
Eriksson, Stockholm, Sweden, Ingela Franck
Lissbrant, Gothenburg, Sweden, Yasin
Folkvaljon, Uppsala, Sweden, Olof Akre,
Stefan Carlsson, Stockholm, Sweden, Linda
Drevin, Uppsala, Sweden, Daniel Makarov,
Stacy Loeb, New York, NY, Ola Bratt,
Helsinborg, Sweden
MP56-13 ADIPOSIS IS AN INDEPENDENT RISKFACTOR FOR DEVELOPING HIGH-RISK
PROSTATE CANCER - A PROSPECTIVE
STUDY
Thomas J. Schnoeller*, Ulm, Germany,
Andres J. Schrader, Münster, Germany,
Florian Jentzmik, Ulm, Germany, Julie
Steinestel, Münster, Germany
MP56-18 NON-SURGICALLY RELATED CAUSES OF
ERECTILE DYSFUNCTION AFTER
BILATERAL NERVE SPARING RADICAL
PROSTATECTOMY: RESULTS FROM A
SINGLE INSTITUTION SERIES
Giorgio Gandaglia*, Nazareno Suardi, Vito
Cucchiara, Milan, Italy, Firas Abdollah,
Detroit, MI, Roberto Bertini, Renzo Colombo,
Andrea Salonia, Nicola Fossati, Milan, Italy,
Maxine Sun, Montreal, Canada, Marta
Picozzi, Milan, Italy, Shahrokh F. Shariat,
MP56-14 PREDICTORS AND ONCOLOGIC
OUTCOMES OF PT0 PROSTATE CANCER IN
RADICAL PROSTATECTOMY SPECIMENS
Daniel Moreira*, Boris Gershman, Stephen
Boorjian, R. Houston Thompson, Igor Frank,
Matthew Tollefson, Matthew Gettman, Rachel
Carlson, Laureano Rangel, R. Jeffrey Karnes,
Rochester, MN
MP56-15 LYMPHOVASCULAR INVASION IS
SIGNIFICANTLY ASSOCIATED WITH
BIOCHEMICAL RELAPSE AFTER RADICAL
PROSTATECTOMY EVEN IN PATIENTS
WITH PT2N0 NEGATIVE RESECTION
MARGIN
Koji Mitsuzuka*, Sendai, Japan, Shintaro
Narita, Akita, Japan, Takuya Koie, Hirosaki,
Japan, Yasuhiro Kaiho, Sendai, Japan,
Norihiko Tsuchiya, Akita, Japan, Takahiro
Yoneyama, Hirosaki, Japan, Narihiko Kakoi,
Sadafumi Kawamura, Tatsuo Tochigi, Natori,
Japan, Tomonori Habuchi, Akita, Japan,
Chikara Ohyama, Hirosaki, Japan, Yoichi
Arai, Sendai, Japan
MP56-19 10-YEAR MORTALITY AFTER RADICAL
PROSTATECTOMY IN THE PROSTATESPECIFIC ANTIGEN SCREENING ERA
Neil Mendhiratta*, Ted Lee, Herbert Lepor,
New York, NY
MP56-20 HYPOGONADISM AND VARICOCELE
STATUS AS RISK FACTORS FOR
ADVERSE PATHOLOGIC FEATURES AT
Bobby Najari*, Ashley Winter, Matthew Katz,
Douglas Scherr, Marc Goldstein, New York, NY
CREDITTM
*Presenting author
181
SUNDAY
MP56-16 VERY LONG TERM OUTCOMES OF
RADICAL PROSTATECTOMY IN PATIENTS
WITH CLINICALLY LOCALIZED PROSTATE
CANCER. RESULTS FROM A SINGLE
INSTITUTION SERIES
Giorgio Gandaglia*, Nazareno Suardi, Marco
Bianchi, Paolo Dell’Oglio, Umberto Capitanio,
Nicola Fossati, Milan, Italy, Firas Abdollah,
Detroit, MI, Marco Moschini, Milan, Italy,
Patrizio Rigatti, Francesco Montorsi, Alberto
MP56-11 PROGNOSTIC VALUE OF FOCAL
POSITIVE SURGICAL MARGINS AFTER
Ki Bom Kim*, In jae Lee, Tae jin Kim, Jong
Jin Oh, Sangchul Lee, Seong-Jin Jeong,
Sung Kyu Hong, Seok-Soo Byun, Seongnamsi, Korea, Republic of, Choong Hee Noh,
Seoul, Korea, Republic of, Sang Eun Lee,
Seongnam-si, Korea, Republic of
3:30 pm - 5:30 pm
KIDNEY CANCER: SURGICAL THERAPY II
Moderators: Robert Uzzo and Casey Ng
ABSTRACT
NUMBER TITLE
MP57-01 COST-EFFECTIVE MANAGEMENT OF
SMALL RENAL MASSES: THE ROLE OF
TUMOR BIOPSY
Michael Rydberg*, Chicago, IL, Sangtae
Park, Evanston, IL
ABSTRACT
NUMBER TITLE
MP57-08 SIGNIFICANCE OF GERIATRIC
NUTRITIONAL RISK INDEX AS A
PROGNOSTIC PREDICTOR IN PATIENTS
WITH NON-METASTATIC RENAL CELL
CARCINOMA UNDERGOING SURGICAL
RESECTION
MP57-02 THE USE OF HEMOSTATIC AGENTS DOES
NOT PREVENT HEMORRHAGIC
COMPLICATIONS OF ROBOTIC PARTIAL
NEPHRECTOMY
benoit peyronnet*, zineddine khene, gregory
verhoest, romain mathieu, Rennes, France,
benjamin pradere, Tours, France, mathieu
roumiguie, jean-baptiste beauval, Toulouse,
France, alexandra masson-lecomte, Créteil,
France, christophe vaessen, hervé baumert,
Paris, France, stéphane droupy, Nimes,
France, alexandre de la taille, Créteil, France,
jean-christophe bernhard, Bordeaux, France,
nicolas doumerc, Toulouse, France, morgan
roupret, Paris, France, karim bensalah,
Rennes, France
MP57-09 COMPARISON OF THE OPEN AND
ROBOTIC APPROACH IN PARTIAL
NEPHRECTOMY FOR HIGHLY COMPLEX
TUMORS (RENAL NEPHROMETRY SCORE
ⱖ 10)
benoit peyronnet*, tarek fardoun, Rennes,
France, thibaut benoit, mathieu roumiguie,
Toulouse, France, gregory verhoest, Rennes,
France, jean-baptiste beauval, michel soulie,
nicolas doumerc, Toulouse, France, karim
bensalah, Rennes, France
MP57-10 INITIAL CLINICAL EXPERIENCE WITH
PERCUTANEOUS IRREVERSIBLE
ELECTROPORATION OF KIDNEY TUMORS
Monica Morgan, Aaron Lay*, Asim Ozayar,
Jeffrey Gahan, Clayton Trimmer, Jeffrey
Cadeddu, Dallas, TX
MP57-03 NON-ISCHEMIC LAPAROSCOPIC PARTIAL
NEPHRECTOMY USING 1318-NM DIODE
LASER FOR SMALL EXOPHYTIC RENAL
TUMORS
Ahmed Magdy*, Katharina Bretterbauer,
Michael Mitterberger, Günter Janetschek,
Salzburg, Austria
MP57-11 PERCUTANEOUS ENDOSCOPIC
RESECTION OF UPPER TRACT
UROTHELIAL NEOPLASMS WITH TUMOR
BURDEN >1.5 CM: 5-YEAR SINGLE
CENTER EXPERIENCE
Joel E. Abbott*, Detroit, MI, Julio G. Davalos,
Baltimore, MD
MP57-04 PREDICTORS OF SURGICAL APPROACH
FOR TREATMENT OF RENAL CELL
CARCINOMA
Manish Patel*, Stephen Strahan, Albert Bang,
Justin Vass, David Smith, Sydney, Australia
MP57-12 NO PROVEN BENEFIT OF
POSTOPERATIVE DRAINAGE AFTER
benoit peyronnet*, zineddine khene, Rennes,
France, benjamin pradere, Tours, France,
gregory verhoest, romain mathieu, Rennes,
France, mathieu roumiguie, jean-baptiste
beauval, Toulouse, France, christophe
vaessen, hervé baumert, Paris, France,
stéphane droupy, Nimes, France, alexandre
de la taille, Créteil, France, jean-christophe
bernhard, Bordeaux, France, nicolas
doumerc, Toulouse, France, morgan roupret,
Paris, France, karim bensalah, Rennes,
France
MP57-05 MATCHED PAIR ANALYSIS OF
TRANSPERITONEAL VERSUS
RETROPERITONEAL ROBOTIC PARTIAL
NEPHRECTOMY
Sevan Stepanian*, Ashraf Haddad, Jason
Kowitz, Cindy Fuller, James Porter, Seattle,
WA
MP57-06 NONOPERATIVE MANAGEMENT DRIVES
RENAL MASS BIOPSY IN THE MODERN
ERA
Matthew Maurice*, Hui Zhu, Simon Kim,
Robert Abouassaly, Cleveland, OH
MP57-07 WHO DIES FROM NEPHRECTOMY AND
WHY DO THEY DIE? - THE
IDENTIFICATION OF RISK FACTORS FOR
PERIOPERATIVE DEATH FOLLOWING
NEPHRECTOMY – A NATIONAL STUDY
Archie Fernando*, Sarah Fowler, Tim
O’Brien, London, United Kingdom
182
MP57-18 ZERO ISCHEMIA LAPAROSCOPIC
PARTIAL NEPHRECTOMY: PRELIMINARY
EXPERIENCE
Roberto Sanseverino*, Umberto Di Mauro,
Oliver Intilla, Tommaso Realfonso, Carmine
Cicalese, Carmine Cicalese, Giorgio
Napodano, Nocera Inferiore, Italy
MP57-14 INTRAOPERATIVE MOLECULAR
DIAGNOSTIC IMAGING CAN IDENTIFY
RENAL CELL CARCINOMA DURING
NEPHRECTOMY
Thomas Guzzo*, Jane Keating, Jack Jiang,
Elizabeth DeJesus, Sunil Singhal,
Philadelphia, PA
MP57-20 VARIANT HISTOLOGY DOES NOT
PREDICT SURVIVAL OUTCOMES AFTER
RADICAL NEPHROURETERECTOMY FOR
UPPER TRACT UROTHELIAL
CARCINOMA: RESULTS FROM THE
CANADIAN UPPER TRACT
COLLABORATION
Lucas Dean*, Adrian Fairey, Niels Jacobsen,
Edmonton, Canada, Simon Tanguay,
Montreal, Canada, Ricardo Rendon, David
Bell, Halifax, Canada, Jonathan Izawa,
Joseph Chin, London, Canada, Anil Kapoor,
Bobby Shayegan, Edward Matsumoto,
Hamilton, Canada, Peter Black, Alan So,
Vancouver, Canada, Jean-Baptiste Lattouf,
Fred Saad, Montreal, Canada, Darrel
Drachenberg, Winnipeg, Canada, Ilias
Cagiannos, Ottawa, Canada, Louis Lacombe,
Yves Fradet, Quebec City, Canada, Wassim
Kassouf, Montreal, Canada
MP57-19 NOVEL PREDICTORS OF EFFICACY IN
PERCUTANEOUS RADIOFREQUENCY
ABLATION OF RENAL CELL CARCINOMA:
R.E.N.A.L. NEPHROMETRY SCORE AND
RENAL CELL CARCINOMA SUBTYPE
Timothy McClure*, Columbus, OH, Allan
Pantuck, James Sayre, Steve Raman, Los
Angeles, CA
MP57-15 EN BLOC LIGATION OF RENAL VESSELS
DURING LAPAROSCOPIC NEPHRECTOMY
AND NEPHROURETERECTOMY
Mariam Hult*, Mikkel Fode, Claus Dahl,
Nessn Azawi, Roskilde, Denmark
MP57-16 ANTIPLATELET/ANTICOAGULATION
THERAPY DOES NOT INCREASE
IMMEDIATE COMPLICATIONS IN
PATIENTS UNDERGOING ROBOTIC
PARTIAL NEPHRECTOMY (RPN)
Andrew Leone*, George Turini, Joseph Brito,
Timothy Tran, Joseph Renzulli, Gyan Pareek,
Dragan Golijanin, Providence, RI
MP57-17 COMPARISON OF SURVIVAL RATES IN
STAGE ONE RENAL CELL CARCINOMA
BETWEEN PARTIAL NEPHRECTOMY AND
RADICAL NEPHRECTOMY PATIENTS
ACCORDING TO AGE DISTRIBUTION
Toshio Takagi*, Tsunenori Kondo, Kenji
Omae, Junpei Iizuka, Hirohito Kobayashi,
Yasunobu Hashimoto, Kazunari Tanabe,
Tokyo, Japan
CREDITTM
3:30 pm - 5:30 pm
Podium Session 31
BLADDER CANCER: INVASIVE I
Moderator: Manish Vira
TIME
3:30
ABSTRACT
NUMBER TITLE
PD31-01 SURVEILLANCE STRATEGIES IN
BLADDER CANCER FOLLOWING RADICAL
CYSTECTOMY: A SYSTEMATIC REVIEW
AND META-ANALYSIS
Suzanne Stewart*, Fares Alahdab, Khalid
Benkhadra, Zhen Wang, Atsushi Sorita,
Stephen Boorjian, Igor Frank, Mohammad
Murad, Rochester, MN
*Presenting author
ABSTRACT
TIME NUMBER TITLE
3:40
PD31-02 PERFORMANCE STATUS AS A
SIGNIFICANT PREDICTOR FOR BLADDER
CANCER PATIENTS TREATED WITH
RADICAL CYSTECTOMY
Nobuyuki Hinata*, Akira Miyazaki, Masatomo
Nishikawa, Hiromoto Tei, Hideaki Miyake,
183
SUNDAY
MP57-13 LAPAROSCOPIC VERSUS
PERCUTANEOUS CRYOABLATION FOR T1
RENAL MASSES: AN ITALIAN
MULTICENTRIC STUDY
Bernardino de Concilio*, Calogero Cicero,
Dario del biondo, Guglielmo Zeccolini,
Bassano del Grappa, Italy, Fulvio Laganà,
Alessandro Pinzani, Dolo, Italy, Piero
Pellegrini, Tiziano Stocca, Gorizia, Italy, Luca
Balestreri, Martina Urbani, Aviano, Italy,
Giovanni Carbognin, Negrar, Italy, Giuseppe
Casarrubea, Fabio Zattoni, Padova, Italy,
Davide Barbisan, Franco Merlo, Treviso, Italy,
Salvatore Siracusano, Fulvio Stacul, Trieste,
Italy, Antonio Celia, Bassano del Grappa,
Italy
3:50
PD31-03 IMPAIRMENT FREE SURVIVAL: A
RELEVANT CLINICAL ENDPOINT FOR
Cheryl Lee*, Stephanie Daignault-Newton,
Linda Drnek, Michael Englesbe, Khaled
Hafez, Brent Hollenbeck, Pearl Lee, Jeffrey
Montgomery, Todd Morgan, Michael
Termanjian, Alon Weizer, Ann Arbor, MI
4:00
PD31-04 ROBOTIC SALVAGE CYSTECTOMY IS
SAFE: MULTI-INSTITUTIONAL
PERIOPERATIVE OUTCOMES
Neel Srikishen*, Houston, TX, Andre Abreu,
Los Angeles, CA, Monty Aghazadeh, Michael
Pan, Houston, TX, Gus Miranda, Monish
Aron, Los Angeles, CA, Brian Miles, Houston,
TX, Inderbir Gill, Mihir Desai, Los Angeles,
CA, Alvin Goh, Houston, TX
4:10
4:20
4:30
4:40
PD31-05 SALVAGE RADICAL CYSTECTOMY AFTER
IRRADIATION FOR MUSCLE INVASIVE
BLADDER CANCER IN QUÉBEC: A
POPULATION-BASED ANALYSIS OF
OUTCOMES
Ahmed S. Zakaria Ahmed*, Fabiano Santos,
Wassim Kassouf, Simon Tanguay, Armen
Aprikian, Montreal, Canada
PD31-06 TEMPORAL TRENDS AND PREDICTORS
OF THE RECEIPT OF ADEQUATE
LYMPHADENECTOMY AT RADICAL
CYSTECTOMY FOR BLADDER CANCER
Alexander Cole*, Boston, MA, Deepansh
Dalela, Detroit, MI, Christian Meyer, Julian
Hanske, Boston, MA, Mani Menon, Detroit,
MI, Adam Kibel, Quoc-Dien Trinh, Boston,
MA
PD31-07 DIFFERENCES IN LYMPH NODE COUNT
AT RADICAL CYSTECTOMY WITH A
STANDARDIZED SURGICAL TEMPLATE
DO NOT INFLUENCE LONG-TERM
SURVIVAL FOR BLADDER CANCER
Elisabeth E. Fransen van de Putte*, Tom J.N.
Hermans, Erik van Werkhoven, Laura S.
Mertens, Richard P. Meijer, Axel Bex, Henk
G. van der Poel, Bas W.G. van Rhijn, Simon
Horenblas, Amsterdam, Netherlands
PD31-08 SARCOMATOID CARCINOMA AND
CARCINOSARCOMA HISTOLOGY OF
BLADDER CANCER PORTEND A
SIGNIFICANTLY WORSE PROGNOSIS
THAN UROTHELIAL CARCINOMA
Susan MacDonald*, Mark Schoenberg,
Farhang Rabbani, Bronx, NY
4:50
PD31-09 CLINICAL FACTORS PREDICTING
PATHOLOGICAL POSITIVE LYMPH NODES
IN CLINICALLY NODE NEGATIVE
PATIENTS TREATED WITH
NEOADJUVANT CHEMOTHERAPY AND
RADICAL CYSTECTOMY
Kamran Zargar-Shoshtari*, Tampa, FL,
Homayoun Zargar, Vancouver, Canada, Colin
P Dinney, Houston, TX, Cesar E Ercole,
Cleveland, OH, Hamidreza Abdi, Vancouver,
Canada, Evan Kovac, Jorge A Garcia,
Andrew J Stephenson, Cleveland, OH, Jay B
Shah, Houston, TX, Peter Black, Vancouver,
Canada, Philippe E Spiess, Tampa, FL
5:00
PD31-10 OUTCOMES FOLLOWING POSTCYSTECTOMY RECURRENCE OF
BLADDER CANCER BASED ON
METASTATIC SITE
Anirban P. Mitra*, David I. Quinn, Los
Angeles, CA, Eila C. Skinner, Stanford, CA,
Tanya B. Dorff, Anne K. Schuckman, Siamak
5:10
PD31-11 NEOADJUVANT DOSE-DENSE
METHOTREXATE, VINBLASTINE,
DOXORUBICIN AND CISPLATIN FOR
Elisabeth E. Fransen van de Putte*, Laura S.
Mertens, Richard P. Meijer, Michiel S. van
der Heijden, J. Martijn Kerst, Andries M.
Bergman, Simon Horenblas, Bas W.G. van
Rhijn, Amsterdam, Netherlands
5:20
PD31-12 PDL1 STATUS IN MUSCLE INVASIVE
UROTHELIAL BLADDER CARCINOMA
(MIBC) IN THE CONTEXT OF
NEOADJUVANT CISPLATIN BASED
CHEMOTHERAPY
Alexander Baras*, Maria Angelica Mendoza,
Gunes Guner, Nilay Gandhi, Jen-Jane Liu,
Janis Taube, Trinity Bivalacqua, George
Netto, Baltimore, MD
5:30
PD31-13 PERI-OPERATIVE MORTALITY AND LONGTERM SURVIVAL AFTER PARTIAL
VERSUS RADICAL CYSTECTOMY FOR
Malek Meskawi*, Montreal, Canada,
Alessandro Larcher, Milan, Italy, Roger
Valdivieso, Vincent Trudeau, Montreal,
Canada, Katharina Boehm, Jonas
Schiffmann, Hamburg, Germany, Maxine
Sun, Pierre Karakiewicz, Montreal, Canada
CREDITTM
184
3:30 pm - 5:30 pm
Podium Session 32
TIME
3:30
ABSTRACT
NUMBER TITLE
PD32-01 COMPARISON OF MRI-US FUSION
TARGETED BIOPSY AND SYSTEMATIC
PROSTATE BIOPSY: SINGLE
INSTITUTION EXPERIENCE IN 604
PATIENTS
Neil Mendhiratta, Michael Fenstermaker,
Richard Huang, New York, NY, James
Wysock, Flushing, NY, Marc Bjurlin, Susan
Marshall, Fang-Ming Deng, Jonathan
Melamed, Ming Zhou, William C. Huang,
Herbert Lepor, Samir S. Taneja, New York,
NY
3:40
PD32-02 OPTIMAL SAMPLING NUMBER IN MRITARGETED BIOPSY
Noboru Numao*, Masaya Ito, Yusuke Uchida,
Takayuki Nakayama, Masaharu Inoue,
Manabu Tatokoro, Minato Yokoyama,
Junichiro Ishioka, Yoh Matsuoka, Kazutaka
Saito, Yasuhisa Fujii, Kazunori Kihara, Tokyo,
Japan
3:50
PD32-03 OUTCOMES OF MRI-US FUSION
TARGETED PROSTATE BIOPSY IN MEN
WITH HISTORY OF PREVIOUS NEGATIVE
BIOPSY: IMPROVED CANCER DETECTION
AND RISK STRATIFICATION
Neil Mendhiratta*, Andrew B Rosenkrantz,
Xiaosong Meng, Michael Fenstermaker,
Richard Huang, New York, NY, James S
Wysock, Flushing, NY, Fang-Ming Deng,
Jonathan Melamed, Ming Zhou, William C
Huang, Herbert Lepor, Samir S Taneja, New
York, NY
4:00
PD32-04 CAN CONFIRMATORY BIOPSY BE
SKIPPED FOR ACTIVE SURVEILLANCE
PATIENTS WITH NEGATIVE MRI
FINDINGS AND A LOW NUMBER OF
POSITIVE CORES ON DIAGNOSTIC
BIOPSY?
Prassannah Satasivam*, Biny Ying Poon,
Hebert Alberto Vargas, Andrew Vickers,
James Eastham, New York, NY
4:10
PD32-05 GRADE CONCORDANCE OF TARGETED
MRI-ULTRASOUND FUSION TARGETED
PROSTATE BIOPSY RESULTS WITH
FINAL PATHOLOGY FOLLOWING
Xiaosong Meng, Fang-Ming Deng, Ming
Zhou, Andrew B. Rosenkrantz, Richard
Huang, Susan Marshall, New York, NY,
James S. Wysock, Flushing, NY, Marc
Bjurlin, William C. Huang, Herbert Lepor,
Samir S. Taneja, New York, NY
*Presenting author
ABSTRACT
TIME NUMBER TITLE
4:20
PD32-06 DETECTION RATES OF 68GALLIUMLABELLED LIGAND OF PSMA PET/CT AND
PET/MRI IN 332 CONSECUTIVE PATIENTS
WITH BIOCHEMICAL RECURRENCY
Tobias Maurer*, Veronika Beck, Ambros
Beer, Michael Souvatzoglou, Konstantin
Holzapfel, Hubert Kübler, Jürgen Erich
Gschwend, Hans-Jürgen Wester, Bernhard
Haller, Markus Schwaiger, Matthias Eiber,
Munich, Germany
185
4:30
PD32-07 PREOPERATIVE LYMPH NODE STAGING
IN INTERMEDIATE TO HIGH-RISK
PROSTATE CANCER PATIENTS USING
68GA-HBED-PSMA PET HYBRID IMAGING
– A PATIENT- AND FIELD-BASED
ANALYSIS
Tobias Maurer*, Lisa Pähr, Michael
Souvatzoglou, Gregor Weirich, Hubert Kübler,
Hans-Jürgen Wester, Bernhard Haller,
Markus Schwaiger, Jürgen Erich Gschwend,
Matthias Eiber, Munich, Germany
4:40
PD32-08 CHOLINE PET/CT SCAN FOR THE
DETECTION OF NODAL RELAPSES OF
PROSTATE CANCER AFTER
BIOCHEMICAL RECURRENCE: RESULTS
FROM A MULTICENTRIC STUDY
Marco Oderda, Paolo Gontero*, Guglielmo
Melloni, Stefania Munegato, Marco Falcone,
Turin, Italy, Hannes Van De Bosche, Steven
Deconinck, Leuven, Belgium, Fabio Zattoni,
Robert Jeffrey Karnes, Rochester, MN,
Steven Joniau, Leuven, Belgium
4:50
PD32-09 VERY LONG-TERM ONCOLOGICAL
OUTCOMES OF PATIENTS TREATED
WITH RADICAL PROSTATECTOMY FOR
NODE POSITIVE PROSTATE CANCER: A
MULTI-INSTITUTIONAL, CONDITIONAL
SURVIVAL ANALYSIS
Marco Moschini*, Alberto Briganti, Marco
Bianchi, Nicola Fossati, Nazareno Suardi,
Andrea Gallina, Giorgio Gandaglia, Cesare
Cozzarini, Umberto Capitanio, Milan, Italy,
Firas Abdollah, Detroit, MI, Francesco
Montorsi, Milan, Italy, R. Jeffrey Karnes,
Rochester, MN
5:00
PD32-10 POSITIVE SURGICAL MARGINS IN
RADICAL PROSTATECTOMY PATIENTS
DO NOT PREDICT LONG-TERM
ONCOLOGICAL OUTCOMES: RESULTS
FROM SEARCH
Prabhakar Mithal*, Rochester, NY, Lauren
Howard, Durham, NC, William Aronson, Los
Angeles, CA, Martha Terris, Augusta, GA,
Matthew Cooperberg, San Francisco, CA,
Christopher Kane, San Diego, CA,
Christopher Amling, Portland, OR, Stephen
SUNDAY
PROSTATE CANCER: STAGING II
Moderators: John Davis and Paul Lange
5:10
5:20
PD32-11 SIGNIFICANT REDUCTION IN
THERAPEUTIC BURDEN FROM USE OF
CCP TEST IN TREATMENT DECISIONS
AMONG NEWLY DIAGNOSED PROSTATE
CANCER PATIENTS IN A LARGE
PROSPECTIVE REGISTRY
Neal Shore*, Myrtle Beach, SC, Judd Boczko,
White Plains, NY, Naveen Kella, San Antonio,
TX, Brian J. Moran, Westmont, IL, Fernando
J. Bianco, Miami Lakes, FL, E. David
Crawford, Aurora, CO, Alison Sibley, Kirstin
M. Roundy, Rajesh Kaldate, Charles Grier,
Michael K. Brawer, Salt Lake City, UT, Mark
L. Gonzalgo, Miami, FL
PD32-12 PROSTATE ATYPIA: DOES REPEAT
BIOPSY DETECT CLINICALLY
SIGNIFICANT PROSTATE CANCER?
Ryan Dorin, Hartford, CT, Scott Wiener*,
Cory Harris, Farmington, CT, Joseph
Wagner, Hartford, CT
CREDITTM
3:30 pm - 5:30 pm
Podium Session 33
KIDNEY CANCER: BASIC RESEARCH III
Moderators: Jodi Maranchie and Guan Wu
TIME
3:30
3:40
3:50
ABSTRACT
NUMBER TITLE
PD33-01 THE VIABILITY, METABOLISM AND
VASCULARIZATION OF RENAL CELL
CARCINOMA CELL LINES AND
XENOGRAFTS CAN BE TARGETED
THROUGH INHIBITION OF ENDOGENOUS
HYDROGEN SULFIDE PRODUCTION
Eric Sonke*, Megan Verrydt, Carl O.
Postenka, Siddika Pardhan, Chantalle J.
Willie, Clarisse Mazzola, Ian Lobb, Ann F.
Chambers, Nicholas E. Power, Hon S. Leong,
Alp Sener, London, Canada
ABSTRACT
TIME NUMBER TITLE
4:00
PD33-04 INVERSE RELATIONSHIP BETWEEN
INSULIN RECEPTOR EXPRESSION AND
CANCER PROGRESSION IN RENAL CELL
CARCINOMA: CLINICAL AND
EXPERIMENTAL EVALUATION
Makoto Takahashi*, Takamitsu Inoue,
Mingguo Huang, Hiroshi Tsuruta, Mitsuru
Saito, Shintaro Narita, Norihiko Tsuchiya,
Tomonori Habuchi, Akita, Japan
PD33-02 OVERCOMING THE OBSTACLE OF
INTRATUMOR GENETIC HETEROGENEITY
IN RENAL CELL CARCINOMA THROUGH
ULTRA DEEP SEQUENCING OF POOLED
REGIONAL TUMOR DNA
Alex Sankin*, Andrew Winer, A. Ari Hakimi,
Elizabeth Wei, Michael Chevinsky, Tarik Silk,
Christopher Jakubowski, Fred Jacques,
Jeremy Durack, Jonathan Coleman, Michael
Berger, Paul Russo, James Hsieh, New York,
NY
PD33-03 TREATMENT OF THE PRIMARY TUMOR
WITH VASCULAR-TARGETED
PHOTODYNAMIC THERAPY (VTP)
OVERCOMES RESISTANCE TO SYSTEMIC
PD-1/PD-L1 INHIBITION: EFFECTS ON
PRIMARY TUMOR CONTROL AND
PREVENTION OF LUNG METASTASIS IN A
PRE-CLINICAL RCC MODEL
Matthew O’Shaughnessy*, Katie Murray,
Stephen LaRosa, Sebastien Monette,
Kwanghee Kim, Renato Beluco Corradi
Fonseca, New York, NY, Avigdor Scherz,
Rehovot, Israel, Jonathan Coleman, New
York, NY
186
4:10
PD33-05 TUMOR-SUPPRESSIVE MICRORNA-29SMEDIATED NOVEL MOLECULAR
PATHWAYS IN RENAL CELL CARCINOMA
Shuichi Tatarano*, Kagoshima, Japan, Rika
Nishikawa, Chiba, Japan, Takeshi
Chiyomaru, Hideki Enokida, Satoru Inoguchi,
Tomoaki Ishihara, Hirofumi Yoshino,
Kagoshima, Japan, Naohiko Seki, Chiba,
Japan, Masayuki Nakagawa, Kagoshima,
Japan
4:20
PD33-06 A RETROSPECTIVE COHORT STUDY OF
RENAL CANCER MOLECULAR
HETEROGENEITY AND DNA
METHYLATION PROGNOSTIC MARKERS
Alexander Laird*, Duncan Sproul, Grant Stewart,
Fiach O’Mahony, Edinburgh, United Kingdom,
Antony Riddick, Cambridge, United Kingdom,
Richard Meehan, Edinburgh, United Kingdom,
David Harrison, St Andrew’s, United Kingdom
4:30
PD33-07 WITHDRAWN
4:40
PD33-08 PAZOPANIB, SUNITINIB, AND AXITINIB
REDUCE EXPANSION OF IN VITRO
INDUCED SUPPRESSIVE MACROPHAGES
Raman Unnikrishnan*, Patricia Rayman, Yu
Yang, Claudia Marcela Diaz-Montero, James
Finke, Cleveland, OH
PD33-09 LOSS OF 5-HYDROXYMETHYLCYTOSINE
FACILITATES THE ESTABLISHMENT OF
UNIQUE ABERRANT DNA METHYLATION
PATTERN TO PROMOTE KIDNEY
TUMORIGENESIS
Liqun Zhou*, Zhongqiang Guo, Xuesong Li,
Beijing, China, People’s Republic of
5:00
PD33-10 RADIATION THERAPY IMPROVES
IMMUNOGENICITY OF HUMAN RENAL
CELL CARCINOMA
Jason Muhitch*, Mohammad Habiby
Kermany, Lilia Heit, Alexander Wald, Mary
Hensen, Scott Abrams, Timothy Winslow,
Anurag Singh, Thomas Schwaab, Buffalo, NY
5:10
PD33-11 METABOLIC MODULATION WITH
DICHLOROACETATE REVERSES THE
WARBURG EFFECT AND REDUCES THE
GROWTH OF CLEAR CELL RENAL CELL
CARCINOMA IN VITRO AND IN VIVO
Adam Kinnaird*, Peter Dromparis, Roxane
Paulin, Bruno Saleme, Trevor Stenson,
Desmond Pink, John Lewis, Evangelos
Michelakis, Edmonton, Canada
5:20
PD33-12 ABERRANT ACTIVATION OF GLI1/2 VIA THE
PHOSPHOINOSITIDE 3-KINASE/AKT
PATHWAY AND ITS THERAPEUTIC VALUE IN
CLEAR-CELL RENAL CELL CARCINOMA
Jiancheng Zhou*, Kaijie Wu, Guodong Zhu,
Xinyang Wang, Dalin He, Xi’an, China,
CREDITTM
3:30 pm - 5:30 pm
Video Session 8
BLADDER ONCOLOGY/TESTIS/TRANSPLANTATION/TRAUMA
Moderators: Reza Ghavamian and Andrew James
ABSTRACT
NUMBER TITLE
V8-01
ROBOTIC RPLND USING THE DAVINCI XI
Ashraf Haddad, James Porter*, Seattle, WA
V8-02
MANAGEMENT OF CHALLENGING
URETHRO-ILEAL ANASTOMOSIS DURING
ROBOTIC INTRACORPOREAL
NEOBLADDER FORMATION
Nima Almassi*, Homayoun Zargar, Vishnu
Ganesan, Amr Fergany, Georges Pascal
Haber, Cleveland, OH
V8-03
STEP-BY-STEP TECHNIQUE FOR
ROBOTIC INTRACORPOREAL BOWEL
ANASTOMOSIS AND DEVELOPMENT OF A
SIMULATION TRAINING MODEL
Friedrich-Carl von Rundstedt*, Selcuk Silay,
Monty Aghazadeh, Alvin Goh, Houston, TX
V8-04
*Presenting author
ABSTRACT
NUMBER TITLE
V8-05
CONCOMITANT HOLMIUM LASER
(HOLEP) AND LAPAROSCOPIC ROBOTASSISTED BLADDER
DIVERTICULECTOMY FOR TREATMENT
OF A LARGE BLADDER TUMOR
Adam C Calaway*, David Y Yang, Jessica E
Paonessa, James E Lingeman, Ronald S
Boris, Indianapolis, IN
PARTIAL CYSTECTOMY WITH
DIVERTICULECTOMY, DISTAL
URETERECTOMY WITH
URETERONEOCYSTOTOMY, AND
BILATERAL PELVIC LYMPHADENECTOMY
FOR MALIGNANT DISEASE IN A BLADDER
DIVERTICULUM
Jed-sian Cheng*, Boston, MA, Glen
Barrisford, Santa Rosa, CA, Mahdi Zangi,
Shahin Tabatabaei, Boston, MA
187
V8-06
BLUE LIGHT CYSTOSCOPY: THE USC
EXPERIENCE
Siamak Daneshmand*, Los Angeles, CA,
Mehrdad Alemozaffar, Atlanta, GA, Hooman
Djaladat, Anne Schuckman, Los Angeles, CA
V8-07
EN BLOC BLADDER TUMOR RESECTION:
BACK TO ONCOLOGIC BASICS
Piruz Motamedinia*, New Hyde Park, NY,
Alexey Martov, Moscow, Russian Federation,
Zeph Okeke, Arthur Smith, New Hyde Park, NY
V8-08
LASER EN BLOC RESECTION OF
BLADDER TUMORS: A EUROPEAN MULTICENTER STUDY TO EVALUATE SAFETY,
EFFICACY AND OUTCOME
Mathias Wolters*, Mario Kramer, Axel
Merseburger, Hannover, Germany, Markus
Riedl, Armin Leitenberger, Wolfsburg,
Germany, Alexey Martov, Nikolay Baykov,
Moscow, Russian Federation, Markus
Kuczyk, Hannover, Germany, Andreas Gross,
Hamburg, Germany, David Leavitt, Arthur
Smith, New York, NY, Thomas Herrmann,
Hannover, Germany
SUNDAY
4:50
V8-09
ROBOTIC-ASSISTED INGUINAL
LYMPHADENECTOMY: EARLY OUTCOMES
AND TECHNICAL MODIFICATIONS
Alexander M. Helfand*, Jeffrey S.
Montgomery, Alon Z. Weizer, Todd M.
Morgan, Ann Arbor, MI
V8-10
ROBOTIC ANTERIOR PELVIC
EXENTERATION WITH INTRACORPOREAL
ILEAL CONDUIT IN A PATIENT WITH
HISTORY OF KIDNEY PANCREAS
TRANSPLANTATION
Yaw Nyame*, Paurush Babbar, Daniel
Greene, Homayoun Zargar Shoshtari,
Venkatesh Krishnamurthi, Georges-Pascal
Haber, Cleveland, OH
V8-11
ROBOTIC PARTIAL AND RADICAL
NEPHRECTOMY IN RENAL ALLOGRAFT:
DEMONSTRATION OF TECHNIQUE
Haidar Abdul-Muhsin*, Nitin Katariya, Erik
Castle, Phoenix, AZ
V8-12
MALFUNCTION OF LINEAR CUTTING
STAPLER IN KIDNEY SURGERY
Rene Sotelo*, Caracas, Venezuela, Erik Castle,
Scottsdale, AZ, Robert De Andrade, Luis
Medina, Leonardo Brunacci, Oscar Martı́n, Igor
Kislinger, Nelson Ramı́rez-Troche, David
Canes, Caracas, Venezuela, Paul Andrews,
Scottsdale, AZ, Camilo Giedelman, Hernán
Aponte, Bogota, Colombia
V8-13
ACUTE INSERTION OF PENILE
PROSTHESES FOR REFRACTORY
ISCHEMIC PRIAPISM
Paul Chung*, Timothy Tausch, Jordan Siegel,
James Flemons, Allen Morey, Dallas, TX
V8-14
ROBOTIC SALVAGE CYSTECTOMY: TIPS
AND TRICKS
Neel Srikishen*, Michael Pan, Monty Aghazadeh,
Brian Miles, Alvin Goh, Houston, TX
CREDITTM
188
Plenary Session
7:30 am - 12:15 pm
7:28
7:30
HIGHLIGHTS: THE SCIENCE OF FEMALE PELVIC HEALTH
Toby Chai
7:40
STATE-OF-THE-ART LECTURE: EFFECTS OF MUSCLE CELL THERAPY IN A NONHUMAN PRIMATE MODEL OF
CHRONIC INTRINSIC URINARY SPHINCTER DEFICIENCY
J. Koudy Williams
7:55
POINT-COUNTERPOINT: REFRACTORY OVERACTIVE BLADDER (OAB) WITH PELVIC ORGAN PROLAPSE (POP)
Moderator:
Kathleen Kobashi
Debaters:
Sandip Vasavada (Con)
E. Ann Gormley (Pro)
8:15
POINT-COUNTERPOINT: OCCULT SUI: WHAT HAVE CLINICAL TRIALS TAUGHT US?
Moderator:
Firouz Daneshgari
Debaters:
Stephen Kraus (Con)
Howard Goldman (Pro)
8:35
PRESIDENTIAL ADDRESS: LEARNING FROM YESTERDAY, LIVING FOR TODAY AND LOOKING FORWARD TO
TOMORROW
William Bohnert
8:55
RAMON GUITERAS LECTURE: TWO DECADES OF INNOVATION IN MINIMALLY INVASIVE UROLOGIC
ONCOLOGIC SURGERY: THE BEST IS YET TO COME
Inderbir Gill
9:15
CRITICAL DISCUSSION: RENAL URETEROSCOPY FOR STONES: TO DUST OR TO BASKET
Critical
Discussant:
Gerhard Fuchs
Presenters:
Ojas Shah (Dust)
Mitchell Humphreys (Basket)
9:35
PANEL DISCUSSION: MINIMALLY INVASIVE URETERAL RECONSTRUCTION
Moderator:
Ashok Hemal
Panelists:
Jihad Kaouk
Louis Kavoussi
Mihir Desai
10:00
AUA GUIDELINE UPDATE: CASTRATION-RESISTANT PROSTATE CANCER
William Lowrance
10:10
BEST ABSTRACT: PI-04: DURABLE REDUCTIONS IN URINARY INCONTINENCE WITH LONG-TERM
ONABOTULINUMTOXINA TREATMENT IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME: FINAL
RESULTS OF 3.5-YEAR STUDY
Victor Nitti*, New York, NY, Dirk De Ridder, Leuven, Belgium, David Sussman, Stratford, NJ, Peter Sand, Evanston,
IL, Karl-Dietrich Sievert, Lubeck, Germany, Christopher Chapple, Sheffield, United Kingdom, Brenda Jenkins, Irvine,
CA, Yan Zheng, Bridgewater, NJ, Sidney Radomski, Toronto, Canada
10:17
BEST ABSTRACT: PI-05: IS RETROPUBIC MID-URETHRAL SLING SAFE AND EFFECTIVE FOR PATIENTS WITH
VALSALVA VOIDING?
Blake Anderson*, Joseph Pariser, Shane Pearce, Gregory Bales, Chicago, IL, Doreen Chung, New York, NY
10:25
STATE-OF-THE-ART LECTURE: UROLOGICAL ASSOCIATION OF ASIA (UAA) LECTURE: IMPACT OF CHRONIC
PROSTATIC INFLAMMATION ON BPH/LUTS
Yoshiyuki Kakehi
10:45
STATE-OF-THE-ART LECTURE: PATHOPHYSIOLOGY AND MANAGEMENT OF URIC ACID STONES
Naim Maalouf
11:00
STATE-OF-THE-ART LECTURE: ANTIBIOTIC STEWARDSHIP
Florian Wagenlehner
11:15
STATE-OF-THE-ART LECTURE: THE BEERS CRITERIA FOR POTENTIALLY INAPPROPRIATE MEDICATION USE
IN OLDER ADULTS
Tomas Griebling
*Presenting author
189
MONDAY
PLENARY I - MONDAY
11:30
PANEL DISCUSSION: SPECIAL CONSIDERATIONS FOR TREATING OAB IN THE ELDERLY: A PRACTICAL
APPROACH
Moderator:
Kevin Pranikoff
Panelists:
E. Camille Vaughan
Hann-Chorng Kuo
Matthias Oelke
11:55
AUA GUIDELINE: INTERSTITIAL CYSTITIS GUIDELINE AMENDMENT
Philip Hanno
12:05
STATE-OF-THE-ART LECTURE: CATHETER ASSOCIATED URINARY TRACT INFECTIONS: DEFINITIONS AND
SIGNIFICANCE IN THE UROLOGIC PATIENT. AN AUA WHITE PAPER
Timothy Averch
12:15
SESSION CONCLUDES
Plenary Session
10:00 am - 12:00 pm
PLENARY II - MONDAY
9:58
10:00
EUROPEAN ASSOCIATION OF UROLOGY (EAU) LECTURE: EARLY DETECTION OF PROSTATE CANCER: THE
EUROPEAN VIEW
Per-Anders Abrahamsson
10:20
POINT-COUNTERPOINT: NEOADJUVANT CHEMOTHERAPY SHOULD BE THE STANDARD IN BULKY INGUINAL
NODES IN PENILE CANCER
Moderator:
Philippe Spiess
Debaters:
Lance Pagliaro (Pro)
Sukhbinder Minhas (Con)
10:40
POINT-COUNTERPOINT: INTERMITTENT VS. MAXIMAL ADT: TRANSLATING RANDOMIZED TRIALS IN
CLINICAL PRACTICE
Moderator:
Robert Flanigan
Debaters:
Maha Hussain (Maximal ADT)
Laurence Klotz (Intermittent)
11:00
STATE-OF-THE-ART LECTURE: MRI & MR FUSION BIOPSY
Samir Taneja
11:15
PANEL DISCUSSION: REDEFINING THE ROLE OF CHEMOTHERAPY IN THE PROSTATE CANCER SEQUENCING
STORY IN CRPC
Moderator:
Martin Gleave
Panelists:
Christopher Logothetis
Axel Heidenreich
Robert Reiter
11:45
STATE-OF-THE-ART LECTURE: PROSTATE CANCER REGISTRY: AN UPDATE
Matthew Cooperberg
12:00
SESSION CONCLUDES
190
8:00 am - 10:00 am
BLADDER CANCER: INVASIVE II
Moderators: Joseph Chin and Marcus Quek
ABSTRACT
NUMBER TITLE
MP58-06 USING ANALYTIC MORPHOMICS TO
UNDERSTAND SHORT-TERM
CONVALESCENCE AFTER BLADDER
SURGERY
Amy Luckenbaugh*, Brent Hollenbeck, Jeffrey
Montgomery, Cheryl Lee, Rodney Dunn,
Michael Englesbe, Stewart Wang, Ann Arbor,
MI
MP58-07 TUMOR PD-L1 AND LYMPHOCYTIC
INFILTRATE FOXP3 STATUS IN NONMUSCLE INVASIVE UROTHELIAL
CARCINOMA OF BLADDER (NMIBC)
Gunes Guner, Maria Angelica Mendoza
Rodriguez, Alexander Baras, Jen-Jane Liu,
Sheila Friedrich Faraj, Nilda GonzalesRoibon, Noah M Hahn, Charles Drake, Trinity
J Bivalacqua, Janis Taube, Baltimore, MD,
Katayoon Rezaei, Washington, DC, George
Netto*, Baltimore, MD
MP58-02 PRE-CHEMOTHERAPY NEUTROPHIL-TOLYMPHOCYTE RATIO CORRELATES WITH
CANCER-SPECIFIC AND OVERALL
MORTALITY IN PATIENTS WITH
METASTATIC UROTHELIAL CARCINOMA
Satoru Taguchi*, Tohru Nakagawa, Akihiko
Matsumoto, Yasushi Nagase, Taketo Kawai,
Yoshinori Tanaka, Kanae Yoshida, Sachi
Yamamoto, Yutaka Enomoto, Yorito Nose,
Toshikazu Sato, Akira Ishikawa, Yukari
Uemura, Tetsuya Fujimura, Hiroshi Fukuhara,
Haruki Kume, Yukio Homma, Tokyo, Japan
MP58-08 FAVORABLE SURVIVAL OUTCOMES
AFTER A CHEMORADIATION-BASED
MULTIMODAL APPROACH AGAINST
WITH HIGH KI-67 EXPRESSION
Soichiro Yoshida*, Kenji Tanabe, Fumitaka
Koga, Masaharu Inoue, Shuichiro Kobayashi,
Junichiro Ishioka, Tomoki Tamura, Emiko
Sugawara, Kazutaka Saito, Takumi Akashi,
Yasuhisa Fujii, Kazunori Kihara, Bunkyo-ku,
Tokyo, Japan
MP58-03 IDENTIFICATION OF SPECIFIC
METHYLATION-BASED BIOMARKERS FOR
THE ASSESSMENT OF THE METASTATIC
RISK OF MUSCLE INVASIVE BLADDER
CANCER
Beatrice Stubendorff, Homburg, Germany,
Kerstin Wilhelm, Jena, Germany, Kathleen
Posselt, Dresden, Germany, James Catto,
Sheffield, United Kingdom, Elke Schaeffeler,
Matthias Schwab, Stuttgart, Germany, Arndt
Hartmann, Erlangen, Germany, Susanne
Füssel, Vladimir Novotny, Dresden, Germany,
Mieczyslaw Gajda, Marc-Oliver Grimm, Jena,
Germany, Michael Stöckle, Kerstin Junker*,
Homburg, Germany
MP58-09 THE PATHOLOGIC FEATURES IN
RADICAL CYSTECTOMY SPECIMENS OF
PATIENTS RECEIVING NEOADJUVANT
CHEMOTHERAPY FOR BLADDER
CANCER: IS TUMOR REGRESSION
IMPORTANT?
Nooshin Karamzadeh Dashti*, Rafael E.
Jimenez, Igor Frank, Stephen A. Boorjian, R.
Houston Thompson, Brian A. Costello, R.
Jeffrey Karnes, John C. Cheville, Rochester,
MN
MP58-04 MUTATION IN MUC6 PREDICTS OVERALL
AND RECURRENCE-FREE SURVIVAL
FOLLOWING RADICAL CYSTECTOMY FOR
Brian Cross*, William LaFramboise, Jeffrey
Gingrich, Somak Roy, Benjamin Davies, Rajiv
Dhir, Pittsburgh, PA
MP58-10 THE ASSOCIATION OF CIRCULATING
TUMOR CELLS AND VARIANT
HISTOLOGY ON OUTCOMES IN
BLADDER TREATED WITH RADICAL
CYSTECTOMY
Armin Soave, Sabine Riethdorf, Lars
Weisbach, Sarah Minner, Oliver Engel, Luis
A. Kluth, Felix K. Chun, Roland Dahlem,
Klaus Pantel, Margit Fisch, Michael Rink*,
Hamburg, Germany
MP58-05 SIGNIFICANCE OF PREOPERATIVE
BUTYRYLCHOLINESTERASE AS AN
INDEPENDENT PREDICTOR OF SURVIVAL
IN PATIENTS WITH MUSCLE-INVASIVE
BLADDER CANCER TREATED WITH
RADICAL CYSTECTOMY
Takuya Koie*, Chikara Ohyama, Hayato
Yamamoto, Shingo Hatakeyama, Atsushi
Imai, Takahiro Yoneyama, Yasuhiro
Hashimoto, Tohru Yoneyama, Yuki Tobisawa,
Kazuyuki Mori, Hiromichi Iwamura, Yuta
Kojima, Tendo Satoh, Naoki Fujita, Jotaro
Mikami, Hirosaki, Japan
*Presenting author
191
MONDAY
ABSTRACT
NUMBER TITLE
MP58-01 NEUTOROPHIL-TO-LYMPHOCYTE RATIO
(NLR) MIGHT BE A NEW PROGNOSIS
MARKER IN BLADDER CANCER
PATIENTS AFTER RADICAL
CYSTECTOMY
Takashi Kawahara*, Kazuhiro Furuya,
Kazuhide Makiyama, Noboru Nakaigawa,
Yokohama, Japan, Hiroshi Miyamoto,
Baltimore, MD, Masahiro Yao, Hiroji Uemura,
Yokohama, Japan
MP58-17 CASE-LOAD IS NOT ASSOCIATED WITH
SURGICAL OUTCOMES OF RADICAL
CYSTECTOMY. A NATION-WIDE STUDY
OF CURRENT PRACTICE
Borja Lopez*, Carlos Llorente, Virginia
Hernández, Enrique De la Peña, Madrid,
Spain, Elia Pérez-Fernández, m, Spain, Maria
A. Gogorcena, Madrid, Spain
MP58-11 DOES SQUAMOUS DIFFERENTIATION
PORTEND WORSE OUTCOMES IN
UROTHELIAL BLADDER CANCER?
David Y Yang, M Francesca Monn, Hristos Z
Kaimakliotis, Jane S Cho*, K Clint Cary, Jose
A Pedrosa, Richard Bihrle, Liang Cheng,
Michael O Koch, Indianapolis, IN
MP58-12 DOES “LOW RISK” MUSCLE INVASIVE
BLADDER CANCER ACTUALLY EXIST?
Eugene Pietzak, III*, Matthew Sterling, S.
Philadelphia, PA
MP58-18 OUTCOME OF METASTATIC UROTHELIAL
CARCINOMA IN GC ERA: PROGNOSTIC
FACTORS FROM REAL-WORLD CLINICAL
PRACTICE IN JAPAN
Junji Ishizaki*, asahikawa, Japan, Takashige
Abe, Keita Minami, Ryuji Matsumoto, Toru
Harabayashi, Sapporo, Japan, Ataru Sazawa,
Obihiro, Japan, Tango Mochizuki, Satoshi
Chiba, Asahikawa, Japan, Tomoshige Akino,
Sapporo, Japan, Masahi Murakumo, Kushiro,
Japan, Naoto Miyajima, kunihiko Tsuchiya,
Satoru Maruyama, Nobuo Shinohara,
Sapporo, Japan
MP58-13 OUTCOME REPORTING AFTER RADICAL
CYSTECTOMY FOR UROTHELIAL
CARCINOMA OF THE BLADDER USING
ONCOLOGICAL TRIFECTA AND
PENTAFECTA
Atiqullah Aziz*, Michael Rink, Marianne
Schmid, Felix Chun, Roland Dahlem,
Hamburg, Germany, Shahrokh F. Shariat,
Vienna, Austria, Margit Fisch, Hamburg,
Germany, Matthias May, Straubing, Germany
MP58-19 FUNCTIONAL OUTCOMES FOLLOWING
RADICAL CYSTECTOMY IN WOMEN WITH
BLADDER CANCER: A SYSTEMATIC
REVIEW
Peter Greene*, E. Sophie Spencer, Matthew
Lyons, Raj Pruthi, Eric Wallen, Michael
Woods, Matthew Nielsen, Chapel Hill, NC,
Cheryl Lee, Ann Arbor, MI, Angela Smith,
Chapel Hill, NC
MP58-14 A NOVEL TOOL TO PREDICT OUTCOMES
USING AGE AND CO-MORBIDITY STATUS
Jasmir Nayak*, Sarah Holt, John Gore,
Jonathan Wright, Mathew Mossanen, Atreya
Dash, Seattle, WA
MP58-15 PREDICTING SURVIVAL AFTER RADICAL
CYSTECTOMY: VALIDATION OF THE
SPARC SCORE
Brian Hu*, Los Angeles, CA, Manuel
Eisenberg, Stephen Boorjian, Igor Frank,
Rochester, MN, Leo Dalag, Kamran
Movassaghi;, Los Angeles, CA, Prabin
Thapa, Rochester, MN, Gus Miranda, Siamak
MP58-20 PREDICTION OF LOCOREGIONAL
CYSTECTOMY FOR UROTHELIAL
CARCINOMA OF THE BLADDER
Atiqullah Aziz*, Hamburg, Germany, Michael
Froehner, Dresden, Germany, Matthias May,
Straubing, Germany, Michael Rink, Felix
Chun, Margit Fisch, Hamburg, Germany,
Vladimir Novotny, Dresden, Germany
MP58-16 PREDICTION OF CANCER-SPECIFIC
SURVIVAL IN PATIENTS WITH RADICAL
USING ARTIFICIAL NEURAL NETWORKS
Philipp Nuhn, Munich, Germany, Atiqullah
Aziz, Hamburg, Germany, Matthias May,
Straubing, Germany, Michael Staehler,
Munich, Germany, Michael Gierth,
Regensburg, Germany, Jörg Ellinger, Stefan
C. Müller, Bonn, Germany, Florian
Wagenlehner, Wolfgang Weidner, Giessen,
Germany, Rudolf Moritz, Edwin Herrmann,
Münster, Germany, Florian Hartmann, MarcOliver Grimm, Jena, Germany, Chris Protzel,
Oliver Hakenberg, Rostock, Germany, Lukas
Lusuardi, Günter Janetschek, Salzburg,
Austria, Murat Gördük, Jan Roigas, Berlin,
Germany, Maximilian Burger, Regensburg,
Germany, Margit Fisch, Hamburg, Germany,
Christian G. Stief, Munich, Germany, Patrick
Bastian, Düsseldorf, Germany, Tobias
Grimm, Alexander Buchner*, Munich,
Germany
CREDITTM
192
8:00 am - 10:00 am
KIDNEY CANCER: SURGICAL THERAPY III
Moderators: Christopher Wood and Jose Karam
ABSTRACT
NUMBER TITLE
MP59-08 POPULATION-BASED COMPARISON OF
CANCER SPECIFIC MORTALITY AFTER
LOCAL TUMOR ABLATION OR NONACTIVE TREATMENT FOR T1A KIDNEY
CANCER: A COMPETING RISK ANALYSIS
Vincent Trudeau*, Alessandro Larcher, Malek
Meskawi, Roger Valdivieso, Katharina
Boehm, Zhe Tian, Montreal, Canada, Nicola
Fossati, Nicolò Buffi, Giovanni Lughezzani,
Giorgio Guazzoni, Milan, Italy, Pierre
Karakiewicz, Maxine Sun, Montreal, Canada
MP59-02 IMPACT OF URETEROSCOPY PRIOR TO
TRACT UROTHELIAL CARCINOMA ON
ONCOLOGIC OUTCOMES
Alex Sankin*, Amy Tin, Roy Mano, Michael
Chevinsky, Chris Jakubowski, Eugene Cha,
Alyssa Yee, Fara Friedman, Daniel Sjoberg,
Behfar Ehdaie, Jonathan Coleman, New
York, NY
MP59-09 IS IT SAFE TO CONTINUE ASPIRIN
DURING LAPAROSCOPIC PARTIAL
NEPHRECTOMY?
Michael Siev*, Paras Shah, David Leavitt,
Simpa Salami, New Hyde Park, NY, Vinoth
Birabaharan, Hempstead, NY, Mathew
Fakhoury, Old Westbury, NY, Manaf Alom,
Jessica Kreshover, Lee Richstone, Manish
Vira, Louis Kavoussi, New Hyde Park, NY
MP59-03 AN EVALUATION OF THE TIMING OF
SURGICAL COMPLICATIONS FOLLOWING
NEPHRECTOMY
Akshay Sood*, Victor Kapoor, Firas Abdollah,
Jesse Sammon, Craig Rogers, Dane Klett,
Wooju Jeong, Ali Dabaja, Detroit, MI,
Marianne Schmid, Adam Kibel, Boston, MA,
James Peabody, Mani Menon, Detroit, MI,
MP59-10 SARCOPENIA AS A PREDICTOR OF
SURVIVAL AFTER CYTOREDUCTIVE
NEPHRECTOMY FOR METASTATIC
Pranav Sharma*, Kamran Zargar-Shoshtari,
Jamie Caracciolo, Mayer Fishman, Michael
Poch, Julio Pow-Sang, Wade Sexton,
Philippe Spiess, Tampa, FL
MP59-04 OPTIMAL TREATMENT FOR 4-10CM
RENAL CELL CARCINOMA: A SURVEY OF
ENDOUROLOGISTS AND UROLOGIC
ONCOLOGISTS
Sara Best, Michael Blute*, Madison, WI,
Brian Lane, Grand Rapids, MI, E. Jason Abel,
Madison, WI
MP59-11 FIBRIN SEALANTS DOES NOT IMPACT
PERIOPERATIVE BLOOD TRANSFUSIONS
RATE IN PATIENTS UNDERGOING
PARTIAL NEPHRECTOMY
Yasmin Abu-Ghanem*, Zohar Dotan, Yizhak
Kaver, Jacob Ramon, Tel Hashomer, Israel
MP59-05 ANALYSIS OF FACTORS AFFECTING
POST-OPERATIVE SPLIT RENAL
FUNCTION AFTER PARTIAL
NEPHRECTOMY USING R.E.N.A.L.
NEPHROMETRY SCORE
Masafumi Kita*, Kazumi Hashizume, Masaki
Watanabe, Junichi Hori, Naoki Wada, Makoto
Azumi, Tatsuya Iwata, Seiji Matsumoto,
Hidehiro Kakizaki, Asahikawa, Japan
MP59-12 FUNCTIONAL & TRIFECTA OUTCOMES IN
SOLITARY KIDNEY: UNCLAMPED VS
CLAMPED PARTIAL NEPHRECTOMY
Andre Luis de Castro Abreu*, Los Angeles,
CA, Rocco Papalia, Rome, Italy, Inderbir Gill,
Los Angeles, CA, Giuseppe Simone,
Rome, Italy, Kelvin Wong, Raed Azhar, Raj
Satkunasivam, Charles Metcalfe, Osamu
Ukimura, Monish Aron, Mihir Desai, Los
Angeles, CA, Michele Gallucci, Rome, Italy
MP59-06 CONTEMPORARY SERIES UTILIZING
MINIMALLY INVASIVE TECHNIQUES FOR
ENUCLEATION VS. TRADITIONAL
PARTIAL NEPHRECTOMY
Michael Hanzly*, Daniel Abbotoy, Terrance
Creighton, Hyung Kim, Eric C. Kauffman,
Thomas Schwaab, Buffalo, NY
MP59-13 TREATMENT OF THE SMALL RENAL
MASS: LESS IS MORE
Dena Moskowitz*, Orange, CA, Jenny Chang,
Argyrios Ziogas, Hoda Anton-Culver, Ralph
Clayman, Irvine, CA
MP59-07 DEFINING THE MALIGNANT POTENTIAL
OF ONCOCYTIC RENAL NEOPLASMS
Chandra K. Flack*, Adam C. Calaway,
Dibson D. Gondim, Muhammad T. Idrees,
Ronald S. Boris, Indianapolis, IN
*Presenting author
MP59-14 OUTCOMES OF RADICAL NEPHRECTOMY
FOR RENAL MASSES IN PATIENTS WITH
END STAGE RENAL DISEASE
Ravi Barod*, Alex Borchert, Deepansh
Dalela, Detroit, MI, Craig Rogers, Plymouth,
MI
193
MONDAY
ABSTRACT
NUMBER TITLE
MP59-01 IMPACT OF BLOOD TRANSFUSIONS ON
ONCOLOGICAL OUTCOMES OF
SURGICALLY TREATED LOCALIZED
Matvey Tsivian, Melissa Mendez*, Durham,
NC, Michael Abern, Chicago, IL, Peter Qi,
Edward Rampersaud, Thomas Polascik,
Durham, NC
MP59-18 COMPREHENSIVE ASSESSMENT OF
CONTEMPORARY SHORT-,
INTERMEDIATE-, AND LONG-TERM
ENDPOINTS AFTER EITHER PARTIAL
NEPHRECTOMY OR MINIMALLY-INVASIVE
RADICAL NEPHRECTOMY
Maxine Sun*, Montreal, Canada, Giorgio
Gandaglia, Milan, Italy, Jonas Schiffmann,
Montreal, Canada, Simon Kim, New Haven,
CT, Alessandro Larcher, Montreal, Canada,
Shahrokh Shariat, New York, NY, Fred Saad,
Pierre Karakiewicz, Montreal, Canada
MP59-15 PERIOPERATIVE AND FUNCTIONAL
OUTCOMES OF ROBOT-ASSISTED
PARTIAL NEPHRECTOMY FOR RENAL
TUMORS >4 CM IN A MULTIINSTITUTIONAL, MULTI-NATIONAL
COHORT
Deepansh Dalela*, Ravi Barod, Akshay Sood,
Detroit, MI, Rajesh Ahlawat, Gurgaon, India,
Sudhir Rawal, Delhi, India, Ben Challacombe,
London, United Kingdom, Francesco
Porpiglia, Torino, Italy, Daniel Moon,
Melbourne, Australia, Nicolomaria Buffi,
Alessandro Larcher, Milan, Italy, Dipen
Parekh, Miami, FL, Giacomo Novara,
Alessandro Volpe, Alex Mottrie, Aalst,
Belgium, Ronney Abaza, Dublin, OH, Craig
Rogers, Plymouth, MI
MP59-19 POPULATION-BASED ASSESSMENT OF
TREATMENT MODALITIES IN THE
ELDERLY WITH LOCALIZED RENAL CELL
CARCINOMA: THE 2000 –2009 UPDATE
Maxine Sun*, Alessandro Larcher, Michael
McCormarck, Montreal, Canada, Shahrokh
Shariat, New York, NY, Luc Valiquette, Fred
Saad, Pierre Karakiewicz, Montreal, Canada
LOCAL TUMOR DESTRUCTION VERSUS
NEPHRECTOMY IN PATIENTS OLDER
THAN 75 YEARS OLD FOR SMALL RENAL
MASSES
Maxine Sun*, Alessandro Larcher, Zhe Tian,
Montreal, Canada, Shahrokh Shariat, New
York, NY, Luc Valiquette, Fred Saad, Pierre
MP59-20 SURGICAL RESECTION OF ISOLATED
RECURRENCE OF RCC: RESULTS FROM A
MULTI-INSTITUTIONAL INTERNATIONAL
COHORT
Christopher Russell*, Philippe E. Spiess,
Tampa, FL, Wassim Kassouf, Montreal,
Canada, Thomas Schwaab, Buffalo, NY,
David D Buethe, Jasreman Dhilon, Wade J.
Sexton, Michael Poch, Julio Powsang,
Tampa, FL, Simon Tanguay, Montreal,
Canada, Sarah P. Psutka, Houston
Thompson, Bradley Leibovich, Rochester,
MN, Michael Hanzly, Buffalo, NY, Stephen
Boorjian, Rochester, MN
MP59-17 RECOVERY IN RENAL FUNCTION AFTER
RADICAL NEPHRECTOMY AND ITS
NEGATIVE PREDICTIVE FACTORS : A
MULTICENTER LONGITUDINAL STUDY
Naoko Kawamura*, Tokyo, Japan
CREDITTM
8:00 am - 10:00 am
PROSTATE CANCER: DETECTION AND SCREENING II
Moderators: Chris Bangma and J. Stephen Jones
ABSTRACT
NUMBER TITLE
MP60-01 PREVALENCE OF NON-RECOMMENDED
SCREENING FOR PROSTATE CANCER
AND BREAST CANCER IN THE UNITED
STATES
Firas Abdollah*, Jesse Sammon, Akshay
Sood, Dane Klett, Daniel Pucheril, Detroit, MI,
Paul Nguyen, Toni Choueiri, Adam Kibel,
Mark Preston, Boston, MA, Mani Menon,
Detroit, MI, Joel Weissman, Quoc-Dien Trinh,
Boston, MA
ABSTRACT
NUMBER TITLE
MP60-02 SINGLE NUCLEOTIDE POLYMORPHISMS
IN SLC45A3 AND KLK3 ARE
CORRELATED WITH SERUM PSA LEVELS
AND ARE POTENTIAL BIOMARKERS FOR
DETECTING PROSTATE CANCER
Naoki Terada*, Chikashi Terao, Koji
Yoshimura, Takashi Kobayashi, Yoshiyuki
Matsui, Takahiro Inoue, Tomomi Kamba,
Fumihiko Matsuda, Osamu Ogawa, Kyoto,
Japan
MP60-03 PROSTATE CANCER IN THE ELDERLY
Barry Stein*, Albany, NY
194
MP60-11 SHOULD A NORMAL MULTIPARAMETRIC
MRI PRECLUDE PROSTATE BIOPSY?
Frederick Dorey, Leonard Marks, Los
Angeles, CA
MP60-04 QUANTITATIVE ASSESSMENT OF T2WEIGHTED MRI TO BETTER IDENTIFY
PATIENTS WITH PROSTATE CANCER IN A
SCREENING POPULATION
Ahmad Algohary*, Satish Viswanath, Prateek
Prasanna, Shivani Pahwa, Vikas Gulani,
Cleveland, OH, Daniel Moses, Ronald Shnier,
Maret Böhm, Anne-Maree Haynes, Phillip
Brenner, Warick Delprado, James Thompson,
Marley Pulbrock, Phillip Stricker, Sydney,
Australia, Lee Ponsky, Anant Madabhushi,
Cleveland, OH
MP60-05 DETERMINED FREE SERUM
TESTOSTERONE REFLECTS BETTER
THAN TOTAL TESTOSTERONE THE RISK
OF PROSTATE CANCER DETECTION
Lucas Regis*, Pol Servian, Cristian Isalt, Ana
Celma, Jacques Planas, Jose Placer, Ines
DeTorres, R Ferrer, Juan Morote, Barcelona,
Spain
MP60-13 EVIDENCE OF PROSTATE CANCER
“REVERSE STAGE MIGRATION” TOWARD
MORE ADVANCED DISEASE AT
DIAGNOSIS
Sean Wessel*, Adam Reese, Philadelphia,
PA
MP60-06 THE PERFORMANCE OF THE 4KSCORE
FOR PREDICTING HIGH-GRADE CANCER
ON BIOPSY OF THE PROSTATE DOES
NOT DEPEND ON THE AGE OF THE
PATIENT
Sanoj Punnen*, Miami, FL, Dan Sjoberg, New
York, NY, Steve Zappala, Andover, MI, Dipen
Parekh, Miami, FL
MP60-14 ARE LOWER PSA LEVELS IN OBESE MEN
DUE TO HEMODILUTION OR LOW
ANDROGENS? RESULTS FROM REDUCE
Howard, Durham, NC, Daniel M. Moreira,
Rochester, MN, Gerald L. Andriole, Jr, St.
Louis, MO, Martha K. Terris, Augusta, GA,
Stephen J. Freedland, Durham, NC
MP60-07 CONFIGURATION AND VALIDATION OF A
NOVEL PROSTATE DISEASE NOMOGRAM
PREDICTING PROSTATE BIOPSY
OUTCOME: A PROSPECTIVE STUDY
CORRELATING CLINICAL INDICATORS
AMONG FILIPINO ADULT MALES WITH
ELEVATED PSA LEVEL
Michael Chua*, Patrick Tanseco, Jonathan
Mendoza, Josefino Castillo, Marcelino
Morales Jr, Saturnino Luna Jr, Quezon City,
Philippines
MP60-15 LOW PERCENTAGE OF FREE PROSTATESPECIFIC ANTIGEN IS A STRONG
PREDICTOR OF LATER DETECTION OF
PROSTATE CANCER AMONG MEN WITH
SERUM LEVELS OF TOTAL PSA 4.0 NG/
ML OR LESS
Mitsuharu Sasaki*, Yamagata-shi, Japan,
Shigeto Ishidoya, Sendai-shi, Japan, Kenji
Numahata, Yamagata-shi, Japan, Yoichi Arai,
Sendai-shi, Japan
MP60-08 PROSTATE HEALTH INDEX IS AN
EFFECTIVE MARKER FOR RISK
STRATIFICATION OF PROSTATE CANCER
PATIENTS
E. David Crawford*, Paul Arangua, Clifford
Jones, Wendy Poage, Aurora, CO, Nelson
Stone, New York, NY, Francisco G. La Rosa,
Aurora, CO, Stacy Loeb, New York, NY,
Priya N. Werahera, Aurora, CO
MP60-16 THE RELATIONSHIP OF BASELINE
PROSTATE SPECIFIC ANTIGEN LEVELS
AND RISK OF FUTURE PROSTATE
BIOPSY POSITIVE FOR
ADENOCARCINOMA AND ITS VARIANCE
BY RACE
Daniel Verges*, William Andrew Sterling,
William Atallah, Jeremy Weedon, Nicholas
Karanikolas, Brooklyn, NY
MP60-09 DOES OBESITY MODIFY THE ABILITY OF
PRE-BIOPSY PSA TO DETECT PROSTATE
CANCER ON REPEAT BIOPSY? RESULTS
FROM THE REDUCE STUDY
Durham, NC, Daniel M. Moreira, Rochester,
NC, Ramiro Castro-Santamaria, King of
Prussia, PA, Gerald L. Andriole, St. Louis,
MO, Stephen J. Freedland, Durham, NC
MP60-17 DOES ATYPICAL SMALL ACINAR
PROLIFERATION ON 1ST REPEAT BIOPSY
INCREASE PROSTATE CANCER
DETECTION?
Ahmed Elshafei, Cleveland, OH, Ayman S.
Moussa*, Giza, Egypt, Heather Neifert,
Ganesh Kartha, J.Stephen Jones, Cleveland,
OH
MP60-10 SHOULD SCREENING FOR PROSTATE
CANCER START BEFORE THE AGE OF
55?
Sigrid Carlsson*, Melissa Assel, David
Ulmert, New York, NY, Axel Gerdtsson,
Malmö, Sweden, Jonas Hugosson,
Gothenburg, Sweden, Andrew Vickers, Hans
Lilja, New York, NY
*Presenting author
195
MONDAY
MP60-12 DOES LARGER TUMOR VOLUME EXPLAIN
THE HIGHER PROSTATE SPECIFIC
ANTIGEN LEVELS IN BLACK MEN WITH
PROSTATE CANCER —RESULTS FROM
THE SEARCH DATABASE
Howard, Durham, NC, Martha K. Terris,
Augusta, GA, William J. Aronson, Los
Angeles, CA, Matthew R. Cooperberg, San
Francisco, CA, Christopher L. Amling,
Portland, OR, Christopher J. Kane, San
Diego, CA, Stephen J. Freedland, Durham,
NC
MP60-20 CAN SERUM ADIPOKINES PREDICT THE
OUTCOME OF PROSTATE BIOPSIES? AN
ASSESSMENT OF THE UTILITY OF
SERUM ADIPOKINES IN 2,404 PATIENTS
Aza Mohammed*, Bimal Bhindi, Michael
Jewett, Alexandre Zlotta, Neil Fleshner, Girish
Kulkarni, Toronto, Canada
MP60-18 PCP-SMART STUDY AND PCRD INDEX:
INTRODUCTION AND RESULTS OF A
NOVEL MATHEMATICAL SIMULATION
MODELING METHOD, DEVISED TO
PREDICT THE OUTCOME OF PROSTATE
BIOPSY
Evangelos Spyropoulos*, Dimitrios Kotsiris,
Aggelos Panagopoulos, Athens, Greece,
Stamatios Mavrikos, Athens, Grenada,
Evangelos Hatziplis, Ioannis Galanakis,
Athens, Greece
CREDITTM
MP60-19 THE ASSOCIATION BETWEEN
METABOLIC SYNDROME AND ADVANCED
PROSTATE CANCER IN CHINESE
PATIENTS RECEIVING RADICAL
PROSTATECTOMY
Guiming Zhang*, Yao Zhu, Shanghai, China,
People’s Republic of, Dahai Dong, Qingdao,
China, People’s Republic of, Chengtao Han,
Chengyuan Gu, Weijie Gu, Xiaojian Qin,
Lijiang Sun, Qingdao, China, People’s
Republic of, Dingwei Ye, Shanghai, China,
8:00 am - 10:00 am
PROSTATE CANCER: BASIC RESEARCH IV
Moderators: Brett Carver and Stephen Boorjian
ABSTRACT
NUMBER TITLE
MP61-01 FUNCTIONAL ROLE OF THE KALLIKREIN
6 REGION OF THE KALLIKREIN LOCUS IN
GENETIC PREDISPOSITION FOR
AGGRESSIVE (GLEASON ⱖ8) PROSTATE
CANCER: FINE-MAPPING AND
METHYLATION STUDY IN A CANADIAN
COHORT AND THE SWISS ARM OF THE
EUROPEAN RANDOMIZED STUDY FOR
Laurent Briollais, Hilmi Ozcelik, Toronto,
Canada, Maciej Kwiatkowski, Aarau,
Switzerland, Jingxiong Xu, Sevtap Savas,
Ekaterina Olkhov-Mitsel, Toronto, Canada,
Franz Recker, Aarau, Switzerland, Cynthia
Kuk, Sally Hanna, Neil E Fleshner, Tristan
Juvet, Matt Friedlander, Hong Li, Karen
Chadwick, John Trachtenberg, Ants Toi,
Theodorus H van der Kwast, Eleftherios P
Diamandis, Bharati Bapat, Alexandre R.
Zlotta*, Toronto, Canada
ABSTRACT
NUMBER TITLE
MP61-03 NEURAL STEM CELLS AND GOLD
NANOPARTICLES AS NOVEL TREATMENT
FOR PROSTATE CANCER – EARLY IN
VITRO STUDIES
Ali Zhumkhawala*, Revathi TirughanaSambandan, Rachael Mooney, Jacob Berlin,
Karen Aboody, Jonathan Yamzon, Duarte,
CA
MP61-04 GENOMIC PROFILING OF KCONFAB MEN
WITH A BRCA MUTATION STATUS AND
PROSTATE CANCER
Ania Sliwinski*, Heather Thorne, Damien
Bolton, Gail Risbridger, Renea Taylor, David
Clouston, Victoria, Australia
MP61-05 IL-15 INCREASES NK FUNCTIONS IN THE
PCA-LYMPHOCYTE MICROENVIRONMENT
BY A PROFOUND INCREASE IN
SHEDDING OF MICA FROM PCA CELLS –
A NOVEL PARADIGM
Christina Alexandra Sakellariou*, Oussama
Elhage, London, United Kingdom, Osamu
Ukimura, Inderbir Gill, Los Angeles, CA,
Richard Smith, Christine Galustian, Prokar
Dasgupta, London, United Kingdom
MP61-02 COPY NUMBER VARIATION OF GSTT1
AND GSTM1 AND THE RISK OF
PROSTATE CANCER IN A CARIBBEAN
POPULATION OF AFRICAN DESCENT
Laurent Brureau*, Elise Emeville, Cedric
Broquere, Severine Ferdinand, Pascal
Blanchet, Luc Multigner, Marc Romana,
Pointe-à-Pitre, Guadeloupe
MP61-06 INCREASED PVT1 EXPRESSION
CORRELATES WITH ADVANCED STAGE
AND HORMONE RESISTANCE OF
PROSTATE CANCER
Ayman Soubra*, Badrinath Konety, Anindya
Bagchi, Minneapolis, MN
196
MP61-09 PROMOTER-TARGETED DOUBLE-STRAND
RNA DUPLEX ENHANCES DPYSL3 GENE
EXPRESSION IN PROSTATE CANCER
CELLS
William Parker*, Qingting Hu, Jiang
Wencong, J. Brantley Thrasher, Benyi Li,
Kansas City, KS
MP61-15 USE OF A NOVEL NEAR-INFRARED
IMAGING AGENT FOR INTRA-OPERATIVE
PROSTATE CANCER DETECTION
Jonathan E Kiechle*, Xinning Wang, Shan
Dong, Steve S Huang, Warren DW Heston,
Lee E Ponsky, James P Basilion, Cleveland,
OH
MP61-10 SILENCING OF PMEPA1 IS ASSOCIATED
WITH ACTIVATION OF AR SIGNALING IN
HUMAN PROSTATE CANCER AND
CASTRATION RESISTANT TUMOR
GROWTH IN NUDE MOUSE
Hua Li*, Elizabeth Umeda, Yingjie Song,
Denise Young, Lakshmi Ravindranath,
Ahmed A. Mohamed, Yongmei Chen,
Shashwat Sharad, Gyorgy Petrovics,
Rockville, MD, David G. McLeod, Bethesda,
MD, Isabell Sesterhenn, Silver Spring, MD,
Taduru Sreenath, Albert Dobi, Shiv
Srivastava, Rockville, MD
MP61-16 ETHNIC DIFFERENCES OF ERG
ONCOGENIC ALTERATION IN PROSTATE
CANCER: CONCLUSIONS FROM 1139
WHOLE MOUNT PROSTATES
Albert Dobi*, Rockville, MD, Michael Degon,
James Farrell, Wagner Baptiste, Bethesda,
MD, Denise Young, Youngmei Chen, Gyorgy
Petrovics, Jennifer Cullen, Rockville, MD,
Jacob Kagan, Sudhir Srivastava, Inger
Rosner, David G. McLeod, Bethesda, MD,
Shiv Srivastava, Rockville, MD, Isabell
Sesterhenn, Silver Spring, MD
MP61-17 CELL-FREE DNA AS A PROGNOSTIC
MARKER FOR RESPONSE TO TAXANBASED CHEMOTHERAPY IN PROSTATE
CANCER (CAP) PATIENTS
David Pfister*, Alexandra Kienel, Daniel
Porres, Timur Kuru, Axel Heidenreich,
Aachen, Germany
MP61-11 SPINK1 DEFINES A MOLECULAR
SUBTYPE OF PROSTATE CANCER MEN
WITH MORE RAPID PROGRESSION FROM
BIOCHEMICAL RECURRENCE TO DEATH
IN AN AT RISK, NATURAL HISTORY
COHORT
Michael Johnson*, Ashley Ross, Baltimore,
MD, Mohammed Alshalalfa, Nicholas Erho,
Kasra Yousefi, Voleak Choerung, San Diego,
CA, Stephanie Glavaris, Helen Fedor, Misop
Han, Elizabeth Humphreys, Alan Partin,
Stephania Bezerra, Sheila Faraj, George
Netto, Bruce Trock, Baltimore, MD, Elai
Davicioni, San Diego, CA, Edward Schaeffer,
Baltimore, MD
MP61-18 ELK-1 PROMOTES PROSTATE CANCER
PROGRESSION AND SILODOSIN THAT
INACTIVATES ELK-1 IN PROSTATE
CANCER CELLS INCREASES SENSITIVITY
TO GEMCITABINE
Takashi Kawahara, Baltimore, MD, Ali
Aljarah, Baghdad, Iraq, Eiji Kashiwagi*,
Yichun Zheng, Baltimore, MD, Yi Li,
Rochester, NY, Hitoshi Ishiguro, Hiroshi
Miyamoto, Baltimore, MD
MP61-12 AN ANDROGEN RECEPTOR SPLICE
VARIANT-TARGETED COMBINATION
THERAPY FOR CASTRATION-RESISTANT
PROSTATE CANCER USING EPI-002 AND
A PI3K/MTOR DUAL INHIBITOR
Minoru Kato*, Marianne D. Sadar, Vancouver,
Canada
MP61-19 A NOVEL STRATEGY TO OPTIMISE
TREATMENT OF DOCETAXEL-RESISTANT
PROSTATE CANCER
Dara Lundon*, Maria Prencipe, Amanda
O’Neill, Sinead Ahearne, Padraig Doolan,
Stephen Madden, Dublin, Ireland, Colm
Morrissey, Seattle, WA, John Fitzpatrick,
William Watson, Dublin, Ireland
MP61-13 DEVELOPMENT OF A MOLECULAR
IMAGING SYSTEM BASED ON THE
TRANSCRIPTIONAL ACTIVITY OF THE
DD3/PCA3 NON-CODING RNA FOR
IMAGING SPECIFICALLY THE PROSTATE
CANCER CELLS
Pallavi Jain*, Bertrand Neveu, Yves Fradet,
Frederic Pouliot, quebec city, Canada
*Presenting author
197
MONDAY
MP61-08 THE TERE1 (UBIAD1) PROTEIN INDUCES
OSTEO-MIMETIC EXPRESSION IN
PROSTATE CANCER CELL LINES:
RELEVANCE TO BONE METASTASIS
William Fredericks*, Frank Rauscher III, S.
Bruce Malkowicz, Philadelphia, PA
MP61-14 MICROCT ANALYSIS REVEALED BONE
REGION-SPECIFIC LOCALIZATION OF
OSTEOLYTIC VERSUS OSTEOBLASTIC
LESIONS IN PCSD1, A NEW PATIENTDERIVED XENOGRAFT MODEL OF BONE
Christina Jamieson*, La Jolla, CA, Takeshi
Hirata, Okayama, Japan, Seung Chol Park,
Iksan, Korea, Republic of, Christina N. Wu,
Michelle Muldong, Elana Godebu, Amy
Strasner, Jason R. Woo, Omer Raheem,
Tomonori Yamaguchi, La Jolla, CA, Hiromi
Kumon, Okayama, Japan, Nicholas A.
Cacalano, Los Angeles, CA, Catriona H.M.
Jamieson, Koichi Masuda, Anna A. Kulidjian,
Christopher J. Kane, La Jolla, CA
MP61-07 SERUM MICRORNA ANALYSIS: A
MINIMALLY INVASIVE ASSAY
CORRELATED WITH UPGRADING IN
PATIENTS WITH LOW-RISK PROSTATE
CANCER
Kari Bailey*, Christopher Lebeis, Drew
Palmer, Shiv Patel, Travis Sullivan, David
Canes, Alireza Moinzadeh, John A. Libertino,
Kimberly M. Reiger-Christ, Burlington, MA
CREDITTM
MP61-20 EVALUATION OF ANDROGEN RECEPTOR
FUNCTION IN AFRICAN AMERICAN AND
CAUCASIAN AMERICAN PROSTATE
CANCERS
Aaron Brothers*, Bethesda, MD, Denise
Young, Youngmei Chen, Gyorgy Petrovics,
Jennifer Cullen, Rockville, MD, Inger Rosner,
David G. McLeod, Bethesda, MD, Albert
Dobi, Shiv Srivastava, Rockville, MD, Isabell
Sesterhenn, Silver Spring, MD
8:00 am - 10:00 am
Podium Session 34
PROSTATE CANCER: LOCALIZED IV
Moderator: Ketan Badani
TIME
8:00
8:10
8:20
8:30
ABSTRACT
NUMBER TITLE
PD34-01 MR-US FUSION BIOPSY VS. TRUS
SATURATION PROSTATE BIOPSY IN
ACTIVE SURVEILLANCE
Chad A. Reichard*, Samuel C. Haywood,
Andrei Purysko, J. Stephen Jones, Eric A.
Klein, Andrew Stephenson, Cleveland, OH
ABSTRACT
TIME NUMBER TITLE
8:40
PD34-05 5-ALPHA REDUCTASE INHIBITORS IN
PATIENTS ON ACTIVE SURVEILLANCE
FOR PROSTATE CANCER: IMPACT ON
DISEASE PROGRESSION AND CURATIVE
INTERVENTION
Andre Luis de Castro Abreu*, Inderbir Gill,
Los Angeles, CA, Duke Bahn, Ventura, CA,
Sunao Shoji, Arnaud Marien, Jie Cai, Sameer
Chopra, Raed Azhar, Kelvin Wong, Charles
Metcalfe, Raj Satkunasivam, Osamu
Ukimura, Los Angeles, CA
PD34-02 OUTCOMES OF MRI-US FUSION
TARGETED BIOPSY IN THE RISK
STRATIFICATION OF ACTIVE
SURVEILLANCE CANDIDATES
Neil Mendhiratta, Michael Fenstermaker,
Richard Huang, New York, NY, James
Jonathan Melamed, Ming Zhou, William C.
Huang, Herbert Lepor, Samir S. Taneja, New
York, NY
PD34-03 TIMING OF THE CONFIRMATORY BIOPSY
IN PROSTATE CANCER ACTIVE
SURVEILLANCE: ANALYSIS OF THE
CANARY PROSTATE CANCER ACTIVE
SURVEILLANCE STUDY (PASS)
Liam C. Macleod*, William J. Ellis, Lisa F.
Newcomb, Yingye Zheng, Seattle, WA,
James D. Brooks, Palo Alto, CA, Peter R.
Carroll, San Francisco, CA, Martin E. Gleave,
Vancouver, Canada, Raymond S. Lance,
Virginia Beach, VA, Peter S. Nelson, Seattle,
WA, Ian M. Thompson, San Antonio, TX,
Andrew A. Wagner, Boston, MA, John T.
Wei, Ann Arbor, MI, Hui-Yu Yang, Daniel W.
Lin, Seattle, WA
PD34-04 FREQUENCY OF PSA TESTING IN MEN ON
CANCER
Leonard Bokhorst*, Arnout Alberts,
Rotterdam, Netherlands, Yoshiyuki Kakehi,
Kagawa, Japan, Antti Rannikko, Helsinki,
Finland, Tom Pickles, Vancouver, Canada,
Riccardo Valdagni, Milan, Italy, Chris
Bangma, Monique Roobol, Rotterdam,
Netherlands
198
8:50
PD34-06 THE EFFECT OF NSAID USE ON DISEASE
PROGRESSION IN PATIENTS ON ACTIVE
SURVEILLANCE FOR PROSTATE CANCER
Gautum Agarwal*, Joseph Spuches, Adam
Luchey, Trushar Patel, Julio Pow-Sang,
Tampa, FL
9:00
PD34-07 CAN GLEASON 7 PROSTATE CANCER
EVER BE LOW-RISK? RESULTS FROM
THE SHARED EQUAL ACCESS REGIONAL
CANCER HOSPITAL (SEARCH) DATABASE
Kathleen McGinley*, Xizi Sun, Lauren
Howard, Durham, NC, William Aronson, Los
Angeles, CA, Martha Terris, Augusta, GA,
Christopher Kane, La Jolla, CA, Christopher
Amling, Portland, OR, Matthew Cooperberg,
San Francisco, CA, Stephen Freedland,
Durham, NC
9:10
PD34-08 TREATMENT DECISION-MAKING
PATTERNS AMONG LOW RISK PROSTATE
CANCER PATIENTS MANAGED ON
ACTIVE SURVEILLANCE IN AN EQUAL
ACCESS HEALTH CARE SETTING
Daniel Kim*, Bethesda, MD, Lauren Hurwitz,
Jennifer Cullen, Rockville, MD, Jane Hudak,
Maryellen Colston, Judith Travis, Bethesda,
MD, Sally Elsamanoudi, Rockville, MD, Inger
Rosner, Bethesda, MD
9:30
PD34-09 COMPARISON OF PATHOLOGIC
OUTCOMES IN MEN WITH FAVORABLERISK PROSTATE CANCER UNDERGOING
DELAYED SURGERY AFTER ACTIVE
SURVEILLANCE VERSUS IMMEDIATE
SURGERY
Jeffrey Tosoian, Debasish Sundi, Bruce
Trock, Patricia Landis, Jonathan Epstein,
Edward Schaeffer, Mufaddal Mamawala*, H.
Ballentine Carter, Baltimore, MD
9:40
PD34-11 PATTERNS OF CARE FOR MEN WITH
PROSTATE CANCER UNDERGOING ACTIVE
SURVEILLANCE AS INITIAL MANAGEMENT
Stacy Loeb*, Dawn Walter, Sasha Dewitt,
Heather T. Gold, Danil V. Makarov, New
York, NY
9:50
PD34-12 EMOTIONAL DISTRESS PREDICTS
CHOOSING SURGERY OVER ACTIVE
SURVEILLANCE IN CLINICALLY LOCALIZED
Heather Orom*, Willie Underwood, D. Lynn
Homish, Buffalo, NY, Deepak Kapoor,
Melville, NY, Christian Nelson, New York, NY,
Zvi Schiffman, Houston, TX, Juan Reyna,
San Antonio, TX
PD34-10 OUTCOMES FOLLOWING IMMEDIATE
VERSUS DELAYED RADICAL
PROSTATECTOMY AMONG PATIENTS ON
CANCER
Pauline Filippou*, Christopher Welty, Janet
Cowan, Peter Carroll, San Francisco, CA
CREDITTM
8:00 am - 10:00 am
Podium Session 35
KIDNEY CANCER: ADVANCED I
Moderator: Viraj Master and Shin Egawa
TIME
8:00
ABSTRACT
NUMBER TITLE
PD35-01 HOW LONG SHOULD BE EXTENDED
FOLLOW UP AFTER SURGERY FOR
RENAL CANCER? RETROSPECTIVE
ANALYSIS OF A COHORT OF PATIENTS
WITH MORE THAN 10 YEARS OF FOLLOW
UP
Francesca Carobbio*, Alessandro Antonelli,
Mario Sodano, Maria Furlan, Giacomo
Galvagni, Alberto Cozzoli, Tiziano Zanotelli,
Claudio Simeone, Brescia, Italy
8:10
PD35-02 EARLY TUMOR SHRINKAGE UNDER
FIRST-LINE TYROSINE KINASE
INHIBITOR AS A SURROGATE ENDPOINT
OF OVERALL SURVIVAL IN PATIENTS
WITH METASTATIC RENAL CELL
CARCINOMA
Hideaki Miyake*, Ken-ichi Harada, Masato
8:20
PD35-03 THE IMPACT OF CHANGE IN SERUM CREACTIVE PROTEIN LEVEL ON THE
PREDICTION OF EFFECTS OF
MOLECULAR TARGETED THERAPY IN
METASTATIC RENAL CELL CARCINOMA
PATIENTS
Jun Teishima*, Kohei Kobatake, Hiroyuki
Kitano, Takashi Babasaki, Hirotaka
Nagamatsu, Keisuke Hieda, Shunsuke
Shinmei, Koichi Shoji, Shogo Inoue,
Tetsutaro Hayashi, Mitsuru Kajiwara, Koji
Mita, Akio Matsubara, Hiroshima, Japan
*Presenting author
ABSTRACT
TIME NUMBER TITLE
8:30
PD35-04 EFFECTS OF PERIOPERATIVE
VARIABLES ON TIMING OF ADJUVANT
RCC THERAPY: RESULTS FROM THE
ASSURE TRIAL (ECOG 2805)
Robert Uzzo*, Philadelphia, PA, Judith
Manola, Boston, MA, Christopher Kane, San
Diego, CA, Christopher Wood, Houston, TX,
Michael Jewett, Toronto, Canada, Robert
DiPaola, New Brunswick, NJ, Naomi Haas,
Philadelphia, PA
199
8:40
PD35-05 MULTICENTER VALIDATION OF
PREDICTIVE MODEL FOR POSTSURGICAL
RECURRENCE IN NON-METASTATIC RCC
WITH THROMBUS
Michael L. Blute, Jr.*, Madison, WI, Timothy
A. Masterson, Indianapolis, IN, Viraj A.
Master, Atlanta, GA, Vitaly Margulis, Dallas,
TX, C. Adam Lorentz, Atlanta, GA, Tyler
Bauman, Kristin Zorn, Madison, WI, Jose A.
Karam, Christopher G. Wood, Houston, TX,
E. Jason Abel, Madison, WI
8:50
PD35-06 VENA CAVOSCOPY IN THE ASSESSMENT
OF INTRALUMINAL VENA CAVAL TUMOR
INVOLVEMENT
Jeffrey Loh-Doyle*, Sumeet Syan-Bhanvadia,
Eli Thompson, Mukul Patil, Hooman Djaladat,
9:00
PD35-07 EVALUATION AND MANAGEMENT OF
RENAL FOSSA RECURRENCE
FOLLOWING NEPHRECTOMY FOR RENAL
CELL CARCINOMA
Sarah Psutka*, Mark Heidenreich, Stephen
Boorjian, G. Christopher Bailey, John Cheville,
Suzanne Stewart, Christine Lohse, Thomas
Atwell, Brian Costello, Bradley Leibovich, R.
Houston Thompson, Rochester, MN
MONDAY
9:20
9:10
PD35-08 POLYMORPHISMS IN VEGFA, VEGFR1, -2
AND -3 ARE ASSOCIATED WITH
RESPONSE AND OUTCOME OF
SUNITINIB-TREATED METASTATIC
RENAL CELL CARCINOMA PATIENTS
Juana Dornbusch, Dresden, Germany, Martina
Walter, Jena, Germany, Andrea Gottschalk,
Dresden, Germany, Alice Obaje, Jena,
Germany, Kerstin Junker, Carsten-Henning
Ohlmann, Homburg/Saar, Germany, Matthias
Meinhardt, Aristeidis Zacharis, Stefan Zastrow,
Dresden, Germany, Marc-Oliver Grimm, Jena,
Germany, Stefanie J. Klug, Susanne Fuessel*,
Manfred P. Wirth, Dresden, Germany
9:20
PD35-09 HIGH-DOSE INTERLEUKEN-2 FOR
METASTATIC RENAL CELL CARCINOMA:
CONTEMPORARY UTILIZATION TRENDS
IN THE UNITED STATES
Christopher Allard*, Francisco GelpiHammerschmidt, Lauren Harshman, Boston,
MA, Izak Faiena, Parth Modi, New Brunswick,
NJ, Benjamin Chung, Stanford, CA, Eric
Singer, New Brunswick, NJ, Steven Chang,
Boston, MA
9:30
9:40
PD35-11 PREOPERATIVE MULTIVARIABLE
PROGNOSTIC MODELS FOR PREDICTION
OF SURVIVAL AND MAJOR
COMPLICATIONS FOLLOWING SURGICAL
RESECTION OF RENAL CELL CARCINOMA
WITH SUPRAHEPATIC CAVAL TUMOR
THROMBUS
Ahmed Q Haddad*, Dallas, TX, Bradley C.
Leibovich, Rochester, MN, E. Jason Abel,
madison, WI, Jun Hang Luo, Laura-Maria
Krabbe, Dallas, TX, R Houston Thompson,
Rochester, MN, Jennifer Heckman, Madison,
WI, Megan Merrill, Houston, TX, Bishoy
Gayed, Arthur I Sagalowsky, Dallas, TX,
Stephen A. Boorjian, Rochester, MN,
Christopher G. Wood, Houston, TX, Vitaly
9:50
PD35-12 NEOADJUVANT SUNITINIB IS
ASSOCIATED WITH IMPROVED
ONCOLOGIC OUTCOMES FOR PATIENTS
WITH TUMOR THROMBUS IN RENAL CELL
CARCINOMA: A MULTICENTER ANALYSIS
Hak Lee*, San Diego, CA, Juan Jimenez,
Cleveland, OH, Song Wang, Omer Raheem,
Kyle Gillis, Amy Alagh, Christopher J. Kane,
San Diego, CA, Michael LIss, San Antonio, TX,
Frederick Millard, San Diego, CA, Brian Lane,
Grand Rapids, MI, Steven Campbell,
Cleveland, OH, Ithaar Derweesh, San Diego,
CA
PD35-10 EVEROLIMUS FOR RENAL
ANGIOMYOLIPOMA ASSOCIATED WITH
TUBEROUS SCLEROSIS COMPLEX:
EFFICACY AND SAFETY AFTER 3.5
YEARS OF TREATMENT IN THE EXIST-2
STUDY
John Bissler*, Memphis, TN, J Kingswood,
Brighton, United Kingdom, Elzbieta
Radzikowska, Warsaw, Poland, Bernard
Zonnenberg, Utrecht, Netherlands, Michael
Frost, St. Paul, MN, Elena Belousova,
Moscow, Russian Federation, Matthias
Sauter, Munich, Germany, Norio Nonomura,
Osaka, Japan, Susanne Brakemeier, Berlin,
Germany, Petrus de Vries, Cape Town,
South Africa, Noah Berkowitz, East Hanover,
NJ, Severine Peyrard, Rueil-Malmaison,
France, Klemens Budde, Berlin, Germany
CREDITTM
8:00 am - 10:00 am
Podium Session 36
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: BASIC RESEARCH II
Moderators: Johanna Hannan and Carol Podlasek
TIME
8:00
ABSTRACT
NUMBER TITLE
PD36-01 A ROLE FOR CTDSPL IN FIBROSIS AND
PLAQUE CALCIFICATION IN PEYRONIE’S
DISEASE
Alexander W. Pastuszak*, Juan Bournat,
Larry I. Lipshultz, Dolores J. Lamb, Houston,
TX
ABSTRACT
TIME NUMBER TITLE
8:10
PD36-02 INCREASED VASCULAR REMODELING
AND CALCIFICATION OF CORONARY AND
INTERNAL PUDENDAL ARTERIES FROM
MEN WITH CARDIOVASCULAR DISEASE
Johanna L Hannan*, Jesse M Hall, Baltimore,
MD, Jacob M Fox, Patrick M Kennedy,
Mackenzie J Clarkson, H Wayne Lambert,
Morgantown, WV, Trinity J Bivalacqua,
Baltimore, MD
200
8:30
8:40
8:50
9:00
PD36-03 BLUNTED NNOS EXPRESSION IN THE
HYPOTHALAMIC PARAVENTRICULAR
NUCLEUS CONTRIBUTE TO DIABETESASSOCIATED MALE SEXUAL BEHAVIOR
DISORDER: CENTRAL ROLE OF TNF-␣
Ting Long*, Shantou, China, People’s
Republic of, Yuanyuan Zhang, Winston
Salem, NC, Huanhuan Wang, Xiaohong Ye,
Hongjie Qiao, Danian Qin, Shantou, China,
PD36-04 TNF-␣ INHIBITS NEURITE OUTGROWTH
FROM THE MAJOR PELVIC GANGLION BY
INDUCING M1/M2 MACROPHAGES EX
VIVO
Hotaka Matsui*, Johanna L. Hannan, Xiaopu
Liu, Ahmet Hoke, Trinity J. Bivalacqua,
Baltimore, MD
PD36-05 PIOGLITAZONE ENHANCES SURVIVAL
AND REGENERATION OF PELVIC
GANGLIA NEURONS AFTER
CAVERNOSAL NERVE INJURY
Eric Katz*, Daniel Heidenberg, Nora Haney,
Taylor Peak, George Lasker, Margaret
Knoedler, Daniel Rittenberg, Bashir Rezk,
Ahmed Moustafa, Zakaria Abd Elmageed,
Faysal Yafi, Suresh Sikka, Asim Abdel
Mageed, Wayne Hellstrom, New Orleans, LA
PD36-06 EFFICACY OF ROLIPRAM LOADED
NANOSPHERES IN LOCALIZED DELIVERY
TO SITES OF NERVE INJURY FOR
PREVENTION OF POST-PROSTATECTOMY
ERECTILE DYSFUNCTION USING A RAT
MODEL OF CAVERNOUS NERVE INJURY
Neal Patel*, Amirali H. Salmasi, Michael
Dinizo, Izak Faiena, New Brunswick, NJ, Ritu
Goyal, Piscataway, NJ, Geun Taek Lee, New
Brunswick, NJ, Johanna L. Hannan, Trinity J.
Bivalacqua, Baltimore, MD, Joachim Kohn,
Piscataway, NJ, Isaac Y. Kim, New
Brunswick, NJ
9:10
PD36-08 LOW OSTEOCALCIN LEVELS ARE AN
INDEPENDENT FACTOR ASSOCIATED
WITH ANDROGEN DEFICIENCY
Brian Le*, Madison, WI, Haolin Chen, Kevin
Billups, Arthur L. Burnett, Barry Zirkin,
Baltimore, MD
9:20
PD36-09 LOW-INTENSITY PULSED ULTRASOUND
RECOVERS ERECTILE FUNCTION IN
STREPTOZOTOCIN-INDUCED DIABETIC
RATS
Hongen Lei, Yongde Xu, Ruili Guan, Zhezhu
Gao, Zhongcheng Xin*, Beijing, China,
9:30
PD36-10 MICROANATOMY AND INNERVATION
PATTERNS OF THE SPERMATIC CORD IN
HUMANS
Koji Shiraishi*, Shintaro Oka, Hideyasu
Matsuyama, Ube, Japan
9:40
PD36-11 THE DIABETES MELLITUS-INDUCED
DYSFUNCTION ON SEMINAL VESICLES
AND VAS DEFERENS IN THE RAT MODEL
Panagiota Tsounapi*, Masashi Honda,
Yonago, Japan, Fotios Dimitriadis,
Thessaloniki, Greece, Shogo Shimizu,
Nankoku, Japan, Michiyo Iguchi, Masaki
Imanishi, Shinji Matsunaga, Bunya
Kawamoto, Katsuya Hikita, Kuniyasu
Muraoka, Takehiro Sejima, Yonago, Japan,
Motoaki Saito, Nankoku, Japan, Nikolaos
Sofikitis, Ioannina, Greece, Shuhei Tomita,
Atsushi Takenaka, Yonago, Japan
9:50
PD36-12 THE SPACE ENVIRONMENT INDUCES
THE ENHANCEMENT OF CAVEOLIN
EXPRESSION AND LEADS TO GERM CELL
APOPTOSIS
Hideyuki Kamisawa*, Kentaro Mizuno,
Satoshi Kurokawa, Yoshinobu Moritoki,
Hidenori Nishio, Akihiro Nakane, Tetsuji
Maruyama, Keiji Fujita, Shoichi Sasaki,
Yutaro Hayashi, Nagoya, Japan, Yoshiyuki
Kojima, Fukushima, Japan, Kenjiro Kohri,
Nagoya, Japan
PD36-07 TADALAFIL PREVENT PENILE NEURONAL
NITRIC OXIDE SYNTHASE LEVELS WHICH
DECREASE WITH CHRONIC PAROXETINE
TREATMENT
Abdullah Gul, Levent Kabasakal, Duygu
Sultan Celik, Atilla Semercioz, Ege Can
Serefoglu*, Istanbul, Turkey
CREDITTM
8:00 am - 10:00 am
Podium Session 37
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: MEDICAL AND NON-SURGICAL THERAPY I
Moderator: Dana Ohl
TIME
8:00
ABSTRACT
NUMBER TITLE
PD37-01 ASSOCIATION BETWEEN
TESTOSTERONE THERAPY AND
THROMBOTIC EVENTS IN ELDERLY MEN
Ranjith Ramasamy*, Jason Scovell, Michael
Mederos, Renzhong Ran, Lakshay Jain,
Dolores Lamb, Larry Lipshultz, Houston, TX
*Presenting author
ABSTRACT
TIME NUMBER TITLE
8:10
PD37-02 PHASE 2 RESULTS OF NOVEL ORAL
THERAPY (TSX-002) IN SYMPTOMATIC
HYPOGONAGAL MEN
Michael Oefelein*, Bakersfield, CA, Guru
Betageri, Pomona, CA
201
MONDAY
8:20
8:20
PD37-03 ASSOCIATION OF FREE TESTOSTERONE
WITH HYPOGONADAL SYMPTOMS IN
MEN WITH NEAR NORMAL TOTAL
TESTOSTERONE LEVELS
Nathan Wilken, Jason Scovell, Ranjith
Ramasamy*, Dolores Lamb, Larry Lipshultz,
Houston, TX
8:30
PD37-04 LONG-TERM TREATMENT WITH
TESTOSTERONE UNDECANOATE (TU) IN
HYPOGONADAL MEN WITH
CARDIOVASCULAR DISEASES (CVD):
OBSERVATIONAL DATA FROM A
REGISTRY STUDY
Ahmad Haider*, Karim Sultan Haider,
Bremerhaven, Germany, Gheorghe Doros,
Abdulmaged Traish, Boston, MA
8:40
8:50
9:00
PD37-05 THE IMPACT OF TESTOSTERONE
SUPPLEMENTATION THERAPY ON THE
INTERNATIONAL INDEX OF ERECTILE
FUNCTION: BEYOND THE LEVELS OF
TESTOSTERONE
Jason Scovell*, Aravind Chandrashekar,
Tariq Hakky, Bryan Pham, Dolores Lamb,
PD37-06 NEEDLE-FREE SUBCUTANEOUS SELF
INJECTION FOR TESTOSTERONE
SUPPLEMENTATION THERAPY
Jeffrey Marotte*, Wilson Alobuia, Rochelle Frazier,
Conway, AR, Richard Stout, Tigard, OR
PD37-07 TESTOSTERONE GEL TREATMENT
SIGNIFICANTLY AMELIORATES URINARY
URGENCY AND SLEEP DISTURBANCE:
DOUBLE-BLIND, PLACEBO-CONTROLLED
CLINICAL TRIAL
Shin-ichi Hisasue*, Hisamitsu Ide, Akira
Tsujimura, Naoya Nagaya, Masaki Kimura,
Amr Abdelhamed, Masato Shirai, Satoru
Muto, Raizo Yamaguchi, Shigeo Horie,
Tokyo, Japan
9:10
PD37-08 EFFICACY AND PHARMACOKINETICS OF
LPCN 1021, A NOVEL ORAL
THERAPY (TRT), IN HYPOGONADAL MEN:
STUDY OF ANDROGEN REPLACEMENT
(SOAR)
Jed C. Kaminetsky*, New York, NY, Anthony
DelConte, Philadelphia, PA, Adrian S. Dobs,
Baltimore, MD, Christina Wang, Pavan
Yadav, Torrance, CA, Srinivasan
Venkateshwaran, Nachiappan Chidambaram,
Satish Nachaegari, Mahesh Patel, Salt Lake
City, UT, Martin M. Miner, Providence, RI
9:20
PD37-09 PREVALENCE OF BONE DENSITY
DEFICIENCIES IN MEN PRESENTING FOR
HYPOGONADISM TREATMENT: DO WE
NEED TO WORRY?
Joseph Ellen*, Igor Sorokin, Clay Mechlin,
Charles Welliver, Andrew McCullough,
Albany, NY
9:30
PD37-10 ERECTILE FUNCTION AFTER RADICAL
PROSTATECTOMY – DO PATIENTS
RETURN TO BASELINE?
Mikkel Fode*, Roskilde and Herlev, Denmark,
Anders Frey, Henrik Jakobsen, Jens
Sønksen, Herlev, Denmark
9:40
PD37-11 STATIN THERAPY MAY IMPROVE LONGTERM SEXUAL FUNCTION AFTER
Alon Mass*, Vinay Prabhu, Darren Bryk,
Herbert Lepor, Lee Zhao, New York, NY
9:50
PD37-12 DAILY TADALAFIL DOES NOT INCREASE
PRIAPISM RATES IN AN
INTRACAVERNOSAL INJECTION (ICI)
REHABILITATION PROGRAM, AFTER
RADICAL PROSTATECTOMY (RP)
Eduardo Miranda*, Sao Paulo, Brazil, Serkan
Deveci, Lawrence Jenkins, Joseph Narus,
John Mulhall, New York, NY
CREDITTM
8:00 am - 10:00 am
Video Session 9
ROBOTICS – RENAL
Moderators: Matthew Gettman and Jeremy Tonkin
ABSTRACT
NUMBER TITLE
V9-01
MULTIPLE RENAL TUMORS
Deepansh Dalela*, Ravi Barod, Detroit, MI,
Craig Rogers, Plymouth, MI
ABSTRACT
NUMBER TITLE
V9-02
SELECTIVE CLAMPING OF THE
SEGMENTARY ARTERY IN ROBOTIC
PARTIAL NEPHRECTOMY OPERATION
Omer Aytaç, Hasan Tavukçu, Haluk
Kulaksizoglu, Fatih Atug*, Istanbul, Turkey
202
ROBOTIC ENUCLEO-RESECTION OF
SMALL RENAL MASSES: A SAFE AND
ONCOLOGICALLY SOUND ALTERNATIVE
TO TRADITIONAL PARTIAL
NEPHRECTOMY
Robert Blackwell*, Gopal Gupta, Maywood, IL
V9-09
NOVEL ROBOTIC SYSTEM FOR SINGLE
PORT PARTIAL NEPHRECTOMY: INITIAL
EXPERIENCE AND TECHNIQUE
Daniel Ramirez*, Cleveland, OH, Vincent
Flammand, Arnauld Villers, Lille, France,
Jihad H. Kaouk, Cleveland, OH
V9-04
PARTIAL NEPHRECTOMY IN PATIENTS
WITH MULTIPLE RENAL LESIONS
AMENABLE TO NEPHRON SPARING
SURGERY
Aryeh Keehn*, Reza Ghavamian, Bronx, NY
V9-10
V9-05
ROBOTIC PARTIAL NEPHRECTOMY WITH
INTRACORPOREAL RENAL
HYPOTHERMIA USING ICE SLUSH
Daniel Ramirez*, Homayoun Zargar, Jayram
Krishnan, Peter Caputo, Oktay Akca, Jihad H.
SIMULATED INANIMATE MODEL FOR
PHYSICAL LEARNING EXPERIENCE
(SIMPLE) FOR ROBOTIC PARTIAL
NEPHRECTOMY USING A 3-D PRINTED
KIDNEY MODEL
Ahmed Ghazi*, Jonathan Stone, Braden
Candela, Michael Richards, Jean Joseph,
Rochester, NY
V9-11
ROBOT-ASSISTED PARTIAL
CARCINOMA AND MANAGEMENT OF
VENOUS TUMOR THROMBUS
Firas Petros*, Edward Nickerson, Geoffrey
Box, Columbus, OH
V9-12
ROBOTIC-ASSISTED PYELOPLASTY IN
TWO PATIENTS WITH DUPLEX KIDNEYS
AND LOWER POLE URETERO-PELVIC
JUNCTION OBSTRUCTION BUT
DIFFERING DISTANCE TO THE URETERAL
JUNCTION
Thomas von Rütte*, Frédéric D. Birkhäuser,
George N. Thalmann, Pascal Zehnder, Bern,
Switzerland
V9-13
ROBOT-ASSISTED LAPAROSCOPIC FLAP
PYELOPLASTY FOR AN EXTENDED
URETERAL STRICTURE: KEY STEPS AND
COMPLICATIONS
Heather Hopf*, Clinton Bahler, Chandru
Sundaram, Indianapolis, IN
V9-14
A NOVEL DEVICE FOR
INTRAPERITONEAL CAMERA CLEANING:
ROBOTIC SURGERY WITH FLOSHIELD
TECHNOLOGY
Julie Wang*, Philip Dorsey, Michael Maddox,
Benjamin Lee, New Orleans, LA
V9-06
V9-07
V9-08
HILAR TUMORS: ZERO ISCHEMIA OR
EARLY UNCLAMPING?
benoit peyronnet*, quentin alimi, tarek
fardoun, romain mathieu, gregory verhoest,
FAST BUT NOT FURIOUS - IMPROVE
YOUR SURGICAL SKILLS FOR THE RACE
AGAINST TIME DURING ROBOTICASSISTED PARTIAL NEPHRECTOMY
USING A VALIDATED PERFUSED
TRAINING MODEL
Philipp Markus Huber*, George N. Thalmann,
Frédéric D. Birkhäuser, Bern, Switzerland,
Andrew J. Hung, Monish Aron, Inderbir S.
Gill, Mihir M. Desai, Los Angeles, CA, Pascal
Zehnder, Bern, Switzerland
PARTIAL NEPHRECTOMY AND
IPSILATERAL PYELOLITHOTOMY IN
INTRARENAL PELVIS
Wai Lee*, Justina Tam, Abram D’Amato,
Pamela Sue Baron, Wayne Waltzer, Anthony
Corcoran, Stony Brook, NY
CREDITTM
*Presenting author
203
MONDAY
V9-03
10:30 am - 12:30 pm
PROSTATE CANCER: LOCALIZED V
Moderators: Douglas Dahl and Herbert Lepor
ABSTRACT
NUMBER TITLE
MP62-01 FUNCTIONAL OUTCOMES IN PATIENTS
WITH CLINICALLY HIGH-RISK PROSTATE
CANCER (PCA) TREATED WITH ROBOTASSISTED LAPAROSCOPIC RADICAL
PROSTATECTOMY (RALP)
Firas Abdollah*, Daniel Pucheril, Jesse
Sammon, Akshay Sood, Dane Klett, Detroit,
MI, Nicola Fossati, Giorgio Gandaglia,
Nazareno Suardi, Giorgio Guazzoni, Manuela
Tutolo, Milan, Italy, Craig Rogers, Hans
Stricker, Wooju Jeong, James Peabody,
Detroit, MI, Francesco Montorsi, Alberto
ABSTRACT
NUMBER TITLE
MP62-06 ROBOTIC VERSUS OPEN SALVAGE
RADICAL PROSTATECTOMIES: A TWO
CENTRE STUDY
Sanchia Goonewardene*, London, United
Kingdom, Faith McMeekin, Bristol, United
Kingdom, Matt Brown, London, United
Kingdom, Raj Persad, Bristol, United
Kingdom, Rick Popert, London, United
Kingdom, David Gillatt, Bristol, United
Kingdom
MP62-07 PREDICTORS OF READMISSION
FOLLOWING OPEN AND MINIMALLY
INVASIVE RADICAL PROSTATECTOMY
USING THE NATIONAL SURGICAL
(NSQIP) DATABASE
Ahmed Sarhan*, David Sharp, Ahmad
Shabsigh, Columbus, OH
MP62-02 PENTAFECTA OUTCOMES PLUS
EVALUATION OF IMMEDIATE
CONTINENCE AFTER ROBOTIC,
EXTRAPERITONEAL, RADICAL
PROSTATECTOMY TECHNIQUE WITH
COMPLETE PRESERVATION OF THE VEIL
OF APHRODITE
Andrea Boni*, Perugia, Italy, Giovanni
Cochetti, Francesco Barillaro, Cottini
Emanuele, Perugia - Terni, Italy, Emanuele
Lepri, Perugia, Italy, Ettore Mearini, Perugia
-Terni, Italy
MP62-08 SIGNIFICANT REDUCTION IN POSITIVE
SURGICAL MARGINS AND BIOCHEMICAL
RECURRENCE RISK AT 2 YEARS NOTED
EARLIER FOR ROBOTIC
PROSTATECTOMY: COMPREHENSIVE
EVALUATION AND CUSUM ANALYSIS OF
ONCOLOGICAL OUTCOMES
Arjun Sivaraman*, Rafael Sanchez Salas,
Dominique Prapotnich, Paris, France, Fabien
Olivier, Kaixin Yu, Christian Doudeau,
Stéphane David, Velizy, France, Eric Barret,
Paris, France, Fernando P Secin, Buenos
Aires, Argentina, Alexandre Ingels, Francois
Rozet, Marc Galiano, Annick Mombet,
Nathalia Cathala, Xavier Cathelineau, Paris,
France
MP62-03 ROBOT ASSISTED RADICAL
PROSTATECTOMY IN HIGH RISK
PROSTATE CANCER
Benjamin Katz*, Sue-Jean Yu, Andrew
Lightfoot, Giovanni Greaves, Elton Llukani,
Alice McGill, Kelly Monahan, David Lee,
Philadelphia, PA
ROBOT ASSISTED VS. OPEN RADICAL
PROSTATECTOMY IN INTERMEDIATE
AND HIGH RISK PATIENTS
Giorgio Gandaglia*, Nazareno Suardi, Nicola
Fossati, Alessandro Larcher, Elena Farina,
Marta Picozzi, Irene Locatelli, Andrea Gallina,
Milan, Italy, Vincenzo Mirone, Naples, Italy,
Giorgio Guazzoni, Francesco Montorsi,
Alberto Briganti, Milan, Italy
MP62-09 LAPAROENDOSCOPIC SINGLE-SITE
RADICAL PROSTATECTOMY VS
CONVENTIONAL LAPAROSCOPIC
PROSPECTIVE RANDOMIZED CLINICAL
TRIAL
Gang Zhu*, Pengjie Wu, Yaqun Zhang,
Shengjie Liu, Bin Jin, Jianlong Wang, Hong
Ma, Xin Chen, Yaoguang Zhang, Ben Wan,
Jianye Wang, Beijing, China, People’s
Republic of
MP62-05 SYSTEMATIC ASSESSMENT OF POSITIVE
SURGICAL MARGINS FEATURES IN OPEN
VS. ROBOT ASSISTED RADICAL
PROSTATECTOMY: IS THERE A
DIFFERENCE?
Giorgio Gandaglia*, Nazareno Suardi, Paolo
Dell’Oglio, Stefano Luzzago, Walter
Cazzaniga, Umberto Capitanio, Marco
Bianchi, Nicola Fossati, Milan, Italy, Shahrokh
F. Shariat, Vienna, Austria, Massimo Freschi,
Milan, Italy, Pierre Karakiewicz, Montreal,
Canada, Francesco Montorsi, Alberto
MP62-10 LESS (LAPAROENDOSCOPIC SINGLE
SITE SURGERY) RADICAL
PROSTATECTOMY USING NEEDLE
FORCEPS (ENDO RELIEF)
Hidetoshi Akita*, Akihiro Nakane, Takahiro
Kobayashi, Kenji Yamada, Ryosuke Ando,
Yutaro Tanaka, Takehiko Okamura, Anjo,
Japan, Takahiro Yasui, Kenjiro Kohri,
Nagoya, Japan
204
MP62-12 NOMOGRAMS PREDICTING 15-YEAR
PROSTATE CANCER SPECIFIC
MORTALITY AND PROSTATE CANCER
RECURRENCE FOLLOWING DEFINITIVE
BRACHYTHERAPY WITH OR WITHOUT
EXTERNAL BEAM RADIATION FOR THE
TREATMENT OF LOCALIZED PROSTATE
CANCER
Adnan Ali*, Nelson Stone, Richard Stock,
Ashutosh Tewari, New York, NY
MP62-18 SURVIVAL AFTER RADICAL
PROSTATECTOMY OR RADIOTHERAPY
AS PRIMARY TREATMENT IN PATIENTS
WITH NON-METASTASIZED PROSTATE
CANCER
Christian Gratzke*, Martin Dörr, Kathleen
Herkommer, Ralf Oberneder, Helmut Baur,
Volker Beer, Claus Belka, Gabriele SchubertFritschle, Dieter Hölzel, Jürgen Gschwend,
Christian Stief, Jutta Engel, Munich, Germany
MP62-13 PRIOR BLADDER OUTFLOW SURGERY OR
LARGE PROSTATE VOLUME DOES NOT
ADVERSELY AFFECT BIOCHEMICAL
RECURRENCE-FREE SURVIVAL IN LOW
DOSE RATE PROSTATE
BRACHYTHERAPY: AN INTERMEDIATE
TERM ANALYSIS
Áine Goggins*, Hidekazu Yamamoto, London,
United Kingdom, Peter Acher, Southend,
United Kingdom, Stephen Morris, Ronald
Beaney, Ben Challacombe, Rick Popert,
MP62-19 FOCAL CRYOTHERAPY DELIVERS
SIMILAR ONCOLOGICAL CONTROL WITH
SIGNIFICANTLY IMPROVED ERECTILE
FUNCTION RECOVERY RATES OVER A
WHOLE GLAND APPROACH
Melissa Mendez*, Thomas Polascik, Niccolo
Passoni, Durham, NC, Julio Pow-Sang,
Tampa, FL, Ahmed El-Shafei, J. Stephen
Jones, Cleveland, OH
MP62-14 LONG-TERM RESULTS OF POSTPROSTATECTOMY RADIOTHERAPY: A
LARGE INSTITUTIONAL EXPERIENCE
Rebecca Clayman*, Adam Feldman, Sigolene
Galland, Douglas Dahl, Francis McGovern,
Aria Olumi, Alec Eidelman, Andrzej
Niemierko, William Shipley, Anthony Zietman,
Jason Efstathiou, Boston, MA
MP62-20 IMPACT OF A PREOPERATIVELY
ESTIMATED PROSTATE VOLUME USING
TRANSRECTAL ULTRASONOGRAPHY ON
SURGICAL AND ONCOLOGICAL
OUTCOMES IN A SINGLE SURGEON’S
EXPERIENCE WITH ROBOT-ASSISTED
Yosuke Hirasawa*, Jun Nakashima, Takeshi
Hashimoto, Yoshihiro Nakagami, Yoshio
Ohno, Makoto Ohori, Kunihiko Yoshioka,
Masaaki Tachibana, Tokyo, Japan
MP62-15 YOUNG AGE PREDICTS FOR TRANSIENT
ELEVATION IN PSA AFTER DEFINITIVE
STEREOTACTIC BODY RADIATION
THERAPY FOR PROSTATE CANCER
Seth Blacksburg*, Matthew Witten, Aaron
Katz, Jonathan Haas, Mineola, NY
MP62-16 FACTORS AFFECTING METASTASIS AND
LONG-TERM SURVIVAL FOLLOWING
PROSTATE BRACHYTHERAPY
Nelson Stone*, Richard Stock, New York, NY
*Presenting author
CREDITTM
205
MONDAY
MP62-17 PREDICTIVE FACTORS OF OUTCOME
FOLLOWING SALVAGE RADIOTHERAPY
ALONE FOR PATIENTS WITH
Wan Song*, Hwang Gyun Jeon, Hyun Hwan
Sung, Seoul, Korea, Republic of, Deok Hyun
Han, , Korea, Republic of, Joon Hyung Park,
Young Hyo Choi, Sang Eun Lee, Byong
Chang Jeong, Seong Il Seo, Seong Soo
Jeon, Han Yong Choi, Hyun Moo Lee, Seoul,
Korea, Republic of
MP62-11 IMPROVED LOCAL CONTROL IS
ASSOCIATED WITH BETTER LONG TERM
SURVIVAL FOLLOWING PROSTATE
BRACHYTHERAPY
Nelson Stone*, Richard Stock, New York, NY
10:30 am - 12:30 pm
KIDNEY CANCER: SURGICAL THERAPY IV
Moderators: Bradley Leibovich and William Huang
ABSTRACT
NUMBER TITLE
MP63-01 MODIFIED FRAILTY INDEX PREDICTS
MORTALITY AND ADVERSE OUTCOMES
IN PATIENTS UNDERGOING RENAL
SURGERY: ANALYSIS OF THE NATIONAL
SURGICAL QUALITY IMPROVEMENT
PROGRAM (NSQIP) DATABASE
Jamie S Pak*, Danny Lascano, Julia B
Finkelstein, Mark V Silva, G Joel DeCastro,
James M McKiernan, Mitchell C Benson, New
York, NY
ABSTRACT
NUMBER TITLE
MP63-06 TRIFECTA OUTCOMES OF ROBOTIC
PARTIAL NEPHRECTOMY FOR T1B
RENAL MASSES: A MULTIINSTITUTIONAL ANALYSIS
Homayoun Zargar*, Cleveland, OH, Craig
Rogers, Detroit, MI, Sam Bhayani, St Louis,
MO, Mohamad Allaf, Baltimore, MD, Jeffrey A
Larson, St Louis, MO, Ravi Barod, Detroit,
MI, Alon Mass, New York, NY, Michael h
Johnson, Baltimore, MD, Michael Stifelman,
New York, NY, Jihad H. Kaouk, Cleveland,
OH
MP63-02 HOW A DONOR NEPHRECTOMY
POPULATION CAN HELP CLARIFY THE
EFFECTS OF WARM RENAL ISCHEMIA
DURING PARTIAL NEPHRECTOMY
Roger Li, Herbert C. Ruckle, Muhannad
Alsyouf*, Michelle Lightfoot, Jared Schober,
David Tryon, Kristene Myklak, David
Culpepper, Daniel Faaborg, Phillip Stokes,
Javier L. Arenas, D. Duane Baldwin, Loma
Linda, CA
MP63-07 EXTERNAL VALIDATION OF DIAMETERAXIAL-POLAR SCORING IN PREDICTING
SURGICAL OUTCOMES OF PARTIAL
NEPHRECTOMY FOR RENAL TUMORS
Linhui Wang*, zhenjie wu, shanghai, China,
MP63-08 PHASE 3 RANDOMIZED TRIAL OF
INTRAVENOUS MANNITOL VERSUS
PLACEBO PRIOR TO RENAL ISCHEMIA
DURING PARTIAL NEPHRECTOMY:
IMPACT ON RENAL FUNCTIONAL
OUTCOMES
Massimiliano Spaliviero*, Nicholas E. Power,
Katie S. Murray, Paul Russo, Daniel D.
Sjoberg, Nicole E. Benfante, Arony J Sun,
Melanie L. Bernstein, Karim A. Touijer, Guido
Dalbagni, Jonathan A. Coleman, New York,
NY
MP63-03 END STAGE RENAL DISEASE AFTER
SURGERY IN PATIENTS WITH NORMAL
PREOPERATIVE KIDNEY FUNCTION: THE
EFFECT OF NEPHRON-SPARING
SURGERY IN DELAYING THE ONSET OF
THE DISEASE
Umberto Capitanio*, Milan, Italy, Carlo
Terrone, Novara, Italy, Alessandro Antonelli,
Brescia, Italy, Andrea Minervini, Florence,
Italy, Francesco Porpiglia, Turin, Italy,
Alessadro Volpe, Novara, Italy, Maria Furlan,
Brescia, Italy, Alberto Briganti, Paolo
Capogrosso, Milan, Italy, Sergio Serni,
Florence, Italy, Claudio Simeone, Brescia,
Italy, Roberto Bertini, Francesco Montorsi,
Milan, Italy
MP63-09 LONG TERM TUMOUR SPECIFIC
SURVIVAL IN PATIENTS UNDERGOING
SURGICAL MANAGEMENT FOR RENAL
CELL CARCINOMA ASSOCIATED WITH AN
INFERIOR VENA CAVA THROMBUS
Wael Khoder*, Armin Becker, Therese
Schülze, Christian Stief, Alexander
Kretschmer, Raphaela Waidelich, Munich,
Germany
MP63-04 CLINICAL AND PATHOLOGICAL LYMPH
NODE PROGRESSION IN PATIENTS WITH
A CT1-T2 N0 M0 RENAL MASS: SHALL WE
FOREVER DISCARD THE USE OF LYMPH
NODE DISSECTION IN LOW RISK
PATIENTS?
Umberto Capitanio*, Ettore Di Trapani, Rayan
Matloob, Paolo Capogrosso, Massimo
Freschi, Cristina Carenzi, Andrea Salonia,
Andrea Russo, Andrea Gallina, Roberto
Bertini, Alberto Briganti, Francesco Montorsi,
Milan, Italy
MP63-10 MINIMUM 5 YEAR FOLLOW-UP AFTER
ROBOTIC PARTIAL NEPHRECTOMY : A
MULTI-INSTITUTIONAL ANALYSIS
Homayoun Zargar*, Cleveland, OH,
Mohamad Allaf, Baltimore, MD, Craig Rogers,
Detroit, MI, Michael Stifelman, New York, NY,
Sam Bhayani, St Louis, MO, Alon Mass, New
York, NY, Ravi Barod, Detroit, MI, Michael h
Johnson, Baltimore, MD, Jeffrey A Larson, St
Louis, MO, Jihad H. Kaouk, Cleveland, OH
MP63-05 ROBOTIC INFERIOR VENA CAVA
THROMBECTOMY AND RADICAL
NEPHRECTOMY FOR LEVEL II AND III
THROMBI: THE USC EXPERIENCE
Charles Metcalfe*, Andre Abreu, Raj
Satkunasivam, Raed Azhar, Kelvin Wong,
Los Angeles, CA, Yi Sun, ShangHai, China,
People’s Republic of, Andre Berger, Monish
Aron, Mihir Desai, Inderbir Gill, Los Angeles,
CA
MP63-11 NATIONAL TRENDS IN THE
PERFORMANCE OF NEPHROURETERECTOMY
Kurt Drury*, M Francesca Monn, Clinton D
Bahler, Eric M DeRoo, Chandru P Sundaram,
Indianapolis, IN
206
MP63-15 THE SUBCLASSIFICATION OF PAPILLARY
RENAL CELL CARCINOMA DOES NOT
AFFECT ONCOLOGICAL OUTCOMES
AFTER NEPHRON SPARING SURGERY
Pierre Bigot*, Angers, France, Jean
Christophe Bernhard, Bordeaux, France,
Inderbir Gill, Los Angeles, CA, Grégory
Verhoest, Rennes, France, Boris Reix, Lille,
France, Evren Suer, Ankara, Turkey,
Masatoshi Eto, Kumamoto, Japan, François
Xavier Nouhaud, Toulouse, France, Vincent
Flammand, Lille, France, Ilker Gökce, Ankara,
Turkey, Toru Matsugasumi, Los Angeles, CA,
Jean Baptiste Beauval, Toulouse, France,
Claire Lenormand, Rouen, France, Yvonne
Chowaniec, Jérôme Rigaud, Nantes, France,
Christian Pfister, Rouen, France, Jean
François Hetet, Nantes, France, Guillaume
Ploussard, Paris, France, Nam Son Vuong,
Bordeaux, France, Eduard Baco, Oslo,
Norway, Morgan Rouprêt, Priscilla Léon,
Paris, France, Adnan El Bakhri, Stéphane
Larré, Reims, France, Xavier Tillou, Arnaud
Doerfler, Caen, France, Aurélien Descazeau,
Limoges, France, Philippe Sebe, Paris,
France, Nicolas Koutlidis, Alexandre
Schneider, Dijon, France, Abdel Rahmène
Azzouzi, Angers, France, Michel Soulié,
Toulouse, France, Karim Bensalah, Rennes,
France, Jean Jacques Patard, Le Kremlin
Bicêtre, France
MP63-13 INCIDENCE OF MAJOR COMPLICATIONS
FOR LAPAROSCOPIC RADICAL AND
ROBOTIC PARTIAL NEPHRECTOMY: A
MATCH-PAIRED ANALYSIS
Oliver Ko*, Daniel Ramirez, Homayoun
Zargar, Oktay Akca, Cleveland, OH, Andrew
McElroy, Rootstown, OH, Georges-Pascal
Haber, Jihad Kaouk, Robert Stein, Cleveland,
OH
MP63-16 ANALYSIS OF THE IMPACT OF
ADHERENT PERI-RENAL FAT ON PERIOPERATIVE OUTCOMES OF ROBOTIC
PARTIAL NEPHRECTOMY
Zine-Eddine Khene*, Benoit Peyronnet,
Romain Mathieu, Tarek Frdoun, Gregory
Verhoest, Karim Bensalah, Rennes, France
MP63-17 TRENDS OF ACUTE KIDNEY INJURY
AFTER RADICAL OR PARTIAL
CARCINOMA
Praful Rafi, London, United Kingdom, Nandita
Krishna, Boston, MA, Akshay Sood,
Deepansh Dalela, Detroit, MI, Felix Chun,
Hamburg, Germany, Adam Kibel, Boston,
MA, Mani Menon, Detroit, MI, Paul Nguyen,
Toni Choueiri, Boston, MA, Margit Fisch,
Hamburg, Germany, Quoc-Dien Trinh,
Boston, MA
MP63-14 FUNCTIONAL RECOVERY FROM
EXTENDED WARM ISCHEMIA
ASSOCIATED WITH PARTIAL
NEPHRECTOMY
Cesar Ercole*, Liliya Velet, Zhiling Zhang,
Erick Remer, Maria Mir, Toshio Takagi,
Sevag Demirjian, Steven Campbell,
Cleveland, OH
MP63-18 SURGICAL TREATMENT IN 1,084
CONSECUTIVE RENAL LESIONS IN A
SINGLE TERTIARY REFERRAL UNITED
KINGDOM CENTER – TARGETED
OUTCOME MEASURES USING A NOVEL
DECISION TREE PLATFORM
Sashi Kommu*, Robert Mcarthur, Rajesh
Nair, Meghana Kulkarni, Prasanna
Sooriakumaran, Panos Tsavalas, Samer
Katmawi-Sabbagh, Pieter le Roux,
Christopher Anderson, London, United
Kingdom
*Presenting author
207
MONDAY
MP63-12 NON CLEAR CELL RENAL CELL
CARCINOMAS: ONCOLOGICAL OUTCOME
AFTER NEPHRON SPARING SURGERY
BASED ON AN INTERNATIONAL
MULTICENTER STUDY
Pierre Bigot*, Angers, France, Jean
Christophe Bernhard, Bordeaux, France,
Inderbir Gill, Los Angeles, CA, Grégory
Verhoest, Rennes, France, Boris Reix, Lille,
France, Evren Suer, Ankara, Turkey,
Masatoshi Eto, Kumamoto, Japan, François
Xavier Nouhaud, Toulouse, France, Vincent
Flammand, Lille, France, Ilker Gökce, Ankara,
Turkey, Toru Matsugasumi, Los Angeles, CA,
Jean Baptiste Beauval, Toulouse, France,
Yvonne Chowaniec, Jérôme Rigaud, Nantes,
France, Claire Lenormand, Christian Pfister,
Rouen, France, Jean François Hetet, Nantes,
France, Guillaume Ploussard, Paris, France,
Nam Son Vuong, Bordeaux, France, Eduard
Baco, Oslo, Norway, Morgan Rouprêt,
Priscilla Léon, Paris, France, Adnan El
Bakhri, Stéphane Larré, Reims, France,
Xavier Tillou, Arnaud Doerfler, Caen, France,
Aurélien Descazeau, Limoges, France,
Philippe Sebe, Paris, France, Nicolas
Koutlidis, Alexandre Schneider, Dijon, France,
Abdel Rahmène Azzouzi, Angers, France,
Michel Soulié, Toulouse, France, Karim
Bensalah, Rennes, France, Jean Jacques
Patard, Le Kremlin Bicêtre, France
MP63-20 DEVELOPMENT AND EXTERNAL
VALIDATION OF A PATHOLOGICAL
NODAL STAGING SCORE FOR PATIENTS
WITH CLEAR CELL RENAL CELL
CARCINOMA
Malte Rieken*, Basel, Switzerland, Stephen
Boorjian, Rochester, MN, Luis Kluth,
Hambug, Germany, Evanguelos Xylinas,
Paris, France, Umberto Capitanio, Alberto
Briganti, Milan, Italy, R. Houston Thompson,
Bradley Leibovich, Rochester, MN, LauraMaria Krabbe, Vitaly Margulis, Dallas, TX,
Jay Raman, Mikhail Regelman, Hershey, PA,
Tobias Klatte, Vienna, Austria, Alexander
Bachmann, Basel, Switzerland, Pierre
Karakiewicz, Montreal, Canada, Morgan
Rouprêt, Paris, France, Richard Lee, Mithat
Gönen, New York, NY, Shahrokh Shariat,
Vienna, Austria
INVASIVE PARTIAL NEPHRECTOMY
USING THE NATIONAL SURGICAL
(NSQIP) DATABASE
Ahmed Serhan, Ahmad Shabsigh*,
Columbus, OH
CREDITTM
10:30 am - 12:30 pm
BLADDER CANCER: NATURAL HISTORY AND PATHOPHYSIOLOGY
Moderators: Arthur Sagalowsky and Scott Tagawa
ABSTRACT
NUMBER TITLE
MP64-01 EXPRESSION PROFILE OF EPITHELIALMESENCHYMAL TRANSITION MARKERS
IN RADICAL CYSTECTOMY SPECIMENS:
COMPARATIVE STUDY BETWEEN
UROTHELIAL AND BILHARZIAL
SQUAMOUS CELL CARCINOMAS OF THE
BLADDER
Satoshi Imai, Hideaki Miyake*, Hosney
Behnsawy, Masato Fujisawa, Kobe, Japan
ABSTRACT
NUMBER TITLE
MP64-04 EFFECT OF METFORMIN USE ON RISK OF
BLADDER CANCER
Abdo Kabarriti*, Ben Boursi, Ronac Mamtani,
Thomas Guzzo, Kevin Haynes, Yu-Xiao
Yang, S. Bruce Malkowicz, Philadelphia, PA
MP64-05 SELF-REPORTED FINASTERIDE USE IS
ASSOCIATED WITH DECREASED
INCIDENCE OF BLADDER CANCER: DATA
FROM THE PROSTATE, LUNG,
COLORECTAL, & OVARIAN CANCER
STUDY
Edwin E. Morales*, San Antonio, TX, Sonja
Grill, Munchen, Germany, Nicholas A.
Freidberg, Ian M. Thompson III, Robert S.
Svatek, Dharam Kaushik, Donna P. Ankerst,
Michael A. Liss, San Antonio, TX
MP64-02 COMPARISON OF GENETIC
ALTERATIONS FROM THE CANCER
GENOME ATLAS BLADDER CANCER
ANALYSIS AND A PROSPECTIVE SET OF
HIGH-GRADE UROTHELIAL CARCINOMA
TUMORS USING A CLINICAL
LABORATORY IMPROVEMENT
AMENDMENTS-CERTIFIED NEXT
GENERATION SEQUENCING ASSAY
Aditya Bagrodia*, Gopa Iyer, Eugene Cha,
Mariel Boyd, Ahmet Zehir, Donavan Cheng,
David Hyman, Hikmat Al-Ahmadie, Richard
Bambury, Maria Arcila, Marc Ladanyi, Agnes
Viale, Berger Michael, Bernard Bochner,
Jonathan Rosenberg, Dean Bajorin, David
Solit, New York, NY
MP64-06 PREOPERATIVE NUTRITIONAL STATUS
AS A PREDICTOR OF RADICAL
CYSTECTOMY POST OPERATIVE
COMPLICATIONS: A NATIONAL
COMPARISON
Richard Matulewicz*, Apas Aggarwal, John
Kim, Shilajit Kundu, Chicago, IL
MP64-07 SIMPLIFIED FRAILTY INDEX PREDICTS
ADVERSE OUTCOMES IN RADICAL
CYSTECTOMY: AN ANALYSIS OF THE
ACS- NSQIP DATABASE
Danny Lascano*, Jamie S Pak, Michael J
Lipsky, Julia B Finkelstein, Mitchell C
Benson, G. Joel DeCastro, James M
McKiernan, New York, NY
MP64-03 THE ACCURACY OF SELF-REPORTED
SMOKING STATUS AMONG BLADDER
CANCER PATIENTS
Alan Thong*, Helena Furberg, Stacey
Petruzella, Emily Zabor, Jamie Ostroff,
Bernard Bochner, New York, NY
208
MP64-15 RENAL FUNCTIONAL OUTCOMES AFTER
RADICAL CYSTECTOMY AND THE
INCREASED RISK OF CHRONIC KIDNEY
DISEASE
Danny Lascano*, Alexa Meyer, Elizabeth
Hagan, Jamie S Pak, LaMont J. Barlow, G.
Joel DeCastro, James M. McKiernan, New
York, NY
MP64-08 ESTABLISHING A CARE COORDINATION
PATHWAY FOR BLADDER CANCER
CYSTECTOMY PATIENTS
Jason Bourque*, Kevin Chan, Timothy
Wilson, Clayton Lau, Bertram Yuh, jonathan
yamzon, Finly Zachariah, Laura Crocitto,
Duarte, CA
MP64-09 DECREASE IN LONG-TERM DISEASESPECIFIC SURVIVAL WITH
PERIOPERATIVE BLOOD TRANSFUSION
Bethany K. Burge*, Robert H. Blackwell,
Evan Carlos, Robert C. Flanigan, Gopal N.
Gupta, Marcus L. Quek, Maywood, IL
MP64-10 PERIOPERATIVE BLOOD TRANSFUSION
IN BLADDER CANCER PATIENTS
UNDERGOING RADICAL CYSTECTOMY IS
ASSOCIATED WITH INCREASED
MORBIDITY AND LENGTH OF STAY BUT
NOT ADVERSE ONCOLOGIC OUTCOMES
Heather Chalfin*, Jen-Jane Liu, Nilay Gandhi,
Zhaoyong Feng, Bruce Trock, Steven Frank,
Trinity Bivalacqua, Baltimore, MD
MP64-17 LACK OF IMPROVEMENT IN RADICAL
CYSTECTOMY OUTCOMES OVER 20
YEARS?
Hristos Kaimakliotis*, Jane S. Cho, M.
Francesca Monn, Jose A. Pedrosa, Paul
Gellhaus, K. Clint Cary, Liang Cheng,
Richard Bihrle, Michael O. Koch, Indianapolis,
IN
MP64-18 ADVERSE ONCOLOGIC OUTCOMES OF
SQUAMOUS CELL CARCINOMA OF
BLADDER AS COMPARED TO
Teodora Kurteva*, Mark Schoenberg,
Farhang Rabbani, Bronx, NY
MP64-11 PROPHYLACTIC MESH PLACEMENT AT
RADICAL CYSTECTOMY TO PREVENT
PARASTOMAL HERNIAS: TECHNIQUE
AND EARLY COMPLICATIONS
Timothy Donahue*, Bethesda, MD, Eugene
K. Cha, Hebert A. Vargas-Alvarez, Guido
Dalbagni, Bernard H. Bochner, New York, NY
MP64-19 THE NATURAL HISTORY OF NONMUSCLE INVASIVE, NESTED VARIANT OF
Abhijith Mally*, Amy Tin, Eugene Cha, Sherri
Donat, Harry Herr, Bernard Bochner, Daniel
Sjoberg, Guido Dalbagni, New York, NY
MP64-12 POSTOPERATIVE ATRIAL FIBRILLATION
PREDICTS FUTURE CARDIOVASCULAR
EVENTS
Robert Blackwell*, Chandy Ellimoottil, Petar
Bajic, Matthew Zapf, Anai Kothari, Paul Kuo,
Robert Flanigan, Marcus Quek, Gopal Gupta,
Maywood, IL
MP64-20 COMPLETE PATHOLOGIC RESPONSE TO
NEOADJUVANT CHEMOTHERAPY FOR
BLADDER CANCER: THE EFFECT OF PRETREATMENT CLINICAL STAGE
William Parker*, Kansas City, KS, Phil Ho,
Jonathon Melquist, Houston, TX, Hadley
Wyre, Moben Mirza, Jeffrey Holzbeierlein,
Kansas City, KS, Ashish Kamat, Houston,
TX, Eugene Lee, Kansas City, KS
MP64-13 HEALTHCARE-ASSOCIATED INFECTIONS
FOLLOWING CYSTECTOMY: ROOM FOR
IMPROVEMENT
Jesse Sammon*, Dane Klett, Firas Abdollah,
Akshay Sood, Daniel Pucheril, Detroit, MI,
Julian Hanske, Christian Meyer, Boston, MA,
James Peabody, Mani Menon, Detroit, MI,
MP64-14 OUTPATIENT CHEMOPROPHYLAXIS AND
RATE OF DEEP VENOUS THROMBOSIS
John Schomburg*, Ayman Soubra, Badrinath
Konety, Minneapolis, MN
*Presenting author
CREDITTM
209
MONDAY
MP64-16 CRITICAL ANALYSIS OF HOSPITAL
READMISSION AND COST BURDEN
AFTER ROBOT-ASSISTED RADICAL
CYSTECTOMY
Kristina Wittig*, Nora Ruel, Bob Hawks, Kevin
Chan, Clayton Lau, Timothy Wilson, Bertram
Yuh, Duarte, CA
10:30 am - 12:30 pm
BLADDER CANCER: INVASIVE III
Moderators: Michael Koch and Masayuki Nakagawa
ABSTRACT
NUMBER TITLE
MP65-01 PELVIC LYMPH NODE DISSECTION ON
THE CONTRALATERAL SIDE CAN BE
LIMITED IN STRICTLY UNILATERALLY
LOCATED BLADDER CANCER
Bernhard Kiss*, Michael Paerli, Daniel
Schöndorf, George N. Thalmann, Beat Roth,
Bern, Switzerland
ABSTRACT
NUMBER TITLE
MP65-06 A MULTI-INSTITUTIONAL ANALYSIS OF
OUTCOMES IN PATIENTS WITH
CLINICALLY NODE POSITIVE
UROTHELIAL BLADDER CANCER
TREATED WITH INDUCTION
CHEMOTHERAPY AND RADICAL
CYSTECTOMY
Kamran Zargar-Shoshtari*, Tampa, FL,
Homayoun Zargar, Vancouver, Canada,
Adrian S Fairey, Los Angeles, CA, Laura S
Mertens, Amsterdam, Netherlands, Colin P
Dinney, Houston, TX, Maria C Mir, Cleveland,
OH, Laura-Maria Krabbe, Dallas, TX, Michael
S Cookson, Oklahoma, OK, Niels-Erik
Jacobsen, Edmonton, Canada, Nilay Gandhi,
Baltimore, MD, Joshua Griffin, Kansas City,
KS, Jeffrey S Montgomery, Ann Arbor, MI,
Nikhil Vasdev, Newcastle Upon Tyne, United
Kingdom, Evan Y Yu, Seattle, WA,
Evanguelos Xylinas, New York, NY, Nicholas
J. Campain, Exeter, United Kingdom, Wassim
Kassouf, Montreal, Canada, Marc A. Dall’Era,
Sacramento, CA, Jo-An Seah, Toronto,
Canada, Pranav Sharma, Tampa, FL, Cesar
E Ercole, Cleveland, OH, Simon Horenblas,
Amsterdam, Netherlands, Srikala S Sridhar,
Toronto, Canada, John S McGrath, Jonathan
Aning, Exeter, United Kingdom, Shahrokh F
Shariat, Vienna, Austria, Jonathan L Wright,
Seattle, WA, Andrew C Thorpe, Newcastle
Upon Tyne, United Kingdom, Todd M
Morgan, Ann Arbor, MI, Jeff M Holzbeierlein,
Kansas City, KS, Trinity J Bivalacqua,
Baltimore, MD, Scott North, Edmonton,
Canada, Daniel A Barocas, Nashville, TN,
Yair Lotan, Dallas, TX, Jorge A Garcia,
Andrew J Stephenson, Cleveland, OH, Jay B
Shah, Houston, TX, Bas W van Rhijn,
Amsterdam, Netherlands, Siamak
Daneshmand, Los Angeles, CA, Philippe E
Spiess, Tampa, FL, Peter Black, Vancouver,
Canada
MP65-02 A PHASE III SURGICAL TRIAL TO
EVALUATE THE BENEFIT OF A
STANDARD VERSUS AN EXTENDED
PELVIC LYMPHADENECTOMY
PERFORMED AT TIME OF RADICAL
CYSTECTOMY FOR MUSCLE INVASIVE
UROTHELIAL CANCER: SWOG S1011
(NCT #01224665)
Seth P. Lerner*, Houston, TX, Catherine M
Tangen, Seattle, WA, Robert S. Svatek, San
Antonio, TX, Theresa M Koppie, Portland,
OR, Ajjai Alva, Ann Arbor, MI, Francisco G
La Rosa, Aurora, CO, Sumanta K Pal,
Duarte, CA, Siamak Daneshmand, Los
Angeles, CA, Colin PN Dinney, Houston, TX,
Adam S Kibel, Boston, MA, Kamal Pohar,
Columbus, OH, Daniel J Canter,
Philadpelphia, PA, Wassim Kassouf,
Montreal, Canada, Rick Bangs, Seattle, WA,
Ian M Thompson, San Antonio, TX
MP65-03 DIFFERENCES IN THE DISTRIBUTION OF
RECURRENCE LOCATIONS BETWEEN
PATIENTS WHO UNDERGO OPEN AND
Daniel Nguyen*, Bashir Al Hussein Al
Awamlh, Xian Wu, Igor Inoyatov, Abimbola
Ayangbesan, Bishoy Faltas, Paul Christos,
Padraic O’Malley, Douglas Scherr, New York,
NY
MP65-04 ONCOLOGICAL AND FUNCTIONAL
OUTCOMES IN MUSCLE-INVASIVE
UNDERGOING BLADDER-SPARING
TREATMENT CONSISTING OF LOW-DOSE
CHEMORADIOTHERAPY AND
CONSOLIDATIVE PARTIAL CYSTECTOMY
Yasuhisa Fujii*, Kazunori Kihara, Hajime
Tanaka, Manabu Tatokoro, Soichiro Yoshida,
Minato Yokoyama, Junichiro Ishioka, Yoh
Matsuoka, Noboru Numao, Kazutaka Saito,
Tokyo, Japan
MP65-07 DIFFERENCES IN THE RECURRENCE
PATTERN AFTER NEOADJUVANT
CHEMOTHERAPY COMPARED TO
SURGERY ALONE IN PATIENTS WITH
Hiromichi Iwamura*, Takuya Koie, Hayato
Yamamoto, Atsushi Imai, Shingo
Hatakeyama, Takahiro Yoneyama, Yasuhiro
Hashimoto, Tohru Yoneyama, Yuki Tobisawa,
Chikara Ohyama, Hirosaki, Japan
MP65-05 DETERMINING THE OPTIMAL TIMING FOR
RADICAL CYSTECTOMY AFTER
NEOADJUVANT CHEMOTHERAPY
Chinedu Mmeje*, Cooper Benson, Graciela
Nogueras-Gonzalez, Isuru Jayaratna, Neema
Navai, Jianjun Gao, Arlene Siefker-Radtke,
Ashish Kamat, Colin Dinney, Jay Shah,
Houston, TX
210
MP65-14 INCIDENCE AND RISK FOR CLOSTRIDIUM
DIFFICILE INFECTIOUS COLITIS IN
PATIENTS UNDERGOING RADICAL
Kashyap Shatagopam*, Nick Liu, M.
Francesca Monn, Clinton Bahler, Hristos
Kaimakliotis, K. Clint Cary, Ronald Boris,
Matthew Mellon, Timothy Masterson, Richard
Bihrle, Richard Foster, Thomas Gardner,
Michael House, Michael Koch, Indianapolis,
IN
MP65-08 A PHARMACODYNAMIC PHASE 0/I STUDY
OF ORAL RAPAMYCIN IN PATIENTS
FOR BLADDER CANCER
Aashish Kabra*, Essel Marie de Leon,
Carolina Livi, Martin Javors, Marlo Nicolas,
David Henkes, Dave Sharp, Tyler Curiel,
Robert Svatek, San Antonio, TX
MP65-09 IMPACT OF PERIOPERATIVE
CHEMOTHERAPY ON SURVIVAL IN
PATIENTS WITH ADVANCED PRIMARY
URETHRAL CANCER: RESULTS OF THE
INTERNATIONAL COLLABORATION ON
PRIMARY URETHRAL CARCINOMA
Georgios Gakis*, Tübingen, Germany, Todd
Morgan, Ann Arbor, MI, Siamak
Daneshmand, Tübingen, CA, Kirk Keegan,
Harras Zaid, Nashville, TN, Jan Hrbacek,
Prague, —, Bedeir Ali-El-Dein, Mansoura,
Egypt, Rebecca Clayman, Boston, MA,
Tilman Todenhöfer, Tübingen, Germany,
Sigolene Galland, Boston, MA, Kola
Olugbade Jr., Ann Arbor, MI, Michael Rink,
Hamburg-Eppendorf, Germany, Hans-Martin
Fritsche, Maximillian Burger, Regensburg,
Germany, Sam Chang, Nashville, TN, Marko
Babjuk, Prague, Czech Republic, George
Thalmann, Bern, Switzerland, Arnulf Stenzl,
Tübingen, Germany, Jason Efstathiou,
Boston, MA
MP65-16 ADMINISTRATION OF POSTOPERATIVE
PARENTERAL NUTRITION DOES NOT
AFFECT ONCOLOGICAL OUTCOMES
AFTER RADICAL CYSTECTOMY (RC) IN
Alvaro Vidal Faune*, Bernhard Kiss, Fiona C.
Burkhard, Urs E. Studer, George N.
Thalmann, Beat Roth, Bern, Switzerland
MP65-17 CYSTECTOMY ENHANCED RECOVERY
PATHWAY: REDUCTION IN LENGTH OF
STAY WITHOUT INCREASED MORBIDITY
OR READMISSIONS
Janet Baack Kukreja*, Maureen Kiernan,
Bethany Schempp, Adriana Hontar, Ahmed
Ghazi, Hani Rashid, Guan Wu, Edward
Messing, Rochester, NY
MP65-10 DELAYED RADICAL CYSTECTOMY IN
PATIENTS WITH MUSCLE-INVASIVE
BLADDER CANCER: A NATIONWIDE
ANALYSIS
Harman Maxim Bruins*, Katja Aben, Tom
Arends, Toine van der Heijden, Fred Witjes,
Nijmegen, Netherlands
MP65-18 CLINICAL CHARACTERISTICS AND
POSTOPERATIVE 30-DAY
COMPLICATIONS ASSOCIATED WITH
NEOBLADDER AT THE TIME OF
CYSTECTOMY: DATA FROM THE NSQIP
DATA BASE
Ryan Werntz*, Yiyi Chen, Joshua Buehler,
Christopher Amling, Theresa Koppie,
Portland, OR
MP65-11 GENDER DISPARITY IN SURVIVAL FROM
BLADDER CANCER CAN NOT BE
EXPLAINED BY LATE PRESENTATION OR
DIFFERENCES IN TREATMENT
Manish Patel*, Albert Bang, David Gillett,
David Smith, Sydney, Australia
MP65-12 CHANGING PATTERNS OF CARE AMONG
PATIENTS WITH STAGE T1 UROTHELIAL
CANCER OF THE BLADDER
Phillipe Nabbout*, Oklahoma City, OK, Sean
Elliott, Oluwakayode Adejoro, Minneapolis,
MN, Joel Slaton, Oklahoma City, OK
MP65-19 AN EVALUATION OF THE TIMING OF
SURGICAL COMPLICATIONS FOLLOWING
RADICAL CYSTECTOMY
Akshay Sood*, Naveen Kachroo, Firas
Abdollah, Jesse Sammon, Dane Klett, Wooju
Jeong, Detroit, MI, Adam Kibel, Marianne
Schmid, Boston, MA, James Peabody, Mani
Menon, Detroit, MI, Quoc-Dien Trinh, Boston,
MA
MP65-13 BROADER SPECTRUM ANTIMICROBIAL
PROPHYLAXIS INCLUDING FUNGAL
COVERAGE SIGNIFICANTLY REDUCES
INFECTIOUS COMPLICATIONS AFTER
RADICAL CYSTECTOMY
Joseph J. Pariser*, Blake B. Anderson,
Shane M. Pearce, Zhe Han, Chicago, IL,
Benjamin D. Brielmaier, Franklin, TN, Emily
Landon, Jennifer C. Pisano, Gary D.
Steinberg, Norm D. Smith, Chicago, IL
MP65-20 DETERMINANTS OF OPERATIVE TIME
FOR BLADDER CANCER PATIENTS
Christopher Filson*, Aaron Laviana, Hung-Jui
Tan, Karim Chamie, Jim Hu, Los Angeles,
CA
CREDITTM
*Presenting author
211
MONDAY
MP65-15 EXTENDED-DURATION ENOXAPARIN
LOWERS THROMBOEMBOLIC EVENTS
AFTER RADICAL CYSTECTOMY
COMPARED TO INPATIENT-ONLY
SUBCUTANEOUS HEPARIN
Joseph J. Pariser*, Shane M. Pearce, Blake
B. Anderson, Vivek N. Prachand, Norm D.
Smith, Gary D. Steinberg, Chicago, IL
10:30 am - 12:30 pm
PROSTATE CANCER: BASIC RESEARCH V
Moderators: Mark Garzotto and Douglas Scherr
ABSTRACT
NUMBER TITLE
MP66-01 SPOP MUTATION LEADS TO GENOMIC
INSTABILITY IN PROSTATE CANCER
Christopher Barbieri*, Gunther Boysen, New
York, NY, Davide Prandi, Trento, Italy, SungSuk Chae, Arun Dahiya, Srilakshmi Nataraj,
Mirjam Blattner, Clarisse Marotz, Limei Xu,
Julie Huang, New York, NY, Paola Lecca,
Trento, Italy, Sagar Chhangawala, Pengbo
Zhou, Andrea Sboner, New York, NY,
Francesca Demichelis, Trento, Italy, Yariv
Houvras, Mark Rubin, New York, NY
ABSTRACT
NUMBER TITLE
MP66-06 OPTIMIZATION OF NANOSTRING
PLATFORM FOR EVALUATION OF
PROSTATE CANCER BIOMARKERS AND
THERAPEUTIC TARGETS IN FFPE
SPECIMENS
Wusheng Yan, Denise Young, Yingjie Song,
Yongmei Chen, Shilpa Katta, Lakshmi
Ravindranath, Jocelyn Lee, Alagarsamy
Srinivasan, Jennifer Cullen, Jacob Kagan,
Sudhir Srivastava, Sudhir Srivastava, Albert
Dobi, Rockville, MD, Inger Rosner, David G.
McLeod, Bethesda, MD, Isabell A.
Sesterhenn, Silver Spring, MD, Shiv
Srivastava, Gyorgy Petrovics*, Rockville, MD
MP66-02 INHIBITION OF LIM-SH3 DOMAIN
PROTEIN1 AUGMENTS THE ANTICANCER EFFECT OF ENZALUTAMIDE IN
PROSTATE CANCER
Takeuchi, Fukuoka, Japan, Jeffrey Leong,
Tabitha Tombe, Kevin Tam, Vancouver,
Canada, Seiji Naito, Fukuoka, Japan, Martin
Gleave, Christopher Ong, Vancouver,
Canada
MP66-07 TARGETING ANDROGEN RECEPTOR NTERMINAL DOMAIN FOR PROSTATE
CANCER IMAGING AND THERAPY
Yusuke Imamura*, Amy H. Tien, Nasrin R.
Mawji, Jian Kun Zhong, Jinhe Pan, KuoShyan Lin, Raymond J. Andersen, Marianne
D. Sadar, Vancouver, Canada
MP66-08 DUAL PATHWAY INHIBITION IN
PROSTATE CANCER
Eugine Lee, Susan Ha, Susan Logan*, New
York, NY
MP66-03 NEXT-GENERATION SEQUENCING OF
CIRCULATING EXOSOMAL RNA FROM
METASTATIC CASTRATE RESISTANT
Elisa Ledet*, Ratish Gambhira, Aryeneesh
Dotiwala, Diptasri Mandal, Oliver Sartor, New
Orleans, LA
MP66-09 REGULATION OF INTRATUMORAL
ANDROGEN SYNTHESIS IN PROSTATE
CANCER BY THE DAB2IP/AKR1C3
SIGNALING AXIS
Kaijie Wu*, Xi’an, China, People’s Republic
of, Bin Wang, Dallas, TX, Jiancheng Zhou,
Xi’an, China, People’s Republic of, Jer-Tsong
Hsieh, Dallas, TX, Dalin He, Xi’an, China,
MP66-04 CABAZITAXEL INHIBITS THE
PROLIFERATION OF HUMAN
CASTRATION-REFRACTORY PROSTATE
CANCER CELLS IN VITRO AND
ENHANCES THE ANTI-TUMOR
PROPERTIES OF THE ANGIO-INHIBITORY
PIGMENT EPITHELIUM-DERIVED FACTOR
IN VIVO WITH A GREATER EFFICACY
THAN DOCETAXEL
Thomas Nelius*, Courtney Jarvis, Dalia
Martinez-Marin, Stephanie Filleur, Lubbock,
TX
MP66-10 CHARACTERIZATION OF
SUSCEPTIBILITY LOCI IN HEREDITARY
PROSTATE CANCER FAMILIES USING
COPY NUMBER VARIATION AND
LINKAGE ANALYSIS
Elisa Ledet, Kirsten Wood*, New Orleans, LA,
Joan Bailey-Wilson, Baltimore, MD, Oliver
Sartor, New Orleans, LA, Marilyn Li, Houston,
TX, Diptasri Mandal, New Orleans, LA
MP66-05 PRETREATMENT SYSTEMIC
INFLAMATORY RESPONSE PARAMETERS
DO NOT PREDICT THE OUTCOME IN MEN
WITH PROSTATE CANCER UNDERGOING
Cédric Poyet*, Jean-Pascal Adank, Etienne
Keller, Ashkan Mortezavi, Tenzin Rabgang,
Bettina Pfister, Tullio Sulser, Thomas
Hermanns, Zürich, Switzerland
MP66-11 ANDROGEN RECEPTOR SPLICE
VARIANTS DIMERIZE TO ACTIVATE GENE
TRANSCRIPTION
Yang Zhan, Duo Xu, Yanfeng Qi, Bo Cao,
Oliver Sartor, Yan Dong*, New Orleans, LA
212
MP66-17 MICRORNA-224 IS DOWN-REGULATED IN
PROSTATE CANCER AND MEDIATES
TUMOR-SUPPRESSIVE EFFECTS IN
VITRO
Felix Bienert, Kati Erdmann*, Susanne
Fuessel, Manfred P. Wirth, Dresden,
Germany
MP66-12 A NOVEL CELL BASED MULTIPLEX
BIOMARKER ASSAY FOR PROSTATE
CANCER DETECTION IN URINE
Shyh-Han Tan*, Kristen P Nickens, Rockville,
MD, Amina Ali, Bethesda, MD, Tatiana
Scoggin, Concord, CA, Lakshmi
Ravindranath, Rockville, MD, David G.
McLeod, Bethesda, MD, David Tacha,
Concord, CA, Shiv Srivastava, Rockville, MD,
Isabell Sesterhenn, Silver Spring, MD,
Gyorgy Petrovics, Rockville, MD
MP66-13 METFORMIN REPRESSES CANCER CELLS
VIA ALTERNATE PATHWAYS IN NCADHERIN WILD TYPE AND N-CADHERIN
DEFICIENT CELLS
Rongbin Ge, Zongwei Wang, Shulin Wu,
Yangjia Zhuo, Aleksandar Otsetov, Boston,
MA, Chao Cai, Weide Zhong, Guangzhou,
China, People’s Republic of, Chin-lee Wu,
Aria Olumi*, Boston, MA
MP66-19 REDUCED AUTOPHAGY LEVELS ARE
ASSOCIATED WITH A HIGHER GLEASON
SCORE, TUMOR STAGE AND AN
INCREASED RATE OF PROSTATE
CANCER SPECIFIC DEATH
Ashkan Mortezavi*, Souzan Salemi, Niels
Rupp, Thomas Hermanns, Tullio Sulser,
Peter J Wild, Daniel Eberli, Zurich,
Switzerland
MP66-14 IDENTIFYING NOVEL NUCLEAR
TRANSPORTER OF AR AND AR(VARIANT)
IN CRPC CELLS: POTENTIAL
IMPLICATIONS IN THERAPY
Mohammad Saleem*, Austin, MN, Badrinath
Konety, Minneapolis, MN, Aijaz Parray, Hifzur
Siddique, Austin, MN, Robert Matusik,
Nashville, TN, Mikihik NAITO, Tokyo, Japan,
Alyssa Langfald, Austin, MN
MP66-20 SIURO-PRIAS-ITA PROJECT: FIVE YEAR
EXPERIENCE ON ACTIVE SURVEILLANCE
Rocco Papalia*, Michele Gallucci, Rome,
Italy, Giario Conti, Como, Italy, Giuseppe
Martorana, Bologna, Italy, Roberto
Sanseverino, Nocera Inferiore, Italy, Ezio
Frego, Marco Tanello, Desenzano, Italy,
Pierpaolo Graziotti, Rozzano, Italy, Andrea
Turci, Cesena, Italy, Pasquale Ditonno, Bari,
Italy, Maurizio Colecchia, Milano, Italy,
Michelangelo Fiorentino, Bologna, Italy,
Rodolfo Montironi, Torrette di Ancona, Italy,
Carlo Patriarca, Como, Italy, Maria Rosa
Raspollini, Firenze, Italy, Tiziana Magnani,
Milano, Italy, Chris Bangma, Rotterdam,
Netherlands, Riccardo Valdagni, Milano, Italy
MP66-15 INHIBITION OF ERG ACTIVITY IN
PATIENT DERIVED PROSTATE CANCER
XENOGRAFTS USING THE SMALL
MOLECULE INHIBITOR YK-4-279
Brian Winters*, Lisha Brown, Ilsa Coleman,
Seattle, WA, Tsion Minas, Washington, DC,
Xiaotun Zhang, Lori Kollath, Holly Nguyen, Peter
Nelson, Eva Corey, Seattle, WA, Aykut Uren,
Washington, DC, Colm Morrissey, Seattle, WA
MP66-16 ANATOMIC TUMOR LOCATION NOT
RACIAL BACKGROUND IMPACTS ETS
FAMILY TRANSCRIPTION FACTOR AND
SPINK1 EXPRESSION IN PROSTATE
CANCER
Farzana Faisal*, Debasish Sundi, Ashley
Ross, Baltimore, MD, Voleak Choeurng,
Nicholas Erho, Mohammed Alshalalfa, Elai
Davicioni, Vancouver, Canada, Tamara
Lotan, Edward Schaeffer, Baltimore, MD
CREDITTM
10:30 am - 12:30 pm
Podium Session 38
PROSTATE CANCER: DETECTION AND SCREENING III
Moderator: Hans Lilja
ABSTRACT
TIME NUMBER TITLE
10:30 PD38-01 HETEROGENEITY OF RECOMMENDED
PSA SCREENING PRACTICES IN MEN
AGED 55-69 IN THE UNITED STATES
Jesse Sammon*, Firas Abdollah, Akshay
Sood, Dane Klett, Daniel Pucheril, James
Peabody, Mani Menon, Detroit, MI, QuocDien Trinh, Boston, MA
*Presenting author
ABSTRACT
TIME NUMBER TITLE
10:40 PD38-02 METASTATIC PROSTATE CANCER IN THE
MODERN ERA OF PSA SCREENING
Philip Fontenot*, Avinash Nehra, Hadley
Wyre, Moben Mirza, Jeffrey Holzbeierlein, J.
Brantley Thrasher, Peter Van Veldhuizen,
Eugene Lee, Kansas City, KS
213
MONDAY
MP66-18 THE EFFECT OF METFORMIN ON
OSTEOMIMICRY AND CANCER-INDUCED
BONE DISEASE IN THE PROSTATE
CANCER-BONE MICROENVIRONMENT IN
VITRO AND IN VIVO
Jessica Whitburn*, James Aylward, Siobhan
Webb, Srinivasa Rao, Freddie Hamdy, Claire
Edwards, Oxford, United Kingdom
10:50
11:00
11:10
PD38-03 THE 4KSCORE IS ASSOCIATED WITH
MORE ADVANCED DISEASE AT RADICAL
PROSTATECTOMY; RESULTS FROM A
MULTI-INSTITUTIONAL PROSPECTIVE
TRIAL
Sanoj Punnen*, Miami, FL, Stephen Zappala,
Andover, MA, Dan Sjoberg, New York, NY,
Vinita Mathur, Michael Reeve, Dipen Parekh,
Miami, FL
PD38-04 PCA3- BASED NOMOGRAM FOR
PREDICTING PROSTATE CANCER AND
HIGH GRADE CANCER ON INITIAL
TRANSRECTAL GUIDED BIOPSY
Ahmed Elshafei*, Cleveland, OH, K. Kent
Chevli, Michael Duff, Cheektowaga, NY,
Peter Walter, Cleveland, OH, Margaret Suraf,
Cheektowaga, NY, Ayman S. Moussa, Giza,
Egypt, Gao Tianming, Shih-Chieh Chueh,
J.Stephen Jones, Cleveland, OH
PD38-05 MAGNETIC RESONANCE
IMAGING/ULTRASOUND FUSION-GUIDED
BIOPSY DETECTS CLINICALLY
SIGNIFICANT PROSTATE CANCER IN THE
CENTRAL GLAND CORRELATING WITH
INDEX LESION
Michele Fascelli*, Thomas Frye, Arvin
George, Steven Abboud, Raju Chelluri,
Richard Ho, Annerleim Walton Diaz, Sandeep
Sankineni, Maria Merino, Baris Turkbey,
Peter Choyke, Bradford Wood, Peter Pinto,
Bethesda, MD
11:20
PD38-06 UNDERSTANDING THE USE OF
PROSTATE BIOPSY AMONG MEN WITH
LIMITED LIFE EXPECTANCY
Firas Abdollah*, Detroit, MI, Zaojun Ye, David
Miller, Susan Linsell, James Montie, Ann
Arbor, MI, James Peabody, Detroit, MI,
Khurshid Ghani, Ann Arbor, MI
11:30
PD38-07 GENETIC CORRECTION OF PSA CAN
REDUCE THE NUMBER OF MEN
DIAGNOSED WITH POTENTIALLY
INSIGNIFICANT PROSTATE CANCER:
RESULTS FROM A SURGICAL AND
ACTIVE SURVEILLANCE COHORT
James Kearns*, Chicago, IL, Brian Helfand,
Evanston, IL, Kimberly Roehl, Chicago, IL,
Kristian Novakovic, Evanston, IL, Phillip
Cooper, William Catalona, Chicago, IL
11:40
PD38-08 PERFORMANCE OF IN-BORE MR-GUIDED
TARGETED PROSTATE BIOPSY FOR
DETECTION OF CLINICALLY SIGNIFICANT
PROSTATE CANCER: A MULTICENTER
STUDY
Ely Felker*, Stephanie Lee-Felker, Los
Angeles, CA, John Feller, Stuart May, Palm
Springs, CA, Robert Princenthal, Martin
Cohen, Thousand Oaks, CA, David Lu,
Daniel Margolis, Grace Kim, Steven Raman,
Los Angeles, CA
11:50
PD38-09 PROSTATE BIOPSY COMPLICATIONS, A
DUAL ANALYSIS
Franklin Gaylis*, Ryan Nasseri, Logan Fink,
Renee Calabrese, Brandon Bosse, Paul
Dato, Edward Cohen, San Diego, CA
12:00
PD38-10 EXTERNAL VALIDATION OF UPDATED
NOMOGRAM PREDICTING PROSTATE
CANCER ON INITIAL TRANSRECTAL
ULTRASOUND GUIDED BIOPSY
Ahmed Elshafei*, Cleveland, OH, Ayman S.
Moussa, Beni -Suef, Egypt, Asmaa Hatem,
Cleveland, OH, K. Kent Chevli, Michael Duff,
William Geary, Peter Walter, Margaret Suraf,
Cheektowaga, NY, Gao Tianming, Andrew
Stephenson, Eric Klein, J.Stephen Jones,
Cleveland, OH
12:10
PD38-11 ADVERSE PATHOLOGY YET
UNDETECTABLE ULTRASENSITIVE PSA:
IS ADJUVANT RADIATION REALLY
NECESSARY?
Ross Simon*, Lauren Howard, Stephen
Freedland, Durham, NC, William Aronson,
Los Angeles, CA, Martha Terris, Augusta,
GA, Christopher Kane, San Diego, CA,
Christopher Amling, Portland, OR, Matthew
Cooperberg, San Francisco, CA, Adriana
Vidal, Durham, NC
12:20
PD38-12 [11C]CHOLINE PET/CT PREDICTS
SURVIVAL IN HORMONE NAÏVE
PROSTATE CANCER PATIENTS WITH
BIOCHEMICAL FAILURE AFTER RADICAL
PROSTATECTOMY
Maria Picchio*, Giampiero Giovacchini, Luigi
Gianolli, Nazareno Suardi, Milan, Italy, Firas
Abdollah, Detroit, MI, Andrea Gallina, Vito
Cucchiara, Giorgio Gandaglia, Marco Bianchi,
Vincenzo Scattoni, Francesco Montorsi,
12:30
PD38-13 REPEAT BIOPSY RATES FOR
PREMALIGNANT LESIONS IN A
COLLABORATIVE
Frank Burks*, Dinesh Telang, Royal Oak, MI,
Alice Liu, Yuqing Gao, Susan Linsell, James
Montie, David Miller, Khurshid Ghani, Ann
Arbor, MI
CREDITTM
214
10:30 am - 12:30 pm
Podium Session 39
BENIGN PROSTATIC HYPERPLASIA: EPIDEMIOLOGY AND NATURAL HISTORY
Moderators: Henry Woo and Naoya Masumori
10:40
PD39-02 ESTROGEN, BUT NOT TESTOSTERONE,
IS ASSOCIATED WITH LOWER URINARY
TRACT SYMPTOMS AT BASELINE AND
FOLLOWING TREATMENT WITH
TADALAFIL: ANALYSIS OF POOLED
CLINICAL TRIALS DATA
Martin Miner*, Providence, RI, Kathryn Egan,
Gayatri Ranganathan, Minhyung Suh,
Watertown, MA, Claus Roehrborn, Dallas,
TX, Gary Wittert, Adelaide, Australia, David
Wong, Xiao Ni, Indianapolis, IN, Raymond
Rosen, Watertown, MA
10:50
PD39-03 ASSOCIATION OF PROSTATE BLOOD
FLOW WITH MALE LOWER URINARY
TRACT SYMPTOMS
Kuan-Yu Wu*, Yao-Lin Kao, Chan-Jung Liu,
Yin-Chien Ou, Yuh-Shyan Tsai, Tzong-Shin
Tsai, Yat-Ching Tong, Tainan, Taiwan
11:00
PD39-04 ASSOCIATION OF URINE CHEMOKINES
WITH CLINICAL ATTRIBUTES OF
BPH/LUTS PATIENTS
Pradeep Tyagi*, Pittsburgh, PA, Jay H.
Fowke, Saundra Motley, Nashville, TN,
Mahendra Kashyap, Subrata Pore, Zhou
Wang, Naoki Yoshimura, Pittsburgh, PA
11:10
11:20
ABSTRACT
TIME NUMBER TITLE
11:30 PD39-07 ABDOMINAL AORTIC ATHEROMATOSIS
AND LOWER URINARY TRACT
SYMPTOMS IN MEN
Gabriel Gouvea*, Jose Ricardo Silvino,
Priscila Kuriki, Viviane Tabone, Raquel
Conceicao, Rogerio Simonetti, Valdemar
Ortiz, Roberto Soler, Sao Paulo, Brazil
PD39-05 WORSENED URINARY STORAGE
SYMPTOMS AND DECREASED QUALITY
OF LIFE PREDICTS LOW TESTOSTERONE
IN A CARDIOLOGY CLINIC POPULATION
Michael Kottwitz*, Springfield, IL, Joel F
Koenig, St. Louis, MO, Bradford Stevenson,
Randy Sulaver, Georgia Mueller, Tobias S
PD39-06 IMPAIRED SLEEP QUALITY PREDICTS
MORE SIGNIFICANT LOWER URINARY
TRACT SYMPTOMS IN MALE SHIFT
WORKERS
Alexander W. Pastuszak*, Jason Scovell,
Justin Badal, Aravind Chandrashekar, Tariq
S. Hakky, Ranjith Ramasamy, Dolores J.
Lamb, Larry I. Lipshultz, Houston, TX
11:40
PD39-08 VOIDING PARAMETERS IN ELDERLY
MALES WITH 5 YEAR FOLLOWUP- WHAT
HAPPENS TO MEN WITH ELEVATED
POSTVOID RESIDUAL URINE?
Giovanni Losco, Lewis Chan*, Vincent Tse,
Vasi Naganathan, Robert Cumming, Sydney,
Australia
11:50
PD39-09 STATIN DRUG USE AND RISK OF
SYMPTOMATIC BENIGN PROSTATIC
HYPERPLASIA (BPH): RESULTS FROM
THE PROSTATE CANCER PREVENTION
TRIAL
Darshan Patel*, James Hotaling, Jeremy
Myers, William Brant, Salt Lake City, UT,
Jeannette Schenk, Seattle, WA
12:00
PD39-10 CHANGES IN BODY MASS INDEX AND
METABOLIC SYNDROME ARE
ASSOCIATED WITH PROSTATE GROWTH
RATE OVER A 5 YEAR PERIOD
Yoon Soo Kyung*, Dalsan You, In Gab
Jeong, Taekmin Kwon, Chunwoo Lee,
Seungbong Han, Hong-Kyu Kim, Choung-Soo
Kim, Myungchan Park, Chanwoo Lee,
Sangjun Yoo, Seoul, Korea, Republic of
12:10
PD39-11 PEAK URINE FLOW PREDICTS
DEVELOPMENT OF SYMPTOMATIC BPH
IN MEN WITH MILD TO NO URINARY
SYMPTOMS: RESULTS FROM REDUCE
Ross Simon*, Lauren Howard, Durham, NC,
Daniel Moreira, Rochester, MN, Stephen
Freedland, Durham, NC, Claus Roehrborn,
Dalllas, TX, Adriana Vidal, Durham, NC
12:20
PD39-12 THE CO-OCCURRING SYNDROME OVERLAP OF ED AND BPH AND THEIR
CLINICAL CORRELATES IN AGING MEN:
RESULTS FROM THE NATIONAL HEALTH
AND NUTRITION EXAMINATION SURVEY
Arthur L. Burnett*, Baltimore, MD, Kathryn
Egan, Minhyung Suh, Watertown, MA, Kevin
T. McVary, Springfield, IL, Claus Roehrborn,
Dallas, TX, David Wong, Xiao Ni,
Indianapolis, IN, Raymond Rosen,
Watertown, MA
CREDITTM
*Presenting author
215
MONDAY
ABSTRACT
TIME NUMBER TITLE
10:30 PD39-01 SEXUAL FUNCTION ASSOCIATED WITH
MEN WITH BENIGN PROSTATIC
HYPERPLASIA: MTOPS COHORT OF
CROSS-SECTIONAL AND LONGITUDINAL
DATA
Michael Butcher*, Springfield, IL, Chyng-Wen
Fwu, Silver Spring, MD, Ziya Kirkali,
Bethesda, MD, Tobias Köhler, Springfield, IL,
Pamela Burrows, Rockville, MD, Paul Eggers,
John Kusek, Bethesda, MD, Kevin McVary,
Springfield, IL
10:30 am - 12:30 pm
Podium Session 40
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: SURGICAL THERAPY II
Moderators: Lawrence Hakim and Ronald Lewis
ABSTRACT
TIME NUMBER TITLE
10:30 PD40-01 3 YEAR OUTCOMES OF THE ZEN TRIAL:
THE MEDTRONIC ZOTAROLIMUSELUTING PERIPHERAL STENT SYSTEM
FOR THE TREATMENT OF ED IN MALES
WITH SUB-OPTIMAL RESPONSE TO PDE5
INHIBITORS
Tobias Kohler*, Springfield, IL, Irwin
Goldstein, San Diego, CA
10:40
PD40-02 PREDICTING ERECTILE DYSFUNCTION
(ED) AFTER DORSAL PLAQUE INCISION
AND GRAFTING IN MEN WITH BASELINE
NORMAL ERECTILE HEMODYNAMICS
Raanan Tal*, Judy Choi, Byron Alex, Stefan
Flores, Christian J. Nelson, John P. Mulhall,
New York, NY
10:50
PD40-03 TARGETED ROBOTIC ASSISTED
MICROSURGICAL DENERVATION OF THE
SPERMATIC CORD FOR THE TREATMENT
OF CHRONIC SCROTAL CONTENT PAIN:
SINGLE CENTER, LARGE SERIES REVIEW
Bayo Tojuola*, Ibrahim Kartal, Jamin
Brahmbhatt, Sijo Parekattil, Clermont, FL
11:00
PD40-04 SALVAGE ULTRASOUND GUIDED
TARGETED MICROCRYOABLATION OF
THE PERI-SPERMATIC CORD FOR
PERSISTENT CHRONIC SCROTAL
CONTENT PAIN AFTER MICROSURGICAL
DENERVATION OF THE SPERMATIC
CORD
11:10
11:20
11:30
ABSTRACT
TIME NUMBER TITLE
11:40 PD40-08 SURGICAL MANAGEMENT OF ERECTILE
DYSFUNCTION IN THE VETERANS
AFFAIRS (VA) POPULATION
John Lacy*, Jonathan Walker, Shubham
Gupta, David Preston, Lexington, KY
PD40-05 SUB-URETHRAL SLING SURGERY FOR
STRESS INCONTINENCE MAY RESULT IN
ORGASMIC DYSFUNCTION THROUGH
DIRECT INJURY TO ANTERIOR VAGINAL
WALL, PERI-URETHRAL PROSTATIC
TISSUE
Nicole Szell*, Detroit, MI, Rose Hartzell,
Deborah Cohen, Sue Goldstein, Joshua
Gonzalez, Irwin Goldstein, San Diego, CA
PD40-06 EFFECT OF OPERATIVE LOCAL
ANESTHESIA ON POSTOPERATIVE PAIN
OUTCOMES OF INFLATABLE PENILE
PROSTHESIS : PROSPECTIVE
COMPARISON OF TWO MEDICATIONS
Marilin Nicholson*, Fernando Bianco, Angel
Perez, Edward Gheiler, Hialeah, FL
11:50
PD40-09 FACTORS CORRELATING WITH SEXUAL
INTEREST AND FUNCTION IN LONGTERM COLORECTAL CANCER
SURVIVORS
Hajar I. Ayoub*, Y. Nancy You, Hop
Sanderson Tran Cao, Chung-Yuan Hu,
Christina Bailey, George Chang, Miguel
Rodriguez-Bigas, John Skibber, O. Lenaine
Westney, Houston, TX
12:00
PD40-10 PENILE IMPLANTS – WHY ARE MEN
DISSATISFIED?
Tobias Kohler*, Springfield, IL, Anthony Bella,
Ottawa, Canada, Edward Karpman, Mountain
View, CA, William Brant, Salt Lake City, UT,
Brian Christine, Homewood, AL, LeRoy
Jones, San Antonio, TX, Bryan Kansas,
Austin, TX, Nelson Bennett, Burlington, MA,
Mohit Khera, Houston, TX, Gerard Henry,
Shreveport, LA
12:10
PD40-11 CONSERVATIVE THERAPY IS A FEASIBLE
AND EFFECTIVE OPTION IN PATIENTS
WITH LOCALIZED INFECTION AFTER
PENILE IMPLANT SURGERY
Mohamad Habous*, Jedda, Saudi Arabia,
Osama Laban, Tabouk, Saudi Arabia, Osama
Abdelwahab, Benha, Egypt, Richard
Santucci, Detroit, MI, Saad Mahmoud, Jedda,
Saudi Arabia, John Mulhall, New York, NY
12:20
PD40-12 COMPARISON OF TWO DIFFERENT
APPROACHES IN CLITORAL
RECONSTRUCTION DURING M TO F SEX
REASSIGNMENT SURGERY
Giovanni Liguori, Trieste, Italy, Paolo Umari*,
Duino-Aurisina, Italy, Nicola Pavan, Michele
Rizzo, Trieste, Italy, Milos Petrovic, Izola,
Slovenia, Stefano Bucci, Giorgio Mazzon,
Giangiacomo Ollandini, Carlo Trombetta,
Trieste, Italy, Emanuele Belgrano, DuinoAurisina, Italy
CREDITTM
PD40-07 THE CARRION CAST: AN UPDATE ON THE
USAGE OF THE INTRACORPORAL
ANTIMICROBIAL DOPED SPACER FOR
THE TREATMENT OF PENILE IMPLANT
INFECTION
Daniel Martinez*, Eihab Alhammali, Tariq
Hakky, Tampa, FL, Paul Perito, Miami, FL,
Justin Parker, Rafael Carrion, Tampa, FL
216
10:30 am - 12:30 pm
Podium Session 41
ABSTRACT
TIME NUMBER TITLE
10:30 PD41-01 TISSUE IS THE ISSUE: THE IMPACT AND
BENEFIT OF PATHOLOGICAL REVIEW
FOR UROTHELIAL CARCINOMA OF THE
BLADDER AT A TERTIARY CARE CANCER
CENTER
Adam Luchey*, Neal Manimala, Shohreh
Dickinson, Jasreman Dhillon, Gautum
Agarwal, Scott Gilbert, Philippe Spiess, Wade
Sexton, Julio Pow-Sang, Michael Poch,
Tampa, FL
10:40
PD41-02 A NEW PROPOSAL FOR T1, HIGH GRADE
(HG) BLADDER CANCER (BCA) MICROSTAGING DEFINITION
Rodolfo Fausto Hurle, Milan, Italy, Carlo
Patriarca, Como, Italy, Luisa Pasini*, Pier
Giuseppe Colombo, Milan, Italy, Giario Natale
Conti, Como, Italy, Massimo Freschi, Fabio
Capogrosso, Marco Moschini, Milan, Italy,
Lucia Ferrari, Como, Italy, Massimo
Maffezzini, Maurizio Colecchia, Tiziana
Magnani, Milan, Italy, Andrea Conti, Como,
Italy, Renzo Colombo, Milan, Italy
10:50
PD41-03 PROGNOSTIC VALUE OF THE PATTERNS
OF PROGRESSION IN T1G3 BLADDER
CANCER ACCORDING TO THE TIMING OF
RECURRENCE
Oscar Rodrı́guez Faba*, Joan Palou, Josep
Maria Gaya, Antonio Rosales, Ruben Parada,
Esteban Emiliani, Humberto Villavicencio,
Barcelona, Spain
11:00
PD41-04 UROTHELIAL BLADDER PTX TUMOURS.
HOW TO PREDICT POSITIVITY OF THE
IMMEDIATE SECOND TUR
Carles Xavier Raventós Busquets*, Ignacio
Arroyo Soto, Carles Gasanz Serrano, Juan
Marı́a Bastarós Hernández, Fernando Lozano
Palacio, Jordi Temprana Salvador, Inés De
Torres Ramı́rez, Miguel Angel López pacios,
Juan Morote Robles, Barcelona, Spain
*Presenting author
ABSTRACT
TIME NUMBER TITLE
11:10 PD41-05 FINAL PATHOLOGIC STAGE AFTER
RADICAL CYSTECTOMY FOR BLADDER
CANCER: DOES PT0 PREDICT BETTER
SURVIVAL THAN PTA/PTIS/PT1?
Homayoun Zargar*, Vancouver, Canada,
Kamran Zargar-Shoshtari, Tampa, FL, Adrian
S Fairey, Los Angeles, CA, Laura S Mertens,
Amsterdam, Netherlands, Colin P Dinney,
Houston, TX, Maria C Mir, Cleveland, OH,
Laura-Maria Krabbe, Dalls, TX, Michael S
Cookson, Oklahoma, OK, Niels-Erik
Jacobsen, Edmonton, Canada, Nilay Gandhi,
Baltimore, MD, Joshua Griffin, Kansas, KS,
Jeffrey S Montgomery, An Arbor, MI, Nikhil
Vasdev, Newcastle upon Tyne, United
Kingdom, Evan Y Yu, Seattle, WA,
Evanguelos Xylinas, New York, NY, Nicholas
J. Campain, Exeter, United Kingdom, Wassim
Kassouf, Montreal, Canada, Marc A. Dall’Era,
Sacramento, CA, Jo-An Seah, Toronto,
Canada, Cesar E Ercole, Cleveland, OH,
Simon Horenblas, Amsterdam, Netherlands,
Srikala S Sridhar, Toronto, Canada, John S
McGrath, Exeter, United Kingdom, Jonathan
Aning, Newcastle upon Tyne, United
Kingdom, Shahrokh F Shariat, Vienna,
Austria, Jonathan L Wright, Seattle, WA,
Andrew C Thorpe, Newcastle upon Tyne,
United Kingdom, Todd M Morgan, An Arbor,
MI, Jeff M Holzbeierlein, Kansas, KS, Trinity
J Bivalacqua, Baltimore, MD, Scott North,
Edmonton, Canada, Daniel A Barocas,
Nashville, TN, Yair Lotan, Dalls, TX, Jorge A
Garcia, Andrew J Stephenson, Cleveland,
OH, Jay B Shah, Houston, TX, Bas W Van
Rhijn, Amsterdam, Netherlands, Siamak
Daneshmand, Los Angeles, CA, Philippe E
Spiess, Tampa, FL, Peter C Black,
Vancouver, Canada
11:20
217
PD41-06 CLINICAL VALUE OF
IMMUNOHISTOCHEMICALLY DETECTED
LYMPHOVASCULAR INVASION IN
TRANSURETHRAL BLADDER TUMOR
RESECTION SPECIMEN FOR BLADDER
CANCER STAGING BEFORE RADICAL
CYSTECTOMY
Tatsuo Gondo*, Jun Nakashima, Rie Inoue,
Takeshi Hashimoto, Yoshio Ohno, Makoto
Ohori, Toshitaka Nagao, Masaaki Tachibana,
Tokyo, Japan
MONDAY
BLADDER CANCER: STAGING
Moderators: Cheryl Lee and Reza Ghavamian
11:30
PD41-07 PROGNOSTIC SIGNIFICANCE OF
LYMPHO-VASCULAR INVASION IN
PATIENTS WITH SQUAMOUS CELL
CARCINOMA IN COMPARISON TO
BLADDER
Kyle Spradling*, Orange, CA, Hassan AbolEnein, Ahmed Mosbah, Mansoura, Egypt,
Zhamshid Okhunov, Jaime Landman,
Orange, CA, Ahmed Shokeir, Mohamed
Ghoneim, Mansoura, Egypt, Ramy Youssef,
Orange, CA
11:40
PD41-08 CAN BLADDER CANCER GENE
EXPRESSION SIGNATURES BE USED TO
PREDICT LYMPH NODE METASTASIS AT
THE TIME OF RADICAL CYSTECTOMY?
Roland Seiler*, Lucia Lam, Nicolas Erho, Elai
Davicioni, Vancouver, Canada, Anirban P
Mitra, Los Angeles, CA, Eila C Skinner,
Stanford, CA, Sia Daneshmand, Los Angeles,
CA, Peter C Black, Vancouver, Canada
11:50
PD41-09 FACTORS DETERMINING LYMPH NODE
YIELD DURING RADICAL CYSTECTOMY
WITH PELVIC LYMPHADENECTOMY
BEFORE AND AFTER IMPLEMENTING
NODE-PACKETING
Anirban P. Mitra*, Los Angeles, CA, Eila C.
Skinner, Stanford, CA, Anne K. Schuckman,
12:00
PD41-10 THE IMPACT OF TUMOR STAGE ON
CANCER SPECIFIC SURVIVAL IN
PATIENTS WITH NODE POSITIVE
UROTHELIAL CANCER OF THE BLADDER
Christopher Welty*, Thomas Sanford, San
Francisco, CA, Jonathan Wright, Seattle, WA,
Peter Carroll, Maxwell Meng, Sima Porten,
San Francisco, CA
12:10
PD41-11 EVALUATION OF A BREAST CANCER
SPECIFIC CIRCULATING TUMOR CELL
(CTC) PLATFORM IN DIFFERENT STAGES
OF BLADDER CANCER REFLECTS A
COMMON MOLECULAR BACKGROUND
Tilman Todenhöfer*, Vancouver, Canada, Jörg
Hennenlotter, Natalie Dorner, Gunthild Beger,
Valentina Gerber, Georgios Gakis, Simone Bier,
Steffen Rausch, Johannes Mischinger, Stefan
Aufderklamm, Tuebingen, Germany, Natalie
Feniuk, Doreen Schellbach, Langenhagen,
Germany, Arnulf Stenzl, Christian Schwentner,
Tuebingen, Germany
12:20
PD41-12 THE DIAGNOSTIC ACCURACY OF 18FFLUORODEOXYGLUCOSE POSITRON
EMISSION TOMOGRAPHY/COMPUTED
TOMOGRAPHY IN STAGING MUSCLEINVASIVE BLADDER CANCER PATIENTS
Ayman Soubra*, Daniel Hayward, Robert
Goldfarb, Philipp Dahm, Jerry Froelich,
Badrinath Konety, Minneapolis, MN
CREDITTM
10:30 am - 12:30 pm
Video Session 10
ROBOTICS – BENIGN DISEASE
Moderators: Joseph Del Pizzo and Ramakrishna Venkatesh
ABSTRACT
NUMBER TITLE
V10-01 INTRAURETERAL INDOCYANINE GREEN
TO FACILITATE ROBOTIC URETEROLYSIS
IN PATIENTS WITH URETERAL
OBSTRUCTION DUE TO
RETROPERITONEAL FIBROSIS
Ziho Lee*, Andrew Harbin, Joshua Kaplan,
Daniel Eun, Philadelphia, PA
V10-02
ABSTRACT
NUMBER TITLE
V10-03 FISTULECTOMY AND FULL THICKNESS
ADVENCEMENT FLAP FOR RECTONEOBLADDER FISTULA
Roberto Ballestero, Marcos Gómez, Sergio
Zubillaga, Truán David, Jose Ignacio Del
Valle, Jose Antonio Portillo, Miguel Correas,
Enrique Ramos, Mario Dominguez, Enrique
Mediavilla, Javier Fuentes, Cesar Jesús
Ballardo, Guillermo Velilla, Jose Luis
Gutiérrez*, Santander, Spain
ROBOT-ASSISTED LAPAROSCOPIC YVPLASTY IN PATIENTS WITH
REFRACTORY BLADDER NECK
CONTRACTURE
Jan Hohenhorst*, Michael Musch, Anne
Pailliart, Heinrich Löwen, Darko Kröpfl,
Essen, Germany
V10-04
218
ROBOTIC PYELOPLASTY USING BARBED
SUTURE: TECHNIQUE, CONTROVERSIES
AND CONSIDERATIONS
Sapan Ambani*, J. Stuart Wolf, Jr., Khurshid
Ghani, Ann Arbor, MI
V10-06
ROBOT ASSISTED BLADDER
AUGMENTATION AND BILATERAL
URETERAL REIMPLANTATION
Antonio Wenceslao Villamil*, David Chavez
Ramos, Carlos Fernando Andrade Becerra,
Matias Ignacio Gonzalez, Oscar Hector
Damia, Gabriel Andres Favre, Juan Carlos
Tejerizo, Buenos aires, Argentina, Erik
Castle, Phoenix, AZ
ROBOTIC AUGMENTED ANASTOMOTIC
URETEROPLASTY WITH BUCCAL
MUCOSA GRAFT INTERPOSITION: A
NOVEL TECHNIQUE FOR THE REPAIR OF
URETERAL STRICTURE
Darren J Bryk*, Yuka Yamaguchi, Sarah A
Mitchell, Michael D Stifelman, Lee C Zhao,
New York, NY
V10-07
STEP-BY-STEP APPROACH FOR ROBOTIC
INTRACORPOREAL CONTINENT
ILEOCECAL AUGMENTATION
CYSTOPLASTY
Samit Soni*, Monty Aghazadeh, Victor Lizarraga,
Rose Khavari, Alvin Goh, Houston, TX
V10-08
ROBOT-ASSISTED ARTIFICIAL URINARY
SPHINCTER IMPLANTATION IN A MALE
FOR NEUROGENIC STRESS URINARY
INCONTINENCE
Cedric Goes*, Anne-Françoise Spinoit,
Nicolaas Lumen, Karel Everaert, Ghent,
Belgium
V10-09
BLADDER NECK SLING IN MALE
EPISPADIAS IN THE PEDIATRIC PATIENT
Patricia Cho*, Ashley Wietsma, Richard Yu,
Marc Cendron, Boston, MA
V10-10
ROBOT-ASSISTED URETEROILEAL
REIMPLANTATION FOR POSTCYSTECTOMY ANASTOMOTIC
STRICTURE
Arie Carneiro, Ostap Dovirak*, Josh Kaplan,
Peter Chang, Andrew A. Wagner, Boston, MA
V10-11
ROBOTIC URETEROLYSIS AND
SKELETONIZATION OF THE RENAL
HILUM FOR SEVERE CASE OF
INTRACTABLE CHYLURIA
Jay Sulek*, Andrew Colhoun, Joseph Habibi,
Lance Hampton, Richmond, VA
V10-12
SINGLE SITE ROBOTIC
URETEROPIELOPLASTY IN AN INVERTED
KIDNEY
Roberto Ballestero, Sergio Zubillaga, Truán
David, Jose Ignacio Del Valle, Jose Antonio
Portillo, Miguel Correas, Enrique Ramos,
Mario Dominguez, Enrique Mediavilla, Javier
Fuentes, Cesar Jesús Carrión, Guillermo
Velilla, Jose Luis Gutiérrez*, Santander,
Spain
V10-13
A NOVEL TECHNIQUE OF ROBOTICASSISTED SIMPLE CYSTECTOMY DURING
ROBOTIC-ASSISTED URINARY
DIVERSION FOR BENIGN INDICATIONS
Granville Lloyd*, Madison, WI
V10-14
ROBOTIC NEPHROLITHOTOMY: VARIOUS
TECHNIQUES FOR EXTRACTION
Matthew Sterling*, Phillip Mucksavage,
Philadelphia, PA
CREDITTM
12:00 pm - 1:30 pm
YOUNG UROLOGISTS FORUM: “THE PRESCRIPTION FOR FINANCIAL HEALTH”
12:00
WELCOME & INTRODUCTIONS
Program Chair: Jennifer Yates
1:15
QUESTION & ANSWER
Ronald Paprocki
12:05
RECOGNITION OF YOUNG UROLOGISTS OF
THE YEAR
Jennifer Yates
1:30
ADJOURN
12:15
PRESENTATION
Ronald Paprocki
12:00 pm - 5:00 pm
RESEARCH ON CALCULUS KINETICS SOCIETY (ROCK)
12:00
INDUSTRY SPONSORED LUNCH SYMPOSIUM
(NON-CME)
1:00
INTRODUCTION
David Goldfarb
*Presenting author
1:05
SESSION 1: UROLOGIC INTERVENTIONS FOR
STONE DISEASE
Moderator: John Denstedt
DEBATE: PCNL FOR THE 2 CM STONE
Glenn Preminger
219
MONDAY
V10-05
3:15
METHODS TO IMPROVE STONE-FREE RATES
WITH URS
Dean Assimos
NEGLECTED METABOLIC VARIABLES ON THE
24H URINE REPORT
John Asplin
3:30
DISCUSSION
3:45
BREAK
1:50
MICRO, MINI, MACRO: WHAT SPEAR TO
CHOOSE FOR PCNL
Ojas Shah
4:00
SESSION 3: CONTROVERSIES IN IMAGING OF
STONES
Moderator: Brian Matlaga
2:00
MANAGEMENT OF STONES IN PREGNANCY
Vernon Pais
2:15
DISCUSSION
2:30
SESSION 2: MEDICAL MANAGEMENT OF
KIDNEY STONES
Moderator: Kristina Penniston
4:15
SMITH-BINDMAN R ET AL IN NEJM: CON: CT
FIRST
Brian Eisner
QUALITY OF CARE FOR PATIENTS WITH
METABOLIC STONE DISEASE
John Hollingsworth
4:30
THEY’RE BOTH WRONG
Mathew Sorensen
4:45
DISCUSSION
5:00
ADJOURN
1:20
DEBATE: URS FOR THE 2 CM STONE
Michael Lipkin
1:35
2:45
DEBATE: GUIDELINES SHOULD BE BASED ON
RANDOMIZED CONTROLLED TRIALS
Margaret Pearle
3:00
DEBATE: GUIDELINES SHOULD BE BASED ON
ALL THE DATA
David Goldfarb
SMITH-BINDMAN R ET AL IN NEJM: PRO U/S
FIRST
Marshall Stoller
CREDITTM
12:15 pm - 5:10 pm
AUA/BRAZILIAN/PORTUGUESE UROLOGY PROGRAM (BPUP)
12:15
Fernando Kim, William Bohnert
12:30
MORE THAN TWO DECADES OF MINIMALLY
INVASIVE SURGERY; DO WE NEED
ROBOTICS?
Louis Kavoussi
12:50
ASSOCIATED ABSTRACT AND Q&A
1:05
WHAT DO WE HAVE AVAILABLE TO TREAT
METASTATIC PROSTATE CANCER?
E. David Crawford
2:50
SUPERFICIAL BLADDER CANCER
TREATMENT: BCG, SURGERY OR
RADIATION?
Sam Chang
3:10
3:25
MANAGEMENT OF UPPER TRACT URINARY
STONE: ESWL VS. URS
Timothy Averch
3:45
4:00
WHAT IS THE OPTIMAL THERAPY FOR
LOWER URINARY TRACT SYMPTOMS WITH
LARGE BPH >100GM?
Wilson Moline
1:25
1:40
USE OF PRE-OPERATIVE ABX IN UROLOGY:
WHEN AND WHICH ONE?
J. Quentin Clemens
4:20
2:00
4:35
2:15
CONTEMPORARY MANAGEMENT OF
HYPERACTIVE BLADDER (BOTULINUM TOXIN,
POSTERIOR TIBIAL NERVE STIMULATION,
ACH MEDS)
John Stoffel
IS IT SAFE TO REPLACE TESTOSTERONE IN
OLDER PATIENTS AND THOSE TREATED FOR
PROSTATE CANCER?
John Mulhall
4:55
5:10
ADJOURN
2:35
CREDITTM
220
12:30 pm - 5:40 pm
RUSSIAN UROLOGY PROGRAM (IRUS)
WELCOME FROM THE IRUS
Lev Elterman
12:35
RUSSIAN UROLOGICAL ASSOCIATION
WELCOME
Dmitry Pushkar
12:40
RECONSTRUCTIVE UROLOGY
Moderator: Alexei Zhivov
2:55
INTRODUCTION OF RUSSIAN ENDOUROLOGY
SOCIETY
Society Chair: Zhamshid Okhunov
CURRENT URETHRAL RECONSTRUCTION
AND SURGICAL OUTCOMES
Jack McAninch
1:00
1:15
1:35
1:55
2:15
2:45
ENDOUROLOGY SOCIETY
TRANSECTING VS NON-TRANSECTING
URETHROPLASTY
Sergey Kotov
3:00
POINT COUNTERPOINT: ROLE OF BIOPSY
MANAGEMENT OF SMALL RENAL MASSES
Debater - Pro: Jaime Landman
Debater - Con: Bradley Leibovich
3:25
BREAK
3:35
UROLOGIC ONCOLOGY
Moderator: Vsevolod Matveev
STATE OF KIDNEY CANCER CARE
Steven Campbell
MALE INCONTINENCE: DIFFICULT
SITUATIONS POST IMPLANTATION
Brian Flynn
3:55
HYPOSPADIAS REPAIR OUTCOMES
Barry Kogan
MINIMALLY INVASIVE INGUINAL
LYMPHADENECTOMY FOR PENILE CANCER
Alejandro Rodriguez
4:10
FEMALE PELVIC FLOOR RECONSTRUCTION
Victor Nitti
PROSTATE CANCER CARE IN RUSSIA
Evgeniy Veliev
4:30
PANEL OF EXPERTS DISCUSSION OF
INTERESTING CASES
OPEN VS. ROBOTIC CYSTECTOMY
Igor Frank
4:50
FOCAL THERAPY FOR PROSTATE CANCER
Rafael Sanchez-Salas
5:10
PANEL OF EXPERTS DISCUSSION OF
INTERESTING CASES
5:40
ADJOURN
BREAK
1:00 pm - 3:00 pm
AUA TOWN HALL 2015: TESTOSTERONE: TOO MUCH OR NOT ENOUGH?
1:00
1:40
PANEL DEBATE: TESTOSTERONE, EXPERT
PANEL TAKES ON QUESTIONS RAISED BY
THE FDA
Moderator: Ajay Nangia
ANDROGEN THERAPEUTICS: ARE YOU AN
EXPERT PROVIDER?
Moderator: Gregory Broderick
THERAPEUTIC OPTIONS AND BEST
PRACTICES IN MANAGEMENT
John Mulhall
TESTOSTERONE IS BEING OVERPRESCRIBED
AND T ADVERTISING IS INAPPROPRIATE
Panelist - Agree: Mark Sigman
Panelist - Disagree: Martin Miner
ERYTHROCYTOSIS COULD THIS BE THE KEY
TO CARDIOVASCULAR RISK
Wayne Hellstrom
AGE DISCRIMINATION OR AGE SPECIFIC
PRECAUTIONS: WILL NEW GUIDELINES FROM
THE FDA PROTECT ELDERLY MALE PATIENTS
OR CONDEMN THEM TO LIVE WITH THE
SYMPTOMS OF HYPOGONADISM
Panelist - Protect: Glenn Cunnigham
Panelist - Condemn: Adrian Dobs
ANABOLIC STEROIDS, A CANDID
CONVERSATION BETWEEN PATIENT AND
PHYSICIAN
Tobias Kohler, Chad Schaive
2:20
TESTOSTERONE INCREASES
CARDIOVASCULAR MORBIDITY
Panelist - Agree: Shehzad Basaria
Panelist - Disagree: Mario Maggi
ANDROGEN TOWN HALL: EXPERT ANSWERS
FOR THE UROLOGIC COMMUNITY
Moderator: Ridwan Shabsigh
Panelists: Mario Maggi, Mark Hirsch, Arthur Burnett,
Mohit Khera, John Mulhall
CREDITTM
*Presenting author
221
MONDAY
12:30
1:00 pm - 3:00 pm
BLADDER CANCER: INVASIVE IV
Moderators: S. Machele Donat and Khurshid Guru
ABSTRACT
NUMBER TITLE
MP67-01 SARCOPENIA AS A PREDICTOR OF
CANCER-SPECIFIC AND OVERALL
SURVIVAL AFTER RADICAL
CYSTECTOMY: IS THERE A GENDER
INFLUENCE?
Ahmed Harraz*, Yasser Osman, Mahmoud
Laymon, Islam Fakhreldin, Osama Mahmoud,
Mona El-Deeb, Ahmed Mosbah, Hassan
Abol-Enein, Atallah Shaaban, Mansoura,
Egypt
ABSTRACT
NUMBER TITLE
MP67-07 NEOADJUVANT CHEMOTHERAPY (NAC)
HAS NO ADVERSE EFFECT ON RADICAL
CYSTECTOMY (RC) OR PERIOPERATIVE
COMPLICATIONS
Mohammed Haseebuddin*, Philadelphia, PA,
Reza Mehrazin, New York, NY, Edouard
Trabulsi, Karthik Devarajan, Yu-Ning Wong,
Jean Hoffman-Censits, Costas Lallas, Rosalia
Viterbo, Alexander Kutikov, Marc Smaldone,
Richard Greenberg, Robert Uzzo, Elizabeth
Plimack, David Chen, Philadelphia, PA
MP67-02 ABCDE: A RISK SCORE FOR PROLONGED
HOSPITALIZATION AMONG PATIENTS
Boris Gershman*, Sarah Psutka, Stephen
Boorjian, Matthew Tollefson, Daniel Moreira,
Prabin Thapa, Robert Tarrell, R. Houston
Thompson, Igor Frank, Rochester, MN
MP67-08 MEDICAL COMORBIDITIES, NOT
NEOADJUVANT CHEMOTHERAPY,
AFFECTS DECLINE IN RENAL FUNCTION
FOLLOWING RADICAL CYSTECTOMY AND
ELIGIBILITY FOR PLATINUM BASED
ADJUVANT CHEMOTHERAPY
Mohammed Haseebuddin*, Daniel Parker,
Zack Piotrowski, Brian Egleston, Nikhil
Wainganker, Rosalia Viterbo, Alexander
Kutikov, Marc Smaldone, Richard Greenberg,
David Chen, Robert Uzzo, Philadelphia, PA
MP67-03 ASSOCIATION OF BODY MASS INDEX
AND REOPERATION FOLLOWING
RADICAL CYSTECTOMY: RESULTS FROM
A MULTI-INSTITUTIONAL DATASET
Sij Hemal*, Louis Krane, Winston-Salem, NC,
Kyle A RIchards, Madison, WI, Michael Liss,
San Antonio, TX, A Karim Kader, San Diego,
CA, Ronald Davis, Winston Salem, NC
MP67-09 PREDICTORS OF WOUND DEHISCENCE IN
A PROSPECTIVE DATASET OF 2,556
CYSTECTOMIES
Christian Meyer*, Julian Hanske, Boston, MA,
Deepansh Dalela, Detroit, MI, Daniel
Pucheril, Boston, MA, Marianne Schmid,
Hamburg, Germany, Jesse Sammon, Mani
Menon, Detroit, MI, Felix Chun, Hamburg,
Germany, Joachim Noldus, Herne, Germany,
Margit Fisch, Hamburg, Germany, Quoc-Dien
Trinh, Boston, MA
MP67-04 IMPACT OF BODY MASS INDEX ON THE
ONCOLOGICAL OUTCOMES OF PATIENTS
TREATED WITH RADICAL CYSTECTOMY
FOR MUSCLE-INVASIVE BLADDER
Yohann Rouscoff*, Nice, France, Yohan Dabi,
Nicolas Barry Delongchamps, Djillali Saighi,
Marc Zerbib, Michael Peyromaure,
Evanguelos Xylinas, Paris, France
MP67-10 INCREASED INFECTIOUS
COMPLICATIONS IN TRANSFUSED
PATIENTS AFTER RADICAL
Jen-Jane Liu*, Bryan Maxwell, Max Kates,
Hiten Patel, Gregory Joice, Nilay Gandhi,
Charles Drake, Steve Frank, Trinity
Bivalacqua, Baltimore, MD
MP67-05 THE IMPACT OF PREOPERATIVE
HYPOALBUMINEMIA ON PERIOPERATIVE
CYSTECTOMY IN 1,262 PATIENTS
Christian Meyer*, Julian Hanske, Boston, MA,
Marianne Schmid, Hamburg, Germany,
Deepansh Dalela, Jesse Sammon, Firas
Abdollah, Mani Menon, Detroit, MI, Joachim
Noldus, Herne, Germany, Margit Fisch, Felix
MP67-11 NUTRITIONAL PREDICTORS OF
PERIOPERATIVE COMPLICATIONS AND
CYSTECTOMY: A POPULATION-BASED
ANALYSIS
Sarah Psutka*, Kristine Thomsen, Elizabeth
Habermann, Matthew Tollefson, Rochester,
MN
MP67-06 POST-OPERATIVE WOUND INFECTIONS
AND STEROID USE ARE INDEPENDENT
RISK FACTORS FOR MIDLINE FASCIAL
DEFECTS IN PATIENTS AFTER RADICAL
CYSTECTOMY WITH ILEAL CONDUIT
Hajar I. Ayoub*, Andrew Pisters, Houston,
TX, Diego Aguilar Palacios, Cuenca,
Ecuador, Wei Wei, Colin P. Dinney, H. Barton
Grossman, Ashish M. Kamat, Jay B. Shah,
O. Lenaine Westney, Houston, TX
MP67-12 THE MODIFIED FRAILTY INDEX AS A
MARKER OF ADVERSE OUTCOMES
DURING CYSTECTOMY FOR UROTHELIAL
CANCER
Max Kates*, Hiten Patel, Gregory Joice,
Jeffrey Tosoian, Nikolai Sopko, Jen-Jane Liu,
Phillip Pierorazio, Trinity Bivalacqua,
Baltimore, MD
222
MP67-14 WHITE BLOOD CELL COUNT AT
DISCHARGE FOLLOWING RADICAL
CYSTECTOMY ASSOCIATES WITH RISK
FOR READMISSION
Philip Abbosh*, Timothy Ito, Jason Mannion,
Andrew McIntosh, Mark Dziemianowicz,
Nikhil Waingankar, Mohammed Haseebuddin,
David Chen, Richard Greenberg, Rosalia
Viterbo, Alexander Kutikov, Robert Uzzo,
Marc Smaldone, Philadelphia, PA
MP67-20 QUALITY OF LIFE ASSESSMENT WITH
ORTHOTOPIC ILEAL NEOBLADDER
RECONSTRUCTION AFTER RADICAL
CYSTECTOMY: RESULTS FROM A
PROSPECTIVE ITALIAN MULTICENTER
OBSERVATIONAL STUDY
Paolo Verze*, Ciro Imbimbo, Vincenzo
Mirone, Naples, Italy, Salvatore Siracusano,
Trieste, Italy, Mauro Niero, Maria Angela
Cerruto, Cristina Lonardi, Walter Artibani,
Verona, Italy, Pierfrancesco Bassi, Rome,
Italy, Massimo Iafrate, Padova, Italy, Marco
Racioppi, Rome, Italy, Renato Talamini,
Stefano Ciciliato, Laura Toffoli, Francesco
Visalli, Trieste, Italy, Davide Massidda,
Carolina D’elia, Giovanni Cacciamani, Davide
De Marchi, Verona, Italy, Tommaso Silvestri,
Trieste, Italy, Massimiliano Creta, Naples,
Italy, Emanuele Belgrano, Trieste, Italy
MP67-15 READMISSION RATE AFTER RADICAL
CYSTECTOMY IN PATIENTS MANAGED
FOLLOWING THE ENHANCED RECOVERY
AFTER SURGERY PROTOCOLS
Emanuela Altobelli*, Stanford, CA, Maurizio
Buscarini, Rome, Italy, Harcharan Gill, Eila
Skinner, Stanford, CA
MP67-16 DETERMINING THE BEST COMPLETE
BLOOD COUNT-BASED BIOMARKER FOR
ONCOLOGIC OUTCOMES FOLLOWING
RADICAL CYSTECTOMY FOR
BLADDER
Bimal Bhindi*, Thomas Hermanns, Yanliang
Wei, Julie Yu, Arnoud Templeton, Aidan
Noon, Jaimin Bhatt, Patrick Richard, Michael
A.S. Jewett, Robert Hamilton, Antonio Finelli,
Neil Fleshner, Alexandre Zlotta, Girish
Kulkarni, Toronto, Canada
CREDITTM
MP67-17 PERIOPERATIVE CHARACTERISTICS OF
ROBOTIC VERSUS OPEN CYSTECTOMY
IN THE ELDERLY POPULATION
Brian Winters*, Prashoban Bremjit, Bruce
Dalkin, Daniel Lin, William Ellis, John Gore,
Michael Porter, Jonathan Harper, Jonathan
Wright, Seattle, WA
MP67-18 A DECADE OF ROBOTIC CYSTECTOMY:
SURGICAL CHARACTERISTICS AND
ONCOLOGIC OUTCOMES
Ali Zhumkhawala*, Spencer Kozinn, Kevin
Chan, Clayton Lau, Nora Ruel, Jonathon
Yamzon, Bertram Yuh, Mark Kawachi,
Timothy Wilson, Duarte, CA
*Presenting author
223
MONDAY
MP67-19 ONCOLOGICAL OUTCOMES OF TOTALLY
INTRACORPOREAL ROBOT-ASSISTED
RADICAL CYSTECTOMY: RESULTS FROM
THE ERUS SCIENTIFIC WORKING GROUP
Justin Collins*, Abolfazl Hosseini, Stockholm,
Sweden, Martin Schumacher, Aarau,
Switzerland, Abdullah Canda, Ankara,
Turkey, Carl Wijburg, Arnhem, Netherlands,
Christian Schwentner, Arnulf Stenzl,
Tubingen, Germany, Derya Balbay, Istanbul,
Turkey, Karel Decaestecker, Ghent, Belgium,
Sebastian Edeling, Saša Pokupic, Hannover,
Germany, Khurshid Guru, Buffalo, NY,
Alexander Mottrie, Aalst, Belgium, Peter
Wiklund, Stockholm, Sweden
MP67-13 GASTROINTESTINAL COMPLICATIONS
USING ENHANCED RECOVERY
PROTOCOL
Siamak Daneshmand*, Soroush T.Bazargani,
Los Angeles, CA, Hamed Ahmadi, Portland,
OR, Gus Miranda, Jie Cai, Anne Schuckman,
Hooman Djaladat, Los Angeles, CA
1:00 pm - 3:00 pm
BLADDER CANCER: BASIC RESEARCH IV
Moderators: Robert Hurst and Shahrokh Shariat
ABSTRACT
NUMBER TITLE
MP68-01 THE LONG NON-CODING RNA HOTAIR
MODULATES EXOSOME CONTENT AND
FUNCTION IN BLADDER CANCER TUMOR
PROGRESSION
Claudia Berrondo*, Jonathan Flax, Edward
Messing, Carla Beckham, Rochester, NY
ABSTRACT
NUMBER TITLE
MP68-06 TISSUE-BASED DNA METHYLATION
PROFILING ESTABLISHES A NOVEL
PANEL OF BIOMARKERS FOR
DISCRIMINATION OF HIGH-GRADE
VERSUS LOW-GRADE BLADDER CANCER
Andrea Savio, Ekaterina Olkhov-Mitsel*, Ken
Kron, Thomas Hermanns, Toronto, Canada,
Bas van Rhijn, Amsterdam, Netherlands,
Alexandre Zlotta, Theodorus van der Kwast,
Bharati Bapat, Toronto, Canada
MP68-02 IMPACT OF 2004 ISUP⫺WHO
CLASSIFICATION ON BLADDER CANCER
GRADING AND POTENTIAL IMPACT ON
TREATMENT
Soum Lokeshwar*, Roberto Ruiz⫺Cordero,
Merce Jorda, Miami, FL, Mark Soloway,
Aventura, FL
MP68-07 THE MEDIATOR COMPLEX SUBUNIT
MED12 IS IMPLICATED IN THE
PROGRESSION OF UROTHELIAL CELL
CARCINOMA OF THE BLADDER
Isabella Syring*, Niklas Klümper, Zaki
Shaikhibrahim, Anne Offermann, Martin
Braun, Mario Deng, Diana Böhm, Angela
Queisser, Anne von Mäßenhausen, Jörg
Ellinger, Stefan C. Müller, Sven Perner,
Bonn, Germany
MP68-03 CANCER STEM-LIKE CELLS AND
EPITHELIAL MESENCHYMAL TRANSITION
IS RESPONSIBLE FOR FAILURE IN
BACILLUS CALMETTE-GUERIN THERAPY
FOR PRIMARY CARCINOMA IN SITU
Masaomi Kuwada*, Yoshitomo Chihara,
Makito Miyake, Satoshi Anai, Nobumichi
Tanaka, Hiroki Kuniyasu, Kiyohide Fujimoto,
Kashihara, Japan
MP68-08 CONNEXIN 43 EXPRESSION PREDICTS
POOR PROGRESSION-FREE SURVIVAL IN
PATIENTS WITH NON-MUSCLE INVASIVE
Cédric Poyet*, Lorenz Buser, Filip Roudnicky,
Michael Detmar, Thomas Hermanns, Doris
Mannhard, Tullio Sulser, Holger Moch, Peter
Wild, Zürich, Switzerland
MP68-04 A FIVE⫺GENE DNA⫺METHYLATION
BIOMARKER PANEL SENSITIVELY
DETECTS BLADDER CANCER AND
DISCRIMINATES BETWEEN HIGH⫺GRADE
AND LOW⫺GRADE DISEASE IN VOIDED
URINE
Thomas Hermanns*, Ekaterina Olkhov-Mitsel,
Andrea Savio, Bethany Gill, Jenna Sykes,
Bimal Bhindi, Tristan Juvet, Cynthia Kuk,
Aidan Noon, Toronto, Canada, Ricardo
Rendon, Halifax, Canada, David Waltregny,
Liege, Belgium, Theodorus H van der Kwast,
Antonio Finelli, Neil E Fleshner, Kirk Lo,
Bharati Bapat, Alexandre R Zlotta, Toronto,
Canada
MP68-09 INSULIN RECEPTOR IS OVEREXPRESSED
IN TUMOR BLOOD VESSELS AND
PREDICTS WORSE OUTCOME IN
BLADDER CANCER
Cédric Poyet*, Filip Roudnicky, Peter Wild,
Lothar Dieterich, Lorenz Buser, Chien Ho,
Tullio Sulser, Vivianne Otto, Michael Detmar,
Zürich, Switzerland
MP68-10 EXPRESSION OF TFAP2C IS ASSOCIATED
WITH THE BASAL MOLECULAR SUBTYPE
OF BLADDER CANCER AND INCREASED
TUMOR AGGRESSIVENESS
Hironobu Yamashita*, Zongyu Zheng, Vasty
Osei Amponsa, Jay Raman, David DeGraff,
Hershey, PA
MP68-05 RESOLVING INTER-PATHOLOGIST
VARIATION IN THE ASSIGNMENT OF
GRADE USING WHOLE TRANSCRIPTOME
ANALYSIS FOR PATIENTS WITH
Aidan Noon*, Yu Liu, Jess Shen, Cynthia
Kuk, Thomas Hermanns, Azar Azad, Joan
Sweet, Toronto, Canada, Eva Comperat,
Paris, France, Theodorus H van der Kwast,
Toronto, Canada, James WF Catto, Sheffield,
United Kingdom, Alexandre R Zlotta, Jeffrey
L Wrana, Toronto, Canada
MP68-11 A PHASE 1B STUDY OF PEMBROLIZUMAB
(PEMBRO; MK-3475) FOR ADVANCED
UROTHELIAL CANCER
Shilpa Gupta*, Tampa, FL, Peter O’Donnell,
Chicago, IL, Elizabeth R. Plimack,
Philadelphia, PA, Ranaan Berger, Tel
Hashomer, Israel, Bruce Montgomery,
Seattle, WA, Karl Heath, Marisa DolledFilhart, Kumudu Pathiraja, Christine K.
Gause, Jonathan Cheng, Rodolfo Perini,
Whitehouse Station, NJ, Joaquim Bellmunt,
Boston, MA
224
MP68-17 NOVEL INTRAVESICAL THERAPIES
IDENTIFIED FROM HIGH THROUGHPUT
SCREENING
Keidren Lewi*, Achuth Nair, Reema Railkar,
Sam Brancato, Iawen Hsu, Quentin Li,
Bethesda, MD, Xiaohu Zhang, Rajarshi Guha,
Rockville, MD, Andrea Apolo, Bethesda, MD,
Dan Theodorescu, Denver, CO, Craig
Thomas, Marc Ferrer, Rockville, MD, Piyush
Agarwal, Bethesda, MD
MP68-12 UTILIZING DNA METHYLATION MARKERS
TO PREDICT BLADDER CANCER STAGE
Chris Duymich, Leonard Dalag, Hooman
Djaladat*, Sameer Chopra, Kamran
Movassaghi, Siamak Daneshmand, Peter
Jones, Gangning Liang, Los Angeles, CA
MP68-13 ESTROGEN RECEPTOR ALPHA
PREVENTS BLADDER CANCER VIA
INPP4B INHIBITED AKT PATHWAY IN
VITRO AND IN VIVO
Chiuan-Ren Yeh*, Iawen Hsu, Rochester,
NY, Hiroshi Miyamoto, Baltimore, MD, XueRu Wu, New York, NY, Chawnshang Chang,
Elizabeth Guancial, Edward M. Messing,
Shuyuan Yeh, Rochester, NY
MP68-14 EXTRACELLULAR VESICLES AS
BIOMARKERS AND DIAGNOSTICS IN
BLADDER CANCER
Christopher Silvers, Chia-Hao Wu, Peng-Nien
Yin, Yu-Ru Liu, Edward Messing, Yi-Fen
Lee*, Rochester, NY
MP68-19 FACTORS ASSOCIATED WITH SURGICAL
SITE INFECTIONS FOLLOWING RADICAL
CYSTECTOMY
Ehab Elzayat*, Ilias Cagiannos, Luke T.
Lavallée, Sonya Cnossen, Ranjeeta Mallick,
Christopher Morash, Rodney H. Breau,
Ottawa, Canada
MP68-15 LYMPH NODE STROMAL CELLS
PROMOTE HIGH GRADE UROTHELIAL
CELL CARCINOMA CANCER
IMPLANTATION, GROWTH,
ANGIOGENESIS, AND METASTASIS IN AN
ORTHOTOPIC PATIENT-DERIVED
XENOGRAFT MODEL
Jessie Gills*, John Nelson, Xin Zhang, New
Orleans, LA, Grace Manesh, Brisbane,
Australia, Shams Halat, New Orleans, LA,
Ashley Richman, Brisbane, Australia, Mark
Matrana, Stephen Bardot, Li Li, New Orleans,
LA
MP68-20 EXPRESSION OF PDL1 (B7-H1) BEFORE
AND AFTER NEOADJUVANT
CHEMOTHERAPY IN UROTHELIAL
CARCINOMA
Ajjai Alva, Andrew McDaniel, Tianyu Zhan,
Hong Xiao, Arul Chinnaiyan, Hui Jiang,
Cheryl Lee*, Rohit Mehra, Ann Arbor, MI
CREDITTM
MP68-16 ASSOCIATION OF GENETIC VARIANTS
WITH THE OCCURRENCE OF BLADDER
CANCER IN AN ARSENIC-EXPOSED
POPULATION
Mario I Fernandez*, Cecilia Vial, Santiago,
Chile, Patricio Valdebenito, Eduardo
Chaparro, Antofagasta, Chile, Karena
Espinoza, Gabriela Repetto, Santiago, Chile
1:00 pm - 3:00 pm
KIDNEY CANCER: ADVANCED II
Moderator: Nathan Lawrentschuk
ABSTRACT
NUMBER TITLE
MP69-01 NANOTECHNOLOGY COMBINATION
THERAPY: SORAFENIB BOUND GOLD
NANORODS PRODUCES HIGHER
TREATMENT RESPONSE WHEN
COMBINED WITH LASER THERMAL
ABLATION IN A RENAL CELL
CARCINOMA ANIMAL MODEL
Cameron Callaghan*, Sree Harsha Mandava,
Donna Peralta, New Orleans, LA, Mostafa
Bouljihad, Covington, LA, Srikanta Dash,
James Liu, Matthew A. Tarr, Micheal
Maddox, Benjamin Lee, New Orleans, LA
*Presenting author
ABSTRACT
NUMBER TITLE
MP69-02 SURVIVAL COMPARISON ANALYSIS OF
TWO HISTORICAL COHORTS OF
PATIENTS (CYTOKINE THERAPY VS.
TARGETED AGENTS) - A EUROPEAN
SINGLE-CENTER EXPERIENCE OVER 26
YEARS
Georg C. Hutterer*, Silvia Golbeck, Edvin
Mrsic, Daniel Krieger, Angelika Bezan,
Johanna Jesche, Karl Pummer, Richard
Zigeuner, Martin Pichler, Graz, Austria
225
MONDAY
MP68-18 MOLECULAR ANALYSIS OF UROTHELIAL
TUMORS IN PATIENTS WITH AND
WITHOUT METASTASIS STRATIFIED BY T
STAGE
Tom Sanford*, Christopher Welty, Max Meng,
Sima Porten, San Francisco, CA
MP69-10 ASSESSMENT OF EFFICACY, SAFETY
AND QUALITY OF LIFE OF 110 PATIENTS
TREATED WITH SUNITINIB AS FIRST-LINE
THERAPY FOR METASTATIC RENAL CELL
CARCINOMA: EXPERIENCE IN REAL
WORLD CLINICAL PRACTICE IN JAPAN
Ken-ichi Harada, Hideaki Miyake*, Masato
MP69-03 CLINICAL OUTCOME OF SINGLE
NUCLEOTIDE POLYMORPHISMS ON
PHARMACOKINETIC GENES IN
JAPANESE METASTATIC RENAL CELL
CARCINOMA PATIENTS TREATED WITH
SUNITINIB
Kazuyuki Numakura*, Norihiko Tsuchiya,
Makoto Takahashi, Hiroshi Tsuruta, Susumu
Akihama, Mitsuru Saito, Tkamitsu Inoue,
Shintaro Narita, Mingguo Huang, Shigeru
Satoh, Tomonori Habuchi, Akita, Japan
MP69-11 CARBONIC ANHYDRASE IX ASSAY: A
PARADIGM SHIFT IN DIAGNOSIS OF
MALIGNANT CYSTIC RENAL LESIONS
Himesh Gandhi*, Appu Thomas, Balagopal T
Nair, Vinoth Kumar Lakshmanan, Kochi, India
MP69-04 NUTRITIONAL SCREENING IS STRONGLY
ASSOCIATED WITH OVERALL SURVIVAL
IN PATIENTS TREATED WITH TARGETED
AGENTS FOR ADVANCED RENAL CELL
CARCINOMA
Gu Weijie*, Zhu Yao, Ye Dingwei, Shanghai,
MP69-12 THE ASSOCIATION OF STATIN THERAPY
WITH CLINICOPATHOLOGIC OUTCOMES
AND SURVIVAL AMONG PATIENTS WITH
LOCALIZED RENAL CELL CARCINOMA
UNDERGOING NEPHRECTOMY
Boyd Viers*, R. Houston Thompson, Sarah
Psutka, Christine Lohse, Bradley Leibovich,
Matthew Tollefson, Stephen Boorjian,
Rochester, MN
MP69-05 EVALUATION OF POST-OPERATIVE
COMPLICATIONS AND PROLONGED
LENGTH OF STAY FOLLOWING
CYTOREDUCTIVE NEPHRECTOMY
Boris Gershman*, Daniel Moreira, Stephen
Boorjian, Christine Lohse, John Cheville,
Brian Costello, Bradley Leibovich, R. Houston
Thompson, Rochester, MN
MP69-13 IMPACT OF METASTASECTOMY ON
PROGNOSIS IN PATIENTS WITH
IN THE TARGETED THERAPY ERA
Dalsan You*, Chunwoo Lee, In Gab Jeong,
Sang Hoon Song, Kun Suk Kim, Cheryn
Song, Jae-Lyun Lee, Bumsik Hong, Hanjong
Ahn, Choung-Soo Kim, Seoul, Korea,
Republic of
MP69-06 HIGH GLASGOW PROGNOSTIC SCORE:
POTENTIAL MARKER TO PREDICT
TARGET RESISTANCE IN METASTATIC
TREATED WITH SUNITINIB
guohai shi*, Shanghai, China, People’s
Republic of
MP69-14 PERIOPERATIVE AND RENAL
FUNCTIONAL OUTCOMES OF PARTIAL
NEPHRECTOMY FOR COMPLEX RENAL
SCORE WITH OR WITHOUT PRESURGICAL SUNITINIB: A MULTICENTER
ANALYSIS
Hak Lee*, San Diego, CA, Juan Jimenez,
Cleveland, OH, Song Wang, Omer Raheem,
Kyle Gillis, Amy Alagh, Christopher J. Kane,
San Diego, CA, Michael LIss, San Antonio,
TX, Frederick Millard, San Diego, CA, Brian
Lane, Grand Rapids, MI, Steven Campbell,
Cleveland, OH, Ithaar Derweesh, San Diego,
CA
MP69-07 IMPACT OF TARGETED AGENTS ON
RENAL FUNCTION IN PATIENTS WITH
METASTATIC RCC
Yuta Kojima*, Jotaro Mikami, Shingo
Hatakeyama, Hayato Yamamoto, Atsushi
Imai, Takahiro Yoneyama, Yashuhiro
Hirosaki, Japan
MP69-08 SYSTEMATIC REVIEW AND METAANALYSIS OF TARGETED THERAPY FOR
OVERALL SURVIVAL, COMPLETE
RESPONSE AND QUALITY OF LIFE FOR
Yong Han, New Haven, CT, Ashley
Wietsma*, Baltimore, MD, Cary Gross, New
Haven, CT, Nilay Shah, Rochester, MN,
Robert Abouassaly, Cleveland, OH, Marc
Smaldone, Philadelphia, PA, Stephen
Boorjian, Rochester, MN, Christopher
Hoimes, Matthew Cooney, Simon Kim,
Cleveland, OH
MP69-15 SUNITINIB PRIOR TO CYTOREDUCTIVE
NEPHRECTOMY IN METASTATIC CLEAR
CELL CARCINOMA
Nima Baradaran*, Harry Drabkin, Stephen
Savage, Charleston, SC
MP69-16 ASSOCIATION BETWEEN PLASMA
CONCENTRATION OF AXITINIB AND
TREATMENT OUTCOME IN ADVANCED
Norihiko Tsuchiya*, Nobuhiro Fujiyama,
Ryoma Igarashi, Naoko Honma, Shintaro
Narita, Takamitsu Inoue, Kazuyuki Numakura,
Susumu Akihama, Mitsuru Saito, Shigeru
Satoh, Masatomo Miura, Tomonori Habuchi,
Akita, Japan
MP69-09 THE CLINICAL BENEFIT OF
METASTASECTOMY IN METASTATIC
RENAL CELL CARCINOMA IN THE ERA OF
TARGETED MOLECULAR THERAPY
Hironori Fukuda*, Tsunenori Kondo, Kenji
Omae, Toshio Takagi, Junpei Iizuka,
Kazunari Tanabe, Tokyo, Japan
226
MP69-18 GENETIC CHARACTERIZATION OF
LACKING PRIMARY RENAL MASS
Elizabeth Y. Wei*, Yingbei Chen, James J.
Hsieh, New York, NY
MP69-20 INTENSIVE LOCAL THERAPY TO BONE
LESIONS MAY IMPROVE SURVIVAL IN
WITH BONE METASTASIS
Hiroshi Fukushima*, Fumitaka Koga,
Yasukazu Nakanishi, Kenichi Tobisu, Tokyo,
Japan
CREDITTM
1:00 pm - 3:00 pm
KIDNEY CANCER: SURGICAL THERAPY V
Moderators: Riccardo Autorino and Karim Touijer
ABSTRACT
NUMBER TITLE
MP70-01 EXTIRPATIVE TREATMENT OF UPPER
CARCINOMA: A 15-YEAR
COMPREHENSIVE REVIEW
Lynn Paik*, Michael Grasso, Bobby
Alexander, Andrew Fishman, New York, NY
ABSTRACT
NUMBER TITLE
MP70-03 POSITIVE SURGICAL MARGINS ARE
ASSOCIATED WITH INCREASED RISK OF
RECURRENCE AFTER PARTIAL
NEPHRECTOMY FOR LOCALIZED RENAL
TUMORS
Daniel Moreira, Paras Shah*, Manaf Alom,
New Hyde Park, NY, Zhamshid Okhunov,
Irvine, CA, Sameer Chopra, Los Angeles, CA,
Aria Razmaria, Chicago, IL, Arvin George,
Christopher Hartman, Oksana Yaskiv, New
Hyde Park, NY, Mihir Desai, Los Angeles,
CA, Joph Steckel, Manish Vira, Lee
Richstone, New Hyde Park, NY, Jaime
Landman, Irvine, CA, Arieh Shalhav,
Chicago, IL, Inderbir Gill, Los Angeles, CA,
Louis Kavoussi, New Hyde Park, NY
MP70-02 CATABOLIC EFFECTS OF SURGICAL
APPROACHES MEASURED BY WEIGHT
CHANGE IN PATIENTS UNDERGOING
PARTIAL NEPHRECTOMY
Homayoun Zargar*, Cleveland, BC, Oktay
Akca, Hiury Andrade, Peter C Caputo, Daniel
Ramirez, Robert J Stein, Khaled Fareed,
Jihad H. Kaouk, Cleveland, OH
MP70-04 ASSOCIATION OF MODIFIABLE AND NONMODIFIABLE RISK FACTORS WITH
PERINEPHRIC ADIPOSE TISSUE:
IMPLICATIONS FOR PARTIAL
NEPHRECTOMY
Ronak Gor*, Robert Uzzo, Tianyu Li, Timothy
Ito, Philip Abbosh, Daniel Canter, Justin
Friedlander, Jay Simhan, Steven Sterious,
David Chen, Rosalia Viterbo, Richard
Greenberg, Marc Smaldone, Alexander
Kutikov, Serge Ginzburg, Philadelphia, PA
*Presenting author
227
MONDAY
MP69-19 EXTENDED ANALYSES OF PHASE II
CLINICAL TRIAL OF SORAFENIB PLUS
INTERFERON-ALPHA TREATMENT FOR
PATIENTS WITH METASTATIC RENAL
CELL CARCINOMA IN JAPAN
Masatoshi Eto*, Yoshiaki Kawano,
Kumamoto, Japan, Yoshihiko Hirao, Nara,
Japan, Koji Mita, Hiroshima, Japan, Yoichi
Arai, Sendai, Japan, Taiji Tsukamoto,
Sapporo, Japan, Katsuyoshi Hashine,
Matsuyama, Japan, Akio Matsubara,
Hiroshima, Japan, Tomoaki Fujioka, Morioka,
Japan, Go Kimura, Tokyo, Japan, Nobuo
Shinohara, Sapporo, Japan, Katsunori
Tatsugami, Fukuoka, Japan, Shiro Hinotsu,
Kyoto, Japan, Seiji Naito, Fukuoka, Japan
MP69-17 THE RELATIONSHIP BETWEEN THE
TIMING OF MAXIMUM TUMOR
SHRINKAGE DURING 1ST-LINE
TARGETED THERAPY AND OVERALL
SURVIVAL OF PATIENTS WITH
Takafumi Yagisawa*, Tsunenori Kondo,
Kazuhiko Yoshida, Kenji Omae, Toshio
Takagi, Junpei Iizuka, Hirohito Kobayashi,
Yasunobu Hashimoto, Kazunari Tanabe,
Tokyo, Japan
MP70-12 IS CONCOMITANT HEPATIC RESECTION
FOR LOCALLY ADVANCED OR
AT THE TIME OF NEPHRECTOMY SAFE?
A MATCHED COHORT STUDY
Sarah Psutka*, R. Houston Thompson,
Stephen Boorjian, John Cheville, Suzanne
Stewart, Christine Lohse, Brian Costello,
Florencia Que, Bradley Leibovich, Rochester,
MN
MP70-05 PREDICTORS OF OPEN CONVERSION
DURING MINIMALLY INVASIVE RENAL
SURGERY IN ENGLAND
Rajesh Nair*, Robert Gray, Christopher J
Anderson, Sarah Fowler, Tim S O’Brien,
Pieter J Le Roux, London, United Kingdom
MP70-06 BLOOD TRANSFUSION AND TIMING
INVASIVE NEPHRECTOMY
Ruben Pinkhasov*, Ariel Schulman, Zuhair
Alhussaini, Mark Cogburn, Ciril Godec, David
Silver, Brooklyn, NY
MP70-13 OPEN PARTIAL NEPHRECTOMY: ONE
NIGHT LENGTH OF STAY IS SAFE AND
COST EFFECTIVE
Mohit Sirohi*, Kyrollis Attalla, Harris Nagler,
Erik Goluboff, New York, NY
MP70-07 NATIONAL PRACTICE PATTERNS AND
OUTCOMES OF ABLATIVE TECHNIQUES
USED TO TREAT PATIENTS WITH STAGE
I KIDNEY CANCER
Hung-Jui Tan*, Andrew T. Lenis, Aaron A.
Laviana, Jim C. Hu, Los Angeles, CA
MP70-14 THE ONCOLOGIC IMPACT OF POSITIVE
VASCULAR WALL SURGICAL MARGINS IN
PATIENTS WITH RENAL CELL
CARCINOMA AND VENOUS TUMOR
THROMBUS UNDERGOING
NEPHRECTOMY
Stephen Boorjian, Christine Lohse, Suzanne
Stewart, Alonso Carrasco, John Cheville,
Bradley Leibovich, Rochester, MN
MP70-08 PARTIAL NEPHRECTOMY FOR T2 RENAL
MASSES: NATIONAL TRENDS AND
ONCOLOGIC EFFICACY
Shaheen Alanee, Max Nutt*, Aaron Moore,
Bradley Holland, Danuta Dynda, Andy Wilber,
Wiley Jenkins, Ahmed El-Zawahry, Bradley
Schwartz, Springfield, IL
MP70-15 INCREASING COMPLEXITY OF TUMOR
THROMBI IN RENAL CELL CARCINOMA
OVER 40 YEARS OF EXPERIENCE
Stephen Boorjian, Christine Lohse, Suzanne
Stewart, John Cheville, Bradley Leibovich,
Rochester, MN
MP70-09 GUIDELINE-ADAPTED USE OF NEPHRONSPARING SURGERY FOR RENAL CELL
CARCINOMA - A CONFIRMATORY TREND
ANALYSIS OVER THE LAST DECADE IN
TWO EUROPEAN REFERRAL CENTERS
Christian Meyer*, Boston, MA, Jens Hansen,
Andreas Becker, Marianne Schmid, Hamburg,
Germany, Quoc-Dien Trinh, Boston, MA,
Thomas Chromecki, Manuela-Christine Kainz,
Georg Hutterer, Karin Kampel-Kettner,
Johanne Jesche, Graz, Austria, Margit Fisch,
Hamburg, Germany, Richard Zigeumer, Graz,
Austria, Chun Felix, Hamburg, Germany
MP70-16 COMPLICATIONS AFTER ROBOTICASSISTED PARTIAL NEPHRECTOMY AT 5
UNITED STATES CENTERS: ANALYSIS OF
1838 CASES
Jeffrey Larson*, Saint Louis, MO, Jihad
Kaouk, Cleveland, OH, Craig Rogers, Detroit,
MI, Michael Stifelman, New York, NY,
Mohamad Allaf, Michael Johnson, Baltimore,
MD, Homayoun Zargar, Cleveland, OH, Alon
Mass, New York, NY, Ravi Barod, Detroit, MI,
Sam Bhayani, St. Louis, MO
MP70-10 ROBOTIC MULTIPLEX PARTIAL
NEPHRECTOMY: COMPARISON OF
RENAL FUNCTION OUTCOMES
STRATIFIED BY CHRONIC KIDNEY
DISEASE STAGE
Ryan Hankins*, Washington, DC, Annerleim
Walton-Diaz, Adam Metwalli, Bethesda, MD
MP70-17 TUMOR SIZE PREDICTS HIGH-GRADE
PATHOLOGY IN PT1A RENAL CELL
CANCER
MP70-11 RADIOGRAPHIC PREDICTORS OF THE
NEED FOR INFERIOR VENA CAVAL
RESECTION DURING NEPHRECTOMY FOR
PATIENTS WITH RENAL CELL
CARCINOMA AND VENOUS TUMOR
THROMBUS
Sarah Psutka*, Stephen Boorjian, R. Houston
Thompson, Grant Schmit, John Schmitz,
Thomas Bower, Suzanne Stewart, Christine
Lohse, John Cheville, Bradley Leibovich,
Rochester, MN
MP70-18 RACIAL DIFFERENCES IN HISTOLOGIC
SUBTYPE OF RENAL CELL CARCINOMA
IN PT1A RENAL CELL CANCER
228
MP70-20 RENAL LESIONS IN THE 80 AND OVER
AGE GROUP - TARGETED TREATMENT
AND OUTCOMES BY POOLED AND
SIGNATURED APPROACH IN A U.K.
TERTIARY REFERRAL RENAL CANCER
CENTER
Sashi Kommu*, Prasanna Sooriakumaran,
Robert Mcarthur, Rajesh Nair, Meghana
Kulkarni, Eleni Anastasiadis, A Pai, Pieter le
Roux, Christopher Anderson, London, United
Kingdom
MP70-19 CRITICAL COMPARISON OF
PERIOPERATIVE, HEMOSTATIC AND
FUNCTIONAL OUTCOMES OF TWO
RUNNING TECHNIQUES OF
RECONSTRUCTIVE RENORRHAPHY IN
MINIMAL INVASIVE NEPHRON SPARING
SURGERY
Alaa Hamada*, Abdulrahman Babaeer, Kelly
Dragon, Boston, MA, Akshay Bhandari, Miami
Beach, MA, Ingolf Tuerk, Boston, MA
CREDITTM
1:00 pm - 3:00 pm
STONE DISEASE: NEW TECHNOLOGY
Moderator: Darren Beiko
TIME
1:00
1:10
1:20
1:30
1:40
ABSTRACT
NUMBER TITLE
PD42-01 REPORT ON THE FEASIBILITY OF
ULTRASOUND TO REPOSITION KIDNEY
STONES IN HUMANS
Jonathan Harper*, Barbrina Dunmire, Bryan
Cunitz, Franklin Lee, Ryan Hsi, Jeff Thiel,
Seattle, WA, James Lingeman, Indianapolis,
IN, Michael Coburn, Houston, TX, Hunter
Wessells, Mathew Sorensen, Michael Bailey,
Seattle, WA
ABSTRACT
TIME NUMBER TITLE
1:50
PD42-06 BALL TIPPED HOLMIUM:YAG OPTICAL
FIBERS FOR FLEXIBLE URETEROSCOPY:
IS THERE A DIFFERENCE?
Sarah Tarplin*, Cleveland, OH, Nolan Farrell,
Columbus, OH, Manoj Monga, Cleveland,
OH, Bodo Knudsen, Columbus, OH
PD42-02 A PRECLINICAL IMAGE-GUIDED
THERAPY SYSTEM FOR BURST WAVE
LITHOTRIPSY
Adam Maxwell*, Bryan Cunitz, Wayne
Kreider, Michael Bailey, Oleg Sapozhnikov,
Franklin Lee, Mathew Sorensen, Jonathan
Harper, Seattle, WA
PD42-03 ROBUST AUTOMATIC RENAL STONE
DETECTION IN ULTRASONIC LIVE
STREAMS FOR IMPROVING
EXTRACORPOREAL SHOCK WAVE
THERAPY
Werner Pomwenger*, Peter Ott, Stefan
Wegenkittl, Reinhold Zimmermann, Salzburg,
Austria, Olaf Gleibe, Axel Koch, Tägerwilen,
Switzerland
PD42-04 INITIAL EXPERIENCE AND COMPARATIVE
EFFICACY OF THE URETRON: A NEW
INTRACORPOREAL ULTRASONIC
LITHOTRIPTOR
Michael S. Borofsky*, Marawan M. El Tayeb,
James E. Lingeman, Indianapolis, IN
PD42-05 LONG-PULSE VERSUS SHORT-PULSE
LASER LITHOTRIPSY PERFORMANCE
*Presenting author
229
2:00
PD42-07 THE EFFECT OF CLEAVE TECHNIQUE
AND LITHOTRIPSY DURATION ON LASER
FIBER POWER OUTPUT
Brandon Peplinski*, Daniel Faaborg, Edna
Miao, Muhannad Alsyouf, Kristene Myklak, D.
Duane Baldwin, Loma Linda, CA
2:10
PD42-08 COMPARISION OF LOW POWER/HIGH
FREQUENCY HOLMIUM LASER SETTINGS
WITH CONVENTIONAL SETTINGS ON
URETERAL AND RENAL STONE
FRAGMENTATION EFFICIENCY
Leonard Glickman*, Ravi Munver,
Hackensack, NJ
2:20
PD42-09 ENDOSCOPIC VALVES AND IRRIGATION
DEVICES: A COMPARATIVE ANALYSIS
Sarah Tarplin*, Michael Byrne, Manoj Monga,
Sri Sivalingam, Cleveland, OH
2:30
PD42-10 A SMART KIDNEY STONE BASKET WITH
FORCE FEEDBACK
Zahra Najafi, Akron, OH, Thomas Tieu,
Springfield, IL, Ajay M. Mahajan, Akron, OH,
Bradley F. Schwartz*, Springfield, IL
2:40
PD42-11 A MECHANICAL COMPARISON OF NEW
URETERAL ACCESS SHEATHS: TERUMO
GLIDEWAY VS. BOSTON SCIENTIFIC
NAVIGATOR HD
Sarah Tarplin*, Cleveland, OH, Nolan Farrell,
Columbus, OH, Michael Byrne, Manoj Monga,
Cleveland, OH
MONDAY
Podium Session 42
2:50
CREDITTM
PD42-12 A URETERAL ACCESS SHEATH MODIFIED
WITH A SCALE REDUCING RADIATION
FLUOROSCOPY DURING RETROGRADE
INTRARENAL SURGERY: A RANDOMIZED
AND FEASIBILITY TRIAL
Guohua Zeng*, Zhijian Zhao, Wenqi Wu, Wen
Zhong, Guangzhou, China, People’s Republic of
1:00 pm - 3:00 pm
Podium Session 43
PROSTATE CANCER: LOCALIZED VI
Moderators: Vipul Patel and Craig Rogers
TIME
1:00
1:10
1:20
1:30
1:40
1:50
ABSTRACT
NUMBER TITLE
PD43-01 LONG-TERM COMPARATIVE MORTALITY
OUTCOMES ACROSS DIFFERENT
PRIMARY TREATMENTS FOR PROSTATE
CANCER
Matthew Cooperberg*, Peter Carroll, San
Francisco, CA
ABSTRACT
TIME NUMBER TITLE
2:00
PD43-07 URINARY DRAINAGE FOLLOWING
PROSTATECTOMY: A PROSPECTIVE
RANDOMIZED CLINICAL TRIAL
COMPARING TRANSURETHRAL VS.
SUPRAPUBIC CATHETERIZATION
Nina Harke*, Michael Godes, Jawid
Habibzada, Katarina Urbanova, Henrik
Zecha, Jorn H. Witt, Gronau, Germany
PD43-02 COMPARATIVE EFFECTIVENESS OF
SURGERY AND RADIATION THERAPY
FOR HIGH RISK PROSTATE CANCER
PATIENTS
Ravishankar Jayadevappa*, Sumedha
Chhatre, Alan Wein, S Bruce Malkowicz,
David Lee, Philadelphia, PA
PD43-03 COMPARATIVE ANALYSIS OF
ONCOLOGIC OUTCOMES FOR OPEN VS.
PROSTATECTOMY IN HIGH-RISK
PROSTATE CANCER: PREDICTION OF
FAVORABLE DISEASE AFTER RADICAL
PROSTATECTOMY
Seung-Kwon Choi*, Myungsun Shim, Aram
Kim, Muyoung Sohn, Donghyun Lee,
Myungchan Park, Cheryn Song, Hanjong
Ahn, Seoul, Korea, Republic of
PD43-04 COMPARING THE 8-YEAR ONCOLOGIC
OUTCOMES OF OPEN AND ROBOTASSISTED RADICAL PROSTATECTOMY
FOR HIGH RISK PROSTATE CANCER
Vidit Sharma*, Marco Moschini, Fabio Zattoni,
Matthew K Tollefson, Stephen A Boorjian, R.
Houston Thompson, Igor Frank, Matthew T
Gettman, R. Jeffrey Karnes, Rochester, MN
PD43-05 ARE LYMPH NODE DISSECTIONS BEING
PERFORMED IN PATIENTS WITH BIOPSY
PROVEN GLEASON 6 DISEASE –
ANALYSIS OF THE SEER DATABASE
Michael Daugherty*, Gennady Bratslavsky,
Oleg Shapiro, Syracuse, NY
PD43-06 EXTENDED VS LIMITED PELVIC
LYMPHADENECTOMY DURING RADICAL
PROSTATECTOMY FOR INTERMEDIATEAND HIGH-RISK PROSTATE CANCER: A
PROSPECTIVE RANDOMIZED TRIAL
Jean F P Lestingi*, Jose Pontes Jr, Leonardo
L Borges, Juliana Ravanini, Giuliano B
Guglielmetti, Mauricio D Cordeiro, Rafael F
Coelho, William C Nahas, Sao Paulo, Brazil
2:10
PD43-08 THE EFFECT OF PRIOR TURP ON
COMPLICATIONS AND LONG-TERM
PROSTATECTOMY: A 25-YEAR SINGLE
INSTITUTION EXPERIENCE
Vidit Sharma*, Marco Moschini, Fabio Zattoni,
Matthew K Tollefson, Stephen A Boorjian, R.
Houston Thompson, Igor Frank, Matthew T
Gettman, R. Jeffrey Karnes, Rochester, MN
2:20
PD43-09 ONCOLOGICAL AND FUNCTIONAL
OUTCOMES FOR AFRICAN AMERICANS
UNDERGOING ROBOTIC ASSISTED
Eugene Pietzak, III, Sylvia Yu, Jeremy
Bonzo*, Benjamin Katz, David I. Lee,
Philadelphia, PA
2:30
PD43-10 VARIATION IN SURGICAL TREATMENT OF
PROSTATE CANCER IN AFRICAN
AMERICAN PATIENTS
Rachel Moses*, Nino Dsebisashvili, Philip
Goodney, Elias Hyams, Lebanon, NH
2:40
PD43-11 CHARACTERISTICS AND MANAGEMENT OF
MEN DEVELOPING LATE BIOCHEMICAL
RECURRENCE (LBCR) FOLLOWING RADICAL
PROSTATECTOMY (RP)
Elton Llukani*, Herbert Lepor, New York, NY
2:50
PD43-12 EFFECT OF TREATMENT DELAY ON LONGTERM OUTCOMES IN MEN UNDERGOING
RADICAL PROSTATECTOMY FOR
PROSTATE CANCER
Udit Singhal*, Louis Lu, Ted Skolarus, Ganesh
Palapattu, Jeffrey Montgomery, Alon Weizer,
Brent Hollenbeck, David Miller, Rohit Mehra,
James Montie, Scott Tomlins, Lakshmi Kunju,
Daniel Hamstra, Felix Feng, Todd Morgan, Ann
Arbor, MI
CREDITTM
230
1:00 pm - 3:00 pm
Podium Session 44
PROSTATE CANCER: DETECTION AND SCREENING IV
Moderator: John Lynch
ABSTRACT
NUMBER TITLE
PD44-01 THE PROSTATE GENETIC SCORE (PGS)
STRATIFIES BASELINE RISK OF
PROSTATE CANCER AND IMPROVES PSA
PERFORMANCE IN THE PLCO TRIAL
Michael Liss*, San Antonio, TX, Jianfeng Xu,
Winston-Salem, NC, Haitio Chen, Shanghai,
China, People’s Republic of, A. Karim Kader,
San Diego, CA
1:10
PD44-02 TRENDS IN PSA UTILIZATION BY
PRIMARY CARE PHYSICIANS: IMPACT OF
THE USPSTF RECOMMENDATION
Ryan Werntz*, Ann Martinez Acevedo,
Michael Conlin, Christopher Amling, Portland,
OR
1:20
PD44-03 MAGNETIC RESONANCE IMAGING-BASED
PROSTATE CANCER SCREENING CAN
INCREASE THE DETECTION OF HIGH
GRADE DISEASE: A COMPARISON OF
CONTEMPORARY STUDY POPULATIONS
Simpa Salami*, Anna Marie Sonstegard,
Oksana Yaskiv, New Hyde Park, NY, Baris
Turkbey, Bethesda, MD, Robert Villani, Eran
Ben-Levi, New Hyde Park, NY, Carl Olsson,
Melville, NY, Pina Sanelli, Ardeshir
Rastinehad, New Hyde Park, NY
1:30
1:40
1:50
ABSTRACT
TIME NUMBER TITLE
2:00
PD44-07 EFFECTIVENESS OF SERUM PSA, URINE
PCA3 AND URINE TMPRSS2:ERG FUSION
AS A NOVEL URINARY BIOMARKER
PANEL IN CLINICAL PRACTICE
John Wei*, Javed Siddiqui, Rabia Siddiqui,
Arul M. Chinnaiyan, Lakshmi P. Kunju, Rohit
Mehra, Debbie Snyder, Scott A. Tomlins, Ann
Arbor, MI
PD44-04 COST OF PROSTATE MRI-US FUSION– A
DECISION ANALYSIS COMPARING COST
EFFECTIVENESS OF SYSTEMATIC
BIOPSY AND MRI-ULTRASOUND FUSION
PROSTATE BIOPSY IN THE INITIAL AND
REPEAT BIOPSY SETTING
Meenakshi Davuluri*, Syracuse, NY, Andrew
Toler, Manchester, NH, Andrij Wojtowycz,
Gennady Bratslavsky, Srinivas Vourganti,
Syracuse, NY
PD44-05 CONTEMPORARY NATIONAL TRENDS OF
PROSTATE CANCER SCREENING AMONG
PRIVATELY INSURED PATIENTS IN THE
UNITED STATES
Simon Kim*, Cleveland, OH, R. Jeffrey
Karnes, Rochester, MN, Cary Gross, New
Haven, CT, Holly Van Houten, Rochester, MI,
Robert Abouassaly, Cleveland, OH, Nilay
Shah, Rochester, MN
PD44-06 CONFIDENCE IN BIOPSY FINDINGS IN
THE ERA OF MRI-TARGETED PROSTATE
SAMPLING
Arvin George*, Bethesda, NY, Nabeel Shakir,
M. Minhaj Siddiqui, Soroush Rais-Bahrami,
Thomas Frye, Steven Abboud, Michele
Fascelli, Richard Ho, Raju Chelluri, Peter L.
Choyke, Baris Turkbey, Bradford J. Wood,
Peter A. Pinto, Bethesda, MD
2:10
PD44-08 ABNORMAL DIGITAL RECTAL
EXAMINATION (DRE) OF THE PROSTATE
INCREASES THE LIKELIHOOD OF
FUTURE HIGH GRADE PROSTATE
CANCER DIAGNOSIS IN PATIENTS WITH
INITIAL BENIGN PROSTATE BIOPSY
Marios Hadjipavlou*, Portsmouth, Hampshire,
United Kingdom, Ahmed Mohamed, Redhill,
Surrey, United Kingdom, Sri Sriprasad,
Sanjeev Madaan, Dartford, Kent, United
Kingdom, Shahid Khan, Abhay Rane, Redhill,
Surrey, United Kingdom
2:20
PD44-09 THE USE OF ACTIVE SURVEILLANCE IN A
CANADIAN HEALTH REGION
Octav Christea*, Andrew Stokl, Joshua
Montroy, Sonya Cnossen, Ranjeeta Mallick,
Ilias Cagiannos, Christopher Morash, Rodney
H. Breau, Ottawa, Canada
2:30
PD44-10 CORRELATION BETWEEN DIAMETER OF
PROSTATE CANCER FOCI ON
MULTIPARAMETRIC PROSTATE MRI AND
WHOLE MOUNT HISTOPATHOLOGY:
STRATIFIED BY PI-RADS AND GLEASON
SCORE
Pooria Khoshnoodi*, Nelly Tan, Daniel J. A.
Margolis, Wei-Chan Lin, Somrach
Thamtorawat, David Y. Lu, Jiaoti Huang,
Robert E. Reiter, Steven S. Raman, Los
Angeles, CA
2:40
PD44-11 UNDERSTANDING THE PERFORMANCE
OF ACTIVE SURVEILLANCE SELECTION
CRITERIA IN REAL-WORLD PRACTICE
Scott Hawken*, Paul Womble, Lindsey Herrel,
Zaojun Ye, Susan Linsell, James Montie,
2:50
PD44-12 FEASIBILITY AND INITIAL RESULTS OF
18
FLUOROCHOLINE PET/MRI/TRUS
FUSION PROSTATE BIOPSY
Jeffrey Montgomery*, Matthew Davenport,
Lakshmi Kunju, Charles Meyer, Ganesh
Palapattu, Todd Morgan, Alon Weizer, David
Miller, Brent Hollenbeck, Morand Piert, Ann
Arbor, MI
CREDITTM
*Presenting author
231
MONDAY
TIME
1:00
1:00 pm - 3:00 pm
Podium Session 45
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: MEDICAL AND NON-SURGICAL THERAPY II
Moderators: TBD
TIME
1:00
ABSTRACT
NUMBER TITLE
PD45-01 A PROSPECTIVE EVALUATION OF
FACTORS AFFECTING SERUM
TESTOSTERONE LEVELS AFTER
TESTOPEL® THERAPY IN PATIENTS WITH
LATE ONSET HYPOGONADISM (LOH): A
SINGLE CENTRE EXPERIENCE
Amit Chakrabarty*, Fenton, MO, Anup Gupta,
Kissimmee, FL
1:10
PD45-02 COMPARISON OF THE EFFICACY OF
CLOMIPHENE CITRATE VERSUS
TESTOSTERONE SUPPLEMENTATION IN
TREATING SYMPTOMS OF
HYPOGONADISM
Nathan Wilken, Jason Scovell, Ranjith
Ramasamy*, Dolores Lamb, Larry Lipshultz,
Houston, TX
1:20
PD45-03 LONG-TERM TREATMENT WITH
TESTOSTERONE UNDECANOATE
INJECTIONS SUSTAINABLY IMPROVES
ERECTILE FUNCTION AND METABOLIC
CONTROL IN HYPOGONADAL MEN WITH
TYPE 2 DIABETES MELLITUS (T2DM)
1:30
ABSTRACT
TIME NUMBER TITLE
2:00
PD45-07 A COMPARISON OF ESTRADIOL LEVELS
AND GYNECOMASTIA RATES IN
HYPOGONADAL MEN USING
CLOMIPHENE CITRATE VERSUS
TRANSDERMAL TESTOSTERONE
Clarisse R Mazzola*, Edoardo Miranda, Joseph
Narus, John P. Mulhall, New York City, NY
PD45-04 INCIDENCE OF PROSTATE CANCER AND
EFFECTS ON PROSTATE-RELATED
PARAMETERS UNDER LONG-TERM
THERAPY WITH TESTOSTERONE
UNDECANOATE INJECTIONS (TU) IN
HYPOGONADAL MEN FOR UP TO 84
MONTHS: REAL-LIFE EXPERIENCE FROM
AN OBSERVATIONAL REGISTRY STUDY
1:40
PD45-05 THE ROLE OF TESTOSTERONE
SUPPLEMENTAL THERAPY IN OPIOIDINDUCED HYPOGONADISM: A
COLLABORATIVE, PROSPECTIVE
ANALYSIS
Omer Raheem*, Joe Acevedo, David Sisul, T.
Mike Hsieh, San Diego, CA
1:50
PD45-06 LONG-TERM EFFECTS ON ERECTILE
FUNCTION UPON TREATMENT UP TO 11
YEARS WITH TESTOSTERONE
UNDECANOATE INJECTIONS (TU) IN
HYPOGONADAL MEN WITH TYPE 2
DIABETES MELLITUS (T2DM): REAL-LIFE
DATA FROM AN OBSERVATIONAL
REGISTRY STUDY
Aksam Yassin*, Yousef Al Mehmadi,
Norderstedt-Hamburg, Germany
2:10
PD45-08 COMPARISON OF CLOMIPHENE CITRATE
AND TRANSDERMAL TESTOSTERONE
REPLACEMENT THERAPY IN THEIR
INFLUENCE ON HORMONAL AND
METABOLIC CHANGES IN THE
TREATMENT OF HYPOGONADISM
Daniel Lee, Long Island City, NY, Adrien
Bernstein*, Alex Sarkisian, Matthew
Wosnitzer, Ashley Winter, Darius Paduch,
New York, NY
2:20
PD45-09 SCROTOX: SALVAGE PERI-SPERMATIC
CORD BOTULINUM-A TOXIN INJECTIONS
FOR PATIENTS WITH REFRACTORY
CHRONIC SCROTAL CONTENT PAIN
AFTER MICROSURGICAL DENERVATION
OF THE SPERMATIC CORD
2:30
PD45-10 THE SAFETY AND EFFICACY OF LI-ESWT
IN 604 PATIENTS FOR ERECTILE
DYSFUNCTION: SUMMARY OF CURRENT
AND EVOLVING EVIDENCE
Robert Feldman*, Middlebury CT, CT, Bela
Denes, Laguna Beach, CA, Boaz Appel,
Haifa, Israel, Satya Srini Vasan, Bangalore,
India, Tamar Shultz, Gaithersburg, MD,
Arthur Burnett, Baltimore, MD
2:40
PD45-11 SEVERE OBSTRUCTIVE SLEEP APNOEA
SYNDROME AND ERECTILE
DYSFUNCTION: A PROSPECTIVE
RANDOMISED STUDY TO COMPARE
SILDENAFIL VS. NASAL CONTINUOUS
POSITIVE AIRWAY PRESSURE
Antonio Luigi Pastore*, Giovanni Palleschi,
Luigi Silvestri, Latina, Italy, Alessandro
Zucchi, Elisabetta Costantini, Perugia, Italy,
Antonio Carbone, Latina, Italy
2:50
PD45-12 AVANAFIL EFFICACY WITHIN 15
MINUTES OF DOSING IN MEN WITH MILD
TO SEVERE ERECTILE DYSFUNCTION BY
DEMOGRAPHIC AND BASELINE CLINICAL
CHARACTERISTICS
Laurence H. Belkoff*, Bala Cynwyd, PA, James
P. Tursi, Jonathan Uy, Ted M. Smith,
Chesterbrook, PA, LeRoy A. Jones Jr, San
Antonio, TX
CREDITTM
232
1:00 pm - 3:00 pm
Video Session 11
ADRENAL/SINGLE PORT SURGERY/LESS/NOTES
Moderators: Jay Bishoff and Chandru Sundaram
V11-02
V11-03
V11-04
V11-05
V11-06
V11-07
V11-08
*Presenting author
ABSTRACT
NUMBER TITLE
V11-09 CASE REPORT OF A LAPAROSCOPIC
EXCISION OF PARA-AORTIC
PHEOCHROMOCYTOMA BY LIGATION OF
LEFT RENAL VEIN WITHOUT
COMPROMISING RENAL FUNCTION
Bruno Benigno*, Gustavo Guimaraes,
Rodrigo Campos, Ricardo Favaretto, Charles
Zurstrassen, Sao Paulo, Brazil
ROBOTIC ASSISTED REDO PARTIAL
NEPHRECTOMY AND PARTIAL
ADRENALECTOMY
Pranav Sharma, Kirsten Janosek Albright,
Ravi Barod*, Craig Rogers, Detroit, MI
EXTRAPERITONEAL LAPAROSCOPIC
APPROACH AND TECHNOLOGY FOR
RESECTION OF COMPLICATE
RETROPERITONEAL TUMOR IN SUPINE
POSITION
Changjun Yin, Nanjing, China, People’s
Republic of
ROBOTIC RIGHT ADRENALECTOMY FOR
PHEOCHROMOCYTOMA
Timothy Brock*, Wesley White, Knoxville, TN
LAPAROENDOSCOPIC SINGLE-SITE
PARTIAL CYSTECTOMY COMBINED WITH
CYSTOSCOPY FOR BLADDER
PARAGANGLIOMA
Teruhiko Tsuru*, Ryuichi Hirota, Fumiyasu
Jo, Keita Takimoto, Tetsuya Yoshida,
Susumu kageyama, Mitsuhiro Narita, Akihiro
Kawauchi, Otsu, Japan
LAPAROSCOPIC RESECTION OF
PARAAORTIC OR PARACAVAL
NEUROGENIC TUMORS
Takashige Abe*, Sapporo, Japan, Ataru
Sazawa, Obihiro, Japan, Toru Harabayashi,
Naoto Miyajima, Kunihiko Tsuchiya, Satoru
Maruyama, Nobuo Shinohara, Sapporo,
Japan
SUCCESSFUL EXCISION OF
RETROCAVAL TUMOR BY
RETROPERITONEOSCOPIC APPROACH IN
TWO PATIENTS
Tomonori Habuchi*, Takamitsu Inoue, Ryuichi
Ito, Akita, Japan, Yasushi Ichimura, Naoko
Kawata, Mito, Japan, Norihiko Tsuchiya,
Akita, Japan, Masahiro Iinuma, Mito, Japan
V11-10
MINI LAPAROSCOPIC PYELOPLASTY OF
A RETROCAVAL URETER
Anibal W.Branco*, Luciano C.Stunitz, Sandro
Nichele, Julio C. Foiatto, Juliano D. Scheffer,
Marcio Gatti, Kleber Stelmasuk, Curitiba,
Brazil
V11-11
TRANS-UMBILICAL LAPAROENDOSCOPIC
SINGLE-SITE EXCISION OF URACHAL
REMNANT WITH PERITONEAL REPAIR
Yuji Maeda*, Manami Tsutsumiuchi,
Yukinosuke Oshinoya, Kenichi Nagano,
Hakusan, Japan
V11-12
LAPARAOENDOSCOPIC SINGLE-SITE
SURGERY (LESS) NEPHRECTOMY: STEP
BY STEP TECHNIQUE
Aly Abdel-Karim*, Elsaid Yahyia, Salah
Elsalmy, Alexandria, Egypt
V11-13
LAPAROENDOSCOPIC SINGLE SITE
NEPHROURETERECTOMY: TECHNIQUE &
INITIAL EXPERIENCE
Jenna She, Alison Rutledge, Albert Tiu*, New
Lambton, Australia
V11-14
LAPARO-ENDOSCOPIC SINGLE SITE
(LESS) PLUS ONE PORT (POP) RADICAL
PROSTATECTOMY
Alexander Tsivian, Roman Bass, Yury
Stanevsky*, Holon, Israel, Matvey Tsivian,
Durham, NC, Mohammed Shahwan, Dmitry
Khunovitch, Shalva Benjamin, Ami Sidi,
Holon, Israel
CREDITTM
LAPAROSCOPIC NEPHRON-SPARING
EXCISION OF HILAR PARAGANGLIOMA:
TIPS AND TECHNIQUE
Rajeev Kumar*, Pragnesh Desai, Niren Rao,
New Delhi, India
233
MONDAY
ABSTRACT
NUMBER TITLE
V11-01 NOTES-ASSISTED LAPAROSCOPIC
TRANSVESICAL BLADDER
DIVERTICULECTOMY
Ahmed Magdy*, Michael Mitterberger, Günter
Janetschek, Salzburg, Austria
1:00 pm - 4:00 pm
EGYPTIAN UROLOGICAL SOCIETY (EUA)
1:00
WELCOME
Society President: Mohamed Eissa
AUA President: William Bohnert
1:10
SESSION I
Chairmen: Mohamed Eissa, Ibrahim Mokhless,
Mostafa Shamaa
2:50
SESSION III
Chairmen: Magdy El-Akkad, Osama Abou Farha,
Abdel Abouzeid
URETHRAL STRICTURES FROM HAMILTON
RUSSELL TO THE PRESENT
Gerald Jordan
IS PRIMARY ADT APPROPRIATE FOR
LOCALIZED PROSTATE CANCER?
James Mohler
3:10
ORGAN PRESERVATION SURGERIES IN
BLADDER CANCER
Nabil Bissada
1:30
RETROPERITONEAL ROBOTIC SURGERY
James Porter
3:30
1:50
REFRACTORY OAB, WHAT DO WE KNOW
Bassem Wadie
DEBATE: VASCULAR CONTROL DURING
LAPAROSCOPIC DONOR NEPHRECTOMY:
STAPLERS VERSUS CLIPS
Moderator: Ahmed Mansour
Debaters: Jim Hu, Mahesh Desai
2:10
COFFEE BREAK
4:00
ADJOURN
2:20
SESSION II
PANEL: CASE SCENARIOS IN BLADDER
CANCER - A PANEL DISCUSSION
Moderator: Mark Soloway
Panelists: Mohamed Rahman, Amr Nowier, Ahmed
Morsi
1:00 pm - 5:00 pm
UROLOGIC SOCIETY FOR TRANSPLANTATION AND RENAL SURGERY (USTRS)
12:00
INDUSTRY LUNCH PROGRAM - TBD (NONCME)
1:00
INTERNATIONAL HOUR: PERSPECTIVES ON
KIDNEY TRANSPLANTATION (CHINA,
REPUBLIC OF KOREA, JAPAN, CUBA)
Woong Kyu Han, Kazunari Tanabe, Octavio Manuel
De La Concepcion Gomez
COMMON AND NOT SO COMMON ASPECTS
OF DIFFERENT KIDNEY TRANSPLANT
PROGRAMS IN EUROPE
Enrique Lledo-Garcia, Arnaldo Figueiredo
2:00
2:30
2:45
BREAK
3:00
THE LIVING DONOR SOFTWARE PROJECT
Claus Niemann
3:30
HISTOTRIPSY OF RENAL LESIONS
William Roberts
4:00
RESIDENT AND FELLOW ABSTRACT
PRESENTATIONS – ANDREW NOVICK AWARD
5:00
USTRS BUSINESS MEETING
CREDITTM
DISCUSSION
1:00 pm - 5:30 pm
AMERICAN SOCIETY FOR MEN’S HEALTH (ASMH)
11:45
MEDICAL TREATMENT FOR MALE BPH/LUTS
AND ASSOCIATED OAB
Steven Kaplan
(NON-CME PORTION OF THE PROGRAM)
INDUSTRY SPONSORED LUNCH PROGRAM
(CME PORTION OF THE PROGRAM
COMMENCES)
1:00
1:15
WELCOME & INTRODUCTION
Program Chair: Culley Carson
ADVANCES IN BPH/LUTS
Moderator: Culley Carson
234
1:30
NEW OPTIONS FOR THE TREATMENT OF BPH/
LUTS
Kevin McVary
1:45
PANEL DISCUSSION
2:15
CONTROVERSIES IN PROSTATE CANCER
Moderator: Ajay Nehra
PSA: WHO TO TEST WITH CURRENT
GUIDELINES
Gerald Andriole
2:45
PANEL DISCUSSION
4:15
CONTROVERSIES IN TESTOSTERONE AND
CVD
Moderator: Culley Carson
ACTIVE SURVEILLANCE: DATA AND
OUTCOMES
Matthew Nielsen
EPIDEMIOLOGIC DATA FOR HYPOGONADISM,
TRT & CV HEALTH
Thomas Walsh
WHAT UROLOGISTS NEED TO KNOW ABOUT
CRPC MANAGEMENT
E. David Crawford
3:00
PSA SCREENING: PRIMARY CARE
PERSPECTIVE
Matt Rosenberg
3:15
REHABILITATION AFTER PROSTATE CANCER
TREATMENT
Moderator: Allen Seftel
EVALUATION & MANAGEMENT OF POST
TREATMENT INCONTINENCE
Kurt McCammon
3:30
RECENT DATA ON POST TREATMENT ED
REHABILITATION
Anthony Bella
3:45
TESTOSTERONE REPLACEMENT AFTER
PROSTATE CANCER TREATMENT
Mohit Khera
4:30
CLINICAL PERSPECTIVE OF CVD AND TRT
Martin Miner
4:45
FDA PANEL DELIBERATIONS FOR TRT & CVD
Culley Carson
4:55
PANEL DISCUSSION
5:00
MEN’S HEALTH CLINIC: ESTABLISHMENT OF
A MEN’S HEALTH PROGRAM
Edward Karpman
5:30
ADJOURN
CREDIT TM
1:15 pm - 5:00 pm
PAN AFRICAN UROLOGICAL SURGEONS ASSOCIATION (PAUSA)/CARIBBEAN UROLOGICAL ASSOCIATION (CURA)
1:15
WELCOME REMARKS (PAUSA PRESIDENT,
CURA PRESIDENT, AUA PRESIDENT)
1:30
SESSION 1
Chairmen: Mobile Kampanga, Ajibola Jeje
2:00
COFFEE BREAK
3:20
SESSION 3: UNUSUAL CASES
Chair: Serigne Gueye
BLADDER CANCER
E. Oluwabunmi Olapade-Olaopa
UPDATE ON PIUTA CENTRES
Serigne Gueye
1:45
3:00
3:40
CONTEMPORARY SURGICAL MANAGEMENT
OF ADRENAL TUMORS
Markarand Khochika
SESSION 4
Chairmen: Mohammed Eissa, Alexander Nwofor
PAUSA 2015 CONGRESS
Mobile Kampanga
SESSION 2: SURGICAL TECHNIQUES –
URETHRAL RECONSTRUCTION
Chairmen: Elijah Kehinde, Sunny Mante
3:50
UPDATE ON THE AFRICAN JOURNAL OF
UROLOGY
Elijah Kehinde
TIPS ON URETHRAL RECONSTRUCTION
Sanjay Kulkarni
4:00
TBD
Emmanuel Abara
2:10
FAILED HYPOSPADIAS REPAIR
Guido Barbagli
4:10
DISCUSSION
2:20
REPAIR OF PAN-URETHRAL STRICTURES:
THE CARIBBEAN EXPERIENCE
Trevor Tulloch
4:30
SESSION 5: AOB
2:30
RECONSTRUCTIVE UROLOGY IN SUBSAHARAN AFRICA
Medina Ndoye
5:00
2:40
PANEL DISCUSSION ON ADULT AND
PEDIATRIC URETHRAL RECONSTRUCTION
*Presenting author
PAUSA/CURA BUSINESS MEETING
Program Chair: E. Oluwabunmi Olapade-Olaopa
235
ADJOURN
MONDAY
2:30
4:00
2:30 pm - 5:40 pm
SOCIETÀ ITALIANA DI UROLOGIA (SIU) / AMERICAN UROLOGICAL ASSOCIATION (AUA) JOINT MEETING
2:30
Society President: Maurizio Brausi
Society Secretary General: Vincenzo Mirone
2:35
THE KIDNEY CANCER SESSION: MINIMALLY
INVASIVE PARTIAL NEPHRECTOMY: ROBOTIC
VS LAPAROSCOPIC APPROACH
Chairmen: Giuseppe Ludovico, Giuseppe Morgia
POINT/COUNTERPOINT: ROBOTIC ASSISTED
PARTIAL NEPHRECTOMY PRO AND CONS
James Porter
3:15
POINT/COUNTERPOINT: LAPAROSCOPIC
PARTIAL NEPHRECTOMY: LIGHTS AND
SHADOWS
Francesco Porpiglia
3:35
THE BLADDER CANCER SESSION
Chairmen: Maurizio Brausi, Donata Villari
STATE OF THE ART LECTURE: THE USE OF
THE BOWEL FOR BLADDER SUBSTITUTION
OVER THE YEARS
Jason Gee
3:55
POINT/COUNTERPOINT: THE ILEAL
RESERVOIR: HAUTMAN NEOBLADDER
FORMED ENTIRELY WITH STAPLES
Giuseppe Carrieri
4:35
THE MEN’S HEALTH SESSION
Chairmen: Ridwan Shabsigh, Vincenzo Mirone
STATE OF THE ART LECTURE: THE STATE OF
MEN’S HEALTH AROUND THE WORLD
Ridwan Shabsigh
STATE OF THE ART LECTURE: PARTIAL
NEPHRECTOMY NOVEL TECHNIQUES: ZERO
ISCHEMIA AND TISSUE SPARING
John Libertino
2:55
4:15
4:55
POINT/COUNTERPOINT DEBATE: WHY THE
UROLOGIST SHOULD BE THE GUARDIAN OF
MEN’S HEALTH
Paolo Verze
5:15
POINT/COUNTERPOINT: UROLOGIC
MALIGNANCIES AND MEN’S HEALTH: WHAT’S
THE IMPACT?
Riccardo Autorino
5:35
GOLDEM ITALIAN ABSTRACT AT AUA 2015
AWARD
Elisabetta Costantini
5:40
ADJOURN
POINT/COUNTERPOINT DEBATE: THE
COLONIC RESERVOIR: SIGMOID ORTHOTOPIC
NEOBLADDER VS THE ILEAL RESERVOIR:
HAUTMAN NEOBLADDER FORMED ENTIRELY
WITH STAPLES
Giulio Nicita
3:00 pm - 5:30 pm
ENDOCRINE FORUM
Moderators: Larry Lipshultz and Abraham Morgentaler
3:00
DEBATE: THE FDA IS RIGHT TO RESTRICT
INDICATIONS FOR TESTOSTERONE THERAPY
Debater - Pro: Toby Chai
Debater - Con: Mark Sigman
3:30
QUESTIONS AND ANSWERS
3:40
GENETIC MARKERS ARE ESSENTIAL IN THE
ASSESSMENT OF A PROSTATE BIOPSY
Debater - Pro: Eric Klein
Debater - Con: Neal Shore
4:10
4:20
INFERTILITY AS A MARKER OF MEN’S
HEALTH
Michael Eisenberg
4:35
4:40
DEBATE: MRI FUSION IS THE NEW
STANDARD FOR PROSTATE BIOPSY
Debater - Pro: Peter Pinto
Debater - Con: S. Larry Goldenberg
5:20
5:30
ADJOURN
CREDITTM
236
3:30 pm - 5:30 pm
LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA)
3:30
KEYNOTE PRESENTATION FROM LOUISIANA
GOVERNOR BOBBY JINDAL
4:30
UPDATE ON THE ASSOCIATION AND NEW
LUGPA INITIATIVES
Society Chair: Gary Kirsh
5:30
ADJOURN
3:30 pm - 5:30 pm
ABSTRACT
NUMBER TITLE
MP71-01 SERUM VITAMIN D LEVELS AND
PROSTATE VOLUME
Yaw Nyame*, Cleveland, OH, Richard Kalu,
Chicago, IL, Ganesh Kartha, Cleveland, OH,
Tyler Maiers, Diana Bowen, Chicago, IL, Rick
Kittles, Tucson, AZ, Adam Murphy, Chicago,
IL
ABSTRACT
NUMBER TITLE
MP71-06 ASSOCIATION OF AUA-SS SUBSCALES
WITH POST LASER PROSTATECTOMY
Abdulrahman Alruwaily*, Rabia Siddiqui,
Maggie Bierlein, Sara Lenherr, John Wei,
Ann Arbor, MI
MP71-07 VALIDATION OF A NEW SOUND-BASED
METHOD FOR RECORDING VOIDING
PARAMETERS USING SIMULTANEOUS
UROFLOWMETRY
Jan Krhut, Marcle Gärtner, Radek Sýkora,
Petr Hurtı́k, Michal Burda, Ostrava, Czech
Republic, Katarı́na Zvarová, Bratislava,
Czech Republic, Peter Zvara*, Burlington, VT
MP71-02 HOW TO CONNECT ANY SMARTPHONE
WITH CYSTOSCOPE IN ENDOSCOPIC
EVALUATION OF BENIGN PROSTATIC
HYPERPLASIA
ERNESTO III ARADA*, Dasmarinas City,
Cavite, Philippines
MP71-03 WAIST CIRCUMFERENCE CAN BE
PREDICTIVE OF POSTOPERATIVE
STORAGE LUTS AFTER SURGERY FOR
BENIGN PROSTATIC HYPERPLASIA
Mauro Gacci, Arcangelo Sebastianelli, Matteo
Salvi, Florence, Italy, Cosimo De Nunzio,
Andrea Tubaro*, Rome, Italy, Linda Vignozzi,
Florence, Italy, Giovanni Corona, Bologna,
Italy, Kevin T McVary, Chicago, IL, Steven A
Kalan, New York, NY, Mario Maggi, Marco
Carini, Sergio Serni, Florence, Italy
MP71-08 METABOLIC PROFILE CAN BE A LEADING
PATHOGENETIC FACTOR FOR BENIGN
PROSTATIC ENLARGEMENT
Mauro Gacci, Matteo Salvi, Arcangelo
Sebastianelli, Florence, Italy, Cosimo De
Nunzio, Rome, Italy, Linda Vignozzi,
Florence, Italy, Giovanni Corona, Bologna,
Italy, Tommaso Jaeger, Tommaso Chini,
Florence, Italy, Giorgio Ivan Russo, Catania,
Italy, Mario Maggi, Florence, Italy, Giuseppe
Morgia, Catania, Italy, Andrea Tubaro*,
Rome, Italy, Marco Carini, Sergio Serni,
Florence, Italy
MP71-04 SIMPLE MODIFICATION OF BLADDER
OUTLET OBSTRUCTION INDEX FOR
BETTER PREDICTION OF
ENDOSCOPICALLY PROVEN PROSTATIC
OBSTRUCTION
Jang Hee Han, Seoul, Korea, Republic of, Ho
Song Yu, Gwangju, Korea, Republic of, Joo
Yong Lee, Joohan Kim, Jong Kyu Kwon, Ho
Chul Choi*, Kang Su Cho, Seoul, Korea,
Republic of
MP71-09 FUNCTIONAL ANALYSIS OF PATIENT
OUTCOMES FOLLOWING DIFFERENT
SURGICAL INTERVENTIONS FOR BENIGN
PROSTATE HYPERPLASIA THROUGH THE
ADMINISTRATION OF AN INDEPENDENT
SURVEY
Haidar Abdul-Muhsin*, Mark Tyson, Paul
Andrews, Erik Castle, Robert Ferrigni, Wolter
Christopher, Swanson Scott, Mitchell
Humphreys, Phoenix, AZ
MP71-05 ENUCLEATION OF THE TRANSITION
ZONE AND THE EFFECT ON PSA IN
SYMPTOMS
Osayuki Nehikhare*, Giancarlo Marra, Sohel
Samad, Janette Kinsella, Oliver Brunckhorst,
Kamran Ahmed, Ben Challacombe, Rick
Popert, London, United Kingdom
*Presenting author
MP71-10 PREDICTORS OF PROSTATE CANCER IN
PATIENTS UNDERGOING HOLMIUM
FOR SYMPTOMATIC BENIGN PROSTATIC
HYPERPLASIA
Mohamed Elkoushy*, Ahmed Elshal, Mostafa
Elhilali, Montreal, Canada
237
MONDAY
BENIGN PROSTATIC HYPERPLASIA: EVALUATION AND SYMPTOMS
Moderators: Lori Lerner and Richard Babayan
MP71-17 LOWER URINARY TRACT SYMPTOMS
AND RISK OF INCIDENT NON-SPINE
FRACTURE AMONG OLDER US MEN
Lynn Marshall, Jodi Lapidus, Portland, OR,
Jack Wiedrick, Portland, OR, OR, Kathleen
Holton, Washington, D.C., DC, Elizabeth
Barrett Connor, J Kellogg Parsons*, La Jolla,
CA
MP71-11 URINARY SYMPTOMS AND MEDICATIONS
USED IN MEN ATTENDING A NATIONAL
HEALTH SCREENING PROGRAM
Nelson Stone*, New York, NY, Wendy
Poage, E. David Crawford, Aurora, CO
MP71-12 INCREASE OF FRAMINGHAM RISK IS
ASSOCIATED WITH SEVERITY OF LOWER
URINARY TRACT SYMPTOMS:
CONFIRMING RELATIONSHIP BETWEEN
BOTH DISEASES
Giorgio Ivan Russo*, Tommaso Castelli,
Salvatore Privitera, Eugenia Fragalà,
Vincenzo Favilla, Giulio Reale, Daniele Urzı̀,
Sebastiano Cimino, Giuseppe Morgia,
Catania, Italy
MP71-18 LOW-VOLUME PROSTATE IN BENIGN
PROSTATIC HYPERPLASIA (BPH): A RISK
FACTOR FOR SYMPTOMATIC BLADDER
DIVERTICULA REQUIRING SURGICAL
TREATMENT
Eduardo Muracca Yoshinaga*,.sao paulo,
Brazil, Elcio Nakano, Giovanni S Marchini,
Renato Hajime Oyama, Paulo Cordeiro,
William C Nahas, Miguel Srougi, Alberto A
MP71-13 A VISUAL ANALOG OF THE
INTERNATIONAL PROSTATE SYMPTOM
SCORE IS A MORE ACCURATE TOOL IN
ASSESSING LOWER URINARY TRACT
SYMPTOMS IN MEN
Rachel Sharon Selekman*, Catherine R
Harris, Pauline Filippou, Thomas Chi, Amjad
Alwaal, Sarah D Blaschko, Benjamin N
MP71-19 MEN WITH MODERATE TO SEVERE
LOWER URINARY TRACT SYMPTOMS
HAVE A HIGHER ESTIMATED RISK OF
DEVELOPING TYPE 2 DIABETES
Jose Ricardo Silvino*, Gabriel Gouvea,
Priscila Kuriki, Viviane Tabone, Raquel
Conceicao, Rogerio Simonetti, Valdemar
Ortiz, Roberto Soler, Sao Paulo, Brazil
MP71-14 VIDEOURODYNAMIC ANALYSIS OF MEN
WITH LOWER URINARY TRACT
DYSFUNCTION AND LARGE POSTVOID
RESIDUAL URINE VOLUME
Jia-Fong Jhang*, Dong-Ling Tang, HannChorng Kuo, Hualien, Taiwan, Yao-Chou
Tsai, New Taipei City, Taiwan
MP71-20 INTRAVESICAL PROSTATIC PROTRUSION
CAN BE THE GOOD PREDICTING FACTOR
ON STORAGE FUNCTION IN PATIENTS
WITH BENIGN PROSTATIC
ENLARGEMENT FROM THE PERSPECTIVE
OF URODYNAMIC STUDY
Yoshihisa Matsukawa*, Shun Takai, Kazuna
Matsuo, Shohei Ishida, Tokunori Yamamoto,
Momokazu Gotoh, Nagoya, Japan
MP71-15 PROSTATE MORPHOLOGY ROLE IN
PATIENTS WITH BENIGN PROSTATE
HYPERPLASIA AND THE RESPONSE TO
MEDICAL THERAPY
Rafael Nunez-Nateras*, Eric Wisenbaugh,
Haidar Abdul-Muhsin, Mark Tyson, Erik
Castle, Paul Andrews, Mitchell Humphreys,
Phoenix, AZ
CREDITTM
MP71-16 GENERATION DIFFERENCE ON THE
ASSOCIATION BETWEEN LOWER
URINARY TRACT SYMPTOMS AND LATEONSET HYPOGONADISM SYMPTOMS:
ANALYSIS OF 1398 HEALTHY YOUNG
AND ELDERLY ADULTS
Hiroshi Kiuchi*, Tetsuji Soda, Kentaro
Takezawa, Shinichiro Fukuhara, Yasushi
Miyagawa, Suita, Osaka, Japan, Akira
Tsujimura, Tokyo, Japan, Tetsuya Takao,
Osaka, Japan, Norio Nonomura, Suita,
Osaka, Japan
238
3:30 pm - 5:30 pm
BLADDER CANCER: INVASIVE V
Moderators: Hassan Abol-Enein and Eila Skinner
ABSTRACT
NUMBER TITLE
MP72-06 THE LONG NON-CODING RNA SNHG18
PROMOTES PPAR␥ FUNCTION AND
“LUMINAL” GENE EXPRESSION IN
Andrea Ochoa*, Jianping Zhang, Woonyoung
Choi, Houston, TX, Gabriel Malouf, Paris,
France, Erika Thompson, John Weinstein,
Nizar Tannir, Colin Dinney, David McConkey,
Xiaoping Su, Houston, TX
MP72-07 NOMOGRAM PREDICTING CANCER
SPECIFIC MORTALITY (CSM) AFTER
RADICAL CYSTECTOMY FOR MUSCLEINVASIVE BLADDER CANCER (BC):
RESULTS OF AN INTERNATIONAL
CONSORTIUM
Maria Carmen Mir*, Cesar Ercole, Andrew
Stephenson, Cleveland, OH
MP72-02 OUTCOME OF PATIENTS WITH
MICROPAPILLARY BLADDER CANCER
TREATED WITH RADICAL CYSTECTOMY
WITH/WITHOUT NEOADJUVANT
CHEMOTHERAPY
Mario I Fernandez*, Stephen B Williams,
Daniel L Willis, Rebecca S Slack, Rian
Dickstein, Sahil Parikh, Arlene O SiefkerRadtke, Charles C Guo, Bogdan A Czerniak,
Jay B Shah, Louis L Pisters, H Barton
Grossman, Colin P Dinney, Ashish M Kamat,
Houston, TX
MP72-08 GEMCITABINE AND CISPLATIN
NEOADJUVANT CHEMOTHERAPY FOR
MUSCLE-INVASIVE UROTHELIAL
CARCINOMA: PREDICTING RESPONSE
AND ASSESSING OUTCOMES
Nilay Gandhi*, Alexander Baras, Enrico
Munari, Sheila Faraj, Baltimore, MD,
Leonardo Reis, Unicamp, Brazil, Jen-Jane
Liu, Max Kates, Mohammad Hoque,
Baltimore, MD, David Berman, Kingston,
Canada, Noah Hahn, Mario Eisenberger,
George Netto, Baltimore, MD, Mark
Schoenberg, Bronx, NY, Trinity Bivalacqua,
Baltimore, MD
MP72-03 RADICAL CYSTECTOMY FOR BLADDER
CANCER IN PATIENTS WITH AND
WITHOUT A HISTORY OF PELVIC
IRRADIATION: A COMPARISON OF
SURVIVAL OUTCOMES AND DIVERSIONRELATED COMPLICATIONS
Daniel Nguyen*, Bashir Al Hussein Al
Awamlh, Bishoy Faltas, Padraic O’Malley,
Abimbola Ayangbesan, Igor Inoyatov, Shiyi
Jin, Douglas Scherr, New York, NY
MP72-09 ADJUVANT CISPLATIN LEADS TO A
LARGER DECLINE IN GFR THAN
NEOADJUVANT CISPLATIN IN RADICAL
CYSTECTOMY PATIENTS
Danny Lascano*, Alexa Meyer, Elizabeth
Hagan, Jamie S Pak, LaMont J. Barlow, G.
Joel DeCastro, James M. McKiernan, New
York, NY
MP72-04 IMPACT OF THE SITE OF RECURRENCE
AFTER RADICAL CYSTECTOMY ON
SURVIVAL: DIFFERENT SITES FOR
DIFFERENT OUTCOMES
Marco Moschini*, Nazareno Suardi, Marco
Bianchi, Vito Cucchiara, Stefano Luzzago,
Milan, Italy, Francesco D’Amato, Vincenzo
Serretta, Palermo, Italy, Alberto Briganti,
Milan, Italy, Shahrokh F. Shariat, Vienna,
Austria, Rocco Damiano, Catanzaro, Italy,
Jeffrey Karnes, Rochester, MN, Francesco
Montorsi, Renzo Colombo, Milan, Italy
MP72-10 PHASE I STUDY OF INTRAVESICAL
RECOMBINANT FOWLPOX-GM-CSF (RFGM-CSF) OR RECOMBINANT FOWLPOXTRICOM (RF-TRICOM) IN PATIENTS WITH
BLADDER CARCINOMA PRIOR TO
Robert Weiss, Mark Stein, Tina Mayer, Amir
Salmasi*, Isaac Kim, Robert DiPaola,
Edmund Lattime, New Brunswick, NJ
MP72-05 COSTS ASSOCIATED WITH BLADDER
CANCER: A DESCRIPTIVE POPULATIONBASED STUDY AMONG PATIENTS WHO
UNDERWENT RADICAL CYSTECTOMY IN
THE PROVINCE OF QUEBEC, CANADA
Fabiano Santos*, Alice Dragomir, Ahmed
Zakaria, Wassim Kassouf, Armen Aprikian,
Montreal, Canada
*Presenting author
MP72-11 OUTCOMES FOLLOWING RADICAL
CYSTECTOMY FOR PLASMACYTOID
UROTHELIAL CARCINOMA: DEFINING
THE NEED FOR IMPROVED LOCAL
CANCER CONTROL
Patrick Cockerill*, John Cheville, Stephen
Boorjian, Andrew Blackburne, Prabin Thapa,
Robert Tarrell, Igor Frank, Rochester, MN
239
MONDAY
ABSTRACT
NUMBER TITLE
MP72-01 RADICAL CYSTECTOMY VERSUS
BLADDER-SPARING TREATMENT FOR
PATIENTS WITH MUSCLE-INVASIVE
URINARY BLADDER: A COMPARATIVE
EFFECTIVENESS POPULATION-BASED
STUDY
Maxine Sun*, Montreal, Canada, Giorgio
Gandaglia, Milan, Italy, Alessandro Larcher,
Michael McCormarck, Montreal, Canada,
Shahrokh Shariat, New York, NY, Luc
Valiquette, Fred Saad, Pierre Karakiewicz,
Montreal, Canada
MP72-12 OUTCOMES OF RADICAL CYSTECTOMY
IN POTENTIAL CANDIDATES FOR
BLADDER PRESERVATION THERAPY
Eugene Pietzak, III*, Matthew Sterling, S.
Philadelphia, PA
MP72-16 MANAGEMENT OF UNRESECTABLE
BLADDER CANCER DIAGNOSED AT TIME
OF PLANNED CYSTECTOMY
Kashyap Shatagopam*, Hristos Kaimakliotis,
Jose Pedrosa, Paul Gellhaus, Michael Koch,
Indianapolis, IN
MP72-13 OUTCOMES OF RADICAL CYSTECTOMY
IN PATIENTS WITH BLADDER CANCER
AND UNCONTROLLED DIABETES: A
POPULATION-BASED STUDY
Izak Faiena*, Viktor Dombrovskiy, Raymond
Sultan, Amirali Salmasi, Eric Singer, Robert
Weiss, New Brunswick, NJ
MP72-17 RADICAL CYSTECTOMY PRACTICES
AMONG URO-ONCOLOGISTS: A STATE OF
THE ART SURVEY
Evan Kovac*, Cleveland, OH, Kamran
Zargar-Shoshtari, Tampa, FL, Homayoun
Zargar, Cesar Ercole, Andrew Stephenson,
Cleveland, OH
MP72-14 CLINICAL LYMPHADENOPATHY (CNⴙ) IN
RADICAL CYSTECTOMY(RC)PATIENTS: A
TRANSATLANTIC COLLABORATION
Marco Moschini*, Milan, Italy, Sia
Daneshmand, Los Angeles, CA, Alberto
Briganti, Milan, Italy, Brian Hu, Gus Miranda,
Los Angeles, CA, Igor Frank, Rochester, MN,
Renzo Colombo, Francesco Montorsi, Milan,
Italy, Jeffrey Karnes, Rochester, MN
MP72-18 PREVALENCE AND COVARIATES OF
(MIBC) SURVIVORS’ INFORMATIONAL
AND SUPPORTIVE CARE NEEDS:
RESULTS FROM A NATIONAL SURVEY
SUPPORTED BY THE BLADDER CANCER
ADVOCACY NETWORK (BCAN)
Nihal Mohamed*, New york, NY
MP72-19 THE IMPACT OF HEALTH RELATED
QUALITY OF LIFE ON CYSTECTOMY
PATIENTS USING THE MEDICAL HEALTH
OUTCOMES STUDY
Brian Winters*, George Schade, Sarah Holt,
John Gore, Atreya Dash, Michael Porter,
Jonathan Wright, Seattle, WA
MP72-15 THE INTERVAL BETWEEN DIAGNOSIS
AND RADICAL CYSTECTOMY DOES NOT
IMPACT THE OUTCOMES OF PATIENTS
TREATED WITH NEOADJUVANT
CHEMOTHERAPY
Evanguelos Xylinas*, Paris, France, Kamran
Zargar-Shoshtari, Tampa, FL, Jay Shah,
houston, TX, Homayoun Zargar, Vancouver,
Canada, Adrian Fairey, Los Angeles, CA,
Laura Mertens, Amsterdam, Netherlands,
Maria Mir, Jorge Garcia, Andrew Stephenson,
Cleveland, OH, Laura-Maria Krabbe, Dallas,
TX, Michael Cookson, Oklahoma, OK, Yair
Lotan, Dallas, TX, Niels-Erik Jacobsen,
Edmonton, Canada, Nilai Gandhi, Baltimore,
MD, Joshua Griffin, Kansas, KS, Jeffrey
Montgomery, Ann Harbor, MI, Nikhil Vasdev,
Newcastle Upon Tyne, United Kingdom, Evan
Yu, Seattle, WA, Nicholas Campain, Exeter,
United Kingdom, Wassim Kassouf, Montreal,
Canada, Marc Dall’Era, Sacramento, CA, JoAn Seah, Toronto, Canada, Cesar Ercole,
Cleveland, OH, Simon Horenblas,
Amsterdam, Netherlands, Srikala Sridhar,
Toronto, Canada, Jonathan McGrath, Exeter,
United Kingdom, Jonathan Aning, Newcastle
Upon Tyne, United Kingdom, Jonathan
Wright, Seattle, WA, Andrew Thorpe,
Newcastle Upon Tyne, United Kingdom, Todd
Morgan, Ann Harbor, MI, Jeff Holzbeierlein,
Kansas, KS, Trinity Bivalacqua, Baltimore,
MD, Scott North, Edmonton, Canada, Daniel
Barocas, Nashville, TN, Siamak
Daneshmand, Los Angeles, CA, Bass Van
Rhijn, Amsterdam, Netherlands, Philippe
Spiess, Tampa, FL, Colin Dinney, houston,
TX, Peter Black, Vancouver, Canada,
Shahrokh Shariat, Vienna, Austria
MP72-20 PLASMACYTOID VARIANT OF
UROTHELIAL CARCINOMA IS
ASSOCIATED WITH E-CADHERIN LOSS
Byron Lee*, Gopa Iyer, S. Paul Gao, Emmet
Jordan, Sasinya Scott, Aravind Bhayankara,
Ricardo Ramirez, Joseph Hreiki, Jonathan
Rosenberg, Dean Bajorin, Bernard Bochner,
Michael Berger, David Solit, Hikmat AlAhmadie, New York, NY
CREDITTM
240
3:30 pm - 5:30 pm
PROSTATE CANCER: ADVANCED I
Moderator: Daniel Petrylak
ABSTRACT
NUMBER TITLE
MP73-05 CARDIOVASCULAR EVENT RISK AS A
FUNCTION OF BASELINE RISK FACTORS
IN PROSTATE CANCER PATIENTS
TREATED WITH DEGARELIX OR
LUTEINISING HORMONE-RELEASING
HORMONE AGONISTS
Igle de Jong*, Groningen, Netherlands, Asa
Tivesten, Gothenburg, Sweden, Alexandre de
la Taille, Creteil, France, Francesco Montorsi,
Milan, Italy, Anders Malmberg, Copenhagen,
Denmark, Bo-Eric Persson, Uppsala, Sweden
MP73-06 STRATIFICATION OF CONTEMPORARY
PATIENTS UNDERGOING RADICAL
PROSTATECTOMY FOR HIGH-RISK
PROSTATE CANCER
Jung Ki Jo*, Ha Rim Kook, Tae Jin Kim,
Hakmin Lee, Seong Jin Jeong, Seok-Soo
Byun, Sang Eun Lee, Sung Kyu Hong,
Seongnam-si, Korea, Republic of
MP73-02 PATIENT UNDERSTANDING REGARDING
END-OF-LIFE PROSTATE CANCER AND
PERSPECTIVES REGARDING
COST/BENEFIT OF CURRENT
TREATMENT PARADIGMS
Tarik Benidir*, Antonio Finelli, Rob Hamilton,
Karen Hersey, Anthony Joshua, Girish
Kulkarni, Alexandre Zlotta, Neil Fleshner*,
Toronto, Canada
MP73-07 BONE MANAGEMENT OF PROSTATE
CANCER: FRAX TOOL COMBINATION
WITH BMD CAN REDUCE UNNECESSARY
TREATMENT
Shusei Fusayasu*, Takashi Kawahara,
Yokohama, Japan, Hiroshi Miyamoto,
Baltimore, MD, Masahiro Yao, Hiroji Uemura,
Yokohama, Japan
MP73-03 REGIONAL DIFFERENCES IN
CARDIOVASCULAR STATUS AND EVENTS
IN PROSTATE CANCER PATIENTS
TREATED WITH A LUTEINISING
HORMONE-RELEASING HORMONE
AGONIST VS ANTAGONIST: RESULTS OF
A POOLED ANALYSIS
Michael Borre*, Aarhus, Denmark, Tom
Keane, Charleston, SC, Zsolt Bosnyak,
Anders Malmberg, Anders Neijber,
Copenhagen, Denmark
MP73-08 PROGRESSION TO CASTRATE
RESISTANCE AND CANCER-SPECIFIC
MORTALITY IN TREATMENT-NAIVE
PATIENTS INITIALLY DIAGNOSED WITH
METASTATIC PROSTATE CANCER:
PROGNOSTIC IMPACTS OF THE SITE OF
METASTASIS AND PAIN
Kyo Chul Koo*, Ho Chul Choi, Sang Un Park,
Ki Hong Kim, Koon Ho Rha, Sung Joon
Hong, Byung Ha Chung, Seoul, Korea,
Republic of
MP73-04 THE ASSOCIATION BETWEEN STATIN
USE AND OUTCOMES IN PATIENTS
INITIATING ANDROGEN DEPRIVATION
THERAPY
Robert Hamilton*, Toronto, Canada, Keyue
Ding, Kingston, Canada, Juanita Crook,
Kelowna, Canada, Christopher O’Callaghan,
Kingston, Canada, Celestia Higano, Seattle,
WA, David Dearnaley, London, United
Kingdom, Eric Horwitz, Philadelphia, PA,
Larry Goldenberg, Vancouver, Canada, Mary
Gospodarawicz, Laurence Klotz, Toronto,
Canada
*Presenting author
MP73-09 TYPE OF ANDROGEN DEPRIVATION
THERAPY AFFECTS METABOLIC
CONDITION AND ADIPOSE TISSUE
DISTRIBUTION
Shingo Hatakeyama*, Hayato Yamamoto,
Atsushi Imai, Takahiro Yoneyama, Yasuhiro
Hirosaki, Japan
241
MONDAY
ABSTRACT
NUMBER TITLE
MP73-01 ANAMEM: PROSPECTIVE AND
OBSERVATIONAL STUDY TO EVALUATE
COGNITIVE CHANGES IN PROSTATE
CANCER PATIENTS UNDERGOING
LUTEINIZING HORMONE-RELEASING
HORMONE ANALOGUE TREATMENT
Juan Morote*, Barcelona, Spain, Ángel
Tabernero, Madrid, Spain, José Luis ÁlvarezOssorio, Cádiz, Spain, Juan Pablo Ciria, San
Sebastián, Spain, José Luis Domı́nguezEscrig, Valencia, Spain, Fernando Vázquez,
Granada, Spain, Javier C. Angulo, Madrid,
Spain, Francisco Javier López, Murcia, Spain,
Ramón De la Iglesia, Lorca, Spain, Jesús
Romero, Alicante, Spain
MP73-16 SOLID DEPOT, CONTINUOUS RELEASE,
SUBCUTANEOUS LEUPROLIDE ACETATE
FORMULATIONS LASTING 1-6 MONTHS
ACHIEVE AND MAINTAIN SERUM
TESTOSTERONE LEVELS BELOW 20NG/
DL IN 4 OPEN LABEL, FIXED DOSE
STUDIES
Neal D. Shore*, Myrtle Beach, SC, John A.
McLane, David Osborne, Alex Yang, Ft.
Collins, CO, E. David Crawford, Aurora, CO
MP73-10 BONE TURNOVER MARKER LEVELS AND
OUTCOMES IN MEN WITH PROSTATE
CANCER AND BONE METASTASES
TREATED WITH BONE ANTIRESORPTIVE
AGENTS
Neal Shore*, Myrtle Beach, SC, Matthew R.
Smith, Boston, MA, Allan Lipton, Hershey,
PA, Janet E. Brown, Sheffield, United
Kingdom, Stephane Oudard, Paris, France,
Michael Carducci, Baltimore, MD, Fred Saad,
Montreal, Canada, Ronaldo Damiao, Rio de
Janeiro, Brazil, Li Zhu, Douglas Warner,
Thousand Oaks, CA, Karim Fizazi, Villejuif,
France
MP73-17 QUALITY OF ADVANCED CANCER CARE
IN AN INTEGRATED
UROLOGY/PALLIATIVE CARE CLINIC
Aaron Laviana*, Carol Bennett, Josemanuel
Saucedo, Jonathan Bergman, Los Angeles,
CA
MP73-11 ANDROGEN DEPRIVATION THERAPY AND
INCREASED NON-CANCER MORTALITY IN
PROSTATE CANCER PATIENTS:
ANALYSIS OF THE NUMBER NEEDED TO
HARM
Firas Abdollah*, Jesse Sammon, Akshay
Sood, Daniel Pucheril, Dane Klett, Detroit, MI,
Maxine Sun, Montreal, Canada, Ayal Aizer,
Toni Choueiri, Boston, MA, Jim Hu, Los
Angeles, CA, Simon Kim, New Haven, CT,
Adam Kibel, Paul Nguyen, Boston, MA, Mani
MA
MP73-18 SARCOPENIC OBESITY ASSOCIATED
WITH ANDROGEN DEPRIVATION
THERAPY IN PATIENTS WITH PROSTATE
CANCER
Koji Mitsuzuka*, Sendai, Japan, Atsushi
Kyan, Shirakawa, Japan, Kazuhiko Orikasa,
Kesen-numa, Japan, Tomonori Sato,
Shirakawa, Japan, Minoru Miyazato,
Okinawa, Japan, Shintaro Narita, Akita,
Japan, Takuya Koie, Hirosaki, Japan,
Tomonori Habuchi, Akita, Japan, Chikara
Ohyama, Hirosaki, Japan, Yoichi Arai,
Sendai, Japan
MP73-12 UNSUSPECTED METASTASES FOUND
DURING SCREENING FOR A TRIAL OF
PATIENTS WITH NON-METASTATIC
CASTRATION RESISTANT PROSTATE
CANCER
E. David Crawford*, Aurora, CO, Jannell R.
DePalantino, Horsham, PA, Philip W. Kantoff,
Boston, MA, Neal Shore, Myrtle Beach, SC,
Willie Underwood, Buffalo, NY, Vijay Reddy,
Horsham, PA, Jim Wang, Raritan, NJ, Suneel
Mundle, Zane Yang, Tracy McGowan,
Horsham, PA, Charles J. Ryan, San
Francisco, CA
MP73-19 PRIMARY ANDROGEN DEPRIVATION
THERAPY INCREASES ALL CAUSE
MORTALITY IN POPULATIONS MATCHED
BY COMORBIDITY ADJUSTED LIFE
EXPECTANCY AND DISEASE RISK
Jesse Sammon*, Firas Abdollah, Detroit, MI,
Gally Reznor, Boston, MA, Daniel Pucheril,
Akshay Sood, Dane Klett, Detroit, MI, Julian
Hanske, Christian Meyer, Boston, MA, Mani
MA
MP73-13 BUDGET IMPACT ANALYSIS OF
ENZALUTAMIDE FOR TREATMENT OF
METASTATIC CASTRATION-RESISTANT
PROSTATE CANCER FROM A US PAYER
PERSPECTIVE
Ken O’Day*, Palm Harbor, FL, Cat N. Bui,
Scott Flanders, Northbrook, IL, Nina
Oestreicher, Peter Francis, San Francisco,
CA, Linda Posta, Northbrook, IL, Breanna
Popelar, Palm Harbor, FL, Hong Tang,
Northbrook, IL, Mark Balk, San Francisco, CA
MP73-20 INTERMITTENT VERSUS CONTINUOUS
ANDROGEN DEPRIVATION IN PATIENTS
WITH RELAPSING OR LOCALLY
ADVANCED PROSTATE CANCER: A
PHASE 3B RANDOMIZED STUDY
(ICELAND)
Claude Schulman, Brussels, Belgium, Erik
Cornel, Hengelo, Netherlands, Vsevolod
Matveev, Moscow, Russian Federation, Jan
Schraml, Usti nad Laben, Czech Republic,
Henri Bensadoun, Lormont, France, Wolfgang
Warnack, Hagenow, Germany, Raj Persad,
Bristol, United Kingdom, Marek Salagierski,
Lodz, Poland, Francisco Gomez Viega, A
Coruna, Spain, Edwina Baskin-Bey, Beatriz
Lopez, Leiden, Netherlands, Bertrand
Tombal*, Brussels, Belgium
MP73-14 PROSTATE CANCER AND ANDROGEN
DEPRIVATION THERAPY-IS IT THE RIGHT
MANAGEMENT?
Sanchia Goonewardene*, London, United
Kingdom, Debbie Sharp, Bristol, United
Kingdom, Raj Persad, London, United
Kingdom
MP73-15 PROSTATE-SPECIFIC ANTIGEN HALFLIFE IDENTIFIED AT THE FIRST FOLLOW
UP TIME IS AN EARLY PROGNOSTIC
FACTOR OF NEWLY DIAGNOSED
Ki Hong Kim*, Kyung Seok Han, Sung Joon
Hong, Seoul, Korea, Republic of
CREDITTM
242
3:30 pm - 5:30 pm
INFERTILITY: THERAPY
Moderators: TBD
ABSTRACT
NUMBER TITLE
MP74-08 IMPORTANCE OF INTRAOPERATIVE
ASSESSMENT OF SPERM
IDENTIFICATION IN PREDICTING THE
FINAL SPERM RETRIEVAL OUTCOME
WITH MICRODISSECTION TESTICULAR
SPERM EXTRACTION
Khalid Alrabeeah*, Audrey Wachter, Evelyne
Boulet, Simon Phillips, Naif AlHathal,
Francois Bissonnette, Isaac Jacques Kadoch,
Armand Zini, Montreal, Canada
MP74-02 INTRA-OPERATIVE FINDINGS INFLUENCE
DECISION MAKING IN VASECTOMY
REVERSAL PROCEDURES - SURVEY OF
FELLOWSHIP-TRAINED, HIGH-VOLUME
SURGEONS
Aravind Chandrashekar*, Houston, TX,
James Dupree, Ann Arbor, MI, Ranjith
Ramasamy, Jason Scovell, Miguel Craig,
Tariq Hakky, Alexander W. Pastuszak, Larry
Lipshultz, Houston, TX
MP74-09 A COMPARISON OF IVF OUTCOMES OF
INTRACYTOPLASMIC SPERM INJECTION
USING SURGICALLY RETRIEVED
TESTICULAR OR FROZEN-THAWED
TESTICULAR SPERMATOZOA
Mehmet Ali Tufekci, Mehmet Murad Basar*,
Zafer Atayurt, Tugba Senel, Semra
Kahraman, Istanbul, Turkey
MP74-03 THE SIGNIFICANCE OF LIGHT
MICROSCOPY FINDINGS AT THE TIME OF
VASOEPIDIDYMOSTOMY
Kevin Ostrowski*, Nicholas Tadros, Jason
Hedges, Eugene Fuchs, Portland, OR
MP74-10 COMPARISON OF FRESH VERSUS
FROZEN TESTICULAR SPERM FOR
IN PATIENTS WITH NONOBSTRUCTIVE
AZOOSPERMIA
Mustafa Bakircioglu*, Meral Gultomruk,
Mustafa Bahceci, Istanbul, Turkey
MP74-04 A SIMPLE AMBULATORY MINI-INCISION
SUPERMICROSURGICAL
VASOVASOSTOMY UNDER LOCAL
ANESTHESIA : USING A SPECIALLY
DESIGNED DOUBLE-RINGED CLAMP
WITHOUT ANY ACCESSORY DEVICES
Hyun Joon Moon*, Seoul, Korea, Republic of
MP74-11 MICRODISSECTION TESTICULAR SPERM
EXTRACTION OUTCOMES FOR MOSAIC
AND NON-MOSAIC KLINEFELTER
SYNDROME PATIENTS
Bobby Najari*, Michael Schulster, Gianpiero
Palermo, Zev Rosenwaks, Peter Schlegel,
New York, NY
MP74-05 PRACTICE PATTERNS IN SURGICAL
STERILIZATION: AN ANALYSIS OF US
UROLOGIST SURGICAL LOGS
Daniel T. Oberlin*, James Kashanian, Marah
Hehemann, Chicago, IL, Christopher Deibert,
Jay I. Sandlow, Milwaukee, WI, Sarah C.
Flury, Robert E. Brannigan, Chicago, IL
MP74-12 IS THERE ANY ROLE OF MEDICAL
TREATMENT OR VARICOCELE REPAIR IN
INFERTILE MEN WHO FAILED INITIAL
TESTICULAR SPERM EXTRACTION?
Selahittin Çayan*, Mersin, Turkey, Abdullah
Tok, Turan Çetin, Adana, Turkey
MP74-06 THE PRIVATES STUDY: PAIN RATES IN
VASECTOMY AND TESTING TO ENSURE
STERILITY
Bradley Holland*, Springfield, IL, Charles
Welliver, Albany, NY, Michael Kottwitz,
Danuta Dynda, Georgia Mueller, Tobias S
MP74-13 PREDICTORS OF SUCCESS AFTER
MICROSCOPIC SUBINGUINAL
VARICOCELECTOMY
Dane Johnson*, Brooke Harnisch, Andrew
Zganjar, Jay Sandlow, Milwaukee, WI
MP74-07 POST-VASECTOMY SEMEN ANALYSIS
OPTIMAL TIMING AND FINANCIAL
IMPLICATIONS OF REPEAT TESTING
Veeru Kasivisvanathan*, Osayuki Nehikhare,
Ahayla Kadirvelarasan, Yasir Ali, Nathan
Golban, Sinthu Kulendran, Theo Malthouse,
Yousif Ali, Ben Challacombe, Paul Hegarty,
Majed Shabbir, London, United Kingdom
*Presenting author
MP74-14 EFFICACY OF MICROSURGICAL
SUBINGUINAL VARICOCELECTOMY
USING INDOCYANINE GREEN
FLUORESCENCE ANGIOGRAPHY
Yasuhiro Shibata*, Sota Kurihara, Yoshiyuki
Miyazawa, Haruo Kato, Hidekazu Koike,
Kazuto Ito, Tetsuya Nakamura, Kazuhiro
Suzuki, Maebashi, Japan
243
MONDAY
ABSTRACT
NUMBER TITLE
MP74-01 VASECTOMY REVERSAL PRACTICE
PATTERN: AN ANALYSIS OF AMERICAN
BOARD OF UROLOGY CASE LOG
Unwanaobong Nseyo*, Nishant Patel, TungChin Hsieh, San Diego, CA
MP74-19 A PROSPECTIVE STUDY OF NATURAL
PREGNANCY RATES IN CLEARED MALE
FACTOR COUPLES
Daniel H. Shin*, Los Angeles, CA, Emily S.
Christensen, Paul J. Turek, San Francisco,
CA
MP74-15 ORAL PROBENECID IMPROVES SPERM
MOTILITY IN MEN WITH SPINAL CORD
INJURY (SCI)
Emad Ibrahim*, Teodoro Aballa, Juan Pablo
de Rivero Vaccari, Robert Keane, W. Dalton
Dietrich, Charles Lynne, Nancy Brackett,
Miami, FL
MP74-20 WHO IS THE MOST SUITABLE
CANDIDATE FOR CLOMIPHENE
TREATMENT? FINDINGS OF AN
OBSERVATIONAL SURVEY IN A COHORT
OF PRIMARY INFERTILE MEN
Luca Boeri*, Alessandro Serino, Eugenio
Ventimiglia, Giovanni La Croce, Paolo
Capogrosso, Marco Paciotti, Angela
Pecoraro, Silvia Ippolito, Giulia Castagna,
Roberta Scano, Dana Kuefner, Milan, Italy,
MP74-16 DEVELOPMENT OF A PRACTICAL ANIMAL
MODEL FOR HUMAN SPERMATOGONIAL
STEM CELL TRANSPLANTATION
Ahmed Hussein*, Giza, Egypt, Matthew
Abad-Santos, Jared Rosen, Pamela Yango,
Nam Tran, James Smith, San Francisco, CA
MP74-17 POTENTIAL OF OPTICAL COHERENCE
TOMOGRAPHY (OCT) AND PROBE-BASED
CONFOCAL LASERENDOMICROSCOPY
(PCLE) IN THE INVESTIGATION OF THE
TESTIS – A FEASIBILITY STUDY
Matthias Trottmann*, Munich, Germany,
Sabine Kölle, Dublin, Ireland, Christian
Homann, Herbert Stepp, Daniel Döring,
Regina Leeb, Sven Reese, Christian G. Stief,
Ronald Sroka, Munich, Germany
CREDITTM
MP74-18 TESTOSTERONE (T) PROFILES OF MEN
AFTER TESTIS SPERM EXTRACTION
(TESE)
Lawrence C. Jenkins*, New York, NY,
Coskun Kacagan, Duzce, Turkey, Christian J.
Nelson, John P. Mulhall, New York, NY
3:30 pm - 5:30 pm
STONE DISEASE: EVALUATION I
Moderators: Bodo Knudsen and Robert Marcovich
ABSTRACT
NUMBER TITLE
MP75-01 DEFINITIVE URETERAL STONE
TREATMENT (DUST) SCORE PREDICTS
OUTCOMES OF URETEROSCOPIC
INTERVENTION IN ACUTE OBSTRUCTIVE
UROPATHY SECONDARY TO
UROLITHIASIS
Timothy Tran*, Simone Thavaseelan, Gyan
Pareek, Providence, RI
ABSTRACT
NUMBER TITLE
MP75-04 THE EFFECT OF STONE PREVENTION
COUNSELING AT THE INITIAL
CONSULTAION ON 24-HOUR URINE
COLLECTION RESULTS (“CLINIC
EFFECT”)
Tarek Alzahrani*, Daniela Ghiculete, Kenneth
Pace, Jason Y. Lee, R.J. D’A. Honey,
Toronto, Canada
MP75-02 DO PATIENT AND STONE FACTORS
DIFFER BETWEEN CALCIUM PHOSPHATE
STONES AND OTHER METABOLIC
STONES UNDERGOING PERCUTANEOUS
NEPHROLITHOTOMY?
Benjamin King*, Burlington, VT, Nazikh
Khater, Duane Baldwin, Loma Linda, CA,
Jared Wachterman, Peter Callas, Burlington,
VT, Jaime Landman, Irvine, CA, Mark Plante,
Burlington, VT, Zhamshid Okhunov, Irivine,
CA, Kevan Sternberg, Burlington, VT
MP75-05 DO WE REALLY NEED TO WEAR PROPER
EYE PROTECTION WHEN USING
HOLMIUM:YAG LASER DURING
ENDOUROLOGICAL PROCEDURES?
RESULTS FROM LAB TEST ON PIG EYES
Luca Villa*, Jonathan Cloutier, Eva Compérat,
Frederic Charlotte, Olivier Traxer, Paris,
France
MP75-06 ACUTE URINARY STONE INCIDENCE AS
A FUNCTION OF TEMPERATURE AND
LAG LENGTH IN A SUBTROPICAL
CLIMATE
Jessica Goetz*, San Antonio, TX, Sonja Grill,
Munich, Germany, Donna Ankerst, Timothy
Tseng, San Antonio, TX
MP75-03 IMPACT OF THE PATIENT POSITION IN
THE OUTCOMES OF PERCUTANEOUS
NEPHROLITHOTOMY FOR COMPLEX
STONES
Fabio C. Vicentini*, Carlos H. Watanabe,
Marcelo Hisano, Rodrigo Perrela, Claudio C.
Murta, Joaquim F. A. Claro, Sao Paulo, Brazil
244
MP75-15 THE CONSEQUENCES OF DELAYING
STONE TREATMENT
Justin Friedlander, Nicholas Kavoussi*,
Shuvro De, Asim Ozayar, Nabeel Shakir, Jodi
Antonelli, Margaret Pearle, Dallas, TX
MP75-08 GEOGRAPHIC LOCATION IS IMPORTANT
FOR INITIAL EVALUATION OF
UROLITHIASIS
Ethan B Fram*, Bronx, NY, Matthew D
Sorensen, Vincent G Bird, Gainesville, FL,
Joshua M Stern, Bronx, NY
MP75-16 CAN WE REDUCE UNPLANNED
READMISSIONS AND EMERGENCY
DEPARTMENT VISITS FOLLOWING
URETEROSCOPY/LASER LITHOTRIPSY? A
MULTIVARIATE ANALYSIS OF A LARGE,
SINGLE INSTITUTION’S EXPERIENCE
Rachel Moses*, Faddy Ghali, Margaret
Menkov, Vernon Pais, Jr., Elias Hyams,
Lebanon, NH
MP75-09 HOW MUCH INFORMATION IS LOST
WHEN ONLY ONE 24-HOUR URINE IS
COLLECTED AS PART OF THE INITIAL
METABOLIC EVALUATION?
Abdulrahman Alruwaily*, Casey Dauw,
Maggie Bierlein, Ann Arbor, MI, John Asplin,
Chicago, IL, Ghani Khurshid, J Stuart Wolf Jr,
MP75-17 IN VIVO RADIATION EXPOSURE DUE TO
URINARY CALCULI IMAGING: SINGLE
ENERGY CT VS. LOW DOSE CT VS. DUAL
SOURCE DUAL ENERGY CT (DECT)
Maria Jepperson, Joseph Cernigliaro, Ibrahim
El-Sayed, William Haley, David Thiel, Abby
Taylor*, Jacksonville, FL
MP75-10 PATIENT EDUCATION AND THE IMPACT
ON URETEROSCOPY EXPERIENCE
Nathan Grunewald*, Carley Davis, Jonathan
Amos, Milwaukee, WI
MP75-18 TIPS AND TRICKS TO DIFFERENTIATE
DISTAL URETERAL STONES FROM
PHLEBOLITHS ON COMPUTERIZED
TOMOGRAPHY
Yiloren Tanidir*, Ahmet Sahan, Mehmet
Kazim Asutay, Ferhad Talibzade, Ilker Tinay,
Ferruh Simsek, Istanbul, Turkey
MP75-11 SHARED DECISION MAKING FOR
SURGICAL STONE DISEASE
Abdullahi Abdulwahab-Ahmed, Robert Brown,
Mohamed Omar*, Sarah Tarplin, Manoj
Monga, Cleveland, OH
MP75-19 A NEW SCORING SYSTEM FOR
PREDICTING UNCOMPLICATED
URETERAL STONES WITHOUT
RADIOLOGICAL IMAGES IN THE
EMERGENCY ROOM: A RETROSPECTIVE
SINGLE-CENTER STUDY
Hiroki Fukuhara*, Hiroshi Kakizaki, Sakata,
Japan, Osamu Ichiyanagi, Yamagata, Japan,
Hisashi Kaneko, Takuya Yamanobe, Shouko
Nakayama, Sakata, Japan, Yoshihiko Tomita,
Yamagata, Japan
MP75-12 A SINGLE DOSE OF INTRAOPERATIVE
ANTIBIOTICS IS SUFFICIENT TO
PREVENT URINARY TRACT INFECTION
DURING URETEROSCOPY
Ben H. Chew, Ryan Flannigan, Vancouver,
Canada, Michael P. Kurtz, Boris Gershman,
Boston, MA, Olga Arsovsksa, Ryan F.
Paterson, Vancouver, Canada, Brian Eisner,
Boston, MA, Dirk Lange*, Vancouver, Canada
MP75-13 STONE CULTURE FOR PATIENTS
UNDERGOING FLEXIBLE
URETEROSCOPY (FURS) AND LASER
STONE FRAGMENTATION FOR RENAL
STONE – DOES IT ADD ANYTHING TO
MANAGEMENT?
Rehan Khan*, Sarah Hunt, Holly Bekarma,
Alison Ramsay, Sarath Krishna Nalagatla,
Airdrie, United Kingdom
MP75-20 ALGORITHM CORRECTING FOR STONE
SIZE DECREASES
MISCHARACTERIZATION OF CALCIUM
OXALATE STONES
Yaniv Larish*, Leonard Glickman, New York,
NY
MP75-14 30 DAY COMPLICATIONS RATES AFTER
URETEROSCOPY AND LASER
LITHOTRIPSY: WHAT ARE THE
PREDICTORS?
Oluwaseun Akinola*, Erin Corsini, Charles
Welliver Jr, Mark White, Albany, NY
*Presenting author
CREDITTM
245
MONDAY
MP75-07 OVER OR UNDER 24-HOUR URINE
COLLECTION: CAN ADJUSTMENTS BE
MADE TO AVOID REPEAT COLLECTION?
Tom Sanford*, Krishna Ramaswamy, Tom
Chi, Marshall Stoller, San Francisco, CA
3:30 pm - 5:30 pm
Podium Session 46
PROSTATE CANCER: DETECTION AND SCREENING V
Moderators: Alan Nieder and Alan Partin
TIME
3:30
ABSTRACT
NUMBER TITLE
PD46-01 TUMOR VOLUME LESS THAN 2.5 ML IS A
SIGNIFICANT CUT OFF VALUE OF
PROGNOSIS IN HIGH RISK PROSTATE
CANCER PATIENTS
Shinichi Sakamoto*, Ayumi Muroi,
Nobusghige Takeshita, Ken Wakai, Shuhei
Kamda, Takeshi Namekawa, Miki Fuse, Koji
Kawamura, Takashi Imamoto, Naoki Nihei,
Tomohiko Ichikawa, Chiba, Japan
3:40
PD46-02 MULTICENTER EVALUATION OF THE
PROSTATE HEALTH INDEX (PHI) FOR
DETECTION OF AGGRESSIVE PROSTATE
CANCER IN BIOPSY-NAÏVE MEN
Claire de la Calle*, Dattatraya Patil, Atlanta,
GA, John Wei, Ann Arbor, MI, Douglas
Scherr, New York, NY, Lori Sokoll, Daniel
Chan, Baltimore, MD, Javed Siddiqui, Ann
Arbor, MI, Juan Miguel Mosquera, Mark
Rubin, New York, NY, Martin Sanda, Atlanta,
GA
3:50
PD46-03 PROSTATE CANCER DETECTION AFTER
THREE NEGATIVE SCREENS WITH A 4YEAR INTERVAL. ERSPC ROTTERDAM
Monique Roobol*, Daan Nieboer, ERSPC
study group Rotterdam, Rotterdam,
Netherlands
4:00
PD46-04 TREATMENT AND SURVIVAL IN MEN
UNDER AGE 55 YEARS DIAGNOSED WITH
GLEASON 8-10 PROSTATE CANCER:
IMPLICATIONS OF PSA SCREENING
Brian Winters, Sarah Holt, Daniel Lin, Michael
Porter, Heather Cheng, Jonathan Wright*,
Seattle, WA
4:10
PD46-05 MULTI-CENTER PROSPECTIVE STUDY OF
URINE RNA TESTING AS A STRATEGY
FOR PROSTATE CANCER SCREENING:
COLLABORATION BETWEEN UROLOGY,
PRIMARY CARE, AND COMMUNITY
OUTREACH
Dattatraya Patil*, Claire de la Calle, Atlanta,
GA, Brandi Weaver, Robin Leach, Ian
Thompson, San Antonio, TX, Lori Sokoll,
Daniel Chan, Baltimore, MD, Jack Groskopf,
Santa Clara, CA, J. Jacques Carter, Boston,
MA, Mersiha Torlak, Martin Sanda, Atlanta,
GA
4:20
ABSTRACT
TIME NUMBER TITLE
4:30
PD46-07 URINARY DNA METHYLATION
BIOMARKERS: A NON-INVASIVE METHOD
FOR PROSTATE CANCER MONITORING
Fang Zhao*, Danny Vesprini, Ekaterina
Olkhov-Mitsel, Darko Zdravic, Alexandre
Zlotta, Vasundara Venkateswaran, Andrew
Loblaw, Theodorus Van Der Kwast, Neil
Fleshner, Laurence Klotz, Bharati Bapat,
Toronto, Canada
PD46-06 PSA BASED SCREENING FOR PROSTATE
CANCER: STARTING TOO LATE AND
NON-COMPLIANCE, LIMITING THE
NUMBER OF SCREENING VISITS,
NEGATIVELY AFFECT PC MORTALITY
REDUCTION
Monique Roobol*, ERSPC study group
Rotterdam, Rotterdam, Netherlands
246
4:40
PD46-08 PROSPECTIVE STUDY OF PRE-BIOPSY
RESONANCE IMAGING (MPMRI)
COMPARED TO TRANSPERINEAL
TEMPLATE MAPPING BIOPSY (TTMB)
FOR DETECTION OF CLINICALLY
SIGNIFICANT PROSTATE CANCER: IS IT
ACCURATE ENOUGH TO GUIDE
SELECTION OF MEN FOR BIOPSY
James Thompson*, Ron Shnier, Daniel
Moses, Phillip Brenner, Warick Delprado,
Minh Tran, Lee Ponsky, Maret Boehm,
Andrew Hayen, Phillip Stricker, Sydney,
Australia
4:50
PD46-09 RISK STRATIFICATION OF AGGRESSIVE
PROSTATE CANCER BASED ON
COMBINED EPIGENETIC AND CLINICAL
DATA OF MEN WITH INITIAL CANCERNEGATIVE BIOPSIES
Alan W Partin*, Baltimore, MD, Leander Van
Neste, Maastricht, Netherlands, Grant D
Stewart, Edinburgh, United Kingdom, Joseph
Bigley, Irvine, CA, David J Harrison, St
Andrews, United Kingdom, Wim Van
Criekinge, Ghent, Belgium, Jonathan I
Epstein, Baltimore, MD
5:00
PD46-10 STANDARDIZED MAGNETIC RESONANCE
IMAGING READING FOR PREDICTION OF
EXTRAPROSTATIC EXTENSION AND
PROSTATECTOMY OUTCOME IN
PATIENTS WITH LOW-, INTERMEDIATEAND HIGH-RISK PROSTATE CANCER
Jan Philipp Radtke*, Maya Müller-Wolf,
Martin Freitag, Constantin Schwab, Gencay
Hatiboglu, Wilfried Roth, Matthias Roethke,
Heinz-Peter Schlemmer, Markus
Hohenfellner, Boris Hadaschik, Dogu Teber,
Heidelberg, Germany
5:10
PD46-11 LOW DOSE SPINAL SADDLE BLOCK
ANESTHESIA IS ASSOCIATED WITH
INCREASED PATIENT TOLERANCE OF
AND WILLINGNESS TO HAVE A REPEAT
PROSTATE BIOPSY
Anselm Obi*, Paul Nnodi, Abakaliki, Nigeria
5:20
CREDITTM
PD46-12 PROSTATE CANCER UPGRADING AT
PROSTATECTOMY: A POPULATIONBASED ANALYSIS OF > 25,000 MEN
Brian Winters, George Schade, Sarah Holt,
Daniel Lin, William Ellis, Bruce Dalkin,
Jonathan Wright*, Seattle, WA
3:30 pm - 5:30 pm
Podium Session 47
TIME
3:30
ABSTRACT
NUMBER TITLE
PD47-01 CHARACTERISTICS OF ANTERIOR
PREDOMINANT PROSTATE CANCER AND
THE USEFULNESS OF
MULTIPARAMETRIC MRI IN DIAGNOSIS
Seung-Kwon Choi*, Myungsun Shim,
Myungchan Park, Aram Kim, Muyoung Sohn,
Donghyun Lee, Sahyun Park, Seoul, Korea,
Republic of, Sejun Park, Ulsan, Korea,
Republic of, Sang Hoon Song, Cheryn Song,
Jun Hyuk Hong, Choung-Soo Kim, Hanjong
Ahn, Seoul, Korea, Republic of
3:40
PD47-02 IMPROVED PRE-RADICAL
PROSTATECTOMY RISK STRATIFICATION
USING PSA DENSITY
Christopher Welty*, Michael Leapman,
Jonathan Brajtbord, Janet Cowan, Matthew
Cooperberg, Peter Carroll, San Francisco, CA
3:50
PD47-03 EXPRESSION OF CYTOPLASMIC ER␤1
AND NUCLEAR ER␤2 IS ASSOCIATED
WITH POOR OUTCOMES FOLLOWING
RADICAL PROSTATECTOMY FOR
George R. Schade*, Sarah K. Holt, Xiaotun
Zhang, Jonathan L. Wright, Shan Shan Zhao,
Suzanne Kolb, Hung-Ming Lam, Seattle, WA,
Linda Levin, Yuet-Kin Leung, Shuk-Mei Ho,
Cincinnati, OH, Janet Stanford, Seattle, WA
4:00
4:10
ABSTRACT
TIME NUMBER TITLE
4:20
PD47-06 INTERMEDIATE PROSTATE CANCER
TREATED BY FOCUSED ULTRASOUND
ABLATION: PROSPECTIVE
MULTICENTRIC LONG-TERM RESULTS IN
1300 PATIENTS
sebastien Crouzet*, Lyon, France, Andreas
Blana, Fuerth, Germany, Stephen Thuroff,
Munich, Germany, Roman Ganzer, Roman
Ganzer, Christian Chaussy, Regensburg,
Germany, Albert Gelet, Lyon, France
PD47-04 PATHOLOGICAL FEATURES OF THE
INDEX AND NON-INDEX LESIONS IN
RADICAL PROSTATECTOMY SPECIMENS:
IMPLICATIONS FOR FOCAL THERAPY
Kent Kanao*, Nagakute, Japan, Keishi
Kajikawa, Nagoya, Japan, Ikuo Kobayashi,
Shingo Morinaga, Hiroyuki Muramatsu,
Genya Nishikawa, Takahiko Yoshizawa,
Yoshiharu Kato, Masahito Watanabe, Kenji
Zennami, Kogenta Nakamura, Makoto
Sumitomo, Nagakute, Japan
PD47-05 PROSPECTIVE COMPARISON OF
ONCOLOGICAL OUTCOMES BETWEEN
FOCAL CRYOTHERAPY VERSUS FOCAL
HIGH-INTENSITY FOCUSED
ULTRASOUND IN LOCALIZED PROSTATE
CANCER
Youness Ahallal*, Eric Barret, Rafael
Sanchez-Salas, Marc Galiano, Francois
Rozet, Xavier Cathelineau, Paris, France
*Presenting author
247
4:30
PD47-07 SEVERE URINARY ADVERSE EVENTS
AFTER HIGH VS. LOW DOSE RATE
PROSTATE BRACHYTHERAPY: A
Daniel Liberman*, Stephanie Jarosek, Beth
Virnig, Sean Elliott, Minneapolis, MN
4:40
PD47-08 IRREVERSIBLE ELECTROPORATION (IRE)
AS A LOCALIZED TREATMENT FOR
PROSTATE CANCER: A REPORT ON
SAFETY AND OUTCOMES
Katie Murray*, John Musser, New York, NY,
Joseph Mashni, Gilbert, AZ, Govindarajan
Srimathveeravalli, Jeremy Durack, Stephen
Solomon, Jonathan Coleman, New York, NY
4:50
PD47-09 WHOLE SURFACE FROZEN SECTION OF
THE PROSTATE AS ONCOLOGIC
PARAMETER TO INTRAOPERATIVELY
TAILOR TREATMENT AND MINIMIZE
POSITIVE MARGIN RATE
Christian von Bodman*, Max Schulmeyer,
Marko Brock, Björn Löppenberg, Florian
Roghmann, Katharina Braun, Herne,
Germany, Florian Sommerer, Bochum,
Germany, Joachim Noldus, Rein Jüri
Palisaar, Herne, Germany
5:00
PD47-10 IMPACT OF METABOLIC SYNDROME ON
STAGE, GRADE AND OVERALL FAILURE
IN MEN UNDERGOING RADICAL
PROSTATECTOMY FOR PROSTATE
CANCER
Bimal Bhindi*, Wen Xie, Girish Kulkarni,
Robert Hamilton, Shabbir Alibhai, Robin
Kalnin, Michael Nesbitt, Antonio Finelli,
Alexandre Zlotta, John Trachtenberg, Neil
Fleshner, Toronto, Canada
MONDAY
PROSTATE CANCER: LOCALIZED VII
Moderators: J. Brantley Thrasher and Byung Ha Chung
5:10
5:20
PD47-11 PREDICTORS OF QUALITY OF LIFE IN
MEN WITH LOCALIZED PROSTATE
CANCER: THE ROLE OF TREATMENT
DECISION MAKING SATISFACTION,
NEUROTICISM, AND SEXUAL
FUNCTIONING
David Victorson*, Evanston, IL, Nathaniel
Sufrin, Brian T. Helfand, Kristian R.
Novakovic, Glenview, IL, Joseph J. Pariser,
Chicago, IL, Michael McGuire, Charles
Brendler, Glenview, IL
PD47-12 LONG TERM IMPACT OF A PROSTATE
CANCER COMMUNITY OF PRACTICE AND
REGIONAL DIAGNOSTIC CENTER
Christopher Morash*, Luke T. Lavallée, Octav
Cristea, Robin Morash, Jennifer Smylie, Dean A.
Fergusson, Ilias Cagiannos, Michael Fung-KeeFung, Rodney H. Breau, Ottawa, Canada
CREDITTM
3:30 pm - 5:30 pm
Podium Session 48
SEXUAL FUNCTION/DYSFUNCTION/ANDROLOGY: PEYRONIE’S DISEASE
Moderator: Anthony Bella
TIME
3:30
3:40
ABSTRACT
NUMBER TITLE
PD48-01 PEYRONIE’S DISEASE FOLLOWING
RADICAL PROSTATECTOMY: INCIDENCE
IN A POPULATION WITH FORMAL PRE
OPERATIVE ASSESSMENT
John Sullivan*, Dublin, Ireland, Raanan Tal,
Matthias Heck, Melanie Bernstein, Christian
Nelson, John Mulhall, New York, NY
PD48-02 SUBCORONAL APPROACH TO
IMPLANTATION
Aaron Weinberg*, New York, NY, Christopher
Deibert, Milwaukee, WI, Matthew Pagano,
New York, NY, Paulo Egydio, São Paulo,
Brazil, Robert Valenzuela, New York, NY
3:50
PD48-03 LONG-TERM RESULTS AFTER PARTIAL
PLAQUE EXCISION AND GRAFTING WITH
COLLAGEN FLEECE IN PEYRONIE’S
DISEASE
Georgios Hatzichristodoulou*, Scarlet
Fiechtner, Jürgen Gschwend, Munich,
Germany, Sven Lahme, Pforzheim, Germany
4:00
PD48-04 EFFECTS OF COLLAGENASE TREATMENT
ON BIOMECHANICAL PROPERTIES OF
PEYRONIE’S PLAQUES
Thomas Schmid*, Vincent Wang, Elizabeth
Shewman, Chicago, IL, Michael McLane,
James Tursi, Malvern, PA, Laurence Levine,
Chicago, IL
4:10
ABSTRACT
TIME NUMBER TITLE
4:20
PD48-06 OUTCOMES ASSOCIATED WITH
COLLAGENASE CLOSTRIDIUM
HISTOLYTICUM TREATMENT FOR
PEYRONIE’S DISEASE BY DURATION OF
DISEASE
Laurence A. Levine*, Chicago, IL, Martin K.
Gelbard, Burbank, CA, James P. Tursi, Ted
M. Smith, Gregory J. Kaufman, Kimberly
Gilbert, Chesterbrook, PA, Jed Kaminetsky,
John P. Mulhall, New York, NY
PD48-05 TRENDS IN THE TREATMENT OF
PEYRONIE’S DISEASE: AN ANALYSIS OF
CASE LOGS FROM AMERICAN
UROLOGISTS
Daniel T. Oberlin*, Joceline S. Liu, Richard S.
Matulewicz, Matthias D. Hofer, Jaclyn
Milrose, Sarah C. Flury, Chicago, IL, Allen F.
Morey, Dallas, TX, Christopher M. Gonzalez,
Chicago, IL
248
4:30
PD48-07 CHANGES IN THE EFFECTS OF
PEYRONIE’S DISEASE AFTER
TREATMENT WITH COLLAGENASE
CLOSTRIDIUM HISTOLYTICUM
ACCORDING TO MEN WITH PEYRONIE’S
DISEASE AND THEIR FEMALE SEXUAL
PARTNERS
Irwin Goldstein*, San Diego, CA, Dean Knoll,
Nashville, TN, Larry I. Lipshultz, Houston, TX,
James P. Tursi, Ted M. Smith, Gregory J.
Kaufman, Kimberly Gilbert, Chesterbrook, PA,
Raymond C. Rosen, Watertown, MA, Chris
G. McMahon, St. Leonards, New South
Wales, Australia
4:40
PD48-08 THE NESBIT PROCEDURE FOR
PEYRONIE’S DISEASE : >SEVEN YEAR
FOLLOW UP
Tet Yap*, Raheem Amr, Spilotros Marco, De
Luca Francesco, Saad Abumelha, Marc Lucky,
Giulio Garaffa, Nim Christopher, Suks Minhas,
Ralph David, London, United Kingdom
4:50
PD48-09 VERSATILE ALGORITHMIC APPROACH
FOR DEFINITIVE STRAIGHTENING
WITHOUT MODELING DURING PENILE
PROSTHESIS SURGERY
Timothy Tausch*, Paul Chung, Jordan Siegel,
Alexandra Klein, Allen Morey, Dallas, TX
5:00
PD48-10 MUST: MULTIPLE SLICE TECHNIQUE FOR
PENILE LENGTHENING AND WIDENING
WITHOUT GRAFTING DURING PENILE
PROSTHESIS INSERTION
Paulo Egydio*, Franklin Kuehhas, Sao Paulo,
5:10
5:20
PD48-11 PENILE CURVATURE SECONDARY TO
PEYRONIE’S DISEASE WITH PENILE
PROSTHESIS AND RELAXING INCISIONS
WITHOUT LOSS OF LENGTH
Aaron Weinberg*, New York, NY, Christopher
Deibert, Milwaukee, WI, Matthew Pagano,
New York, NY, Paulo Egydio, São Paulo,
PD48-12 RELATIONSHIP OF FACTORS
ASSOCIATED WITH PEYRONIE’S DISEASE
(PD) THAT AFFECT PD BOTHER AND
Ege Serefoglu*, Mehmet Berktas, Istanbul,
Turkey, Faysal Yafi, New Orleans, LA, Ted
Smith, Gregory Kaufman, Genzhou Liu,
Chesterbrook, PA, Wayne Hellstrom, New
Orleans, LA
CREDITTM
3:30 pm - 5:30 pm
KIDNEY CANCER: SURGICAL THERAPY VI
Moderator: Amr Fergany
TIME
3:30
3:40
ABSTRACT
NUMBER TITLE
PD49-01 IDENTIFYING PATIENTS AT HIGH RISK
OF PERI-OPERATIVE DEATH FROM
SIMULTANEOUS UROLOGICAL AND
CARDIAC SURGERY FOR TUMOURS
INVOLVING THE INFERIOR VENA CAVA
(IVC)
Archie Fernando*, Sheena Patel, Kay
Thomas, Conal Austin, Tim O’Brien, London,
United Kingdom
ABSTRACT
TIME NUMBER TITLE
4:10
PD49-05 COMPARISON OF RENAL FUNCTION
DETRIMENTS AFTER LOCAL TUMOR
ABLATION OR PARTIAL NEPHRECTOMY
FOR RENAL CELL CARCINOMA
Alessandro Larcher*, Malek Meskawi,
Katharina Boehm, Roger Valdivieso, Vincent
Trudeau, Zhe Tian, Montreal, Canada, Nicola
Fossati, New York, NY, Giovanni Lughezzani,
Nicolò Buffi, Giorgio Guazzoni, Francesco
Montorsi, Milan, Italy, Maxine Sun, Pierre
PD49-02 ROBOTIC PARTIAL NEPHRECTOMY
VERSUS LAPAROSCOPIC PARTIAL
NEPHRECTOMY: COMPARISON OF THE
LEARNING CURVES
benoit peyronnet*, damien chaste, zineddine
khene, romain mathieu, gregory verhoest,
3:50
PD49-03 MORTALITY, MORBIDITY AND
HEALTHCARE EXPENDITURES AFTER
LOCAL TUMOR ABLATION OR PARTIAL
NEPHRECTOMY FOR T1A KIDNEY
CANCER
Alessandro Larcher*, Maxine Sun, Malek
Meskawi, Katharina Boehm, Roger
Valdivieso, Jonas Schiffmann, Zhe Tian,
Vincent Trudeau, Montreal, Canada, Nicola
Fossati, New York, NY, Nicolò Buffi,
Francesco Montorsi, Giorgio Guazzoni, Milan,
Italy, Pierre Karakiewicz, Montreal, Canada
4:00
PD49-04 PERIOPERATIVE ASPIRIN USE
ASSOCIATED WITH INCREASED RISK
FOR BLEEDING COMPLICATION
FOLLOWING PARTIAL NEPHRECTOMY
Timothy Ito*, Robert Uzzo, Philip Abbosh,
Nikhil Waingankar, Mohammed Haseebuddin,
David Chen, Marc Smaldone, Richard
Greenberg, Daniel Canter, Rosalia Viterbo,
Alexander Kutikov, Serge Ginzburg,
Philadelphia, PA
*Presenting author
249
4:20
PD49-06 DELAYED INTERVENTION OF SMALL
RENAL MASSES ON ACTIVE
SURVEILLANCE
Mohit Gupta*, Paul Crispen, Gainesville, FL
4:30
PD49-07 IMPACT OF AORTIC CALCIFICATION
BURDEN ON RENAL FUNCTION
RECOVERY IN RCC PATIENTS AFTER
RADICAL NEPHRECTOMY
Ken Fukushi*, Shingo Hatakeyama, Hayato
Yamamoto, Atsushi Imai, Takahiro
Yoneyama, Yasuhiro Hashimoto, Takuya
Koie, Chikara Ohyama, Hirosaki, Japan
MONDAY
Podium Session 49
4:40
PD49-08 TRENDS IN THE USE OF PARTIAL
NEPHRECTOMY FOR CT1 RENAL
TUMORS: ANALYSIS OF A 10-YR
EUROPEAN MULTICENTER DATASET
Giuseppe Simone*, turin, Italy, Cosimo De
Nunzio, Isabella Sperduti, Rome, Italy, Luca
Cindolo, Vasto, Italy, Devis Collura, Turin,
Italy, Sabine Brookman-May, Munich,
Germany, Rocco Papalia, Mariaconsiglia
Ferriero, Costantino Leonardo, Rome, Italy,
Orietta Dalpiaz, Graz, Austria, Michele Lodde,
Emanuela Trenti, Bolzano, Italy, Stefan Hatzl,
Graz, Austria, Antonio Pastore, Giovanni
Palleschi, Latina, Italy, Giuseppe
Lotrecchiano, Luigi Salzano, Benevento, Italy,
Antonio Carbone, Latina, Italy, Ottavio De
Cobelli, Milan, Italy, Andrea Tubaro, Rome,
Italy, Luigi Schips, Vasto, Italy, Richard
Zigeuner, Graz, Austria, Giovanni Muto, turin,
Italy, Michele Gallucci, Rome, Italy
4:50
PD49-09 MATCHED ANALYSIS OF CANCERSPECIFIC SURVIVALS BETWEEN
PAPILLARY TYPE-2 VERSUS CLEAR-CELL
Giuseppe Simone*, Rocco Papalia,
Mariaconsiglia Ferriero, Manuela Costantini,
Riccardo Mastroianni, Salvatore Guaglianone,
Michele Gallucci, Rome, Italy
5:00
PD49-10 TECHNIQUE, TUMOR SIZE OR INHERENT
PATIENT COMORBIDITIES: WHAT DRIVES
LONG-TERM RENAL FUNCTIONAL
OUTCOMES IN PATIENTS UNDERGOING
PARTIAL NEPHRECTOMY?
Louis Krane*, James T Rague, Ahmed
Aboumohamed, Ashok K Hemal, Winston
Salem, NC
5:10
PD49-11 SURGICAL CHRONIC KIDNEY DISEASE
APPEARS TO BE A DISTINCT SUBTYPE
OF CHRONIC KIDNEY DISEASE BASED
ON MORTALITY RISKS FOLLOWING
RENAL SURGERY
Ronak Gor*, Robert Uzzo, Tianyu Li,
Mohammed Haseebuddin, Nikhil Waingankar,
Serge Ginzburg, Marc Smaldone, Alexander
Kutikov, Philadelphia, PA
5:20
PD49-12 CLINICOPATHOLOGIC
CHARACTERISTICS AND SURVIVAL FOR
ADULT RENAL SARCOMA: A
Daniel Moreira*, Boris Gershman, R. Houston
Thompson, Scott Okuno, Steven Robinson,
Bradley Leibovich, Stephen Boorjian,
Rochester, MN
CREDITTM
3:30 pm - 5:30 pm
Video Session 12
RECONSTRUCTION
Moderators: Richard Lee and Hadley Wood
ABSTRACT
NUMBER TITLE
V12-01 LAPAROSCOPIC OMENTOPLASTY TO
SUPPORT ANASTOMOTIC
URETHROPLASTY IN COMPLEX AND
REDO PELVIC FRACTURE URETHRAL
DEFECT PATIENTS
Sanjay B. Kulkarni*, Walid Shahrour, Pankaj
Joshi, Craig Hunter, Sandesh Surana, pune,
India, Guido Barbagli, Arezzo, Italy
V12-02
ABSTRACT
NUMBER TITLE
V12-03 IN-SITU ROBOTIC ILEAL NEOBLADDER:
TIPS TO AVOID COMPLICATIONS
Jayram Krishnan*, Las Vegas, NV, Daniel
Ramirez, Jihad Kaouk, Cleveland, OH
V12-04
PEDICLE PREPUTIAL TUBE FOR PELVIC
FRACTURE URETHRAL DEFECT AND
ISCHEMIC BULBAR URETHRA
Sandesh Surana, Sanjay Kulkarni, Pune,
India
250
ONE-STAGE RECONSTRUCTION OF
OBLITERATIVE DISTAL ANTERIOR
URETHRAL STRICTURES WITH
CIRCULAR BUCCAL MUCOSA GRAFT
Fikret Fatih Onol*, Sinasi Yavuz Onol, Ahmet
Bindayi, Ahmet Tahra, Ugur Boylu, Eyüp Veli
Küçük, Istanbul, Turkey
V12-06
V12-07
THE PATIO-REPAIR FOR
URETHROCUTANEOUS FISTULA:
PRESERVE THE TRACT AND TURN IT
INSIDE OUT
Jennifer Kranz*, Petra Anheuser, Joachim
Steffens, Eschweiler, Germany, Peter
Malone, Reading, United Kingdom
RETROPERITONEAL LAPAROSCOPIC
REIMPLANTATION OF THE LEFT RENAL
VEIN FOR NUTCRACKER SYNDROME
Ming Chen*, Tao Tao, Bin Xu, Lei Zhang,
Shu-qiu Chen, Xiao-wen Zhang, Yu Yang,
TOTALLY INTRACORPOREAL ROBOTASSISTED VESCICA ILEALE PADOVANA
(VIP) USING STAPLERS: A STEPWISE
APPROACH
Rocco Papalia*, Giuseppe Simone,
Salvatore Guaglianone, Gallucci Michele,
Rome, Italy
V12-08
EXTRAPERITONEAL ROBOT-ASSISTED
REPAIR OF A PELVIC FRACTURE
ASSOCIATED URETHRAL INJURY
Vineet Agrawal, Helen R Levey*, Robert
Davis, Jean Joseph, Rochester, NY
V12-09
COMPLEX ROBOTIC URETEROPLASTY
USING BUCCAL MUCOSAL ONLAY GRAFT
FOR TREATMENT OF 3CM PROXIMAL
URETERAL STRICTURE
Carrie Stewart*, Michael Maddox, Michael
Ellis, Benjamin Lee, New Orleans, LA
V12-10
HAND-ASSISTED LAPAROSCOPIC RIGHT
COLON MOBILIZATION FOR CONTINENT
CUTANEOUS ILEAL CECOCYSTOPLASTY
Travis Pagliara*, Daniel Liberman, Sean
V12-11
ROBOTIC ILEAL URETER: STEP BY STEP
Sameer Chopra*, Charles Metcalfe, Andre
Luis de Castro de Abreu, Raj Satkunasivam,
Raed A. Azhar, Inderbir Gill, Monish Aron,
Mihir Desai, Andre K. Berger, Los Angeles,
CA
V12-12
TWO-STAGE URETHROPLASTY WITH
PREFABRICATED GRACILIS-BUCCAL
MUCOSA COMPOSITE FLAP
Stephen Blakely, Henry Okafor*, Dmitriy
Nikolavsky, Syracuse, NY
V12-13
URETHROLYSIS FOR SYNTHETIC PERIURETHRAL BULKING AGENT
COLLECTION
Tony Nimeh*, William Kobak, Whitney
Halgrimson, Ervin Kocjancic, Chicago, IL
V12-14
SYNCHRONOUS PANNICULECTOMY AND
ILEAL CONDUIT REVISION FOR OBESE
PATIENTS WITH STOMAL STENOSIS
Michael Garcia-Roig*, David Pan, Devendar
Katkoori, Murugesan Manoharan, Miami, FL
CREDITTM
5:00 pm - 6:00 pm
SWIU WOMEN LEADERS IN UROLOGY FORUM
Grand Salon C @ Hilton New Orleans Riverside
5:00
CREDITTM
CONTROVERSIES IN SUI EVALUATION AND
TREATMENT
Moderator: Leslie Rickey
Panelists: Melissa Kaufman, Una Lee, Donna Deng
5:30 pm - 7:00 pm
AQUA REGISTRY FORUM
Jefferson Ballroom @ Hilton New Orleans Riverside
5:30
OPENING REMARKS
J. Quentin Clemens
5:35
AQUA VIDEO SHOW
5:40
HOW REGISTRY CAN BENEFIT SURGICAL
SPECIALTY, SPECIALTY SOCIETY AND
HEALTHCARE SYSTEM
David Hoyt
6:00
EXPERIENCE WITH IMPLEMENTING A
REGISTRY FROM A PHYSICIAN PERSPECTIVE
William Rich
*Presenting author
251
6:20
PANEL DISCUSSION
Moderator: J. Quentin Clemens
Panelists: Mathew Cooperberg, David Hoyt, William
Rich, Tim Parr (software), Diane Bieri (General
Counsel), Alec Koo (Site Representative-Skyline
Urology)
6:35
AUDIENCE QUESTIONS
6:45
CLOSING REMARKS
J. Stuart Wolf
7:00
ADJOURN
MONDAY
V12-05
NOTES
Plenary Session
7:30 am - 4:00 pm
7:28
7:30
STATE-OF-THE-ART LECTURE: CONTEMPORARY UPDATE ON TREATMENT OF NON INVASIVE BLADDER
CANCER
Sam Chang
7:45
STATE-OF-THE-ART LECTURE: BACILLUS CALMETTE-GUERIN (BCG) REFRACTORY CARCINOMA IN SITU (CIS)
OF THE BLADDER
Michael Cookson
8:00
SOCIÉTÉ INTERNATIONALE D’UROLOGIE (SIU) LECTURE: REDEFINING OPTIMAL SURGICAL MANAGEMENT
OF MUSCLE INVASIVE BLADDER CANCER
Peter Black
8:20
POINT-COUNTERPOINT: NEOADJUVANT CHEMOTHERAPY FOR MIBC IS BEST
Moderator:
Colin Dinney
Debaters:
Badrinath Konety (Con)
Ralph deVere White (Pro)
8:40
STATE-OF-THE-ART LECTURE: RAPAMYCIN IMPROVES T CELL IMMUNITY IN CANCER
Robert Svatek
8:55
STATE-OF-THE-ART LECTURE: MANAGEMENT OF RADIATION INDUCED URETERAL STRICTURES
Hadley Wyre
9:10
PANEL DISCUSSION: CHEMOTHERAPY VS. RPLND FOR STAGE II NSGCT DISEASE
Moderator:
Joel Sheinfeld
Panelists:
Richard Foster
Andrew Stephenson
Timothy Masterson
9:35
STATE-OF-THE ART LECTURE: VASECTOMY AND PROSTATE CANCER - RECENT DEVELOPMENT: A CRITICAL
ANALYSIS
Thomas Walsh
9:50
BEST ABSTRACT: PI-06: TCF21, A NOVEL METASTASIS SUPPRESSOR, PROMOTES THE ACQUISITION OF A
LUMINAL PHENOTYPE IN HUMAN BLADDER CANCER
Isuru Jayaratna*, Houston, TX, Sima Porten, San Francisco, CA, Beat Roth, Bern, Switzerland, Tiewei Cheng,
Jonathan Melquist, Woonyoung Choi, Shanna Pretzsch, Jolanta Bondaruk, Charles Guo, Bogdan Czerniak, David
McConkey, Colin Dinney, Houston, TX
9:57
BEST ABSTRACT: PI-07: A TRANSPLANT-BASED SURGICAL APPROACH MAY IMPROVE POSTOPERATIVE
COMPLICATIONS IN CASES OF RENAL CELL CARCINOMA AND TUMOR THROMBUS
Estefania Linares Espinós*, Javier González, Juan I. Martı́nez-Salamanca, Madrid, Spain, Giacomo Novara, Padua,
Italy, Roberto Bertini, Milan, Italy, Joaquı́n Carballido, Madrid, Spain, Thomas Chromecki, Graz, Germany, Gaetano
Ciancio, Miami, FL, Siamak Daneshmand, Los Angeles, CA, Christopher Evans, Sacramento, CA, Paolo Gontero,
Turin, Italy, Alex Haferkamp, Frankfurt, Germany, Markus Hohenfellner, Heidelberg, Germany, William C. Huang, New
York, NY, Theresa Koppie, Portland, OR, Danny Lascano, New York, NY, Adam Lorentz, Atlanta, GA, Alon Y. Mass,
New York, NY, Viraj Master, Atlanta, GA, James McKiernan, New York, NY, Carmen Mir, Miami, FL, Carrie
Mlynarczyk, New York, NY, Francesco Montorsi, Milan, Italy, Hao Nguyen, Sacramento, CA, Sascha Pahernik,
Heidelberg, Germany, Juan Palou, Barcelona, Spain, Raj Pruthi, Chapel Hill, NC, Oscar Rodrı́guez-Faba, Barcelona,
Spain, Paul Russo, Douglas S. Scherr, New York, NY, Shahrokh Shariat, Vienna, Austria, Martin Spahn, Wuzburg,
Germany, Carlo Terrone, Novara, Italy, Derya Tilki, Sacramento, CA, Daniel Vergho, Wuzburg, Germany, Eric Wallen,
Chapel Hill, NC, Richard Zigeuner, Graz, Austria, John A. Libertino, Burlington, MA
10:04
BEST ABSTRACT: PI-08: COMBINING URINE PCA3 AND TMPRSS2:ERG TESTS TO REFINE PROSTATE CANCER
DETECTION - VALIDATION STUDY AND HEALTH ECONOMIC ANALYSIS
Martin Sanda*, Atlanta, GA, Ziding Feng, Houston, TX, John Wei, Ann Arbor, MI, David Howard, Atlanta, GA, Mark
Rubin, New York, NY, Jack Groskopf, San Diego, CA, Lori Sokoll, Daniel Chan, Baltimore, MD, Meredith Regan,
Boston, MA, Dattatraya Patil, Atlanta, GA, Simpa Salami, Manhasset, NY, Javed Siddiqui, Ann Arbor, MI, Douglas
Scherr, New York, NY, Jacob Kagan, Sudhir Srivastava, Bethesda, MD, Ian Thompson, San Antonio, TX, Aaron Joon,
Houston, TX, Arul Chinnayian, Scott Tomlins, Ann Arbor, MI
10:11
BEST ABSTRACT: PI-09: PRECLINICAL TESTING OF SMALL MOLECULE HIF2␣ INHIBITOR IN ZEBRAFISH AND
MOUSE MODELS OF VHL-DEFICIENT RENAL CELL CARCINOMA
Meike Schneider*, Ana Metelo, Haley Noonan, Xiang Li, Jing Youngnam, Nick Olson, Rania Baker, Charlestown, MA,
Lee Kamentsky, Cambridge, MA, Yiyun Zhang, Charlestown, MA, Anne Carpenter, Cambridge, MA, Jing-Ruey Yeh,
Randall Peterson, Othon Iliopoulos, Charlestown, MA
*Presenting author
253
TUESDAY
PLENARY I - TUESDAY
10:18
BEST ABSTRACT: PI-10: DECLINING RATES OF RETROPERITONEAL LYMPH NODE DISSECTION FOR STAGE I
NON-SEMINOMATOUS GERM CELL TUMORS: RESULTS FROM THE NATIONAL CANCER DATABASE
Mohammed Haseebuddin*, Elizabeth Handorf, Alexander Kutikov, Nikhil Wainganker, Yu-Ning Wong, Elizabeth
Plimack, Robert Uzzo, Marc Smaldone, Philadelphia, PA
10:30
PANEL DISCUSSION: A DECADE OF FOLLOW UP: WHAT LESSONS HAVE WE LEARNED?
10:30
MID URETHRAL SLING
Carl Klutke
10:40
Timothy Boone
10:50
PERCUTANEOUS SURGERY FOR STONES
Jorge Gutierrez-Aceves
11:00
CYSTECTOMY FOR INVASIVE BLADDER CANCER
Oliver Hakenberg
11:10
CONTINENT DIVERSIONS
Joachim Thüroff
11:20
SCREENING FOR PROSTATE CANCER
Fritz Schroder
11:30
ROBOTIC PROSTATECTOMY
Mani Menon
11:40
CHANGES IN PROSTATE GRADING
Jonathan Epstein
11:50
PARTIAL NEPHRECTOMY
Paul Russo
12:00
BREAK
1:00
HIGHLIGHTS OF THE AUA’S NATIONAL CURRICULUM FOR MEDICAL STUDENT EDUCATION
Paul Turek
1:08
TOP 3 AWARD WINNING VIDEOS
TAKE HOME MESSAGES
1:30
PROSTATE CANCER
Gyung Sung
1:40
BASIC SCIENCE RESEARCH
Sunil Sudarshan
1:50
INFECTION/INFLAMMATION
Majid Mirzazadeh
2:00
INFERTILITY/ANDROLOGY
Ranjith Ramasamy
2:10
STONE DISEASE/ENDOUROLOGY
Benjamin Canales
2:20
TRANSPLANTATION/VASCULAR SURGERY
Dicken Ko
2:30
PENILE, TESTIS AND URETHRAL CANCER
Makarand Khochikar
2:40
TRAUMA/RECONSTRUCTION/DIVERSION
Robert Kovell
2:50
SEXUAL FUNCTION/DYSFUNCTION
Landon Trost
3:00
FEMALE UROLOGY/INCONTINENCE/URODYNAMICS
Gamal Ghoniem
3:10
BPH/LUTS
Richard Lee
254
3:20
MINIMALLY INVASIVE SURGERY (LAPAROSCOPY/ROBOTICS)
Benjamin Lee
3:30
OUTCOMES ANALYSIS
Karim Chamie
3:40
KIDNEY CANCER
Gennady Bratslavsky
3:50
BLADDER CANCER
Amar Singh
4:00
SESSION CONCLUDES
Plenary Session
10:00 am - 12:05 pm
9:58
10:00
STATE-OF-THE-ART LECTURE: SHARED DECISION MAKING
Danil Makarov
10:15
STATE-OF-THE-ART LECTURE: AUA CENSUS REPORT
J. Quentin Clemens
10:30
CRITICAL DISCUSSION: A KIDNEY TRANSPLANT ROTATION IS A WASTE OF TIME FOR A UROLOGY RESIDENT
Critical Discussant: Michael Coburn
Presenters:
Leonard Gomella
Patrick Luke
10:50
STATE-OF-THE-ART LECTURE: UROLOGIC ASPECTS OF ADULT POLYCYSTIC KIDNEY DISEASE
Paul Andrews
11:05
STATE-OF-THE-ART LECTURE: ULTRASOUND PROPULSION OF STONES
Michael Bailey, Jonathan Harper
11:20
STATE-OF-THE-ART LECTURE: ROLE OF ROBOTIC SURGERY IN RENAL TRANSPLANTATION
Rajesh Ahlawat
11:35
STATE-OF-THE-ART LECTURE: UPDATE ON RADIUM RA 223 DICHLORIDE THERAPY, POST FDA APPROVAL
Erik Mittra
11:50
STATE-OF-THE-ART LECTURE: CONSENSUS STATEMENT ON ADVANCED PRACTICE PROVIDERS
Aaron Spitz
12:05
SESSION CONCLUDES
8:00 am - 10:00 am
INFERTILITY: BASIC RESEARCH, PHYSIOLOGY, PATHOPHYSIOLOGY
Moderators: Dolores Lamb and Marc Goldstein
ABSTRACT
NUMBER TITLE
MP76-01 EXPRESSION AND ROLE OF LEPTIN
UNDER HYPOXIC CONDITIONS IN HUMAN
TESTIS: ORGANOTYPIC IN-VITRO
CULTURE EXPERIMENT AND CLINICAL
STUDY ON PATIENTS WITH VARICOCELE
Kai Ni, Klaus Steger, Giessen, Germany, Hao
Yang, Hongxiang Wang, Kai Hu, Bin Chen*,
*Presenting author
ABSTRACT
NUMBER TITLE
MP76-02 SPERM PROTAMINE MRNA RATIO AND
DNA FRAGMENTATION INDEX
REPRESENT RELIABLE CLINICAL
BIOMARKERS FOR MEN WITH
VARICOCELE AFTER MICROSURGICAL
VARICOCELE LIGATION
Kai Ni, Klaus Steger*, Giessen, Germany,
Hao Yang, Hongxiang Wang, Kai Hu, Bin
Chen, Shanghai, China, People’s Republic of
255
TUESDAY
PLENARY II - TUESDAY
MP76-09 DIFFERENTIATING KLINEFELTER
SYNDROME FROM OTHER ETIOLOGIES
OF AZOOSPERMIA USING MICRORNA
Jennifer Reifsnyder*, Anna Mielnik, Peter
Schlegel, Darius Paduch, New York, NY
MP76-03 CORRELATIONS BETWEEN
HISTOPATHOLOGY, PROTAMINE-MRNA
EXPRESSION AND SPERM RETRIEVAL
OUTCOME IN TESTICULAR BIOPSIES
FROM SUBFERTILE MEN
Adrian Pilatz, Hans-Christian Schuppe, Julia
Wolf, Judith Fechner, Thorsten Diemer,
Martin Bergmann, Wolfgang Weidner, Klaus
Steger*, Giessen, Germany
MP76-10 MSH5 DEFICIENCIES IN A SUBSET OF
NOA MEN
Koji Chiba*, Alex Ridgeway, Larry Lipshultz,
Houston, TX, Masato Fujisawa, Kobe, Japan,
Dolores Lamb, Houston, TX
MP76-04 SPERMATOGENESIS OF TUMORBEARING TESTES IN GERM CELL
TESTICULAR CANCER PATIENTS
Keisuke Suzuki*, Takeshi Shin, Yukihito
Shimomura, Toshiyuki Iwahata, Ryo Sato,
Koujiro Nishio, Hiroshi Yagi, Gaku Arai,
Shigehiro Soh, Hiroshi Okada, Koshigaya,
Japan
MP76-11 IDENTIFICATION OF
SPERMATOGENICALLY ACTIVE REGIONS
IN RAT TESTIS BY USING NARROW BAND
IMAGING SYSTEM
Noritoshi Enatsu*, Hideaki Miyake, Masato
Fujisawa, Kobe city, Japan
MP76-12 GRANDPATERNAL AGE AND SEMEN
QUALITY: EVIDENCE FROM THE UTAH
POPULATION DATABASE
James Hotaling, Ross Anderson*, Heidi
Hanson, Darshan Patel, Jeffrey Redshaw,
Chong Zhang, Angela Presson, Kenneth
Aston, Douglas Carrell, Ken Smith, Salt Lake
City, UT
MP76-05 LENGTH OF INFERTILITY AFFECTS
SEMINAL PARAMETERS - FINDINGS OF A
CROSS-SECTIONAL SURVEY IN WHITEEUROPEAN MEN PRESENTING FOR
PRIMARY COUPLE’S INFERTILITY
Eugenio Ventimiglia*, Luca Boeri, Paolo
Capogrosso, Giovanni La Croce, Alessandro
Serino, Giulia Castagna, Angela Pecoraro,
Marco Paciotti, Roberta Scano, Alberto
Briganti, Milan, Italy, Francesco Cantiello,
MP76-13 EFFECTS OF PERINATAL AND/OR
POSTNATAL HIGH-FAT DIET ON
TESTICULAR MORPHOLOGY AND SPERM
PARAMETERS IN ADULT WISTAR RATS
Pamella Campos-Silva, Flavia FernandesLima, Angelo Fernandes-Neto, Diogo B. De
Souza, Waldemar S. Costa, Francisco J. B.
Sampaio, Rio de Janeiro, Brazil, Fernanda
A. M. Nascimento, Macaé, Brazil, Bianca M.
Gregorio*, Rio de Janeiro, Brazil
MP76-06 WHOLE-EXOME SEQUENCING IDENTIFIES
NOVEL HOMOZYGOUS MUTATION IN
NPAS2 IN FAMILY WITH
NONOBSTRUCTIVE AZOOSPERMIA
Ranjith Ramasamy*, Houston, TX, Emre
Bakircioglu, Istanbul, Turkey, Cenk Cengiz,
Ender Karaca, Jason Scovell, Matthew
Bainbridge, James Lupski, Dolores Lamb,
Houston, TX
MP76-14 POSTTRANSLATIONAL MODIFICATIONS
BY SUMOYLATION AFFECT ACTIVITY OF
SERTOLI CELL SIGNALLING NETWORKS
Keisuke Okada*, KeumSil Hwang, Patricia
Morris, New York, NY
MP76-07 ANTIOXIDANTS ADMINISTRATION
MANAGED TO RESCUE TESTICULAR
CELLS’ DNA OXIDATIVE DAMAGE AND
APOPTOSIS BILATERALLY, IN THE
UNILATERALLY CRYPTORCHIDIZED RAT
MODEL
Panagiota Tsounapi*, Masashi Honda,
Yonago, Japan, Fotios Dimitriadis,
Thessaloniki, Greece, Shogo Shimizu,
Nankoku, Japan, Michiyo Iguchi, Masaki
Imanishi, Shinji Matsunaga, Bunya
Kawamoto, Katsuya Hikita, Kuniyasu
Muraoka, Takehiro Sejima, Yonago, Japan,
Motoaki Saito, Nankoku, Japan, Nikolaos
Sofikitis, Ioannina, Greece, Shuhei Tomita,
Atsushi Takenaka, Yonago, Japan
MP76-15 DIETARY HABITS AND REPRODUCTIVE
HEALTH - RESULTS OF A SOCIOLOGICAL
CASE-CONTROL STUDY
Luca Boeri*, Alessandro Galdini, Roberta
Scano, Eugenio Ventimiglia, Alessandro
Serino, Paolo Capogrosso, Giovanni La
Croce, Giulia Castagna, Silvia Ippolito, Luca
Valsecchi, Enrico Papaleo, Massimo
Candiani, Francesco Montorsi, Andrea
MP76-16 IMPACT OF PRECISE MODULATION OF
REACTIVE OXYGEN SPECIES LEVELS ON
SPERMATOZOA PROTEINS IN INFERTILE
MEN
Rakesh Sharma*, Ashok Agarwal, Ahmet
Ayaz, Edmund Sabanegh, Cleveland, OH
MP76-08 THE EFFECT OF BOSENTAN, AN
ENDOTHELIN-1 RECEPTOR ANTAGONIST
ON TESTICULAR TISSUE OXIDANT AND
ANTIOXIDANT LEVELS IN DIABETIC RATS
Erdal Alkan, Istanbul, Turkey, RüstemAnýl
Urgan, Erzurum, Turkey, Mehmet Murad
Basar*, Istanbul, Turkey, Zekai Halýcý,
Erzurum, Turkey, Mevlana Derya Balbay,
Istanbul, Turkey, Harun Un, Agri, Turkey,
Hasan Tarik Atmaca, Kirikkale, Turkey
MP76-17 SUPPLEMENTATION OF CRYOMEDIUM
WITH CATALASE AND N-ACETYL
CYSTEINE IMPROVES HUMAN SPERM
POST-THAW MOTILITY
Yoshitomo Kobori*, Craig Niederberger, Gail
Prins, Chicago, IL
256
MP76-20 HUMAN SPERM MIRNA PROFILE IN
PATIENTS WITH NORMOZOOSPERMIA
AND TERATOZOOSPERMIA
Amin Herati*, Anna Mielnik, Peter Schlegel,
Darius Paduch, New York, NY
MP76-18 MALE INFERTILITY AND SINGLE
NUCLEOTIDE POLYMORPHISMS OF THE
NOVEL SEX-LINKED TESTIS-SPECIFIC
RETROTRANSPOSED PGAM4 GENE
Yasushi Miyagawa*, Tetsuji Soda, Kentaro
Takezawa, Shinichiro Fukuhara, Hiroshi
Kiuchi, Suita, Japan, Hidenobu Okuda,
Victoria, Australia, Hiromitsu Tanaka, Sasebo,
Japan, Norio Nonomura, Suita, Japan
CREDITTM
MP76-19 DNA FRAGMENTATION MAPPING OF THE
MALE GENITAL TRACT
Ashley Winter*, Bobby Najari, Gianpiero
Palermo, Darius Paduch, Marc Goldstein,
New York, NY
8:00 am - 10:00 am
ABSTRACT
NUMBER TITLE
MP77-01 NATURAL HISTORY OF PROSTATIC
LESIONS ON SERIAL MULTIPARAMETRIC
MRI
Samrad Ghavimi, Richard Savdie*,
Hamidreza Abdi, Silvia Chang, Alison Harris,
Lindsay Machan, Martin Gleave, Alan So,
Larry Goldenberg, Peter Black, Vancouver,
Canada
ABSTRACT
NUMBER TITLE
MP77-04 MEN UNDER THE AGE OF 55 YEARS
HAVE SIMILAR PROSTATE CANCER
PATHOLOGY AS OLDER MEN:
IMPLICATIONS FOR THE AUA
SCREENING POLICY
Nandu Dantanarayana*, Tania Hossack, Paul
Cozzi, Andrew Brooks, Howard Lau, Warwick
Delprado, Manish Patel, Sydney, Australia
MP77-05 IS RACE PREDICTIVE OF A FUTURE
PROSTATE CANCER DIAGNOSIS AFTER
AN INITIAL NEGATIVE BIOPSY?
William A. Sterling*, Jeffrey P. Weiss, David
Schreiber, Nicholas Karanikolas, Jeremy
Weedon, Komal Mehta, William Atallah, Ari
Bergman, Brooklyn, NY
MP77-02 THE ANTITHROMBOTIC AGENTS DO NOT
NEED TO DISCONTINUE PRIOR
TRANSRECTAL ULTRASOUND-GUIDED
PROSTATE BIOPSY: A SINGLE CENTER
EXPERIENCE
Kuniaki Tanabe*, Yasuhiro Maki, Kyoko
Koike, Hirohito Kobayashi, Ebina-shi, Japan,
Takashi Arai, Kita-Kyushu-shi, Japan,
Yukihiro Kondo, Bunkyo-ku, Japan, Tomotaka
Hattori, Naoki Kawamura, Ebina-shi, Japan
MP77-06 FATE OF PATHOLOGICAL GLEASON
SCORE 7 (3ⴙ4) IN CANDIDATES FOR
ACTIVE SURVEILLANCE; ROYAL
MARSDEN HOSPITAL CRITERIA
Jung Ki Jo*, In Jae Lee, Tae Jin Kim, Kwang
Mo Kim, Young Ik Lee, Hakmin Lee,
Sangchul Lee, Seong Jin Jeong, Sung Kyu
Hong, Seok-Soo Byun, Sang Eun Lee, Jong
Jin Oh, Seongnam-si, Korea, Republic of
MP77-03 GLEASON SCORE UPGRADING TO 8-10
PREDICTS BIOCHEMICAL RECURRENCE
IN MEN UNDERGOING RADICAL
PROSTATECTOMY: ANALYSIS ON 7310
HIGH-RISK PATIENTS FROM THE
EMPACT DATABASE
Marco Oderda, Paolo Gontero*, Giancarlo
Marra, Turin, Italy, Rafael Sanchez-Salas,
Paris, France, Joachen Walz, Hamburg,
Germany, Patrick Bastian, Muinchen,
Germany, Felix Chun, Hamburg, Germany,
Henk Van Der Poel, Amsterdam,
Netherlands, Markus Graefen, Hamburg,
Germany, Bertrand Tombal, Leuven, Belgium,
Giansilvio Marchioro, Novara, Italy, Piotr
Chlosta, Kielce, Poland, Lorenzo Tosco,
Leuven, Belgium, Marco Bianchi, Alberto
Briganti, Milan, Italy, Martin Spahn, Bern,
Switzerland, Robert Jeffrey Karnes,
Rochester, MN, Steven Joniau, Leuven,
Belgium
*Presenting author
MP77-07 THE PREVALENCE OF PROSTATE BIOPSY
GLEASON SCORE > 7(3ⴙ4) EXCEEDS
40% IN YOUNG PUERTO RICAN MEN
SCREENED FOR PROSTATE CANCER: A
CASE FOR EARLY DETECTION BEFORE
AGE 55 IN THIS POPULATION
Patricia Maymi*, Ricardo Sanchez-Ortiz, San
Juan, PR
MP77-08 EMPIRIC ANTIBIOTICS FOR AN
ELEVATED PROSTATE-SPECIFIC
ANTIGEN (PSA) LEVEL: A METAANALYSIS ON 862 PATIENTS
Stefano Picozzi, Dario Ratti, Stefano
Casellato, Elisabetta Finkelberg, Giorgio
Bozzini, Carlo Marenghi, Serena Maruccia,
Luca Carmignani*, San Donato Milanese,
Italy
257
TUESDAY
PROSTATE CANCER: DETECTION AND SCREENING VI
Moderators: Robert Weiss and Manfred Wirth
MP77-09 LONG-TERM RISK OF PROSTATE
CANCER IS DIRECTLY RELATED TO
BASELINE PSA:
Kara Choate, Jonathan Gelfond, Donna
Ankerst*, Javier Hernandez, Robin Leach, Ian
Thompson Jr., San Antonio, TX
MP77-16 THE USE OF DECISIONAL AIDS FOR
PROSTATE CANCER SCREENING: A
META-ANALYSIS
Jody Purifoy*, Benjamin Schurhamer,
Matthew Katz, Sheila Thomas, Barbara Pate,
Rodney Davis, Little Rock, AR
MP77-10 THE INFLUENCE OF PHYSICIAN
RECOMMENDATION ON PSA SCREENING
Daniel Pucheril*, Deepansh Dalela, Jesse
Sammon, Akshay Sood, Detroit, MI, Maxine
Sun, Montreal, Canada, Julian Hanske,
Christian Meyer, Quoc-Dien Trinh, Boston,
MA, Mani Menon, Firas Abdollah, Detroit, MI
MP77-17 PERFORMANCE OF URINARY
BIOMARKER PCA3 AMONG MEN
UNDERGOING TARGETED MRIULTRASOUND FUSION BIOPSY
Xiaosong Meng, Andrew B. Rosenkrantz,
MP77-11 PROSTATIC CAPSULAR INVASION: CAN
PREOPERATIVE MP-MRI PREDICT THE
PATHOLOGICAL ANALYSIS?
Francesco Porpiglia, Matteo Manfredi*,
Fabrizio Mele, Orbassano (Turin), Italy,
Filippo Russo, Daniele Regge, Candiolo
(Turin), Italy, Agostino De Pascale,
Orbassano (Turin), Italy, Stefano Cirillo,
Torino, Italy, Enrico Bollito, Mauro Papotti,
Cristian Fiori, Orbassano (Turin), Italy
MP77-18 OUTCOMES OF MRI-US FUSION
WITH HISTORY OF PROSTATIC
INTRAEPITHELIAL NEOPLASIA AND/OR
ATYPICAL SMALL ACINAR
PROLIFERATION: EVIDENCE FOR AN
ALTERATION OF CURRENT PRACTICE
Ming Zhou, William C Huang, Herbert Lepor,
Samir S Taneja, New York, NY
MP77-12 CONTEMPORARY PATTERNS OF SELFREPORTED PSA SCREENING IN U.S.
VETERANS
Daniel Pucheril*, Jesse Sammon, Akshay
Sood, Firas Abdollah, Detroit, MI, Toni
Choueiri, Julian Hanske, Christian Meyer,
Paul Nguyen, Adam Kibel, Boston, MA, Mani
Menon, Detroit, MI, Joel Weissmann, QuocDien Trinh, Boston, MA
MP77-19 BASELINE PSA LEVELS IN MEN AGED 4060 ARE INFLUENCED BY RACE, BODY
MASS INDEX (BMI) AND
WAIST-CIRCUMFERENCE: A CROSSSECTIONAL POPULATION-BASED STUDY
USING THE NATIONAL HEALTH AND
NUTRITION EXAMINATION SURVEY
(NHANES, 2001-2010)
Mark A Preston*, Julie L Batista, Samuel F
Peisch, Sarah Markt, Taylor Medwig, Kathryn
M Wilson, Quoc-Dien Trinh, Adam S Kibel,
Meir Stampfer, Lorelei A Mucci, Boston, MA
MP77-13 DEFICIENCIES IN PSA SCREENING
PRACTICES IN BLACK MEN AGED 55-69
IN THE UNITED STATES
Jesse Sammon*, Firas Abdollah, Akshay
Sood, Dane Klett, Daniel Pucheril, James
Peabody, Mani Menon, Detroit, MI, QuocDien Trinh, Boston, MA
MP77-14 OUTCOMES OF MRI-US FUSION
WITHOUT HISTORY OF PREVIOUS
BIOPSY: REDUCTION OF OVERDETECTION AND IMPROVED RISK
STRATIFICATION
Jonathan Melamed, Ming Zhou, William C
Huang, Herbert Lepor, Samir S Taneja, New
York, NY
MP77-20 AMONG MEN WITH LOW-GRADE
PROSTATE CANCER ON PROSTATE
BIOPSY, THE 4KSCORE PREDICTS MORE
AGGRESSIVE PROSTATE CANCER AT
PROSTATECTOMY
Sanoj Punnen*, Miami, FL, Stephen Zappala,
Andover, MA, Dan Sjoberg, New York, NY,
Vinita Mathur, Michael Reeve, Dipen Parekh,
Miami, FL
CREDITTM
MP77-15 PRESENCE OF MRI SUSPICIOUS LESION
PREDICTS CLINICALLY SIGNIFICANT
PROSTATE CANCER FOR BIOPSY NAÏVE
PATIENTS
Eric H Kim*, Adam J Rensing, Joel M Vetter,
Kathryn J Fowler, Gerald L Andriole, John K.
Weaver, St. Louis, MO
258
8:00 am - 10:00 am
PROSTATE CANCER: LOCALIZED VIII
Moderator: Jean Joseph
ABSTRACT
NUMBER TITLE
MP78-01 CONTEMPORARY MANAGEMENT OF
PROSTATE CANCER PATIENTS SUITABLE
FOR ACTIVE SURVEILLANCE: A
Nicola Fossati, Justin K. Lee, New York, NY,
Quoc-Dien Trinh, Boston, MA, Jesse
Sammon, Akshay Sood, Detroit, MI,
Alessandro Larcher, Giorgio Gandaglia,
Giorgio Guazzoni*, Milan, Italy, Pierre I
Karakiewicz, Montreal, Canada, Shahrokh F.
Shariat, Vienna, Austria, Francesco Montorsi,
Alberto Briganti, Milan, Italy, Mani Menon,
Firas Abdollah, Detroit, MI
ABSTRACT
NUMBER TITLE
MP78-05 OPEN VERSUS ROBOT-ASSISTED
CONTEMPORARY ANALYSIS OF AN ALLPAYER DISCHARGE DATABASE
Jeffrey Leow*, Christian Meyer, Julian
Hanske, Boston, MA, Marianne Schmid,
Hamburg, Germany, Benjamin Chung,
Stanford, CA, Quoc-Dien Trinh, Steven
Chang, Boston, MA
MP78-02 RELATIONSHIP BETWEEN THE
CONTINUITY AND DISCONTINUITY OF
TWO POSITIVE CORES IN PROSTATE
BIOPSY SPECIMENS FOR THE
PREDICTION OF LOW-RISK PROSTATE
CANCER AND IDENTIFICATION OF
CANDIDATES FOR ACTIVE
SURVEILLANCE
Sangjun Yoo*, Chanwoo Lee, Mooyoung
Sohn, Chunwoo Lee, Seoul, Korea, Republic
of, Sungwoo Hong, Hyung Jee Kim,
Cheonan, Korea, Republic of, Sang Hoon
Song, Kun Suk Kim, Dalsan You, Taekmin
Kwon, In Gab Jeong, Seoul, Korea, Republic
of, Sungchan Park, Kyung Hyun Moon,
Ulsan, Korea, Republic of, Jun Hyuk Hong,
Hanjong Ahn, Choung-Soo Kim, Seoul,
Korea, Republic of
MP78-07 SALVAGE RADICAL PROSTATECTOMY
FOR LOCALLY RECURRENT PROSTATE
CANCER AFTER PRIMARY
RADIOTHERAPY: A LARGE
INSTITUTIONAL SERIES WITH 15 YEAR
FOLLOW UP
Vidit Sharma*, Eugene D Kwon, Laureano J
Rangel, R. Jeffrey Karnes, Rochester, MN
MP78-08 LONG-TERM MORBIDITY AND
ONCOLOGICAL OUTCOMES OF SALVAGE
CRYOTHERAPY OF RADIO-RECURRENT
PROSTATE CANCER
Michele Billia*, Khurram Mutahir Siddiqui,
Clarisse R. Mazzola, Christopher Goodman,
Andrew Williams, Joseph Chin, London,
Canada
MP78-03 ASSOCIATION BETWEEN NUMBER OF
PROSTATE BIOPSIES AND PATIENTREPORTED FUNCTIONAL OUTCOMES
AFTER RADICAL PROSTATECTOMY:
IMPLICATIONS FOR ACTIVE
SURVEILLANCE PROTOCOLS
Christopher Anderson*, Amy Tin, Daniel
Sjoberg, John Mulhall, Jaspreet Sandhu,
Karim Touijer, Vincent Laudone, James
Eastham, Peter Scardino, Behfar Ehdaie,
New York, NY
MP78-09 5-YEARS BIOCHEMICAL RECURRENCE
AND OVERALL SURVIVAL RATES AFTER
RADICAL PROSTATECTOMY OR HIGH
DOSE RADIATION BRACHYTHERAPY
WITH ADDITIONAL EXTERNAL BEAM IN
PATIENTS WITH CLINICALLY LOCALIZED
PROSTATE CANCER
Katharina Boehm*, Hans Lesmana, Jonas
Schiffmann, Hamburg, Germany, Alessandro
Larcher, Milan, Italy, Rudolf Schwarz, Derya
Tilki, Hamburg, Germany
MP78-04 INFLUENCE OF RADICAL
PROSTATECTOMY ON SERUM
BIOAVAILABLE TESTOSTERONE LEVEL
IN JAPANESE PATIENTS WITH
LOCALIZED PROSTATE CANCER: A
LONGITUDINAL STUDY
Shoichiro Iwatsuki*, Shoichi Sasaki, Yasue
Kubota, Hiroki Kubota, Hiroyuki Kamiya,
Yukihiro Umemoto, Kenjiro Kohri, Nagoya,
Japan
*Presenting author
MP78-10 CONTEMPORARY USE OF ADJUVANT
AND SALVAGE RADIOTHERAPY
IN THE STATE OF MICHIGAN
Todd Morgan*, David Miller, Khurshid Ghani,
Felix Feng, Susan Linsell, Yuqing Gao,
James Montie, Ann Arbor, MI, Michael Cher,
Detroit, MI
259
TUESDAY
MP78-06 PROPHYLACTIC ANTIBIOTIC TREATMENT
FOR LAPAROSCOPIC ROBOT ASSISTED
RADICAL PROSTATECTOMY – DID THE
AUA GUIDELINES MAKE A CHANGE?
Miki Haifler*, Tel Aviv, Israel, Yoram Mor,
Zohar Dotan, Dorit Zilberman, Ramat gan,
Israel
MP78-15 BIOCHEMICAL RECURRENCE AFTER
RADICAL PROSTATECTOMY: WHO IS AT
RISK OF DYING FROM PROSTATE
CANCER?
Nazareno Suardi*, Giorgio Gandaglia, Paolo
Dell’Oglio, Umberto Capitanio, Niccolò M.
Passoni, Marco Bianchi, Milan, Italy, Firas
Abdollah, Detroit, MI, Pierre Karakiewicz,
Montreal, Canada, Sharokh Shariat, Vienna,
Austria, Giorgio Guazzoni, Francesco
MP78-11 PERIRECTAL HYDROGEL SPACER
APPLICATION IN MEN RECEIVING
PROSTATE RADIOTHERAPY: A
PROSPECTIVE MULTICENTER
Christopher Pieczonka*, Neil Mariados,
Syracuse, NY, John Sylvester, East
Bradenton, FL, Phillip Aliotta, Christopher
Skomra, Cheektowaga, NY, Larry Karsh,
Brian Smith, Denver, CO, Richard Hudes,
Owings Mills, MD, David Beyer, Phoenix, AZ,
Steven Kurtzman, Al Tiara, Campbell, CA,
Jeffrey Bogart, Syracuse, NY, Alex Hsi,
Poulsbo, WA, C. Garo Gholodian, Reno, NV,
Lee Ponsky, Rodney Ellis, Cleveland, OH,
Mark Logsdon, Seth Rosenthal, Sacramento,
CA, Kevin Forsythe, Springfeild, OR, Hong
Zhang, Rochester, NY, Edward Soffen,
Freehold, NJ, Neal Shore, Myrtle Beach, SC,
Constantine Mantz, Fort Meyers, FL, Peter
Nieh, Atlanta, GA, Misop Han, Baltimore, MD
MP78-16 GLYCEMIC CONTROL STATUS AS A
INDEPENDENT PROGNOSTIC FACTOR
FOR BIOCHEMICAL RECURRENCE AFTER
Hakmin Lee*, Ha Rim Kook, Seok-Soo Byun,
Sang Eun Lee, Sung Kyu Hong, Seongnam,
Korea, Republic of
MP78-17 IDENTIFYING THE MOST INFORMATIVE
PREDICTION-TOOL FOR CANCER
SPECIFIC MORTALITY AFTER RADICAL
PROSTATECTOMY: COMPARATIVE
ANALYSIS OF THREE COMMONLY USED
PREOPERATIVE PREDICTION MODELS
Katharina Boehm*, Hamburg, Germany,
Alessandro Larcher, Milan, Italy, Jonas
Schiffmann, Samy Leyh-Bannurah, Uwe
Michl, Hamburg, Germany, Thomas Steuber,
Ha, Germany, Lars Budaeus, Hamburg,
Germany
MP78-12 ASSOCIATION OF CIGARETTE SMOKING
AND SMOKING CESSATION WITH
BIOCHEMICAL RECURRENCE IN
PROSTATECTOMY FOR PROSTATE
CANCER
Malte Rieken*, Basel, Switzerland, Luis Kluth,
Hambug, Germany, Harun Fajkovic, Vienna,
Austria, Pierre Karakiewicz, Montreal,
Canada, Yair Lotan, Dallas, TX, Christian
Seitz, Vienna, Austria, Alberto Briganti, Milan,
Italy, Morgan Rouprêt, Paris, France,
Wolfgang Loidl, Linz, Austria, Richard Lee,
New York, NY, Quoc-Dien Trinh, Boston, MA,
Peter Nyirady, Budapest, Hungary, Alexander
Bachmann, Basel, Switzerland, Gholam-Reza
Pourmand, Tehran, Islamic Republic of Iran,
Shahrokh Shariat, Vienna, Austria
MP78-18 IMPACT OF CAPSULAR INCISION DURING
RADICAL PROSTATECTOMY ON
BIOCHEMICAL RECURRENCE RATES
Philipp Mandel*, Pierre Tennstedt, Luis Kluth,
Alexander Haese, Hartwig Huland, Markus
Graefen, Derya Tilki, Hamburg, Germany
MP78-19 PREDICTING PATHOLOGIC OUTCOMES IN
PATIENTS UNDERGOING ROBOTASSISTED RADICAL PROSTATECTOMY
FOR HIGH-RISK PROSTATE CANCER: A
PREOPERATIVE NOMOGRAM
Jesse Sammon, Daniel Pucheril, Deepansh
Dalela, Mireya Diaz, James Peabody, Detroit,
MI, Quoc-Dien Trinh, Boston, MA, Mani
Menon, Detroit, MI
MP78-13 PROGNOSTIC VALUE OF TUMOR VOLUME
ON DISEASE PROGRESSION OF
PROSTATECTOMY FOR NODE POSITIVE
PROSTATE CANCER
Alessandro Nini*, Giorgio Gandaglia, Umberto
Capitanio, Vincenzo Scattoni, Emanuele
Zaffuto, Marco Bianchi, Nicola Fossati,
Massimo Freschi, Milan, Italy, Francesco
Cantiello, Rocco Damiano, Catanzaro, Italy,
Vincenzo Mirone, Naples, Italy, Francesco
MP78-20 OPEN RADICAL PROSTATECTOMY IN
TRANSPLANT PATIENTS
Burkhard Beyer*, Thomas Steuber, Philipp
Schriefer, Uwe Michl, Hans Heinzer, Thorsten
Schlomm, Hartwig Huland, Markus Graefen,
Derya Tilki, Hamburg, Germany
MP78-14 REDUCING DECISIONAL CONFLICT IN
MEN MAKING TREATMENT DECISIONS
ABOUT LOCALIZED PROSTATE CANCER
David Johnson*, Dana Mueller, Mary Dunn,
Angela Smith, Michael Woods, Eric Wallen,
Raj Pruthi, Matthew Nielsen, Chapel Hill, NC
CREDITTM
260
8:00 am - 10:00 am
TRANSPLANTATION & VASCULAR SURGERY: RENAL TRANSPLANTATION & VASCULAR SURGERY I
Moderators: David Goldfarb and Mark Jordan
ABSTRACT
NUMBER TITLE
MP79-01 VITRIFICATION OF METANEPHROS:
WOULD IT BE THE FUTURE NEPHROBIOBANK TO PROVIDE AN UNLIMITED
SUPPLY OF KIDNEYS FOR THE HUMAN
BEING?
Cesar Vera-Donoso*, Paterna, Spain,
Joaquı́n Garcı́a-Domı́nguez, Silvia VicenteFerrer, Estrella Jimenez-Trigos, José VicenteAntón, Francisco Marco-Jiménez, Valencia,
Spain
ABSTRACT
NUMBER TITLE
MP79-08 SURGICAL MANAGEMENT OF RENAL
ARTERY STENOSIS DUE TO TAKAYASU’S
AORTOARTERITIS:RESULTS FROM A
TERTIARY CARE CENTER IN SOUTH
INDIA
John S. Banerji*, Antony Devasia, Nitin S.
Kekre, Vellore, India, Ninan K. Chacko,
Dhaka, Bangladesh, Ganesh Gopalakrishnan,
Coimbatore, India
MP79-10 SILDENAFIL ACTIVATES NRF2
DEPENDENT ANTI-OXIDANT GENES AND
ANTI-APOPTOTIC BCL-2 GENE AND
INHIBITS PRO-INFLAMMATORY
CYTOKINES GENES IN RAT MODEL OF
RENAL ISCHEMIA/REPERFUSION INJURY
Mohamed Zahran*, Abdelaziz Hussein,
Ahmed Harraz, Amira Awadalla, Shery
Khater, Nashwa Barakat, Ahmed Shokeir,
Mansoura, Egypt
MP79-03 WAG THE DOG?: PSA SCREENING IN
KIDNEY TRANSPLANT CANDIDATES
Daniel Canter*, Wynnewood, PA, Gerardo
Vitiello, Blayne Sayed, Ken Ogan, Nicole
Turgeon, Atlanta, GA
MP79-04 NATIONAL TRENDS AND RACIAL
DISPARITIES IN LIVING KIDNEY
DONATION: ANALYSIS OF THE UNITED
NETWORK OF ORGAN SHARING 19982011
Akshay Sood*, Firas Abdollah, Dane Klett,
Wooju Jeong, James Peabody, Detroit, MI,
Quoc-Dien Trinh, Boston, MA, Mani Menon,
Jesse Sammon, Detroit, MI
MP79-11 IMPROVING MATCHING STRATEGIES IN
KIDNEY PAIRED DONATION: THE 7-YEAR
EVOLUTION OF A WEB-BASED VIRTUAL
MATCHING SYSTEM
David Fumo*, Victor Kapoor, Toledo, OH, Laurie
Reece, Jonathan Kopke, Maumee, OH, Stanislaw
Stepkowski, Toledo, OH, Susan Rees, Maumee,
OH, Michael Rees, Toledo, OH
MP79-05 RESECTION OF THE INFERIOR VENA
CAVA WITHOUT GRAFTING IN
ADVANCED UROLOGIC MALIGNANCY
Jeffrey Loh-Doyle*, Sumeet Syan-Bhanvadia,
Eli Thompson, Mukul Patil, Siamak
MP79-12 HOW LONG IS TOO LONG? AN ANALYSIS
OF THE IMPACT OF BRIDGE DONOR
WAITING TIME ON PAIRED DONATION
TRANSPLANTS
David Fumo*, Timothy Suttle, Ryan Flynn,
Toledo, OH, Laurie Reece, Maumee, OH,
Stanislaw Stepkowski, Michael Rees, Toledo,
OH, Jonathan Kopke, Maumee, OH
MP79-06 VOLUME SUPERSEDES SPECIALTY
DURING RENAL TRANSPLANTATION
Aaron Laviana*, Diana Kang, Hung-Jui Tan,
Jim Hu, Los Angeles, CA
MP79-13 POST-OPERATIVE INTRAVENOUS
HEPARIN INFUSION IMPROVES SHORT
AND LONG TERM SIMULTANEOUS
KIDNEY-PANCREAS TRANSPLANT
OUTCOMES
Patrick Anderson*, Ghaleb Aboalsamh, Amira
Al Abbassi, Vivian McAlister, Patrick Luke,
Alp Sener, London, Canada
MP79-07 USEFULNESS OF KIDNEY
PREIMPLANTATION BIOPSIES FROM
DECEASED DONORS FOR KIDNEY
TRANSPLANT ALLOCATION
David Lorente Garcia*, Enrique Trilla Herrera,
Cristian Isalt Lemonche, Lucas Regis Placido,
Pol Servian Vives, Moreso Mateos Francesc,
Daniel Seron Micas, Clara Garcia Carro,
Maria Teresa Salcedo, Juan Morote Robles,
Barcelona, Spain
*Presenting author
261
TUESDAY
MP79-09 DO ANTICOAGULANT AND
ANTIPLATELET AGENTS PREVENT
ACUTE GRAFT THROMBOSIS IN RENAL
TRANSPLANTATION? A META-ANALYSIS
OF CASE SERIES STUDIES
Rodrigo Guerra*, Paulo Kawano, Joao
Amaro, Regina El Dib, Botucatu, Brazil
MP79-02 LAPAROSCOPIC NEPHRECTOMY WITH
AUTOTRANSPLANTATION: SAFETY,
EFFICACY AND LONG-TERM DURABILITY
Geraldine Tran*, Krishna Ramaswamy,
Thomas Chi, Maxwell Meng, Anobel Odisho,
Chris Freise, Marshall Stoller, San Francisco,
CA
MP79-18 DOES ROUTINE URETERAL STENTING IN
KIDNEY TRANSPLANTATION REALLY
REDUCE URETERAL COMPLICATION
RATES?
Samuel C. Haywood*, Chad A. Reichard,
Daniel A. Shoskes, Cleveland, OH
MP79-14 MINIMALLY INVASIVE KIDNEY
TRANSPLANTATION: PERIOPERATIVE
CONSIDERATIONS AND KEY 6-MONTH
OUTCOMES
Akshay Sood*, Detroit, MI, Prasun Ghosh,
Gurgaon, India, Wooju Jeong, Mahendra
Bhandari, Detroit, MI, Rajesh Ahlawat,
Gurgaon, India, Mani Menon, Detroit, MI
MP79-19 OUTCOME OF RENAL TRANSPLANT IN
PEDIATRIC PATIENTS WITH
OBSTRUCTIVE UROPATHY AND VOIDING
DYSFUNCTION
Ismail Saad, Mostafa Sheba*, Hesham
Badawy, Fatina Fadel, Cairo, Egypt
MP79-15 UROLOGICAL COMPLICATIONS IN
PEDIATRIC PATIENTS UNDERGOING
RENAL TRANSPLANTATION
Irina Stanasel*, Cagatay Afsarlar, Houston,
TX, Hoang Lee, Temple, TX, Abhishek Seth,
Chester Koh, Patricio Gargollo, Edmond
Gonzales, David Roth, Nicolette Janzen,
Houston, TX
MP79-20 THE IMPACT OF URETERAL
COMPLICATIONS AFTER PEDIATRIC
Julia B Finkelstein*, Jamie S Pak, Jennifer J Ahn,
Jason P Van Batavia, Mark V Silva, Namrata G
Jain, Shumyle Alam, New York, NY
MP79-16 HEAT SHOCK PROTEIN 90 IS A
POTENTIAL NEW BIOMARKER OF
SEVERE ACUTE REJECTION AFTER
Takeshi Maehana*, Toshiaki Tanaka, Hiroshi
Kitamura, Nobuyuki Fukuzawa, Satoshi
Takahashi, Sapporo, Japan, Hideki Ishida,
Tokyo, Japan, Hiroshi Harada, Sapporo,
Japan, Kazunari Tanabe, Tokyo, Japan,
Naoya Masumori, Sapporo, Japan
CREDITTM
MP79-17 FOLLOW UP AFTER 4 YEARS OF
URETERAL STENOSIS IN TRANSPLANT
KIDNEY MANAGED WITH LONG-TERM
THERMO-EXPANDABLE METALLIC STENT
Helena Vila Reyes*, Lluis Riera Canals, Joan
Dominguez Elias, Laia Pujol Galarza, Eladio
Franco Miranda, Barcelona, Spain
8:00 am - 10:00 am
STONE DISEASE: EVALUATION II
Moderator: Duane Baldwin
ABSTRACT
NUMBER TITLE
MP80-01 HOW OFTEN ARE OBSTRUCTING
URETERAL STONES ASSOCIATED WITH
NORMAL URINE DIPSTICK AND SERUM
WBC?
Yan Song, Natalia Hernandez*, Andrew
Stamm, Brian Eisner, Boston, MA
ABSTRACT
NUMBER TITLE
MP80-04 CULTURING THE RIGHT
MICROORGANISMS IN PATIENTS
UNDERGOING PERCUTANEOUS
NEPHROLITHOTOMY (PCNL) AND
FLEXIBLE URETEROSCOPY (FURS) FOR
RENAL STONES – CAN WE DO ANY
MORE?
Rehan Khan*, Sarah Hunt, Holly Bekarma,
Alison Ramsay, Sarath Krishna Nalagatla,
Airdrie, United Kingdom
MP80-02 INCREASED URINARY CALCIUM
EXCRETION IS MORE COMMON IN
YOUNGER STONE FORMERS
Balaji Reddy*, Haresh Thummar, Usama
Khater, Rachel Shapiro, Lynn Cochran,
Mantu Gupta, New York, NY
MP80-05 PREDICTORS OF SEPTIC SHOCK IN
PATIENTS WITH OBSTRUCTIVE
PYELONEPHRITIS DUE TO CALCULI
Jodi Antonelli*, Monica Morgan, Justin
Friedlander, Niccolo Passoni, Adam Cohen,
Daniel Mollengarten, Jeffrey Shoss, Clayton
Trimmer, Sanjeeva Kalva, Yair Lotan,
Margaret Pearle, Dallas, TX
MP80-03 KIDNEY STONE INCIDENCE RATES
AMONG CHILDREN AND ADULTS IN
SOUTH CAROLINA FROM 1997-2012
Gregory Tasian*, Michelle Ross, Lihai Song,
Philadelphia, PA, Christopher Saigal, Los
Angeles, CA, Ron Keren, Susan Furth,
Philadelphia, PA
262
MP80-06 NEPHROLITHIASIS IN ISRAEL –
EPIDEMIOLOGICAL CHARACTERISTICS
OF RETURN PATIENTS
Yasmin Abu-Ghanem, Tomer Erlich, Nir
Kleinmann, Harry Winkler, Dorit Zilberman*,
Ramat Gan, Israel
MP80-15 CAN FUNCTIONAL STUDIES BE
OBVIATED IN MANAGEMENT OF
URETERIC CALCULUS? A RANDOMIZED
STUDY
Raman Tanwar, Nikhil Khattar, Rishi Nayyar*,
Rajeev Sood, New Delhi, India
MP80-07 VITAMIN D AND SERUM LIPID PROFILE:
ASSOCIATION WITH 24-HOUR URINE
PARAMETERS
Aaron Potretzke*, Jeffrey Larson, Joel Vetter,
Alana Desai, St. Louis, MO
MP80-16 RISING INCIDENCE OF HYPEROXALURIA
IN STONE-FORMING PATIENTS:
CHRONOLOGICAL AND GEOGRAPHICAL
DIFFERENCES
Kyle Spradling*, Zhamshid Okhunov, Melissa
Suarez, Jaime Landman, Ramy Youssef,
Orange, CA
MP80-08 METABOLIC CHARACTERISTICS OF
BRUSHITE STONE FORMERS
Tracy Marien*, S. Duke Herrell, Nicole Miller,
Nashville, TN
MP80-09 RISK OF CHRONIC KIDNEY DISEASE IN
BRUSHITE STONE FORMERS COMPARED
TO IDIOPATHIC CALCIUM OXALATE
STONE FORMERS AT LONG-TERM
FOLLOW-UP
Christopher Jaeger*, Daniel Yelfimov, Amy
Krambeck, Rochester, MN
MP80-18 GENETIC DIAGNOSIS TRIAL BY SINGLE
NUCLEOTIDE POLYMORPHISM ANALYSIS
FROM A CASE-CONTROL STUDY, USING
THREE NOVEL LOCI ASSOCIATED WITH
SUSCEPTIBILITY TO UROLITHIASIS
FROM A GENOME-WIDE ASSOCIATION
STUDY (GWAS)
Takahiro Yasui*, Atsushi Okada, Masayuki
Usami, Shuzo Hamamoto, Ryosuke Ando,
Yasunori Itoh, Keiichi Tozawa, Shoichi
Sasaki, Yutaro Hayashi, Nagoya, Japan,
Yoshikazu Sato, Sapporo, Japan, Yoshihito
Higashi, Kenjiro Kohri, Nagoya, Japan
MP80-10 URETEROSCOPIC GRADING SYSTEM FOR
RENAL PAPILLAE: IMPLICATIONS ON
ETIOLOGY OF STONE FORMATION AND
RECURRENCE
Blake Anderson*, Shane Pearce, Anna
Zisman, Elaine Worcester, Fredric Coe,
Glenn Gerber, Chicago, IL
MP80-11 COMPARISION OF EXTRACORPOREAL
SHOCK WAVE LITHOTRIPSY VERSUS
URETEROSCOPY HOLMIUM LASER
LITHOTRIPSY IN THE MANAGEMENT OF
URETERAL STONES: A COSTEFFECTIVENESS ANALYSIS
Alberto Budı́a*, Vicent Caballer, José Daniel
López-Acón, David Vivas-Consuelo, Marı́a
Ángeles Conca, Pilar Bahı́lo, Marta
Trassierra, Valencia, Spain
MP80-19 URINE PROTEOMIC ANALYSIS IN
CYSTINURIC PATIENTS WITH RENAL
STONES
Larisa Kovacevic*, Hong Lu, Yegappan
Lakshmanan, Joseph A Caruso, Detroit, MI,
David Goldfarb, New York, New York
MP80-20 PROCALCITONIN SHOWS SUPERIOR
SPECIFICITY IN PREDICTING INFECTION
IN THE SETTING OF OBSTRUCTIVE
URETERAL CALCULI
Dimitri Papagiannopoulos*, Patrick Whelan,
Waseem Ahmad, James Rybak, Dino
Rumoro, Leslie Deane, Ajay Nehra, Chicago,
IL
MP80-12 COST ANALYSIS OF URETERAL
STENTING AFTER UNCOMPLICATED
URETEROSCOPIC LASER LITHOTRIPSY
FOR UROLITHIASIS: A DECISION MODEL
ANALYSIS
Hin Yu Vincent Tu*, Edward Matsumoto,
Hamilton, Canada
CREDITTM
MP80-13 DOES THE PEAK INSPIRATORY
PRESSURE INCREASE IN THE PRONE
POSITION? AN ANALYSIS RELATED TO
BMI
Michael Siev*, Piruz Motamedinia, David
Leavitt, David Hoenig, Arthur Smith, Zeph
Okeke, New Hyde Park, NY
MP80-14 SLEEP POSTURE COULD PREDICT THE
SIDE OF UNILATERAL UROLITHIASIS
FORMATION
Wei-Ming Cheng*, Tuz-Hao Huang, Yu-Hua
Fan, Alex T. L. Lin, Kuang-Kuo Chen, ShiChuan Chang, Taipei City, Taiwan
*Presenting author
263
TUESDAY
MP80-17 DO 24-HOUR URINE
SUPERSATURATIONS PREDICT STONE
COMPOSITION?
Mohamed Omar*, Cleveland, OH, Alaa El
Mahdy, Ahmed Gamal, Cairo, Egypt, Manoj
Monga, Cleveland, OH
8:00 am - 10:00 am
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: FEMALE UROLOGY
Moderators: Paulo Palma and Nitin Kekre
ABSTRACT
NUMBER TITLE
MP81-01 A NOVEL ROLE OF EPITHELIAL
PERMEABILITY IN VISCERAL ORGAN
CROSS TALK
Alexander Parker*, Ehsan Mohommadi, Karl
Tyler, Robert E. Hurst, Beverley GreenwoodVan Meerveld, Oklahoma City, OK
ABSTRACT
NUMBER TITLE
MP81-10 LONG-TERM RESULTS OF SALVAGE
AUTOLOGOUS FASCIAL SLING
PLACEMENT FOLLOWING FAILED
SYNTHETIC MIDURETHRAL SLING FOR
STRESS URINARY INCONTINENCE IN
WOMEN
Steven Petrou, Andrew Davidiuk*, Bhupendra
Rawal, David Thiel, Jacksonville, FL
MP81-02 ABNORMAL SENSORY PROTEIN
EXPRESSION AND UROTHELIAL
DYSFUNCTION IN HUMAN KETAMINE
RELATED CYSTITIS
Yao-Chou Tsai*, New Taipei City, Taiwan,
Jia-Fong Jhang, Hsiu-Chen Huang, HannChorng Kuo, Hualien, Taiwan
MP81-11 INTIAL RETENTION AFTER
MACROPLASTIQUE® INJECTION AS A
PREDICTOR OF SUCCESS
Himanshu Aggarwal*, Philippe Zimmern,
Dallas, TX
MP81-12 CLINICAL COURSE OF URINARY
INCONTINENCE IN WOMEN WITH TYPE I
DIABETES: LONGITUDINAL FINDINGS
FROM DCCT/EDIC
Sarah K. Holt*, Seattle, WA, J. Quentin
Clemens, Ann Arbor, MI, James Hotaling,
Salt Lake City, UT, Alan M. Jacobsen,
Mineola, NY, Barbara H. Braffett, Patricia A.
Cleary, Rockville, MD, Hunter Wessells,
Seattle, WA, Aruna V. Sarma, and the DCCT/
EDIC Research Group, Ann Arbor, MI
MP81-03 PREDICTIVE FACTORS FOR A
SUCCESSFUL ONABOTULINUMTOXINA
INJECTION TREATMENT FOR
REFRACTORY INTERSTITIAL CYSTITIS/
BLADDER PAIN SYNDROME
Yuh-Chen Kuo*, Taipei, Taiwan, Dong-Ling
Tang, Hann-Chorng Kuo, Hualien, Taiwan
MP81-04 STRESS AND OVERACTIVE BLADDR
SYMPTOMS
H. Henry Lai*, Vivien Gardner, Joel Vetter,
Gerald Andriole, St Louis, MO
MP81-13 OUTCOMES OF TREATMENT OF STRESS
URINARY INCONTINENCE ASSOCIATED
WITH FEMALE URETHRAL DIVERTICULA
Drew Freilich*, Ross Rames, Charleston, SC,
Ahmed El-Zawahry, Springfield, IL, Eric
Rovner, Charleston, SC, Michelle Koski, San
Marcos, CA
MP81-05 TRANSVAGINAL MESH IN THE MEDIA
FOLLOWING THE 2011 FDA UPDATE
Kevin Koo*, E. Ann Gormley, Lebanon, NH
MP81-06 CHANGES IN FEMALE UROLOGIC CASE
DISTRIBUTION WITH NEW
SUBSPECIALTY CERTIFICATION AND
SURGEON GENDER
Joceline S. Liu*, Johnathan Doolittle, Matthias
D. Hofer, Sarah C. Flury, Stephanie J. Kielb,
Chicago, IL
MP81-14 FEMALE URETHRAL STRICTURE: MORE
COMMON THAN YOU THINK
Marco Spilotros*, Eskinder Solomon,
Mahreen Pakzad, Rizwan Hamid, Jeremy
Ockrim, Tamsin Greenwell, London, United
Kingdom
MP81-07 MANAGEMENT OF PATIENTS SEEKING
CARE FOR STRESS URINARY
INCONTINENCE OVER THE PAST FOUR
YEARS: HAVE RATES OF MESH SLINGS
DECREASED?
Aqsa Khan*, Nirit Rosenblum, Benjamin
Brucker, Victor Nitti, New York City, NY
MP81-15 LONG-TERM OUTCOME OF
URETHROVAGINAL FISTULA REPAIR
Dominic Lee, Philippe Zimmern*, Dallas, TX
MP81-16 SELF IMAGING AND SEXUAL FUNCTION
AFTER MARTIUS FLAP SURGERY
George Kasyan*, Nataliya Tupikina, Yury
Kupriyanov, Boris Godunov, Dmitry Pushkar,
Moscow, Russian Federation
MP81-08 HOW WELL CAN UROLOGY TRAINEES
DETECT SUBURETHRAL MESH USING
TRANSLABIAL ULTRASOUND IN
COMPARISON TO A RADIOLOGIST?
Daniel Faaborg*, Andrea Staack, Glen
Rouse, Muhannad Alsyouf, Kristene Myklak,
Roger Li, Loma Linda, CA
MP81-17 SOLVENT DEHYDRATED DERMAL
ALLOGRAFT (AXIS™) AUGMENTED
CYSTOCELE REPAIR: LONGITUDINAL
LONG-TERM RESULTS
Saad Juma, Encinitas, CA, Omer Raheem*,
San Diego, CA
MP81-09 SURGEONS’ ATTITUDES TOWARDS
SLING TENSIONING DURING SURGERY
FOR FEMALE STRESS URINARY
INCONTINENCE
Ali Borazjani*, Javier Pizarro, Howard
Goldman, Cleveland, OH
264
MP81-20 THE LONG-TERM SAFETY, TRENDS AND
RE-INTERVENTIONS IN THE SURGICAL
MANAGEMENT OF STRESS URINARY
INCONTINENCE
Bilal Chughtai, Adrien Bernstein*, Jessica
Buck, Jialin Mao, Abby Isaacs, Richard Lee,
Alexis Te, Steven Kaplan, Art Sedrakyan,
New York, NY
MP81-18 ABDOMINAL VS LAPAROSCOPIC
SACROCOLPOPEXY: A RANDOMIZED
CONTROLLED TRIAL
Manuel Di Biase*, Luigi Mearini, Alessandro
Zucchi, Michele Del Zingaro, Amelia
Pietropaolo, Eleonora Salvini, Antonella
Giannantoni, Elisabetta Costantini, Perugia,
Italy
INVASIVE SACRAL COLPOPEXY USING
THE NATIONAL SURGICAL QUALITY
DATABASE
Ahmed Sarhan*, Ahmad Shabsigh, Ketul
Shah, Columbus, OH
CREDITTM
8:00 am - 10:00 am
ABSTRACT
NUMBER TITLE
MP82-01 LONG-TERM OUTCOMES OF VERY HIGH
RISK PROSTATE CANCER PATIENTS
PROSTATECTOMY WITH OR WITHOUT
ADJUVANT TREATMENTS. RESULTS OF A
COMPETING RISKS, MULTI
INSTITUTIONAL ANALYSIS
Marco Bianchi*, Milan, Italy, R. Jeffrey
Karnes, Rochester, MN, Steven Joniau,
Leuven, Belgium, Giorgio Gandaglia, Milan,
Italy, Martin Spahn, Bern, Switzerland, Paolo
Gontero, Turin, Italy, Rafael Sanchez Salas,
Xavier Cathelineau, Paris, France, Burkhard
Kneitz, Wurzburg, Germany, Felix K. H.
Chun, Hamburg, Germany, Pierre
Karakiewicz, Montreal, Canada, Markus
Graefen, Hamburg, Germany, Giansilvio
Marchioro, Novara, Italy, Detlef Frohneberg,
Karlsruhe, Germany, Hein Van Poppel,
Leuven, Belgium, Francesco Montorsi,
ABSTRACT
NUMBER TITLE
MP82-03 SALVAGE LYMPH NODE DISSECTION FOR
CLINICALLY RECURRENT PROSTATE
CANCER: WHICH PATIENTS DO BENEFIT
FROM THIS APPROACH?
Nazareno Suardi*, Giorgio Gandaglia, Marco
Bianchi, Ettore Di Trapani, Alessandro Nini,
Vito Cucchiara, Walter Cazzaniga, Stefano
Luzzago, Marta Picozzi, Roberto Bertini,
Italy
MP82-04 PELVIC EXENTERATION IN PATIENTS
WITH NON-METASTATIC, LOCALLY
ADVANCED CASTRATION-RESISTANT
PROSTATE CANCER
Timothy F. Donahue*, Bethesda, MD, Michael
J. Morris, Susan F. Slovin, Howard I. Scher,
Peter T. Scardino, Bernard H. Bochner, New
York, NY
MP82-05 A COMPARISON OF DIFFERENT
TREATMENT OPTIONS FOR LYMPH
NODE-POSITIVE PROSTATE CANCER AT
Derya Tilki*, Pierre Tennstedt, Thomas
Steuber, Patrick Tober, Christian Meyer,
Rudolf Schwarz, Markus Graefen, Hartwig
Huland, Sascha Ahyai, Hamburg, Germany
MP82-02 LONG-TERM OUTCOMES OF PATIENTS
WITH SEMINAL VESICLE INVASION AT
RADICAL PROSTATECTOMY: THE
IMPORTANCE OF A MULTIMODAL
APPROACH TO INCREASE PATIENT
SURVIVAL
Marco Moschini*, Milan, Italy, R. Jeffrey
Karnes, Rochester, MN, Nazareno Suardi,
Cesare Cozzarini, Giorgio Gandaglia, Nicola
Fossati, Marco Bianchi, Emanuele Zaffuto,
Alessandro Larcher, Milan, Italy, Firas
Abdollah, Detroit, MI, Francesco Montorsi,
*Presenting author
MP82-06 TEMPLATE-BASED SALVAGE EXTENDED
PELVIC LYMPH NODE DISSECTION IN
RECURRENT PROSTATE CANCER WITH
LYMPH NODE METASTASES
Daniar Osmonov, Alexey Aksenov*, Carsten
Maik Naumann, Moritz Hamann, Klaus-Peter
Jünemann, Kiel, Germany
265
TUESDAY
PROSTATE CANCER: ADVANCED II
Moderator: Neal Shore
MP82-12 OUTCOMES OF SALVAGE PROSTATE
CRYOABLATION AFTER PRIMARY
EXTERNAL BEAM RADIATION OR
BRACHYTHERAPY: IS THERE A
DIFFERENCE?
Matthew Ingham*, Norfolk, VA, Ahmed ElShafei, Cleveland, OH, Robert Given, Norfolk,
VA, Stephen Jones, Cleveland, OH
MP82-07 DOES LOCAL TREATMENT OF THE
PRIMARY TUMOR IMPROVE SURVIVAL OF
PATIENTS? RESULTS FROM A
Nicola Fossati, New York, NY, Quoc-Dien
Trinh, Boston, MA, Jesse Sammon, Akshay
Sood, Detroit, MI, Alessandro Larcher, Milan,
Italy, Maxine Sun, Pierre I Karakiewicz,
Montreal, Canada, Giorgio Guazzoni*,
Italy, Mani Menon, Firas Abdollah, Detroit, MI
MP82-13 REDUCTION IN EARLY BIOCHEMICAL
RECURRENCE INTERMEDIATE RISK
PATIENTS UNDERGOING ROBOTASSISTED EXTENDED PELVIC
LYMPHADENECTOMY FOR PROSTATE
CANCER
Bertram Yuh*, Pasadena, CA, Nora Ruel,
Timothy Wilson, Duarte, CA
MP82-08 BIOCHEMICAL RECURRENCE FREE
SURVIVAL OF ACTIVE SURVEILLANCE
CANDIDATE ACCORDING TO THE
ADVERSE PATHOLOGIC OUTCOMES OF
Juhyun Park*, Songzhe Piao, Sung Yong
Cho, Seung Bae Lee, Hyeon Jeong, Chang
Wook Jeong, Ja Hyeon Ku, Cheol Kwak,
Hyeon Hoe Kim, Seoul, Korea, Republic of
MP82-14 THE PATTERN OF RECURRENT
PROSTATE CANCER IN PNⴙ POST
RADICAL PROSTATECTOMY HAS
INDEPENDENT PROGNOSTIC CAPABILITY
Marco Moschini*, Fabio Zattoni, Rochester,
MN, Alberto Briganti, Milan, Italy, Eugene
Kwon, Jeffrey Karnes, Rochester, MN
MP82-09 PROSTATE SPECIFIC MEMBRANE
ANTIGEN ANTIBODY DRUG CONJUGATE
(PSMA ADC) IN PATIENTS (PTS) WITH
PROGRESSIVE METASTATIC
CANCER (MCRPC) FOLLOWING
ABIRATERONE AND/OR ENZALUTAMIDE
(ABI/ENZ): RESULTS FROM A PHASE 2
STUDY
Daniel Petrylak*, New Haven, CT, Nicholas
Vogelzang, Las Vegas, NV, Kamal Chatta,
Seattle, WA, Mark Fleming, Norfolk, VA,
David Smith, Ann Arbor, MI, Leonard
Appleman, Pittsburgh, PA, Arif Hussain,
Baltimore, MD, Manuel Modiano, Parminder
Singh, Tucson, AZ, Scott Tagawa, New York,
NY, Ira Gore, Birmingham, AL, Ed McClay,
Encinitas, CA, Anthony Mega, Providence,
RI, Oliver Sartor, New Orleans, LA, Brad
Somer, Memphis, TN, Raymond Wadlow,
Fairfax, VA, Neal Shore, Myrtle Beach, SC,
Nancy Stambler, Vincent DiPippo, Robert
Israel, Tarrytown, NY
MP82-15 DOES EARLY ANDROGEN DEPRIVATION
THERAPY AFTER BIOCHEMICAL
PROSTATECTOMY INCREASE OVERALL
SURVIVAL? RESULTS FROM SEARCH
Stephen Freedland*, Lauren Howard,
Durham, NC, Christopher Amling, Portland,
OR, Matthew Cooperberg, San Francisco,
CA, Christopher Kane, San Diego, CA,
Martha Terris, Augusta, GA, William Aronson,
Los Angeles, CA
MP82-16 LONG-TERM CLINICAL RECURRENCE
RATE IN PROSTATE CANCER (PCA)
PATIENTS WITH ADVERSE
PATHOLOGICAL CHARACTERISTICS AT
RADICAL PROSTATECTOMY (RALP)
Firas Abdollah*, Akshay Sood, Dane Klett,
Jesse Sammon, Daniel Pucheril, Detroit, MI,
Burkhard Beyer, Hamburg, Germany, Nicola
Fossati, Giorgio Gandaglia, Nazareno Suardi,
Milan, Italy, Craig Rogers, Wooju Jeong,
James Peabody, Detroit, MI, Alexander
Haese, Hamburg, Germany, Francesco
Montorsi, Milan, Italy, Markus Graefen,
Hamburg, Germany, Alberto Briganti, Milan,
Italy, Mani Menon, Detroit, MI
MP82-10 PSMA-RADIOGUIDED SURGERY:
INTRODUCING MOLECULAR SURGERY IN
PATIENTS WITH RECURRENT PROSTATE
CANCER
Tobias Maurer*, Martina Weineisen, HansJürgen Wester, Margret Schottelius, Asli
Okur, Gregor Weirich, Hubert Kübler, Markus
Schwaiger, Jürgen Erich Gschwend,
Benjamin Frisch, Matthias Eiber, Munich,
Germany
MP82-17 ONCOLOGICAL OUTCOMES IN PN1
PROSTATE CANCER (PCA) PATIENTS
TREATED WITH ROBOTIC-ASSISTED
PROSTATECTOMY (RALP)
Firas Abdollah*, Daniel Pucheril, Jesse
Sammon, Akshay Sood, Dane Klett, Detroit,
MI, Burkhard Beyer, Hamburg, Germany,
Nicola Fossati, Giorgio Gandaglia, Nazareno
Suardi, Milan, Italy, Hans Stricker, Wooju
Jeong, James Peabody, Detroit, MI,
Alexander Haese, Hamburg, Germany,
Francesco Montorsi, Milan, Italy, Markus
Graefen, Hamburg, Germany, Alberto
MP82-11 IMPACT OF TUMOR VOLUME
PERCENTAGE TO PROSTATE VOLUME
ON THE RISK OF BIOCHEMICAL
PROSTATECTOMY
Ohseong Kwon, Hakmin Lee, Jung Ki Jo,
Young Ik Lee, Ki Bom Kim, In Jae Lee,
Seongnam, Korea, Republic of, Choong Hee
Noh, Seoul, Korea, Republic of, Jeong Hyun
Kim, Chuncheon, Korea, Republic of, Jong
Jin Oh, Sangchul Lee, Sung Kyu Hong,
Seok-Soo Byun, Sang Eun Lee, Seong Jin
Jeong*, Seongnam, Korea, Republic of
266
MP82-20 PREOPERATIVE MULTIPARAMETRIC
PROSTATE MRI IDENTIFIES PATIENTS AT
RISK FOR LYMPH NODE INVOLVEMENT
AT RADICAL PROSTATECTOMY
Annerleim Walton Diaz, Steven Abboud*,
Arvin George, Raju Chelluri, Michele Fascelli,
Richard Ho, Thomas P Frye, Sandeep
Sankineni, Maria J Merino, Baris Turkbey,
Bradford J Wood, Peter L Choyke, Peter A
Pinto, Bethesda, MD
MP82-18 EFFECT OF NEOADJUVANT DOCETAXEL
CHEMOTHERAPY COMBINED WITH
ADJUVANT CHEMOTHERAPY COMPARED
WITH RADICAL PROSTATECTOMY ALONE
IN PATIENTS WITH HIGH RISK PROSTATE
CANCER
Wansuk Kim*, Busan, Korea, Republic of,
Cheryn Song, Hanjong Ahn, Seoul, Korea,
Republic of
MP82-19 CAN MULTIPARAMETRIC MAGNETIC
RESONANCE IMAGING PREDICT
RADICAL PROSTATECTOMY?
IMPLICATIONS FOR PREOPERATIVE
STAGING AND SURGICAL PLANNING
Richard Ho*, Arvin George, Thomas Frye,
Steven Abboud, Raju Chelluri, Michele
Fascelli, Nabeel Shakir, Annerleim WaltonDiaz, Sandeep Sankineni, Maria Merino,
Baris Turkbey, Peter Choyke, Peter Pinto,
Bethesda, MD
CREDITTM
8:00 am - 10:00 am
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: PELVIC PROLAPSE
Moderators: Shlomo Raz and Priya Padmanabhan
TIME
8:00
8:10
8:20
8:30
ABSTRACT
NUMBER TITLE
PD50-01 BONE MORPHOGENETIC PROTEIN 1 IS
UPREGULATED IN WOMEN WITH PELVIC
ORGAN PROLAPSE
Ali Borazjani*, Nathan Kow, Samantha Harris,
Beri Ridgeway, Margot Damaser, Cleveland,
OH
ABSTRACT
TIME NUMBER TITLE
8:40
PD50-05 SURGICAL MANAGEMENT OF ICS/IUGA
CLASS 1-4 TRANSVAGINAL MESH (TVM)
PROLAPSE KIT COMPLICATIONS: 8-YEAR
REVIEW OF 82 PATIENTS FROM A SINGLE
CENTER
Kirk Anderson*, Paul Knoll, Nicholas Westfall,
Aurora, CO, Ketul Shah, Columbus, OH,
Brian Flynn, Aurora, CO
PD50-02 IMPACT OF MRI DEFECOGRAPHY ON
CLINICAL EVALUATION AND SURGICAL
MANAGEMENT OF PELVIC ORGAN
PROLAPSE
Maude Carmel*, Gaurav Khatri, April Bailey,
Philippe Zimmern, Dallas, TX
PD50-03 SEXUAL FUNCTION IN FEMALE PATIENTS
WHO UNDERWENT PELVIC FLOOR
RECONSTRUCTION WITH FOLLOW-UP
FOR A MINIMUM OF 5 YEARS
Katsuhiko Sato*, Fuminori Sacurai, Akiko Ito,
Yasutaka Murata, Daisaku Ashikari, Daisuke
Obinata, Junichi Mochida, Kenya Yamaguchi,
Satoru Takahashi, Tokyo, Japan
PD50-04 TRANSVAGINAL MESH INCREASES THE
RISK OF BLEEDING AND ORGAN
SURGICAL SITE INFECTION IN VAGINAL
PELVIC RECONSTRUCTION SURGERY:
RESULTS FROM A MULTI-INSTITUTIONAL
PROSPECTIVELY MAINTAINED DATASET
Devin Haddad*, Louis Krane, Gopal Badlani,
Majid Mirzazadeh, Winston-Salem, NC
*Presenting author
267
8:50
PD50-06 PROLAPSE RECURRENCE AFTER
TRANSVAGINAL MESH REMOVAL
Tanner Rawlings*, Rebecca Lavelle, Burhan
Coskun, Feras Alhalabi, Alana Christie,
Philippe Zimmern, Dallas, TX
9:00
PD50-07 CYSTOCELE REPAIR WITH NON-FROZEN
CADAVERIC FASCIA LATA: LONG-TERM
RESULTS
Jennifer Sung*, Los Angeles, CA, Kulwant
Singh, Fontana, CA, Sharron Mee, Gary
Leach, Los Angeles, CA
9:10
PD50-08 PREDICTORS OF REGRET AFTER
COLPOCLEISIS FOR PELVIC ORGAN
PROLAPSE: A SYSTEMATIC REVIEW
Juzar Jamnagerwalla*, Karyn Eilber, Los
Angeles, CA, Samantha Jagannathan, Saint
Louis, MO, Niv Hakami-Majd, Eugene
Shkolyar, Jennifer Anger, Los Angeles, CA
9:20
PD50-09 ASSESSMENT OF RATES OF
CONCOMITANT SLING PLACEMENT AT
TIME OF PELVIC ORGAN PROLAPSE
SURGERY SINCE RELEASE OF THE 2011
FDA HEALTH NOTIFICATION
Erin Ohmann*, Aqsa Khan, Benjamin
Brucker, Scott Smilen, Nirit Rosenblum,
Victor Nitti, New York, NY
TUESDAY
Podium Session 50
9:30
PD50-10 ASSESSING THE LEARNING CURVE OF
ROBOTIC SACROCOLPOPEXY
Brian Linder*, Mallika Anand, Amy Weaver,
Joshua Woelk, Christopher Klingele, Emanuel
Trabuco, John Occhino, John Gebhart,
Rochester, MN
9:40
PD50-11 PROLAPSE REPAIR WITH AND WITHOUT
APICAL RESUSPENSION - PRACTICE
PATTERNS AMONGST CERTIFYING
AMERICAN UROLOGISTS
Joceline S. Liu*, Matthias D. Hofer, Stephanie
J. Kielb, Sarah C. Flury, Chicago, IL
9:50
PD50-12 COMPARISON OF OPERATIVE AND
PERIOPERATIVE OUTCOMES BETWEEN
ROBOTIC ASSISTED PROLAPSE REPAIR
AND TRANSVAGINAL MESH REPAIR
Priyanka Gupta*, Michael Ehlert, Kim A.
Killinger, Judith A. Boura, Royal Oak, MI,
Renee Cholyway, Brian Odom, Rochester,
MI, Melissa Fischer, Jamie Bartley, Jason
Gilleran, Larry T. Sirls, Royal Oak, MI
CREDITTM
10:30 am - 12:30 pm
PROSTATE CANCER: LOCALIZED IX
Moderators: Arieh Shalhav and William Catalona
ABSTRACT
NUMBER TITLE
MP83-01 TRANSPERINEAL MRI-TARGETED BIOPSY
VERSUS TRANSPERINEAL TEMPLATE
PROSTATE MAPPING BIOPSY IN THE
DETECTION OF LOCALISED RADIORECURRENT PROSTATE CANCER
Abi Kanthabalan*, Mohammed Abl-Azzeez,
Manit Arya, Alex Freeman, Clare Allen, Alex
kirkham, Shonit Punwani, Mark Emberton,
Hashim Ahmed, London, United Kingdom
ABSTRACT
NUMBER TITLE
MP83-05 THE EFFECT OF NERVE-SPARING ON
URINARY CONTINENCE AFTER RADICAL
PROSTATECTOMY: IS IT THE
PRESERVATION OF THE
NEUROVASCULAR BUNDLES OR THE
SURGICAL TECHNIQUE WHICH LEADS TO
IMPROVED CONTINENCE RATES?
Derya Tilki*, Sascha Ahyai, Pierre Tennstedt,
Markus Graefen, Hartwig Huland, Uwe Michl,
Hamburg, Germany
MP83-02 COMBINATION OF MULTI-PARAMETRIC
MAGNETIC RESONANCE IMAGING (MPMRI) AND TRANSPERINEAL TEMPLATEGUIDED MAPPING BIOPSY (TTMB) OF
THE PROSTATE TO IDENTIFY
CANDIDATES FOR HEMI-ABLATIVE
FOCAL THERAPY
Minh Tran*, James Thompson, Maret Boehm,
Marley Pulbrook, Daniel Moses, Ron Shnier,
Phillip Brenner, Warick Delprado, AnneMaree Haynes, Richard Savdie, Phillip
Stricker, Sydney, Australia
MP83-06 IS INVERSE STAGE MIGRATION A
SUSTAINING PHENOMENON IN PATIENTS
UNDERGOING RADICAL
PROSTATECTOMY?
Andreas Becker*, Luis Kluth, Jens Hansen,
Christian Meyer, Pierre Tennstedt, Lars
Budaeus, Thomas Steuber, Felix K.H. Chun,
Hamburg, Germany
MP83-07 SALVAGE RADICAL PROSTATECTOMY
FOR RECURRENT PROSTATE CANCER:
VERIFICATION OF EAU GUIDELINE
CRITERIA
Philipp Mandel*, Thomas Steuber, Sascha
Ahyai, Hamburg, Germany, Maximilian
Kriegmair, Mannheim, Germany, Jonas
Schiffmann, Hans Heinzer, Uwe Michl,
Thorsten Schlomm, Alexander Haese,
Hartwig Huland, Markus Graefen, Derya Tilki,
Hamburg, Germany
MP83-03 NATURAL HISTORY OF MEN WITH A
POSITIVE PROSTATE BIOPSY THAT IS
OVERTURNED TO NEGATIVE AFTER A
SECOND PATHOLOGICAL OPINION
Eduardo Hernandez-Cardona*, Juan SerranoOlmo, Ricardo Sanchez-Ortiz, San Juan, PR
MP83-04 POTENTIAL FOR FAILURE OF FOCAL
PROSTATE HEMI-ABLATION STRATEGIES
Padraic O’Malley*, Bashir Al Hussein Al
Awamlh, Alexander M Sarkisian, Shiyi Jin,
Daniel P Nguyen, Richard Lee, Douglas S
Scherr, Christopher E Barbieri, Michael P
Hermann, New York, NY
MP83-08 THIRTY YEARS OF RADICAL
PROSTATECTOMIES AT A SINGLE
TERTIARY CARE REFERRAL CENTER
Paolo Dell’Oglio*, Nazareno Suardi, Giovanni
Lughezzani, Giorgio Gandaglia, Marco
Bianchi, Nicola Fossati, Giuliana Lista,
Roberta Lucianò, Massimo Freschi, Milan,
Italy, Vincenzo Mirone, Naples, Italy, Giorgio
Guazzoni, Patrizio Rigatti, Francesco
268
MP83-14 PSYCHOSOCIAL DISTRESS, FEAR OF
PROGRESSION AND NEED FOR
PSYCHOSOCIAL TREATMENT IN
SPORADIC AND FAMILIAL PROSTATE
CANCER PATIENTS
Kathleen Herkommer*, Anna Willms, Birgit
Marten-Mittag, Peter Herschbach, Juergen
Gschwend, Andreas Dinkel, Munich,
Germany
MP83-09 TO PREDICT A GOOD CANDIDATE WHO
UNDERGO A PERMANENT IODINE-125
SEED IMPLANTATION IN RESPECT OF
URINARY MORBIDITY FROM THE
RESULTS OF A NATIONWIDE COHORT
STUDY IN JAPAN
Nobumichi Tanaka*, Kashihara, Japan,
Atsunori Yorozu, Tokyo, Japan, Shinichiro
Maruo, Shinsuke Kojima, Kobe, Japan,
Toshio Ohashi, Tokyo, Japan, Norihisa
Katayama, Okayama, Japan, Shiro Saito,
Takushi Dokiya, Tokyo, Japan, Masanori
Fukushima, Kobe, Japan, Hidetoshi
Yamanaka, Takasaki, Japan, Kiyohide
Fujimoto, Kashihara, Japan
MP83-10 EXPRESSION OF ANDROGEN AND
GLUCOCORTICOID RECEPTORS IN
RESIDUAL CANCER CELLS AFTER
NEOADJUVANT CHEMOHORMONAL
THERAPY WITH DOCETAXEL FOR HIGHRISK LOCALIZED PROSTATE CANCER
Shintaro Narita*, Akita, Akita, Japan,
Taketoshi Nara, Mingguo Huang, Hiroshi
Tsuruta, Susumu Akihama, Mitsuru Saito,
Takamitsu Inoue, Norihiko Tsuchiya, Shigeru
Satoh, Tomonori Habuchi, Akita, Japan
MP83-16 HETEROGENEITY IN DⴕAMICO LOW-RISK
PROSTATE CANCER: DIFFERENCES IN
UPGRADING AND UPSTAGING
ACCORDING TO ACTIVE SURVEILLANCE
ELIGIBILITY
Sami-Ramzi Leyh-Bannurah*, Jonas
Schiffman, Hans Heinzer, Georg Salomon,
Thorsten Schlomm, Stefan Steurer, Guido
Sauter, Burkhard Beyer, Katharina Boehm,
Derya Tilki, Uwe Michl, Hartwig Huland,
Markus Graefen, Lars Budäus, Hamburg,
Germany, Pierre Karakiewicz, Montreal,
Canada
MP83-11 LONG-TERM PATIENT-REPORTED
FUNCTIONAL OUTCOMES FOLLOWING
OPEN, LAPAROSCOPIC, AND ROBOTICASSISTED RADICAL PROSTATECTOMY
PERFORMED BY HIGH VOLUME
SURGEONS
Boris Gershman*, Sarah Psutka, Rochester,
MN, Francis McGovern, Douglas Dahl,
Shahin Tabatabaei, Boston, MA, Matthew
Gettman, Igor Frank, Rachel Carlson,
Rochester, MN, Michael Barry, Michael Blute,
Boston, MA, R. Jeffrey Karnes, Rochester,
MN
MP83-17 IMPACT OF INTRA-OPERATIVE
TRANSFUSION ON SURVIVAL OF
PATIENTS WITH CLINICALLY LOCALIZED
PROSTATE CANCER UNDERGOING
Marco Moschini*, Milan, Italy, R. Jeffrey
Karnes, Rochester, MN, Nazareno Suardi,
Giorgio Gandaglia, Marco Bianchi, Nicola
Fossati, Ettore Di Trapani, Andrea Gallina,
Umberto Capitanio, Andrea Salonia,
Italy
MP83-12 SALVAGE ROBOT-ASSISTED RADICAL
PROSTATECTOMY FOR RECURRENT
PROSTATE CANCER
Andre Luis de Castro Abreu*, Monish Aron,
Noah Swann, Los Angeles, CA, Srinivas
Samavedi, Anthony Bates, Sanket Chauhan,
Celebration, FL, Sameer Chopra, Raed
Azhar, Kelvin Wong, Raj Satkunasivam,
Charles Metcalfe, Los Angeles, CA, Tadzia
Thurn, Celebration, FL, Osamu Ukimura,
Mihir Desai, Inderbir Gill, Los Angeles, CA,
Vipul Patel, Celebration, FL
MP83-18 LYMPHATIC VESSEL INVASION
PREDICTS BIOCHEMICAL RECURRENCE
IN ORGAN CONFINED PROSTATE
CANCER. RESULTS OF 2316 EUROPEAN
PATIENTS WITHOUT LYMPHNODE
DISSECTION
Katharina Boehm*, Meike Adam, Hamburg,
Germany, Alessandro Larcher, Milan, Italy,
Jonas Schiffmann, Hamburg, Germany,
Hartwig Huland, Georg Salomon, Hamburg,
Germany
MP83-13 COMPARATIVE MORBIDITY OF ABLATIVE
ENERGY BASED SALVAGE TREATMENTS
FOR RADIO-RECURRENT PROSTATE
CANCER
Khurram Siddiqui*, Michele Billia, Clarisse R.
Mazzola, Andrew Williams, London, Canada,
Ali Al Zahrani, Dammam, Saudi Arabia,
Joseph Chin, London, Canada
*Presenting author
MP83-19 REAL-WORLD USE OF EPIC FOR
CLINICAL PRACTICE (EPIC-CP) TO
ASSESS PATIENT-REPORTED PROSTATE
CANCER QUALITY-OF-LIFE IN THE
CLINICAL SETTING
Peter Chang*, Arie Carneiro, Ostap Dovirak,
Kimberly Taylor, Catrina Crociani, Kyle
McAnally, Boston, MA, Andrew Percy,
Richmond, VA, Martin G Sanda, Atlanta, GA,
Andrew A Wagner, Boston, MA
269
TUESDAY
MP83-15 THE IMPACT OF NOT DETERMINABLE
SURGICAL MARGINS AFTER RADICAL
PROSTATECTOMY
Sascha Ahyai*, Pierre Tenstedt, Felix Chun,
Thorsten Schlomm, Corinna Widmer, Guido
Sauter, Hartwig Huland, Markus Graefen,
Derya Tilki, Hamburg, Germany
CREDITTM
MP83-20 DISCORDANCE BETWEEN LOCATION OF
POSITIVE CORES IN BIOPSY AND
LOCATION OF POSITIVE SURGICAL
MARGIN FOLLOWING RADICAL
PROSTATECTOMY
Ji Won Kim*, Dong Yeub Ham, Woo Suk
Choi, Hyoung Keun Park, Sung Hyun Paick,
Hyeong Gon Kim, Young Soo Lho, Seoul,
Korea, Republic of
10:30 am - 12:30 pm
KIDNEY CANCER: SURGICAL THERAPY VII
Moderators: Ithaar Derweesh and Vitaly Margulis
ABSTRACT
NUMBER TITLE
MP84-01 ISCHEMIA DURING NEPHRON-SPARING
SURGERY RESULTS IN DECREASE OF
OVERALL AND SPLIT FUNCTION OF THE
KIDNEY
Oleksandr Stakhovskyi*, Oleg Voylenko, Iurii
Vitruk, Eduard Stakhovsky, Kiev, Ukraine
ABSTRACT
NUMBER TITLE
MP84-06 HISTOLOGY IMPACTS SURVIVAL
OUTCOMES IN CONTEMPORARY
PATIENTS UNDERGOING PRIMARILY
PARTIAL NEPHRECTOMY FOR RENAL
CELL CARCINOMA
Daniel Nguyen*, Emily Vertosick, Renato
Beluco Corradi, Antoni Vilaseca, Daniel
Sjoberg, Nicole Benfante, Paul Russo, New
York, NY
MP84-02 DIFFERING KIDNEY FUNCTION
OUTCOMES FOLLOWING KIDNEY
CANCER SURGERY IN THE VETERANS
HEALTH ADMINISTRATION
Remy Lamberts*, Stanford, CA, I-Chun
Thomas, Palo Alto, CA, Benjamin Chung,
Geoffrey Sonn, Alice Fan, Sandy Srinivas,
Todd Wagner, Glen Chertow, James Brooks,
John Leppert, Stanford, CA
MP84-07 RISK STRATIFICATION FOR ADVERSE
OUTCOMES FOLLOWING RENAL MASS
EXCISION
Timothy Ito*, Philip Abbosh, Nikhil
Waingankar, Mohammed Haseebuddin,
Serge Ginzburg, Daniel Canter, David Chen,
Richard Greenberg, Rosalia Viterbo,
Alexander Kutikov, Marc Smaldone, Robert
Uzzo, Philadelphia, PA
MP84-03 CLINICAL, PATHOLOGICAL AND RENAL
FUNCTIONAL OUTCOMES OF PARTIAL
AND RADICAL NEPHRECTOMY IN
ELDERLY PATIENTS
Yajie An, Mark Ball*, Michael Gorin, Phillip
Pierorazio, Mohamad Allaf, Baltimore, MD
MP84-08 PATHOLOGICAL UPSTAGING OF
CLINICAL T1 RENAL CELL CARCINOMA:
A MULTI-INSTITUTIONAL ANALYSIS OF
OUTCOMES
Jasmir Nayak*, Seattle, WA, Premal Patel,
Jennifer Bjazevic, Winnipeg, Canada, Olli
Saarela, Toronto, Canada, Zhihui Liu,
Toronto, ON, Anil Kapoor, Hamilton, Canada,
Simon Tanguay, Montreal, Canada, Antonio
Finelli, Toronto, Canada, Ricardo Rendon,
Halifax, Canada, Ron Moore, Edmonton,
Canada, Rodney Breau, Ottawa, Canada,
Jun Kawakami, Calgary, Canada, Peter
Black, Vancouver, Canada, Darrel
Drachenberg, Winnipeg, Canada
MP84-04 GENDER AND RACIAL DISPARITIES IN
UTILIZATION OF PARTIAL
NEPHRECTOMY FOR RENAL MASSES
Shane Pearce*, Zoe Steinberg, Chicago, IL,
Richard Zigeuner, Graz, Austria, Chaidir
Mochtar, Jakarta, Indonesia, Guillermo
Gueglio, Buenos Aires, Argentina, Arieh
Shalhav, Scott Eggener, Chicago, IL, M. Pilar
Laguna, Amsterdam, Netherlands
MP84-05 VARIATION IN SURGICAL MARGIN
STATUS BY SURGICAL APPROACH
AMONG PATIENTS UNDERGOING
PARTIAL NEPHRECTOMY FOR SMALL
RENAL MASSES
Jonathan E. Kiechle, Robert Abouassaly,
William Tabayoyong*, Shan Dong, Cleveland,
OH, Marc C. Smaldone, Philadelphia, PA,
Edward E. Cherullo, Cleveland, OH, Cary P.
Gross, New Haven, CT, Nilay D. Shah,
Rochester, MN, Hui Zhu, Simon P. Kim,
Cleveland, OH
MP84-09 MULTICENTER VALIDATION OF ABILITY
OF SURGEON ASSESSMENT OF RENAL
PRESERVATION IN COMPARISON TO
MEASUREMENT WITH 3D IMAGE
ANALYSIS
Conrad Tobert*, Iowa City, IA, Toshio Takagi,
Cleveland, OH, Michael Liss, Hak Lee, Ithaar
Derweesh, San Diego, CA, Steven Campbell,
Cleveland, OH, Brian Lane, Grand Rapids, MI
270
MP84-16 CLINICAL RELEVANCE OF THE SMALL
RENAL MASS AND IMPLICATION ON
CLINICAL MANAGEMENT IN THE
ELDERLY PATIENT
Douglas Russell*, Mitchell Wachtel, Heiko de
Riese, Allan Haynes, Werner de Riese,
Lubbock, TX
MP84-10 THE CONTEMPORARY INCIDENCE AND
CONSEQUENCES OF RHABDOMYOLYSIS
FOLLOWING RENAL SURGERY: A
Francisco Gelpi-Hammerschmidt*, Ilker Tinay,
Christopher Allard, Boston, MA, Li-Ming Su,
Gainesville, FL, Mark Preston, Adam Kibel,
Ye Wang, Deborah Hess, James Hwong,
Boston, MA, Benjamin Chung, Stanford, CA,
Steven Chang, Boston, MA
MP84-11 NUTRITIONAL PREDICTORS OF
PERIOPERATIVE COMPLICATIONS AND
NEPHRECTOMY: A POPULATION-BASED
ANALYSIS
Sarah Psutka*, Kristine Thomsen, Elizabeth
Habermann, Matthew Tollefson, Rochester,
MN
MP84-18 SURGICAL MANAGEMENT FOR LOCAL
RETROPERITONEAL RECURRENCE FOR
RENAL CELL CARCINOMA AFTER
RADICAL NEPHRECTOMY
Arun Thomas*, Mehrad Adibi, Borregales
Leonardo, Ly Hoang, Pheroze Tamboli,
Surena Matin, Wood Christopher, Jose
Karam, Houston, TX
MP84-12 PATIENT-REPORTED QUALITY OF LIFE
AND CONVALESCENCE AFTER
MINIMALLY INVASIVE KIDNEY CANCER
SURGERY
Peter Chang*, Boston, MA, Jialin Mao, New
York, NY, Kimberly Taylor, Ostap Dovirak,
Arie Carneiro, Kyle McAnally, Catrina
Crociani, Boston, MA, Andrew Percy,
Richmond, VA, Andrew A Wagner, Boston,
MA
MP84-19 EXTENT OF LYMPH NODE DISSECTION IN
UROTHELIAL CARCINOMA IS
ASSOCIATED WITH BETTER SURVIVAL
Dominic Tang*, Nashville, TN, Sanjay Patel,
Chicago, IL, Daniel Barocas, Matthew
Resnick, Sam Chang, Nashville, TN
MP84-13 SELECTIVE ANGIOEMBOLIZATION FOR
RENAL VASCULAR LESIONS FOLLOWING
PARTIAL NEPHRECTOMY DOES NOT
AFFECT CLINICAL AND RENAL
FUNCTION OUTCOMES: A MATCHED
SERIES COMPARISON
Ilana Jacobs*, Asim Ozayar, Monica Morgan,
Clayton Trimmer, Jeffrey Cadeddu, Jeffrey
Gahan, Dallas, TX
MP84-20 CHANGING PRACTICE PATTERNS FOR
THE MANAGEMENT OF UPPER TRACT
UROTHELIAL CARCINOMA WITH
NEPHROURETERECTOMY: A 10-YEAR
Francisco Gelpi-Hammerschmidt*,
Christopher Allard, Jeffrey Leow, Ye Wang,
Boston, MA, Benjamin Chung, Stanford, CA,
Steven Chang, Boston, MA
MP84-14 VARIABILITY IN GROWTH KINETICS OF
SMALL RENAL MASSES ON ACTIVE
SURVEILLANCE
Hiten Patel*, Michael Johnson, Baltimore,
MD, Peter Chang, Andrew Wagner, Boston,
MA, James McKiernan, New York, NY,
Mohamad Allaf, Philip Pierorazio, Baltimore,
MD
CREDITTM
MP84-15 NATIONAL TRENDS OF LOCAL ABLATIVE
THERAPY AMONG YOUNG PATIENTS
WITH SMALL RENAL MASSES
Jonathan E Kiechle*, Shan Dong, Robert
Abouassaly, Hui Zhu, Edward E Cherullo,
Cleveland, OH, Nilay D Shah, Rochester,
MN, Dean Nakamoto, Cleveland, OH, Marc C
Smaldone, Philadelphia, PA, Matthew M
Cooney, Simon P Kim, Cleveland, OH
*Presenting author
271
TUESDAY
MP84-17 CONTEMPORARY PRACTICE PATTERNS
FOR PATIENTS WITH STAGE IV RENAL
CELL CARCINOMA: A NATIONAL CANCER
DATABASE ANALYSIS
Zachary Piotrowski*, Elizabeth Handorf,
Alexander Kutikov, Nathan Peffer, Nikhil
Wainganker, Mohammed Haseebuddin,
Philadelphia, PA, Anthony Corcoran, East
Setauket, NY, Simon Kim, Cleveland, OH,
Stephen Boorjian, Rochester, MN, Robert
Uzzo, Marc Smaldone, Philadelphia, PA
10:30 am - 12:30 pm
TRANSPLANTATION & VASCULAR SURGERY: RENAL TRANSPLANTATION & VASCULAR SURGERY II
Moderators: Peter Bretan and Puneet Sindhwani
ABSTRACT
NUMBER TITLE
MP85-01 GRAFT OUTCOME DISPARITY IN A
SINGLE RENAL TRANSPLANT CENTER
BASED ON RECIPIENT GEOGRAPHIC
ORIGIN
Weikai Qu, Ryan Flynn*, David Fumo,
Timothy Suttle, Steven Selman, Michael
Rees, Jorge Ortiz, Toledo, OH
ABSTRACT
NUMBER TITLE
MP85-08 INCIDENCE OF PROSTATE CANCER
AFTER SOLID ORGAN
TRANSPLANTATION AS A FUNCTION OF
TIME
Ethan B Fram*, Kara L Watts, Farhang
Rabbani, Bronx, NY
MP85-09 PREDICTIVE FACTORS AND FORMULA OF
CHRONIC RENAL INSUFFICIENCY AFTER
RADICAL NEPHRECTOMY
Thibaut Benoit*, Xavier Game, Rouvellat
Philippe, Nicolas Doumerc, Mathieu
Roumiguie, Jean Baptiste Beauval, Michel
Soulie, Pascal Rischmann, Bernard
Malavaud, Toulouse, France
MP85-02 OPTIMAL MANAGEMENT OF DISTAL
URETERIC STRICTURE FOLLOWING
RENAL TRANSPLANTATION: A
SYSTEMATIC REVIEW
Justin Kwong*, Danielle Schiefer, Ghaleb
Anas, Jason Archambault, Patrick Luke, Alp
Sener, London, Canada
MP85-10 PROSTATE CANCER SCREENING AND
TREATMENT OF RENAL TRANSPLANT
CANDIDATES: A SURVEY OF US
TRANSPLANT CENTERS
Greg Gin*, John Sfakianos, Reza Mehrazin,
Susan Lerner, Courtney Phillips, New York,
NY
MP85-03 PROSPECTIVE MEASUREMENT OF
PLASMA NEUTROPHIL GELATINASEASSOCIATED LIPOPROTEIN IN LIVING
KIDNEY DONOR NEPHRECTOMY
Young Eun Yoon*, Seoul, Korea, Republic of,
Kyung Hwa Choi, Seongnam-si, Korea,
Republic of, Kwang Hyun Kim, Seung Choul
Yang, Woong Kyu Han, Seoul, Korea,
Republic of
MP85-11 ARE KIDNEY TRANSPLANT PATIENTS
WITH CLOSTRIDIUM DIFFICILE COLITIS
AT INCREASED RISK FOR REJECTION?
Chad A. Reichard*, Samuel C. Haywood,
Daniel A. Shoskes, Cleveland, OH
MP85-04 PREDICTIVE RISK FACTORS OF POSTTRANSPLANT HIGH-GRADE CMV
REACTIVATION IN CMV-SEROPOSITIVE
PATIENTS IN THE MODERN
IMMUNOSUPPRESSIVE ERA
Mitsuru Saito*, Shigeru Satoh, Hiroshi
Tsuruta, Susumu Akihama, Takamitsu Inoue,
Shintaro Narita, Norihiko Tsuchiya, Tomonori
MP85-12 RISK FACTORS OF LOWER URINARY
TRACT DYSFUNCTION AND SYMPTOMS
AFTER SUCCESSFUL RENAL
TRANSPLANTATION
Takahiko Mitsui*, Ken Morita, Daiki Iwami,
Takeya Kitta, Yukiko Kanno, Kimihiko Moriya,
Nobuo Shinohara, Sapporo, Japan
MP85-05 RADICAL PROSTATECTOMY IN RENAL
TRANSPLANT RECIPIENTS:
COMPARISON OF FEASIBILITY AND
PERIOPERATIVE OUTCOMES BASED ON
SURGICAL APPROACH
Benjamin A Sherer*, Krishnan Warrior,
Oyedolamu Olaitan, Ajay Nehra, Leslie A
Deane, Chicago, IL
MP85-13 DYSLIPIDEMIA IN THE FIRST YEAR
AFTER KIDNEY TRANSPLANTATION:
INCIDENCE, CLINICAL
CHARACTERISTICS,
PHARMACOKINETICS OF
IMMUNOSUPPRESSIVE DRUGS, AND
RELATED GENOMIC POLYMORPHISMS
Kazuyuki Numakura*, Shigeru Satoh,
Norihiko Tsuchiya, Komine Naoki, Mitsuru
Saito, Tkamitsu Inoue, Shintaro Narita,
Hideaki Kagaya, Masatomo Miura, Tomonori
MP85-06 INCIDENCE AND MANAGEMENT OF
BLADDER CANCER AFTER RENAL
TRANSPLANTATION: A
MULTIINSTITUTIONAL ANALYSIS
Oscar Rodrı́guez Faba*, Claudia Caliolo,
Joan Palou, Barcelona, Spain, Carlo Terrone,
Novara, Italy, Javier Burgos, Enrique Lledó,
Madrid, Spain, Alberto Breda, Barcelona,
Spain
MP85-14 IS THERE A ROLE FOR
PRECONDITIONING THE KIDNEY BEFORE
WARM ISCHEMIA WITH SILDENAFIL?
Khaled Mursi*, Mohamed El-Ghoneimy,
Mohamed Badawy, Olfat Hammam, Soheir
Mansy, Tarek Leithy, Ahmed Morsy, Cairo,
Egypt
MP85-07 RENAL TRANSPLANTATION AFTER
RENAL TUMOUR EXCISION: A
SYSTEMATIC REVIEW
Jinna Yao*, Howard MH Lau, Richard Allen,
Henry CC Pleass, Vincent WT Lam, Sydney,
Australia
272
MP85-18 HEALTH-RELATED QUALITY OF LIFE
(QOL) AFTER RADICAL RETROPUBIC
PROSTATECTOMY (RRP) FOR LOCALIZED
PROSTATE CANCER (PC) IN KIDNEY
TRANSPLANT PATIENTS (KTX): LONG
TERM RESULTS
Ioannis Antonopoulos*, Bianca Moraes,
Kleiton Ribeiro, Affonso Piovesan, Hideki
Kanashiro, William Nahas, Sao Paulo, Brazil
MP85-15 NEPHRECTOMY INDUCED CHRONIC
KIDNEY DISEASE (CKD) AND THE
HEALTH-RELATED QUALITY OF LIFE
(HRQOL) OF LIVING KIDNEY DONORS
(LKDS)
Xiao Han*, Singapore, Singapore, Yu Ming
Lim, Scotland, United Kingdom, Lata Raman,
Bee Choo Tai, Hersharan Kaur, Ting Hui,
Angeline Goh, Anantharaman Vathsala, Ho
Yee Tiong, Singapore, Singapore
MP85-20 NO IMPACT OF COLD ISCHEMIA TIME,
OPERATIVE TIME, OR TIME OF DAY
TRANSPLANT PERFORMED ON
DECEASED DONOR RENAL TRANSPLANT
GRAFT SURVIVAL WITH ALEMTUZUMAB
INDUCTION
Pamela Baron*, Felix Cheung, Michael Ernst,
Bennet Hong, George Zhou, Carrie Lindower,
Wayne Waltzer, Frank Darras, Stony Brook,
NY
MP85-17 IS PATIENT’S BMI A DETERMINANT OF
MORBIDITY IN RENAL
TRANSPLANTATION?
Vanessa Queruel*, Rémi Kabore, Adeline
Guillaume, Karine Moreau, Karen Leffondre,
Lionel Couzi, Pierre Merville, Alice Quinart,
Julien Rogier, Patrick Tauzin-Fin, Jean-Marie
Ferriere, Jean-Christophe Bernhard,
BORDEAUX, France
CREDITTM
10:30 am - 12:30 pm
PROSTATE CANCER: DETECTION AND SCREENING VII
Moderators: Daniel Barocas and William Aronson
ABSTRACT
NUMBER TITLE
MP86-01 INFECTIOUS COMPLICATIONS OF
PROSTATE BIOPSY: THE CHANGES IN
ANTIBIOTICS RESISTANCE PATTERNS –
THE REVIEW OF 10-YEAR PERIOD
Ales Cermak*, Natalia Mareckova, Dalibor
Pacik, Roman Wasserbauer, Brno, Czech
Republic
ABSTRACT
NUMBER TITLE
MP86-03 PREDICTION OF OVERALL AND
CLINICALLY SIGNIFICANT CANCER RISK
ON MRI-TARGETED AND SYSTEMATIC
PROSTATE BIOPSY USING PREBIOPSY
NOMOGRAMS
Marc Bjurlin*, James Wysock, New York, NY,
Saradwata Sakar, Rajesh Venkataraman,
Grass Valley, CA, Xiaosong Meng, Michael
Fenstermaker, Neil Mendhiratta, Gregory
Fernandez, Andrew Rosenkrantz, Samir
MP86-02 PREDICTIVE VALUE OF PATHOLOGIC
PARAMETERS AND ERG ONCOPROTEIN
EXPRESSION IN THE STRATIFICATION OF
PROSTATE CANCER RISK ASSOCIATED
WITH HIGH GRADE PROSTATIC
INTRAEPITHELIAL NEOPLASIA (HGPIN)
DIAGNOSIS IN PROSTATE NEEDLE
BIOPSY
Rajal Shah*, Irving, TX, Savvas Mendrinos,
Union, NJ
*Presenting author
MP86-04 NOVEL TECHNIQUES OF THREEDIMENSIONALLY DOCUMENTED BIOPSYMAPPING ALLOW SERIAL MONITORING
OF CELL-CYCLE PROGRESSION BY REVISITING CANCER FOCI
Osamu Ukimura*, Mitchell Gross, Andre Luis
de Castro Abreu, Raed Azhar, Toru
Matsugasumi, Manju Aron, Inderbir Gill, Los
Angeles, CA
273
TUESDAY
MP85-19 TREATMENT OF TRANSPLANT URETER
STRICTURES WITH URETERAL DILATION
AND URETERONEOCYSTOSTOMY:
OUTCOMES FROM A 14 YEAR
EXPERIENCE
John Stoffel*, Randall Sung, Gary Faerber,
James Shields, Stuart Wolf, Yihung Huang,
Ann Arbor, MI
MP85-16 TRANSIENT LYMPHOPENIA BREAKS
COSTIMULATORY BLOCKADE-BASED
TRANSPLANT TOLERANCE AND
INITIATES ALLOGRAFT REJECTION
Shoichi Iida*, Tokyo, Japan, Toshihiro Suzuki,
Chiba, Japan, Kazunari Tanabe, Tokyo,
Japan, Anna Valujskikh, Robert Fairchild,
Cleveland, OH, Ryo Abe, Chiba, Japan
MP86-11 PROSTATE SPECIFIC ANTIGEN VELOCITY
AS A PREDICTIVE BIOMARKER IN A
PROSPECTIVE PROSTATE CANCER
SCREENING STUDY OF MEN WITH
GENETIC PREDISPOSITION
Christina G Selkirk*, Evanston, IL, Christos
Mikropoulos, Sibel Saya, Elizabeth Bancroft,
Tokhir Dadaev, Sutton, United Kingdom,
Charles Brendler, Evanston, IL, Elizabeth
Page, Daniel A Leongamornlert, Natalie
Taylor, Edward J Saunders, Clara CiezaBorrela, The IMPACT study collaborators,
Sutton, United Kingdom, Sue Moss, London,
United Kingdom, Zsofia Kote-Jarai, Sutton,
United Kingdom, Brian T Helfand, Evanston,
IL, Rosalind A Eeles, Sutton, United Kingdom
MP86-05 FAILURE OF PROSTATE SPECIFIC
ANTIGEN DECREASE BY FIFTY PERCENT
FROM BASELINE FOLLOWING 5 ALPHA
REDUCTASE INHIBITOR IS ASSOCIATED
WITH HIGH POSITIVE RATE OF
PROSTATE CANCER AT SUBSEQUENT
BIOPSY IN REAL-LIFE SETTING
Kenya Yamaguchi*, Akiko Ito, Daisaku
Ashikari, Yasutaka Murata, Daisuke Obinata,
Tsuyoshi Matsui, Katsuhiko Sato, Junichi
Mochida, Yataro Yamanaka, Satoru
Takahashi, Tokyo, Japan
MP86-06 IMPACT OF PSA SCREENING ON STAGE
MIGRATION OF PROSTATE CANCER:
TRENDS IN CLINICOPATHOLOGIC
CHARACTERISTICS OVER THE PAST 14
YEARS
Myungsun Shim*, Myungchan Park, Aram
Kim, In Gab Jeong, Cheryn Song, ChoungSoo Kim, Hanjong Ahn, Seoul, Korea,
Republic of
MP86-12 REDEFINING THE DIGITAL RECTAL
EXAMINATION OF THE PROSTATE
Dara Lundon*, Dublin, Ireland, Stacy Loeb,
New York, NY, Robert Foley, William Watson,
Padraig Daly, Nicholas Hegarty, Kiaran
O’Malley, David Galvin, John Fitzpatrick,
Dublin, Ireland
MP86-07 ASSOCIATION OF METFORMIN USE WITH
PROSTATE CANCER INCIDENCE IN A
PROSPECTIVE SCREENING TRIAL
(ERSPC AARAU)
Marco Randazzo*, Thomas Hermanns,
Cedric Poyet, Zürich, Switzerland, Josef
Beatrice, Andreas Huber, Rainer Grobholz,
Aarau, Switzerland, Lukas Manka,
Braunschweig, Germany, Stephen Wyler,
Franz Recker, Maciej Kwiatkowski, Aarau,
Switzerland
MP86-13 INCREASED PROSTATE CANCER
DETECTION WITH MAGNETIC
RESONANCE IMAGING-ULTRASOUND
FUSION BIOPSY IN MEN REQUIRING
REPEAT BIOPSY
Ramkishen Narayanan, Buffalo, NY, K. Kent
Chevli*, David Cipolla, William Geary,
Margaret Suraf, Michael Duff, Cheektowaga,
NY
MP86-14 DOES A SECOND CONFIRMATORY PSA
ABOVE 4.0NG/ML LEAD TO THE
DIAGNOSIS OF MORE CLINICALLY
SIGNIFICANT PROSTATE CANCER?
Ryan Werntz*, Wesley Stoller, Mark Garzotto,
Portland, OR
MP86-08 CONFIRMATION: ANALYSIS OF PSA
TRENDS HELPS IDENTIFY DEADLY
PROSTATE CANCERS PRIOR TO BIOPSY
R. Jeffrey Karnes*, Rochester, MN, Stacy
Loeb, New York, NY, Preston C. Sprenkle,
New Haven, CT, Christopher Morrell,
Baltimore, MD, F. Roy MacKintosh, Lori
Rawson, Reno, NV, Thomas Neville, Incline
Village, NV
MP86-15 CREATION OF THE TORONTO BIOPSY
AVOIDANCE TOOLS (T-BAT) WITH
CLINICAL PARAMETER-ONLY AND
ADIPOKINE BIOMARKER-AUGMENTED
VERSIONS
Bimal Bhindi*, Aza Mohammed, Haiyan
Jiang, Robert Hamilton, Ants Toi, Antonio
Finelli, John Trachtenberg, Alexandre Zlotta,
Theodorus van der Kwast, Andrew Evans,
Neil Fleshner, Girish Kulkarni, Toronto,
Canada
MP86-09 INCIDENTAL FINDINGS ON
RESONANCE IMAGING OF THE
PROSTATE: PREVALENCE AND CLINICAL
RELEVANCE
Tatiana Martins*, Yves Bohrer, Thais Mussi,
Ronaldo Baroni, São Paulo, Brazil
MP86-10 CLINICAL PROSTATE CANCER RISK
PREDICTION DERIVED FROM TARGETED
BIOPSY
Michael Leapman*, Katsuto Shinohara,
Niloufar Ameli, Maxwell Meng, Matthew
Cooperberg, Peter Carroll, San Francisco, CA
MP86-16 FATE OF PROSTATE CANCER ANTIGEN 3
(PCA3) LEVELS MORE THAN 100: DOES
INFLAMMATION PLAY A ROLE??
Thamir Alkasab*, Girish Kulkarni, Robert
Hamilton, Alexander Zlotta, Antonio Finelli,
Michael Jewett, Neil Fleshner, Toronto,
Canada
MP86-17 CLINICALLY SIGNIFICANT INCIDENTAL
PROSTATE CANCER DETECTED IN
RADICAL CYSTOPROSTATECTOMY
SPECIMENS
Swar Shah*, Soroush Bazaragani, Gus
Miranda, Hooman Djaladat, Anne
Schuckman, Siamak Daneshmand, Los
Angeles, CA
274
MP86-20 HIGH GRADE INTRAEPITHELIAL
NEOPLASIA (HGPIN) IN AFRICAN
AMERICAN MEN: SHOULD IMMEDIATE
RE-BIOPSY BE RECOMMENDED?
Ibraheem Malkawi*, Min Jun, Lira
Chowdhury, Ranko Miocinovic, Detroit, MI
MP86-18 MRI TARGETED BIOPSY MAY ENHANCE
DIAGNOSTIC PERFORMANCE OF
SIGNIFICANT PROSTATE CANCER
DETECTION COMPARED TO STANDARD
BIOPSY: A SYSTEMATIC REVIEW AND
META-ANALYSIS
Ivo Schoots, Monique Roobol*, Arnout
Alberts, Daan Nieboer, Chris Bangma, Ewout
Steyerberg, Myriam Hunink, Rotterdam,
Netherlands
CREDITTM
MP86-19 IN-BORE MRI-GUIDED TARGETED
PROSTATE BIOPSY (MRGTBX): PI RADS
BASED PROSTATE CANCER DETECTION
AND GLEASON UPGRADING ON 3T
COMPARED TO TRUS BIOPSY IN MEN
WITH ELEVATED PSA
Wei Chan Lin*, Nelly Tan, Pooria
Khoshnoodi, Daniel Margolis, David Lu,
Steven Raman, Los Angeles, CA
10:30 am - 12:30 pm
PROSTATE CANCER: ADVANCED III
Moderators: Joseph Renzulli, II and Thomas Keane
ABSTRACT
NUMBER TITLE
MP87-01 DO PRIMARY HORMONAL THERAPY
OUTCOMES PREDICT SUBSEQUENT
RESPONSE TO ABIRATERONE OR
ENZALUTAMIDE IN METASTATIC
CANCER?
Jonathan Hung, Rochester, MI, Andrew R.
Taylor, George W. Divine, Detroit, MI, Jason
M. Hafron*, Troy, MI, Clara Hwang, Detroit,
MI
ABSTRACT
NUMBER TITLE
MP87-04 TIMING OF SALVAGE ANDROGEN
DEPRIVATION THERAPY FOLLOWING
PROSTATE RADIOTHERAPY DOES NOT
ADVERSELY AFFECT ALL-CAUSE OR
PROSTATE CANCER SPECIFIC SURVIVAL
Daniel Sagalovich*, Michael Leapman, John
Sfakianos, Simon Hall, Richard Stock, Nelson
Stone, New York, NY
MP87-05 INCREASING USE OF HOSPICE SERVICES
FOR METASTATIC PROSTATE CANCER
MODERATES THE ECONOMIC BURDEN
OF HOSPITAL ADMISSIONS FOR
Jesse Sammon*, Akshay Sood, Firas
Abdollah, Dane Klett, Detroit, MI, Matthew
Hayn, Adam Kibel, Boston, MA, James
Peabody, Detroit, MI, Briony Varda, Boston,
MA, Mani Menon, Detroit, MI, Quoc-Dien
Trinh, Boston, MA
MP87-02 PROGNOSTIC VALUE OF NEUTROPHILTO-LYMPHOCYTE RATIO AND
ESTABLISHMENT OF NOVEL RISK
STRATIFICATION MODEL IN
CANCER PATIENTS TREATED WITH
DOCETAXEL CHEMOTHERAPY
Yoshihiro Nakagami*, Jun Nakashima, Yoshio
Ohno, Ohori Makoto, Masaaki Tachibana,
Tokyo, Japan
MP87-06 NADIR TESTOSTERONE AFTER LONGTERM FOLLOW-UP PREDICTS
PROGNOSIS OF PROSTATE CANCER
PATIENTS TREATED WITH COMBINED
ANDROGEN BLOCKADE
Shuhei Kamada*, Shinichi Sakamoto,
Keisuke Ando, Ayumi Muroi, Miki Fuse, Koji
Kawamura, Takashi Imamoto, Chiba city,
Japan, Hiroyoshi Suzuki, Sakura city, Japan,
Maki Nagata, Yokohama city, Japan, Naoki
Nihei, Chiba city, Japan, Koichiro Akakura,
Tokyo, Japan, Tomohiko Ichikawa, Chiba city,
Japan
MP87-03 EVALUATION OF THE ER␣ AGONIST,
GTX-758 (250 MG DAILY), IN MEN WITH
METASTATIC (MCRPC) AND NONMETASTATIC CASTRATION RESISTANT
PROSTATE CANCER (NMCRPC)
Evan Yu*, Seattle, WA, Michael Hancock,
Memphis, TN, Tamás Babicz, Nyı́regyháza,
Hungary, William Aronson, Los Angeles, CA,
Zsuzsanna Pápai, Lajos Géczi, Budapest,
Hungary, Robert Getzenberg, Memphis, TN
*Presenting author
275
TUESDAY
MP87-07 PROGNOSTIC FACTORS FOR OVERALL
SURVIVAL IN PATIENTS WITH
CANCER TREATED BY INTERMITTENT
CHEMOTHERAPY WITH DOCETAXEL AND
PREDNISOLONE
Shintaro Narita*, Akita, Akita, Japan, Takuya
Koie, Hirosaki, Japan, Shigeyuki Yamada,
Kazuhiko Orikasa, Sendai, Japan, Shigeki
Matsuo, Akita, Japan, Hiroshi Aoki, Shigeto
Ishidoya, Sendai, Japan, Senji Hoshi,
Yamagata, Japan, Norihiko Tsuchiya, Akita,
Japan, Chikara Ohyama, Hirosaki, Japan,
Yoichi Arai, Sendai, Japan, Tomonori
MP87-12 RADIUM-223 DICHLORIDE IN EXPANDEDACCESS SETTING IN THE UNITED
STATES: OVERALL AND CONCURRENT
EXPERIENCE WITH ABIRATERONE OR
ENZALUTAMIDE
Neal Shore*, Myrtle Beach, SC, Nicholas
Vogelzang, Las Vegas, NV, Daniel
Fernandez, Tampa, FL, Michael Morris, New
York, NY, Andrei Iagaru, Stanford, CA, Alan
Brown, Fort Myers, FL, Christopher Sweeney,
Matthew R. Smith, Boston, MA, Adam P.
Dicker, Yu-Ning Wong, Philadelphia, PA,
Keith Bangerter, Jeremy Gratt, Oana
Petrenciuc, Whippany, NJ, Oliver Sartor, New
Orleans, LA
MP87-08 IS COMPUTERIZED TOMOGRAPHY A
NECESSARY PART OF A PROSTATE
CANCER METASTATIC WORKUP?
RESULTS FROM SEARCH
Brian Hanyok*, Lauren Howard, Durham, NC,
Christopher Amling, Portland, OR, William
Aronson, Los Angeles, CA, Matthew
Kane, San Diego, CA, Martha Terris,
Augusta, GA, Stephen Freedland, Durham,
NC
MP87-13 IMPACT OF PRE-TREATMENT PSA LEVEL
ON CANCER CONTROL AFTER EARLY
SALVAGE RADIATION THERAPY POST
RADICAL PROSTATECTOMY: NEED FOR
PATIENT STRATIFICATION ACCORDING
TO PROSTATE CANCER FEATURES
Nicola Fossati*, Milan, Italy, R. Jeffrey
Karnes, Rochester, MN, Cesare Cozzarini,
Claudio Fiorino, Milan, Italy, Steven Joniau,
Leuven, Belgium, Wolfgang Hinkelbein,
Berlin, Germany, Karin Haustermans,
Leuven, Belgium, Bertrand Tombal, Brussels,
Belgium, Shahrokh F. Shariat, Vienna,
Austria, Pierre I. Karakiewicz, Montreal,
Canada, Gregor Goldner, Vienna, Austria,
Francesco Montorsi, Milan, Italy, Hein Van
Poppel, Leuven, Belgium, Thomas Wiegel,
Ulm, Germany, Alberto Briganti, Milan, Italy
MP87-09 WHEN IS AN EQUIVOCAL BONE SCAN
NOT REALLY EQUIVOCAL? RESULTS
FROM SEARCH
Brian Hanyok*, Lauren Howard, Durham, NC,
Christopher Amling, Portland, OR, William
Aronson, Los Angeles, CA, Matthew
Kane, San Diego, CA, Martha Terris,
Augusta, GA, Stephen Freedland, Durham,
NC
MP87-14 ADJUVANT RADIOTHERAPY IN
PROSTATE CANCER PATIENTS TREATED
WITH SURGERY: THE IMPACT OF AGE
AND TUMOR CHARACTERISTICS
Jesse Sammon, Detroit, MI, Quoc-Dien Trinh,
Boston, MA, Francesco Montorsi, Alberto
Briganti, Milan, Italy, James Peabody, Detroit,
MI, Pierre Karakiewicz, Montreal, Canada,
Mani Menon, Detroit, MI, Maxine Sun,
Montreal, Canada
MP87-10 ALP AND BONE SCAN FLARE
FOLLOWING ENZALUTAMIDE
TREATMENT OF CASTRATION
RESISTANT PROSTATE CANCER (CRPC)
WITH BONE METASTASIS
Senji Hoshi*, Kunihisa Nezu, Hidenori Kanno,
Teppei Ookubo, Mituharu Sasaki, Kenji
Numahata, Kiyotugu Hoshi, Satoru Kanto,
Isoji Sasagawa, Yamagata, Japan, Yuuichi
Ishizuka, Hideaki Izumi, Kunio Ono,
Ishinomaki, Japan, Vladimir Bilim, Niigata,
Japan
MP87-15 RANDOMIZED PHASE 2 STUDY
EVALUATING OPTIMAL SEQUENCING OF
SIPULEUCEL-T AND ANDROGEN
DEPRIVATION THERAPY (STAND) IN
BIOCHEMICALLY RECURRENT
PROSTATE CANCER: PRELIMINARY
CLINICAL OUTCOMES
Adam Kibel*, Boston, MA, Charles Drake,
Baltimore, MD, George Adams, Homewood,
AL, Lawrence Karsh, Denver, CO, Aymen
Elfiky, Boston, MA, Neal Shore, Myrtle
Beach, SC, Nicholas Vogelzang, Las Vegas,
NV, John Corman, Robert Tyler, Johnathan
Maher, Todd DeVries, Nadeem Sheikh,
Seattle, WA, Emmanuel Antonarakis,
Baltimore, MD
MP87-11 ALKALINE PHOSPHATASE VELOCITY AS
A PREDICTOR OF BONE METASTASIS
AND OVERALL SURVIVAL IN CASTRATE
PATIENTS
Timothy Donahue*, Inger Rosner, Bethesda,
MD, Jennifer Cullen, Huai-Ching Kuo, Lauren
Hurwitz, Yongmei Chen, Rockville, MD,
Melanie Bernstein, Jonathan Coleman, Daniel
Danila, New York, NY, Adam Metwalli,
Bethesda, MD
276
MP87-19 EFFECT OF ABIRATERONE ACETATE AND
LOW DOSE PREDNISONE ON PROSTATESPECIFIC ANTIGEN IN PATIENTS WITH
NON-METASTATIC CASTRATIONRESISTANT PROSTATE CANCER: THE
RESULTS FROM IMPACT OF A
BIRATERONE ACETATE IN PROSTATESPECIFIC ANTIGEN CORE STUDY
Charles J. Ryan*, San Francisco, CA, E.
David Crawford, Aurora, CO, Neal D. Shore,
Myrtle Beach, SC, Willie Underwood, Buffalo,
NY, Jim Wang, Jannell DePalantino, Anil
Londhe, Zane Yang, Shawn Black, Tracy
McGowan, Horsham, PA, Philip W. Kantoff,
Boston, MA
MP87-17 EXPLORING THE INCIDENCE OF
ABIRATERONE ACETATE WITHDRAWAL
RESPONSES
Rajasree Pia Chowdry*, Brian Lewis, Elisa
Ledet, Jonathan Silberstein, Oliver Sartor,
New Orleans, LA
MP87-20 ANDROGEN RECEPTOR VARIANT-7
PLAYS AN ESSENTIAL ROLE IN
DEVELOPMENT AND PROGRESSION OF
CANCER
Yuanyuan Qu*, Dingwei Ye, Bo Dai, Hailiang
Zhang, Yao Zhu, Shanghai, China, People’s
Republic of
MP87-18 ASSESSMENT OF CORTICOSTEROID (CS)ASSOCIATED ADVERSE EVENTS (AES)
WITH LONG-TERM (LT) EXPOSURE TO
LOW-DOSE PREDNISONE (P) GIVEN WITH
ABIRATERONE ACETATE (AA) TO
METASTATIC CASTRATION-RESISTANT
PROSTATE CANCER (MCRPC) PATIENTS
(PTS)
Leonard G. Gomella*, Philadelphia, PA, Kim
N. Chi, Vancouver, Canada, Johann S. de
Bono, Sutton, United Kingdom, Karim Fizazi,
Villejuif, France, Kurt Miller, Berlin, Germany,
Dana E. Rathkopf, New York, NY, Charles J.
Ryan, San Francisco, CA, Howard I. Scher,
New York, NY, Neal D. Shore, Myrtle Beach,
SC, Peter De Porre, Beerse, Belgium, Anil
Londhe, Tracy McGowan, Horsham, PA,
Nonko Pelhivanov, Raritan, NJ, Robert
Charnas, Los Angeles, CA, Mary B. Todd,
Raritan, NJ, Bruce Montgomery, Seattle, WA
CREDITTM
10:30 am - 12:30 pm
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: MALE INCONTINENCE: THERAPY
Moderators: TBD
ABSTRACT
NUMBER TITLE
MP88-01 OVEREXPRESSION OF NEUROTROPHINS
IN BLADDER OVERACTIVITY IS
MODULATED BY EXPRESSION OF
MICRORNAS
Subrata Pore*, Mahendra Kashyap, Naoki
*Presenting author
ABSTRACT
NUMBER TITLE
MP88-02 DEVELOPMENT OF A NOVEL ARTIFICIAL
URINARY SPHINCTER (AUS): THE
PRECISION MEDICAL DEVICES (PMD)
FLOW CONTROL DEVICE (FCD) FOR
MANAGEMENT OF SPHINCTERIC
DEFICIENCY USING BLUETOOTH
TECHNOLOGY
Angelo Gousse, Miramar, FL, Peter Sayet,
Fort Lauderdale, FL, Christopher Gomez*,
Miami, FL
277
TUESDAY
MP87-16 NOVEL ANTIANDROGEN ARN-509 IN
HIGH-RISK NONMETASTATIC
CANCER
Neal D. Shore*, Myrtle Beach, SC,
Emmanuel S. Antonarakis, Baltimore, MD,
Charles J. Ryan, San Francisco, CA, William
R. Berry, Raleigh, NC, Glenn Liu, Madison,
WI, Celestia Higano, Seattle, WA, Edna
Chow Maneval, San Diego, CA, Rajesh
Bandekar, Spring House, PA, Carla J. de
Boer, Leiden, Netherlands, Mary B. Todd,
Raritan, NJ, Margaret K. Yu, Los Angeles,
CA, Dana E. Rathkopf, New York, NY,
Matthew R. Smith, Boston, MA
MP88-10 IMPACT OF RADIOTHERAPY ON URINARY
CONTINENCE AND QOL AFTER RADICAL
PROSTATECTOMY
Joanne Nyarangi-Dix*, Johannes Steimer,
Hildegard Jakobi, Boris Hadaschik, Markus
Hohenfellner, Heidelberg, Germany
MP88-03 ARGUS-T DEVICE IN MALE URINARY
INCONTINENCE: SHORT-TERM RESULTS
IN 182 PATIENTS
Salvatore Siracusano*, Trieste, Italy,
Alexander Kugler, Gottingen, Germany,
Michele Favro, Novara, Italy, Carlo Tallarigo,
San Bonifacio - Verona, Italy, Francesco
Visalli, Stefano Ciciliato, Trieste, Italy, Mauro
Saccomanni, San Bonifacio - Verona, Italy,
Laura Toffoli, Tommaso Silvestri, Renato
Talamini, Trieste, Italy
MP88-11 EXTERNAL BEAM RADIATION THERAPY
AFTER MALE TRANSOBTURATOR SLING
PLACEMENT INCREASES FAILURE
RATES
Ngoc-Bich Le, Durham, NC, Aaron Lentz,
Raleigh, NC, George Webster, Andrew
MP88-04 URINARY INCONTINENCE AND
SATISFACTION WITH TREATMENTS
AFTER ROBOTIC ASSISTED RADICAL
PROSTATECTOMY
Avinash Chennamsetty*, Hafron Jason, Royal
Oak, MI, Behdod Poushanchi, Scott Pew,
Rochester, MI, Jay Hollander, Kim Killinger,
Mary Coffey, Kenneth Peters, Royal Oak, MI
MP88-12 EFFECTS OF RADIATION THERAPY ON
DEVICE SURVIVAL AMONG INDIVIDUALS
WITH ARTIFICIAL URINARY SPHINCTERS
Marcelino Rivera*, Matthew Ziegelmann,
Brian Linder, Boyd Viers, Laureano Rangel,
Daniel Elliott, Rochester, MN
MP88-05 RETROPUBIC INTRACORPOREAL
PLACEMENT OF SUBURETHRAL
AUTOLOGOUS SLING DURING ROBOTIC
RADICAL PROSTATECTOMY TO IMPROVE
EARLY URINARY CONTINENCE
RECOVERY: PRELIMINARY DATA
Matteo Ferrari*, Matteo Luigi Zanoni, Mattia
Nicola Sangalli, Fabio Fabbri, Massimo
Ghezzi, Francesco Cristiano Sozzi, Patrizio
Rigatti, Andrea Cestari, Milan, Italy
MP88-13 MALE SLING AND ARTIFICIAL URETHRAL
SPHINCTER FOR INCONTINENCE
AMONGST CERTIFYING AMERICAN
UROLOGISTS
Joceline S. Liu*, Matthias D. Hofer, Jaclyn
Milose, Daniel T. Oberlin, Sarah C. Flury,
Chicago, IL, Allen F. Morey, Dallas, TX, Chris
M. Gonzalez, Chicago, IL
MP88-06 THE MECHANISM OF ACTION OF THE
MALE TRANSOBTURATOR SLING IS VIA
INCREASED FUNCTIONAL LENGTH OF
THE MEMBRANOUS URETHRA: A
PROSPECTIVE, CONTROLLED STUDY
USING DYNAMIC MRI
John Patrick Selph*, Mustafa Bashir,
Shubham Gupta, Michael J. Belsante,
Durham, NC, Timothy Brand, Timothy
Tausch, Tacoma, WA, Jessica Lloyd,
Zachariah Goldsmith, Andrew Peterson,
Durham, NC
MP88-14 ARTIFICIAL URINARY SPHINCTER
OUTCOMES IN OCTOGENARIANS
Matthew J Ziegelmann*, Brian J Linder,
Joshua Piotrowski, Boyd R Viers, David
Barrett, Daniel S Elliott, Rochester, MN
MP88-07 OBESITY IS ASSOCIATED WITH MALE
TRANSOBTURATOR SLING FAILURE
Durham, NC, Aaron Lentz, Raleigh, NC,
Ngoc-Bich Le, George Webster, Andrew
MP88-16 A PROSPECTIVE EVALUATION OF
COMPLICATIONS AFTER ARTIFICIAL
URINARY SPHINCTER PLACEMENT AND
THEIR IMPACT ON DEVICE SURVIVAL
Brian Linder*, Joshua Piotrowski, Matthew
Zieglemann, Tanner Miest, Marcelino Rivera,
Christina Ogle, Daniel Elliott, Rochester, MN
MP88-15 LOCATION OF AUS PRESSURE
REGULATING BALLOON: FUNCTIONAL
OUTCOMES OF HIGH SUBMUSCULAR
POSITION ARE EQUIVALENT TO SPACE
OF RETZIUS
Nirmish Singla*, Jay Simhan, Jordan Siegel,
Timothy Tausch, Allen Morey, Dallas, TX
MP88-08 EFFICACY AND SAFETY OF THE
ADVANCE XP MALE SLING IN THE LONGTERM FOLLOW-UP: RESULTS FROM A
PROSPECTIVE TRIAL
Alexander Kretschmer*, Markus Grabbert,
Christian G. Stief, Ricarda M. Bauer, Munich,
Germany
MP88-17 NATIONAL MULTI-INSTITUTIONAL
COMPARISON OF 30-DAY
POSTOPERATIVE COMPLICATION AND
READMISSION RATES FOR MALE
URETHRAL SLINGS AND ARTIFICIAL
URINARY SPHINCTERS
Benjamin Breyer*, Amjad Alwaal, Catherine
Harris, Thomas Gaither, Jack McAninch,
Isabel Allen, San Francisco, CA
MP88-09 ADVANCE XP MALE SLING: OUTCOME OF
A PROSPECTIVE MULTICENTER STUDY
Ricarda Bauer*, Benedikt Klehr, Munich,
Germany, Christian Gozzi, Brixen, Italy,
Alexander Kretschmer, Munich, Germany,
Peter Rehder, Innsbruck, Austria, Florian
May, Dachau, Germany, Christian Stief,
Munich, Germany, Roland Homberg, Hamm,
Germany, Peter Gebhartl, Voecklabruck,
Austria
MP88-18 DOES USE OF A SECOND CUFF IMPROVE
ARTIFICIAL SPHINCTER
EFFECTIVENESS? EVALUATION USING A
COMPARATIVE CADAVER MODEL
Madeleine Manka*, E. James Wright,
Baltimore, MD
278
MP88-20 SUCCESS RATES OF ARTIFICIAL
URINARY SPHINCTER PLACEMENT
FOLLOWING URETHROPLASTY
Christopher Powell*, Travis Dum, Kansas
City, KS, William Brant, Salt Lake City, UT,
Joshua Broghammer, Kansas City, KS
MP88-19 POST-OPERATIVE ANTIBIOTICS AFTER
PRIMARY ARTIFICIAL URINARY
SPHINCTER PLACEMENT DO NOT
REDUCE INFECTION OR EROSION RATES
J. Patrick Selph*, Michael Belsante, Divya
Ajay, Aaron Lentz, George Webster, NgocBich Le, Andrew Peterson, Durham, NC
CREDITTM
10:30 am - 12:30 pm
URODYNAMICS/INCONTINENCE/FEMALE UROLOGY: NON-NEUROGENIC VOIDING DYSFUNCTION
Moderators: Alan Wein and Deborah Lightner
ABSTRACT
NUMBER TITLE
MP89-07 A NOMOGRAM FOR EVALUATION OF
DETRUSOR CONTRACTILITY IN WOMEN
Francoise Valentini*, Pierre Nelson, Paris,
France
MP89-08 UNDERACTIVE BLADDER IS NOT A
SYMPTOM COMPLEX
Melissa Laudano, Matthew Benedon, Michael
Stern, Jerry Blaivas*, New York, NY
MP89-02 SINGLE CENTER EXPERIENCE: SACRAL
NEUROMODULATION REPROGRAMMING
RATES
Sara Lenherr*, Cynthia Stroup, Heather
Crossley, Samuel Kaufman, Anne Cameron,
John Stoffel, Ann Oldendorf, J. Quentin
Clemens, Ann Arbor, MI
MP89-09 COEXISITING DEPRESSIVE SYMPTOMS
DO NOT LIMIT THE BENEFITS OF
CHRONIC NEUROMODULATION
Luke Edwards*, Jonathon Fergus, Peters
Kenneth, Mike Ehlert, Priyanka Gupta, Jason
Gilleran, Jamie Bartley, Kim Killinger, Judith
Boura, Cheryl Wolfert, Janice Tomakowski,
Royal Oak, MI
MP89-03 THE IMPACT OF PRIOR BACK SURGERY
ON UROLOGIC DIAGNOSES AND
NEUROMODULATION OUTCOMES
Priyanka Gupta*, Michael Ehlert, Jamie
Bartley, Kim A. Killinger, Judith A. Boura,
Jason Gilleran, Cheryl Wolfert, Kenneth M.
Peters, Royal Oak, MI
MP89-10 THE IMPACT OF BASELINE FUNCTIONAL
BLADDER CAPACITY ON
NEUROMODULATION OUTCOMES
Michael Ehlert*, Kim A. Killinger, Judith A.
Boura, Jason Gilleran, Priyanka Gupta,
Cheryl Wolfert, Jamie Bartley, Kenneth M.
Peters, Royal Oak, MI
MP89-04 LONG-TERM EFFICACY OF SACRAL
NERVE STIMULATION IMPLANTATION
FOR NON-OBSTRUCTIVE URINARY
RETENTION REFRACTORY TO MEDICAL
THERAPY
Charles Snyder*, James Cummings, Majdee
Islam, Woodson Smelser, Columbia, MO
MP89-11 CT-GUIDED SACRAL
NEUROMODULATION S3 - A NEW
TARGETED APPROACH AFTER INITIAL
TREATMENT FAILURE: THE FIRST 10
PATIENTS
Sophina Trubel*, Elsbethen, Austria, Elena
Esra Foditsch, Günter Janetschek, Reinhold
Posch-Zimmermann, Salzburg, Austria
MP89-05 CHARACTERISTICS OF SEASONAL
VARIATIONS IN NOCTURIA
Jin Wook Kim, Du Geon Moon, Young Tae
Moon, Kyung Do Kim, Soon Chul Myung, Tae
Hyoung Kim, In Ho Chang, Byung Hoon Chi,
Se Young Choi, Seung Hyun Ahn, Jae Duck
Choi, Jung Hoon Kim, Min Su Kim*, Jong
Kyu Kwon, Seoul, Korea, Republic of, Seo
Yeon Lee, Kyunggido, Korea, Republic of
MP89-12 DOES A LOWER VOLTAGE ATTAINED FOR
GOOD BELLOWS AND IPSILATERAL
PLANTAR FLEXION WITH TINED LEAD
PLACEMENT PORTEND A BETTER
OUTCOME FOR OVERACTIVE BLADDER
SYMPTOMS WITH SACRAL
NEUROMODULATION?
Serge Marinkovic*, Detroit, MI
MP89-06 WHEN NOCTURIA IMPROVES, WHAT
GETS BETTER?
Joshua Aizen, Jonathan Gerber*, Komal
Mehta, Jeffrey P. Weiss, Brooklyn, NY
*Presenting author
279
TUESDAY
ABSTRACT
NUMBER TITLE
MP89-01 PUDENDAL NEUROMODULATION AFTER
FAILED SACRAL STIMULATION
Kenneth M. Peters*, Kim A. Killinger, Michael
Ehlert, Priyanka Gupta, Jamie Bartley, Cheryl
Wolfert, Judith A. Boura, Jason Gilleran,
Royal Oak, MI
MP89-18 TURP/KTPLAP: AN EFFECTIVE
TREATMENT FOR MEN WITH DETRUSOR
UNDERACTIVITY (DU) & BLADDER
OUTLET OBSTRUCTION (BOO)
Michael Tyler*, Matthew Benedon, Joshua
Aizen, Anand Badri, Jeffrey Weiss, Jerry
Blaivas, New York, NY
MP89-13 ONABOTULINUMTOXIN A IN PATIENTS
WITH A HISTORY OF PRIOR PELVIC
RADIATION THERAPY
David Flores*, Kansas City, KS, Stephen
Mock, Nashville, TN, Joshua Broghammer,
Tomas Griebling, Kansas City, KS, Roger
Dmochowski, Nashville, TN, Priya
Padmanabhan, Kansas City, KS
MP89-19 INCREASE OF SUBMUCOSAL
INFLAMMATION AND DECREASE OF
UROTHELIAL BARRIER FUNCTION ARE
FOUND IN PATIENTS WITH DETRUSOR
UNDERACTIVITY - AN
IMMUNOHISTOCHEMISTRY STUDY
Shiu-Dong Chung*, New Taipei City, Taiwan,
Jia-Hui Chang, Hann-Chorng Kuo, Hualien,
Taiwan
MP89-14 COMPARISON OF ULTRASTRUCTURAL
FEATURES IN FEMALE AND MALE
BLADDER OUTLET OBSTRUCTION – A
POTENTIAL ROLE FOR DIAGNOSTIC
DETRUSOR MUSCLE BIOPSY
Audrey Wang, Susan Brammah, Vincent Tse,
Lewis Chan*, Sydney, Australia
MP89-15 NOMOGRAMS ALLOWING EVALUATION
OF BLADDER OUTLET OBSTRUCTION
(BOO) IN MEN FROM FREE UROFLOWS
(FF)
Francoise Valentini*, Pierre Nelson, Paris,
France
MP89-20 BDNF OVEREXPRESSION ALTERS THE
PHENOTYPE OF CHOLINERGIC NEURONS
IN RAT BLADDER
Mahendra Kashyap*, Subrata Pore, Willam C
Degroat, Christopher J Chermansky, Naoki
MP89-16 ASSOCIATIONS BETWEEN HUMAN
AUTONOMIC NERVOUS SYSTEM
ACTIVITY AND URINARY FREQUENCY
USING 24-HOUR AMBULATORY
ELECTROCARDIOGRAPHY
Seiji Matsumoto*, Yuichiro Kawamura,
Nobuyuki Sato, Naoyuki Hasebe, Hidehiro
Kakizaki, Asahikawa, Japan
CREDITTM
MP89-17 DIFFERENT INJECTION NUMBER OF
INTRAVESICAL ONABOTULINUMTOXINA
INJECTION FOR OVERACTIVE BLADDER
SYNDROME DOES NOT AFFECT
TREATMENT OUTCOME - A
PROSPECTIVE RANDOMIZED
COMPARATIVE STUDY
Chun-Hou Liao*, New Taipei City, Taiwan,
Jing-Hui Tian, Hann-Chorng Kuo, Hualien,
Taiwan
10:30 am - 12:30 pm
Podium Session 51
STONE DISEASE: EVALUATION III
Moderators: Patrick Mufarrij and Matthew Dunn
ABSTRACT
TIME NUMBER TITLE
10:30 PD51-01 MULTI-CENTRE EVALUATION AND
COMPARISON OF STONE SCORING
SYSTEMS IN PREDICTING OUTCOMES
AFTER PERCUTANEOUS
NEPHROLITHOTOMY
Thomas Tailly*, London, Canada, Zhamshid
Okhunov, Irvine, CA, Brandon Nadeau,
Melissa Huynh, Daniel Olvera-Posada,
Husain Alenezi, Philippe Violette, London,
Canada, Arash Akhavein, Gainesville, FL,
Kevin Labadie, Irvine, CA, Justin Amann,
London, Canada, Vincent Bird, Gainesville,
FL, Jaime Landman, Irvine, CA, John
Denstedt, Hassan Razvi, London, Canada
ABSTRACT
TIME NUMBER TITLE
10:40 PD51-02 THE NATURAL HISTORY OF
ASYMPTOMATIC RENAL STONES: A
SYSTEMATIC REVIEW AND METAANALYSIS
Khurshid Ghani*, Abdulrahman Alruwaily,
Mary Rogers, Maggie Bierlein, Whitney
Townsend, Casey Dauw, J. Stuart Wolf, Jr,
10:50
280
PD51-03 LEISURE TIME PHYSICAL ACTIVITY,
SMOKING AND RISK OF RECENT
UROLITHIASIS
Michael Soueidan*, Susan J. Bartlett, Yasser
A. Noureldin, Ross E. Andersen, Sero
Andonian, Montreal, Canada
PD51-04 HYPERCALCIURIA: EVALUATION OF
GENDER DIFFERENCE AND METABOLIC
ABNORMALITIES
John Lynam*, Omar Ayyash, Ahmadullah
Daud, Ilan Kafka, Stephen Jackman, Timothy
Averch, Pittsburgh, PA
12:00
PD51-10 OVERUTILIZATION OF CT IMAGING IN
PATIENTS WITH KNOWN URINARY
TRACT CALCULI
Daniel Zainfeld*, Andrew Arther, Bradley
Wilson, Jeffrey Holzbeirlein, David Duchene,
Kansas City, KS
11:10
PD51-05 THE BURDEN OF KIDNEY STONES IN
PRIMARY CARE
Melissa Mendez*, Michael Lipkin, Glenn
Preminger, Charles Scales, Durham, NC
12:10
11:20
PD51-06 THE PERCPETION OF HAVING RENAL
CALCULI MAY AFFECT DISEASESPECIFIC HEALTH-RELATED QUALITY OF
LIFE IN ASYMPTOMATIC STONE
PATIENTS
Kristina L Penniston*, Brian C Sninsky,
Stephen Y Nakada, Madison, WI
PD51-11 FACTORS PREDICTING SURGICAL
INTERVENTION IN PEDIATRIC
NEPHROLITHIASIS PATIENTS
Esther Jun, Peter D. Metcalfe*, Todd R.
Alexander, Edmonton, Canada
12:20
PD51-12 LOW URINE PH AND ASSOCIATED
HYPOCITRATURIA ARE RISK FACTORS
FOR URINARY STONE FORMATION IN
ELDERLY STONE PATIENTS
Young-Won Kim, Sung Pil Seo, Yunbyung
Chae, Cheongju, Korea, Republic of, InChang Cho, Seoul, Korea, Republic of, Hoon
Jang, Daejun, Korea, Republic of, TongWook Kim, Cheongju, Korea, Republic of,
Hyung-Jee Kim, Cheonan, Korea, Republic
of, Won Tae Kim*, Yong-June Kim, Seok
Joong Yun, Wun-Jae Kim, Sang-Cheol Lee,
Cheongju, Korea, Republic of
11:30
PD51-07 NUTRITIONAL INTAKE ASSESSMENT IN
PATIENTS WITH UROLITHIASIS: A
DECISION IMPACT ANALYSIS
Avory Heningburg, Nashville, TN, Alana
Desai, Alethea Paradis, Joel Vetter, Adrienne
Kuxhausen, Leslie McIntosh, Anthony
Juehne, Gerald Andriole, Brian Benway*,
Saint Louis, MO
11:40
PD51-08 VITAMIN D DEFICIENCY TREATED WITH
WEEKLY 50,000 IU VITAMIN D
SUPPLEMENTATION INCREASES RENAL
STONE RISK
Sangtae Park*, Natalie Fahey, Brittany Lapin,
Jaclyn Pruitt, Chi Wang, Evanston, IL
11:50
PD51-09 HIGH PREVALENCE OF KIDNEY STONES
IN PEDIATRIC PATIENTS WITH ASTHMA
Ganesh Kartha*, Suzy Comhair, Manoj
Monga, Serpil C Erzurum, Cleveland, OH
CREDITTM
10:30 am - 12:30 pm
Podium Session 52
INFERTILITY: EVALUATION
Moderator: Ates Kadioglu
ABSTRACT
TIME NUMBER TITLE
10:30 PD52-01 CYSTIC FIBROSIS TRANSMEMBRANE
REGULATOR (CFTR) GENE SEQUENCING
IDENTIFIES DIFFERENT MUTATIONS
WHEN COMPARED WITH ROUTINE
MUTATION SCREENING IN
AZOOSPERMIC MEN
Alexander W. Pastuszak*, Evan P. Wenker,
Tariq S. Hakky, Aravind Chandrashekar,
Ranjith Ramasamy, Dolores J. Lamb, Larry I.
Lipshultz, Houston, TX
10:40
ABSTRACT
TIME NUMBER TITLE
10:50 PD52-03 CYTOGENETIC ABNORMALITIES IN MEN
WITH SUBFERTILITY. ANALYSIS OF THE
FREQUENCY OF ABNORMALITIES AND
DETERMINATION OF A THRESHOLD
SPERM CONCENTRATION FOR GENETIC
TESTING
Amr Abdel Raheem*, Francesco De Luca,
Saad Abumelha, Tet Yap, Fahd Almashat,
Giulio Garaffa, Nim Christopher, Suks
Minhas, David Ralph, London, United
Kingdom
PD52-02 ULTRA-STRUCTURAL DEFECTS IN
IMMOTILE SPERM: CHARACTERIZATION
OF ELECTRON MICROSCOPY FINDINGS
Ryan Flannigan*, Vancouver, Canada, Jared
M. Bieniek, Brendan Mullen, Ethan D.
Grober, Kirk C. Lo, Keith A. Jarvi, Toronto,
Canada
*Presenting author
11:00
281
PD52-04 FLUORESCENCE IN-SITU HYBRIDIZATION
DETECTS INCREASED SPERM
ANEUPLOIDY IN MEN WITH RECURRENT
PREGNANCY LOSS
Ranjith Ramasamy*, Jason Scovell, Houston,
TX, Jason Kovac, Indianapolis, IN, Peter
Cook, Larry Lipshultz, Dolores Lamb,
Houston, TX
TUESDAY
11:00
11:10
PD52-05 THE CLINICAL VALUE OF ASSESSING
SPERM CHROMOSOMAL ANEUPLOIDY IN
COUPLES UNDERGOING FAILED
(ICSI) AND ITS CORRELATION WITH
SEMEN PARAMETERS
Fahad AlMashat*, Tet Yap, Shabana Bora,
George Rozis, Saad Abumelha, Hossam
Abdalla, Yau Thum, Suks Minhas, London,
United Kingdom
11:20
PD52-06 LOW BIRTH WEIGHT IS ASSOCIATED
WITH A HIGHER RATE OF HEALTHSIGNIFICANT COMORBIDITIES AND
WORSE SEMINAL PARAMETERS –
RESULTS OF A CROSS-SECTIONAL
STUDY IN PRIMARY INFERTILE PATIENTS
Luca Boeri, Paolo Capogrosso, Eugenio
Ventimiglia, Alessandro Serino, Giovanni La
Croce, Angela Pecoraro*, Marco Paciotti,
Silvia Ippolito, Giulia Castagna, Roberta
Scano, Milan, Italy, Rocco Damiano,
11:30
PD52-07 TIME FOR PUBLIC HEALTH ACTION ON
INFERTILITY: UPDATES FROM THE
CENTERS FOR DISEASE CONTROL AND
PREVENTION
Lee Warner*, steve schrader, Richard Wang,
atlanta, GA
11:40
PD52-08 INEQUITY BETWEEN MALE AND FEMALE
INFERTILITY COVERAGE IN STATE
INSURANCE LAWS
James Dupree*, Ann Arbor, MI, Ryan Dickey,
11:50
PD52-09 OUT OF POCKET COSTS OF MALE
INFERTILITY CARE AND ASSOCIATED
FINANCIAL STRAIN
Peter Elliott*, Los Angeles, CA, Matthew
Abad-Santos, Patti Katz, James Smith, San
Francisco, CA
12:00
PD52-10 VALIDATION OF THE AMERICAN SOCIETY
FOR REPRODUCTIVE MEDICINE
GUIDELINES/RECOMMENDATIONS IN
CAUCASIAN-EUROPEAN MEN
PRESENTING FOR COUPLE’S
INFERTILITY
Eugenio Ventimiglia*, Giovanni La Croce,
Paolo Capogrosso, Luca Boeri, Alessandro
Serino, Giulia Castagna, Angela Pecoraro,
Marco Paciotti, Silvia Ippolito, Dana Kuefner,
Roberta Scano, Milan, Italy, Rocco Damiano,
12:10
PD52-11 EFFICACY OF STANDARDIZED NURSING
FERTILITY COUNSELING ON SPERM
BANKING RATES IN CANCER PATIENTS
Katherine Rotker*, Hari Vigneswaran, Danly
Omil-Lima, Grayson Baird, Mark Sigman,
Kathleen Hwang, Providence, RI
12:20
PD52-12 THE IMPACT OF HYPERTENSION AND
ANTIHYPERTENSIVES ON SEMEN
QUALITY
David Guo*, Shufeng Li, Barry Behr, Michael
Eisenberg, Palo Alto, CA
CREDITTM
282
2015 Annual Meeting Exhibits
(as of April 9, 2015)
Booth(s)
21st Century Oncology LLC
1006
3DSystems, Simbionix Products
953
A&E Endoscopy
1821
A.M.I. Gmbh
2443
Abbott Molecular
2437
AbbVie
1323
Accordion Medical
261
Actavis Pharma
1917
Advanced Endoscopy Devices, Inc.
1907
Allergan
517
AllMeds Specialty Practice Services
1461
AmbiMedInc.
1853
American College of Cryo Surgery
2302
American Medical Endoscopy / Strauss
Surgical
857
AMS, an Endo International Company 1337
AnazaoHealth Corporation
1448
Ashlar Medical, LLC
1758
ASSI-Accurate Surgical & Scientific Inst 1652
Astellas Pharma US
1017
AUA History Booth
637
AUA RESIDENTS BOWL
1401
AUA Resource Center
1529
Augmenix
761
Bard
301
Bavarian Nordic
1753
Bayer HealthCare
2225
Beckman Coulter, Inc.
2623
Beijing Weili New Century Science &
Technology Co.
2149
Best Medical International
863
Biobot Surgical PTE LTD
2617
biolitec biomedical technology, GmbH 353
BK Ultrasound
747
Bolang Endoscope
2306
Boston Scientific
137
Bostwick Laboratories
2137
Business & Beignets
1961
Byram Healthcare
2265
Calcula Technologies Inc
2112
Canadian Urological Association
2010
Care Credit
2308
CareCloud
1920
Caresono Technology Co., Ltd.
862
Carilion Clinic
2304
Case Recruiters
2009
Cellay Inc.
1908
Chinese Urological Association
1865
Citizens Memorial Hospital
2156
Clarus Medical, Clearwater, Inspektor 1560
Cogentix Medical
1523
Colegio Mexicano de Urologı́a
Nacional A.C.
1960
Coloplast Corp.
445
Community Health Systems
1858
Confederacion Americana de Urologia 1859
Convergent Laser Technologies
807
Cook Medical
1201
CoreTherm Medical, Inc.
1809
Corinth MedTech
1357
CryoLife
1926
CS Surgical, Inc
1849
C-SATS, Inc
2518
Cubist Pharmaceuticals
1953
dBMEDx, Inc.
2116
Dendreon
437
Designs for Vision, Inc.
1910
Dianon-Litholink Corporation
1040
Direx
359
Dornier MedTech
151
Dr. Fuji
2310
Dysaer
2253
Ecleris USA
2352
EDAP-TMS
925
Edgepark Medical Supplies/UroMed
2402
Egyptian Urological Association
1956
Eigen
817
Elite Medical Scribes
2718
ELMED Medical Systems
161
Elsevier
1801
Booth(s)
Empower Pharmacy
EMS Electro Medical Systems S.A.
Encore, Inc.
Endo Pharmaceuticals Inc.
Endo Pharmaceuticals Inc.
Endocure Technologies
Endourological Society, Inc.
Enovative Technologies
ERBE USA, Inc.
Essia Health
Ethicon Biosurgery
European Association of Urology
Exact Imaging (formerly Imagistx)
Ferring Pharmaceuticals Inc.
First Quality Products
FMD, LLC
Galil Medical USA
GE Healthcare
Genentech
GenomeDx Biosciences
Genomic Health, Inc.
Global Medical Endoscopy, Inc.
Global Men’s Health
Foundation-Panama Summit
Greenwald Surgical Company, Inc.
Hawaiian Moon
Healthmate International, LLC
HealthTronics
Histosonics, Inc.
Hitachi Aloka Medical
HRA Healthcare Research & Analytics
ICU Theater
Imprimis Pharmaceuticals, Inc.
INEX Surgical Inc.
Infinite Therapeutics
InPracSys
Intellisphere LLC
International Kidney Stone Institute
International Society For Sexual
Medicine
Intl. Continence Society
Intuitive Surgical
Invivo
IU Kelley School of Business,
Physican MBA
IVUmed
Janssen Biotech, Inc.
Japanese Urological Association
Kaiser Permanente
KARL STORZ Endoscopia - Latino
America
KARL STORZ Endoscopy - America, Inc.
Keeler Instruments Inc.
Klein Surgical, Inc
Koelis
LABORIE
Leiter’s Compounding
LEONI Fiber Optics, Inc.
LifePoint Hospitals
LISA Laser USA
LocumTenens.com
LP Surgical Fibers (formerly Laser
Peripherals)
Lumenis, Inc.
Magic Race LLC
Mallinckrodt Pharmaceuticals
Marina Medical Instruments
MasterPharm Compuounding
Pharmacy
MaxiFlex, LLC
McAirlaids Inc.
Mcube Technology Co., Ltd.
MDxHealth
Med Fibers, Inc.
Meda Co., LTD
MedEvolve
Medical Imaging Innovations
Medical Lasers Direct
Medifix Inc.
Mediplus
283
2147
907
2261
117
937
1952
2520
2204
1843
2017
2203
1940
917
1641
2201
941
801
1016
2619
2529
1517
2007
1856
945
2057
2719
309
1554
1601
2114
1043
2309
1553
2053
1653
1548
2006
1827
1561
317
1541
2524
1026
1617
1962
1024
453
1007
949
1044
2108
607
2307
1936
2023
2237
2419
2200
1317
601
2005
2152
2636
2103
2404
2105
2125
963
1455
2255
1054
2244
2242
1559
Booth(s)
Medispec Ltd.
Medivation, Inc.
MedReviews, LLC
Med-Sonics
Medtronic
Merck & Co., Inc
meridianEMR and UroChartEHR
Metamark Genetics, Inc.
Mianyang Meike Electronic Equipment
Co., Ltd
Microsurgery Instruments, Inc.
MIM Software Inc.
MiMedx
Mimic Technologies, Inc.
Ministry Health Care
Miraca Life Sciences
Mission Pharmacal Company
MMS-USA, Inc.
Modernizing Medicine
Myriad Genetic Laboratories, Inc.
Nanovibronix
National Institute of Diabetes &
Digestive & Kidney Diseases
Neomedics
NeoTract, Inc.
New York Section, AUA
NextMed
North Central/South Central/
Southeastern Sections AUA
Northgate Technologies
Nurse Rosie Products
NxThera, Inc.
Nymox Pharmaceutical Corporation
Olympus America Inc.
OPKO Health INC.
Optical Integrity, Inc.
Orascoptic
Otto Trading
Pacific Edge
Patient Prompt
PercuVision, LLC
PersonalizeDx
PFM Medical
Photocure
Physician Owned Surgery Centers
PracticeLink.com
Profound Medical
Progenics Pharmaceuticals, Inc.
Progressive Medical Inc.
Prometheus Laboratories Inc.
Prostate Conditions Education Council
Prostate Conditions Education Council
Prosurg, Inc.
Pulse Systems Inc.
QDX Pathology Services
Quanta System SPA
Quill/Surgical Specialties
Raja and Associates
Realton Corporation
REFLEXONIC, LLC
Retrophin
Richard Wolf Medical Instruments
Richard Wolf Medical Instruments
Rocamed
Rose Micro Solutions
Russer Brasil Ltda
SafeOp Surgical, Inc
Sagent Pharmaceuticals
Samsung Electronics America
Sanofi
ScribeAmerica
Sedation Systems LLC
SH Medical Corporation
Shenzhen Huikang Medical Apparatus
Co. LTD.
Siemens Healthcare
Sigma Tau Pharmaceuticals
847
561
1457
1550
825
2417
509
2161
2110
1906
2209
1446
755
1918
1927
1701
1609
2027
1763
2408
2644
2208
1937
2522
1837
1762
864
2246
2153
1825
101
2317
2106
2202
1930
1922
2206
2523
1450
2021
1001
2717
2248
1659
1845
1658
2642
1046
1048
1752
2516
647
553
2400
2539
1760
701
2412
837
943
2445
1052
1852
1916
2537
2117
1759
905
2207
1347
2300
2631
1654
2637
337
2429
Signostics Limited
Simulated Surgical Systems, LLC
Snap On Optics
Snap On Optics
Sociedad Argentina de Urologia
Sociedad Dominicana de Urologia
Sociedad Mexicana de Urologia, A.C.
Sociedad Peruana de Urologia
Sociedade Brasileira de Urologia
Societe Internationale D’Urologie
Society of Government Service
Urologists
Society of Nuclear Medicine and
Molecular Imaging
Sonacare Medical
Sontec Instruments
Sony Electronics
Special Surgery Resources & Repair,
Inc.
SpermCheck
Springer
SRS Medical Corp.
2736
1454
1944
2313
1857
1863
1861
1958
1855
1028
1563
1854
501
1000
2154
1451
2410
2629
2337
Staff Care
Stryker Endoscopy
Supramedical LLC
Surgical Tables, Inc.
SurgiQuest
SurgiTel/General Scientific
Swan Valley Medical
TaeWoong Medical Co., LTD.
Tecnofarma
Teleflex
The Prometheus Group
TheraCoat
Thomas Health Systems
Physician Parmers
Tolmar Pharmaceuticals
TOTO
Townsend Surgical
United Endoscopy
United Medical Systems, Inc.
Universal Hospital Services
University Compounding Pharmacy
UroGPO
284
2305
957
961
1020
461
2301
901
2552
2353
1447
2217
1351
2721
2245
1355
1817
1900
1036
1757
2047
2728
UroGyn Medical, Inc.
Urology Times
UroPath Diagnostics
USMD, Inc.
Utah Medical Products, Inc.
Vantage Oncology
Vascular Technology
Vasectomystore.com
VasectoPeaz, a product of FrozenPeaz
Verathon Medical
Vesiflo, Inc.
Vox Scripta LLC
Well Lead Medical Co. Ltd.
WeShare
Western Section, AUA
Wiley
Wolters Kluwer Health
Xodus Medical
Zephyr Surgical Implants
ZyDoc Transcription
1947
1829
1946
1557
2205
2421
653
2143
1546
1909
1727
2716
860
2519
1565
2406
2303
2101
2109
2453
FRI-II ⫽ History Forum I-II, p ⫽ page
AUTHOR INDEX
A
Aaron, Lorne
MP1-03
Abacan, Allyssa
MP43-05
Abad-Santos, Matthew MP74-16, PD52-09
Aballa, Teodoro
MP74-15
Abara, Emmanuel Okechukwu
p235
Abaza, Ronney
MP59-15, PD18-05,
PD18-06, p154
Abbas, Mahmoud
MP26-04
Abbasoglu, Semra
MP34-12
Abbosh, Philip
MP47-04, MP47-20,
MP67-14, MP70-04, MP84-07,
PD49-04
Abbotoy, Daniel
MP59-06
Abbott, Joel E.
MP57-11
Abboud, Steven
MP14-16, MP17-13,
MP48-04, MP82-19, MP82-20, PD4-10,
PD30-02, PD38-05, PD44-06
Abboudi, Hamid
MP23-20
Abd El-Hakium, Amr
MP48-10
Abd Elmageed, Zakaria
PD36-05
Abdalla, Hossam
PD52-05
Abdel Mageed, Asim
PD36-05
Abdel Raheem, Amr
PD52-03
Abd-El-Barr, Abd-El-Rahman
MP54-07
Abdel-Bary, Ahmed
MP48-10
Abdel-Gawad, Mahmoud
PD4-01
Abdelhamed, Amr
PD37-07
Abdel-Hamid, Mohamed
MP38-12,
PD23-05
Abdel-Karim, Aly
V11-12
Abdel-Mageed, Asim
MP15-19
Abdel-Rahim, Mona A.
PD23-05
Abdel-Raouf, Romayla
PD23-05
Abdelrazzak, Omar
MP38-12
Abdelsalam, Yasser
MP40-01
Abdelsayed, George
MP14-01
Abdelwahab, Osama
MP3-08, PD40-11
Abdi, Hamid
MP1-07
Abdi, Hamidreza
MP77-01, PD31-09
Abdo, Carmita
MP43-17
Abdollah, Firas
MP4-14, MP4-16,
MP9-08, MP9-14, MP24-06, MP32-08,
MP48-13, MP54-07, MP56-02,
MP56-03, MP56-05, MP56-16,
MP56-18, MP59-03, MP60-01,
MP62-01, MP64-13, MP65-19,
MP67-05, MP73-11, MP73-19,
MP77-10, MP77-12, MP77-13,
MP78-01, MP78-15, MP78-19,
MP79-04, MP82-02
Abdul-Muhsin, Haidar
MP71-09,
MP71-15, PD5-11, V8-11
Abdulwahab-Ahmed, Abdullahi MP75-11
Abe, Ryo
MP85-16
Abe, Takashige
MP45-01, MP58-18,
V11-06
Abedi, Garen
PD7-04, PD13-04
Abel, E. Jason
MP26-08, MP26-09,
MP35-17, MP39-15, MP44-16,
MP59-04, PD4-08, PD35-05, PD35-11,
p10
Abele, John
p100
Aben, Katja
MP65-10
Aberger, Michael
V3-11
Abern, Michael
MP14-13, MP53-12,
MP59-01
Abl-Azzeez, Mohammed
MP83-01
Aboalsamh, Ghaleb
MP79-13
Abol-Enein, Hassan MP67-01, PD23-01,
PD41-07, p58, p59, p237
Aboody, Karen
MP49-17, MP61-03
Abou, Diane
MP46-19
Abou Farha, Osama
p234
Abouassaly, Robert
MP16-10, MP44-10,
MP56-06, MP57-06, MP69-08,
MP84-05, MP84-15, PD29-07,
PD44-05, p100
Abouelleil, Mourad
MP39-02, V7-06
Aboumarzouk, Omar
MP28-10
Aboumohamed, Ahmed
MP7-03,
MP44-06, PD9-09, PD49-10, V3-05
Abouzeid, Abdel
p234
Abraham, George
V5-05
Abraham, Nitya
PD28-08, V2-01
Abrahamsson, Per-Anders
p190
Abrams, Paul
p21
Abrams, Scott
PD33-10
Abramson, Richard D.
MP45-14
Abrate, Alberto
MP6-07
Abreu Clavijo, Diego
PD29-04
Abreu, Andre
MP63-05, PD31-04
Abreu, Andre Luis De Castro
MP86-04,
PD9-07
Abshire, Caleb
PD15-10
Abu-Ghanem, Yasmin MP59-11, MP80-06
Abumelha, Saad
PD48-08, PD52-03,
PD52-05
Acevedo, Alice C.
MP31-10
Acevedo, Joe
PD45-05
Acher, Peter
MP62-13
Ackerman, Anicka
MP20-14
Ackerman, Anne L.
MP11-17
Ackerman, Lenny
V2-03
Acuna, Juan
MP26-15
Adam, Meike
MP83-18
Adams, George
MP87-15
Adams, George W.
MP6-12
Adams-Huet, Beverley
MP41-14
Adank, Jean-Pascal
MP66-05
Adejoro, Oluwakayode
MP10-07,
MP65-12, PD17-04
Aden, James
PD21-10
Adibi, Mehrad
MP84-18
Adler, Howard L.
FRII-02
Adomat, Hans
MP46-06, MP46-14
Adsul, Prajakta
MP18-15
Advani, Shailesh
MP52-11
Afari, Niloofar
MP27-04
Afiadata, Achankeng MP14-17, MP16-20
Afsarlar, Cagatay
MP40-10, MP79-15
Afshar, Ali
MP53-03
Afshar, Kourosh
p59
Afshar-Oromieh, Ali
MP53-08
Agag, Ayman
MP36-06
Agarwal, Arnav
MP42-19
Agarwal, Ashok
MP76-16
Agarwal, Gautum
PD34-06, PD41-01
Agarwal, Neeraj
PII-LBA10
Agarwal, Piyush
MP49-20, MP68-17,
p144
Aggarwal, Apas
MP5-18, MP64-06
Aggarwal, Himanshu MP81-11, PD10-05
Aghazadeh, Monty
PD19-07, PD19-08,
PD31-04, V8-03, V8-14, V10-07
Agoritsas, Thomas
MP42-19
285
Agrawal, Madhu
Agrawal, Vineet
p58
MP3-05, MP23-13,
V4-06, V12-08
Agudelo, Jose
V6-08
Aguilar Palacios, Diego
MP67-06
Aguilar, Diego
V7-11
Aguiniga, Lizath
MP12-02
Ahaghotu, Chiledum
p175
Ahallal, Youness
MP3-04, PD47-05
Aharony, Shachar
MP12-05, PD1-08
Ahearn, Thomas
MP6-15
Ahearne, Sinead
MP61-19
Ahin, Ali Feyzullah
MP7-20
Ahlawat, Rajesh
MP59-15, MP79-14,
p255
Ahlborn, David
PD30-04
Ahlering, Thomas
MP53-16, PD18-01,
p153, p166
Ahmad, Nida
MP19-03, MP19-11
Ahmad, Waseem
MP80-20
Ahmad, Yaser
MP22-15, MP22-19
Ahmadi, Hamed
MP5-06, MP27-10,
MP67-13, PD23-09
Ahmed Taha-Neto, Khaled
MP22-16
Ahmed, Abdullahi
PD8-05
Ahmed, Abul-Fotouh MP18-02, MP38-02
Ahmed, Ahmed S. Zakaria
PD31-05
Ahmed, Hashim MP48-15, MP83-01, p174
Ahmed, Kamran
MP22-05, MP22-09,
MP23-02, MP23-05, MP23-16,
MP23-20, MP71-05, V5-02
Ahn, Hanjong
MP44-11, MP53-16,
MP69-13, MP78-02, MP82-18,
MP86-06, PD43-03, PD47-01, p172
Ahn, Han-Jong
MP47-05
Ahn, Jennifer J.
MP25-19, MP54-15,
MP79-20
Ahn, Seung Hyun
MP89-05
Ahn, Tai Young
MP19-19
’Aho, Tevita Futo
MP13-04
Ahyai, Sascha
MP3-16, MP15-15,
PD22-12, MP82-05, MP83-05,
MP83-07, MP83-15
Aikawa, Ken
MP12-17
Aitken, Karen J.
MP19-05, MP20-02,
MP21-15
Aizawa, Masataka
MP2-19
Aizawa, Naoki
MP8-06, MP12-03
Aizen, Joshua
MP89-06, MP89-18
Aizer, Ayal
MP73-11
Ajay, Divya MP88-07, MP88-11, MP88-19,
PD22-05, PD24-11, PD24-12, PD26-07,
V3-01
Akaihata, Hidenori
MP12-17
Akakura, Koichiro
MP87-06
Akashi, Takumi
MP58-08
Akbulut, Mehmet Fatih
MP28-20
Akca, Oktay
MP35-07, MP50-15,
MP63-13, MP70-02, V4-01, V4-11,
V9-05
Akdogan, Bulent
MP42-20, MP48-11
Akhavein, Arash
MP30-13, PD51-01
Akihama, Susumu
MP39-10, MP46-16,
MP69-03, MP69-16, MP83-10,
MP85-04
Akin, Oguz MP35-03, MP44-15, MP53-20
Akino, Hironobu
MP12-04
Akino, Tomoshige
MP58-18
Akinola, Oluwaseun
MP75-14
Akita, Hidetoshi
MP62-10
Akiyama, Yoshiyuki
MP8-06, MP12-03
Akre, Olof
MP4-19, MP56-17
Aksenov, Alexey
MP82-06
Al Abbassi, Amira
MP79-13
Al Hussein Al Awamlh, Bashir MP6-02,
MP32-16, MP65-03, MP72-03,
MP83-04, PD2-02, PD26-09
Al Mehmadi, Yousef MP27-03, PD45-06
Al Salhi, Yazan
MP18-20
Al Zahrani, Ali
MP83-13
Alagh, Amy
MP69-14, PD35-12
Alagiri, Madhu
MP54-17
Alahdab, Fares
PD31-01
Al-Ahmadie, Hikmat MP7-13, MP36-12,
MP64-02, MP72-20
Alam, Asher
MP13-04
Alam, Ridwan
MP42-04
Alam, Shumyle
MP54-15, MP79-20
Alanee, Shaheen
MP4-20, MP9-06,
MP70-08
Albala, David
MP1-19, MP53-16, p12
Albayrak, Selami
MP28-16, V4-01
Albersen, Maarten
MP18-19, MP19-16,
MP19-18, MP21-06, MP52-05, PD2-05
Albert, Botchway
MP43-19
Albertini, Aline
PD5-04
Alberts, Arnout
MP86-18, PD34-04
Albertsen, Peter
PII-LBA5, p58, p136
Albiges, Laurence
MP50-07
Albisinni, Simone
MP9-20, MP27-19
Albo, Michael
p44
Alcaraz Asensio, Antonio
MP50-18
Alcaraz, Antonio
p176
Al-Dessoukey, Ahmad Aref
MP48-10
Aldousari, Saad
V6-02
Alemozaffar, Mehrdad
MP35-14,
MP44-08, V8-06
Alenezi, Husain
MP30-20, PD51-01
Alenizi, Abdullah
MP13-16, MP43-04
Alesawi, Anwar
MP43-04
Alex, Byron
PD40-02
Alexander, Bobby
MP70-01
Alexander, Paul
MP42-19
Alexander, Richard
PD6-03
Alexander, Todd R.
PD51-11
Alexandrov, Assen
V2-05
Alford, Scott
MP5-14, MP23-07
Algaba, Ferran
PD7-10
Algohary, Ahmad
MP60-04
Alhalabi, Feras
PD50-06
Alhammali, Eihab
PD40-07
Alhathal, Naif
MP74-08
Al-Hathal, Naif
MP43-04
Al-Hothi, Hana’A
PD28-09
Alhussaini, Zuhair
MP70-06
Ali, Adnan
MP62-12
Ali, Amina
MP66-12
Ali, Hussien
MP30-06
Ali, Sahirzeeshan
MP6-18
Ali, Sohrab Naushad
MP34-07
Ali, Yasir
MP74-07
Ali, Yousif
MP74-07
Alibhai, Shabbir
MP4-05, MP42-01,
MP42-06, PD47-10
Ali-El-Dein, Bedeir
MP33-10, MP65-09,
PD9-02, PD17-10, PD23-05
Alimi, Quentin
V9-06
Aliotta, Phillip
MP78-11
Aljarah, Ali
Alkan, Erdal
Alkaram, Ahmed
Alkasab, Thamir
Alkattan, Abdulaziz
Allaf, Mohamad
MP47-19,
MP63-10,
MP70-18,
MP61-18
MP76-08
PD7-11
MP86-16
PD1-05, PD10-02
MP35-16, MP39-13,
MP50-01, MP63-06,
MP70-16, MP70-17,
MP84-03, MP84-14,
PD15-11, p101
Allan, Robert
MP35-04
Allard, Christopher
MP5-11, MP50-08,
MP50-19, MP84-10, MP84-20,
PD25-10, PD35-09
Allegro, Rosalinda
MP45-10
Alleluia, Vincent
MP23-09
Allen, Clare
MP83-01
Allen, Frances
MP11-04, MP33-01
Allen, Isabel
MP9-12, MP88-17
Allen, Richard
MP85-07
Almallah, Zaki
p12
Al-Marzouq, Ahmad
V6-02
Almashat, Fahad
PD52-05
Almashat, Fahd
PD52-03
Almassi, Nima
V8-02
Al-Matar, Ashraf
MP14-08
Alobuia, Wilson
PD37-06
Alom, Manaf
MP18-01, MP30-08,
MP59-09, MP70-03, V2-08
Al-Omar, Osama
V7-13
Alonge, Vincenza
MP26-18, MP45-10
Alrabeeah, Khalid
MP74-08
Alruwaily, Abdul
MP16-19, MP41-04
Alruwaily, Abdulrahman
MP3-18,
MP71-06, MP75-09, PD51-02
Alsaigh, Naimat
MP33-10
Al-Sayed, Fahmy
MP2-10
Alshalalfa, Mohammed
MP6-09,
MP55-18, MP61-11, MP66-16
Alsikafi, Nejd
PD14-08
Alsyouf, Muhannad MP28-15, MP30-01,
MP30-10, MP38-04, MP38-15,
MP63-02, MP81-08, PD15-09,
PD21-03, PD42-07
Altamirano-Dimas, Manuel
MP36-17,
MP49-09
Althof, Stanley
p56
Altobelli, Emanuela
MP20-10, MP67-15
Altok, Muammer
MP7-20
Alva, Ajjai
MP65-02, MP68-20
Álvarez Maestro, Mario
PD29-04
Álvarez, Ariana
MP38-11
Alvarez, Joann
MP27-11, PD23-11
Álvarez-Ossorio, José Luis
MP73-01
Alwaal, Amjad
MP15-03, MP71-13,
MP88-17, PD26-05
Alyami, Fahad
MP40-18, V7-10
Al-Yousef, Rawan
V6-02
Alzahrani, Tarek
MP30-11, MP75-04,
PD13-08
Amann, Justin
PD51-01
Amaro, Joao
MP79-09
Ambani, Sapan
PD21-04, V10-04, p18
Ameli, Niloufar
MP42-12, MP53-18,
MP86-10
Amelsberg, Andree
PII-LBA10
Amend, Bastian
MP19-13, PD24-01
Ameri, Carlos
p176
Ameye, Filip MP9-20, MP27-19, PD5-08,
286
PD5-10
Amin, Ali
MP14-17
Amin, Jay
MP35-12
Amling, Christopher
MP4-17, MP14-12,
MP53-01, MP53-02, MP53-12,
MP60-12, MP65-18, MP82-15,
MP87-08, MP87-09, PD32-10,
PD34-07, PD38-11, PD44-02
Amon-Sesmero, Jose
p9
Amorós-Torres, Araceli
V6-13
Amos, Jonathan
MP75-10
Amparore, Daniele
MP3-04
Amr, Raheem
PD2-01, PD48-08
Amundsen, Cindy
MP8-04
An, Jian
MP55-01
An, Yajie
MP84-03
Anai, Satoshi
MP68-03
Anand, Ajay
PD16-07
Anand, Mallika
PD50-10
Anas, Ghaleb
MP85-02
Anastasiadis, Eleni
MP70-20
Andersen, Raymond J.
MP66-07
Andersen, Ross E.
PD51-03
Anderson, Blake
MP29-10, MP37-18,
MP65-13, MP65-15, MP80-10,
PD18-02, PI-05
Anderson, Christopher
MP63-18,
MP70-05, MP70-20, MP78-03
Anderson, Jeff
PD1-05, PD10-02
Anderson, Kirk
PD22-02, PD50-05
Anderson, Kyle
V6-09
Anderson, Patrick
MP79-13
Anderson, Paul
PD5-02, p20
Anderson, Roger
MP14-10
Anderson, Roosevelt
PD25-12
Anderson, Ross
MP76-12
Anderson, Shane
p10
Andersson, Karl-Erik
MP8-06, p21, p78
Ando, Keisuke
MP87-06
Ando, Ryosuke
MP33-13, MP34-02,
MP34-11, MP34-13, MP34-15,
MP41-03, MP46-12, MP55-04,
MP62-10, MP80-18, PD17-05
Ando, Takashi
MP55-16
Andonian, Sero MP30-13, PD51-03, p10
Andrade Becerra, Carlos Fernando
V10-05
Andrade, Hiury
MP35-07, MP50-15,
MP70-02, V4-01, V4-11
Andrade, José Lamartine De Andrade
MP8-09
Andreoni, Cassio
p112
Andrews, Paul
MP4-11, MP71-09,
MP71-15, V8-12, p255
Andrich, Daniela
MP29-06, MP29-07,
MP29-08, PD14-03, PD14-11,
PD22-01, PD22-06, PI-01, p20
Andriole, Gerald
MP1-13, PD6-01, PIILBA2, MP42-02, MP60-09, MP60-14,
MP77-15, MP81-04, PD51-07, p11,
p139, p174, p235
Anger, Jennifer
MP24-13, MP24-15,
PD21-07, PD27-06, PD28-03, PD50-08,
p11, p84, p170
Angermeier, Kenneth
PD14-10, V4-01,
p13, p20
Angst, Roland
PD25-04
Angulo, Javier
MP52-04, MP73-01
Anheuser, Petra
V12-05
Anikst, Victoria
Aning, Jonathan
MP20-10
MP65-06, MP72-15,
PD41-05
Anjikar, Chandrashekar
PD4-01
Anjiki, Haruki
MP11-06
Anjum, Faqar
MP28-18
Ankerst, Donna
MP64-05, MP75-06,
MP77-09
Anselmo, Christophe
V5-01
Anson-Cartwright, Lynn
MP10-10
Antolak, Stanley
p10
Antonarakis, Emmanuel
MP87-15,
MP87-16, p85
Anton-Culver, Hoda
MP59-13
Antonelli, Alessandro MP44-04, MP63-03,
PD35-01
Antonelli, Jodi
MP27-07, MP41-14,
MP41-14, MP75-15, MP80-05,
PD13-12
Antonini, Gabriele
MP45-16
Antonopoulos, Ioannis
MP85-18
Antunes, Alberto A.
MP3-12, MP8-07,
PD5-04, MP21-10, MP31-17, MP71-18
Antunes-Lopes, Tiago
PD27-12
Aoki, Hiroshi
MP87-07
Aoki, Yoshitaka
MP12-04
Aoki, Yujiro
MP54-04
Apfelbeck, Maria
MP26-17, PD9-04
Apodaca, Gerard
MP21-04
Apolikhin, Oleg
MP43-10
Apolo, Andrea
MP68-17
Aponte, Hernán
V8-12
Appel, Boaz
PD45-10
Appleman, Leonard
MP82-09
Aprikian, Armen
MP72-05, PD12-01,
PD31-05
Aquino Fournier, Catharine
MP31-01
Arada III, Ernesto
MP23-01, MP71-02
Arai, Gaku
MP76-04
Arai, Takashi
MP77-02
Arai, Yoichi MP2-19, MP56-15, MP60-15,
MP69-19, MP73-18, MP87-07, PD3-02
Arakawa, Soichi
PD8-08, PD8-10
Araki, Isao
MP27-02
Arangua, Paul
MP6-06, MP48-02,
MP60-08, V4-09
Arbuckle, Cody
PD18-01
Archambault, Jason
MP85-02
Arcila, Maria
MP64-02
Ardelt, Petere
PD17-11
Arellano, Ronald S.
MP50-09
Arenas, Javier L.
MP30-01, MP30-10,
MP38-15, MP63-02, PD15-09, PD21-03
Arends, Tom
MP65-10
Arias, Euro
V6-08
Arichi, Naoko
MP11-06, MP39-16,
MP47-11
Arikan, Ozgur
MP48-01
Arisan, Damla
MP33-19
Arisan, Serdar
MP33-19
Arisawa, Chizuru
PD17-07
Ark, Jacob
PD23-11
Arlen, Angela M.
MP54-02
Armagan, Abdullah
PD13-09
Armenakas, Noel
p10
Armitage, James
MP30-07
Armstrong, Andrew
PII-LBA10
Arnaud, Alexis
MP38-10
Arnold, Rebecca S.
MP47-15
Arnouk, Alex
MP7-01
Aron, Manju
MP86-04
Aron, Monish
MP15-20, MP23-15,
MP59-12, MP63-05, MP83-12, PD9-07,
PD31-04, V9-07, V12-11, p9, p72, p130
Aronen, Hannu
MP17-07
Aronson, William
MP4-17, MP6-08,
MP14-12, MP32-12, MP53-01,
MP53-02, MP53-12, MP60-12,
MP82-15, MP87-03, MP87-08,
MP87-09, PD32-10, PD34-07,
PD38-11, p273
Arora, Jaspreet
MP39-01, PD15-10
Arreola, Manuel
PD4-03
Arroyo Soto, Ignacio
PD41-04
Arsovsksa, Olga
MP75-12
Arther, Andrew
PD51-10
Artibani, Walter
MP67-20, PD9-03
Arulraja, Evangeline
MP14-11
Arya, Manit
MP83-01
Asai, Akihiro
MP49-02, MP55-03
Asai, Seiji
PD4-07
Asakuma, Junichi
MP7-11
Asangani, Irfan
MP37-02
Asano, Takako
MP7-11
Asano, Tomohiko
MP7-11
Asanuma, Hiroshi
MP35-20, MP54-04,
PD17-03
Asci, Ramazan
MP43-12
Ashcraft, Keith
MP36-07
Ashikari, Daisaku
MP86-05, PD50-03
Ashley, Richard
FRII-06, MP3-06
Aslan, Guven
MP42-20
Aslan, Yilmaz
MP40-10
Asplin, John
MP34-16, MP75-09, p220
Asquarova, Fotima
MP30-13
Assaly, Rana
MP52-06
Assel, Melissa
MP2-13, MP10-13,
MP53-20, MP60-10
Assimos, Dean
MP28-08, MP30-17,
MP34-17, PD13-03, p13, p100, p220
Aston, Kenneth
MP76-12
Asutay, Mehmet Kazim
MP75-18
Atala, Anthony
MP8-03, MP21-08,
MP29-18, MP29-19, p44, p56
Atallah, William
MP60-16, MP77-05
Atar, Arda
MP34-12, MP38-07
Atayurt, Zafer
MP74-09
Athanasiou, Stavros
PII-LBA9
Atiga, Chase
MP30-10
Atis, Ramazan Gokhan
MP48-01
Atkinson, Gary
PD20-01
Atmaca, Hasan Tarik
MP76-08
Attalla, Kyrollis
MP70-13
Attaya, Hosam
MP38-19
Attwood, Kristopher
MP4-07, MP50-06
Atug, Fatih
V9-02, p9, p101
Atwell, Thomas
PD35-07
Au, Jason
MP40-10
Aufderklamm, Stefan MP1-16, PD41-11
Auffenberg, Gregory
MP27-20
Auge, Brian
p94
Austenfeld, Marcus
FRII-12
Austin, Conal
PD49-01
Austin, J. Christopher
p18
Austin, Paul
MP40-02, p13, p59
Autieri, Domenico
MP18-20
Autorino, Riccardo
MP3-04, MP50-15,
p57, p227, p236
287
Autran, Anamaria
PD29-04
Autran-Gomez, Ana Maria
MP42-17
Auvinen, Anssi
PD6-02, PD6-09
Avelino, Antonio
MP8-20
Averch, Timothy
MP27-07, MP41-08,
PD19-02, PD19-03, PD19-04, PD19-05,
PD51-04, p190, p220
Aviram, Galit
PD13-10
Awadalla, Amira
MP79-10, PD23-01
Awamleh, Bashir
MP16-02
Awori, Quentin
V3-08
Awrey, Shannon
MP36-17, MP49-09
Ayangbesan, Abimbola
MP65-03,
MP72-03
Ayaz, Ahmet
MP76-16
Aydin, Abdullatif
MP22-09, MP23-05,
MP23-16
Aydur, Emin
PD27-03
Aylward, James
MP66-18
Ayoub, Hajar
MP67-06, PD25-12,
PD40-09, V3-03
Ayres, Benjamin
MP10-16
Aytaç, Omer
V9-02
Ayyash, Omar
PD51-04
Azad, Azar
MP68-05
Azadzoi, Kazem
MP8-08
Azawi, Nessn
MP57-15
Azhar, Raed MP3-03, MP15-20, MP59-12,
MP63-05, MP83-12, MP86-04, PD9-07,
PD34-05, V12-11
Aziz, Atiqullah
MP2-10, MP2-12,
MP58-13, MP58-16, MP58-20
Azuma, Haruhito
MP7-02, MP46-08
Azuma, Satoshi
V7-12
Azumi, Makoto
MP59-05
Azzis, Olivier
MP38-10
Azzouzi, Abdel Rahmène
MP63-12,
MP63-15
B
Baack Krukreja, Janet E.
MP26-14,
MP51-11
Baack Kukreja, Janet
MP65-17, p11
Babaeer, Abdulrahman
MP70-19
Babaian, Richard
p136
Babasaki, Takashi
PD35-03
Babayan, Richard
p237
Babbar, Paurush
V8-10
Babcook, Melissa
MP8-05
Babicz, Tamás
MP87-03
Babjuk, Marek
PD17-11, PD29-12
Babjuk, Marko
MP26-04, MP65-09
Bach, Thorsten
MP13-10, MP13-11,
MP13-12
Bachir, Souid M.
MP28-12
Bachmann, Alexander MP3-20, MP63-20,
MP78-12, PD5-08, PD5-10
Bachrack, Laurie
PD20-09
Backman, Vadim
MP1-20
Baco, Eduard
MP63-12, MP63-15
Bacro, Thierry
PD7-08
Badal, Justin
PD39-06
Badalato, Gina
MP38-05
Badani, Ketan
MP1-09, MP53-11,
MP53-16, PD13-11, p198
Badawy, Ahmed
MP40-01
Badawy, Hesham
MP79-19
Badawy, Mohamed
MP85-14
Badhiwala, Niraj
PD5-05
Badkhshan, Shervin
MP4-07, MP35-12
Badlani, Gopal
MP3-09, MP22-13,
PD5-07, PD50-04, p18, p58, p71, p100,
p117, p173
Badran, Yasser
MP18-02, MP38-02
Badri, Anand
MP89-18
Bae, Jaehyun
MP16-11
Bagchi, Anindya
MP61-06
Bagley, Demetrius H.
MP23-14, p13
Bagli, Darius
MP19-05, MP20-02,
MP21-15
Bagrodia, Aditya
MP2-06, MP7-07,
MP7-13, MP7-17, MP11-16, MP36-12,
MP64-02
Bahceci, Mustafa
MP74-10
Bahı́lo, Pilar
MP38-11, MP80-11
Bahlani, Sonia
PD20-11
Bahler, Clinton
MP11-13, MP63-11,
MP65-14, PD3-09, PD15-03, PD15-05,
PD21-12, V5-12, V9-13
Bahn, Duke
PD34-05
Baik, Seung
MP13-07
Bailey, April
PD50-02
Bailey, Christina
PD40-09
Bailey, G. Christopher
PD35-07
Bailey, George
MP41-05, PD28-02
Bailey, Howard
MP26-01
Bailey, Kari FRII-04, MP7-01, MP47-10,
MP61-07
Bailey, Michael
MP17-01, MP39-14,
PD42-01, PD42-02, p255
Bailey-Wilson, Joan
MP66-10
Bainbridge, Matthew
MP76-06
Baird, Grayson
PD52-11
Bajic, Petar
MP64-12
Bajorin, Dean
MP7-13, MP10-01,
MP10-05, MP10-12, MP10-13,
MP10-19, MP11-16, MP36-12,
MP64-02, MP72-20
Bajory, Zoltan
p101
Baker, L. A.
MP40-05
Baker, Linda
MP40-03, MP40-12
Baker, Rania
PI-09
Bakircioglu, Emre
MP76-06
Bakircioglu, Mustafa
MP74-10
Balaji, K. C.
p145
Balbay, Mevlana Derya
MP18-18,
MP67-19, MP76-08, p101, p137
Baldini, Teri
MP16-04, MP32-09
Baldwin, D. Daniel
MP30-10
Baldwin, D. Duane
MP28-15, MP30-01,
MP30-10, MP38-15, MP63-02,
PD15-09, PD21-03, PD42-07
Baldwin, Duane
MP30-13, MP38-04,
MP75-02, p262
Bales, Gregory T.
MP18-03, MP29-10,
PD26-12, PI-05
Balestreri, Luca
MP57-13
Balicer, Ran
MP32-17
Balk, Mark
MP73-13
Ball, Mark MP35-16, MP39-13, MP47-19,
MP50-01, MP84-03, PD15-11
Ballardo, Cesar Jesús
V10-03
Ballestero, Roberto
V10-03, V10-12
Ballesteros, Ceasar
MP23-01
Ballow, Daniel
MP22-10
Balog, Brian M.
MP8-10
Balthazar, Andrea
PD8-11
Bambury, Richard
Banaei, Niaz
Bancroft, Elizabeth
Bandekar, Rajesh
Banerjee, Sulagna
Banerji, John S.
MP64-02
MP20-10
MP86-11
MP87-16
MP55-13
MP10-15, MP42-13,
MP79-08
Banez, Lionel
MP14-13
Bang, Albert
MP57-04, MP65-11
Bang, Woo Jin
PD29-08
Bangerter, Keith
MP87-12
Bangma, Chris
MP66-20, MP86-18,
PD34-04, p194
Bangs, Rick
MP65-02
Baniel, Jack
MP28-14, MP32-17,
MP41-16, PD11-12, PD17-11, PD17-12
Banihani, Omaya
MP40-11
Banno, Rika
MP33-18
Bannowsky, Andreas MP17-15, MP52-17
Bantleon, Rüdiger
MP11-19
Bapat, Bharati
MP6-14, MP61-01,
MP68-04, MP68-06, PD46-07
Baptiste, Wagner
MP61-16
Baradaran, Nima
MP40-13, MP69-15
Barakat, Nashwa
MP79-10
Barakat, Tamer S.
PD23-05
Baran, Caner
MP28-16
Baras, Alexander
MP58-07, MP72-08,
PD31-12
Barazani, Yagil
MP43-15
Barbagli, Guido
MP19-15, PD14-10,
V12-01, p11, p235
Barbe, Mary
MP12-05
Barbee, R. Wayne
MP12-15, MP12-16
Barber, Austin
MP32-13
Barber, Neil MP3-01, MP13-14, PD5-08,
PD5-10
Barbieri, Christopher MP6-02, MP17-12,
MP66-01, MP83-04
Barbisan, Davide
MP57-13
Bar-Chama, Natan
MP51-04
Bardot, Stephen
MP47-18, MP68-15
Barel, Assaf
V6-03
Barillaro, Francesco
MP62-02
Barinova, Mariya
MP17-20
Barkin, Jack
MP3-02
Barlass, Usman
MP55-13
Barlow, Lamont
MP4-15, MP26-11,
MP26-13, MP32-07, MP64-15,
MP72-09, PD17-09
Barnes, Justin
PD27-01
Barney, Shane
MP26-15
Barocas, Daniel
MP5-07, PD6-05,
MP20-12, PD12-03, PD12-06,
MP27-11, PD23-11, PII-LBA5,
MP49-01, MP65-06, PD41-05,
MP72-15, MP84-19, p9, p12, p273
Barod, Ravi
MP59-14, MP59-15,
MP63-06, MP63-10, MP70-16,
MP70-17, MP70-18, V9-01, V11-02
Baron, Benoit
PII-LBA4
Baron, Pamela FRI-09, MP85-20, V9-08
Baron, Thomas
MP27-06
Barone, Hugo
MP3-12
Barone, Mark
V3-08
Baroni, Ronaldo
MP86-09
Baronio, Roberta
PII-LBA9
Barret, Eric
MP42-17, MP48-16,
MP62-08, PD47-05
288
Barrett Connor, Elizabeth
MP71-17
Barrett, David
MP88-14
Barrisford, Glen
V8-04
Barrisford, Glen W.
MP5-11, MP50-07
Barros Filho, Tarcisio
MP43-17
Barry Delongchamps, Nicolas
MP67-04
Barry, Michael
MP83-11
Bartlett, Susan J.
PD51-03
Bartley, Jamie
MP89-01, MP89-03,
MP89-09, MP89-10, PD21-06,
PD27-10, PD50-12
Bartoletti, Riccardo
PD17-11
Barton, Joanna
PD27-11
Bartsch Jr., Georg
MP8-11
Basar, Mehmet Murad
MP74-09,
MP76-08
Basaria, Shehzad
p221
Bascom, Alexandra
MP15-13
Bashir, Mustafa
MP88-06
Basilion, James P.
MP61-15
Baskin, Avi S.
MP16-09
Baskin-Bey, Edwina
MP73-20
Bass, Roman
V11-14
Bassett, Jeffrey
PD23-11
Bassett, Mitchell
MP14-13, PD11-02
Bassi, Pierfrancesco
MP67-20, PD9-03
Bastarós Hernández, Juan Marı́a
PD41-04
Bastarós, Juan M.
MP6-01
Bastian, Patrick
MP58-16, MP77-03
Basto, Marni
V4-04
Bastos-Netto, Jose Murillo
MP51-10
Batbold, Dulguun
MP52-08
Bates, Anthony
MP83-12, V4-07, V4-08
Bates, Carlton
MP52-18
Batista, Julie L.
MP77-19
Batra, Vikram Shah MP15-14, PD14-09,
PD22-03
Batson, Jacob
PD4-03
Battistella, Linamara
MP43-17
Bauer, Ricarda M.
MP88-08, MP88-09
Baum, Yoram
MP35-14, MP44-08
Bauman, Tyler
MP6-10, MP31-08,
MP39-15, PD35-05
Baumert, Hervé
MP13-19, MP57-02,
MP57-12
Baumgarten, Lyle
MP17-02
Baumgartner, Timothy
MP16-01,
PD21-10, PD22-07
Baumunk, Daniel
MP14-19
Baur, Helmut
MP62-18
Bausum, Anna
MP35-14
Bavaria, Tom
PD10-01
Bavendam, Tamara
p175
Bayatli, Nur
MP52-13
Baykov, Nikolay
MP26-04, V8-08
Bayne, David
MP17-05
Bazaragani, Soroush
MP86-17, PD9-01
Bazargani, Soroush
MP5-06, MP67-13,
PD23-09
Bazzi, Wassim M.
MP50-16
Beachy, Philip
p70
Beahrs, Randolf
PII-LBA1
Beaney, Ronald
MP62-13
Beatrice, Josef
MP86-07
Beaudry, Guillaume
MP1-03
Beauval, Jean-Baptiste
MP57-02,
MP57-09, MP57-12, MP63-12,
MP63-15, MP85-09
Bechis, Seth MP5-11, MP30-18, MP31-15,
PI-02, MP50-07
Beck, Veronika
PD32-06
Beckel, Jonathan
MP21-16
Becker, Andreas
MP3-16, MP70-09,
MP83-06
Becker, Armin
MP63-09
Beckham, Carla
MP49-07, MP68-01
Beckler, Carlee
MP15-20
Bedard, Philippe
MP10-10
Beebe, Heather
MP51-04
Beebe-Dimmer, Jennifer
MP14-15, PIILBA3
Beer, Ambros
PD32-06
Beer, Tomasz
p136
Beer, Volker
MP62-18
Beger, Gunthild
PD41-11
Behl, Robert
p100
Behnsawy, Hosney
MP64-01
Behr, Barry
PD52-12
Behr-Roussel, Delphine MP52-06, PD1-03
Behre, Hermann
PII-LBA6
Beier, Jörn
PD22-11
Beiko, Darren
p229
Bekarma, Holly
MP75-13, MP80-04
Bekelman, Justin
PD12-04
Belew, Daniel
PD29-02
Belgrano, Emanuele
MP67-20, PD9-03,
PD40-12
Belka, Claus
MP62-18
Belkoff, Laurence H.
PD45-12
Bell, David
MP57-20
Bell, Robert H.
MP49-09
Bella, Anthony
PD26-06, PD26-10,
PD40-10, p55, p235, p248
Belldegrun, Arie
MP47-06
Bellei, Luca
MP53-09
Bellmunt, Joaquim
MP68-11
Bello, Fernando
MP22-09, MP23-05
Bellott-Mcgrath, Gabriel
MP16-17
Bellucci, Carlos
MP43-17
Belousova, Elena
PD35-10
Belsante, Michael
MP25-11, MP88-06,
MP88-07, MP88-11, MP88-19,
PD22-05, PD24-11, PD24-12, PD26-07,
V3-01
Beltran, Luis
MP1-10
Belucci, Carlos
MP51-10
Beluco Corradi, Renato
MP84-06,
PD33-03
Belzer, Susan
PII-LBA2
Benabdallah, Justin
MP49-11
Benayoun, Serge
MP43-04
Benchek, Penny
PD27-05
Benedon, Matthew
MP15-10, MP89-08,
MP89-18, PD21-11
Benejam, Joan
PD5-08, PD5-10
Benfante, Nicole
MP7-07, MP50-18,
MP63-08, MP84-06
Benham, Aaron
MP10-07
Benidir, Tarik
MP73-02
Benigni, Fabio
MP34-20
Benigno, Bruno
V11-09
Benjamin, Pradère
MP13-15, PD5-09
Benjamin, Shalva
V5-14, V11-14
Benkhadra, Khalid
PD31-01
Ben-Levi, Eran
MP11-10, MP17-09,
PD44-03
Bennett, Carol
MP32-04, MP32-12,
MP73-17
Bennett, David A.
MP33-06
Bennett, Jason
PD27-07
Bennett, Nelson
PD26-02, PD26-06,
PD26-10, PD26-11, PD40-10, p55
Bennett, William
MP40-20, MP54-19
Benoit, Peyronnet
MP13-15, PD5-09
Benoit, Thibaut
MP57-09, MP85-09
Bensadoun, Henri
MP73-20
Bensalah, Karim
MP2-06, MP2-09,
MP2-12, MP3-19, MP7-01, MP7-09,
MP13-13, MP13-18, MP38-10,
MP57-02, MP57-09, MP57-12,
MP63-12, MP63-15, MP63-16,
PD49-02, V9-06
Benson, Cooper
MP65-05, V3-03
Benson, Mitchell
MP1-09, PD17-09,
PD29-01, PD30-04, MP4-15, MP14-03,
MP25-19, MP63-01, MP64-07, p18
Bentink, Stefan
PII-LBA2
Benway, Brian
MP30-03, PD18-09,
PD51-07
Beraldi, Eliana
MP46-15
Berg, William
MP53-11
Berger, Andre
MP15-20, V12-11,
MP63-05, PD9-07
Berger, Delaney
MP1-19
Berger, Michael
MP7-13, MP36-12,
MP72-20, PD33-02
Berger, Ranaan
MP68-11
Berges, Richard
MP3-01, PD16-08
Bergman, Andries M.
PD31-11
Bergman, Ari
MP53-11, MP77-05
Bergman, Jonathan MP32-12, MP41-10,
MP73-17
Bergmann, Martin
MP76-03
Bergstralh, Eric
MP24-07, MP33-07,
MP41-05
Bergu, Berk
MP40-03
Berkowitz, Noah
PD35-10
Berktas, Mehmet
PD48-12
Berlin, Jacob
MP49-17, MP61-03
Berman, David
MP5-02, MP72-08
Bernabé, Jacques
MP52-06, PD1-03
Bernardo, Norberto
p176
Bernat, Jennifer
MP27-12, MP27-17
Berney, Daniel
MP1-10
Bernhard, Jean-Christophe
MP23-15,
MP57-02, MP57-12, MP63-12,
MP63-15, MP85-17
Bernie, Aaron
V3-08
Bernstein, Adrien
MP81-20, PD45-08
Bernstein, Melanie
MP10-12, MP44-15,
MP50-16, MP63-08, MP87-11,
PD48-01
Berquet, Gaetan
MP38-10
Berrondo, Claudia
MP49-07, MP68-01
Berry, Katherine
MP23-10
Berry, Matthew
PD20-09
Berry, William R.
MP87-16
Bertini, Roberto
MP4-16, MP44-04,
MP56-18, MP63-03, MP63-04,
MP82-03, PI-07
Bertrand, Laura
MP39-18
Bessa Jr., Jose
MP51-10
Best, Carolyn
p17, p18, p118, p169
Best, Sara
FRI-14, MP20-09, MP35-17,
MP44-16, MP59-04, p10
Betageri, Guru
PD37-02
289
Bettiga, Ariana
MP52-07
Beverly, Devon
MP14-11
Bex, Axel
PD31-07
Beyer, Burkhard
MP4-14, MP9-04,
MP78-20, MP82-16, MP82-17,
MP83-16, PD30-06, PD30-07,
PD30-08, PD30-10
Beyer, David
MP78-11
Bezan, Angelika
MP69-02
Bezerra, Stephania
MP53-17, MP61-11
Bhandari, Akshay
MP70-19, PD2-08
Bhandari, Mahendra
MP79-14
Bhanot, Umeshkumar
MP47-09
Bharadwaj, S.
MP21-08
Bhatnagar, Neera
MP42-19
Bhatt, Deep
MP15-17
Bhatt, Jaimin
MP50-13, MP67-16
Bhattacharyya, Pallab
PD1-12
Bhayani, Samuel
MP63-06, MP63-10,
MP70-16, MP70-17, MP70-18,
PD18-09, V5-11, p12, p58
Bhayankara, Aravind
MP72-20
Bhindi, Bimal
MP60-20, MP67-16,
MP68-04, MP86-15, PD47-10
Bhojani, Naeem
MP3-15, MP13-14,
MP34-19
Bhowmick, Neil
MP20-04
Bianchi, Gianpaolo
MP19-15
Bianchi, Marco
MP4-16, MP48-13,
MP56-02, MP56-03, MP56-05,
MP56-10, MP56-16, MP62-05,
MP72-04, MP77-03, MP78-13,
MP78-15, MP82-01, MP82-02,
MP82-03, MP83-08, MP83-17,
PD30-03, PD32-09, PD38-12
Bianco, Fernando
PD32-11, PD40-06,
V4-05
Bienert, Felix
MP66-17
Bieniek, Jared M.
PD52-02
Bienvenu, James
V2-09
Bienz, Marc MP13-14, MP13-16, MP43-04
Bier, Simone
MP1-16, PD41-11
Bieri, Diane
p251
Bierlein, Maggie
MP3-18, MP16-19,
MP41-04, MP71-06, MP75-09,
PD51-02
Biewenga, Eric
PD15-08
Bigley, Joseph
MP6-12, PD46-09
Bigot, Pierre
MP63-12, MP63-15
Bihrle, Richard
MP10-08, MP10-17,
MP29-11, MP29-12, MP58-11,
MP64-17, MP65-14
Bilal, Khawaja
MP32-19, PD12-12
Bilim, Vladimir
MP87-10
Billia, Michele
MP78-08, MP83-13
Billis, Athanase
MP45-07
Billups, Kevin
PD36-08, p175
Binbay, Murat
MP28-20, p101
Bindayi, Ahmet
V12-04
Bing, Megan T.
MP39-18
Bini, Vittorio
MP6-07
Birabaharan, Vinoth
MP59-09
Birbe, Ruth
PD4-09
Bird, Erin
PD27-07
Bird, Vincent
FRII-05, MP27-07,
MP30-13, MP75-08, PD51-01
Birder, Lori MP21-04, MP21-16, PD7-05,
p17, p73
Birkhäuser, Frédéric D.
V9-07, V9-12
Bishoff, Jay
p10, p153, p233
Bissada, Nabil
MP10-07, p234
Bissler, John
PD35-10
Bissonnette, Francois
MP74-08
Bitker, Marc-Olivier
PD10-11
Bivalacqua, Trinity MP19-16, MP19-18,
MP21-06, MP52-05, MP58-07,
MP64-10, MP65-06, MP67-10,
MP67-12, MP72-08, MP72-15,
PD17-06, PD31-12, PD36-02, PD36-04,
PD36-06, PD41-05, p55, p84, p160
Biyani, Chandra Shekhar
MP28-10
Bizic, Marta
MP52-15
Bjazevic, Jennifer
MP84-08
Björklund, Johan
MP4-19
Bjurlin, Marc
MP18-16, MP86-03,
PD32-01, PD32-05
Blachon, Jean-Luc
PD1-03
Black, Peter MP1-07, MP36-17, MP49-09,
MP49-13, MP57-20, MP65-06,
MP72-15, MP77-01, MP84-08,
PD31-09, PD41-05, PD41-08, p253
Black, Shawn
MP87-19
Blackburne, Andrew MP72-11, PD28-02
Blacksburg, Seth
MP62-15
Blackwell, Robert
MP18-11, MP44-12,
MP49-08, MP64-09, MP64-12, PD4-05,
V9-03
Bladou, Franck
PD12-01
Blaheta, Roman
MP8-11
Blaivas, Jerry
MP15-10, MP89-08,
MP89-18, PD21-11, p21, p164
Blakely, Stephen
V3-02, V12-12
Blana, Andreas
PD47-06
Blanchard, Shawnna
MP16-07
Blanchet, Pascal
MP61-02
Blankstein, Udi
MP22-07
Blaschke, Simon
MP14-19
Blaschko, Sarah D.
MP71-13
Blattner, Mirjam
MP66-01
Bloom, David
FRII-14, p59
Blot, William
PD23-11
Blute, Michael
MP26-08, MP26-09,
MP35-09, MP37-20, MP44-16,
MP50-07, MP50-08, MP50-09,
MP55-11, MP59-04, MP83-11,
PD35-05, p58, p157
Blute Jr., Robert
MP5-16, PD12-05
Bochner, Bernard
MP7-13, MP11-16,
MP36-12, MP64-02, MP64-03,
MP64-11, MP64-19, MP72-20,
MP82-04, PD9-11, PD17-06, p44
Bock, Cathryn
MP14-15
Boczko, Judd
PD32-11
Bodakci, Mehmet Nuri
PD13-09
Boehm, Katharina
MP59-08, MP78-09,
MP78-17, MP83-16, MP83-18,
PD30-06, PD31-13, PD49-03, PD49-05
Boehm, Maret
MP83-02, PD46-08
Boelkins, Brad
MP44-02, MP44-19
Boeri, Luca MP4-10, MP51-17, MP51-18,
MP74-20, MP76-05, MP76-15,
PD52-06, PD52-10
Bogache, William
MP3-02
Bogart, Jeffrey
MP78-11
Böhm, Diana
MP68-07
Böhm, Maret
MP60-04
Bohnert, William p118, p189, p220, p234
Bohrer, Yves
MP86-09
Bokhorst, Leonard
Bolduc, Stephane
Bolenz, Christian
PD34-04
p17, p44
MP2-06, MP2-09,
MP7-09
Bollig-Fischer, Aliccia
MP53-19
Bollito, Enrico
MP53-05, MP53-09,
MP53-10, MP77-11
Bolton, Damien
MP22-01, MP55-05,
MP61-04, PD5-01, p139, p173
Bolton, Sue
MP14-15
Bond, Christopher
MP52-12
Bonds, Roger
p57
Bondaruk, Jolanta
MP45-06, PI-06
Bonham, Michael
MP1-01
Boni, Andrea
MP62-02, PD10-04
Boniol, Mathieu
MP4-09
Bonkat, Gernot
MP3-20
Bonzo, Jeremy
MP10-09, PD43-09
Boone, Timothy
MP21-20, PD1-05,
PD10-02, PD24-03, p254
Boonkaew, Benjawan
MP39-01
Boorjian, Stephen
MP20-19, MP20-20,
MP24-07, MP29-15, MP29-16,
MP35-02, MP35-18, MP35-19,
MP44-14, MP50-10, MP56-14,
MP58-09, MP58-15, MP59-20,
MP63-20, MP67-02, MP69-05,
MP69-08, MP69-12, MP70-11,
MP70-12, MP70-14, MP70-15,
MP72-11, MP84-17, PD12-09,
PD17-06, PD29-06, PD31-01, PD35-07,
PD35-11, PD43-04, PD43-08, PD49-12,
p12, p58, p173, p196
Booth, Christopher
MP5-02
Bora, Shabana
PD52-05
Borazjani, Ali MP8-10, MP81-09, PD50-01
Borchert, Alex
MP59-14
Bordier, Benoit
MP13-17
Borer, Joseph G.
V7-04
Borges, Fernando
PD5-01, PD43-06
Borgmann, Hendrik
MP8-11
Borin, James
p57, p79
Boris, Ronald
MP3-15, MP35-10,
MP59-07, MP65-14, V8-05
Borisko, Elyse
PD7-08
Borkowetz, Angelika MP17-10, MP48-05
Borofsky, Michael PD42-04, V3-12, V6-11
Borok, Jenna
MP24-15
Boronat, Francisco
MP38-11
Borre, Michael
MP73-03
Bos, Derek
PD25-10
Bosch, Ruud
MP14-04
Bosl, George
MP10-01, MP10-05,
MP10-12, MP10-13, MP10-19, p11
Bosnyak, Zsolt
MP73-03
Boss, Andreas
MP19-14
Bosse, Brandon
PD38-09
Bostrom, Peter J.
MP17-07
Bota, Maria
MP4-09
Bottaro, Donald P.
MP6-17
Bottero, Danilo
MP26-05
Botto, Henry
MP31-03
Boulet, Evelyne
MP74-08
Boulet, Sheree
MP24-11
Bouljihad, Mostafa
MP15-19, MP69-01
Boura, Judith
MP89-01, MP89-03,
MP89-09, MP89-10, PD20-08,
PD27-10, PD50-12
Bourboulia, Dimitra
MP39-02
290
Bournat, Juan
PD36-01
Bourque, Jason
MP64-08
Boursi, Ben MP5-08, MP14-14, MP64-04
Boute, Maaike
MP23-03
Bowen, Diana
MP31-18, MP71-01
Bowen, Diana K.
MP53-14, V7-07
Bower, Thomas
MP70-11
Bowlin, Paul
MP40-18, V7-10
Box, Geoffrey
PD18-05, PD19-02,
PD19-03, PD19-04, PD19-05, V9-11,
p19
Boxler, Silvan
MP53-08, MP56-04
Boyce, Susie
MP6-20
Boyd, Mariel
MP64-02
Boylan, Colm
MP17-14
Boyle, Peter
MP4-09
Boylu, Ugur
V12-04
Boysen, Gunther
MP66-01
Boz, Mustafa Yucel
MP28-16
Bozkurt, Ozan
MP25-08
Bozzini, Giorgio
FRI-11, MP18-19,
MP77-08, PD2-05
Bozzini, Gregory
MP7-01, MP7-05,
MP7-06, PD29-12
Brachulis, Andrew
PD19-06, PD30-05
Brackett, Nancy
MP74-15
Bradley, Catherine
MP27-04
Braffett, Barbara H.
MP81-12
Braga, Luis
MP54-05, V7-01
Brahmbhatt, Jamin
PD40-03, PD40-04,
PD45-09
Brajtbord, Jonathan
MP5-01, PD15-12,
PD47-02
Brakemeier, Susanne
PD35-10
Brammah, Susan
MP89-14
Brancato, Sam
MP68-17
Branco, Anibal W.
V3-10, V11-10
Brand, Timothy
MP88-06, PD19-02,
PD19-03, PD19-04, PD19-05, PD19-11,
p135
Brandao, Luis Felipe
MP50-15, V4-11
Brandes, Steven
FRI-13, MP15-07,
MP18-08, MP18-09, MP29-05,
PD11-01
Brannigan, Robert E.
PI-03, MP74-05,
p12, p18, p117
Brant, William
MP88-20, PD11-02,
PD11-08, PD26-06, PD26-10, PD39-09,
PD40-10
Brasel, Alicia
MP5-15
Bratslavsky, Gennady
MP39-02,
MP44-13, PD3-03, PD43-05, PD44-04,
V3-02, p57, p255
Bratt, Ola
MP42-10, MP56-17
Braudmeier-Fleming, Andrea
PD20-09
Braun, Katharina
MP37-10, PD47-09
Braun, Martin
MP68-07
Brausi, Maurizio
p23, p236
Brawer, Michael
MP1-08, MP1-10,
PD32-11
Breau, Rodney H.
MP68-19, PD44-09,
PD47-12, MP84-08
Brechtel, Anette
MP27-14
Breda, Alberto MP85-06, PD13-05, V5-06,
V5-09, p56
Breen, Kieran J.
MP6-20
Brehmer, Marianne
PD13-05
Bremjit, Prashoban
MP67-17
Brendler, Charles
MP1-20, MP86-11,
PD47-11, MP84-08
MP60-04, MP83-02,
PD46-08
Brenner, Walburgis
MP39-04
Bresee, Catherine
MP24-15, PD21-07,
PD28-03
Bretan, Peter
p272
Bretterbauer, Katharina
MP57-03
Brewer, Katherine
PD9-11
Brewin, James
MP22-09, MP23-05
Breyer, Benjamin
MP9-12, MP15-03,
MP15-17, MP18-04, PI-01, MP71-13,
MP88-17, PD11-02, PD14-07, PD26-05
Brielmaier, Benjamin D.
MP65-13
Briganti, Alberto
MP2-12, MP4-14,
MP4-16, MP24-06, MP48-13, MP51-18,
MP56-02, MP56-03, MP56-05,
MP56-10, MP56-16, MP56-18,
MP62-01, MP62-04, MP62-05,
MP63-03, MP63-04, MP63-20,
MP72-04, MP72-14, MP76-05,
MP77-03, MP78-01, MP78-12,
MP78-13, MP78-15, MP82-01,
MP82-02, MP82-0
Briggman, Joseph
PD25-12
Briggs, Tim
MP43-13
Briollais, Laurent
MP61-01
Bristow, Robert G.
MP37-11
Britez, Lucas
PD11-10
Brito, Joseph
MP57-16
Britto, Cesar
V5-01
Brock, Gerald
PII-LBA6, p55
Brock, Marko
PD47-09
Brock, Timothy
V11-04
Brockman, John A.
PD18-09
Broderick, Gregory
MP51-19, p9, p55,
p56, p117, p221
Brodszky, Valentin
p101
Broghammer, Joshua MP88-20, MP89-13,
PD14-08, V3-11, p173
Brookman-May, Sabine
PD49-08
Brooks, Andrew
MP77-04
Brooks, David C.
MP5-04, MP5-13,
PD9-09
Brooks, James
MP1-17, MP6-13,
MP84-02, PD34-03, p85
Brooks, Jillene
MP8-04
Broquere, Cedric
MP61-02
Brotherhood, Hilary
PD13-07
Brothers, Aaron
MP61-20
Brown, Alan
MP87-12
Brown, Anna
MP48-04
Brown, Elizabeth T. MP15-12, PD11-04,
PD14-05
Brown, Gordon
PII-LBA2, p72
Brown, J. Quincy
PD15-01
Brown, James A.
MP39-18
Brown, Janet E.
MP73-10
Brown, Kevin
MP23-06
Brown, Lisha
MP66-15
Brown, Matt
MP62-06
Brown, Matthew
MP35-13
Brown, Robert
MP75-11
Brown, Thomas
PD5-01
Brownrigg, Natasha
V7-01
Broxmeyer, Hal
MP19-20
Bruce, Mark
MP21-07
Bruce, R. Douglas
p175
Bruce, Richard
MP11-02
Brenner, Phillip
Brucker, Benjamin
MP81-07, PD50-09
Brugarolas, James
MP11-14, MP47-06
Bruggmann, Rémy
MP31-01
Bruins, Harman Maxim
MP65-10
Brunacci, Leonardo
V8-12
Brunckhorst, Oliver MP22-09, MP23-05,
MP23-20, MP71-05
Brureau, Laurent
MP61-02
Bruschini, Homero
MP43-17
Bruyere, Frank
PD5-08, PD5-10
Bryant, Richard
MP55-12
Bryk, Darren
MP15-11, MP29-01,
PD37-11, V10-06
Bucci, Stefano
PD40-12
Buchner, Alexander MP26-17, MP58-16,
PD9-04
Buchwald, Dedra
PD8-09, PD20-07
Buck, Andrew
PD4-12
Buck, Jessica
MP81-20
Buckley, Jean
MP38-06
Buckley, Jill
MP15-02, p18, p95
Budaeus, Lars
MP78-17, MP83-06
Budäus, Lars
MP83-16, PD30-07
Budde, Klemens
PD35-10
Budı́a, Alberto
MP38-11, MP80-11
Budnik, Justin
MP51-11
Buehler, Joshua
MP65-18
Buerki, Christine
MP1-11
Buethe, David D.
MP59-20
Buffi, Nicolò MP6-07, MP59-08, MP59-15,
PD49-03, PD49-05, p153
Buffington, Phillip
MP4-03
Bugeja, Simon
MP29-06, MP29-07,
MP29-08, PD14-03, PD14-11,
PD22-01, PD22-06
Bui, Cat N.
MP73-13
Bui, Don
MP30-14
Bui, Hoai
MP36-02
Buldu, Ibrahim
MP38-20, PD13-09
Bultman, Eric
MP44-16
Bumbasirevic, Uros
MP52-15
Burda, Michal
MP71-07
Burge, Bethany K.
MP64-09
Burger, Maximillian
MP2-10, MP58-16,
MP65-09
Burges, Alexander
V7-05
Burgess, Neil
MP30-07
Burgmann, Maximiliane
V7-05
Burgos, Javier
MP85-06
Burgu, Berk
MP40-05, MP40-12
Burke, Emily
MP1-01
Burke, Michael
MP32-10
Burkhard, Fiona C.
MP31-01, MP65-16
Burks, David
p13
Burks, Frank
MP42-05, PD12-02,
PD38-13, p13, p73
Burnett, Arthur
MP4-09, MP52-05,
PD36-08, PD39-12, PD45-10, p12, p55,
p117, p221
Burrows, Pamela
PD39-01
Bury, Matthew
MP19-03, MP19-11
Buscarini, Maurizio
MP20-10, MP67-15
Buse, Stephan
V2-05
Buser, Lorenz
MP68-08, MP68-09
Busetto, Gian Maria
MP45-16
Bush, Jonathan W.
V7-07
Bush, Nicol
p12, p20
Bushell, Colleen
PD20-09
Bushnel, Daniel
MP52-18
291
Butcher, Michael MP43-19, PD39-01, p73
Butler, Christi
MP14-17
Büttner, Hartwig
MP42-07
Buttyan, Ralph
MP36-17, MP37-01,
MP46-06, p124
Buzi, Ruth
MP43-05
Byrne, Michael
MP41-15, PD42-09,
PD42-11
Byun, Hye Jin
MP54-10
Byun, Seok-Soo
MP37-08, MP42-16,
MP44-09, MP56-11, MP73-06,
MP77-06, MP78-16, MP82-11
C
Caballer, Vicent
MP80-11
Caballero-Romeu, Juan-Pablo
V6-13
Cabrera, Fernando
MP20-14, MP28-09,
MP33-12
Cabrera, Marino
V4-12
Cacalano, Nicholas A.
MP61-14
Cacciamani, Giovanni MP67-20, PD9-03
Cadeddu, Jeffrey
MP11-14, MP57-10,
MP84-13, p96
Cagiannos, Ilias
MP57-20, MP68-19,
PD44-09, PD47-12
Cai, Chao
MP66-13
Cai, Jie
MP5-06, MP27-10, MP56-07,
MP67-13, PD9-07, PD23-09, PD34-05
Cai, Tommaso
PD17-11
Cai, Yang
MP55-19
Caicedo, Juan Ignacio
MP25-16
Cain, Mark
MP40-20, MP54-19, p11
Cakir, Omer
MP33-19
Calabrese, Renee
PD38-09
Calaway, Adam C.
MP35-10, MP59-07,
V8-05
Caldamone, Anthony A.
FRI-07, p118
Caldovic, Ljubica
MP20-07, MP20-08
Caliolo, Claudia
MP85-06
Callaghan, Cameron MP39-01, MP69-01,
PD15-10
Callas, Peter
MP75-02
Calvaresi, Anne
p100
Calvert, Robert
MP41-13
Calves, Jehanne
MP13-13, MP13-18
Camacho, Amparo
MP43-18
Camacho, Ignacio
V4-08
Cambareri, Gina
MP54-17, PD22-10
Cameron, Anne P.
MP89-02, PD1-09,
PD10-07, PD10-09, PD10-12, V2-02,
p84
Campain, Nicholas
MP65-06, MP72-15,
PD41-05
Camparo, Philippe
MP31-03
Campbell, Brittany
MP37-11
Campbell, Bruce
p11
Campbell, Douglas
PII-LBA3
Campbell, Jeffrey B.
MP54-08
Campbell, Kevin
PD28-07
Campbell, Logan
MP9-08, MP24-20
Campbell, Marian
MP23-06
Campbell, Steven
MP63-14, MP69-14,
MP84-09, PD29-09, PD35-12, p12,
p18, p100, p221
Campeau, Lysanne
p18
Campos, Felix
PD14-11, PD22-01
Campos Jr., Olávio
MP8-09
Campos, Rodrigo
V11-09
Campos-Juanatey, Felix
MP44-15
Campos-Silva, Pamella
MP52-20,
MP76-13
Canakci, Cengiz
MP48-01
Canales, Benjamin
MP33-03, MP33-09,
MP33-11, MP34-09, PD4-03, p254
CAnary Pathology Team Investigating
Tissue Biomarkers (CAPIT)
MP1-17,
MP6-13
Canby-Hagino, Edith
PD22-07
Cancel-Tassin, Géraldine
MP7-12
Canda, Abdullah
MP67-19
Candela, Braden
MP23-09, V9-10
Candiani, Massimo
MP76-15
Canes, David
MP7-01, MP61-07, V4-12,
V8-12, p100
Canfield, Steven
MP52-11, p162
Cangemi, Antonina Graziella
MP45-10
Canning, Douglas A.
V7-04, p18
Cannon, Glenn
MP40-11, MP54-18
Canon, Stephen
PD24-07
Canter, Daniel
MP16-12, MP24-05,
MP65-02, MP70-04, MP79-03,
MP84-07, PD17-06, PD49-04, p132
Cantiello, Francesco MP76-05, MP78-13
Cantley, Lewis
MP46-10
Cantrill, Christopher
PII-LBA1
Cantwell, Anthony
MP3-02
Cao, Bo
MP66-11
Capitán, Carlos
MP13-20, PD5-08,
PD5-10
Capitanio, Umberto MP44-04, MP44-17,
MP48-13, MP56-02, MP56-03,
MP56-16, MP62-05, MP63-03,
MP63-04, MP63-20, MP78-13,
MP78-15, MP83-17, PD29-12, PD32-09
Capogrosso, Fabio
PD41-02
Capogrosso, Paolo
MP4-10, MP44-04,
MP51-17, MP51-18, MP63-03,
MP63-04, MP74-20, MP76-05,
MP76-15, PD52-06, PD52-10
Capolicchio, Gianpaolo
p17
Caputo, Peter
MP35-07, MP50-15,
MP70-02, V4-01, V4-11, V9-05
Caracciolo, Jamie
MP59-10
Carballido, Joaquı́n MP44-17, MP52-04,
PI-07
Carbognin, Giovanni
MP57-13
Carbone, Antonio
MP18-20, PD9-12,
PD45-11, PD49-08
Carducci, Michael
MP73-10
Caremel, Romain
MP12-05
Carenzi, Cristina
MP63-04
Carini, Marco
MP71-03, MP71-08
Caris, Christien
PD16-08
Carlos, Evan
MP64-09
Carlos, Silva
PD27-12
Carlson, Rachel
MP6-05, MP56-14,
MP83-11
Carlsson, Martin
PD27-06
Carlsson, Sigrid
MP60-10
Carlsson, Stefan
MP4-19, MP56-17
Carmel, Maude
PD50-02
Carmignani, Luca
FRI-11, MP77-08
Carmona, Oswaldo
V4-12
Carneiro, Arie
MP32-05, MP48-16,
MP83-19, MP84-12, V10-10
Carneiro, Bruno D.B.
MP22-16
Carney, Kenneth
p13
Carobbio, Francesca
PD35-01
Carons, Akin
V2-08
Carons, Akinwunmi
V2-07
Carpenter, Anne
PI-09
Carrasco, Alonso
MP70-14
Carrell, Douglas
MP76-12, p153
Carrier, Serge
p55
Carrieri, Giuseppe
p51, p236
Carrión, Cesar Jesús
V10-12
Carrion, Rafael
MP23-11, PD26-02,
PD26-04, PD40-07, p55, p140
Carro, Clara Garcia
MP79-07
Carroll, Aaron
MP40-20, MP54-19
Carroll, Peter MP1-05, PD6-06, PD12-11,
MP24-08, PD15-12, PII-LBA2,
MP42-12, MP53-18, PD34-03,
PD34-10, PD41-10, PD43-01, PD47-02,
MP86-10, p100, p136, p174
Carson, Culley
p30, p234, p235
Carter, Christopher
MP35-04
Carter, H. Ballentine
MP1-15, MP9-02,
MP24-16, MP42-04, PD6-04, PD34-09
Carter, J. Jacques
PD46-05
Carter, Stacey
MP41-10
Caruso, Carla
MP7-09
Caruso, Joseph A.
MP40-15, MP80-19
Carvalho, Fabricio
MP43-17
Carvalho, Raphael Farias
MP21-09
Carvalho, Vitalino
p71
Carvalho-Dias, Emanuel
MP31-16
Carver, Brett
MP10-01, MP10-05,
MP10-12, MP10-13, MP10-19, p11,
p196
Carvo, Ingrid
MP11-14
Cary, K. Clint
MP10-08, MP10-17,
MP58-11, MP64-17, MP65-14
Casale, Pasquale
MP54-15
Casanova, Juan
V4-02
Casarrubea, Giuseppe
MP57-13
Casellato, Stefano
MP77-08
Caskurlu, Turhan
MP25-12, MP48-01
Castagna, Giulia
MP4-10, MP51-17,
MP51-18, MP74-20, MP76-05,
MP76-15, PD52-06, PD52-10
Castaldo, Luigi
MP26-05
Casteels, Cindy
PD7-02
Castelblanco, Diana
MP25-16
Castellan, Miguel
p17, p31
Castelli, Tommaso
MP26-16, MP71-12,
PD10-03
Castelo-Branco, Pedro
MP37-11
Castiglione, Fabio
MP15-16, MP19-16,
MP19-18
Castillejos-Molina, Ricardo A.
MP25-18
Castillo Cadiz, Octavio
PD29-04
Castillo, Alex
MP24-01
Castillo, Josefino
MP60-07
Castillo, Octavio
MP3-04
Castle, Erik MP4-11, MP71-09, MP71-15,
PD15-08, V8-11, V8-12, V10-05, p10,
p72
Castro Neves, Oseas
PD3-04
Castro-Nallar, Eduardo
MP20-07,
MP20-08
Castro-Santamaria, Ramiro
MP1-13,
MP42-02, MP60-09, PD6-01
Casuscelli, Jozefina
MP47-14
Catalona, William
MP53-04, PD38-07,
p11, p72, p268
Cataño, Juan Guillermo
MP25-16
292
Catanzaro, Mario
Catchpole, Ken
Cates, Justin
Cathala, Nathalia
MP10-11
PD21-07
MP49-01
MP42-17, MP48-16,
MP62-08
Cathcart, Paul
MP43-13
Cathelineau, Xavier MP42-17, MP48-16,
MP56-10, MP62-08, MP82-01,
PD47-05
Cattaneo, Francesco
PD19-01
Catto, James
MP58-03, MP68-05, p44
Cavalcanti, Andre
p20
Ç

new orleans - AUA2015 Annual Meeting

Transcription

Similar documents

Overheads - ElamIT.net

Diapositiva 1

Meeting Program - AUA2016 Annual Meeting

Presentazione di PowerPoint

Trattamento delle metastasi ossee

View entire article. - Faculty of Arts and Science

Diapositiva 1 - Terapia Intensiva dell`età Pediatrica (0

2015 New Associates - Society of Actuaries

ROAD MAP PILOT PROJECT PENGEMBANGAN INDUSTRI OBAT